
<html lang="en"     class="pb-page"  data-request-id="9a79dc21-7005-451f-9689-71a191bace61"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c00093;issue:issue:10.1021/jmcmar.2020.63.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Monomeric Targeted Protein Degraders" /></meta><meta name="dc.Creator" content="Emily J.  Hanan" /></meta><meta name="dc.Creator" content="Jun  Liang" /></meta><meta name="dc.Creator" content="Xiaojing  Wang" /></meta><meta name="dc.Creator" content="Robert A.  Blake" /></meta><meta name="dc.Creator" content="Nicole  Blaquiere" /></meta><meta name="dc.Creator" content="Steven T.  Staben" /></meta><meta name="dc.Description" content="The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several ad..." /></meta><meta name="Description" content="The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several ad..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 30, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00093" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00093" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00093" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00093" /></link>
        
    
    

<title>Monomeric Targeted Protein Degraders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00093" /></meta><meta property="og:title" content="Monomeric Targeted Protein Degraders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0029.jpeg" /></meta><meta property="og:description" content="The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacology. While engineered heterodimeric molecules have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degradation observed for smaller, monomeric molecules. Methods and tools for evaluating protein degradation as well as a discussion of physical properties of monomeric vs engineered heterodimeric degraders are presented." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00093"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00093">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00093&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00093&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00093&amp;href=/doi/10.1021/acs.jmedchem.0c00093" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 11330-11361</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02138" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00176" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Monomeric Targeted Protein Degraders</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Emily J. Hanan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emily J. Hanan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emily+J.++Hanan">Emily J. Hanan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Liang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Liang">Jun Liang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaojing Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaojing Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaojing++Wang">Xiaojing Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert A. Blake</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert A. Blake</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department Biochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Blake">Robert A. Blake</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicole Blaquiere</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicole Blaquiere</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Blaquiere">Nicole Blaquiere</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Steven T. Staben</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven T. Staben</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#bccfc8d9cad9d2c8cffcdbd9d2d992dfd3d1"><span class="__cf_email__" data-cfemail="0f7c7b6a796a617b7c4f686a616a216c6062">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+T.++Staben">Steven T. Staben</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6137-6517" title="Orcid link">http://orcid.org/0000-0002-6137-6517</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00093&amp;href=/doi/10.1021%2Facs.jmedchem.0c00093" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 11330–11361</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 30, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 January 2020</li><li><span class="item_label"><b>Published</b> online</span>30 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11330%26pageCount%3D32%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEmily%2BJ.%2BHanan%252C%2BJun%2BLiang%252C%2BXiaojing%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D20%26contentID%3Dacs.jmedchem.0c00093%26title%3DMonomeric%2BTargeted%2BProtein%2BDegraders%26numPages%3D32%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11361%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00093"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6352</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00093" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Monomeric Targeted Protein Degraders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;J. Hanan&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Xiaojing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Blake&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Blaquiere&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;T. Staben&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;11330-11361&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00093&quot;},&quot;abstract&quot;:&quot;The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacology. While engineered heterodimeric molecules have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degradation observed for smaller, monomeric molecules. Methods and tools for evaluating protein degradation as well as a discussion of physical properties of monomeric vs engineered heterodimeric degraders are presented.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00093&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00093" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00093&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00093" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00093&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00093" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00093&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00093&amp;href=/doi/10.1021/acs.jmedchem.0c00093" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00093" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00093" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26pmid%3D32352776%26genre%3Darticle%26aulast%3DHanan%26date%3D2020%26atitle%3DMonomeric%2BTargeted%2BProtein%2BDegraders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/jmcmar.2020.63.issue-20/20201022/jmcmar.2020.63.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacology. While engineered heterodimeric molecules have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degradation observed for smaller, monomeric molecules. Methods and tools for evaluating protein degradation as well as a discussion of physical properties of monomeric vs engineered heterodimeric degraders are presented.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Emerging advances in the design and application of heterodimeric small molecules have promoted an expansion of interest and effort in the medicinal chemistry of inducing target protein degradation. Engineered small molecules incorporating an E3-ubiquitin ligase binder (most typically binders of CRL2<sup>VHL</sup> and CRL4<sup>CRBN</sup>) linked to a target protein binder, sometimes termed PROTACs (proteolysis targeting chimeras), have gained considerable momentum in recent years with the first example just reaching the clinic at the time of this Perspective. These new modalities have attracted considerable interest in the industry as highlighted by several review articles.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Compared with a more standard mechanism of simple inhibition, mechanisms of inducing protein degradation can provide several well-noted<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> advantages. These include the potential for more profound pharmacology and extended duration of action in the absence of drug treatment, both a result of protein removal versus more traditional inhibition of enzymatic function.</div><div class="NLM_p last">Outside these rationally engineered heterodimeric molecules, a number of smaller, monomeric molecules have been discovered that induce target protein degradation. This Perspective serves to remind practicing drug discovery scientists of these examples, often serendipitously discovered through empirical approaches. The scope of this article is limited to monomeric small molecules that directly (or in an induced manner) bind to target proteins of interest and promote degradation of said proteins. In this Perspective we first seek to provide an overview of methods for measuring protein degradation and useful tools for elucidating the mechanism of degrader phenotypes. We will then highlight examples of protein degradation by monomeric small molecules, first examining kinases and then non-kinase proteins, followed by examples of protein degradation by ligase-binding neosubstrate recruiters. Finally, this Perspective will conclude with a viewpoint on the opportunities and advantages of monomeric protein degraders relative to nondegrader small molecule inhibitors and heterodimeric protein degraders. We are hopeful that the Perspective provides sufficient exemplification, contrast of physicochemical properties, and tools and techniques for discovery and evaluation to encourage the reader to also consider and test for monomeric targeted protein degraders.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Methods of Measuring Protein Degradation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52586" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52586" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The methods used to measure protein degradation are essentially those used to measure the level of individual proteins in cells, and the degradation of the protein is inferred by the change in the level of protein after a defined incubation period. Most techniques do not consider the ongoing protein synthesis that opposes the degradation process but rather measure a net change in protein (the assumption being that protein synthesis rates do not change appreciably in the time frame of the assay and the changes in protein levels are driven primarily by protein degradation processes). These methods can be categorized as fixed end-point methods used to track the level of a single specific protein or to track multiple proteins at the same time, kinetic measurement methods used to track the change in the level of a protein over time, or methods to track average lifetime of a protein. Within drug discovery programs, there are a number of ways to measure loss of target proteins. Selection among these various methods is typically dependent on the stage of the discovery program and associated needs (i.e., throughput, level of quantitation, availability of reagents).</div><div class="NLM_p">The simplest method that is often selected by research labs to measure protein degradation for a small number of samples is the Western blot method.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> This has the advantage of simplicity, lack of requirement for complex expensive instruments, and agility to monitor new proteins based simply on the availability of suitable antibodies. It is a low throughput method requiring manual steps, is typically only semiquantitative, and requires the measurement of control proteins or total protein levels to calibrate for the effects that compounds can have on cell viability or other confounding effects on protein levels. An alternative to the Western blot method is the automated capillary electrophoresis method.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In this method the proteins in a cell lysate are separated by charge or size and then immobilized on the capillary wall. As with the Western blotting method the proteins are detected with a primary antibody and an enzyme-conjugated secondary antibody which is used to detect and quantify the amount of protein. The advantage of this system is the ability to automate, although it does require specialized equipment.</div><div class="NLM_p">The sandwich enzyme-linked immunosorbent assay (ELISA) method<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> offers a simple and higher-throughput alternative to Western blotting for measuring the amount of a specific protein in cell lysate. However, it requires two antibodies that are specific to the protein of interest in order to capture and then detect the protein. The cell lysate is transferred into the microtiter plate, which has been precoated with the primary antibody that captures the protein of interest. Then a detection antibody and a secondary enzyme-conjugated antibody are used to detect the amount of protein that has been captured from the lysate, typically using a colorimetric substrate. The AlphaLISA (amplified luminescent proximity homogeneous assay) method offers a higher throughput alternative to the ELISA method and has the advantage of being a homogeneous assay format.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> It is similar to the ELISA method in that it requires two antibodies that bind to different epitopes of the protein of interest. The ternary complex of the two antibodies and protein is detected by virtue of the diffusion of short lifetime singlet oxygen molecules, generated by high energy irradiation of donor beads bound to one antibody, and the distance that they can diffuse within their lifetime (approximately 200 nm) to acceptor beads bound to the second antibody. The singlet oxygen molecules excite a cascading series of chemical reactions on the acceptor beads that generate a chemiluminescent signal. In the absence of an antibody/protein ternary complex the singlet state oxygen molecules produced by the donor bead go undetected. The AlphaLISA method is often superior to methods such as TR-FRET (time resolved fluorescence resonance energy transfer) for the detection of proteins in cell lysates, since it is less prone to interference from components in crude cell lysates.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">Quantitative fluorescence imaging is a particularly versatile method for measuring changes in protein levels in adherent cells,<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> although it can also be applied to normally nonadherent cells.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> Otherwise its application is limited only by the availability of suitable antibodies for detecting the protein of interest. It has the advantage of allowing measurements in individual cells, which are therefore independent of cell number and the cell viability artifacts that are inherent in bulk measurements. The technique permits the multiplexed measurement of several proteins simultaneously enabling the detection of changes in the protein of interest along with control proteins or total cellular protein levels.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Immunofluorescence imaging typically uses specific antibodies to detect proteins in situ within adherent cells that have been fixed (typically with formaldehyde) and is therefore usually used as a fixed end point assay. The most versatile and robust format is the secondary (indirect) immunofluorescence method in which a primary (unlabeled) antibody is bound to the protein of interest and then fluorescently labeled using a fluorophore conjugated secondary antibody that cross-links the primary antibodies in place.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> A range of different automated fluorescence imaging systems acquire fluorescence images of the samples stained for the proteins of interest and use image analysis methods to quantify fluorescence intensities (and consequently the level of specific proteins) in different regions of the cells.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> In the case of nonadherent cell types, flow cytometry is often a more suitable method than fluorescence imaging. Flow cytometry is a method that can be used to detect protein levels either on the cell surface or within the cell using intracellular staining procedures.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23−26)</a> Flow cytometry also uses the quantitation of fluorescence in individual cells as a means to measure protein levels and is potentially more sensitive than fluorescence imaging (although without subcellular localization information). The proteins of interest can be detected using intracellular staining techniques<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (there are diverse fluorophores that can be used to directly label the primary antibodies), or the proteins of interest can be expressed fused to a variety of different fluorescent proteins.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Each of the fluorophores can be detected by virtue of its characteristic excitation and emission wavelengths, after correcting for potential spectral overlap, and the technique is capable of multiplexed measurements of several proteins at once.</div><div class="NLM_p">An important parameter to consider when measuring protein degradation is the kinetics. Both the rate and the duration of the change in the level of the protein are important pharmacological parameters that may be optimized. The assay methods that are best suited to monitoring the kinetics of changing protein levels typically involve expressing the protein of interest with a tag that enables its detection in real time. Tags include fluorescent proteins (e.g., green fluorescence protein, GFP),<a onclick="showRef(event, 'ref15 ref28'); return false;" href="javascript:void(0);" class="ref ref15 ref28">(15,28)</a> the halotag domain (which can be fluorescently labeled with a chloroalkyl fluorophore),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> or a luminescent protein domain such as nanoluciferase.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Each of these tags enable the real-time measurement of changing protein levels and therefore measurement of their rates, their maximal extent (<i>D</i><sub>max</sub>), and their duration. Importantly, the halotag strategy differs from the other approaches in that it offers the possibility of pulse-labeling the protein with the chloroalkyl fluorophore and therefore the ability to derive protein degradation rates that are uncoupled from protein synthesis rates. The study by Riching et al. is a good example, demonstrating the utility of kinetic degradation measurements, using the HiBiT tag/LgBiT nanoluciferase system to measure the degradation kinetics of BET family members (BRD2, -3, and -4) caused by the bivalent degraders MZ1 and dBET1.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The HiBiT peptide is a small tag (11 amino acids) that is expressed as a fusion with the protein of interest. It spontaneously binds to an inactive form of nanoluciferase (LgBiT) that lacks this 11 amino acid sequence. The HiBiT/LgBiT complex forms an intact nanoluciferase through enzyme-fragment complementation, generating a nanoluciferase signal that is proportional to the amount of protein that is tagged with the HiBiT peptide tag.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> This system enables the real-time monitoring of protein levels using the nanoluciferase signal, with the advantage of minimizing the size of the tag (and interference caused by the tag). Kinetic measurements are possible for more than 24 h (using a stabilized nanoluciferase substrate). These studies revealed the complex patterns of the onset and duration of protein degradation caused by different compounds, and they suggest that fixed time point measurements could misrepresent DC<sub>50</sub> (concentration causing a 50% reduction in the level of the protein) potencies. Different BET family members had different initial degradation rates and different rates of recovery, often with complex multiphasic profiles. Importantly, this study suggests that the type of tag used to track the level of the protein of interest can influence the protein degradation kinetics. Experiments comparing the effect of a whole nanoluciferase tag versus a small HiBiT tag of ectopically expressed BRD4 treated with MZ1 revealed that the larger tag resulted in a compressed degradation window, slower degradation rate, reduced potency, and more rapid recovery relative to the HiBiT tagged BRD4.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> When applying these methods, researchers should understand whether the degradation rates of tagged proteins differ from the degradation rates of native untagged proteins and interpret their data within the limitations of the techniques.</div><div class="NLM_p">The preceding methods are applicable for the measurement of changes in the level of individual prespecified proteins of interest but cannot detect unanticipated, unlooked-for protein degradation effects. When it comes to the question of the specificity of a degrader, the most powerful techniques are those of global proteomics mass spectrometry and isobaric tags for relative and absolute quantification (iTRAQ) and tandem mass tag (TMT), reviewed by Rauniyar and Yates<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and Bakalarski and Kirkpatrick.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> These labeling techniques use amine-reactive chemical tags to chemically label the primary amines in the peptides (peptide N termini and the amines of lysines) and are capable of determining the changes in as many as 7000 proteins.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The advantage of the global proteomics methods is that they can survey the effects of a degrader much more broadly across the proteome in an unbiased manner. The disadvantage of such global proteomics studies is that they are limited by the number of samples that can be analyzed at any one time (unlike the tagged-protein methods described above), typically, up to 11 samples in a single experiment. A typical TMT procedure involves the alkylation of proteins (in urea cell lysates) with iodoacetamide, digestion with lys-C and trypsin before labeling with TMT labeling reagents.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The labeled TMT tryptic peptides are then separated by reversed phase liquid chromatography before detection and quantification by Orbitrap-based mass spectrometry. Like the majority of methods used to measure protein degradation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), these proteomics methods infer degradation through changes in the level of a specific protein. An alternative strategy would be to combine mass spectrometry based measurements with pulse-labeling using metabolic labels such as azidohomoalanine, (a CLICK chemistry enabled amino acid analog) or mixtures of “light”, “medium”, or “heavy” isotope-labeled essential amino acids, which are used in pSILAC (pulsed stable isotope labeling by amino acids in culture) experiments in combination with mass spectrometry based measurements.<a onclick="showRef(event, 'ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39">(36−39)</a> Such pulse labeling approaches would enable the direct measurement of protein degradation, as opposed to the inferred degradation that the measurement of steady state protein levels provides.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Methods of measuring protein degradation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The choice of which method(s) to apply to a small molecule degrader project will depend on many factors: biology of the target, cell-line being used, required scale and throughput of assays, the type of data desired, and availability of equipment and resources. Typically, an early stage project will deploy the simpler assay formats whereas a late stage project will deploy the more equipment intensive information rich assays. No matter which technique is chosen, one should consider the type of data that are used to guide the optimization of the degraders. When describing the pharmacological effects of compounds in fixed-end point in vitro pharmacology assays, it is typically the potency that is the focus, with data types such as IC<sub>50</sub>/EC<sub>50</sub>/DC<sub>50</sub> (half maximal inhibitory/effective/degradation concentration) referring to the concentration of a compound that induces a response halfway between a baseline and a maximum after a specified exposure time. However, the maximum extent of protein degradation caused by a particular compound can be less than 100% degradation; this maximum extent cannot be surpassed no matter how high the concentration of compound. This phenomenon is illustrated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, which shows the different extent of estrogen receptor degradation achievable by various selective estrogen receptor modulators and degraders (SERMs and SERDs). Thus, when evaluating molecules that induce target degradation, it is also very important to measure and optimize for maximum degradation (<i>D</i><sub>max</sub>) and not just the DC<sub>50</sub>. No matter which methods are chosen to measure protein degradation, the full picture of the efficacy of a compound requires the measurement of several different parameters including potency, maximum degradation, and the kinetics of the change in protein levels. This is relevant because the effectiveness of a degrader will be, in part, determined by how much protein degradation is required in order to achieve a biological effect.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The graph depicts the relative change in estrogen receptor α (ERα) protein levels caused by selective estrogen receptor modulators and degraders (SERMs and SERDs) in MCF7 breast cancer cells, measured using quantitative fluorescence imaging (previously unpublished data). Each of the drugs results in the reduction of ERα to a new steady state level that represents the maximum percentage degradation that is achievable by each drug in this cell type and these assay conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To date, the majority of monomeric degraders have been identified through serendipitous observation rather than a directed search or design (for example, see refs <a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a>). Compounds that promote degradation over simple inhibition may display more robust or surprising phenotypes, and thus their discovery may result from careful analysis of existing data. For example, degraders may have cellular EC<sub>50</sub> values that are atypical relative to nondegrading molecules directed at the same target.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> This phenomenon has been most widely reported for bivalent degrader molecules but is also common for monomeric degraders and may result from the catalytic nature of degrader molecules.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Useful Tools for Mechanistic Elucidation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This section aims to highlight some tool molecules that should be commonly utilized to better understand the mechanism of compounds that induce a concentration-dependent loss of the target protein of interest (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). These molecules block distinct steps in various processes that influence protein level homeostasis. As such, changes observed to a degradation phenotype with and without these tool compounds may help inform research teams of mechanism, prompt additional experimentation, and/or guide testing and optimization strategies.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0022.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Tool compounds to aid in mechanistic experiments for targeted protein degraders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cycloheximide (<b>1</b>) is a broad acting protein synthesis inhibitor that can be used as a mechanistic probe to understand the kinetics of targeted protein degradation. This compound binds to the E-site of the 60s ribosome which blocks eF2-mediated tRNA translocation.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">A proteasome-dependent mechanism of degradation can be rescued by inhibitors that block the protease activity of the human 20S-proteasome, although cytotoxic effects of these reagents limit the useful experimental period to under 24 h. The most commonly used proteasome inhibitors for in vitro experiments are MG132 (<b>2</b>),<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45−47)</a> carfilzomib (<b>3</b>),<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and bortezomib (<b>4</b>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Proteins degraded by the lysosomal-autophagy pathway can be modulated by tool compounds that disrupt autophagosome formation, endosome maturation, and lysosomal lytic activity. Most commonly used are lysosomotropic agents such as chloroquine (CQ, <b>5</b>) and more recently a dimerized version known as Lys05 (<b>6</b>).<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> Molecules of this class are known to accumulate in lysosomes. Their mechanism of lytic inhibition is still debated but likely includes deacidification of the lysosome and partial impairment of lysosomal enzymes.</div><div class="NLM_p">HSP90 is a molecular chaperone that is an important player in protein homeostasis for a wide variety of “client” proteins.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The inhibition of HSP90 can provide a useful positive control for reducing the level of a protein in an assay or a screen for degraders of a protein if that protein is a client of HSP90. Natural product based geldanamycin (<b>7</b>) and 17-<i>N</i>-allylamino-17-demethoxygeldanamycin (17AAG, <b>8</b>) are commonly used in vitro tools that block ATP-binding to HSP90 and thus the important ATPase dependent conformational changes important for HSP90 function.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Medicinal chemistry efforts have provided a number of non-natural HSP90 inhibitors,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> but use as tool molecules in vitro has been limited.</div><div class="NLM_p last">Scientists at Millennium Pharmaceuticals invented a suite of substrate-assisted inhibitors with variant selectivity for E1-like enzymes. These molecules, which are particularly useful for testing the involvement of various aspects of the ubiquitin system in a protein degradation effect, form tight binding inhibitors in situ through enzyme assisted conjugation of a sulfamate moiety to ubiquitin or ubiquitin-like proteins. Compound <b>9</b><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> broadly blocks ubiquitin-dependent phenomena by inhibiting E1–E2 transthiolation. Compound <b>10</b> (MLN7243) is a mechanism-based inhibitor of UAE (Ubiquitin Activating Enzyme) with decent selectivity over other E1 ubiquitin-like activating enzymes.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> MLN4924 (<b>11</b>) is reported to be a mechanism-based selective inhibitor of NEDD8-activating enzyme (NAE).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> As neddylation is an important step in the activation of Cullin-RING E3 ligases, a degradation phenotype rescued by treatment with <b>11</b> may be suggestive of a mechanism that is dependent on this family of ligases.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Degradation of Kinases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Kinases represent a well-trodden class of target proteins that have most typically been targeted by ATP-competitive inhibitors. Targeting degradation of kinases represents a promising alternative strategy as many kinases have known scaffolding functions in addition to their enzymatic activity. In addition, inhibitor-induced degradation may provide an alternative mechanism for selectivity as well as dampen responsiveness to mechanisms of pathway reactivation that are frequently observed for kinase inhibition. The degradation of kinases by both heterodimeric and monomeric small molecules has been the subject of a brief highlight,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and we expand on the latter below.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">BRAF, EGFR, HER2: Degradation through Chaperone Deprivation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62026" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62026" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is estimated that the HSP90 chaperone system influences 60% of the proteome. For kinases, it is hypothesized that interaction with HSP90 and co-recruited Cdc37 protects unstable kinases from degradation while providing a tunable mechanism to suppress their activity.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> Multiple phosphorylation events on HSP90 and co-chaperone Cdc37 influence specificity and stage of the chaperone kinase cycle.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> A recent cryo-EM structure of CDK4 with HSP90/Cdc37 indicates separation of the N- and C-lobe of CDK4 to allow Cdc37 insertion and HSP90 interaction and provides a model for interaction of HSP90/Cdc37 with “client” kinases (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0023.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) A composition model of CDK4/Cdc37/HSP90 cryo-EM structures (CDK4 cyan, Cdc37 orange, HSP90 salmon/mauve) displayed from PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWK">5FWK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWP">5FWP</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWM">5FWM</a>. (b) CDK4 from the complex with Cdc37/HSP90 compared to a normal closed state (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96">2W96</a>, cyclin-D removed for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Polier and co-workers have found that active-site kinase binders can prevent HSP90/Cdc37 interaction and result in destabilization of the targeted kinases.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> They hypothesize that stabilization of a folded state by kinase inhibitors can dissuade the dissociation of the N- and C-lobes necessary for Cdc37 insertion, this chaperone deprivation leading to ubiquitination and proteasome-mediated degradation of the targeted kinases. Vemurafenib (<b>12</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) was shown to antagonize Cdc37 and HSP90 binding to B-Raf<sup>V600E</sup> through a series of biochemical and/or cellular coimmunoprecipitation studies. Inhibition of the coimmunoprecipitation of HSP90 and Cdc37 with B-Raf<sup>V600E</sup> was robust in HT29 cells treated with <b>12</b> (4.6 μM, 10× GI<sub>50</sub>). At that concentration, after 24 h, loss of B-Raf<sup>V600E</sup> was observed by Western blot while levels of other pathway kinases (MEK1/2, ERK1/2) were not influenced. Similar results were obtained with multikinase inhibitor sorafenib (<b>13</b>). For vemurafenib, the degradation phenotype in HT29 cells was substantially rescued by proteasome inhibition with MG132 (<b>2</b>). A similar degradation phenotype was observed for erlotinib (<b>14</b>) (inhibition of Cdc37 and HSP90 coimmunoprecipitation and EGFR<sup>G719S</sup> depletion at >30 μM at 24 h in SW48 cells) and lapatanib (<b>15</b>) (inhibition of Cdc37 and HSP90 coimmunoprecipitation and Her2 depletion at 150 nM at 24 h in BT474 cells). In a separate disclosure, Zhang et al. corroborated that degradation of HER2 in SKBR3 and AU565 cells treated with irreversible inhibitor neratinib (<b>16</b>) is a result of HSP90 deprivation.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In this case, the authors show neratinib and lapatanib dependent ubiquitylation and that degradation of HER2 is promoted by neratinib and lapatanib dependent endocytic trafficking to the lysosome.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0024.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinase inhibitors reported to promote degradation of associated targets through a mechanism that includes chaperone deprivation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">JAK2/3</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2017, scientists from Pfizer reported pyrrolopyridine compound <b>17</b> (PF-956980, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> to deplete levels of JAK2 and JAK3 in human peripheral blood monocytes (hPBMCs) in vitro.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The Janus kinases (JAK1, JAK2, JAK3, and TYK2) are a family of tyrosine kinases that transduce extracellular stimulus by >50 cytokines and growth factors by mediating phosphorylation of signal transducers and activators of transcription (STATs).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Upon phosphorylation, STATs dimerize, translocate to the nucleus, and modulate gene transcription. Dysregulation of the JAK-STAT pathway is thought to be a critical component of several autoimmune diseases as well as cancers.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Medicinal chemistry programs directed at JAKs<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> have yielded marketed therapeutics ruxolitinib (not shown)<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and tofacitinib (<b>18</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>),<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> both of which are reported to be ATP-competitive, reversible inhibitors of the kinase function of JAK kinases.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0025.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and biochemical potency of compounds <b>17</b> and <b>18</b>.<a onclick="showRef(event, 'ref64 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref64 ref70 ref71">(64,70,71)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>17</b> is reported to be an ATP-competitive, reversible pan-JAK inhibitor that has moderate selectivity over the homologous kinase TYK2 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> JAK levels in hPBMCs were determined after treatment with <b>17</b> by Western blot. A concentration and time dependent loss of JAK2 and JAK3, but not JAK1, was observed; depletion of JAK2 and JAK3 occurring after treatment with <b>17</b> (0.1–10 μM) at 22 h after treatment.</div><div class="NLM_p">Although clearly a binder to JAK proteins, mechanistic studies led the authors to suggest a transcriptional effect of compound <b>17</b>. Proteasome inhibition (MG132 and carfilzomib, <b>2</b> and <b>3</b>) resulted in significant JAK2/3 depletion in the presence or absence of compound <b>17</b>, making it difficult to ascertain whether depletion is proteasome dependent. Blocking protein resynthesis (cycloheximide, <b>1</b>) resulted in depletion of JAK2/3 in a rate that was not strongly influenced by co-treatment with compound <b>17</b>. This experiment suggests that compound <b>17</b> could be itself altering the rate of JAK2/3 synthesis. Indeed, qPCR analysis indicated a significant reduction in the level of mRNAs for JAK2 and JAK3 after 22 h treatment of <b>17</b> in hPBMCs (∼50% at 1 μM). It is unclear whether JAK/STAT signaling directly regulates JAK 2/3 gene transcription or whether this is an off-target effect of the compound (note that the compound does not appear to inhibit BRD4, which eliminates one possibility of a transcriptional effect). Proteome-wide selectivity was not determined; however loss of specific kinases TYK2, ERK2, p38, and BTK was not observed. The lack of JAK1 depletion is especially notable given similar biochemical potency of <b>17</b> against all three JAKs.</div><div class="NLM_p last">It is curious to note that compound <b>17</b> is highly homologous to tofacitinib (<b>18</b>) as well as other pyrrolopyridine JAK inhibitors. To our knowledge, depletion of JAK isozymes by any of the many known JAK inhibitors has not been reported except for <b>17</b>. Understanding the relationship (if any) between compound structure, affinity, and extent of JAK2/3 depletion could shed further light on the mechanism of action of compound <b>17</b>.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">LRRK2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhibition of leucine-rich repeat kinase 2 (LRRK2) is of significant interest in the treatment of Parkinson’s disease (PD) due to the association of gain-of-function mutations (most commonly G2019S) in the <i>LRRK2</i> gene with inherited autosomal dominant PD.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Investigations of the molecular and cellular consequences of LRRK2 inhibition have revealed a complex relationship between kinase activity, phosphorylation status, and steady-state protein levels that have implications for the clinical evaluation of LRRK2 inhibitors.</div><div class="NLM_p">LRRK2 is phosphorylated at multiple serine residues, including Ser910 and Ser935, by other upstream kinases.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> Although there are not autophosphorylation sites, the LRRK2 kinase domain plays some role in regulating this status; it has been postulated that inhibition of LRRK2 kinase activity stimulates a regulatory feedback loop with subsequent dephosphorylation of Ser 910 and 935. This dephosphorylation event is commonly utilized as a measurement of LRRK2 inhibitor activity in cells.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> In 2015, Zhao and Lobbestael separately reported that selective inhibition of LRRK2 kinase activity with small molecules consistently resulted in decrease of LRRK2 protein levels.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> In SH-SY5Y cells stably overexpressing LRRK2, treatment with a variety of LRRK2 inhibitors including MLi-2 (<b>19</b>) and G1023 (<b>20</b>) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) resulted in a rapid dephosphorylation at S935, with a decrease in total LRRK2 levels emerging between 8 and 24 h. LRRK2 mRNA levels remained constant suggesting a post-translational regulatory change.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Blocking lysosomal degradation with either <b>5</b> or bafilomycin A did not impact the decrease in LRRK2 protein levels; however treatment of cells with <b>2</b> to block proteosomal degradation did prevent inhibitor-induced loss of LRRK2.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> Treatment of either SH-SY5Y or HEK293 cells expressing LRRK2 with <b>20</b> also resulted in an increase in LRRK2 ubiquitylation, consistent with inhibitor-induced ubiquitylation and proteasomal degradation.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In vivo, treatment of mice with either <b>19</b> or <b>20</b> resulted in decreases in both LRRK2 S935 phosphorylation and total LRRK2 levels in brain, lung, and kidney tissues.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0026.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures and biochemical activity for selected LRRK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine whether ubiquitylation is triggered by dephosphorylation of LRRK2, the peptide difopein was used to inhibit phospho-dependent binding of LRRK2 to 14-3-3 proteins, resulting in dephosphorylation at S935 without perturbing LRRK2 kinase activity, and was found to result in LRRK2 ubiquitylation similar to that induced by <b>20</b>.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Additionally, blockage of PP1-mediated dephosphorylation of LRRK2 with calyculin resulted in a decrease in LRRK2 ubiquitylation after inhibitor treatment.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> These data support a link between LRRK2 dephosphorylation and the ubiquitylation and subsequent proteasomal degradation of the protein and suggest that all LRRK2 kinase inhibitors induce protein degradation. While many groups have published data for LRRK2 inhibitors without noting LRRK2 depletion, Lobbestael noted that LRRK2 inhibition and dephosphorylation (the typical readout for cellular LRRK2 assays) occur quickly. Many investigators may evaluate cellular consequences only within the first few hours of inhibitor treatment and not beyond the 8 h that appears to be required for significant LRRK2 degradation.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">The implications of affecting LRRK2 protein levels first emerged with the study of LRRK2 knockout mice. Multiple groups have reported on tissue pathology in LRRK2 knockout (KO) mice, including microvacuolation in lung and kidney tissues.<a onclick="showRef(event, 'ref79 ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81">(79−81)</a> Mice carrying a kinase-inactivating point mutation D1994S (kinase dead, KD) had pathological findings in kidney tissue but not lung tissue.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Complicating interpretation of these results (deconvolution of kinase activity vs other protein function) was the observation that KD mice also had significantly reduced levels of LRRK2 protein in the kidney. In vivo experiments with selective LRRK2 inhibitors GNE7915 (<b>21</b>) and GNE0877 (<b>22</b>) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) resulted in no pathological findings in rodents despite evidence of LRRK2 kinase inhibition in brain, kidney, and lung tissues, assessed by a reduction in pS935 LRRK2, normalized for total LRRK2 protein.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> A decrease in total LRRK2 protein levels was observed in kidney tissues, with no decrease in total LRRK2 protein in lung and brain. However, non-human primates treated with <b>21</b> showed a reduction in pS935 as well as total LRRK2 protein levels in brain, kidney, and lung tissue and also resulted in a finding of increased vacuolation of type II pneumocytes in the lungs. In vivo evaluation of <b>19</b> with extended dosing in the MitoPark mouse model showed marked inhibition of pS935 in the brain, lung, and kidney, coupled with a significant reduction in LRRK2 protein in lung and kidney tissues.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Recapitulating the lung phenotype of LRRK2 KO mice, treatment with <b>19</b> was associated with slight enlargement of alveolar epithelial cells with features consistent with type II pneumocytes showing increased vacuolation.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><div class="NLM_p">In 2014, Skibinski et al. published results from an in vitro model that enabled analysis of neuronal cultures with single-cell resolution, evaluating viability and LRRK2 protein levels.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Consistent with the hypothesis that links the activating mutation G2019S with neuronal toxicity, they found that neurons transfected with G2019S LRRK2 were 50% more likely to die during a 7-day experiment relative to neurons transfected with wild-type LRRK2. To test the influence of LRRK2 kinase activity, neurons were transfected with G2019S/D1994A LRRK2. The D1994A mutation blocks kinase activity and significantly reduced toxicity to neurons compared with the G2019S single mutation; however the double mutation was also associated with reduced steady-state levels of LRRK2. When cohorts of neurons were matched for similar levels of total LRRK2, the kinase-dead constructs no longer afforded a reduction in toxicity. Similarly, pharmacological inhibition of LRRK2 kinase activity with the small molecule inhibitor LRRK2-IN-1<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> (<b>23</b>) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) reduced apparent G2019S toxicity, but after normalizing for LRRK2 protein levels at the single cell level, it again had no effect on neuronal survival.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The authors concluded that a reduction in protein levels accounted for the improvement in neuronal survival resulting from a disruption of LRRK2 kinase activity.</div><div class="NLM_p last">All of the above studies suggest that kinase inhibition and degradation are intimately linked with both efficacy and peripheral toxicity for LRRK2 inhibitors and may have implications on whether a therapeutic index is achievable with LRRK2 inhibitors for the treatment of PD.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">PI3Kα</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a major regulator of tumor cell growth, proliferation, and survival.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Solid tumor malignancies frequently include dysregulation of the PI3K/Akt/mTOR signaling pathway through a variety of mechanisms, including activating and transforming “hotspot” mutations of <i>PIK3CA</i>, the gene that encodes the p110α catalytic subunit of PI3Kα.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Hotspot mutations of <i>PIK3CA</i>, in particular the kinase domain mutation H1047R, are highly prevalent in breast cancer.<a onclick="showRef(event, 'ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90">(88−90)</a> Considerable interest in pursuing PI3K as a therapeutic target has led to the advancement of multiple inhibitors to clinical trials.<a onclick="showRef(event, 'ref91 ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref91 ref92 ref93">(91−93)</a></div><div class="NLM_p">Early public presentations have described selective degradation of the PI3Kα protein by the inhibitors taselisib (<b>24</b>) and GDC-0077 (<b>25</b>) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref94 ref95 ref96 ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref94 ref95 ref96 ref97 ref98">(94−98)</a> These compounds are reported to act by a dual mechanism of action, directly blocking kinase signaling as well as inducing degradation of the mutant p110α protein in a dose- and time-dependent manner. This degradation is reported to be ubiquitin- and proteasome-dependent, with protein depletion rescued by both E1 and proteasome inhibitors.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> The degradation was found to be specific to the mutant form of p110α, with mass spectrometry analysis showing no significant change in wild-type p110α levels.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> It is hypothesized that this mutant-selective MOA is the basis for increased activity, as measured by reduction of pathway biomarkers, inhibition of cell proliferation, and increased apoptosis, in mutant cell lines relative to PIK3CA wild-type cells for these two inhibitors. As there are important roles for all PI3K isoforms in normal physiology, with wild-type PI3Kα being involved in metabolic homeostasis, it is postulated that the selective degradation of mutant p110α may lead to an improved therapeutic index in the clinic, with selectivity among the PI3K isoforms also playing a role in minimizing treatment-related toxicities.<a onclick="showRef(event, 'ref94 ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref94 ref99 ref100">(94,99,100)</a> Compound <b>24</b> inhibits PI3Kα vs PI3Kδ equally but spares inhibition of PI3Kβ, whereas <b>25</b> is reported to inhibit PI3Kα with >300-fold selectivity vs all of the other class I isoforms.<a onclick="showRef(event, 'ref96 ref98'); return false;" href="javascript:void(0);" class="ref ref96 ref98">(96,98)</a> Phase III clinical trial data for <b>24</b> were recently reported for the treatment of patients with ER-positive, HER2-negative, PIK3CA mutant locally advanced, or metastatic breast cancer. Compound <b>24</b>, in combination with fulvestrant, afforded improved mPFS relative to placebo + fulvestrant; however, adverse events led to an increase in discontinuations and dose reductions relative to placebo.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0027.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Clinical inhibitors of PI3Kα that induce selective degradation of mutant p110α.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Interestingly, current reports indicate that p110α degradation is not a universal mechanism of action for PI3K inhibitors, with clinical inhibitors other than <b>24</b> and <b>25</b> being unable to induce strong degradation of the mutant p110α protein, including pan-PI3K and PI3Kα selective molecules.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Similar to other inhibitor-induced degradation events, this degradation phenotype requires analysis at longer time points (8–24 h) as opposed to the shorter time points (<2 h) that are typical for measuring kinase inhibition.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The mechanism by which <b>24</b> and <b>25</b> induce mutant p110α degradation and why that mechanism is not shared by other inhibitors have not been reported.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">PDGFRα</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Dihydroartemisinin (DHA, <b>26</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), a derivative of the antimalarial agent artemisinin,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> has been shown to be toxic to ovarian cancer cells with IC<sub>50</sub> values in the 1–20 μM range, 5- to 10-fold selective vs normal ovarian cell lines.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> Many possible mechanisms for this activity have been investigated.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> A recent report in 2017 by Wang and co-workers demonstrated that DHA selectively inhibited PDGFRα-positive ovarian cancer growth and metastasis by inducing degradation of PDGFRα protein (platelet-derived growth factor receptor-alpha).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Human A2780 ovarian cells treated with 10 μM DHA were analyzed for treatment-related changes in protein expression, and PDGFRα was identified as a cellular target of DHA. PDGFRα is a membrane bound receptor tyrosine kinase involved in the development and progression of ovarian cancer.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> It was found that the DHA-induced suppression of cell growth and repression of the epithelial-mesenchymal transition are dependent on downregulation of PDGFRα. Mechanistic studies elucidated that DHA decreased PDGFRα protein expression by inducing its ubiquitylation and proteasomal degradation (rescued by pretreatment with proteasome inhibitor <b>2</b>) while exerting no significant effect on PDGFRα mRNA transcription level. Such downregulation of PDGFRα protein expression was also observed in the tumor samples from in vivo studies after the treatment with DHA at doses where moderate tumor growth and metastasis inhibition were observed. A biotin conjugated variant was used as a tool to pull down PDGFRα in a concentration dependent manner. There is minimal structural information; however it was demonstrated that <b>26</b> binds to the cytoplasmic and not the extracellular domain of PDGFRα through comparison of full length and chimeric receptors.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0028.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structure of dihydroartemisinin (DHA, <b>26</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">c-Kit</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00537" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00537" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The stem cell factor receptor c-Kit represents an attractive target for therapeutic intervention.<a onclick="showRef(event, 'ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref108 ref109">(108,109)</a> c-Kit is a member of the type III family of receptor tyrosine kinases and transduces a variety of downstream signaling pathways, including PI3K/AKT, Ras-ERK, and Src-signaling pathways. Deregulation of c-Kit, including overexpression and gain-of-function mutation, has been identified in a number of human malignancies. Not surprisingly, there is a long list of clinical trials examining the effects of c-Kit inhibitors in different types of cancers.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> In addition, a number of multikinase inhibitors that inhibit c-Kit activity along with other kinases have been approved as drugs to treat various diseases.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Two of these approved drugs, namely, imatinib and masitinib (<b>27</b> and <b>28</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), were found to induce the downregulation of wild-type c-Kit at 2 μM concentration.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Studies performed with ±CHX (<b>1</b>), as well as pulse-chase experiments using [<sup>35</sup>S]Cys/Met, suggested that the effect of imatinib (<b>27</b>) was not due to an inhibition of protein synthesis. Degradation of c-Kit was not rescued by co-treatment with a proteasome inhibitor, suggesting a nonproteasomal pathway for degradation. Methylamine co-treatment, however, did substantially rescue the phenotype suggesting a lysosomal mechanism for c-Kit degradation.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Consistent with this hypothesis, the degradation phenotype of <b>27</b> and <b>28</b> was rescued upon preincubation with methyl-β-cyclodextrin (MβCD), a known inhibitor of internalization of cell surface proteins.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> Interestingly, a multikinase inhibitor sorafenib (<b>13</b>) was shown to induce the downregulation of both wild-type and gatekeeper-T670I mutant c-Kit, while <b>27</b>, unable to potently bind the ATP-pocket of T670I, only downregulated wild-type c-Kit. These data indicate that ATP pocket-binding is crucial for imatinib-induced c-Kit internalization and the subsequent degradation process.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Downregulators of c-Kit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">BTK</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is a member of TEC family non-receptor tyrosine kinases that plays a critical role in B-lineage lymphoid cells. BTK was originally linked to X-linked agammaglobulinemia, an immune disorder where patients fail to produce mature B-cells as a result of BTK mutations.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> In addition, deregulation of BTK has been observed in many B-cell-driven malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM), for which ibrutinib demonstrated impressive efficacy in patients.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> As such, extensive efforts have been invested in inhibiting BTK for both cancers and immune diseases.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Ibrutinib (<b>29</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) is an irreversible BTK inhibitor and the first approved molecule targeting BTK. Similar to ibrutinib, QL47 (<b>30</b>), reported by Liu and Gray from University of Science and Technology of China and Harvard Medical School, respectively, is an irreversible inhibitor of BTK that forms a covalent bond at the Cys481 residue.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Compound <b>30</b> was 10-fold less potent than <b>29</b> in a biochemical BTK assay, albeit with better kinase selectivity. It was found that treatment with compound <b>30</b> (1 μM) degraded BTK by about 50% in the HEK293T cell line, and this result was confirmed in the Ramos cell line. The degradation may have been a result of covalent modification of BTK for two reasons. First, degradation of BTK was not observed in C481S BTK expressing cells. Second, irreversible inhibitors of BTK such as <b>29</b> and spebrutinib (AVL-292, <b>31</b>) at 1 μM also degraded BTK while a reversible inhibitor did not. As a comparison, it is worth noting that treatment with compound <b>29</b> at 10 μM or below in K562 and THP-1 cells, or at 3 μM or below in Ramos cells, did not induce BTK degradation.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compounds reported to promote loss of BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Chk1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15174" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15174" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Mechanistic studies from Massey et al. at Vernalis R&D Ltd. indicate that the potent and selective Chk1 inhibitor V1548411 (compound <b>32</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) induces degradation of Chk1.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Compound <b>32</b> is an ATP-competitive active site inhibitor that was identified through fragment based discovery utilizing structure-guided drug design.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Three lymphoma cell lines (Jurkat, Raji, and U937) were treated with <b>32</b> for 24 h, and a dose-dependent decrease of Chk1 protein levels was observed by Western blot. The loss of Chk1 was most pronounced in Raji cells where maximal degradation was observed between 250 and 500 nM concentrations of <b>32</b>. Minimal degradation of Chk1 was observed after 8 h of treatment, and 24 h was required to obtain maximal loss. Degradation of Chk1 was proven to be proteasome dependent since co-treatment of <b>32</b> and the proteasome inhibitor <b>2</b> resulted in less Chk1 degradation compared to <b>32</b> alone. It is not clear whether this is a general phenotype observed with all ATP-competitive Chk1 inhibitors as the authors did not examine additional molecules in this study.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chk1 downregulator V158411 (<b>32</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec13" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Degradation of Non-Kinase Proteins</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">While kinases represent a significant proportion of the proteins known to be degraded by the action of monomeric small molecules, a variety of non-kinase proteins have also been identified. Similar to kinases, degradation of these proteins may result in more pronounced pharmacology by inhibiting additional nonenzymatic functions as well as abrogating feedback/resistance mechanisms.</div></div><div id="sec14" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">cIAP</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">IAPs (inhibitor of apoptosis proteins) are important E3 ligases that are known to regulate cell survival and oncogenesis.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> Gene amplification and increased expression of IAPs have been observed in a number of tumor types.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> One of the major cellular functions of IAPs is to sequester, and thus inhibit, proapoptotic caspases.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> This led to a hypothesis that inhibition of caspase binding to IAPs would enhance the activity of apoptosis inducing agents and thus be therapeutically valuable in a host of cancers.</div><div class="NLM_p">The primary approach to targeting IAPs has been through peptidic and small-molecule mimicry of the N-terminal moiety (AVPI) of Smac (aka DIABLO).<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Depending on structural features, these compounds bind with variant selectivity to the BIR2 and BIR3 (BIR = baculoviral IAP repeat) domains of IAPs (IAP1/2, XIAP, etc.). A surprising finding was that small molecule binders to the BIR3 domain of IAPs promote rapid, proteasome- and ubiquitin-dependent loss of cIAP1 and cIAP2.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127,128)</a></div><div class="NLM_p">Peptidomimetic BIR3-binding IAP antagonists (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>a), represented by clinical molecules GDC-0152 (<b>33</b>)<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> and SM406 (<b>34</b>),<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> satisfy key interactions achieved with the AVPI Smac N-terminus. Common features include a proline or proline mimetic in P3, a hydrophobic arene in P4, and an <i>N</i>-methylalanine P1. Representative is the crystal structure of <b>33</b> in the BIR3 domain of cIAP1 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>b). Two adjacent carboxylates in the BIR3 domain (Asp306 and Glu311) interact with the amino terminus, while backbone interactions with Arg300 and Gly298 are satisfied by the three amides of <b>33</b>. There have been limited reports of cIAP antagonists that did not start via a peptidomimetic strategy. Most notable here is an elegant fragment-based approach that evolved to ASTX660 (<b>35</b>), a molecule with only a single amide and lacking the common <i>N</i>-methylalanine moiety.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (a) Structures of representative BIR3-binding IAP antagonists: GDC-0152 (<b>33</b>), SM-406 (<b>34</b>), ASTX660 (<b>35</b>), and MV1 (<b>36</b>). (b) Crystal structure of cIAP-BIR3 (gray) in complex with <b>33</b> (cyan), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UW4">3UW4</a>.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All strong BIR3-binding IAP antagonists induce the above-mentioned degradation phenotype. Mechanistic studies utilizing MV1 (<b>36</b>) are illustrative.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127,128)</a> Compound <b>36</b> binds potently to the BIR3 domains of cIAP1 and XIAP (<i>K</i><sub>D</sub> = 6 nM and 16 nM, respectively). In MDA-MB-231 cells, treatment with <b>36</b> (5 μM) results in nearly complete loss of cIAP1 and substantial loss of cIAP2 at 15 and 60 min, respectively, post-treatment by Western blot analysis. The nonbinding enantiomer of MV1 was also tested at 5 μM test concentration, and cIAP levels were comparable to a DMSO-treated control. The degradation phenotype observed with <b>36</b> was completely rescued by prior treatment with <b>2</b> (20 μM) demonstrating a mechanistic dependence on the proteasome. More potent cIAP BIR3 binders promote degradation at lower concentration; for example, treatment with <b>35</b> (0.22 nM) demonstrates 50% depletion of cIAP in MDA-MB-231 cells. Biochemical and structural studies<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> have suggested BIR3-binding antagonists destabilize a closed/autoinhibited form of cIAP, resulting in increased dimerization, autoubiquitylation, and proteasomal degradation (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). The RING domain of cIAP is essential for E3-ligase function and has been shown to be sequestered when cIAP is in a compact conformation created by interaction between the BIR3 and RING domains. This interaction is effectively competed by BIR3-binding antagonists leading to conformational changes that promote dimerization through the RING domain, E2–Ub binding, and autoubiquitylation. Interestingly, although <b>36</b> and most other IAP antagonists bind the BIR3 domain of XIAP, degradation of XIAP is not observed suggesting this mechanism is unique to the ability of cIAP1/2 to adopt this autoinhibited state.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Proposed mechanism for IAP-antagonist induced ubiquitylation of cIAP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec15" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">EZH2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Scientists from Shanghai Jiao Tong University School of Medicine and Shanghai Research Institute of Stomatology in 2017 reported that covalent inhibitors of enhancer of zeste homolog 2 (EZH2) <b>37</b> and <b>38</b> (GNA and GNA002, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) trigger EZH2 degradation both in vitro and in vivo.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> EZH2 is the catalytic subunit of the polycomb repressor complex 2 (PRC2) and is a suppressor of gene expression via trimethylation of histone H3 at the K27 residue (H3K27Me3).<a onclick="showRef(event, 'ref134 ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref134 ref135 ref136">(134−136)</a> Overexpression of and gain-of-function mutations in EZH2, which increase the suppression of downstream tumor suppressor targets, have been correlated with human malignancies, spurring interest in therapeutic EZH2 modulation.<a onclick="showRef(event, 'ref137 ref138 ref139 ref140 ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref137 ref138 ref139 ref140 ref141 ref142">(137−142)</a> Several EZH2 inhibitors have entered the clinic, including tazemetostat and CPI-1205.<a onclick="showRef(event, 'ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref143 ref144">(143,144)</a> However, in addition to its trimethyltransferase activity, PRC2-independent oncogenic roles for EZH2 as a transcriptional coactivator may not be addressed by existing enzymatic inhibitors.<a onclick="showRef(event, 'ref145 ref146 ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref145 ref146 ref147 ref148">(145−148)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures and activity of compounds <b>37</b> and <b>38</b> and structure of GSK126 (<b>39</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A library of 1215 natural compounds was screened against HN-6 cells for ability to reduce levels of EZH2, as measured by immunofluorescent tagging of an EZH2 antibody. The screen identified gambogenic acid (GNA, <b>37</b>) as a possible EZH2 degrader. Activity of <b>37</b> against cancer cell lines has previously been described<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149,150)</a> but without a full understanding of its molecular mechanism. Subsequently, affinity pull-down assays with biotinylated-<b>37</b> identified HSP90, tubulin, and EZH2 as potential interacting proteins of <b>37</b>. It was further demonstrated that biotinylated <b>37</b> did not associate with the close homolog EZH1 or two other SET domain containing methyl transferases, SET8 and ESET. Noting the Michael acceptor within the chemical structure of <b>37</b> and the potential for covalent interaction, systematic mutation of cysteine residues within EZH2 identified the mutation C688S in the SET domain as preventing association between biotinylated <b>37</b> and EZH2, consistent with a covalent interaction between C688 and <b>37</b>. The specificity for EZH2 over the highly homologous EZH1 is also consistent with the requirement for such a covalent interaction, since EZH1 contains a serine in the corresponding EZH2-C668 position.</div><div class="NLM_p">Several analogs were synthesized and <b>38</b> was identified as a more potent binder of EZH2 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Supporting a specific covalent interaction with EZH2, <b>38</b> was observed to decrease H3K27Me3 levels in UMSCC-12 cancer cells expressing wild-type EZH2 but not in cells expressing the C668S mutant. When compared to a previously reported inhibitor of EZH2 trimethylase activity, GSK126 (<b>39</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>),<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> compound <b>38</b> similarly reduced EZH2-mediated H3K27 trimethylation in Cal-27 cells but also led to a dose-dependent reduction in endogenous EZH2 protein abundance when cells were treated with <b>38</b> (0.5–2 μM) for 12–48 h. However, EZH2 mRNA levels were not significantly affected, suggesting the effect on protein levels may be due to post-transcriptional regulation. Treatment of Cal-27 cells with <b>38</b> was found to result in the dissociation of the functional PRC2 complex as well as a reduction in abundance of multiple PRC2 components (EZH2, SUZ12, and EED), with the specificity of the interaction again confirmed by showing a lack of effect in Cal-27 cells bearing the C668S EZH2 mutant. Additional specificity was demonstrated by confirming that levels of other methyl transferases (ESET and SET8) were not affected by <b>38</b> treatment.</div><div class="NLM_p">It was found that the <b>38</b>-induced decrease in EZH2 levels could be inhibited by proteasome inhibitor <b>2</b>, coinciding with an increase in ubiquitylation of EZH2. To elucidate the mechanism of induced ubiquitylation, a series of ubiquitin E3 ligases were depleted by siRNA, and depletion of endogenous COOH terminus of Hsp70-interacting protein (CHIP) was found to result in an increase in endogenous EZH2 levels. In vitro GST-pull-down assays showed that in the presence of <b>38</b>, CHIP interacts with the wild-type EZH2 SET domain but not the C668S mutant EZH2 SET domain. Additionally, depletion of endogenous CHIP using shRNA constructs both increased endogenous EZH2 levels and afforded resistance to <b>38</b>-induced EZH2 degradation in UMSCC-12 cells.</div><div class="NLM_p">Both <b>37</b> and <b>38</b> were found to inhibit the proliferation of a panel of cancer cell lines with IC<sub>50</sub> values between 0.2 and 6 μM. Treatment with <b>38</b> was found to induce apoptotic pathways, at least in part through increased expression of the proapoptotic protein Bim (an EZH2 downstream transcriptional target). Interestingly, <b>38</b> but not <b>39</b> inhibited Akt phosphorylation, with the effect again specific to wild-type cells and not those bearing the C668S EZH2 mutation, suggesting that the effects of EZH2 on Akt is independent of its PRC2 trimethylase activity. In vivo, <b>38</b> was found to suppress growth in a Cal-27 xenograft mouse model at 100 mg/kg po QD, with reduced EZH2 levels in xenograft tissues following treatment with <b>38</b> but not cisplatin.</div><div class="NLM_p last">It is currently not clear why <b>37</b> and <b>38</b> induce EZH2 degradation while other inhibitors do not. Compounds <b>37</b> and <b>38</b> are unique in that they appear to covalently modify EZH2, whereas other reported inhibitors are noncovalent. They are also structurally quite distinct from other reported EZH2 inhibitors, which share a common pyridone motif. The key cysteine residue responsible for covalent interaction with <b>37</b> and <b>38</b> is adjacent to the reported binding site for pyridone-containing inhibitors,<a onclick="showRef(event, 'ref144 ref152'); return false;" href="javascript:void(0);" class="ref ref144 ref152">(144,152)</a> but there are likely divergent protein contacts between the different chemotypes. Determining whether the covalent modification vs chemotype and specific binding site contacts is the key driver for PRC2 dissociation and CHIP-mediated ubiquitylation will require further study.</div></div><div id="sec16" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">MYCN/Aurora A</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Amplification and overexpression of MYCN (the gene encoding the transcriptional factor N-Myc) are oncogenic drivers in human neuroendocrine tumors.<a onclick="showRef(event, 'ref153 ref154 ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref153 ref154 ref155 ref156">(153−156)</a> While of therapeutic interest, using small molecules to directly target N-Myc by disrupting its protein–protein interactions has not yet led to successful drugs.<a onclick="showRef(event, 'ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref157 ref158">(157,158)</a> A potential new strategy for targeting N-Myc has emerged, avoiding the challenges of PPI drug discovery, by using small molecules to take advantage of N-Myc’s normal degradation pathway. During mitosis, after phosphorylation by CDK1 and GSK3, N-Myc is targeted by the ubiquitin ligase Fbxw7 for degradation via the ubiquitin proteasome pathway.<a onclick="showRef(event, 'ref156 ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref156 ref159 ref160">(156,159,160)</a> Aurora-A regulates the turnover of N-Myc protein by associating with N-Myc and preventing Fbxw7-directed ubiquitylation and degradation.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> This stabilization of N-Myc does not involve the catalytic activity of Aurora-A; however, the N-Myc/Aurora-A complex does involve the Aurora-A kinase domain, leading to the potential for Aurora-A inhibitors that affect the kinase domain conformation to disrupt this complex and influence N-Myc protein degradation.</div><div class="NLM_p">A study by Brockmann et al. in 2013 evaluated this potential mechanism for a class of inhibitors reported to distort the Aurora-A kinase domain.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Closely related ATP-competitive Aurora-A inhibitors MLN8054 (<b>40</b>) and MLN8237 (<b>41</b>) (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) are reported to induce a DFG-up conformation.<a onclick="showRef(event, 'ref163 ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref163 ref164 ref165">(163−165)</a> Upon treatment with either <b>40</b> or <b>41</b>, MYCN-amplified neuroblastoma cells (IMR-32 and IMR-5) showed a dose-dependent decrease in both autophosphorylation of Aurora-A and in N-Myc protein levels, while MYCN mRNA expression was not affected.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The loss of N-Myc could be prevented by co-treatment with a proteasome inhibitor (<b>2</b>) or by depletion of Fbxw7. Treatment of IMR-32 cells with either <b>40</b> or <b>41</b> decreased the amount of Aurora-A that co-precipitated with N-Myc, suggesting that a direct interaction between the two proteins is disrupted by the small molecules.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures and activity of selected Aurora-A inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Gustafson and co-workers at the University of California, San Francisco, in 2014 took this work a step further by designing Aurora-A inhibitors that were predicted to induce an even greater degree of conformational disruption.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> A set of inhibitors were synthesized based on either the diaminopyrimidine scaffold (VX-680, <b>42</b>) or a pyrazolopyrimidine scaffold, both known to inhibit Aurora-A, appending biphenyl urea and amide moieties predicted to stabilize alternate conformations of the kinase domain.<a onclick="showRef(event, 'ref166 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref166 ref167 ref168">(166−168)</a> The inhibitors were evaluated in Kelly MYCN-amplified neuroblastoma cells for their ability to decrease N-Myc protein levels as well as reduce the phosphorylation of histone H3 (p-H3), a substrate for Aurora-A. The most active molecule (CD532, <b>43</b>) resulted in nearly complete N-Myc loss with significant p-H3 loss, contrasting with its precursor <b>42</b> that ablated p-H3 but demonstrated only modest effects on N-Myc levels. Further evaluation of compounds <b>40</b>–<b>43</b> in SK-N-BE(2) cells indicated p-H3 suppression for all compounds and cytotoxicity EC<sub>50</sub> values for <b>41</b> and <b>43</b> of 40.89 and 223.2 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). Treatment with <b>42</b> did not result in loss of N-Myc, whereas modest to strong loss of N-Myc was observed upon treatment with <b>41</b> and <b>43</b>, respectively, with an EC<sub>50</sub> for N-Myc knockdown of ∼0.25 μM for <b>43</b>. The maximal cytotoxicity for <b>41</b> and <b>43</b> correlates with the extent of N-Myc knockdown and not the degree of direct Aurora-A inhibition, consistent with an N-Myc-dependent driver of cytotoxicity (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</div><div class="NLM_p">A crystal structure of <b>43</b> with Aurora-A confirmed the expected binding mode, with the diaminopyrimidine interacting with hinge residues.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Compared to an Aurora-A apo structure, the biphenyl urea of <b>43</b> induced a displacement of the β1 and β2 strands in the N-terminal domain, a rotation and shift that result in a 6.2 Å movement of the N-terminal domain relative to the C-terminal domain. Additionally, the kinase domain is stabilized in an inactive conformation, with the catalytic HRD aspartic acid displaced from a catalytically functional orientation. A comparison of Aurora-A crystal structures as either apo, <b>41</b>-bound, or <b>43</b>-bound indicated a correlation between the degree of conformational disruption and the relative induced loss of N-Myc protein.<a onclick="showRef(event, 'ref166 ref169'); return false;" href="javascript:void(0);" class="ref ref166 ref169">(166,169)</a></div><div class="NLM_p last">With efficacy hypothesized to be driven primarily by N-Myc loss, a panel of 169 genetically characterized tumor cell lines were screened against <b>43</b>. Sensitivity to <b>43</b> was found to correlate with a MYC signature, with MYCN-amplified cell lines displaying significantly increased susceptibility to <b>43</b>.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> In vivo, treatment with compound <b>40</b> or <b>41</b> reduced N-Myc levels in TH-MYCN neuroblastoma tumors in mice and increased survival relative to vehicle-treated mice.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Likewise, <b>43</b> reduced N-Myc protein levels in a neuroblastoma model (MYCN-amplified SMS-KCN xenografts) after 2 days and reduced N-Myc protein levels, reduced tumor burden, and extended survival in mice with subcutaneous SHH-subtype medulloblastoma.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> These studies support the use of small-molecule Aurora-A inhibitors to target N-Myc by inducing a conformational change to disrupt N-Myc binding and effect the degradation of N-Myc.</div></div><div id="sec17" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Bcl6</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bcl6 is a transcription factor required for germinal centers (GCs) within lymph nodes in which B cells mature and are selected for expression of high-affinity antibodies. Aberrant Bcl6 regulation, including elevated expression, activating mutations, and translocations, leads to lymphoid malignancies such as diffuse large B cell lymphoma (DLBCL). Even though Bcl6 functions as a transcriptional repressor that binds DNA and interacts with other transcriptional co-repressors as part of the BTB/POZ complex, it was hypothesized that small molecules could be discovered that compete with binding of co-repressors and therefore lead to pharmacological inhibition and disease modulation.</div><div class="NLM_p">Scientists at Boehringer Ingelheim and Forma screened a library of 1.7 million compounds, and a pyrimidine hit with moderate potency (IC<sub>50</sub> = 18 μM) was identified using a fluorescence polarization assay.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Structure-based design led to rapid progress resulting in compounds such as <b>44</b> and <b>45</b> with low single digit nM IC<sub>50</sub> values (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). A subset of compounds exemplified by <b>45</b>, however, tended to show atypical behavior in causing Bcl6 protein to precipitate in biophysical assays, even though cocrystal structures were obtained and differential scanning fluorimetry (DSF) showed similar stabilization of the Bcl6 complex as regular inhibitors represented by <b>44</b>. Concluding that this subset of compounds was not simply denaturing the protein, the authors further examined their interaction with Bcl6 through hydrogen–deuterium exchange mass spectrometry (HDX MS). It was noteworthy that compounds that induced degradation, such as <b>45</b>, induced significantly more protection from HDX in areas farther removed than would have been expected based on their structures with Bcl6.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0009.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures and activity of compounds <b>44</b> and <b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">When tested in cells, this subset of compounds was shown to reduce Bcl6 protein by ∼50% in 5 min and over 90% in 2 h. This effect was demonstrated to be proteasome dependent, as addition of a proteasome inhibitor (<b>2</b>) resulted in blocking of Bcl6 degradation, with concomitant appearance of slower moving bands on Western blot, suggestive of ubiquitylation of Bcl6. Compounds <b>44</b> and <b>45</b> demonstrated a marked difference in ability to regulate downstream target genes which the authors attributed to the degrader MOA of compound <b>45</b>. Treatment of SU-DHL-4 cells with degrader compound <b>45</b> induced the expression of over 80 genes, compared to only 17 for <b>44</b>. The most significantly induced genes included many known Bcl6-regulated genes such as ATM, PRDM1, PTPN6, CD69, IRF4, and DUSP5. Although there was good overlap for genes upregulated by both compounds, the amplitude of upregulation was consistently higher for <b>45</b>. As far as growth inhibition is concerned, degraders such as <b>45</b> were consistently more potent than molecules that did not promote Bcl6 degradation such as <b>44</b> (IC<sub>50</sub> of 10 vs 1000 nM); much higher drug concentrations were required to observe antiproliferative effects for compounds that lacked the degradation mechanism.</div></div><div id="sec18" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Androgen Receptor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Prostate cancer (PC) is the second most common cancer in men and is estimated to account for 225 000 new cases in North America in 2015 alone. Fortunately, the majority (∼80%) of new cases are diagnosed as localized diseases in early stages, for which a good survival rate is still achievable via radiation therapy and surgery. However, ∼20% of PCs are either metastatic or castration-resistant with poor prognosis, and as a result, significant unmet medical need remains. Androgen and androgen receptor (AR) play a critical role in the initiation and progression of PC, and current standard of treatment rely on either blocking the biosynthesis of androgen (CYP17 inhibitors) or antagonists that compete with androgen for binding with AR. However, the disease frequently progresses and becomes drug-resistant. Several possible resistance mechanisms have been reported, including AR overexpression, AR mutations that either reduce the affinity of antagonists or render them agonists, and AR splice variants that completely lack the ligand binding domain (LBD). It is hypothesized that some of these resistance mechanisms may be avoided by compounds that can induce the degradation of AR.</div><div class="NLM_p">In 2013 and 2016, Njar and co-workers reported a series of steroid-derived compounds that promoted degradation of AR.<a onclick="showRef(event, 'ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref171 ref172">(171,172)</a> The starting point of their effort was <b>46</b> (galeterone), a compound that reached phase III clinical trials with its own unique dual mechanisms of being an AR antagonist and CYP17 inhibitor (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). Galeterone (<b>46</b>) is noted by Njar et al. to be a modest downregulator of AR in LNCap (full-length AR) and CWR22Rv1 (truncated AR) prostate lines when tested at 15 μM for 24 h. Through systematic SAR studies, it was noted that the C3-modifications, as in carbamate <b>47</b> and ether <b>48</b>, resulted in more complete degradation phenotypes while minimizing CYP17 inhibition. For example, treatment with compound <b>48</b> (15 μM) completely degrades AR in LNCap and CWR22Rv1 lines after 24 h and only weakly inhibits CYP17 (IC<sub>50</sub> > 15 μM). It is interesting to note that compounds that degrade AR had 2.4- to 18-fold greater antiproliferative effects in the CWR22Rv1 line compared to <b>46</b>. The authors also noted that strong binding affinity to the LBD was not always observed with these compounds and not directly correlative with antiproliferative effects or level of AR degradation. Therefore, it is not yet clear at this time whether the observed AR degradation by such compounds is a result of AR binding or through other mechanisms.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0010.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Steroidal antagonists and degraders of androgen receptor (AR).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another set of AR degraders was discovered through rational design based on modeling of the FDA-approved AR-antagonist enzalutamide (<b>49</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Compounds such as UT-155 (<b>50</b>) and UT-69 (<b>51</b>) emerged as promising leads, but further characterization of the two compounds showed divergent behavior: while <b>51</b> inhibited the R1881-dependent transcriptional activity of AR response genes such as NDRG1 and MT2A at 1 and 2 h, <b>50</b> failed to do so at such time points. This discrepancy was interpreted as <b>51</b> eliciting its function through competitive antagonism while <b>50</b> relies on a degradation mechanism. Neither compound altered expression of AR at the mRNA level, and both compounds were selective against a panel of other nuclear hormone receptors. The investigators went on to show that AR degradation by <b>50</b> is proteosome dependent, as proteasome inhibitor <b>4</b> rescued AR degradation. Therefore, the evidence so far suggests that observed AR degradation is likely mediated through binding to AR and not through gene downregulation. Strikingly, <b>50</b> could also induce AR degradation in 22RV1 cells which express the truncated and clinically relevant AR-V7 and a synthetic variant lacking LBD. It is interesting to note that compound <b>50</b> was shown to bind to the AF-1 domain by SPR, with a measured <i>K</i><sub>d</sub> of 1.3 μM, whereas <b>49</b> failed to show any sign of binding. This evidence was further confirmed by NMR STD using the AF-1 domain of AR, while a negative control (<b>49</b>) failed to show any sign of binding. When the transcriptome was examined in LNCaP cells treated with either <b>50</b> or enzalutamide for 2 days, <b>50</b> altered the expression profiles of ∼3000 genes while <b>49</b> altered 927. Although there were ∼300 genes that overlapped between the two compounds, <b>50</b> altered gene expression more robustly: the highest changes after compound <b>50</b> treatment were between 350- and 550-fold, compared with a maximal 22-fold observed for the cells treated with compound <b>49</b>. This difference was considered an important contributing factor to the observed in vitro and in vivo potency between the two compounds and potentially speaks to a differentiating feature that is a result of a degrader MOA. More recently, the authors published a comprehensive account of their SAR exploration, with additional in vitro/in vivo data.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> First, the authors noted that the potency measured by AR binding (<i>K</i><sub>i</sub>) or AR antagonism (transactivation IC<sub>50</sub>) for different compounds correlated poorly with their selective androgen receptor degrader (SARD) activity. Good correlation was noted between degradation of both full length and a splice variant. This seems consistent with the above data suggesting binding to the AF-1 domain which is shared between the AR WT and splice variant.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0011.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Nonsteroidal antagonists and degraders of androgen receptor (AR).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In silico screening by Cherkasov and colleagues led to a series of 10-benzylidene-10<i>H</i>-anthracen-9-ones, such as compound <b>52</b> (VPC-3045, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), that promote degradation of AR across multiple PC cell lines despite their weak antagonistic activity against AR.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> The compounds were confirmed to reduce AR protein level in a time- and dose-dependent manner through Western blot, with no change in total AR mRNA in response to compound treatment. The investigators went on to show that these analogs do not bind to the LBD and do not inhibit AR translocation to the nucleus in cells. A cycloheximide (<b>1</b>) co-treatment experiment indicated the compounds promote AR-degradation as opposed to influencing the rate of AR synthesis. Proteasome dependence of the degradation was not reported.</div><div class="NLM_p last">Scientists at AstraZeneca reported discovery of a series of AR degraders starting from a 100K compound directed high-throughput screening set (including bias toward a 2D-pharmacophore).<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176,177)</a> Early lead compound <b>53</b> (ARD1, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) did not display detectable displacement of ligand-binding to the LBD of AR by FRET but was found to bind to the full-length AR, albeit weakly (66% inhibition at 10 μM). The authors hypothesize this weak binding interaction is sufficient to promote modulation of AR levels. Further optimization led to <b>54</b> (AZD3514) which advanced into phase 1 clinical trials.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Binding of compound <b>54</b> to AR is modest (<i>K</i><sub>i</sub> ∼ 5 μM for LBD, <i>K</i><sub>i</sub> = 2.2 μM for full-length) and promotes downregulation of AR in LNCaP cells with an IC<sub>50</sub> = 1.78 μM. Further characterization of the mechanism of <b>54</b><a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> indicates consistent in vitro and in vivo degradation of AR. Similar to enzalutamide (<b>49</b>), compound <b>54</b> robustly inhibits translocation of AR to the nucleus induced by 30 min DHT treatment. Isotopic labeling and pulse-chase experimentation indicate that <b>54</b> decreases the rate of synthesis of AR in the absence or presence of DHT. The mechanism of this effect is not well understood and does not appear driven purely by influences on AR transcription.</div></div><div id="sec19" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Estrogen Receptor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Estrogen receptor-positive (ER+) is the most prevalent subtype of breast cancer (BC) accounting for ∼70% of all diagnoses. Estrogen receptor α (ERα) has been a well-validated target for treating BC, going back to over half a century from the discovery of tamoxifen, a selective estrogen receptor modulator (SERM). More recently, there has been a resurgence of interest in targeting ER for BC. In 2013, a number of groups independently reported the discovery of <i>ESR1</i> mutations in 20–30% of relapsed BC patients, providing a scientific rationale for drug resistance.<a onclick="showRef(event, 'ref180 ref181 ref182 ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref180 ref181 ref182 ref183 ref184">(180−184)</a></div><div class="NLM_p">Among all targets discussed in this Perspective, ERα has probably received the most effort toward generation of orally bioavailable monomeric degrader compounds, and a recent highlight article features work in this area.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Fulvestrant (<b>55</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), an approved and commonly utilized drug, was initially designed as a pure ER antagonist. It was later found to also induce ER degradation in vitro and in vivo. Compound <b>55</b> is thought to bind to monomeric ER and prevent dimerization, nuclear translocation, and promotes subsequent degradation.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Clinically administered <b>55</b> requires intramuscular administration in a proprietary formulation of castor oil and alcohols. ER degradation with <b>55</b> in the clinic is not typically complete,<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> likely due to its unique physicochemical and pharmacokinetic properties, but provides proof-of-concept efficacy for selective estrogen receptor degradation (SERD) and an impetus for discovery of oral agents. Minimal work has been published related to oral derivatives of <b>55</b>; however boronic acid <b>56</b> (ZB716), reported by Wang and coauthors, was shown to deplete ERα with similar efficacy/potency to <b>55</b> and is bioavailable after PO dosing in mice.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0013.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Steroidal antagonists and degraders of ERα.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Work on nonsteroidal SERDs/SERMs as potential oral therapies has advanced significantly, and several therapies have entered and remain in clinical trials. A selection of published ERα degraders is shown in <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0014.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Representative nonsteroidal antagonists and degraders of ERα.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>57</b> was discovered using known ERα agonist cyclofenil as a starting point.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Katzenellenbogen and co-workers employed systematic SAR to move from agonist to antagonist activity as well as drive toward an ERα-degrading phenotype. The ERα DC<sub>50</sub> in MCF7 cells for compound <b>57</b> is 0.53 nM and <i>D</i><sub>max</sub> = 70%. They reported a strong correlation between the percentage of ERα remaining and the maximum percentage of antiproliferative activity of compounds. In other words, compounds that strongly degraded ERα were also the most antiproliferative. They hypothesized side-chain composition (in this case an acrylic amide) to be important for promoting antagonism over agonism as well as the degradation mechanism of action. A group at Novartis disclosed tetrahydroisoquinoline <b>58</b> as a potent (DC<sub>50</sub> = 0.9 nM) and nearly complete (<i>D</i><sub>max</sub> = 87%) degrader of ERα in MCF7 cells.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Key within the degradation SAR disclosed was the installation of the acrylic acid moiety. Following crystal structure analysis they hypothesized that displacement of helix-12 contributes to minimizing coactivator binding leading to instability of ERα and degradation. A scaffold-hop from clinical compound AZD9496 (<b>59</b>)<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> delivered another degrader/antagonist in fused indazole <b>60</b>,<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> both of which were claimed to be ERα degraders. Compound <b>60</b> has a drug-like lipophilicity (log <i>D</i><sub>7.4</sub> = 2.6) and binds and degrades ERα at low, sub-nM concentrations. Scientists at Novartis recently reported SAR that led to development candidate LSZ102 (<b>61</b>).<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> This compound is currently in phase 1 clinical trials. They utilized the benzothiophene core of arzoxifene as a starting point, and key was the installation of an acrylic acid substituent to achieve potent antagonist/degrader phenotypes as well as suitable solubility properties. Compound <b>61</b> is a potent (DC<sub>50</sub> = 0.2 nM) and efficient (<i>D</i><sub>max</sub> = 83%) degrader of ERα. Degradation was shown to be proteasome dependent as treatment with MG132 (<b>2</b>) rescued loss of ERα. Interestingly, compound <b>61</b> is one of the few reported compounds that display a more potent degradation phenotype than fulvestrant in MCF7 cells. This degradation phenotype was also observed in tumor xenograft studies. A crystal structure of compound <b>61</b> in the ligand binding domain of ERα is shown in <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a> and is illustrative of this class of ERα antagonists/degraders. The ligand is bound in a highly lipophilic pocket, with the phenol group mimicking the A-ring phenol of estradiol, making critical H-bonding interactions with Arg394 and Glu353. Scientists at Seragon discovered selective antagonist/degrader GDC-0810 (ARN-810, <b>62</b>).<a onclick="showRef(event, 'ref194 ref195'); return false;" href="javascript:void(0);" class="ref ref194 ref195">(194,195)</a> Treatment of MCF7 cells with compound <b>62</b> resulted in potent and robust degradation of ERα (DC<sub>50</sub> = 0.7 nM, <i>D</i><sub>max</sub> = 90%). In a follow-on study compound <b>62</b> was further characterized in a series of in vitro and in vivo experiments.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> A time course study indicated maximal degradation of ERα at 4 h post-treatment. Degradation of ERα was rescued by pretreatment with proteasome inhibitor <b>2</b>. On the basis of a broad peptide interaction assay, compound <b>62</b> was hypothesized to create a distinct conformation of ERα compared to simple antagonists (i.e., 4-hydroxy-tamoxifen). Besides acrylic acid, ERα degraders with a basic amino group were also reported. In 2018, Fanning and coauthors published their discovery of a pure antiestrogen and SERD <b>63</b> (OP-1074), through careful profiling of stereo- and regioisomers of methyl-substituted pyrrolidines.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> It is noteworthy that among the various stereoisomers, only <b>63</b> exhibited the desired pure antiestrogen/SERD profiles while the rest behaved as SERMs. The distinct profile of <b>63</b> was rationalized as disrupting the conformation of helix-12, by multiple high-resolution X-ray cocrystal structures, as well as assays that measured mobility of helix-12. Seragon scientists also published their medicinal chemistry optimization effort that led to the discovery of GDC-0927 (<b>64</b>).<a onclick="showRef(event, 'ref197 ref198'); return false;" href="javascript:void(0);" class="ref ref197 ref198">(197,198)</a> Starting also with a chromene core, they systematically optimized ERα degradation with a basic amino side chain. This effort eventually led to the identification of <b>64</b> with a fluoromethyl azetidine group which showed inverse agonist effect on uterine wet weight assay and robust efficacy in a MCF7 tamoxifen-resistant xenograft model. Coincidentally, a series of ERα degraders with a basic amino side chain was also reported by researchers at Sanofi.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> SAR optimization, particularly for the purpose of lowering lipophilicity and improving metabolic stability, led them to replace a phenol with a carboxylic acid, eventually resulting in identification of their clinical candidate SAR439859 (<b>65</b>). Another noteworthy study shedding light on mechanism of actions for ERα degraders was recently published.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Through extensive profiling of a panel of reported SERM/SERDs and a structurally similar nondegrader to GDC-0927, the authors discovered that ER loss might not be the primary driver of distinctive phenotype between SERD vs SERM. Instead, ligand-induced ER intranuclear immobilization might be the underlying mechanism responsible for their difference in cells.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0015.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. X-ray structure of LSZ102 (cyan, <b>61</b>) bound to the LBD of ERα (gray) [PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F">6B0F</a>]. The ligand is tightly enclosed by a series of α helices.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec20" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Ligase-Binding Neosubstrate Recruiters</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">An exciting mechanism for degrading target proteins of interest is to rely on inducing neosubstrate recognition by E3 ubiquitin ligases. In these cases, binding of a monomeric molecule to an E3 ligase results in enhanced affinity to substrates that are subsequently ubiquitylated by the E3. Where structural characterization has been possible, it has been shown that the monomeric molecule promotes conformational changes that enhance E3 ligase–substrate interactions at the binding site of the monomeric molecule. This mechanism has been exploited for a number of different classes of proteins, and it is expected to have broad applicability.<a onclick="showRef(event, 'ref1 ref201'); return false;" href="javascript:void(0);" class="ref ref1 ref201">(1,201)</a></div></div><div id="sec21" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">CRL4<sup>CRBN</sup></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cereblon (CRBN) is the substrate receptor component of the cullin-4 RING ligase (CRL4) complex, Cul4-Rbx1-DDB1-CRBN, a multisubunit E3 ligase complex known collectively as CRL4<sup>CRBN</sup> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). CRBN has recently been identified as the protein target for thalidomide (<b>66</b>, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Prior to the identification of CRBN as the binding target, <b>66</b> was observed to have pleiotropic effects in multiple cell types, including the inhibition of TNF-α release in lipopolysaccharide (LPS) stimulated hPBMCs,<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> the stimulation of IL-2 and IFN-γ release in T cells,<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> and antiangiogenic activity.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> In an effort to identify more potent effectors of these immunomodulatory properties, pomalidomide (<b>67</b>) and lenalidomide (<b>68</b>) were identified (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>)<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> and as a group are known as immunomodulatory drugs, or IMiDs (compounds <b>66</b>–<b>68</b>).</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0016.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. (a) Assembled subunits that make up the active E3 ligase CRL4<sup>CRBN</sup>; CRBN = cereblon, DDB1 = DNA damage-binding protein 1, CUL4A = Cullin 4A, RBX1 = RING box protein 1, E2/Ub = ubiquitin charged ubiquitin-conjugating enzyme. (b) Structures of the original immunomodulatory drugs (“IMiDs”): thalidomide (<b>66</b>), pomalidomide (<b>67</b>), and lenalidomide (<b>68</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The discovery of CRBN as the primary binding target for IMiDs prompted a flurry of discoveries elucidating the mechanism of action of these molecules. Most surprisingly, these studies demonstrated that, among a number of other mechanisms contributing to observed phenotypes, IMiD molecules induce recruitment of neosubstrates to CRBN. In two landmark studies, it was demonstrated that IMiD-induced, CRBN-dependent ubiquitylation and degradation of lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos) resulted in downregulation of interferon regulatory factor 4 (IRF4) and MYC, as well as upregulation of IL-2 production in T cells.<a onclick="showRef(event, 'ref207 ref208'); return false;" href="javascript:void(0);" class="ref ref207 ref208">(207,208)</a> This pivotal finding marked the discovery of a novel mechanism of drug action, in which non-native substrates are recruited to an E3 ligase by small molecule binding. IMiDs appear to bind to the thalidomide binding domain (TBD) of CRBN to change the surface of the protein, resulting in a neomorphic surface with different recognition of substrates varying with the structure of the small molecule (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0017.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (a) Simplified model of IMiD induced degradation mechanism of action. Additional CRL4<sup>CRBN</sup> subunits are omitted for clarity. (b) Crystal structure of <b>68</b> bound to human CRBN-DDB1 highlighting key interactions with the thalidomide-binding-domain (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TZ4">4TZ4</a>). (c) Crystal structure of the CRBN (cyan)–<b>68</b> (orange)–CK1α (magenta) complex (DDB1 ommitted for clarity) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FQD">5FQD</a>). (d) Key interactions between CRBN surface residues and CK1α β-hairpin loop residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The TBD of CRBN has an arrangement of three tryptophan residues (Trp380, Trp386, and Trp400), referred to as the “tri-Trp pocket” as can be seen in the structure of <b>68</b> bound to human CRBN (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>b).<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> The glutarimide ring anchors the molecule with three hydrogen bonds to residues His378 (backbone C═O and side chain N–H) and Trp380 (backbone N–H). The isoindolinone moiety is exposed on the surface of the protein with no hydrogen-bonding interactions being made with the carbonyl oxygen or aniline NH<sub>2</sub>. Interestingly, the surface conformation of human CRBN near the TBD in the β-sheet region changes significantly when bound to <b>68</b> in comparison to <b>67</b> and <b>66</b> (not shown). These relatively minor chemical differences appear to have a major influence on protein conformation, suggesting a possible mechanism for the recruitment of different substrates based on protein surface changes.</div><div class="NLM_p">Casein kinase 1α (CK1α) is one of the degraded neosubstrates induced by <b>68</b>.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> Quite notably, a ternary complex crystal structure of CK1α/CRBN/<b>68</b> was recently solved (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FQD">5FQD</a>, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>c,d). CK1α appears to bind the combined surface of CRBN-<b>68</b> via a β-hairpin loop, which has the effect of shifting <b>68</b> 2.5 Å closer to parts of the CRBN backbone.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> The authors rationalize that this shift would not be accommodated by ligands with the phthalimide carbonyl of IMiDs such as <b>66</b> which may explain some of the different substrate specificity observed for <b>68</b>.</div><div class="NLM_p">Scientists at Celgene have expanded on this concept to discover a suite of neosubstrate inducing CRBN binders (<b>69</b>–<b>72</b>, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>) as well as strongly contributing to the mechanistic understanding of their novel MOAs.<a onclick="showRef(event, 'ref212 ref213 ref214'); return false;" href="javascript:void(0);" class="ref ref212 ref213 ref214">(212−214)</a> It is exciting to see emerging structural hypotheses of features that dictate likelihood of a substrate being recruited via this mechanism. The structural variation on the IMiD ligands influences experimentally determined CRBN affinity, neosubstrate identity, and neosubstrate/CRBN/IMiD ternary complex binding constants. In an example, CC-885 (<b>71</b>), an analog of <b>68</b> featuring a chloroaryl urea functionality extending from the 5-position (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>), exhibits CRBN-dependent degradation of GSPT1, a translation termination factor.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> This novel mechanism of action confers subnanomolar potency to this compound in patient-derived AML lines.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0018.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Later generation IMiDs from scientists at Celgene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec22" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">CUL4<sup>DCAF15</sup></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A degradation mechanism was recently disclosed by a group from UTSWMC for a class of clinically evaluated sulfonamide anticancer agents.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> Indisulam (<b>73</b>, E7070) was discovered by scientists at Esai by phenotypic optimization of antiproliferative activity in several cancer cell lines (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>).<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> The mechanism of this antiproliferative effect was left unvalidated until the 2017 study by Han et al.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> The delineation of the mechanism started with a forward genetic screen looking for rescue of the antiproliferative effect of <b>73</b>. This screen identified that select mutations in RBM39 rescued the <b>73</b> phenotype. The authors then found that <b>73</b>, and also other clinically tested sulfonamides CQS (chloroquinoxaline sulfonamide, <b>74</b>) and tasisulam (<b>75</b>), facilitates the recruitment of RBM39 to the CUL4-DCAF15 E3 ligase complex inducing ubiquitylation and proteasomal degradation of RBM39.<a onclick="showRef(event, 'ref215 ref216'); return false;" href="javascript:void(0);" class="ref ref215 ref216">(215,216)</a> Treatment with <b>73</b> (2 μM, 8 h) induces nearly complete degradation of RBM39 in HCT-116 cells that is rescued by proteasome inhibition (<b>4</b>) as well as rescued by the NEDD8 inhibitor MLN4924. Notably, cancer cell line sensitivity to <b>73</b> was highly correlated to DCAF15 expression. RBM39 is a protein that associates with pre-mRNA, and the authors hypothesized loss of this key protein results in dysregulation of splicing and the observed antiproliferative phenotype. Thus, splicing inhibitor sulfonamides (“SPLAMs”) represents yet another class of neosubstrate inducing ligase binders (similar to the IMiD examples above). Recently, a structural analysis of neosubstrate recruitment has been presented based on cocrystal structures.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0019.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures of splicing inhibitor sulfonamides (“SPLAMs”).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec23" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusion/Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57023" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57023" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The authors of this Perspective have all been part of Genentech teams that have discovered and advanced monomeric targeted protein degraders to clinical trials (targets = ERα, cIAP, PI3Kα). Our perspective is 3-fold: (1) we believe promoting loss of a target, in many cases, can be advantageous compared to standard mechanisms of inhibition; (2) monovalent or induced bivalent mechanisms of protein degradation have been observed for a diverse array of targets (i.e., kinases, transcription factors, RNA binding proteins, nuclear hormone receptors, E3-ligases, translation termination factors); (3) project scientists should proactively look for degradation phenotypes of nonchimeric small molecules, from screening through hit triage and lead optimization in addition to considering an engineered heterodimeric molecule strategy. Our hypothesis is that many of these monovalent molecules modulate the native mechanisms of protein homeostasis for their given targets. A better understanding of native mechanisms of turnover for a given target could be enabling. However, it is highly likely nonchimeric small molecules that promote degradation will not be possible for all target proteins of interest. A priori, it is difficult to know which targets can succumb to degradation by this approach; a variety of mechanisms have been observed, and so a high degree of empiricism will be necessary. It is also likely in many cases that even after empirical discovery of a small molecule degrader, rationalization of structural features contributing to a degradation MOA will not be well understood. For example, not all estrogen-competitive ERα binders promote strong degradation of ERα. Structural rationalization of features that contribute to ERα degradation is under debate. Yet, monitoring the degradation phenotype during optimization has led to the advance of several ERα degraders to clinical trials. We believe the challenges and uncertainties surrounding discovery and rational design of these small molecules are significant compared to the rational engineering and discovery of heterodimeric molecules. However, these risks are offset by the more desirable drug-like properties of monomeric small molecule degraders relative to engineered heterodimeric ones.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> For illustrative purposes we compare the calculated physicochemical properties of a large number of heterodimeric molecules disclosed in the literature to a representative set of monomeric ones presented in this Perspective (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). Heterodimeric compounds directed at Cul4<sup>CRBN</sup> (<i>n</i> = 488, <b>66</b>, <b>67</b> and <b>68</b> based) and Cul2<sup>VHL</sup> (<i>n</i> = 344, based on VH032) and representative monomeric degraders (<i>n</i> = 39) are compared. The set of heterodimeric compounds was generated by a combination of keyword and substructure searching in CAS.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> Although there are limitations in drawing specific conclusions from this analysis given different stages of molecules in all classes (early tool through clinically approved therapy), bulk property trends are evident that are known to correlate with drug-like properties. Another caveat to this analysis is that calculations for TPSA and lipophilicity for these beyond rule-of-5 heterodimeric molecules may be limited due to conformational flexibility that could alter experimental polarity. Nevertheless, the heterodimeric compounds trend toward significantly higher molecular weight, TPSA, and number of rotatable bonds, properties that typically dictate low passive permeability and low oral bioavailability for small molecules.<a onclick="showRef(event, 'ref4 ref219'); return false;" href="javascript:void(0);" class="ref ref4 ref219">(4,219)</a> If nonoral routes of administration are pursued (iv or sc), acceptability of dosing frequency for a given patient population becomes a more pressing consideration. Heterodimeric molecules also trend toward higher lipophilicity (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), a property highly correlated with decreased aqueous solubility and high turnover by oxidative metabolism among other attributes. Low permeability and low solubility space could present delivery challenges regardless of route of administration. Selected literature examples of heterodimeric<a onclick="showRef(event, 'ref220 ref221 ref222 ref223'); return false;" href="javascript:void(0);" class="ref ref220 ref221 ref222 ref223">(220−223)</a> and monomeric targeted protein degraders from this manuscript directed at the same target highlight these physicochemical property differences; <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a> displays structures of degraders of ERα, AR, and Bcl6.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0020.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Calculated properties of CRBN-directed heterodimeric compounds (<i>n</i> = 488), VHL-directed heterodimeric compounds (<i>n</i> = 344), and representative monomeric compounds from this Perspective (<i>n</i> = 39, 1–3 per target protein discussed): (a) molecular weight comparison; (b) number of rotatable bonds comparison, prediction of rotatable bonds using the standard methods implemented in the Open Eye software package; (c) TPSA comparison, showing calculated topological polar surface area estimated using the standard methods implemented in the Open Eye software package;<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> (d) calculated log <i>D</i> at pH = 7.4, showing the logarithm of the distribution coefficient calculated using MoKa (Molecular Discovery, version 2.6.4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0021.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Representative AR, ERα, and Bcl6 targeted modalities that promote degradation. Calculations for properties were done using the same software as in <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is recognized that rule-of-5 properties may not be the best way to evaluate heterodimeric targeted protein degraders. Their catalytic mechanism of action, theoretically necessitating only transient target and ligase binding, may not require high drug exposures at their site of action. In contrast, depending on mechanism, the above monomeric small molecule targeted protein degraders may require more complete and sustained target occupancy to promote loss of the target protein. It is interesting to note that some of the monomeric molecules described above need relatively high concentration to promote thorough degradation of their target proteins, while others do not. It should also be noted that a number of heterodimeric compounds in the above analysis have properties more consistent with traditional drug-like chemical space, particularly those directed at co-opting Crl4<sup>CRBN</sup>. This strategy may be most successful when target ligands can be incorporated, and linkers can be optimized, which result in heterodimeric molecules nearer to this property space.</div><div class="NLM_p last">We are hopeful this Perspective will continue to encourage practicing drug discovery scientists to consider multiple paths to pursuing targeted protein degradation. In addition to rationally engineered heterodimeric targeted protein degraders, significant opportunities exist for the discovery of smaller, potentially more drug-like compounds that induce target protein degradation. We very much look forward to emerging discoveries in this area and anticipate continued broad clinical impact of these approaches.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes.si"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00093" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00093?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00093</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Spatial data file as indicated in ref <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00093/suppl_file/jm0c00093_si_001.sdf" class="ext-link">SDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00093/suppl_file/jm0c00093_si_001.sdf">jm0c00093_si_001.sdf (5.22 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00093" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven T. Staben</span> - <span class="hlFld-Affiliation affiliation">Department
of Discovery Chemistry and , Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6137-6517" title="Orcid link">http://orcid.org/0000-0002-6137-6517</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6112150417040f15122106040f044f020e0c"><span class="__cf_email__" data-cfemail="c7b4b3a2b1a2a9b3b487a0a2a9a2e9a4a8aa">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily J. Hanan</span> - <span class="hlFld-Affiliation affiliation">Department
of Discovery Chemistry and , Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Liang</span> - <span class="hlFld-Affiliation affiliation">Department
of Discovery Chemistry and , Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaojing Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Discovery Chemistry and , Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Blake</span> - <span class="hlFld-Affiliation affiliation">Department Biochemical and Cellular
Pharmacology and , Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Blaquiere</span> - <span class="hlFld-Affiliation affiliation">Department
of Discovery Chemistry and , Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        N.B.: Novartis, Inc., 5300 Chiron Way, Emeryville, CA 94608</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Employed by Genentech, stock owner in Roche.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Emily J. Hanan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=BIO-d7e2520-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Emily J. Hanan</b> received her Bachelor’s degree in Chemistry from Stanford University in 2002. She began her industrial career at Sunesis Pharmaceuticals as a medicinal chemist where she contributed to multiple oncology and immunology programs. In 2008 Emily joined the Discovery Chemistry group at Genentech where she has contributed to multiple therapeutic programs across oncology, neurodegeneration, and infectious disease, including the PI3Kα inhibitor/degrader GDC-0077. Emily is currently a scientist and project team leader focusing on oncology.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Jun Liang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=BIO-d7e2525-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jun Liang</b> graduated from Harvard University with a Ph.D. degree in 2000, after finishing the total synthesis of neocarzinostatin chromophore in the laboratory of Professor Andrew G. Myers. Subsequently, he joined Merck Research Lab at Rahway, NJ, and later moved to Merck, San Diego. Since 2005, he has been with Genentech where he worked on many target classes spanning various therapeutic areas. His current interest focuses on monovalent degraders and targeting RNAs.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Xiaojing Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=BIO-d7e2530-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiaojing Wang</b> received her B.S. degree from Peking University and her Ph.D. degree in the lab of Prof. Alan R. Katritzky from University of Florida and was a postdoctoral fellow at RTI International. She has pursued drug discovery of various disease indications at ISIS (now Ionis) and Scios (a Johnson and Johnson company). Currently at Genentech, Xiaojing is a principal scientist and a project team leader. She has led multidisciplinary teams into nominating several early development candidates, some of which are in active clinical trials. Xiaojing serves as a member of the steering committee and editorial board of Chemistry in Cancer Research Working Group of AACR.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Robert A. Blake</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=BIO-d7e2535-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Robert A. Blake</b> completed his doctoral studies in the Department of Pharmacology at Oxford University in 1995. He carried out postdoctoral studies at Sugen Inc. where he developed the selective Src family kinase inhibitor SU6656 and demonstrated that Src regulates PKCδ protein degradation. He continued his scientific career in drug discovery at Sugen, Exelixis, iPierian and joined Genentech in 2012. He has published on inhibitors of HSP90, protein kinases, tankyrase, and deubiquitinases and on high content fluorescence imaging and novel target engagement methods. He was a member of the team that developed the angiogenesis inhibitor SUTENT and the team that developed the estrogen receptor antagonist/degrader GDC-9545. His current focus is the development of drugs that act through modulating target protein homeostasis, particularly protein degradation.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Nicole Blaquiere</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=BIO-d7e2540-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Nicole Blaquiere</b> obtained her Master’s degree in Organic Chemistry in 2008 under the supervision of the late Professor Keith Fagnou at the University of Ottawa, where she studied biomimetic decarboxylative aldol reactions and ruthenium-catalyzed dehydrogenation of ammonia boranes. She has been practicing industrial medicinal chemistry since 2008 with experience in oncology, immunology, tropical diseases, and targeted protein degradation.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Steven T. Staben</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=BIO-d7e2545-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Steve T. Staben</b> completed Ph.D. studies in the lab of Prof. Dean Toste at Berkeley in 2007. His entire postgraduate career has been as a medicinal chemist at Genentech where he is currently an Associate Director and Principal Scientist. Steve has contributed to multiple therapeutic programs across cancer, immunology, and cancer immunology leading to the advancement of several clinical small molecule inhibitors. He maintains basic research interest in the invention of new therapeutic modalities including targeted protein degraders.</p></figure></div><div class="ack" id="ACK-d7e2555-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34525" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34525" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Ignacio Aliagas for providing advice on calculated properties.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">17AAG</td><td class="NLM_def"><p class="first last">17-<i>N</i>-allylamino-17-demethoxygeldanamycin</p></td></tr><tr><td class="NLM_term">AF1</td><td class="NLM_def"><p class="first last">activation function 1 domain</p></td></tr><tr><td class="NLM_term">AKT1</td><td class="NLM_def"><p class="first last">AKT serine/threonine kinase 1</p></td></tr><tr><td class="NLM_term">AlphaLISA</td><td class="NLM_def"><p class="first last">amplified luminescent proximity homogeneous assay</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">androgen receptor</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BC</td><td class="NLM_def"><p class="first last">breast cancer</p></td></tr><tr><td class="NLM_term">BCL6</td><td class="NLM_def"><p class="first last">B-cell lymphoma 6 protein</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extraterminal</p></td></tr><tr><td class="NLM_term">BIR</td><td class="NLM_def"><p class="first last">baculoviral IAP repeat</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain containing 4</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">Cdc37</td><td class="NLM_def"><p class="first last">cell division cycle 37</p></td></tr><tr><td class="NLM_term">CHIP</td><td class="NLM_def"><p class="first last">COOH terminus of Hsp70-interacting protein</p></td></tr><tr><td class="NLM_term">Chk1</td><td class="NLM_def"><p class="first last">checkpoint kinase 1</p></td></tr><tr><td class="NLM_term">CHX</td><td class="NLM_def"><p class="first last">cycloheximide</p></td></tr><tr><td class="NLM_term">CK1α</td><td class="NLM_def"><p class="first last">casein kinase 1α</p></td></tr><tr><td class="NLM_term">c-KIT</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase KIT</p></td></tr><tr><td class="NLM_term">CD117</td><td class="NLM_def"><p class="first last">cluster of differentiation 117</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">CQ</td><td class="NLM_def"><p class="first last">chloroquine</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">cereblon</p></td></tr><tr><td class="NLM_term">CRL</td><td class="NLM_def"><p class="first last">Cullin/RING ubiquitin ligase</p></td></tr><tr><td class="NLM_term">cryo EM</td><td class="NLM_def"><p class="first last">cryoelectron microscopy</p></td></tr><tr><td class="NLM_term">CUL4A</td><td class="NLM_def"><p class="first last">Cullin 4A</p></td></tr><tr><td class="NLM_term">DC<sub>50</sub></td><td class="NLM_def"><p class="first last">degradation concentration 50%</p></td></tr><tr><td class="NLM_term">DDB1</td><td class="NLM_def"><p class="first last">DNA damage-binding protein 1</p></td></tr><tr><td class="NLM_term">DHA</td><td class="NLM_def"><p class="first last">dihydroartemisinin</p></td></tr><tr><td class="NLM_term">DHT</td><td class="NLM_def"><p class="first last">dihydrotestosterone</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B cell lymphoma</p></td></tr><tr><td class="NLM_term"><i>D</i><sub>max</sub></td><td class="NLM_def"><p class="first last">degradation maximum</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">DSF</td><td class="NLM_def"><p class="first last">differential scanning fluorimetry</p></td></tr><tr><td class="NLM_term">E1</td><td class="NLM_def"><p class="first last">E1 ubiquitin-activating enzyme</p></td></tr><tr><td class="NLM_term">E2</td><td class="NLM_def"><p class="first last">E2 ubiquitin-conjugating enzyme</p></td></tr><tr><td class="NLM_term">E2/Ub</td><td class="NLM_def"><p class="first last">ubiquitin charged ubiquitin-conjugating enzyme</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">effective concentration 50%</p></td></tr><tr><td class="NLM_term">eF2</td><td class="NLM_def"><p class="first last">elongation factor 2</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ER+</td><td class="NLM_def"><p class="first last">estrogen receptor-positive</p></td></tr><tr><td class="NLM_term">ERα</td><td class="NLM_def"><p class="first last">wstrogen receptor α</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">ESET</td><td class="NLM_def"><p class="first last">ERG-associated protein with SET domain</p></td></tr><tr><td class="NLM_term">ESR1</td><td class="NLM_def"><p class="first last">estrogen receptor gene encoding ERα protein</p></td></tr><tr><td class="NLM_term">EZH2</td><td class="NLM_def"><p class="first last">enhancer of zeste 2 homolog</p></td></tr><tr><td class="NLM_term">Fbxw7</td><td class="NLM_def"><p class="first last">F-box and WD repeat domain containing 7</p></td></tr><tr><td class="NLM_term">GC</td><td class="NLM_def"><p class="first last">germinal center</p></td></tr><tr><td class="NLM_term">GFP</td><td class="NLM_def"><p class="first last">green fluorescence protein</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">growth inhibition 50%</p></td></tr><tr><td class="NLM_term">GNA</td><td class="NLM_def"><p class="first last">gambogenic acid</p></td></tr><tr><td class="NLM_term">GSK3</td><td class="NLM_def"><p class="first last">glycogen synthase kinase-3</p></td></tr><tr><td class="NLM_term">HDX MS</td><td class="NLM_def"><p class="first last">hydrogen–deuterium exchange mass spectrometry</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">hPBMC</td><td class="NLM_def"><p class="first last">human peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">IAP</td><td class="NLM_def"><p class="first last">inhibitor of apoptosis proteins</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">inhibitor concentration 50%</p></td></tr><tr><td class="NLM_term">IFN-γ</td><td class="NLM_def"><p class="first last">interferon γ</p></td></tr><tr><td class="NLM_term">IKZF1</td><td class="NLM_def"><p class="first last">transcription factor Ikaros</p></td></tr><tr><td class="NLM_term">IKZF3</td><td class="NLM_def"><p class="first last">transcription factor Aiolos</p></td></tr><tr><td class="NLM_term">IL-2</td><td class="NLM_def"><p class="first last">interleukin 2</p></td></tr><tr><td class="NLM_term">IMiD</td><td class="NLM_def"><p class="first last">immunomodulatory imide drugs</p></td></tr><tr><td class="NLM_term">IRF4</td><td class="NLM_def"><p class="first last">interferon regulatory factor 4</p></td></tr><tr><td class="NLM_term">iTRAQ</td><td class="NLM_def"><p class="first last">isobaric tags for relative and absolute quantification</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>D</sub></td><td class="NLM_def"><p class="first last">equilibrium dissociation constant</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase dead</p></td></tr><tr><td class="NLM_term">KO</td><td class="NLM_def"><p class="first last">knockout</p></td></tr><tr><td class="NLM_term">LBD</td><td class="NLM_def"><p class="first last">ligand binding domain</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">LRRK2</td><td class="NLM_def"><p class="first last">leucine-rich repeat kinase 2</p></td></tr><tr><td class="NLM_term">MβCD</td><td class="NLM_def"><p class="first last">methyl-β-cyclodextrin</p></td></tr><tr><td class="NLM_term">MCF-7</td><td class="NLM_def"><p class="first last">Michigan Cancer Foundation-7 cell line</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">mPFS</td><td class="NLM_def"><p class="first last">median progression-free survival</p></td></tr><tr><td class="NLM_term">mRNA</td><td class="NLM_def"><p class="first last">messenger ribonucleic acid</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mechanistic target of rapamycin kinase</p></td></tr><tr><td class="NLM_term">MYCN</td><td class="NLM_def"><p class="first last">gene encoding the transcriptional factor N-Myc</p></td></tr><tr><td class="NLM_term">NAE</td><td class="NLM_def"><p class="first last">NEDD8-activating enzyme</p></td></tr><tr><td class="NLM_term">NEDD8</td><td class="NLM_def"><p class="first last">NEDD8 ubiquitin-like modifier</p></td></tr><tr><td class="NLM_term">NMR STD</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance saturation transfer difference spectroscopy</p></td></tr><tr><td class="NLM_term">p38</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinases MAPK14</p></td></tr><tr><td class="NLM_term">PC</td><td class="NLM_def"><p class="first last">prostate cancer</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">PDGFRα</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor-α</p></td></tr><tr><td class="NLM_term">p-H3</td><td class="NLM_def"><p class="first last">phosphohistone H3</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">PIK3CA</td><td class="NLM_def"><p class="first last">phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit α</p></td></tr><tr><td class="NLM_term">PP1</td><td class="NLM_def"><p class="first last">protein phosphatase 1</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">PRC2</td><td class="NLM_def"><p class="first last">polycomb repressor complex 2</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">pSILAC</td><td class="NLM_def"><p class="first last">pulsed stable isotope labeling by amino acids in culture</p></td></tr><tr><td class="NLM_term">qPCR</td><td class="NLM_def"><p class="first last">quantitative polymerase chain reaction</p></td></tr><tr><td class="NLM_term">Ras</td><td class="NLM_def"><p class="first last">rat sarcoma gene</p></td></tr><tr><td class="NLM_term">RBX1</td><td class="NLM_def"><p class="first last">RING box protein 1</p></td></tr><tr><td class="NLM_term">RING domain</td><td class="NLM_def"><p class="first last">“really interesting new gene” domain</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SARD</td><td class="NLM_def"><p class="first last">selective androgen receptor degrader</p></td></tr><tr><td class="NLM_term">SERD</td><td class="NLM_def"><p class="first last">selective estrogen receptor degrader</p></td></tr><tr><td class="NLM_term">SERM</td><td class="NLM_def"><p class="first last">selective estrogen receptor modulator</p></td></tr><tr><td class="NLM_term">SET8</td><td class="NLM_def"><p class="first last">histone methyltransferase, also known as PR-Set7 and SETD8</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small interfering ribonucleic acid</p></td></tr><tr><td class="NLM_term">Smac</td><td class="NLM_def"><p class="first last">second mitochondria-derived activator of caspases encoded by the DIABLO gene</p></td></tr><tr><td class="NLM_term">SPLAM</td><td class="NLM_def"><p class="first last">splicing inhibitor sulfonamide</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">sarcoma proto-oncogene tyrosine-protein kinase Src</p></td></tr><tr><td class="NLM_term">STATs</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">TBD</td><td class="NLM_def"><p class="first last">thalidomide binding domain</p></td></tr><tr><td class="NLM_term">TMT</td><td class="NLM_def"><p class="first last">tandem mass tag</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor α</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">Von Hippel–Lindau E3 ubiquitin ligase</p></td></tr><tr><td class="NLM_term">WM</td><td class="NLM_def"><p class="first last">Waldenström’s macroglobulinemia</p></td></tr><tr><td class="NLM_term">XIAP</td><td class="NLM_def"><p class="first last">X-linked inhibitor of apoptosis</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 224 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span> <span> </span><span class="NLM_article-title">Development of Targeted Protein Degradation Therapeutics</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0362-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41589-019-0362-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31527835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslygur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=937-944&issue=10&author=P.+P.+Chamberlainauthor=L.+G.+Hamann&title=Development+of+Targeted+Protein+Degradation+Therapeutics&doi=10.1038%2Fs41589-019-0362-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Development of targeted protein degradation therapeutics</span></div><div class="casAuthors">Chamberlain, Philip P.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">937-944</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted protein degrdn. as a therapeutic modality has seen dramatic progress and massive investment in recent years because of the convergence of two key scientific breakthroughs: optimization of first-generation peptidic proteolysis-targeted chimeras (PROTACs) into more drug-like mols. able to support in vivo proof of concept and the discovery that clin. mols. function as degraders by binding and repurposing the proteins cereblon and DCAF15.  This provided clin. validation for the general approach through the cereblon modulator class of drugs and provided highly drug-like and ligand-efficient E3 ligase binders upon which to tether target-binding moieties.  Increasingly rational and systematic approaches including biophys. and structural studies on ternary complexes are being leveraged as the field advances.  In this Perspective we summarize the discoveries that have laid the foundation for future degrdn. therapeutics, focusing on those classes of small mols. that redirect E3 ubiquitin ligases to non-native substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfcIEwVR-Xq7Vg90H21EOLACvtfcHk0lieeISjPfb5VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslygur%252FF&md5=468e3fd87ba2b21607dac8b495e5ecf6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0362-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0362-y%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DDevelopment%2520of%2520Targeted%2520Protein%2520Degradation%2520Therapeutics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26issue%3D10%26spage%3D937%26epage%3D944%26doi%3D10.1038%2Fs41589-019-0362-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maniaci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Bifunctional Chemical Probes Inducing Protein-Protein Interactions</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cbpa.2019.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31419624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=145-156&author=C.+Maniaciauthor=A.+Ciulli&title=Bifunctional+Chemical+Probes+Inducing+Protein-Protein+Interactions&doi=10.1016%2Fj.cbpa.2019.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional chemical probes inducing protein-protein interactions</span></div><div class="casAuthors">Maniaci, Chiara; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145-156</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inducing biomol. interactions with synthetic mols. to impact biol. function is a concept of enormous appeal.  Recent years have seen a resurgence of interest in designing bispecific mols. that serve as bridging agents to bring proteins together.  Pioneering structural and biophys. investigation of ternary complexes formed by mono-functional and bifunctional ligands highlights that proximity-induced stabilization or de novo formation of protein-protein interactions is a common feature of their mol. recognition.  In this review, we illustrate these concepts and advances with representative case studies, and highlight progress over the past three years, with particular focus on recruitment to E3 ubiquitin ligases by 'mol. glues' and chimeric dimerizers (PROTACs) for targeted protein degrdn.  This approach promises to significantly expand the range of tractable targets for chem. biol. and therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobXJM1PThHPbVg90H21EOLACvtfcHk0ljXBO0pvMoY3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbjF&md5=4302bb010003177f4f5e5c3d4a401dc9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DManiaci%26aufirst%3DC.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DBifunctional%2520Chemical%2520Probes%2520Inducing%2520Protein-Protein%2520Interactions%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D52%26spage%3D145%26epage%3D156%26doi%3D10.1016%2Fj.cbpa.2019.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">PROteolysis TArgeting Chimeras (PROTACs) - Past, Present and Future</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2019.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ddtec.2019.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31200855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BB3M3mvFWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=15-27&author=M.+Petterssonauthor=C.+M.+Crews&title=PROteolysis+TArgeting+Chimeras+%28PROTACs%29+-+Past%2C+Present+and+Future&doi=10.1016%2Fj.ddtec.2019.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future</span></div><div class="casAuthors">Pettersson Mariell; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The majority of currently used therapeutics are small molecule-based and utilize occupancy-driven pharmacology as the mode of action (MOA), in which the protein function is modulated via temporary inhibition.  New modalities that operate using alternative MOAs are essential for tapping into the "undruggable" proteome.  The PROteolysis Targeting Chimera (PROTAC) technology provides an attractive new approach that utilizes an event-driven MOA.  Small molecule-based heterobifunctional PROTACs modulate protein target levels by hijacking the ubiquitin-proteasome system to induce degradation of the target.  Here, we address important milestones in the development of the PROTAC technology, as well as emphasize key findings from this previous year and highlight future directions of this promising drug discovery modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCRHissLLXoRfKb6ELK8t0fW6udTcc2ebRm9SABuu5eLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mvFWkuw%253D%253D&md5=c629f3128321e136f1f247e05ee6f182</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2019.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2019.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DPettersson%26aufirst%3DM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DPROteolysis%2520TArgeting%2520Chimeras%2520%2528PROTACs%2529%2520-%2520Past%252C%2520Present%2520and%2520Future%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2019%26volume%3D31%26spage%3D15%26epage%3D27%26doi%3D10.1016%2Fj.ddtec.2019.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallan, C.</span></span> <span> </span><span class="NLM_article-title">Proteolysis Targeting Chimeras (PROTACs) in “Beyond Rule-of-Five” Chemical Space: Recent Progress and Future Challenges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2019.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31047748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1555-1564&issue=13&author=S.+D.+Edmondsonauthor=B.+Yangauthor=C.+Fallan&title=Proteolysis+Targeting+Chimeras+%28PROTACs%29+in+%E2%80%9CBeyond+Rule-of-Five%E2%80%9D+Chemical+Space%3A+Recent+Progress+and+Future+Challenges&doi=10.1016%2Fj.bmcl.2019.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges</span></div><div class="casAuthors">Edmondson, Scott D.; Yang, Bin; Fallan, Charlene</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional compds. with mol. wts. and other properties that lie outside the classic 'rule-of-five' space.  Consequently, PROTACs have unique challenges assocd. with their development as potential therapeutic agents.  This review summarizes and analyzes a representative set of recent PROTACs and highlights some of the potential future challenges facing this promising modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcS0gIul-K7Vg90H21EOLACvtfcHk0lijX06uu_KjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D&md5=62a74500178bd711b1ddaa33d731b960</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DFallan%26aufirst%3DC.%26atitle%3DProteolysis%2520Targeting%2520Chimeras%2520%2528PROTACs%2529%2520in%2520%25E2%2580%259CBeyond%2520Rule-of-Five%25E2%2580%259D%2520Chemical%2520Space%253A%2520Recent%2520Progress%2520and%2520Future%2520Challenges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D13%26spage%3D1555%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2019.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Towbin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staehelin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, J.</span></span> <span> </span><span class="NLM_article-title">Immunoblotting in the Clinical Laboratory</span>. <i>J. Clin. Chem. Clin. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=2681521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaL1MXlslShtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1989&pages=495-501&issue=8&author=H.+Towbinauthor=T.+Staehelinauthor=J.+Gordon&title=Immunoblotting+in+the+Clinical+Laboratory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoblotting in the clinical laboratory</span></div><div class="casAuthors">Towbin, H.; Staehelin, T.; Gordon, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Chemistry and Clinical Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">495-501</span>CODEN:
                <span class="NLM_cas:coden">JCCBDT</span>;
        ISSN:<span class="NLM_cas:issn">0340-076X</span>.
    </div><div class="casAbstract">A review with 42 refs.  The basic principles of protein blotting are outlined and illustrated with some examples related to clin. applications, and differences between these and classical methods are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9f_ADICvAbVg90H21EOLACvtfcHk0lijX06uu_KjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlslShtbo%253D&md5=3d7dccbca1f6a24019126b2e48e7a4e1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTowbin%26aufirst%3DH.%26aulast%3DStaehelin%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DJ.%26atitle%3DImmunoblotting%2520in%2520the%2520Clinical%2520Laboratory%26jtitle%3DJ.%2520Clin.%2520Chem.%2520Clin.%2520Biochem.%26date%3D1989%26volume%3D27%26issue%3D8%26spage%3D495%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span> <span> </span><span class="NLM_article-title">Immunodetection of Proteins by Western Blotting</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1385/0-89603-204-3:221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1385%2F0-89603-204-3%3A221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23150313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK38XmsVyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=221-233&author=C.+J.+Hendersonauthor=C.+R.+Wolf&title=Immunodetection+of+Proteins+by+Western+Blotting&doi=10.1385%2F0-89603-204-3%3A221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Immunodetection of proteins by Western blotting</span></div><div class="casAuthors">Henderson, Colin J.; Wolf, C. Roland</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">Immunochem. Protoc.</span>),
    <span class="NLM_cas:pages">221-33</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">The procedure for Western blotting of peptides and proteins sepd. on a denaturing polyacrylamide gel system is detailed.  This procedure is used routinely for the anal. of peptides from a variety of subcellular fractions of whole tissue and cell lines and has evolved over a no. of years.  Many different immunoblotting procedures are currently available; details of variations from the 125I-protein-A method described here are given, as are brief amendments covering electrotransfer from 2-dimensional and isoelec. focusing systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgOh5AQrx9vbVg90H21EOLACvtfcHk0lijX06uu_KjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVyjtrk%253D&md5=1ed6ce4801b7ba594430512239348129</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1385%2F0-89603-204-3%3A221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F0-89603-204-3%253A221%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DC.%2BJ.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26atitle%3DImmunodetection%2520of%2520Proteins%2520by%2520Western%2520Blotting%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D1992%26volume%3D10%26spage%3D221%26epage%3D233%26doi%3D10.1385%2F0-89603-204-3%3A221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, V. M.</span></span> <span> </span><span class="NLM_article-title">Protein Detection by Simple Western Analysis</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1312</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-2694-7_47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F978-1-4939-2694-7_47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26044028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbgs1Oksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1312&publication_year=2015&pages=465-468&author=V.+M.+Harris&title=Protein+Detection+by+Simple+Western+Analysis&doi=10.1007%2F978-1-4939-2694-7_47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Protein detection by Simple Western® analysis</span></div><div class="casAuthors">Harris Valerie M</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1312</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">465-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein Simple© has taken a well-known protein detection method, the western blot, and revolutionized it.  The Simple Western® system uses capillary electrophoresis to identify and quantitate a protein of interest.  Protein Simple© provides multiple detection apparatuses (Wes, Sally Sue, or Peggy Sue) that are suggested to save scientists valuable time by allowing the researcher to prepare the protein sample, load it along with necessary antibodies and substrates, and walk away.  Within 3-5 h the protein will be separated by size, or charge, immuno-detection of target protein will be accurately quantitated, and results will be immediately made available.  Using the Peggy Sue instrument, one study recently examined changes in MAPK signaling proteins in the sex-determining stage of gonadal development.  Here the methodology is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq2usTPByFh2HOrQ6qeX-mfW6udTcc2eZypO752Fsje7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbgs1Oksw%253D%253D&md5=243a3117c68541fb2b53950eb743e270</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2694-7_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-2694-7_47%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DV.%2BM.%26atitle%3DProtein%2520Detection%2520by%2520Simple%2520Western%2520Analysis%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2015%26volume%3D1312%26spage%3D465%26epage%3D468%26doi%3D10.1007%2F978-1-4939-2694-7_47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katunuma, N.</span></span> <span> </span><span class="NLM_article-title">Use of Rabbit Antibody IgG Bound Onto Plain and Aminoalkylsilyl Glass Surface for the Enzyme-Linked Sandwich Immunoassay</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1093/oxfordjournals.jbchem.a131678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1093%2Foxfordjournals.jbchem.a131678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=408341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaE2sXltVSgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1977&pages=261-266&issue=1&author=K.+Katoauthor=Y.+Hamaguchiauthor=S.+Okawaauthor=E.+Ishikawaauthor=K.+Kobayashiauthor=N.+Katunuma&title=Use+of+Rabbit+Antibody+IgG+Bound+Onto+Plain+and+Aminoalkylsilyl+Glass+Surface+for+the+Enzyme-Linked+Sandwich+Immunoassay&doi=10.1093%2Foxfordjournals.jbchem.a131678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Use of rabbit antibody IgG bound onto plain and aminoalkylsilyl glass surface for the enzyme-linked sandwich immunoassay</span></div><div class="casAuthors">Kato, Kanefusa; Hamaguchi, Yoshitaka; Okawa, Sachiyo; Ishikawa, Eiji; Kobayashi, Keiko; Katunuma, Nobuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">261-6</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">Rabbit antibody IgG was bound onto aminoalkylsilyl or plain glass rods by simple adsorption.  For comparison, rabbit antibody IgG was also bound onto glutaraldehyde-activated aminoalkylsilyl glass rods.  These antibody-glass rods were tested by the sandwich procedure using Fab' fragments of rabbit antibody conjugated with β-D-galactosidase from Escherichia coli.  The glutaraldehyde-activated aminoalkylsilyl glass showed the largest capacity to bind antigen and the plain glass showed the smallest.  However, the antibody-glass rods prepd. by simple adsorption were as useful for the sandwich immunoassay of macromol. antigens as those prepd. with glutaraldehyde.  With all the antibody-glass rods prepd., 0.1-10 fmol of ornithine δ-aminotransferase from rat liver and 2,4-dinitrophenyl human IgG were measurable.  More than 10 fmol of the antigens may be measurable with larger amts. of the antibody-β-D-galactosidase complexes, although the non-specific binding of the complexes to the solid phase increases to limit the sensitivity of the immunoassay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJIgjGujt-RLVg90H21EOLACvtfcHk0ljqF0golmtWww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXltVSgu7w%253D&md5=13a3a9e2b33543e30672ee3adb9f0879</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a131678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a131678%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DY.%26aulast%3DOkawa%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DE.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DKatunuma%26aufirst%3DN.%26atitle%3DUse%2520of%2520Rabbit%2520Antibody%2520IgG%2520Bound%2520Onto%2520Plain%2520and%2520Aminoalkylsilyl%2520Glass%2520Surface%2520for%2520the%2520Enzyme-Linked%2520Sandwich%2520Immunoassay%26jtitle%3DJ.%2520Biochem.%26date%3D1977%26volume%3D82%26issue%3D1%26spage%3D261%26epage%3D266%26doi%3D10.1093%2Foxfordjournals.jbchem.a131678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornbeck, P. V.</span></span> <span> </span><span class="NLM_article-title">Enzyme-Linked Immunosorbent Assays</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2.1.1</span>– <span class="NLM_lpage">2.1.23</span>, <span class="refDoi"> DOI: 10.1002/0471142735.im0201s110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2F0471142735.im0201s110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2015&pages=2.1.1-2.1.23&issue=1&author=P.+V.+Hornbeck&title=Enzyme-Linked+Immunosorbent+Assays&doi=10.1002%2F0471142735.im0201s110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F0471142735.im0201s110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471142735.im0201s110%26sid%3Dliteratum%253Aachs%26aulast%3DHornbeck%26aufirst%3DP.%2BV.%26atitle%3DEnzyme-Linked%2520Immunosorbent%2520Assays%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2015%26volume%3D110%26issue%3D1%26spage%3D2.1.1%26epage%3D2.1.23%26doi%3D10.1002%2F0471142735.im0201s110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aydin, S.</span></span> <span> </span><span class="NLM_article-title">A Short History, Principles, and Types of ELISA, and Our Laboratory Experience with Peptide/Protein Analyses Using ELISA</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2015.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.peptides.2015.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25908411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1Sruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=4-15&author=S.+Aydin&title=A+Short+History%2C+Principles%2C+and+Types+of+ELISA%2C+and+Our+Laboratory+Experience+with+Peptide%2FProtein+Analyses+Using+ELISA&doi=10.1016%2Fj.peptides.2015.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA</span></div><div class="casAuthors">Aydin, Suleyman</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4-15</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Playing a crit. role in the metabolic homeostasis of living systems, the circulating concns. of peptides/proteins are influenced by a variety of patho-physiol. events.  These peptide/protein concns. in biol. fluids were measured using various methods, the most common of which is enzymic immunoassay EIA/ELISA and which guide the clinicians in diagnosing and monitoring diseases that inflict biol. systems.  All the techniques where enzymes were employed to show antigen-antibody reactions are generally referred to as enzymic immunoassay EIA/ELISA method.  The basic principles of EIA and ELISA are the same.  The main objective of this review is to present an overview of the historical journey that had led to the invention of EIA/ELISA, an indispensible method for medical and research labs., types of ELISA developed after its invention [direct (the first ELISA method invented), indirect, sandwich and competitive methods], problems encountered during peptide/protein analyses (pre-anal., anal. and post-anal.), rules to be followed to prevent these problems, and the authors' lab. experience of >15 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruTnWISClXpbVg90H21EOLACvtfcHk0ljqF0golmtWww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1Sruro%253D&md5=9db04530496e40dc07254ebd31f98ac5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2015.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2015.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DAydin%26aufirst%3DS.%26atitle%3DA%2520Short%2520History%252C%2520Principles%252C%2520and%2520Types%2520of%2520ELISA%252C%2520and%2520Our%2520Laboratory%2520Experience%2520with%2520Peptide%252FProtein%2520Analyses%2520Using%2520ELISA%26jtitle%3DPeptides%26date%3D2015%26volume%3D72%26spage%3D4%26epage%3D15%26doi%3D10.1016%2Fj.peptides.2015.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span> <span> </span><span class="NLM_article-title">A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides</span>. <i>Curr. Chem. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.2174/1875397300802010040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F1875397300802010040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20161842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVWhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=40-47&issue=1&author=Y.+Duauthor=F.+R.+Khuriauthor=H.+Fu&title=A+Homogenous+Luminescent+Proximity+Assay+for+14-3-3+Interactions+with+Both+Phosphorylated+and+Nonphosphorylated+Client+Peptides&doi=10.2174%2F1875397300802010040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A homogenous luminescent proximity assay for 14-3-3 interactions with both phosphorylated and nonphosphorylated client peptides</span></div><div class="casAuthors">Du, Yuhong; Khuri, Fadlo R.; Fu, Haian</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The 14-3-3 proteins are a family of dimeric eukaryotic proteins that mediate both phosphorylation-dependent and -independent protein-protein interactions.  Through these interactions, 14-3-3 proteins participate in the regulation of a wide range of cellular processes, including cell proliferation, cell cycle progression, and apoptosis.  Because of their fundamental importance, 14-3-3 proteins have also been implicated in a variety of diseases, including cancer and neurodegenerative disorders.  In order to monitor 14-3-3/client protein interactions for the discovery of small mol. 14-3-3 modulators, we have designed and optimized 14-3-3 protein binding assays based on the amplified luminescent proximity homogeneous assay (AlphaScreen) technol.  Using the interaction of 14-3-3 with a phosphorylated Raf-1 peptide and a nonphosphorylated R18 peptide as model systems, we have established homogenous "add-and-measure" high-throughput screening assays.  Both assays achieved robust performance with S/B ratios above 7 and Z' factors above 0.7.  Application of the known antagonistic peptides in our studies further validated the assay for screening of chem. compd. libraries to identify small mols. that can modulate 14-3-3 protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6cZFi3G3hbVg90H21EOLACvtfcHk0linQzTn09tsmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVWhurs%253D&md5=3317b19dd61113832e0b6d249fcb6cae</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1875397300802010040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397300802010040%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DY.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DFu%26aufirst%3DH.%26atitle%3DA%2520Homogenous%2520Luminescent%2520Proximity%2520Assay%2520for%252014-3-3%2520Interactions%2520with%2520Both%2520Phosphorylated%2520and%2520Nonphosphorylated%2520Client%2520Peptides%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2008%26volume%3D2%26issue%3D1%26spage%3D40%26epage%3D47%26doi%3D10.2174%2F1875397300802010040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eglen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouleau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielefeld, M.</span></span> <span> </span><span class="NLM_article-title">The Use of AlphaScreen Technology in HTS: Current Status</span>. <i>Curr. Chem. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.2174/1875397300801010002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F1875397300801010002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20161822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=2-10&issue=1&author=R.+M.+Eglenauthor=T.+Reisineauthor=P.+Robyauthor=N.+Rouleauauthor=C.+Illyauthor=R.+Boss%C3%A9author=M.+Bielefeld&title=The+Use+of+AlphaScreen+Technology+in+HTS%3A+Current+Status&doi=10.2174%2F1875397300801010002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The use of AlphaScreen technology in HTS: Current status</span></div><div class="casAuthors">Eglen, Richard M.; Reisine, Terry; Roby, Philippe; Rouleau, Nathalie; Illy, Chantal; Bosse, Roger; Bielefeld, Martina</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-10</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay Screen) is versatile assay technol. developed to measuring analytes using a homogeneous protocol.  This technol. is an example of a bead-based proximity assay and was developed from a diagnostic assay technol. known as LOCI (Luminescent Oxygen Channeling Assay).  Here, singlet oxygen mols., generated by high energy irradn. of Donor beads, travel over a constrained distance (approx. 200 nm) to Acceptor beads.  This results in excitation of a cascading series of chem. reactions, ultimately causing generation of a chemiluminescent signal.  In the past decade, a wide variety of applications has been reported, ranging from detection of analytes involved in cell signaling, including protein:protein, protein:peptide, protein:small mol. or peptide:peptide interactions.  Numerous homogeneous HTS-optimized assays have been reported using the approach, including generation of second messengers (such as accumulation of cAMP, cyclic GMP, inositol [1, 4, 5] trisphosphate or phosphorylated ERK) from liganded GPCRs or tyrosine kinase receptors, post-translational modification of proteins (such as proteolytic cleavage, phosphorylation, ubiquitination and sumoylation) as well as protein-protein and protein-nucleic acid interactions.  Recently, the basic AlphaScreen technol. was extended in that the chem. of the Acceptor bead was modified such that emitted light is more intense and spectrally defined, thereby markedly reducing interference from biol. fluid matrixes (such as trace hemolysis in serum and plasma).  In this format, referred to as AlphaLISA, it provides an alternative technol. to classical ELISA assays and is suitable for high throughput automated fluid dispensing and detection systems.  Collectively, AlphaScreen and AlphaLISA technologies provide a facile assay platform with which one can quantitate complex cellular processes using simple no-wash microtiter plate based assays.  They provide the means by which large compd. libraries can be screened in a high throughput fashion at a diverse range of therapeutically important targets, often not readily undertaken using other homogeneous assay technologies.  This review assesses the current status of the technol. in drug discovery, in general, and high throughput screening (HTS), in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4coo45wvUbbVg90H21EOLACvtfcHk0linQzTn09tsmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D&md5=4d35f83091184d6eb4d1b76444754707</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F1875397300801010002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397300801010002%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.%2BM.%26aulast%3DReisine%26aufirst%3DT.%26aulast%3DRoby%26aufirst%3DP.%26aulast%3DRouleau%26aufirst%3DN.%26aulast%3DIlly%26aufirst%3DC.%26aulast%3DBoss%25C3%25A9%26aufirst%3DR.%26aulast%3DBielefeld%26aufirst%3DM.%26atitle%3DThe%2520Use%2520of%2520AlphaScreen%2520Technology%2520in%2520HTS%253A%2520Current%2520Status%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2008%26volume%3D1%26issue%3D1%26spage%3D2%26epage%3D10%26doi%3D10.2174%2F1875397300801010002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span> <span> </span><span class="NLM_article-title">Cellular Screening Assays Using Fluorescence Microscopy</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1016/S1471-4892(01)00092-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS1471-4892%2801%2900092-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=11764781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFOisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=533-539&issue=5&author=R.+A.+Blake&title=Cellular+Screening+Assays+Using+Fluorescence+Microscopy&doi=10.1016%2FS1471-4892%2801%2900092-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular screening assays using fluorescence microscopy</span></div><div class="casAuthors">Blake, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-539</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  The recent development of automated fluorescence imaging systems has enabled fluorescence microscopy to be used for the purposes of compd. screening.  This information-rich technique has found various applications, including screening for the effect of kinase inhibitors on the cytoskeleton, agonist-stimulated receptor internalization, and protein phosphorylation and acetylation.  The discovery of novel fluorescent proteins and new fluorescent dyes will find many applications in multichannel fluorescence imaging assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvnw-vrC-qJbVg90H21EOLACvtfcHk0liKHOw8yh0IQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFOisr0%253D&md5=1ec689b223b9d83d3f68b4055cbb6c4a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1471-4892%2801%2900092-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4892%252801%252900092-3%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DR.%2BA.%26atitle%3DCellular%2520Screening%2520Assays%2520Using%2520Fluorescence%2520Microscopy%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2001%26volume%3D1%26issue%3D5%26spage%3D533%26epage%3D539%26doi%3D10.1016%2FS1471-4892%2801%2900092-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span> <span> </span><span class="NLM_article-title">High-Content Analysis in Preclinical Drug Discovery</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.2174/138620708783877780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F138620708783877780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18336214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslCisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=216-230&issue=3&author=P.+Dennerauthor=J.+Schmalowskyauthor=S.+Prechtl&title=High-Content+Analysis+in+Preclinical+Drug+Discovery&doi=10.2174%2F138620708783877780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">High-content analysis in preclinical drug discovery</span></div><div class="casAuthors">Denner, Philip; Schmalowsky, Janine; Prechtl, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-230</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  High-Content Anal. (HCA) has developed into an established tool and is used in a wide range of academic labs. and pharmaceutical research groups.  HCA is now routinely proving to be effective in providing functionally relevant results.  It is essential to select the appropriate HCA application with regard to the targeted compd.'s cellular function.  The cellular impact and compd. specificity as revealed by HCA anal. facilitates reaching definitive conclusions at an early stage in the drug discovery process.  This technol. therefore has the potential to substantially improve the efficiency of pharmaceutical research.  Recent advances in fluorescent probes have significantly boosted the success of HCA.  Auto-fluorescent proteins which minimally hinder the functioning of the living cell were playing a decisive role in cell biol. research.  For companies the severely restricted license conditions regarding auto-fluorescent proteins hamper their general use in pharmaceutical research.  This has opened the field for other solns. such as self-labeling protein technol., which could potentially replace the well established methods that utilize auto-fluorescent proteins.  In addn., direct labeling techniques have improved considerably and may supersede many of the approaches based on fusion proteins.  Following sample prepn., treated cells are imaged and the resulting multiple fluorescent signals are subjected to contextual and statistical anal.  The extraordinary advantage of HCA is that it enables the large-scale and simultaneous quantification and correlation of multiple phenotypic responses and physiol. reactions using sophisticated software solns. that permit assay-specific image anal.  Hence, HCA once more has demonstrated its outstanding potential to significantly support establishing effective pharmaceutical research processes to both advance research projects and cut costs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAmqzHcxZ0rLVg90H21EOLACvtfcHk0liKHOw8yh0IQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslCisL8%253D&md5=528fa42c18fb54e0945ea318dfdd8b92</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F138620708783877780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620708783877780%26sid%3Dliteratum%253Aachs%26aulast%3DDenner%26aufirst%3DP.%26aulast%3DSchmalowsky%26aufirst%3DJ.%26aulast%3DPrechtl%26aufirst%3DS.%26atitle%3DHigh-Content%2520Analysis%2520in%2520Preclinical%2520Drug%2520Discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26issue%3D3%26spage%3D216%26epage%3D230%26doi%3D10.2174%2F138620708783877780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, N.</span></span> <span> </span><span class="NLM_article-title">Fluorescent Proteins and Engineered Cell Lines</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1385/1-59745-217-3:165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1385%2F1-59745-217-3%3A165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2006&pages=165-187&author=N.+Thomas&title=Fluorescent+Proteins+and+Engineered+Cell+Lines&doi=10.1385%2F1-59745-217-3%3A165"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1385%2F1-59745-217-3%3A165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59745-217-3%253A165%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DN.%26atitle%3DFluorescent%2520Proteins%2520and%2520Engineered%2520Cell%2520Lines%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2006%26volume%3D356%26spage%3D165%26epage%3D187%26doi%3D10.1385%2F1-59745-217-3%3A165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D.</span></span> <span> </span><span class="NLM_article-title">Attaching Suspension Cells to Slides Using a Cytocentrifuge</span>. <i>Cold Spring Harbor Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">pdb.prot4291</span>, <span class="refDoi"> DOI: 10.1101/pdb.prot4291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1101%2Fpdb.prot4291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=pdb.prot4291&author=E.+Harlowauthor=D.+Lane&title=Attaching+Suspension+Cells+to+Slides+Using+a+Cytocentrifuge&doi=10.1101%2Fpdb.prot4291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1101%2Fpdb.prot4291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fpdb.prot4291%26sid%3Dliteratum%253Aachs%26aulast%3DHarlow%26aufirst%3DE.%26aulast%3DLane%26aufirst%3DD.%26atitle%3DAttaching%2520Suspension%2520Cells%2520to%2520Slides%2520Using%2520a%2520Cytocentrifuge%26jtitle%3DCold%2520Spring%2520Harbor%2520Protoc.%26date%3D2006%26spage%3Dpdb.prot4291%26doi%3D10.1101%2Fpdb.prot4291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D.</span></span> <span> </span><span class="NLM_article-title">Attaching Suspension Cells to Slides Using Chemical Linkers</span>. <i>Cold Spring Harbor Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">pdb.prot4292</span>, <span class="refDoi"> DOI: 10.1101/pdb.prot4292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1101%2Fpdb.prot4292" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=pdb.prot4292&author=E.+Harlowauthor=D.+Lane&title=Attaching+Suspension+Cells+to+Slides+Using+Chemical+Linkers&doi=10.1101%2Fpdb.prot4292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1101%2Fpdb.prot4292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fpdb.prot4292%26sid%3Dliteratum%253Aachs%26aulast%3DHarlow%26aufirst%3DE.%26aulast%3DLane%26aufirst%3DD.%26atitle%3DAttaching%2520Suspension%2520Cells%2520to%2520Slides%2520Using%2520Chemical%2520Linkers%26jtitle%3DCold%2520Spring%2520Harbor%2520Protoc.%26date%3D2006%26spage%3Dpdb.prot4292%26doi%3D10.1101%2Fpdb.prot4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teramura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekdahl, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, B.</span></span> <span> </span><span class="NLM_article-title">Cell Adhesion Induced Using Surface Modification with Cell-Penetrating Peptide-Conjugated Poly(Ethylene Glycol)-Lipid: a New Cell Glue for 3D Cell-Based Structures</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b14584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b14584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyrt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=244-254&issue=1&author=Y.+Teramuraauthor=S.+Asifauthor=K.+N.+Ekdahlauthor=E.+Gustafsonauthor=B.+Nilsson&title=Cell+Adhesion+Induced+Using+Surface+Modification+with+Cell-Penetrating+Peptide-Conjugated+Poly%28Ethylene+Glycol%29-Lipid%3A+a+New+Cell+Glue+for+3D+Cell-Based+Structures&doi=10.1021%2Facsami.6b14584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Adhesion Induced Using Surface Modification with Cell-Penetrating Peptide-Conjugated Poly(ethylene glycol)-Lipid: A New Cell Glue for 3D Cell-Based Structures</span></div><div class="casAuthors">Teramura, Yuji; Asif, Sana; Ekdahl, Kristina N.; Gustafson, Elisabet; Nilsson, Bo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">244-254</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We synthesized a novel material, cell-penetrating peptide-conjugated poly(ethylene glycol)-lipid (CPP-PEG-lipid), that can induce the adhesion of floating cells.  Firm cell adhesion with spreading could be induced by cell surface modification with the CPP-PEG-lipids.  Cell adhesion was induced by CPPs but not by any other cationic short peptides we tested.  Here, we demonstrated adherence using the floating cell line CCRF-CEM as well as primary human T cells, B cells, erythrocytes, and hepatocytes.  As compared to cells grown in suspension, adherent cells were more rapidly induced to attach to substrates with the cell-surface modification.  The crit. factor for attachment was localization of CPPs at the cell membrane by PEG-lipids with PEG > 20 kDa.  These cationic CPPs on PEG chains were able to interact with substrate surfaces such as polystyrene (PS) surfaces, glass surfaces, and PS microfibers that are neg. charged, inducing firm cell adhesion and cell spreading.  Also, as opposed to normal cationic peptides that interact strongly with cell membranes, CPPs were less interactive with the cell surfaces because of their cell-penetrating property, making them more available for adhering cells to the substrate surface.  No effects on cell viability or cell proliferation were obsd. after the induction of cell adhesion.  With this technique, cells could be easily immobilized onto PS microfibers, an important step in fabricating 3D cell-based structures.  Cells immobilized onto 3D PS microfibers were alive, and human hepatocytes showed normal prodn. of urea and albumin on the microfibers.  This method is novel in inducing firm cell adhesion via a one-step treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLoWYxS2RPXbVg90H21EOLACvtfcHk0lg7pV1nJcyCGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyrt7vE&md5=8ae54e2cc42ad0446334fd487fcfa19f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b14584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b14584%26sid%3Dliteratum%253Aachs%26aulast%3DTeramura%26aufirst%3DY.%26aulast%3DAsif%26aufirst%3DS.%26aulast%3DEkdahl%26aufirst%3DK.%2BN.%26aulast%3DGustafson%26aufirst%3DE.%26aulast%3DNilsson%26aufirst%3DB.%26atitle%3DCell%2520Adhesion%2520Induced%2520Using%2520Surface%2520Modification%2520with%2520Cell-Penetrating%2520Peptide-Conjugated%2520Poly%2528Ethylene%2520Glycol%2529-Lipid%253A%2520a%2520New%2520Cell%2520Glue%2520for%25203D%2520Cell-Based%2520Structures%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2017%26volume%3D9%26issue%3D1%26spage%3D244%26epage%3D254%26doi%3D10.1021%2Facsami.6b14584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quah, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, C. R.</span></span> <span> </span><span class="NLM_article-title">Monitoring Lymphocyte Proliferation in Vitro and in Vivo with the Intracellular Fluorescent Dye Carboxyfluorescein Diacetate Succinimidyl Ester</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2049</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnprot.2007.296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17853860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2049-2056&issue=9&author=B.+J.+Quahauthor=H.+S.+Warrenauthor=C.+R.+Parish&title=Monitoring+Lymphocyte+Proliferation+in+Vitro+and+in+Vivo+with+the+Intracellular+Fluorescent+Dye+Carboxyfluorescein+Diacetate+Succinimidyl+Ester&doi=10.1038%2Fnprot.2007.296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester</span></div><div class="casAuthors">Quah, Ben J. C.; Warren, Hilary S.; Parish, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2049-2056</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol outlines the carboxyfluorescein diacetate succinimidyl ester (CFSE) method for following the proliferation of human lymphocytes in vitro and mouse lymphocytes both in vitro and in vivo.  The method relies on the ability of CFSE to covalently label long-lived intracellular mols. with the highly fluorescent dye, carboxyfluorescein.  Following each cell division, the equal distribution of these fluorescent mols. to progeny cells results in a halving of the fluorescence of daughter cells.  The CFSE labeling protocol described, which typically takes <1 h to perform, allows the detection of up to eight cell divisions before CFSE fluorescence is decreased to the background fluorescence of unlabeled cells.  Protocols are outlined for labeling large and small nos. of human and mouse lymphocytes, labeling conditions being identified that minimize CFSE toxicity but maximize the no. of cell divisions detected.  An important feature of the technique is that division-dependent changes in the expression of cell-surface markers and intracellular proteins are easily quantified by flow cytometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop6vkbNREW8rVg90H21EOLACvtfcHk0lg7pV1nJcyCGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FL&md5=201f688e3fe9b95681d418001dc80a32</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.296%26sid%3Dliteratum%253Aachs%26aulast%3DQuah%26aufirst%3DB.%2BJ.%26aulast%3DWarren%26aufirst%3DH.%2BS.%26aulast%3DParish%26aufirst%3DC.%2BR.%26atitle%3DMonitoring%2520Lymphocyte%2520Proliferation%2520in%2520Vitro%2520and%2520in%2520Vivo%2520with%2520the%2520Intracellular%2520Fluorescent%2520Dye%2520Carboxyfluorescein%2520Diacetate%2520Succinimidyl%2520Ester%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26issue%3D9%26spage%3D2049%26epage%3D2056%26doi%3D10.1038%2Fnprot.2007.296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchser, W.</span>; <span class="NLM_string-name">Collins, M.</span>; <span class="NLM_string-name">Garyantes, T.</span>; <span class="NLM_string-name">Guha, R.</span>; <span class="NLM_string-name">Haney, S.</span>; <span class="NLM_string-name">Lemmon, V.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Trask, O. J.</span></span> <span> </span><span class="NLM_article-title">Assay Development Guidelines for Image-Based High Content Screening, High Content Analysis and High Content Imaging</span>. In  <i>Assay Guidance Manual</i> [Online]; <span class="NLM_contrib-group"><span class="NLM_string-name">Sittampalam, G. S.</span>, <span class="NLM_string-name">Coussens, N. P.</span>, <span class="NLM_string-name">Brimacombe, K.</span>, <span class="NLM_string-name">Grossman, A.</span>, <span class="NLM_string-name">Arkin, M.</span>, <span class="NLM_string-name">Auld, D.</span>, <span class="NLM_string-name">Austin, C.</span>, <span class="NLM_string-name">Baell, J.</span>, <span class="NLM_string-name">Bejcek, B.</span>, <span class="NLM_string-name">Caaveiro, J. M. M.</span>, <span class="NLM_string-name">Chung, T. D. Y.</span>, <span class="NLM_string-name">Dahlin, J. L.</span>, <span class="NLM_string-name">Devanaryan, V.</span>, <span class="NLM_string-name">Foley, T. L.</span>, <span class="NLM_string-name">Glicksman, M.</span>, <span class="NLM_string-name">Hall, M. D.</span>, <span class="NLM_string-name">Haas, J. V.</span>, <span class="NLM_string-name">Inglese, J.</span>, <span class="NLM_string-name">Iversen, P. W.</span>, <span class="NLM_string-name">Kahl, S. D.</span>, <span class="NLM_string-name">Kales, S. C.</span>, <span class="NLM_string-name">Lal-Nag, M.</span>, <span class="NLM_string-name">Li, Z.</span>, <span class="NLM_string-name">McGee, J.</span>, <span class="NLM_string-name">McManus, O.</span>, <span class="NLM_string-name">Riss, T.</span>, <span class="NLM_string-name">Trask, O. J. J.</span>, <span class="NLM_string-name">Weidner, J. R.</span>, <span class="NLM_string-name">Wildey, M. J.</span>, <span class="NLM_string-name">Xia, M.</span>, <span class="NLM_string-name">Xu, X.</span></span>, Eds.; <span class="NLM_publisher-name">Eli Lilly & Company and the National Center for Advancing Translational Sciences</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2004</span>; <a href="https://www.ncbi.nlm.nih.gov/books/NBK53196/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK53196/</a> (accessed March 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=W.+Buchser&author=M.+Collins&author=T.+Garyantes&author=R.+Guha&author=S.+Haney&author=V.+Lemmon&author=Z.+Li&author=O.+J.+Traskauthor=G.+S.+Sittampalam&author=N.+P.+Coussens&author=K.+Brimacombe&author=A.+Grossman&author=M.+Arkin&author=D.+Auld&author=C.+Austin&author=J.+Baell&author=B.+Bejcek&author=J.+M.+M.+Caaveiro&author=T.+D.+Y.+Chung&author=J.+L.+Dahlin&author=V.+Devanaryan&author=T.+L.+Foley&author=M.+Glicksman&author=M.+D.+Hall&author=J.+V.+Haas&author=J.+Inglese&author=P.+W.+Iversen&author=S.+D.+Kahl&author=S.+C.+Kales&author=M.+Lal-Nag&author=Z.+Li&author=J.+McGee&author=O.+McManus&author=T.+Riss&author=O.+J.+J.+Trask&author=J.+R.+Weidner&author=M.+J.+Wildey&author=M.+Xia&author=X.+Xu&title=Assay+Guidance+Manual"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBuchser%26aufirst%3DW.%26atitle%3DAssay%2520Development%2520Guidelines%2520for%2520Image-Based%2520High%2520Content%2520Screening%252C%2520High%2520Content%2520Analysis%2520and%2520High%2520Content%2520Imaging%26btitle%3DAssay%2520Guidance%2520Manual%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%26pub%3DEli%2520Lilly%2520%2526%2520Company%2520and%2520the%2520National%2520Center%2520for%2520Advancing%2520Translational%2520Sciences%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandavilli, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. S.</span></span> <span> </span><span class="NLM_article-title">General Staining and Segmentation Procedures for High Content Imaging and Analysis</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1683</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7357-6_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F978-1-4939-7357-6_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29082484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaitbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1683&publication_year=2018&pages=21-31&author=K.+M.+Chambersauthor=B.+S.+Mandavilliauthor=N.+J.+Dolmanauthor=M.+S.+Janes&title=General+Staining+and+Segmentation+Procedures+for+High+Content+Imaging+and+Analysis&doi=10.1007%2F978-1-4939-7357-6_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">General staining and segmentation procedures for high content imaging and analysis</span></div><div class="casAuthors">Chambers, Kevin M.; Mandavilli, Bhaskar S.; Dolman, Nick J.; Janes, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1683</span>
        (<span class="NLM_cas:issue">High Content Screening</span>),
    <span class="NLM_cas:pages">21-31</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Automated quant. fluorescence microscopy, also known as high content imaging (HCI), is a rapidly growing anal. approach in cell biol.  Because automated image anal. relies heavily on robust demarcation of cells and subcellular regions, reliable methods for labeling cells is a crit. component of the HCI workflow.  Labeling of cells for image segmentation is typically performed with fluorescent probes that bind DNA for nuclear-based cell demarcation or with those which react with proteins for image anal. based on whole cell staining.  These reagents, along with instrument and software settings, play an important role in the successful segmentation of cells in a population for automated and quant. image anal.  In this chapter, we describe std. procedures for labeling and image segmentation in both live and fixed cell samples.  The chapter will also provide troubleshooting guidelines for some of the common problems assocd. with these aspects of HCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYzCb2juHZCrVg90H21EOLACvtfcHk0lhxxmgLlLEezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaitbfE&md5=e15d3716e8a8015b503dd0421a92576e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7357-6_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7357-6_2%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DK.%2BM.%26aulast%3DMandavilli%26aufirst%3DB.%2BS.%26aulast%3DDolman%26aufirst%3DN.%2BJ.%26aulast%3DJanes%26aufirst%3DM.%2BS.%26atitle%3DGeneral%2520Staining%2520and%2520Segmentation%2520Procedures%2520for%2520High%2520Content%2520Imaging%2520and%2520Analysis%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2018%26volume%3D1683%26spage%3D21%26epage%3D31%26doi%3D10.1007%2F978-1-4939-7357-6_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, F.</span></span> <span> </span><span class="NLM_article-title">New Developments and Novel Applications in High Throughput and High Content Imaging</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1002/cyto.a.22921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcyto.a.22921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27564063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2szkvVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=705-707&issue=8&author=M.+E.+Calvertauthor=A.+M.+Wardauthor=G.+D.+Wrightauthor=F.+Bard&title=New+Developments+and+Novel+Applications+in+High+Throughput+and+High+Content+Imaging&doi=10.1002%2Fcyto.a.22921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New developments and novel applications in high throughput and high content imaging</span></div><div class="casAuthors">Calvert Meredith E K; Ward Alex M; Wright Graham D; Bard Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry. Part A : the journal of the International Society for Analytical Cytology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">705-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrL0J-xPHBpZggzHGM8X5CfW6udTcc2eYlfrBRpjiBgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szkvVegtg%253D%253D&md5=191afb75328b91554530fb2990545109</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.22921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.22921%26sid%3Dliteratum%253Aachs%26aulast%3DCalvert%26aufirst%3DM.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BM.%26aulast%3DWright%26aufirst%3DG.%2BD.%26aulast%3DBard%26aufirst%3DF.%26atitle%3DNew%2520Developments%2520and%2520Novel%2520Applications%2520in%2520High%2520Throughput%2520and%2520High%2520Content%2520Imaging%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2016%26volume%3D89%26issue%3D8%26spage%3D705%26epage%3D707%26doi%3D10.1002%2Fcyto.a.22921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, M. E.</span></span> <span> </span><span class="NLM_article-title">Pushing the Boundaries of High Content Imaging</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1002/cyto.a.23063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcyto.a.23063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28222254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ptVyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=113-114&issue=2&author=G.+D.+Wrightauthor=A.+M.+Wardauthor=F.+Bardauthor=M.+E.+Calvert&title=Pushing+the+Boundaries+of+High+Content+Imaging&doi=10.1002%2Fcyto.a.23063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pushing the boundaries of high content imaging</span></div><div class="casAuthors">Wright Graham D; Ward Alex M; Bard Frederic; Calvert Meredith E K</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry. Part A : the journal of the International Society for Analytical Cytology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-114</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3fLYiHvqnzZdYoSR9eyvsfW6udTcc2eYlfrBRpjiBgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ptVyrsw%253D%253D&md5=6c00b6b4ed088093f9209e504a248f55</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.23063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.23063%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DG.%2BD.%26aulast%3DWard%26aufirst%3DA.%2BM.%26aulast%3DBard%26aufirst%3DF.%26aulast%3DCalvert%26aufirst%3DM.%2BE.%26atitle%3DPushing%2520the%2520Boundaries%2520of%2520High%2520Content%2520Imaging%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2017%26volume%3D91%26issue%3D2%26spage%3D113%26epage%3D114%26doi%3D10.1002%2Fcyto.a.23063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizada, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiraz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalbant, A.</span></span> <span> </span><span class="NLM_article-title">Flow Cytometry: Basic Principles and Applications</span>. <i>Crit. Rev. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.3109/07388551.2015.1128876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.3109%2F07388551.2015.1128876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26767547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=163-176&issue=2&author=A.+Adanauthor=G.+Alizadaauthor=Y.+Kirazauthor=Y.+Baranauthor=A.+Nalbant&title=Flow+Cytometry%3A+Basic+Principles+and+Applications&doi=10.3109%2F07388551.2015.1128876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Flow cytometry: basic principles and applications</span></div><div class="casAuthors">Adan, Aysun; Alizada, Gunel; Kiraz, Yagmur; Baran, Yusuf; Nalbant, Ayten</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biotechnology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-176</span>CODEN:
                <span class="NLM_cas:coden">CRBTE5</span>;
        ISSN:<span class="NLM_cas:issn">0738-8551</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Flow cytometry is a sophisticated instrument measuring multiple phys. characteristics of a single cell such as size and granularity simultaneously as the cell flows in suspension through a measuring device.  Its working depends on the light scattering features of the cells under investigation, which may be derived from dyes or monoclonal antibodies targeting either extracellular mols. located on the surface or intracellular mols. inside the cell.  This approach makes flow cytometry a powerful tool for detailed anal. of complex populations in a short period of time.  This review covers the general principles and selected applications of flow cytometry such as immunophenotyping of peripheral blood cells, anal. of apoptosis and detection of cytokines.  Addnl., this report provides a basic understanding of flow cytometry technol. essential for all users as well as the methods used to analyze and interpret the data.  Moreover, recent progresses in flow cytometry have been discussed in order to give an opinion about the future importance of this technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgb2jCpKQ5LVg90H21EOLACvtfcHk0lim7KoGEGOBpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKhsL4%253D&md5=bea04538a4b554e8502fbe2030f58c99</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3109%2F07388551.2015.1128876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07388551.2015.1128876%26sid%3Dliteratum%253Aachs%26aulast%3DAdan%26aufirst%3DA.%26aulast%3DAlizada%26aufirst%3DG.%26aulast%3DKiraz%26aufirst%3DY.%26aulast%3DBaran%26aufirst%3DY.%26aulast%3DNalbant%26aufirst%3DA.%26atitle%3DFlow%2520Cytometry%253A%2520Basic%2520Principles%2520and%2520Applications%26jtitle%3DCrit.%2520Rev.%2520Biotechnol.%26date%3D2017%26volume%3D37%26issue%3D2%26spage%3D163%26epage%3D176%26doi%3D10.3109%2F07388551.2015.1128876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspersson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Flow Cytometry for Drug Discovery: Principles, Applications, and Case Studies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1844</span>– <span class="NLM_lpage">1850</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.drudis.2017.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28916303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1844-1850&issue=12&author=M.+Dingauthor=K.+Kasperssonauthor=D.+Murrayauthor=C.+Bardelle&title=High-Throughput+Flow+Cytometry+for+Drug+Discovery%3A+Principles%2C+Applications%2C+and+Case+Studies&doi=10.1016%2Fj.drudis.2017.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput flow cytometry for drug discovery: principles, applications, and case studies</span></div><div class="casAuthors">Ding, Mei; Kaspersson, Karin; Murray, David; Bardelle, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1844-1850</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Flow cytometry is a technol. providing multiparametric anal. of single cells or other suspension particles.  High-throughput (HT) flow cytometry has become an attractive screening platform for drug discovery.  In this review, we highlight the recent HT flow cytometry applications, and then focus on HT flow cytometry deployment at AstraZeneca (AZ).  Practical considerations for successful HT flow cytometry assay development and screening are provided based on experience from four project case studies at AZ.  We provide an overview of the scientific rationale, explain why HT flow cytometry was chosen and how HT flow cytometry assays deliver new ways to support the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVkzNwaV50drVg90H21EOLACvtfcHk0lim7KoGEGOBpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsbbK&md5=7c7684d096a2b343b3c5baa0dc121b69</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DM.%26aulast%3DKaspersson%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DD.%26aulast%3DBardelle%26aufirst%3DC.%26atitle%3DHigh-Throughput%2520Flow%2520Cytometry%2520for%2520Drug%2520Discovery%253A%2520Principles%252C%2520Applications%252C%2520and%2520Case%2520Studies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26issue%3D12%26spage%3D1844%26epage%3D1850%26doi%3D10.1016%2Fj.drudis.2017.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitson-Salazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prussin, C.</span></span> <span> </span><span class="NLM_article-title">Detection of Intracellular Cytokines by Flow Cytometry</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">6.24.1</span>– <span class="NLM_lpage">6.24.18</span>, <span class="refDoi"> DOI: 10.1002/0471142735.im0624s110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2F0471142735.im0624s110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2015&pages=6.24.1-6.24.18&author=Y.+Yinauthor=A.+Mitson-Salazarauthor=C.+Prussin&title=Detection+of+Intracellular+Cytokines+by+Flow+Cytometry&doi=10.1002%2F0471142735.im0624s110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2F0471142735.im0624s110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471142735.im0624s110%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DY.%26aulast%3DMitson-Salazar%26aufirst%3DA.%26aulast%3DPrussin%26aufirst%3DC.%26atitle%3DDetection%2520of%2520Intracellular%2520Cytokines%2520by%2520Flow%2520Cytometry%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2015%26volume%3D110%26spage%3D6.24.1%26epage%3D6.24.18%26doi%3D10.1002%2F0471142735.im0624s110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maciorowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chattopadhyay, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P.</span></span> <span> </span><span class="NLM_article-title">Basic Multicolor Flow Cytometry</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">5.4.1</span>– <span class="NLM_lpage">5.4.38</span>, <span class="refDoi"> DOI: 10.1002/cpim.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcpim.26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=5.4.1-5.4.38&author=Z.+Maciorowskiauthor=P.+K.+Chattopadhyayauthor=P.+Jain&title=Basic+Multicolor+Flow+Cytometry&doi=10.1002%2Fcpim.26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcpim.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpim.26%26sid%3Dliteratum%253Aachs%26aulast%3DMaciorowski%26aufirst%3DZ.%26aulast%3DChattopadhyay%26aufirst%3DP.%2BK.%26aulast%3DJain%26aufirst%3DP.%26atitle%3DBasic%2520Multicolor%2520Flow%2520Cytometry%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2017%26volume%3D117%26spage%3D5.4.1%26epage%3D5.4.38%26doi%3D10.1002%2Fcpim.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, W. G.</span></span> <span> </span><span class="NLM_article-title">Fluorescent Proteins for Flow Cytometry</span>. <i>Curr. Protoc. Cytom.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">9.12.1</span>– <span class="NLM_lpage">9.12.20</span>, <span class="refDoi"> DOI: 10.1002/cpcy.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcpcy.17" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2017&pages=9.12.1-9.12.20&issue=1&author=T.+S.+Hawleyauthor=R.+G.+Hawleyauthor=W.+G.+Telford&title=Fluorescent+Proteins+for+Flow+Cytometry&doi=10.1002%2Fcpcy.17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcpcy.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpcy.17%26sid%3Dliteratum%253Aachs%26aulast%3DHawley%26aufirst%3DT.%2BS.%26aulast%3DHawley%26aufirst%3DR.%2BG.%26aulast%3DTelford%26aufirst%3DW.%2BG.%26atitle%3DFluorescent%2520Proteins%2520for%2520Flow%2520Cytometry%26jtitle%3DCurr.%2520Protoc.%2520Cytom.%26date%3D2017%26volume%3D80%26issue%3D1%26spage%3D9.12.1%26epage%3D9.12.20%26doi%3D10.1002%2Fcpcy.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duc, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span> <span> </span><span class="NLM_article-title">Labelling HaloTag Fusion Proteins with HaloTag Ligand in Living Cells</span>. <i>Bio-Protoc</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">e2526</span>, <span class="refDoi"> DOI: 10.21769/BioProtoc.2526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.21769%2FBioProtoc.2526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28966948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlGktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e2526&issue=17&author=H.+N.+Ducauthor=X.+Ren&title=Labelling+HaloTag+Fusion+Proteins+with+HaloTag+Ligand+in+Living+Cells&doi=10.21769%2FBioProtoc.2526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Labelling HaloTag fusion proteins with HaloTag ligand in living cells</span></div><div class="casAuthors">Duc, Huy Nguyen; Ren, Xiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Bio-Protocol</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2526/1-2526/8</span>CODEN:
                <span class="NLM_cas:coden">BIOPCG</span>;
        ISSN:<span class="NLM_cas:issn">2331-8325</span>.
    
            (<span class="NLM_cas:orgname">Bio-Protocol LLC</span>)
        </div><div class="casAbstract">HaloTag has been widely used to label proteins in vitro and in vivo.  In this protocol, we describe labeling HaloTag-Cbx fusion proteins by HaloTag ligands for live-cell single-mol. imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq4vqfXFZvErVg90H21EOLACvtfcHk0ljfc5x-ooc7gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlGktLc%253D&md5=53ef81ff0d936149e13b4ced06b5c225</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.21769%2FBioProtoc.2526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21769%252FBioProtoc.2526%26sid%3Dliteratum%253Aachs%26aulast%3DDuc%26aufirst%3DH.%2BN.%26aulast%3DRen%26aufirst%3DX.%26atitle%3DLabelling%2520HaloTag%2520Fusion%2520Proteins%2520with%2520HaloTag%2520Ligand%2520in%2520Living%2520Cells%26jtitle%3DBio-Protoc%26date%3D2017%26volume%3D7%26issue%3D17%26spage%3De2526%26doi%3D10.21769%2FBioProtoc.2526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riching, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDougall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasta, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span> <span> </span><span class="NLM_article-title">Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2758</span>– <span class="NLM_lpage">2770</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00692</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00692" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOrtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2758-2770&issue=9&author=K.+M.+Richingauthor=S.+Mahanauthor=C.+R.+Coronaauthor=M.+McDougallauthor=J.+D.+Vastaauthor=M.+B.+Robersauthor=M.+Urhauthor=D.+L.+Daniels&title=Quantitative+Live-Cell+Kinetic+Degradation+and+Mechanistic+Profiling+of+PROTAC+Mode+of+Action&doi=10.1021%2Facschembio.8b00692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action</span></div><div class="casAuthors">Riching, Kristin M.; Mahan, Sarah; Corona, Cesear R.; McDougall, Mark; Vasta, James D.; Robers, Matthew B.; Urh, Marjeta; Daniels, Danette L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2758-2770</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new generation of heterobifunctional small mols., termed proteolysis targeting chimeras (PROTACs), targets proteins for degrdn. through recruitment to E3 ligases and holds significant therapeutic potential.  Despite numerous successful examples, PROTAC small mol. development remains laborious and unpredictable, involving testing compds. for end-point degrdn. activity at fixed times and concns. without resolving or optimizing for the important biol. steps required for the process.  Given the complexity of the ubiquitin proteasomal pathway, technologies that enable real-time characterization of PROTAC efficacy and mechanism of action are crit. for accelerating compd. development, profiling, and improving guidance of chem. structure-activity relationship.  Here, the authors present an innovative, modular live-cell platform utilizing endogenous tagging technologies and apply it to monitoring PROTAC-mediated degrdn. of the bromodomain and extra-terminal family members.  The authors show comprehensive real-time degrdn. and recovery profiles for each target, precisely quantifying degrdn. rates, maximal levels of degrdn. (Dmax), and time frame at Dmax.  These degrdn. metrics show specific PROTAC and family member-dependent responses that are closely assocd. with the key cellular protein interactions required for the process.  Kinetic studies show cellular ternary complex stability influences potency and degrdn. efficacy.  Meanwhile, the level of ubiquitination is highly correlated to degrdn. rate, indicating ubiquitination stemming from productive ternary complex formation is the main driver of the degrdn. rate.  The approaches applied here highlight the steps at which the choice of E3 ligase handle can elicit different outcomes and discern individual parameters required for degrdn., ultimately enabling chem. design strategies and rank ordering of potential therapeutic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnkETO-K622bVg90H21EOLACvtfcHk0ljfc5x-ooc7gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOrtbbM&md5=9a2a3162dd930ac04622db6990c0d748</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00692%26sid%3Dliteratum%253Aachs%26aulast%3DRiching%26aufirst%3DK.%2BM.%26aulast%3DMahan%26aufirst%3DS.%26aulast%3DCorona%26aufirst%3DC.%2BR.%26aulast%3DMcDougall%26aufirst%3DM.%26aulast%3DVasta%26aufirst%3DJ.%2BD.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26atitle%3DQuantitative%2520Live-Cell%2520Kinetic%2520Degradation%2520and%2520Mechanistic%2520Profiling%2520of%2520PROTAC%2520Mode%2520of%2520Action%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D2758%26epage%3D2770%26doi%3D10.1021%2Facschembio.8b00692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwinn, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encell, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkowski, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=467-474&issue=2&author=M.+K.+Schwinnauthor=T.+Machleidtauthor=K.+Zimmermanauthor=C.+T.+Eggersauthor=A.+S.+Dixonauthor=R.+Hurstauthor=M.+P.+Hallauthor=L.+P.+Encellauthor=B.+F.+Binkowskiauthor=K.+V.+Wood&title=CRISPR-Mediated+Tagging+of+Endogenous+Proteins+with+a+Luminescent+Peptide&doi=10.1021%2Facschembio.7b00549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide</span></div><div class="casAuthors">Schwinn, Marie K.; Machleidt, Thomas; Zimmerman, Kris; Eggers, Christopher T.; Dixon, Andrew S.; Hurst, Robin; Hall, Mary P.; Encell, Lance P.; Binkowski, Brock F.; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">467-474</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Intracellular signaling pathways are mediated by changes in protein abundance and post-translational modifications.  A common approach for investigating signaling mechanisms and the effects induced by synthetic compds. is through overexpression of recombinant reporter genes.  Genome editing with CRISPR/Cas9 offers a means to better preserve native biol. by appending reporters directly onto the endogenous genes.  An optimal reporter for this purpose would be small to negligibly influence intracellular processes, be readily linked to the endogenous genes with minimal exptl. effort, and be sensitive enough to detect low expressing proteins.  HiBiT is a 1.3 kDa peptide (11 amino acids) capable of producing bright and quant. luminescence through high affinity complementation (KD = 700 pM) with an 18 kDa subunit derived from NanoLuc (LgBiT).  Using CRISPR/Cas9, we demonstrate that HiBiT can be rapidly and efficiently integrated into the genome to serve as a reporter tag for endogenous proteins.  Without requiring clonal isolation of the edited cells, we were able to quantify changes in abundance of the hypoxia inducible factor 1A (HIF1α) and several of its downstream transcriptional targets in response to various stimuli.  In combination with fluorescent antibodies, we further used HiBiT to directly correlate HIF1α levels with the hydroxyproline modification that mediates its degrdn.  These results demonstrate the ability to efficiently tag endogenous proteins with a small luminescent peptide, allowing sensitive quantitation of the response dynamics in their regulated expression and covalent modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzCZoXuuYB37Vg90H21EOLACvtfcHk0lh2CymJTYnpeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKmur7I&md5=0d02aa711b02f68a5a54b72b968f6292</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00549%26sid%3Dliteratum%253Aachs%26aulast%3DSchwinn%26aufirst%3DM.%2BK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DEggers%26aufirst%3DC.%2BT.%26aulast%3DDixon%26aufirst%3DA.%2BS.%26aulast%3DHurst%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DM.%2BP.%26aulast%3DEncell%26aufirst%3DL.%2BP.%26aulast%3DBinkowski%26aufirst%3DB.%2BF.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DCRISPR-Mediated%2520Tagging%2520of%2520Endogenous%2520Proteins%2520with%2520a%2520Luminescent%2520Peptide%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D2%26spage%3D467%26epage%3D474%26doi%3D10.1021%2Facschembio.7b00549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkowski, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valley, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidugiris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benink, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenheimer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaubert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encell, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">Engineered Luciferase Reporter From a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1857</span>, <span class="refDoi"> DOI: 10.1021/cb3002478</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb3002478" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Smu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1848-1857&issue=11&author=M.+P.+Hallauthor=J.+Unchauthor=B.+F.+Binkowskiauthor=M.+P.+Valleyauthor=B.+L.+Butlerauthor=M.+G.+Woodauthor=P.+Ottoauthor=K.+Zimmermanauthor=G.+Vidugirisauthor=T.+Machleidtauthor=M.+B.+Robersauthor=H.+A.+Beninkauthor=C.+T.+Eggersauthor=M.+R.+Slaterauthor=P.+L.+Meisenheimerauthor=D.+H.+Klaubertauthor=F.+Fanauthor=L.+P.+Encellauthor=K.+V.+Wood&title=Engineered+Luciferase+Reporter+From+a+Deep+Sea+Shrimp+Utilizing+a+Novel+Imidazopyrazinone+Substrate&doi=10.1021%2Fcb3002478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate</span></div><div class="casAuthors">Hall, Mary P.; Unch, James; Binkowski, Brock F.; Valley, Michael P.; Butler, Braeden L.; Wood, Monika G.; Otto, Paul; Zimmerman, Kristopher; Vidugiris, Gediminas; Machleidt, Thomas; Robers, Matthew B.; Benink, Helene A.; Eggers, Christopher T.; Slater, Michael R.; Meisenheimer, Poncho L.; Klaubert, Dieter H.; Fan, Frank; Encell, Lance P.; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioluminescence methodologies have been extraordinarily useful due to their high sensitivity, broad dynamic range, and operational simplicity.  These capabilities have been realized largely through incremental adaptations of native enzymes and substrates, originating from luminous organisms of diverse evolutionary lineages.  We engineered both an enzyme and substrate in combination to create a novel bioluminescence system capable of more efficient light emission with superior biochem. and phys. characteristics.  Using a small luciferase subunit (19 kDa) from the deep sea shrimp Oplophorus gracilirostris, we have improved luminescence expression in mammalian cells ∼2.5 million-fold by merging optimization of protein structure with development of a novel imidazopyrazinone substrate (furimazine).  The new luciferase, NanoLuc, produces glow-type luminescence (signal half-life >2 h) with a specific activity ∼150-fold greater than that of either firefly (Photinus pyralis) or Renilla luciferases similarly configured for glow-type assays.  In mammalian cells, NanoLuc shows no evidence of post-translational modifications or subcellular partitioning.  The enzyme exhibits high phys. stability, retaining activity with incubation up to 55 °C or in culture medium for >15 h at 37 °C.  As a genetic reporter, NanoLuc may be configured for high sensitivity or for response dynamics by appending a degrdn. sequence to reduce intracellular accumulation.  Appending a signal sequence allows NanoLuc to be exported to the culture medium, where reporter expression can be measured without cell lysis.  Fusion onto other proteins allows luminescent assays of their metab. or localization within cells.  Reporter quantitation is achievable even at very low expression levels to facilitate more reliable coupling with endogenous cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlTT1m2z_bZLVg90H21EOLACvtfcHk0lh2CymJTYnpeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Smu7%252FN&md5=0581a7e44935671471577ade1ff538eb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcb3002478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb3002478%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BP.%26aulast%3DUnch%26aufirst%3DJ.%26aulast%3DBinkowski%26aufirst%3DB.%2BF.%26aulast%3DValley%26aufirst%3DM.%2BP.%26aulast%3DButler%26aufirst%3DB.%2BL.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DVidugiris%26aufirst%3DG.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DBenink%26aufirst%3DH.%2BA.%26aulast%3DEggers%26aufirst%3DC.%2BT.%26aulast%3DSlater%26aufirst%3DM.%2BR.%26aulast%3DMeisenheimer%26aufirst%3DP.%2BL.%26aulast%3DKlaubert%26aufirst%3DD.%2BH.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DEncell%26aufirst%3DL.%2BP.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DEngineered%2520Luciferase%2520Reporter%2520From%2520a%2520Deep%2520Sea%2520Shrimp%2520Utilizing%2520a%2520Novel%2520Imidazopyrazinone%2520Substrate%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26issue%3D11%26spage%3D1848%26epage%3D1857%26doi%3D10.1021%2Fcb3002478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rauniyar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.,  3.</span></span> <span> </span><span class="NLM_article-title">Isobaric Labeling-Based Relative Quantification in Shotgun Proteomics</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5293</span>– <span class="NLM_lpage">5309</span>, <span class="refDoi"> DOI: 10.1021/pr500880b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr500880b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyrsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=5293-5309&issue=12&author=N.+Rauniyarauthor=J.+R.+Yates&title=Isobaric+Labeling-Based+Relative+Quantification+in+Shotgun+Proteomics&doi=10.1021%2Fpr500880b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Isobaric Labeling-Based Relative Quantification in Shotgun Proteomics</span></div><div class="casAuthors">Rauniyar, Navin; Yates, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5293-5309</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Mass spectrometry plays a key role in relative quant. comparisons of proteins to understand their functional role in biol. systems upon perturbation.  The authors review studies that examine different aspects of isobaric labeling-based relative quantification for shotgun proteomic anal.  In particular, the authors focus on different types of isobaric reagents and their reaction chem. (e.g., amine-, carbonyl-, and sulfhydryl-reactive).  Various factors, such as ratio compression, reporter ion dynamic range, and others, cause an underestimation of changes in relative abundance of proteins across samples, undermining the ability of the isobaric labeling approach to be truly quant.  These factors that affect quantification and the suggested combinations of exptl. design and optimal data acquisition methods to increase the precision and accuracy of the measurements are discussed.  Finally, the extended application of isobaric labeling-based approach in hyperplexing strategy, targeted quantification, and phosphopeptide anal. were also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAnWzL7zw5bVg90H21EOLACvtfcHk0ljcyBzgmTGFxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyrsbzE&md5=5a5286bac4061c3026d978a39e73319d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fpr500880b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr500880b%26sid%3Dliteratum%253Aachs%26aulast%3DRauniyar%26aufirst%3DN.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26atitle%3DIsobaric%2520Labeling-Based%2520Relative%2520Quantification%2520in%2520Shotgun%2520Proteomics%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2014%26volume%3D13%26issue%3D12%26spage%3D5293%26epage%3D5309%26doi%3D10.1021%2Fpr500880b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakalarski, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span> <span> </span><span class="NLM_article-title">A Biologist’s Field Guide to Multiplexed Quantitative Proteomics</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1074/mcp.O115.056986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fmcp.O115.056986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26873251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFOrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1489-1497&issue=5&author=C.+E.+Bakalarskiauthor=D.+S.+Kirkpatrick&title=A+Biologist%E2%80%99s+Field+Guide+to+Multiplexed+Quantitative+Proteomics&doi=10.1074%2Fmcp.O115.056986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Biologist's Field Guide to Multiplexed Quantitative Proteomics</span></div><div class="casAuthors">Bakalarski, Corey E.; Kirkpatrick, Donald S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1489-1497</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">High-throughput genomic and proteomic studies have generated near-comprehensive catalogs of biol. constituents within many model systems.  Nevertheless, static catalogs are often insufficient to fully describe the dynamic processes that drive biol.  Quant. proteomic techniques address this need by providing insight into closely related biol. states such as the stages of a therapeutic response or cellular differentiation.  The maturation of quant. proteomics in recent years has brought about a variety of technologies, each with their own strengths and weaknesses.  It can be difficult for those unfamiliar with this evolving landscape to match the expt. at hand with the best tool for the job.  Here, we outline quant. methods for proteomic mass spectrometry and discuss their benefits and weaknesses from the perspective of the biologist aiming to generate meaningful data and address mechanistic questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyZP47hxg6ybVg90H21EOLACvtfcHk0lgrAnF9ruTY-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFOrt7s%253D&md5=d9dfb4544b22488b0465f6d71f39b60e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fmcp.O115.056986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.O115.056986%26sid%3Dliteratum%253Aachs%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26atitle%3DA%2520Biologist%25E2%2580%2599s%2520Field%2520Guide%2520to%2520Multiplexed%2520Quantitative%2520Proteomics%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2016%26volume%3D15%26issue%3D5%26spage%3D1489%26epage%3D1497%26doi%3D10.1074%2Fmcp.O115.056986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D. W.</span></span> <span> </span><span class="NLM_article-title">Quantitative Comparisons of Large Numbers of Human Plasma Samples Using TMT10plex Labeling</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1619</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7057-5_22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F978-1-4939-7057-5_22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28674894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2isLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1619&publication_year=2017&pages=319-337&author=P.+Liuauthor=L.+A.+Beerauthor=B.+Kyauthor=K.+T.+Barnhartauthor=D.+W.+Speicher&title=Quantitative+Comparisons+of+Large+Numbers+of+Human+Plasma+Samples+Using+TMT10plex+Labeling&doi=10.1007%2F978-1-4939-7057-5_22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative comparisons of large numbers of human plasma samples using TMT10plex labeling</span></div><div class="casAuthors">Liu, Pengyuan; Beer, Lynn A.; Ky, Bonnie; Barnhart, Kurt T.; Speicher, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1619</span>
        (<span class="NLM_cas:issue">Serum/Plasma Proteomics</span>),
    <span class="NLM_cas:pages">319-337</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">One strategy for improving the throughput of human plasma proteomic discovery anal. while maintaining good depth of anal. is to multiplex using isobaric tags.  At present, the greatest multiplexing that is com. available uses the TMT10plex kit.  As an example of this approach, we describe efficient shotgun discovery proteomics of large nos. of human plasma to identify potential biomarkers.  In the anal. strategy, a common pooled ref. was used to enable comparisons across multiple expts.  Duplicate samples showed excellent overall reproducibility across different TMT expts.  Data filters that improved the quality of individual peptide and protein quantitation included using a filter for purity of the targeted precursor ion in the isolation window and using only unique peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYRfEefoIV_rVg90H21EOLACvtfcHk0lgrAnF9ruTY-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2isLjI&md5=c0bf757ada5b9a03eb2b82c3c2a42887</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7057-5_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7057-5_22%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBeer%26aufirst%3DL.%2BA.%26aulast%3DKy%26aufirst%3DB.%26aulast%3DBarnhart%26aufirst%3DK.%2BT.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26atitle%3DQuantitative%2520Comparisons%2520of%2520Large%2520Numbers%2520of%2520Human%2520Plasma%2520Samples%2520Using%2520TMT10plex%2520Labeling%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2017%26volume%3D1619%26spage%3D319%26epage%3D337%26doi%3D10.1007%2F978-1-4939-7057-5_22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClatchy, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkallah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.,  3.</span></span> <span> </span><span class="NLM_article-title">Quantitative Analysis of Newly Synthesized Proteins</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1744</span>– <span class="NLM_lpage">1762</span>, <span class="refDoi"> DOI: 10.1038/s41596-018-0012-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41596-018-0012-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30038347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOis7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1744-1762&issue=8&author=Y.+Maauthor=D.+B.+McClatchyauthor=S.+Barkallahauthor=W.+W.+Woodauthor=J.+R.+Yates&title=Quantitative+Analysis+of+Newly+Synthesized+Proteins&doi=10.1038%2Fs41596-018-0012-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of newly synthesized proteins</span></div><div class="casAuthors">Ma, Yuanhui; McClatchy, Daniel B.; Barkallah, Salim; Wood, William W.; Yates, III, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1744-1762</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Measuring proteome response to perturbations is crit. for understanding the underlying mechanisms involved.  Traditional quant. proteomic methods are limited by the large nos. of proteins in the proteome and the mass spectrometer's dynamic range.  A previous method uses the biorthogonal reagent azidohomoalanine (AHA), a methionine analog, for labeling, enrichment and detection of newly synthesized proteins (NSPs).  Newly synthesized AHA proteins can be coupled to biotin via CuAAC-mediated click chem. and enriched using avidin-based affinity purifn.  The combination of AHA-mediated NSP labeling with metabolic stable isotope labeling allows quantitation of low-abundant, newly secreted proteins by mass spectrometry (MS).  However, the resulting multiplicity of labeling complicates NSP anal.  We developed a new NSP quantification strategy, called HILAQ (heavy isotope-labeled azidohomoalanine quantification), that uses a heavy isotope-labeled AHA mol. to enable NSP labeling, enrichment, identification and quantification.  In addn., the AHA-peptide enrichment used in HILAQ improves both the identification and quantification of NSPs over AHA-protein enrichment.  Here, we provide a description of the HILAQ method that includes procedures for (i) pulse-labeling and harvesting NSPs; (ii) addn. of biotin by click reaction; (iii) protein pptn.; (iv) protein digestion; (v) enrichment of AHA-biotin peptides by NeutrAvidin beads and four-step elution; (vi) MS anal.; and (vii) data anal. for the identification and quantification of NSPs by ProLuCID and pQuant.  We demonstrate our HILAQ approach by identifying NSPs from cell cultures, but we anticipate that it can be adapted for applications in animal models.  The whole protocol takes ∼6 d to complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHtHGCDdsc47Vg90H21EOLACvtfcHk0liq3UlpXVovnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOis7rO&md5=a93767e88af5b979057b4d02e10c39de</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41596-018-0012-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41596-018-0012-y%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMcClatchy%26aufirst%3DD.%2BB.%26aulast%3DBarkallah%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DW.%2BW.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26atitle%3DQuantitative%2520Analysis%2520of%2520Newly%2520Synthesized%2520Proteins%26jtitle%3DNat.%2520Protoc.%26date%3D2018%26volume%3D13%26issue%3D8%26spage%3D1744%26epage%3D1762%26doi%3D10.1038%2Fs41596-018-0012-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.,  3.</span></span> <span> </span><span class="NLM_article-title">Proteomics and Pulse Azidohomoalanine Labeling of Newly Synthesized Proteins: What Are the Potential Applications?</span>. <i>Expert Rev. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1080/14789450.2018.1500902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1080%2F14789450.2018.1500902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30005169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=545-554&issue=7&author=Y.+Maauthor=J.+R.+Yates&title=Proteomics+and+Pulse+Azidohomoalanine+Labeling+of+Newly+Synthesized+Proteins%3A+What+Are+the+Potential+Applications%3F&doi=10.1080%2F14789450.2018.1500902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomics and pulse azidohomoalanine labeling of newly synthesized proteins: what are the potential applications?</span></div><div class="casAuthors">Ma, Yuanhui; Yates, John R. III</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Proteomics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">545-554</span>CODEN:
                <span class="NLM_cas:coden">ERPXA3</span>;
        ISSN:<span class="NLM_cas:issn">1478-9450</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Measuring the immediate changes in cells that arise from changing environmental conditions is crucial to understanding the underlying mechanisms involved.  These changes can be measured with metabolic stable isotope fully labeled proteomes, but requires looking for changes in the midst of a large background.  In addn., labeling efficiency can be an issue in primary and fully differentiated cells.  Azidohomoalanine (AHA), an analog of methionine, can be accepted by cellular translational machinery and incorporated into newly synthesized proteins (NSPs).  AHA-NSPs can be coupled to biotin via CuAAC-mediated click-chem. and enriched using avidin-based affinity purifn.  Thus, AHA-contg. proteins or peptides can be enriched and efficiently sepd. from the whole proteome.  In this review, we describe the development of mass spectrometry (MS) based AHA strategies and discuss their potential to measure proteins involved in immune response, secretome, gut microbiome, and proteostasis as well as their potential for clin. uses.  AHA strategies have been used to identify synthesis activity and to compare two biol. conditions in various biol. model organisms.  In combination with instrument development, improved sample prepn. and fractionation strategies, MS-based AHA strategies have the potential for broad application, and the methods should translate into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0XqsmQfzr4LVg90H21EOLACvtfcHk0liq3UlpXVovnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtrjM&md5=e48f427e02d7956dfdaf3416b05e5dbe</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F14789450.2018.1500902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14789450.2018.1500902%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26atitle%3DProteomics%2520and%2520Pulse%2520Azidohomoalanine%2520Labeling%2520of%2520Newly%2520Synthesized%2520Proteins%253A%2520What%2520Are%2520the%2520Potential%2520Applications%253F%26jtitle%3DExpert%2520Rev.%2520Proteomics%26date%3D2018%26volume%3D15%26issue%3D7%26spage%3D545%26epage%3D554%26doi%3D10.1080%2F14789450.2018.1500902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. M.</span></span> <span> </span><span class="NLM_article-title">Nonradioactive Quantification of Autophagic Protein Degradation with L-Azidohomoalanine Labeling</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1038/nprot.2016.160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnprot.2016.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28079880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=279-288&issue=2&author=J.+Wangauthor=J.+Zhangauthor=Y.+M.+Leeauthor=S.+Ngauthor=Y.+Shiauthor=Z.+C.+Huaauthor=Q.+Linauthor=H.+M.+Shen&title=Nonradioactive+Quantification+of+Autophagic+Protein+Degradation+with+L-Azidohomoalanine+Labeling&doi=10.1038%2Fnprot.2016.160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Nonradioactive quantification of autophagic protein degradation with L-azidohomoalanine labeling</span></div><div class="casAuthors">Wang, Jigang; Zhang, Jianbin; Lee, Yew Mun; Ng, Shukie; Shi, Yin; Hua, Zi-Chun; Lin, Qingsong; Shen, Han-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-288</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">At present, several assays that use radioisotope labeling to quantify the degrdn. of long-lived proteins have been developed to measure autophagic flux.  Here, we describe a nonradioactive pulse-chase protocol using L-azidohomoalanine (AHA) labeling to quantify long-lived protein degrdn. during autophagy.  AHA is used as a surrogate for L-methionine, and, when added to cultured cells grown in methionine-free medium, AHA is incorporated into proteins during de novo protein synthesis.  After a chase period to remove short-lived proteins, autophagy is induced by starvation or other stimuli.  Cells then undergo a 'click' reaction between the azide group of AHA and a fluorescently tagged alkyne probe.  The AHA-contg. proteins can then be detected by flow cytometry.  This protocol is nonradioactive, sensitive and quant., and it is easy to perform.  It is also applicable to various cell culture systems.  The whole protocol is estd. to take 4-5 d to complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCPShpR6gY7LVg90H21EOLACvtfcHk0liucsGBYvMLEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVSjsQ%253D%253D&md5=40ebc7715edbfaf52bd7a001d2695b26</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2016.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2016.160%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BM.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DHua%26aufirst%3DZ.%2BC.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DH.%2BM.%26atitle%3DNonradioactive%2520Quantification%2520of%2520Autophagic%2520Protein%2520Degradation%2520with%2520L-Azidohomoalanine%2520Labeling%26jtitle%3DNat.%2520Protoc.%26date%3D2017%26volume%3D12%26issue%3D2%26spage%3D279%26epage%3D288%26doi%3D10.1038%2Fnprot.2016.160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tom
Dieck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nehring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartnik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieterich, D. C.</span></span> <span> </span><span class="NLM_article-title">Metabolic Labeling with Noncanonical Amino Acids and Visualization by Chemoselective Fluorescent Tagging</span>. <i>Curr. Protoc. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7.11.1</span>– <span class="NLM_lpage">7.11.29</span>, <span class="refDoi"> DOI: 10.1002/0471143030.cb0711s56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2F0471143030.cb0711s56" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=7.11.1-7.11.29&author=S.+Tom%0ADieckauthor=A.+M%C3%BCllerauthor=A.+Nehringauthor=F.+I.+Hinzauthor=I.+Bartnikauthor=E.+M.+Schumanauthor=D.+C.+Dieterich&title=Metabolic+Labeling+with+Noncanonical+Amino+Acids+and+Visualization+by+Chemoselective+Fluorescent+Tagging&doi=10.1002%2F0471143030.cb0711s56"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2F0471143030.cb0711s56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471143030.cb0711s56%26sid%3Dliteratum%253Aachs%26aulast%3DTom%2BDieck%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DNehring%26aufirst%3DA.%26aulast%3DHinz%26aufirst%3DF.%2BI.%26aulast%3DBartnik%26aufirst%3DI.%26aulast%3DSchuman%26aufirst%3DE.%2BM.%26aulast%3DDieterich%26aufirst%3DD.%2BC.%26atitle%3DMetabolic%2520Labeling%2520with%2520Noncanonical%2520Amino%2520Acids%2520and%2520Visualization%2520by%2520Chemoselective%2520Fluorescent%2520Tagging%26jtitle%3DCurr.%2520Protoc.%2520Cell%2520Biol.%26date%3D2012%26volume%3D56%26spage%3D7.11.1%26epage%3D7.11.29%26doi%3D10.1002%2F0471143030.cb0711s56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+Protein+Degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lhwvRt7Xc7tSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&issue=2&author=I.+Churcher&title=Protac-Induced+Protein+Degradation+in+Drug+Discovery%3A+Breaking+the+Rules+or+Just+Making+New+Ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0lhwvRt7Xc7tSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-Induced%2520Protein%2520Degradation%2520in%2520Drug%2520Discovery%253A%2520Breaking%2520the%2520Rules%2520or%2520Just%2520Making%2520New%2520Ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Kinase Downregulators</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.chembiol.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29174540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=30-35&issue=1&author=L.+H.+Jones&title=Small-Molecule+Kinase+Downregulators&doi=10.1016%2Fj.chembiol.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Kinase Downregulators</span></div><div class="casAuthors">Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-35</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">New opportunities to advance small-mol. kinase ligands that downregulate their cognate target binding proteins are discussed.  Rationally designed heterobifunctional kinase degraders are compared with ATP site ligands that were serendipitously found to cause kinase downregulation.  These approaches could be particularly useful in the treatment of cancers since many kinases are known to remodel pro-oncogenic protein-protein interactions, which could be destroyed by small-mol.-mediated kinase depletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbltft5F3cs7Vg90H21EOLACvtfcHk0ljRXS28LeeHJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfO&md5=b3d575658b082f1f879651ea296ce58f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSmall-Molecule%2520Kinase%2520Downregulators%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D30%26epage%3D35%26doi%3D10.1016%2Fj.chembiol.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantawy, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span> <span> </span><span class="NLM_article-title">The Selective Estrogen Receptor Downregulator GDC-0810 Is Efficacious in Diverse Models of ER+ Breast Cancer</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e15828</span>, <span class="refDoi"> DOI: 10.7554/eLife.15828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.7554%2FeLife.15828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27410477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e15828&author=J.+D.+Josephauthor=B.+Darimontauthor=W.+Zhouauthor=A.+Arrazateauthor=A.+Youngauthor=E.+Ingallaauthor=K.+Walterauthor=R.+A.+Blakeauthor=J.+Nonomiyaauthor=Z.+Guanauthor=L.+Kategayaauthor=S.+P.+Govekauthor=A.+G.+Laiauthor=M.+Kahramanauthor=D.+Brighamauthor=J.+Sensintaffarauthor=N.+Luauthor=G.+Shaoauthor=J.+Qianauthor=K.+Grillotauthor=M.+Moonauthor=R.+Prudenteauthor=E.+Bischoffauthor=K.-J.+Leeauthor=C.+Bonnefousauthor=K.+L.+Douglasauthor=J.+D.+Julienauthor=J.+Y.+Nagasawaauthor=A.+Aparicioauthor=J.+Kaufmanauthor=B.+Haleyauthor=J.+M.+Giltnaneauthor=I.+E.+Wertzauthor=M.+R.+Lacknerauthor=M.+A.+Nanniniauthor=D.+Sampathauthor=L.+Schwarzauthor=H.+C.+Manningauthor=M.+N.+Tantawyauthor=C.+L.+Arteagaauthor=R.+A.+Heymanauthor=P.+J.+Rixauthor=L.+Friedmanauthor=N.+D.+Smithauthor=C.+Metcalfeauthor=J.+H.+Hager&title=The+Selective+Estrogen+Receptor+Downregulator+GDC-0810+Is+Efficacious+in+Diverse+Models+of+ER%2B+Breast+Cancer&doi=10.7554%2FeLife.15828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span></div><div class="casAuthors">Joseph, James D.; Darimont, Beatrice; Zhou, Wei; Arrazate, Alfonso; Young, Amy; Ingalla, Ellen; Walter, Kimberly; Blake, Robert A.; Nonomiya, Jim; Guan, Zhengyu; Kategaya, Lorna; Govek, Steven P.; Lai, Andiliy G.; Kahraman, Mehmet; Brigham, Dan; Sensintaffar, John; Lu, Nhin; Shao, Gang; Qian, Jing; Grillot, Kate; Moon, Michael; Prudente, Rene; Bischoff, Eric; Lee, Kyoung-Jin; Bonnefous, Celine; Douglas, Karensa L.; Julien, Jackaline D.; Nagasawa, Johnny Y.; Aparicio, Anna; Kaufman, Josh; Haley, Benjamin; Giltnane, Jennifer M.; Wertz, Ingrid E.; Lackner, Mark R.; Nannini, Michelle A.; Sampath, Deepak; Schwarz, Luis; Manning, Henry Charles; Tantawy, Mohammed Noor; Arteaga, Carlos L.; Heyman, Richard A.; Rix, Peter J.; Friedman, Lori; Smith, Nicholas D.; Metcalfe, Ciara; Hager, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e15828/1-e15828/34</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies.  The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERa signaling, and provides a strong rationale for continued targeting of ERa.  Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERa degrdn., antagonism and pharmacokinetic properties.  GDC-0810 induces a distinct ERa conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action.  GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERa mutations.  GDC-0810 is currently being evaluated in Phase II clin. studies in women with ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML4fZixufB7Vg90H21EOLACvtfcHk0lgDIT188S6Ebg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D&md5=cfdf9624f8b260a732b92caab0bb2d58</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.7554%2FeLife.15828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.15828%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DZ.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DJulien%26aufirst%3DJ.%2BD.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DNannini%26aufirst%3DM.%2BA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSchwarz%26aufirst%3DL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26aulast%3DTantawy%26aufirst%3DM.%2BN.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520Selective%2520Estrogen%2520Receptor%2520Downregulator%2520GDC-0810%2520Is%2520Efficacious%2520in%2520Diverse%2520Models%2520of%2520ER%252B%2520Breast%2520Cancer%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3De15828%26doi%3D10.7554%2FeLife.15828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Poetsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyler, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1038/nchembio.304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnchembio.304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20118940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=209-217&issue=3&author=T.+Schneider-Poetschauthor=J.+Juauthor=D.+E.+Eylerauthor=Y.+Dangauthor=S.+Bhatauthor=W.+C.+Merrickauthor=R.+Greenauthor=B.+Shenauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+Elongation+by+Cycloheximide+and+Lactimidomycin&doi=10.1038%2Fnchembio.304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin</span></div><div class="casAuthors">Schneider-Poetsch, Tilman; Ju, Jianhua; Eyler, Daniel E.; Dang, Yongjun; Bhat, Shridhar; Merrick, William C.; Green, Rachel; Shen, Ben; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-217</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the protein synthesis inhibitor cycloheximide (CHX) has been known for decades, its precise mechanism of action remains incompletely understood.  The glutarimide portion of CHX is seen in a family of structurally related natural products including migrastatin, isomigrastatin, and lactimidomycin (LTM).  We found that LTM, isomigrastatin, and analogs have a potent antiproliferative effect on tumor cell lines and selectively inhibit translation.  A systematic comparative study of the effects of CHX and LTM on protein synthesis revealed both similarities and differences between the two inhibitors.  Both LTM and CHX were found to block the translocation step in elongation.  Footprinting expts. revealed protection of a single cytidine nucleotide (C3993) in the E-site of the 60S ribosomal subunit, thus defining a common binding pocket for the two inhibitors in the ribosome.  These results shed new light on the mol. mechanism of inhibition of translation elongation by both CHX and LTM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsVhn_TkyD-LVg90H21EOLACvtfcHk0lgDIT188S6Ebg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D&md5=77e621c87b496cd697f77299623b9f06</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.304%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider-Poetsch%26aufirst%3DT.%26aulast%3DJu%26aufirst%3DJ.%26aulast%3DEyler%26aufirst%3DD.%2BE.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520Elongation%2520by%2520Cycloheximide%2520and%2520Lactimidomycin%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26issue%3D3%26spage%3D209%26epage%3D217%26doi%3D10.1038%2Fnchembio.304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, Y.</span></span> <span> </span><span class="NLM_article-title">Synthetic Study of Peptide Aldehydes</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3106</span>– <span class="NLM_lpage">3113</span>, <span class="refDoi"> DOI: 10.1248/cpb.23.3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1248%2Fcpb.23.3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaE28XptVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1975&pages=3106-3113&issue=12&author=A.+Itoauthor=R.+Takahashiauthor=C.+Miuraauthor=Y.+Baba&title=Synthetic+Study+of+Peptide+Aldehydes&doi=10.1248%2Fcpb.23.3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic study of peptide aldehydes</span></div><div class="casAuthors">Ito, Akira; Takahashi, Rieko; Miura, Chieko; Baba, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3106-13</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">Ac-Leu-Leu-R [R = L- or D-NHCH(CH2Ph)CHO, L-NHCH(CH2C6H4OH-4)CHO, L-NHCH(CH2R1)CHO, R1 = 3-indolyl] were prepd. from benzyloxycarbonyl-α-aminoaldehyde semicarbazones derived from benzyloxycarbonyl amino acid esters by redn. with (Me2CHCH2)2AlH.  The racemization of the aldehyde of the purified analogs was examined using the analytical ion exchange chromatog. of diastereomers produced by the condensation of L-aspartic acid with aminoalcohols, which were obtained by the NaBH4 redn. of the synthesized peptide aldehydes followed by acid hydrolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSRjA5l9vB7Vg90H21EOLACvtfcHk0liVfVSjLwrpgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XptVGksA%253D%253D&md5=cbd5b79f0fc52c5092c022622c6f8fe6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1248%2Fcpb.23.3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.23.3106%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DMiura%26aufirst%3DC.%26aulast%3DBaba%26aufirst%3DY.%26atitle%3DSynthetic%2520Study%2520of%2520Peptide%2520Aldehydes%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1975%26volume%3D23%26issue%3D12%26spage%3D3106%26epage%3D3113%26doi%3D10.1248%2Fcpb.23.3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Proteasome Block the Degradation of Most Cell Proteins and the Generation of Peptides Presented on MHC Class I Molecules</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(94)90462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS0092-8674%2894%2990462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=8087844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=761-771&issue=5&author=K.+L.+Rockauthor=C.+Grammauthor=L.+Rothsteinauthor=K.+Clarkauthor=R.+Steinauthor=L.+Dickauthor=D.+Hwangauthor=A.+L.+Goldberg&title=Inhibitors+of+the+Proteasome+Block+the+Degradation+of+Most+Cell+Proteins+and+the+Generation+of+Peptides+Presented+on+MHC+Class+I+Molecules&doi=10.1016%2FS0092-8674%2894%2990462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules</span></div><div class="casAuthors">Rock, Kenneth L.; Gramm, Colette; Rothstein, Lisa; Clark, Karen; Stein, Ross; Dick, Lawrence; Hwang, Daniel; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">761-71</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Reagents that inhibit the ubiquitin-proteasome proteolytic pathway in cells have not been available.  Peptide aldehydes that inhibit major peptidase activities of the 20S and 26S proteasomes are shown to reduce the degrdn. of protein and ubiquitinated protein substrates by 26S particles.  Unlike inhibitors of lysosomal proteolysis, these compds. inhibit the degrdn. of not only abnormal and short-lived polypeptides but also long-lived proteins in intact cells.  The authors used these agents to test the importance of the proteasome in antigen presentation.  When ovalbumin is introduced into the cytosol of lymphoblasts, these inhibitors block the presentation on MHC class I mols. of an ovalbumin-derived peptide by preventing its proteolytic generation.  By preventing peptide prodn. from cell proteins, these inhibitors block the assembly of class I mols.  Therefore, the proteasome catalyzes the degrdn. of the vast majority of cell proteins and generates most peptides presented on MHC class I mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVw5InxABShLVg90H21EOLACvtfcHk0liVfVSjLwrpgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D&md5=2960e350aedb5a0d9e04d672f96f9c4f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2894%2990462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252894%252990462-6%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DGramm%26aufirst%3DC.%26aulast%3DRothstein%26aufirst%3DL.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DInhibitors%2520of%2520the%2520Proteasome%2520Block%2520the%2520Degradation%2520of%2520Most%2520Cell%2520Proteins%2520and%2520the%2520Generation%2520of%2520Peptides%2520Presented%2520on%2520MHC%2520Class%2520I%2520Molecules%26jtitle%3DCell%26date%3D1994%26volume%3D78%26issue%3D5%26spage%3D761%26epage%3D771%26doi%3D10.1016%2FS0092-8674%2894%2990462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, H. N.</span></span> <span> </span><span class="NLM_article-title">Evidence That a Rapidly Turning Over Protein, Normally Degraded by Proteasomes, Regulates Hsp72 Gene Transcription in HepG2 Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span> (<span class="NLM_issue">40</span>),  <span class="NLM_fpage">24769</span>– <span class="NLM_lpage">24775</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.40.24769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fjbc.271.40.24769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=8798747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK28XmtFegs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=24769-24775&issue=40&author=M.+Zhouauthor=X.+Wuauthor=H.+N.+Ginsberg&title=Evidence+That+a+Rapidly+Turning+Over+Protein%2C+Normally+Degraded+by+Proteasomes%2C+Regulates+Hsp72+Gene+Transcription+in+HepG2+Cells&doi=10.1074%2Fjbc.271.40.24769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells</span></div><div class="casAuthors">Zhou, Mingyue; Wu, Xujun; Ginsberg, Henry N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24769-24775</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Heat shock protein 72/73 (Hsp70) is a cytosolic mol. chaperone that carries out fundamental roles under both normal and stress situations.  There is great interest in delineating the mechanisms whereby Hsp70 levels are regulated.  We obsd. that N-acetyl-leucyl-leucyl-norleucinal (ALLN), a synthetic aldehydic tripeptide that inhibits proteasomes, markedly induced Hsp70 levels (up to 30-fold above base line in HepG2 cells and human endothelial cells).  Induction of Hsp70 by ALLN was dose-dependent and not related to cell toxicity.  ALLN selectively increased Hsp70 levels without affecting Hsp25, Hsp27, Hsp60, Hsp86, Hsp90, Hsp104, or Bip (Ig heavy chain binding protein) in HepG2 cells.  ALLN induced Hsp70 not only by stabilizing the protein but also by dramatically increasing its synthesis.  The modulation of Hsp70 synthesis by ALLN resulted from a rapid and marked increase in transcription of the hsp72 gene, since the induction of hsp72 mRNA was blocked in cells co-treated with actinomycin D. hsp72 mRNA levels were affected in a time-dependent manner by exposure to ALLN; significant elevations occurred within 60 min of treatment, and a decline to background levels was obsd. by 7 h of recovery.  The ALLN-induced increase in hsp72 gene expression was assocd. with trimerization of the heat shock transcriptional factor (HSF1).  ALLN did not affect the steady-state level of HSF1 protein.  The effects of ALLN appeared to require de novo protein synthesis, since the induction of both HSF1 trimerization and hsp72 transcription was blocked by co-treatment with cycloheximide.  When we tested a series of protease inhibitors, only the related aldehydic tripeptides, N-acetyl-leucyl-leucyl-methioninal and the proteasome inhibitor, Cbz-leucyl-leucyl-leucinal, induced Hsp70 levels.  The specific proteasome inhibitor, lactacystin, which has a different structure, also induced Hsp70 levels.  Overall, our results suggest that a rapidly turning over protein that is normally degraded by proteasomes may be involved in the regulation of Hsp70 synthesis via effects on the hsp70 transcriptional factor, HSF1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_XJac9ixawrVg90H21EOLACvtfcHk0lhqYnbMdkYYgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtFegs7Y%253D&md5=98f05922d79f91f8d5bc12bea411dfa7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.40.24769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.40.24769%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGinsberg%26aufirst%3DH.%2BN.%26atitle%3DEvidence%2520That%2520a%2520Rapidly%2520Turning%2520Over%2520Protein%252C%2520Normally%2520Degraded%2520by%2520Proteasomes%252C%2520Regulates%2520Hsp72%2520Gene%2520Transcription%2520in%2520HepG2%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26issue%3D40%26spage%3D24769%26epage%3D24775%26doi%3D10.1074%2Fjbc.271.40.24769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dajee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidig, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallone, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molineaux, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6383</span>– <span class="NLM_lpage">6391</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-06-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17616698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6383-6391&issue=13&author=S.+D.+Demoauthor=C.+J.+Kirkauthor=M.+A.+Aujayauthor=T.+J.+Buchholzauthor=M.+Dajeeauthor=M.+N.+Hoauthor=J.+Jiangauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=F.+Parlatiauthor=K.+D.+Shenkauthor=M.+S.+Smythauthor=C.+M.+Sunauthor=M.+K.+Valloneauthor=T.+M.+Wooauthor=C.+J.+Molineauxauthor=M.+K.+Bennett&title=Antitumor+Activity+of+PR-171%2C+a+Novel+Irreversible+Inhibitor+of+the+Proteasome&doi=10.1158%2F0008-5472.CAN-06-4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span></div><div class="casAuthors">Demo, Susan D.; Kirk, Christopher J.; Aujay, Monette A.; Buchholz, Tonia J.; Dajee, Maya; Ho, Mark N.; Jiang, Jing; Laidig, Guy J.; Lewis, Evan R.; Parlati, Francesco; Shenk, Kevin D.; Smyth, Mark S.; Sun, Congcong M.; Vallone, Marcy K.; Woo, Tina M.; Molineaux, Christopher J.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6383-6391</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma.  However, significant toxicities have restricted the intensity of bortezomib dosing.  Here we describe the antitumor activity of PR-171, a novel epoxyketone-based irreversible proteasome inhibitor that is currently in clin. development.  In comparison to bortezomib, PR-171 exhibits equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome.  In cell culture, PR-171 is more cytotoxic than bortezomib following brief treatments that mimic the in vivo pharmacokinetics of both mols.  Hematol. tumor cells exhibit the greatest sensitivity to brief exposure, whereas solid tumor cells and nontransformed cell types are less sensitive to such treatments.  Cellular consequences of PR-171 treatment include the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.  Administration of PR-171 to animals results in the dose-dependent inhibition of the chymotrypsin-like proteasome activity in all tissues examd. with the exception of the brain.  PR-171 is well tolerated when administered for either 2 or 5 consecutive days at doses resulting in >80% proteasome inhibition in blood and most tissues.  In human tumor xenograft models, PR-171 mediates an antitumor response that is both dose and schedule dependent.  The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clin. dosing schedule.  These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clin. testing of PR-171 in the treatment of hematol. malignancies using dose-intensive schedules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzP-VJ4DNRbVg90H21EOLACvtfcHk0lhxQQrquQG2Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D&md5=301bcab3e60cbfd518b2f88fb479fa79</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4086%26sid%3Dliteratum%253Aachs%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DVallone%26aufirst%3DM.%2BK.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DMolineaux%26aufirst%3DC.%2BJ.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520Activity%2520of%2520PR-171%252C%2520a%2520Novel%2520Irreversible%2520Inhibitor%2520of%2520the%2520Proteasome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D13%26spage%3D6383%26epage%3D6391%26doi%3D10.1158%2F0008-5472.CAN-06-4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Inhibitor PS-341 in Cancer Therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10499643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFyjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=2638-2645&issue=9&author=B.+A.+Teicherauthor=G.+Araauthor=R.+Herbstauthor=V.+J.+Palombellaauthor=J.+Adams&title=The+Proteasome+Inhibitor+PS-341+in+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor PS-341 in cancer therapy</span></div><div class="casAuthors">Teicher, Beverly A.; Ara, Gulshan; Herbst, Roy; Palombella, Vito J.; Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The anticancer activity of the boronic acid dipeptide proteasome inhibitor PS-341 was examd. in vitro and in vivo.  PS-341 was a potent cytotoxic agent toward MCF-7 human breast carcinoma cells in culture, producing an IC90 of 0.05 μM on 24 h of exposure to the drug.  In the EMT-6 tumor cell survival assay, PS-341 was equally cytotoxic administered p.o. or by i.p. injection up to a dose of 2 mg/kg.  PS-341 was also toxic to the bone marrow colony-forming unit-granulocyte macrophage.  PS-341 increased the tumor cell killing of radiation therapy, cyclophosphamide, and cisplatin in the EMT-6/Parent tumor, but was not able to overcome the in vivo resistance of the EMT-6/CTX and EMT-6/CDDP tumors.  In the tumor growth delay assay, PS-341 administered p.o. had antitumor activity against the Lewis lung carcinoma, both primary and metastatic disease.  In combination, regimens with 5-fluorouracil, cisplatin, Taxol and adriamycin, PS-341 seemed to produce primarily additive tumor growth delays against the s.c. tumor and was highly effective against disease metastatic to the lungs.  The proteasome is an interesting new target for cancer therapy, and the proteasome inhibitor PS-341 warrants continued investigation in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1t9w6rX80frVg90H21EOLACvtfcHk0lhxQQrquQG2Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFyjtro%253D&md5=585dee69fcb728c0e9a50d1d65ebfc2e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DAra%26aufirst%3DG.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520Proteasome%2520Inhibitor%2520PS-341%2520in%2520Cancer%2520Therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26issue%3D9%26spage%3D2638%26epage%3D2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahlberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenstam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaumann, H.</span></span> <span> </span><span class="NLM_article-title">Degradation of Short and Long Lived Proteins in Isolated Rat Liver Lysosomes. Effects of pH, Temperature, and Proteolytic Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">5847</span>– <span class="NLM_lpage">5854</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=3988775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaL2MXktVChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=5847-5854&issue=9&author=J.+Ahlbergauthor=A.+Berkenstamauthor=F.+Henellauthor=H.+Glaumann&title=Degradation+of+Short+and+Long+Lived+Proteins+in+Isolated+Rat+Liver+Lysosomes.+Effects+of+pH%2C+Temperature%2C+and+Proteolytic+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of short and long lived proteins in isolated rat liver lysosomes.  Effects of pH, temperature, and proteolytic inhibitors</span></div><div class="casAuthors">Ahlberg, Jeanne; Berkenstam, Anders; Henell, Fredrik; Glaumann, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5847-54</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Various inhibitors of proteolysis were tested on lysosomes isolated from livers of rats injected with [14C]leucine 15 min (short labeling time) and 16 h (long labeling time) before killing.  Intact lysosomes were incubated with different inhibitors (leupeptin, propylamine, E-64, pepstatin, and chloroquine) in increasing concns.  None of these caused >40-75% inhibition of proteolysis irresp. of labeling protocol.  Chloroquine was the most effective inhibitor, followed by leupeptin, propylamine, E-64, and pepstatin.  When lysosomes were incubated with various combinations of inhibitors, including a weak base and an enzyme inhibitor, a somewhat higher inhibition (86%) was obtained.  To assess if lysosomes are active in the degrdn. of both short- and long-lived proteins, lysosomes were isolated from livers of rats labeled with [14C]leucine for various time intervals.  The highest fractional proteolytic rates were seen for short lived proteins.  If the recovery of the isolated lysosomes is taken into consideration, ∼80% (short labeling time) and 90% (long labeling time) of the total proteolysis in the homogenate could be accounted for by lysosomes.  Isolated Golgi, mitochondrial, and microsomal fractions displayed negligible proteolytic activities.  The cytosol contributed 20% of the total protein breakdown of short lived proteins, whereas insignificant proteolysis was recovered in the cytosolic fraction following long time labeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtbFLpBXmi17Vg90H21EOLACvtfcHk0lhii0RlzgIJHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktVChsr8%253D&md5=19d82fa8e2fa9b47c33229e0428640c3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAhlberg%26aufirst%3DJ.%26aulast%3DBerkenstam%26aufirst%3DA.%26aulast%3DHenell%26aufirst%3DF.%26aulast%3DGlaumann%26aufirst%3DH.%26atitle%3DDegradation%2520of%2520Short%2520and%2520Long%2520Lived%2520Proteins%2520in%2520Isolated%2520Rat%2520Liver%2520Lysosomes.%2520Effects%2520of%2520pH%252C%2520Temperature%252C%2520and%2520Proteolytic%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26issue%3D9%26spage%3D5847%26epage%3D5854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaravadi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span> <span> </span><span class="NLM_article-title">Lys05: a New Lysosomal Autophagy Inhibitor</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi"> DOI: 10.4161/auto.20958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.4161%2Fauto.20958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22878685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=1383-1384&issue=9&author=R.+K.+Amaravadiauthor=J.+D.+Winkler&title=Lys05%3A+a+New+Lysosomal+Autophagy+Inhibitor&doi=10.4161%2Fauto.20958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Lys05: a new lysosomal autophagy inhibitor</span></div><div class="casAuthors">Amaravadi, Ravi K.; Winkler, Jeffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1383-1384</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Lys05 is a previously undescribed dimeric chloroquine which more potently accumulates in the lysosome and blocks autophagy compared with HCQ.  Lys05 produced more potent antitumor activity as a single agent both in vitro and in vivo in multiple human cancer cell lines and xenograft models compared with HCQ.  Initial structure-activity relationship studies demonstrated that the increased activity assocd. with Lys05 was due to the bivalent aminoquinoline rings, C7-Chlorine, and a short triamine linker.  While lower doses of Lys05 were well tolerated and assocd. with anti-tumor activity, at the highest dose tested, Lys05 produced Paneth cell dysfunction and intestinal toxicity, similar to what can be obsd. in mice and humans with genetic defects in the autophagy gene ATG16L1.  Lys05 is therefore a new lysosomal autophagy inhibitor that has potential to be developed further into a drug for cancer and other medical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnTN3s5fp9bVg90H21EOLACvtfcHk0ljbJZny6lZHVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ktLk%253D&md5=174288b34f302deec1374b00e6688195</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.4161%2Fauto.20958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.20958%26sid%3Dliteratum%253Aachs%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26atitle%3DLys05%253A%2520a%2520New%2520Lysosomal%2520Autophagy%2520Inhibitor%26jtitle%3DAutophagy%26date%3D2012%26volume%3D8%26issue%3D9%26spage%3D1383%26epage%3D1384%26doi%3D10.4161%2Fauto.20958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schopf, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biebl, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, J.</span></span> <span> </span><span class="NLM_article-title">The HSP90 Chaperone Machinery</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrm.2017.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28429788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2mtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=345-360&issue=6&author=F.+H.+Schopfauthor=M.+M.+Bieblauthor=J.+Buchner&title=The+HSP90+Chaperone+Machinery&doi=10.1038%2Fnrm.2017.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 chaperone machinery</span></div><div class="casAuthors">Schopf, Florian H.; Biebl, Maximilian M.; Buchner, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">345-360</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The heat shock protein 90 (HSP90) chaperone machinery is a key regulator of proteostasis under both physiol. and stress conditions in eukaryotic cells.  As HSP90 has several hundred protein substrates (or 'clients'), it is involved in many cellular processes beyond protein folding, which include DNA repair, development, the immune response and neurodegenerative disease.  A large no. of co-chaperones interact with HSP90 and regulate the ATPase-assocd. conformational changes of the HSP90 dimer that occur during the processing of clients.  Recent progress has allowed the interactions of clients with HSP90 and its co-chaperones to be defined.  Owing to the importance of HSP90 in the regulation of many cellular proteins, it has become a promising drug target for the treatment of several diseases, which include cancer and diseases assocd. with protein misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGQAAfluC3NbVg90H21EOLACvtfcHk0ljbJZny6lZHVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2mtbw%253D&md5=65931b74cf0a4fb5e60c936177829bd4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.20%26sid%3Dliteratum%253Aachs%26aulast%3DSchopf%26aufirst%3DF.%2BH.%26aulast%3DBiebl%26aufirst%3DM.%2BM.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DThe%2520HSP90%2520Chaperone%2520Machinery%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26issue%3D6%26spage%3D345%26epage%3D360%26doi%3D10.1038%2Fnrm.2017.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimnaugh, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Heat Shock Protein HSP90-Pp60v-Src Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8324</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.18.8324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.91.18.8324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=8078881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8324-8328&issue=18&author=L.+Whitesellauthor=E.+G.+Mimnaughauthor=B.+De+Costaauthor=C.+E.+Myersauthor=L.+M.+Neckers&title=Inhibition+of+Heat+Shock+Protein+HSP90-Pp60v-Src+Heteroprotein+Complex+Formation+by+Benzoquinone+Ansamycins%3A+Essential+Role+for+Stress+Proteins+in+Oncogenic+Transformation&doi=10.1073%2Fpnas.91.18.8324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span></div><div class="casAuthors">Whitesell, Luke; Mimnaugh, Edward G.; De Costa, Brian; Myers, Charles E.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8324-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanisms by which oncogenic tyrosine kinases induce cellular transformation are unclear.  Herbimycin A, geldanamycin, and certain other benzoquinone ansamycins display an unusual capacity to revert tyrosine kinase-induced oncogenic transformation.  As an approach to the study of v-src-mediated transformation, the authors examd. ansamycin action in transformed cells and found that drug-induced reversion could be achieved without direct inhibition of src phosphorylating activity.  To identify mechanisms other than kinase inhibition for drug-mediated reversion, the authors prepd. a solid phase-immobilized geldanamycin deriv. and affinity pptd. the mol. targets with which the drug interacted.  In a range of cell lines, immobilized geldanamycin bound elements of a major class of heat shock protein (HSP90) in a stable and pharmacol. specific manner.  Consistent with these binding data, the authors found that sol. geldanamycin and herbimycin A inhibited specifically the formation of a previously described src-HSP90 heteroprotein complex.  A related benzoquinone ansamycin that failed to revert transformed cells did not inhibit the formation of this complex.  These results demonstrate that HSP participation in multimol. complex formation is required for src-mediated transformation and can provide a target for drug modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfTW8DJOglQLVg90H21EOLACvtfcHk0lhhXU266kmpEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D&md5=18f1cad01698df44adaa05ef3da9f850</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.18.8324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.18.8324%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DMimnaugh%26aufirst%3DE.%2BG.%26aulast%3DDe%2BCosta%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DInhibition%2520of%2520Heat%2520Shock%2520Protein%2520HSP90-Pp60v-Src%2520Heteroprotein%2520Complex%2520Formation%2520by%2520Benzoquinone%2520Ansamycins%253A%2520Essential%2520Role%2520for%2520Stress%2520Proteins%2520in%2520Oncogenic%2520Transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D18%26spage%3D8324%26epage%3D8328%26doi%3D10.1073%2Fpnas.91.18.8324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Development of Heat Shock Protein (Hsp90) Inhibitors to Combat Resistance to Tyrosine Kinase Inhibitors Through Hsp90-Kinase Interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5563</span>– <span class="NLM_lpage">5586</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5563-5586&issue=12&author=M.+Wangauthor=A.+Shenauthor=C.+Zhangauthor=Z.+Songauthor=J.+Aiauthor=H.+Liuauthor=L.+Sunauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Development+of+Heat+Shock+Protein+%28Hsp90%29+Inhibitors+to+Combat+Resistance+to+Tyrosine+Kinase+Inhibitors+Through+Hsp90-Kinase+Interactions&doi=10.1021%2Facs.jmedchem.5b01106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions</span></div><div class="casAuthors">Wang, Meining; Shen, Aijun; Zhang, Chi; Song, Zilan; Ai, Jing; Liu, Hongchun; Sun, Liping; Ding, Jian; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5563-5586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases.  Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against the kinase-pos. na.ovrddot.ive and mutant models.  However, clin. trials of these inhibitors are unsuccessful due to insufficient clin. benefits and nonoptimal safety profiles.  Recently, much progress has been reported on the Hsp90-cochaperone-client complex, which will undoubtedly assist in the understanding of the interactions between Hsp90 and its clients.  Meanwhile, Hsp90 inhibitors have shown promise against patients' resistance caused by early generation tyrosine kinase inhibitors (TKIs), and at least 13 Hsp90 inhibitors are being reevaluated in the clinic.  In this regard, the objectives of the current perspective are to summarize the structure and function of the Hsp90-cochaperone-client complex, to analyze the structural and functional insights into the Hsp90-client interactions to address several existing unresolved problems with Hsp90 inhibitors, and to highlight the preclin. and clin. studies of Hsp90 inhibitors as an effective treatment against resistance to tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogrgsVY9MSMrVg90H21EOLACvtfcHk0lhhXU266kmpEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOls7s%253D&md5=2408b273b2a00136223ff21709c7ae2d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01106%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Heat%2520Shock%2520Protein%2520%2528Hsp90%2529%2520Inhibitors%2520to%2520Combat%2520Resistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%2520Through%2520Hsp90-Kinase%2520Interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D12%26spage%3D5563%26epage%3D5586%26doi%3D10.1021%2Facs.jmedchem.5b01106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Studies of Substrate-Assisted Inhibition of Ubiquitin-Activating Enzyme by Adenosine Sulfamate Analogues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">40867</span>– <span class="NLM_lpage">40877</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.279984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fjbc.M111.279984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21969368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=40867-40877&issue=47&author=J.+J.+Chenauthor=C.+A.+Tsuauthor=J.+M.+Gavinauthor=M.+A.+Milhollenauthor=F.+J.+Bruzzeseauthor=W.+D.+Mallenderauthor=M.+D.+Sintchakauthor=N.+J.+Bumpauthor=X.+Yangauthor=J.+Maauthor=H.-K.+Lokeauthor=Q.+Xuauthor=P.+Liauthor=N.+F.+Benceauthor=J.+E.+Brownellauthor=L.+R.+Dick&title=Mechanistic+Studies+of+Substrate-Assisted+Inhibition+of+Ubiquitin-Activating+Enzyme+by+Adenosine+Sulfamate+Analogues&doi=10.1074%2Fjbc.M111.279984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues</span></div><div class="casAuthors">Chen, Jesse J.; Tsu, Christopher A.; Gavin, James M.; Milhollen, Michael A.; Bruzzese, Frank J.; Mallender, William D.; Sintchak, Michael D.; Bump, Nancy J.; Yang, Xiaofeng; Ma, Jingya; Loke, Huay-Keng; Xu, Qing; Li, Ping; Bence, Neil F.; Brownell, James E.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">40867-40877</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin-activating enzyme (UAE or E1) activates ubiquitin via an adenylate intermediate and catalyzes its transfer to a ubiquitin-conjugating enzyme (E2).  MLN4924 is an adenosine sulfamate analog that was identified as a selective, mechanism-based inhibitor of NEDD8-activating enzyme (NAE), another E1 enzyme, by forming a NEDD8-MLN4924 adduct that tightly binds at the active site of NAE, a novel mechanism termed substrate-assisted inhibition.  In the present study, substrate-assisted inhibition of human UAE (Ube1) by another adenosine sulfamate analog, 5'-O-sulfamoyl-N6-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine (Compd. I), a nonselective E1 inhibitor, was characterized.  Compd. I inhibited UAE-dependent ATP-PPi exchange activity, caused loss of UAE thioester, and inhibited E1-E2 transthiolation in a dose-dependent manner.  Mechanistic studies on Compd. I and its purified ubiquitin adduct demonstrate that the proposed substrate-assisted inhibition via covalent adduct formation is entirely consistent with the three-step ubiquitin activation process and that the adduct is formed via nucleophilic attack of UAE thioester by the sulfamate group of Compd. I after completion of step 2.  Kinetic and affinity anal. of Compd. I, MLN4924, and their purified ubiquitin adducts suggest that both the rate of adduct formation and the affinity between the adduct and E1 contribute to the overall potency.  Because all E1s are thought to use a similar mechanism to activate their cognate ubiquitin-like proteins, the substrate-assisted inhibition by adenosine sulfamate analogs represents a promising strategy to develop potent and selective E1 inhibitors that can modulate diverse biol. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiclhUT_b-7Vg90H21EOLACvtfcHk0lgHuiFqwh2MXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE&md5=2362ac83bb8acf0de63162bac731c6e7</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.279984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.279984%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.-K.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBence%26aufirst%3DN.%2BF.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DMechanistic%2520Studies%2520of%2520Substrate-Assisted%2520Inhibition%2520of%2520Ubiquitin-Activating%2520Enzyme%2520by%2520Adenosine%2520Sulfamate%2520Analogues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D47%26spage%3D40867%26epage%3D40877%26doi%3D10.1074%2Fjbc.M111.279984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Inhibitor of the Ubiquitin Activating Enzyme for Cancer Treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nm.4474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnm.4474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29334375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=186-193&issue=2&author=M.+L.+Hyerauthor=M.+A.+Milhollenauthor=J.+Ciavarriauthor=P.+Flemingauthor=T.+Traoreauthor=D.+Sappalauthor=J.+Huckauthor=J.+Shiauthor=J.+Gavinauthor=J.+Brownellauthor=Y.+Yangauthor=B.+Stringerauthor=R.+Griffinauthor=F.+Bruzzeseauthor=T.+Soucyauthor=J.+Duffyauthor=C.+Rabinoauthor=J.+Ricebergauthor=K.+Hoarauthor=A.+Lublinskyauthor=S.+Menonauthor=M.+Sintchakauthor=N.+Bumpauthor=S.+M.+Pulukuriauthor=S.+Langstonauthor=S.+Tirrellauthor=M.+Kurandaauthor=P.+Veibyauthor=J.+Newcombauthor=P.+Liauthor=J.+T.+Wuauthor=J.+Poweauthor=L.+R.+Dickauthor=P.+Greenspanauthor=K.+Galvinauthor=M.+Manfrediauthor=C.+Claiborneauthor=B.+S.+Amidonauthor=N.+F.+Bence&title=A+Small-Molecule+Inhibitor+of+the+Ubiquitin+Activating+Enzyme+for+Cancer+Treatment&doi=10.1038%2Fnm.4474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span></div><div class="casAuthors">Hyer, Marc L.; Milhollen, Michael A.; Ciavarri, Jeff; Fleming, Paul; Traore, Tary; Sappal, Darshan; Huck, Jessica; Shi, Judy; Gavin, James; Brownell, Jim; Yang, Yu; Stringer, Bradley; Griffin, Robert; Bruzzese, Frank; Soucy, Teresa; Duffy, Jennifer; Rabino, Claudia; Riceberg, Jessica; Hoar, Kara; Lublinsky, Anya; Menon, Saurabh; Sintchak, Michael; Bump, Nancy; Pulukuri, Sai M.; Langston, Steve; Tirrell, Stephen; Kuranda, Mike; Veiby, Petter; Newcomb, John; Li, Ping; Wu, Jing Tao; Powe, Josh; Dick, Lawrence R.; Greenspan, Paul; Galvin, Katherine; Manfredi, Mark; Claiborne, Chris; Amidon, Benjamin S.; Bence, Neil F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis.  The therapeutic potential of this pathway has been validated by the clin. successes of a no. of UPS modulators, including proteasome inhibitors and immunomodulatory imide drugs (IMiDs).  Here we identified TAK-243 (formerly known as MLN7243) as a potent, mechanism-based small-mol. inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade.  TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways.  TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses.  Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biol. and for assessment of UAE inhibition as a new approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GCsna-MdUrVg90H21EOLACvtfcHk0lgpWEfWendjDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D&md5=06010b7eb1cc59cf3687b9c52844eb96</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnm.4474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4474%26sid%3Dliteratum%253Aachs%26aulast%3DHyer%26aufirst%3DM.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DCiavarri%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DSappal%26aufirst%3DD.%26aulast%3DHuck%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DGavin%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DHoar%26aufirst%3DK.%26aulast%3DLublinsky%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DKuranda%26aufirst%3DM.%26aulast%3DVeiby%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DPowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGreenspan%26aufirst%3DP.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DClaiborne%26aufirst%3DC.%26aulast%3DAmidon%26aufirst%3DB.%2BS.%26aulast%3DBence%26aufirst%3DN.%2BF.%26atitle%3DA%2520Small-Molecule%2520Inhibitor%2520of%2520the%2520Ubiquitin%2520Activating%2520Enzyme%2520for%2520Cancer%2520Treatment%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D2%26spage%3D186%26epage%3D193%26doi%3D10.1038%2Fnm.4474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talreja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of NEDD8-Activating Enzyme as a New Approach to Treat Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span> (<span class="NLM_issue">7239</span>),  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1038/nature07884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature07884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19360080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=732-736&issue=7239&author=T.+A.+Soucyauthor=P.+G.+Smithauthor=M.+A.+Milhollenauthor=A.+J.+Bergerauthor=J.+M.+Gavinauthor=S.+Adhikariauthor=J.+E.+Brownellauthor=K.+E.+Burkeauthor=D.+P.+Cardinauthor=S.+Critchleyauthor=C.+A.+Cullisauthor=A.+Doucetteauthor=J.+J.+Garnseyauthor=J.+L.+Gaulinauthor=R.+E.+Gershmanauthor=A.+R.+Lublinskyauthor=A.+McDonaldauthor=H.+Mizutaniauthor=U.+Narayananauthor=E.+J.+Olhavaauthor=S.+Pelusoauthor=M.+Rezaeiauthor=M.+D.+Sintchakauthor=T.+Talrejaauthor=M.+P.+Thomasauthor=T.+Traoreauthor=S.+Vyskocilauthor=G.+S.+Weatherheadauthor=J.+Yuauthor=J.+Zhangauthor=L.+R.+Dickauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=S.+P.+Langston&title=An+Inhibitor+of+NEDD8-Activating+Enzyme+as+a+New+Approach+to+Treat+Cancer&doi=10.1038%2Fnature07884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span></div><div class="casAuthors">Soucy, Teresa A.; Smith, Peter G.; Milhollen, Michael A.; Berger, Allison J.; Gavin, James M.; Adhikari, Sharmila; Brownell, James E.; Burke, Kristine E.; Cardin, David P.; Critchley, Stephen; Cullis, Courtney A.; Doucette, Amanda; Garnsey, James J.; Gaulin, Jeffrey L.; Gershman, Rachel E.; Lublinsky, Anna R.; McDonald, Alice; Mizutani, Hirotake; Narayanan, Usha; Olhava, Edward J.; Peluso, Stephane; Rezaei, Mansoureh; Sintchak, Michael D.; Talreja, Tina; Thomas, Michael P.; Traore, Tary; Vyskocil, Stepan; Weatherhead, Gabriel S.; Yu, Jie; Zhang, Julie; Dick, Lawrence R.; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Langston, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7239</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. development of an inhibitor of cellular proteasome function suggests that compds. targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies.  NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome.  Substrates of cullin-RING ligases have important roles in cellular processes assocd. with cancer cell growth and survival pathways.  Here we describe MLN4924, a potent and selective inhibitor of NAE.  MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells by a new mechanism of action, the deregulation of S-phase DNA synthesis.  MLN4924 suppressed the growth of human tumor xenografts in mice at compd. exposures that were well tolerated.  Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8fx7OnZtYjbVg90H21EOLACvtfcHk0lhLGEyQbvSoBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D&md5=365d4b4feac3994849050e00f1aae5e0</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature07884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07884%26sid%3Dliteratum%253Aachs%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCardin%26aufirst%3DD.%2BP.%26aulast%3DCritchley%26aufirst%3DS.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DDoucette%26aufirst%3DA.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DGaulin%26aufirst%3DJ.%2BL.%26aulast%3DGershman%26aufirst%3DR.%2BE.%26aulast%3DLublinsky%26aufirst%3DA.%2BR.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DTalreja%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26atitle%3DAn%2520Inhibitor%2520of%2520NEDD8-Activating%2520Enzyme%2520as%2520a%2520New%2520Approach%2520to%2520Treat%2520Cancer%26jtitle%3DNature%26date%3D2009%26volume%3D458%26issue%3D7239%26spage%3D732%26epage%3D736%26doi%3D10.1038%2Fnature07884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duda, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, B. A.</span></span> <span> </span><span class="NLM_article-title">Structural Insights Into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>134</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2008.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18805092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sns7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2008&pages=995-1006&issue=6&author=D.+M.+Dudaauthor=L.+A.+Borgauthor=D.+C.+Scottauthor=H.+W.+Huntauthor=M.+Hammelauthor=B.+A.+Schulman&title=Structural+Insights+Into+NEDD8+Activation+of+Cullin-RING+Ligases%3A+Conformational+Control+of+Conjugation&doi=10.1016%2Fj.cell.2008.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into NEDD8 activation of Cullin-RING ligases: conformational control of conjugation</span></div><div class="casAuthors">Duda, David M.; Borg, Laura A.; Scott, Daniel C.; Hunt, Harold W.; Hammel, Michal; Schulman, Brenda A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">995-1006</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cullin-RING ligases (CRLs) comprise the largest ubiquitin E3 subclass, in which a central cullin subunit links a substrate-binding adaptor with an E2-binding RING.  Covalent attachment of the ubiquitin-like protein NEDD8 to a conserved C-terminal domain (ctd) lysine stimulates CRL ubiquitination activity and prevents binding of the inhibitor CAND1.  Here we report striking conformational rearrangements in the crystal structure of NEDD8∼Cul5ctd-Rbx1 and SAXS anal. of NEDD8∼Cul1ctd-Rbx1 relative to their unmodified counterparts.  In NEDD8ylated CRL structures, the cullin WHB and Rbx1 RING subdomains are dramatically reoriented, eliminating a CAND1-binding site and imparting multiple potential catalytic geometries to an assocd. E2.  Biochem. analyses indicate that the structural malleability is important for both CRL NEDD8ylation and subsequent ubiquitination activities.  Thus, our results point to a conformational control of CRL activity, with ligation of NEDD8 shifting equil. to disfavor inactive CAND1-bound closed architectures, and favor dynamic, open forms that promote polyubiquitination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmwB4M6C7dU7Vg90H21EOLACvtfcHk0lh-yke2HaY5Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sns7rN&md5=379107aaeb4c0824f9fa352e4aa34edb</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DD.%2BM.%26aulast%3DBorg%26aufirst%3DL.%2BA.%26aulast%3DScott%26aufirst%3DD.%2BC.%26aulast%3DHunt%26aufirst%3DH.%2BW.%26aulast%3DHammel%26aufirst%3DM.%26aulast%3DSchulman%26aufirst%3DB.%2BA.%26atitle%3DStructural%2520Insights%2520Into%2520NEDD8%2520Activation%2520of%2520Cullin-RING%2520Ligases%253A%2520Conformational%2520Control%2520of%2520Conjugation%26jtitle%3DCell%26date%3D2008%26volume%3D134%26issue%3D6%26spage%3D995%26epage%3D1006%26doi%3D10.1016%2Fj.cell.2008.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span> <span> </span><span class="NLM_article-title">How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">811</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.tibs.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28784328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1entLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=799-811&issue=10&author=K.+A.+Verbaauthor=D.+A.+Agard&title=How+Hsp90+and+Cdc37+Lubricate+Kinase+Molecular+Switches&doi=10.1016%2Fj.tibs.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches</span></div><div class="casAuthors">Verba, Kliment A.; Agard, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">799-811</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Hsp90/Cdc37 chaperone system interacts with and supports 60% of the human kinome.  Not only are Hsp90 and Cdc37 generally required for initial folding, but many kinases rely on the Hsp90/Cdc37 throughout their lifetimes.  A large fraction of these 'client' kinases are key oncoproteins, and their interactions with the Hsp90/Cdc37 machinery are crucial for both their normal and malignant activity.  Recently, advances in single-particle cryo-electron microscopy (cryoEM) and biochem. strategies have provided the first key mol. insights into kinase-chaperone interactions.  The surprising results suggest a re-evaluation of the role of chaperones in the kinase lifecycle, and suggest that such interactions potentially allow kinases to more rapidly respond to key signals while simultaneously protecting unstable kinases from degrdn. and suppressing unwanted basal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGaSubzxlym7Vg90H21EOLACvtfcHk0lh-yke2HaY5Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1entLvF&md5=34a329cf822ebbb8776b9e03451f0e6b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26atitle%3DHow%2520Hsp90%2520and%2520Cdc37%2520Lubricate%2520Kinase%2520Molecular%2520Switches%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26issue%3D10%26spage%3D799%26epage%3D811%26doi%3D10.1016%2Fj.tibs.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoraki, M. A.</span></span> <span> </span><span class="NLM_article-title">Molecular Chaperones and Protein Kinase Quality Control</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2006.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.tcb.2006.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17184992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1Sms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=87-92&issue=2&author=A.+J.+Caplanauthor=A.+K.+Mandalauthor=M.+A.+Theodoraki&title=Molecular+Chaperones+and+Protein+Kinase+Quality+Control&doi=10.1016%2Fj.tcb.2006.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular chaperones and protein kinase quality control</span></div><div class="casAuthors">Caplan, Avrom J.; Mandal, Atin K.; Theodoraki, Maria A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Hsp90-Cdc37 chaperone pair has special responsibility for folding of protein kinases.  This function has made Hsp90 a target for new chemotherapeutic approaches, and several compds. are currently being tested for their ability to inhibit many different kinases simultaneously.  Not all kinases are sensitive to these inhibitors, however, and this difference might depend on how each kinase interacts with Hsp90 and Cdc37 during folding of the nascent chain and thereafter.  Indeed, several kinases require the persistent presence of both chaperones after initial folding and some of these kinases seem to be particularly sensitive to Hsp90 inhibitors.  This requirement might relate to conformational changes that take place during the protein kinase activity cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYJvSw0DtYnLVg90H21EOLACvtfcHk0ljgp1vqJX4PQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1Sms7s%253D&md5=6595e47928ff70cd6d1686364ffde72e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2006.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2006.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DCaplan%26aufirst%3DA.%2BJ.%26aulast%3DMandal%26aufirst%3DA.%2BK.%26aulast%3DTheodoraki%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520Chaperones%2520and%2520Protein%2520Kinase%2520Quality%2520Control%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2007%26volume%3D17%26issue%3D2%26spage%3D87%26epage%3D92%26doi%3D10.1016%2Fj.tcb.2006.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keramisanou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasantha Kumar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Vaart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelis, I.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation Induced Cochaperone Unfolding Promotes Kinase Recruitment and Client Class-Specific Hsp90 Phosphorylation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">265</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02711-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41467-017-02711-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29343704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvhs12muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=265&issue=1&author=A.+B.+Bachmanauthor=D.+Keramisanouauthor=W.+Xuauthor=K.+Beebeauthor=M.+A.+Mosesauthor=M.+V.+Vasantha+Kumarauthor=G.+Grayauthor=R.+E.+Noorauthor=A.+van+der%0AVaartauthor=L.+Neckersauthor=I.+Gelis&title=Phosphorylation+Induced+Cochaperone+Unfolding+Promotes+Kinase+Recruitment+and+Client+Class-Specific+Hsp90+Phosphorylation&doi=10.1038%2Fs41467-017-02711-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation induced cochaperone unfolding promotes kinase recruitment and client class-specific Hsp90 phosphorylation</span></div><div class="casAuthors">Bachman Ashleigh B; Keramisanou Dimitra; Vasantha Kumar M V; Gray Geoffrey; Noor Radwan Ebna; van der Vaart Arjan; Gelis Ioannis; Xu Wanping; Beebe Kristin; Moses Michael A; Neckers Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During the Hsp90-mediated chaperoning of protein kinases, the core components of the machinery, Hsp90 and the cochaperone Cdc37, recycle between different phosphorylation states that regulate progression of the chaperone cycle.  We show that Cdc37 phosphorylation at Y298 results in partial unfolding of the C-terminal domain and the population of folding intermediates.  Unfolding facilitates Hsp90 phosphorylation at Y197 by unmasking a phosphopeptide sequence, which serves as a docking site to recruit non-receptor tyrosine kinases to the chaperone complex via their SH2 domains.  In turn, Hsp90 phosphorylation at Y197 specifically regulates its interaction with Cdc37 and thus affects the chaperoning of only protein kinase clients.  In summary, we find that by providing client class specificity, Hsp90 cochaperones such as Cdc37 do not merely assist in client recruitment but also shape the post-translational modification landscape of Hsp90 in a client class-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7izekEYEuoxLDWw4HIq2sfW6udTcc2eZgLAONZe8d27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvhs12muw%253D%253D&md5=7bdc49c613d47135b952650239f031a2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02711-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02711-w%26sid%3Dliteratum%253Aachs%26aulast%3DBachman%26aufirst%3DA.%2BB.%26aulast%3DKeramisanou%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26aulast%3DVasantha%2BKumar%26aufirst%3DM.%2BV.%26aulast%3DGray%26aufirst%3DG.%26aulast%3DNoor%26aufirst%3DR.%2BE.%26aulast%3Dvan%2Bder%2BVaart%26aufirst%3DA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DGelis%26aufirst%3DI.%26atitle%3DPhosphorylation%2520Induced%2520Cochaperone%2520Unfolding%2520Promotes%2520Kinase%2520Recruitment%2520and%2520Client%2520Class-Specific%2520Hsp90%2520Phosphorylation%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D265%26doi%3D10.1038%2Fs41467-017-02711-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samant, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span> <span> </span><span class="NLM_article-title">ATP-Competitive Inhibitors Block Protein Kinase Recruitment to the Hsp90-Cdc37 System</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnchembio.1212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23502424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVKgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=307-312&issue=5&author=S.+Polierauthor=R.+S.+Samantauthor=P.+A.+Clarkeauthor=P.+Workmanauthor=C.+Prodromouauthor=L.+H.+Pearl&title=ATP-Competitive+Inhibitors+Block+Protein+Kinase+Recruitment+to+the+Hsp90-Cdc37+System&doi=10.1038%2Fnchembio.1212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system</span></div><div class="casAuthors">Polier, Sigrun; Samant, Rahul S.; Clarke, Paul A.; Workman, Paul; Prodromou, Chrisostomos; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">307-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinase clients are recruited to the Hsp90 mol. chaperone system via Cdc37, which simultaneously binds Hsp90 and kinases and regulates the Hsp90 chaperone cycle.  Pharmacol. inhibition of Hsp90 in vivo results in degrdn. of kinase clients, with a therapeutic effect in dependent tumors.  We show here that Cdc37 directly antagonizes ATP binding to client kinases, suggesting a role for the Hsp90-Cdc37 complex in controlling kinase activity.  Unexpectedly, we find that Cdc37 binding to protein kinases is itself antagonized by ATP-competitive kinase inhibitors, including vemurafenib and lapatinib.  In cancer cells, these inhibitors deprive oncogenic kinases such as B-Raf and ErbB2 of access to the Hsp90-Cdc37 complex, leading to their degrdn.  Our results suggest that at least part of the efficacy of ATP-competitive inhibitors of Hsp90-dependent kinases in tumor cells may be due to targeted chaperone deprivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopGiAehQefXbVg90H21EOLACvtfcHk0lhPgeGsrVMI8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVKgtLw%253D&md5=628085339cdaae95e62644d66b3b03a6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1212%26sid%3Dliteratum%253Aachs%26aulast%3DPolier%26aufirst%3DS.%26aulast%3DSamant%26aufirst%3DR.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DATP-Competitive%2520Inhibitors%2520Block%2520Protein%2520Kinase%2520Recruitment%2520to%2520the%2520Hsp90-Cdc37%2520System%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D5%26spage%3D307%26epage%3D312%26doi%3D10.1038%2Fnchembio.1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Neratinib Induces ErbB2 Ubiquitylation and Endocytic Degradation via HSP90 Dissociation in Breast Cancer Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.canlet.2016.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27597738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2016&pages=176-185&issue=2&author=Y.+Zhangauthor=J.+Zhangauthor=C.+Liuauthor=S.+Duauthor=L.+Fengauthor=X.+Luanauthor=Y.+Zhangauthor=Y.+Shiauthor=T.+Wangauthor=Y.+Wuauthor=W.+Chengauthor=S.+Mengauthor=M.+Liauthor=H.+Liu&title=Neratinib+Induces+ErbB2+Ubiquitylation+and+Endocytic+Degradation+via+HSP90+Dissociation+in+Breast+Cancer+Cells&doi=10.1016%2Fj.canlet.2016.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells</span></div><div class="casAuthors">Zhang, Yingqiu; Zhang, Jinrui; Liu, Congcong; Du, Sha; Feng, Lu; Luan, Xuelin; Zhang, Yayun; Shi, Yulin; Wang, Taishu; Wu, Yue; Cheng, Wei; Meng, Songshu; Li, Man; Liu, Han</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-185</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase ErbB2/HER2 is frequently obsd. to be overexpressed in human cancers, leading to over activation of downstream signaling modules.  HER2 pos. is a major type of breast cancer for which ErbB2 targeting is already proving to be an effective therapeutic strategy.  Apart from antibodies against ErbB2, the small mol. tyrosine kinase inhibitor lapatinib has had successful clin. outcomes, and other inhibitors such as neratinib are currently undergoing clin. investigations.  In this study we report the effects of lapatinib and neratinib on the mRNA and protein levels of the ErbB2 receptor.  We provide evidence that neratinib-induced down regulation of ErbB2 occurs through ubiquitin-mediated endocytic sorting and lysosomal degrdn.  At the mechanistic level, neratinib treatment leads to HSP90 release from ErbB2 and its subsequent ubiquitylation and endocytic degrdn.  Our findings provide novel insights into the mechanism of ErbB2 inhibition by neratinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvWoy_iFPS7bVg90H21EOLACvtfcHk0lhPgeGsrVMI8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqtbnJ&md5=cfa019e3fd86f1cdd43b7d39053bcbfc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DLuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DMeng%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DNeratinib%2520Induces%2520ErbB2%2520Ubiquitylation%2520and%2520Endocytic%2520Degradation%2520via%2520HSP90%2520Dissociation%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D382%26issue%3D2%26spage%3D176%26epage%3D185%26doi%3D10.1016%2Fj.canlet.2016.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshinsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaux, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span> <span> </span><span class="NLM_article-title">The Specificity of JAK3 Kinase Inhibitors</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-09-115030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1182%2Fblood-2007-09-115030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18094329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2155-2157&issue=4&author=P.+S.+Changelianauthor=D.+Moshinskyauthor=C.+F.+Kuhnauthor=M.+E.+Flanaganauthor=M.+J.+Munchhofauthor=T.+M.+Harrisauthor=D.+A.+Whippleauthor=J.+L.+Dotyauthor=J.+Sunauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=D.+G.+Perregauxauthor=P.+S.+Sawyerauthor=E.+M.+Kudlacz&title=The+Specificity+of+JAK3+Kinase+Inhibitors&doi=10.1182%2Fblood-2007-09-115030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The specificity of JAK3 kinase inhibitors</span></div><div class="casAuthors">Changelian, Paul S.; Moshinsky, Deborah; Kuhn, Cyrille F.; Flanagan, Mark E.; Munchhof, Michael J.; Harris, Thomas M.; Doty, Jonathan L.; Sun, Jianmin; Kent, Craig R.; Magnuson, Kelly S.; Perregaux, David G.; Sawyer, Perry S.; Kudlacz, Elizabeth M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2155-2157</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compd. being evaluated in clin. trials for rheumatoid arthritis and prevention of allograft rejection.  PF-956980 was evaluated against a panel of 30 kinases, and found to have nanomolar potency against only JAK3.  Cellular and whole blood activity of this compd. parallels its potency and selectivity in enzyme assays.  It was effective in vivo at inhibiting the delayed type hypersensitivity reaction in mice.  We compared 2 com. available JAK3 inhibitors (WHI-P131 and WHI-P154) in the same panel of biochem. and cellular assays and found them to be neither potent nor selective for JAK3.  Both were found to be nanomolar inhibitors of the EGF receptor family of kinases.  As these compds. were used in numerous publications in the transplant and autoimmune disease literature, their specificity should be considered when interpreting these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-xhj-I5327Vg90H21EOLACvtfcHk0liwwdj9PoFlVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVeitrw%253D&md5=bbcf27a841692f796d1fcdc382745bc3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-09-115030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-09-115030%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DMoshinsky%26aufirst%3DD.%26aulast%3DKuhn%26aufirst%3DC.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26atitle%3DThe%2520Specificity%2520of%2520JAK3%2520Kinase%2520Inhibitors%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26issue%3D4%26spage%3D2155%26epage%3D2157%26doi%3D10.1182%2Fblood-2007-09-115030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive Pan-JAK Inhibitor</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1183</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVyrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1183-1187&issue=5&author=S.+D.+Fieldauthor=J.+Arkinauthor=J.+Liauthor=L.+H.+Jones&title=Selective+Downregulation+of+JAK2+and+JAK3+by+an+ATP-Competitive+Pan-JAK+Inhibitor&doi=10.1021%2Facschembio.7b00116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor</span></div><div class="casAuthors">Field, S. Denise; Arkin, Jacob; Li, Jing; Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1183-1187</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-956980 has been used previously as a JAK3-selective chem. probe in numerous cell-based expts.  Here, we report that not only is PF-956980 a pan-JAK ATP-competitive inhibitor but it also causes selective redn. of endogenous JAK2 and JAK3 protein levels in human primary immune cells (in a time-dependent manner), leaving the other JAK family members (JAK1 and TYK2) unchanged.  We found that PF-956980 selectively downregulated JAK2 and JAK3 mRNA, corresponding to changes obsd. at the protein level.  This work highlights therapeutic opportunities for the development of pharmacol. inhibitors that also modulate the expression of their cognate binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolA7-3oHqu-LVg90H21EOLACvtfcHk0lhX3O-Z_vZ-Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVyrs78%253D&md5=8c38a7120b8c401047b9b298ff602748</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00116%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DS.%2BD.%26aulast%3DArkin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSelective%2520Downregulation%2520of%2520JAK2%2520and%2520JAK3%2520by%2520an%2520ATP-Competitive%2520Pan-JAK%2520Inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26issue%3D5%26spage%3D1183%26epage%3D1187%26doi%3D10.1021%2Facschembio.7b00116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and Consequences of Jak-STAT Signaling in the Immune System</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/ni.3691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fni.3691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28323260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=374-384&issue=4&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+and+Consequences+of+Jak-STAT+Signaling+in+the+Immune+System&doi=10.1038%2Fni.3691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and consequences of Jak-STAT signaling in the immune system</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">374-384</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases of the Jak ('Janus kinase') family and transcription factors (TFs) of the STAT ('signal transducer and activator of transcription') family constitute a rapid membrane-to-nucleus signaling module that affects every aspect of the mammalian immune system.  Research on this paradigmatic pathway has experienced breakneck growth in the quarter century since its discovery and has yielded a stream of basic and clin. insights that have profoundly influenced modern understanding of human health and disease, exemplified by the bench-to-bedside success of Jak inhibitors ('jakinibs') and pathway-targeting drugs.  Here we review recent advances in Jak-STAT biol., focusing on immune cell function, disease etiol. and therapeutic intervention, as well as broader principles of gene regulation and signal-dependent TFs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUlP3emd5BrVg90H21EOLACvtfcHk0lhX3O-Z_vZ-Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D&md5=b50a88aee2b64fcb85c9a64d4ec1724e</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fni.3691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3691%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520and%2520Consequences%2520of%2520Jak-STAT%2520Signaling%2520in%2520the%2520Immune%2520System%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26issue%3D4%26spage%3D374%26epage%3D384%26doi%3D10.1038%2Fni.3691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&issue=1&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+Pathway%3A+Impact+on+Human+Disease+and+Therapeutic+Intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0lj5x85SLAXtWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520Pathway%253A%2520Impact%2520on%2520Human%2520Disease%2520and%2520Therapeutic%2520Intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26issue%3D1%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&issue=12&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lj5x85SLAXtWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3212</span>– <span class="NLM_lpage">3217</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1078-0432.CCR-12-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22544377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3212-3217&issue=12&author=A.+Deisserothauthor=E.+Kaminskasauthor=J.+Grilloauthor=W.+Chenauthor=H.+Saberauthor=H.+L.+Luauthor=M.+D.+Rothmannauthor=S.+Brarauthor=J.+Wangauthor=C.+Garnettauthor=J.+Bullockauthor=L.+B.+Burkeauthor=A.+Rahmanauthor=R.+Sridharaauthor=A.+Farrellauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+Approval%3A+Ruxolitinib+for+the+Treatment+of+Patients+with+Intermediate+and+High-Risk+Myelofibrosis&doi=10.1158%2F1078-0432.CCR-12-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span></div><div class="casAuthors">Deisseroth, Albert; Kaminskas, Edvardas; Grillo, Joseph; Chen, Wei; Saber, Haleh; Lu, Hong L.; Rothmann, Mark D.; Brar, Satjit; Wang, Jian; Garnett, Christine; Bullock, Julie; Burke, Laurie B.; Rahman, Atiqur; Sridhara, Rajeshwari; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3212-3217</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the U.S.  Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.  This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2).  The primary efficacy endpoint was the proportion of patients who experienced a redn. in spleen vol. of ≥35% at 24 wk (study 1) or 48 wk (study 2).  The key secondary endpoint in study 1 was the proportion of patients who experienced a ≥50% improvement from baseline in myelofibrosis total symptom score at 24 wk.  The results of these studies showed that a greater proportion of patients treated with ruxolitinib experienced a ≥35% redn. in spleen vol. as compared with those treated with placebo (42% vs. 1%, P < 0.0001) or best available therapy (29% vs. 0%, P < 0.0001).  A greater proportion of patients in study 1 experienced a ≥50% redn. in the myelofibrosis total symptom score during treatment with ruxolitinib than with placebo (46% vs. 5%, P < 0.0001).  Ruxolitinib treatment was assocd. with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia.  This is the first drug approved for myelofibrosis.  Clin Cancer Res; 18(12); 3212-7. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44NYcMOixiLVg90H21EOLACvtfcHk0liIB6DBTI9ZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D&md5=6ed7731730708b8a8cbdc5d766065ddb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0653%26sid%3Dliteratum%253Aachs%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%2BL.%26aulast%3DRothmann%26aufirst%3DM.%2BD.%26aulast%3DBrar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DL.%2BB.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520Approval%253A%2520Ruxolitinib%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Intermediate%2520and%2520High-Risk%2520Myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D12%26spage%3D3212%26epage%3D3217%26doi%3D10.1158%2F1078-0432.CCR-12-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&issue=24&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+Potent+and+Selective+Janus+Kinase+%28JAK%29+Inhibitor+for+the+Treatment+of+Autoimmune+Diseases+and+Organ+Transplant+Rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0liIB6DBTI9ZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%2520and%2520Organ%2520Transplant%2520Rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elrick, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funckes-Shippy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saabye, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. L.</span></span> <span> </span><span class="NLM_article-title">Anti-Inflammatory Activity and Neutrophil Reductions Mediated by the JAK1/JAK3 Inhibitor, CP-690,550, in Rat Adjuvant-Induced Arthritis</span>. <i>J. Inflammation (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1186/1476-9255-7-41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20701804" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41-53&issue=1&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-Inflammatory+Activity+and+Neutrophil+Reductions+Mediated+by+the+JAK1%2FJAK3+Inhibitor%2C+CP-690%2C550%2C+in+Rat+Adjuvant-Induced+Arthritis&doi=10.1186%2F1476-9255-7-41"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-Inflammatory%2520Activity%2520and%2520Neutrophil%2520Reductions%2520Mediated%2520by%2520the%2520JAK1%252FJAK3%2520Inhibitor%252C%2520CP-690%252C550%252C%2520in%2520Rat%2520Adjuvant-Induced%2520Arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26issue%3D1%26spage%3D41%26epage%3D53%26doi%3D10.1186%2F1476-9255-7-41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greggio, E.</span></span> <span> </span><span class="NLM_article-title">LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/1570159X13666151030102847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F1570159X13666151030102847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26517051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlCgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=214-225&issue=3&author=J.-M.+Taymansauthor=E.+Greggio&title=LRRK2+Kinase+Inhibition+as+a+Therapeutic+Strategy+for+Parkinson%E2%80%99s+Disease%2C+Where+Do+We+Stand%3F&doi=10.2174%2F1570159X13666151030102847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?</span></div><div class="casAuthors">Taymans, Jean-Marc; Greggio, Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-225</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">One of the most promising therapeutic targets for potential disease modifying treatment of Parkinson's disease (PD) is leucine-rich repeat kinase 2 (LRRK2).  Specifically, targeting LRRK2's kinase function has generated a lot of interest from both industry and academia.  This work has yielded several published studies showing the feasibility of developing potent, selective and brain permeable LRRK2 kinase inhibitors.  The availability of these exptl. drugs is contributing to filling in the gaps in our knowledge on the safety and efficacy of LRRK2 kinase inhibition.  Recent studies of LRRK2 kinase inhibition in preclin. models point to potential undesired effects in peripheral tissues such as lung and kidney.  Also, while strategies are now emerging to measure target engagement of LRRK2 inhibitors, there remains an important need to expand efficacy studies in preclin. models of progressive PD.  Future work in the LRRK2 inhibition field must therefore be directed towards developing mols. and treatment regimens which demonstrate efficacy in mammalian models of disease in conditions where safety liabilities are reduced to a min.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrE-1Rx3Jzh7Vg90H21EOLACvtfcHk0lgPWXyVcznCJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlCgu74%253D&md5=f68fc6814e2add4836aefe53321d1199</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F1570159X13666151030102847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X13666151030102847%26sid%3Dliteratum%253Aachs%26aulast%3DTaymans%26aufirst%3DJ.-M.%26aulast%3DGreggio%26aufirst%3DE.%26atitle%3DLRRK2%2520Kinase%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%252C%2520Where%2520Do%2520We%2520Stand%253F%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2016%26volume%3D14%26issue%3D3%26spage%3D214%26epage%3D225%26doi%3D10.2174%2F1570159X13666151030102847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gloeckner, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zweydorf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarioglu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueffing, M.</span></span> <span> </span><span class="NLM_article-title">Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1745</span>, <span class="refDoi"> DOI: 10.1021/pr9008578</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr9008578" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFejt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1738-1745&issue=4&author=C.+J.+Gloecknerauthor=K.+Boldtauthor=F.+von+Zweydorfauthor=S.+Helmauthor=L.+Wiesentauthor=H.+Sariogluauthor=M.+Ueffing&title=Phosphopeptide+Analysis+Reveals+Two+Discrete+Clusters+of+Phosphorylation+in+the+N-Terminus+and+the+Roc+Domain+of+the+Parkinson-Disease+Associated+Protein+Kinase+LRRK2&doi=10.1021%2Fpr9008578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2</span></div><div class="casAuthors">Gloeckner, Christian Johannes; Boldt, Karsten; von Zweydorf, Felix; Helm, Sandra; Wiesent, Ludwig; Sarioglu, Hakan; Ueffing, Marius</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1738-1745</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) that increase its kinase activity assoc. with familial forms of Parkinson disease (PD).  As phosphorylation dets. the functional state of most protein kinases, we systematically mapped LRRK2 phosphorylation sites by mass spectrometry.  Our anal. revealed a high degree of constitutive phosphorylation in a narrow serine-rich region preceding the LRR-domain.  Allowing de novo autophosphorylation of purified LRRK2 in an in vitro autokinase assay prior to mass spectrometric anal., we discovered multiple sites of autophosphorylation.  Solely serine and threonine residues were found phosphorylated suggesting LRRK2 as a true serine threonine kinase.  Autophosphorylation mainly targets the ROC GTPase domain and its clustering around the GTP binding pocket of ROC suggests cross-regulatory activity between kinase and Roc domain.  In conclusion, the phosphoprotein LRRK2 functions as an autocatalytically active serine threonine kinase.  Clustering of phosphosites within two discrete domains suggest that phosphorylation may regulate its biol. functions in a yet unknown fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu6BAiUXeTVbVg90H21EOLACvtfcHk0ljPYoiuWalvBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFejt7g%253D&md5=c20f1e8a727b8fc5f2d33b685f808725</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fpr9008578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr9008578%26sid%3Dliteratum%253Aachs%26aulast%3DGloeckner%26aufirst%3DC.%2BJ.%26aulast%3DBoldt%26aufirst%3DK.%26aulast%3Dvon%2BZweydorf%26aufirst%3DF.%26aulast%3DHelm%26aufirst%3DS.%26aulast%3DWiesent%26aufirst%3DL.%26aulast%3DSarioglu%26aufirst%3DH.%26aulast%3DUeffing%26aufirst%3DM.%26atitle%3DPhosphopeptide%2520Analysis%2520Reveals%2520Two%2520Discrete%2520Clusters%2520of%2520Phosphorylation%2520in%2520the%2520N-Terminus%2520and%2520the%2520Roc%2520Domain%2520of%2520the%2520Parkinson-Disease%2520Associated%2520Protein%2520Kinase%2520LRRK2%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2010%26volume%3D9%26issue%3D4%26spage%3D1738%26epage%3D1745%26doi%3D10.1021%2Fpr9008578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobbestael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J.-M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of LRRK2: From Kinase to Substrate</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1042/BST20120128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBST20120128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22988873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOjurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1102-1110&issue=5&author=E.+Lobbestaelauthor=V.+Baekelandtauthor=J.-M.+Taymans&title=Phosphorylation+of+LRRK2%3A+From+Kinase+to+Substrate&doi=10.1042%2FBST20120128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of LRRK2: from kinase to substrate</span></div><div class="casAuthors">Lobbestael, Evy; Baekelandt, Veerle; Taymans, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1102-1110</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The PD (Parkinson's disease) protein LRRK2 (leucine-rich repeat kinase 2) occurs in cells as a highly phosphorylated protein, with the majority of phosphosites clustering in the region between the ankyrin repeat and leucine-rich repeat domains.  The observation that several pathogenic variants of LRRK2 display strongly reduced cellular phosphorylation suggests that phosphorylation of LRRK2 is involved in the PD pathol. process.  Furthermore, treatment of cells with inhibitors of LRRK2 kinase activity, which are currently considered as potential disease-modifying therapeutics for PD, leads to a rapid decrease in the phosphorylation levels of LRRK2.  For these reasons, understanding the cellular role and regulation of LRRK2 as a kinase and as a substrate has become the focus of intense investigation.  In the present review, we discuss what is currently known about the cellular phosphorylation of LRRK2 and how this relates to its function and dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFV1_upRIH2bVg90H21EOLACvtfcHk0lh7G4YPpD5OiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOjurzN&md5=013ec8ec8243d2a08b01a4bf01b80f08</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1042%2FBST20120128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20120128%26sid%3Dliteratum%253Aachs%26aulast%3DLobbestael%26aufirst%3DE.%26aulast%3DBaekelandt%26aufirst%3DV.%26aulast%3DTaymans%26aufirst%3DJ.-M.%26atitle%3DPhosphorylation%2520of%2520LRRK2%253A%2520From%2520Kinase%2520to%2520Substrate%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2012%26volume%3D40%26issue%3D5%26spage%3D1102%26epage%3D1110%26doi%3D10.1042%2FBST20120128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzamko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of LRRK2 Kinase Activity Leads to Dephosphorylation of Ser(910)/Ser(935), Disruption of 14-3-3 Binding and Altered Cytoplasmic Localization</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1042/BJ20100784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBJ20100784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20659021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=405-413&issue=3&author=N.+Dzamkoauthor=M.+Deakauthor=F.+Hentatiauthor=A.+D.+Reithauthor=A.+R.+Prescottauthor=D.+R.+Alessiauthor=R.+J.+Nichols&title=Inhibition+of+LRRK2+Kinase+Activity+Leads+to+Dephosphorylation+of+Ser%28910%29%2FSer%28935%29%2C+Disruption+of+14-3-3+Binding+and+Altered+Cytoplasmic+Localization&doi=10.1042%2FBJ20100784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization</span></div><div class="casAuthors">Dzamko, Nicolas; Deak, Maria; Hentati, Faycal; Reith, Alastair D.; Prescott, Alan R.; Alessi, Dario R.; Nichols, R. Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant no. of Parkinson's disease patients.  Since a common mutation that replaces Gly2019 with a serine residue enhances kinase catalytic activity, small-mol. LRRK2 inhibitors might have utility in treating Parkinson's disease.  However, the effectiveness of inhibitors is difficult to assess, as no physiol. substrates or downstream effectors have been identified that could be exploited to develop a robust cell-based assay.  The authors recently established that LRRK2 bound 14-3-3 protein isoforms via its phosphorylation of Ser910 and Ser935.  In the present study they show that treatment of Swiss 3T3 cells or lymphoblastoid cells derived from control or a Parkinson's disease patient harboring a homozygous LRRK2(G2019S) mutation with two structurally unrelated inhibitors of LRRK2 (H-1152 or sunitinib) induced dephosphorylation of endogenous LRRK2 at Ser910 and Ser935, thereby disrupting 14-3-3 interaction.  The results suggest that H-1152 and sunitinib induce dephosphorylation of Ser910 and Ser935 by inhibiting LRRK2 kinase activity, as these compds. failed to induce significant dephosphorylation of a drug-resistant LRRK2(A2016T) mutant.  Moreover, consistent with the finding that non-14-3-3-binding mutants of LRRK2 accumulated within discrete cytoplasmic pools resembling inclusion bodies, the authors obsd. that H-1152 causes LRRK2 to accumulate within inclusion bodies.  These findings indicate that dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and/or monitoring LRRK2 cytoplasmic localization can be used as an assay to assess the relative activity of LRRK2 inhibitors in vivo.  These results will aid the elaboration and evaluation of LRRK2 inhibitors.  They will also stimulate further research to understand how phosphorylation of Ser910 and Ser935 is controlled by LRRK2, and establish any relationship to development of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwgToKFLmVu7Vg90H21EOLACvtfcHk0lgqT9SRKgEB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL&md5=f14dd622d2b2fa3f7495c990e65bbbfc</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1042%2FBJ20100784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100784%26sid%3Dliteratum%253Aachs%26aulast%3DDzamko%26aufirst%3DN.%26aulast%3DDeak%26aufirst%3DM.%26aulast%3DHentati%26aufirst%3DF.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26atitle%3DInhibition%2520of%2520LRRK2%2520Kinase%2520Activity%2520Leads%2520to%2520Dephosphorylation%2520of%2520Ser%2528910%2529%252FSer%2528935%2529%252C%2520Disruption%2520of%252014-3-3%2520Binding%2520and%2520Altered%2520Cytoplasmic%2520Localization%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26issue%3D3%26spage%3D405%26epage%3D413%26doi%3D10.1042%2FBJ20100784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vancraenenbroeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Raeymaecker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobbestael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J.-M.</span></span> <span> </span><span class="NLM_article-title">In Silico, in Vitro and Cellular Analysis with a Kinome-Wide Inhibitor Panel Correlates Cellular LRRK2 Dephosphorylation to Inhibitor Activity on LRRK2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.3389%2Ffnmol.2014.00051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24917786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVChsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=51&author=R.+Vancraenenbroeckauthor=J.+De+Raeymaeckerauthor=E.+Lobbestaelauthor=F.+Gaoauthor=M.+De+Maeyerauthor=A.+Voetauthor=V.+Baekelandtauthor=J.-M.+Taymans&title=In+Silico%2C+in+Vitro+and+Cellular+Analysis+with+a+Kinome-Wide+Inhibitor+Panel+Correlates+Cellular+LRRK2+Dephosphorylation+to+Inhibitor+Activity+on+LRRK2&doi=10.3389%2Ffnmol.2014.00051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2</span></div><div class="casAuthors">Vancraenenbroeck, Renee; De Raeymaecker, Joren; Lobbestael, Evy; Gao, Fangye; De Maeyer, Marc; Voet, Arnout; Baekelandt, Veerle; Taymans, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Leucine-rich repeat kinase 2 (LRRK2) is a complex, multidomain protein which is considered a valuable target for potential disease-modifying therapeutic strategies for Parkinson's disease (PD).  In mammalian cells and brain, LRRK2 is phosphorylated and treatment of cells with inhibitors of LRRK2 kinase activity can induce LRRK2 dephosphorylation at a cluster of serines including Ser910/935/955/973.  It has been suggested that phosphorylation levels at these sites reflect LRRK2 kinase activity, however kinase-dead variants of LRRK2 or kinase activating variants do not display altered Ser935 phosphorylation levels compared to wild type.  Furthermore, Ser910/935/955/973 are not autophosphorylation sites, therefore, it is unclear if inhibitor induced dephosphorylation depends on the activity of compds. on LRRK2 or on yet to be identified upstream kinases.  Here we used a panel of 160 ATP competitive and cell permeable kinase inhibitors directed against all branches of the kinome and tested their activity on LRRK2 in vitro using a peptide-substrate-based kinase assay.  In neuronal SH-SY5Y cells overexpressing LRRK2 we used compd.-induced dephosphorylation of Ser935 as readout.  In silico docking of selected compds. was performed using a modeled LRRK2 kinase structure.  Receiver operating characteristic plots demonstrated that the obtained docking scores to the LRRK2 ATP binding site correlated with in vitro and cellular compd. activity.  We also found that in vitro potency showed a high degree of correlation to cellular compd. induced LRRK2 dephosphorylation activity across multiple compd. classes.  Therefore, acute LRRK2 dephosphorylation at Ser935 in inhibitor treated cells involves a strong component of inhibitor activity on LRRK2 itself, without excluding a role for upstream kinases.  Understanding the regulation of LRRK2 phosphorylation by kinase inhibitors aids our understanding of LRRK2 signaling and may lead to development of new classes of LRRK2 kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOkDJX9D3umrVg90H21EOLACvtfcHk0lgqT9SRKgEB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVChsb%252FK&md5=e489943d1d2337897ddb460ff21f9cb7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00051%26sid%3Dliteratum%253Aachs%26aulast%3DVancraenenbroeck%26aufirst%3DR.%26aulast%3DDe%2BRaeymaecker%26aufirst%3DJ.%26aulast%3DLobbestael%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DDe%2BMaeyer%26aufirst%3DM.%26aulast%3DVoet%26aufirst%3DA.%26aulast%3DBaekelandt%26aufirst%3DV.%26aulast%3DTaymans%26aufirst%3DJ.-M.%26atitle%3DIn%2520Silico%252C%2520in%2520Vitro%2520and%2520Cellular%2520Analysis%2520with%2520a%2520Kinome-Wide%2520Inhibitor%2520Panel%2520Correlates%2520Cellular%2520LRRK2%2520Dephosphorylation%2520to%2520Inhibitor%2520Activity%2520on%2520LRRK2%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D51%26doi%3D10.3389%2Ffnmol.2014.00051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molitor, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span> <span> </span><span class="NLM_article-title">LRRK2 Dephosphorylation Increases Its Ubiquitination</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>469</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1042/BJ20141305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBJ20141305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25939886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12itr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2015&pages=107-120&issue=1&author=J.+Zhaoauthor=T.+P.+Molitorauthor=J.+W.+Langstonauthor=R.+J.+Nichols&title=LRRK2+Dephosphorylation+Increases+Its+Ubiquitination&doi=10.1042%2FBJ20141305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 dephosphorylation increases its ubiquitination</span></div><div class="casAuthors">Zhao, Jing; Molitor, Tyler P.; Langston, J. William; Nichols, R. Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Activating mutations in the leucine rich repeat protein kinase 2 (LRRK2) gene are the most common cause of inherited Parkinson's disease (PD).  LRRK2 is phosphorylated on a cluster of phosphosites including Ser-910, Ser-935, Ser-955 and Ser-973, which are dephosphorylated in several PD-related LRRK2 mutants (N1437H, R1441C/G, Y1699C and I2020T) linking the regulation of these sites to PD.  These serine residues are also dephosphorylated after kinase inhibition and lose 14-3-3 binding, which serves as a pharmacodynamic marker for inhibited LRRK2.  Loss of 14-3-3 binding is well established, but the consequences of dephosphorylation are only now being uncovered.  Potent and selective inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser-935 then ubiquitination and degrdn. of a significant fraction of LRRK2.  GNE1023 treatment decreased the phosphorylation and stability of LRRK2 in expression systems and endogenous LRRK2 in A549 cells and in mouse dosing studies.  The authors next established that LRRK2 is ubiquitinated through at least Lys-48 and Lys-63 ubiquitin linkages in response to inhibition.  To study the link between dephosphorylation induced by inhibitor treatment and LRRK2 ubiquitination, the authors studied LRRK2 in conditions where it is dephosphorylated such as expression of PD mutants [R1441G, Y1699C and I2020T] or by blocking 14-3-3 binding to LRRK2 via difopein expression, and found LRRK2 is hyper-ubiquitinated.  Calyculin A treatment prevents inhibitor and PD mutant induced dephosphorylation and reverts LRRK2 to a lesser ubiquitinated species, thus directly implicating phosphatase activity in LRRK2 ubiquitination.  This dynamic dephosphorylation-ubiquitination cycle could explain detrimental loss-of-function phenotypes found in peripheral tissues of LRRK2 kinase inactive mutants, LRRK2 KO (knockout) animals and following LRRK2 inhibitor administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxqm5oSlvVrbVg90H21EOLACvtfcHk0livc6G6m9DAxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12itr7J&md5=6b343827aa9df5dab3c83fbd745491c0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1042%2FBJ20141305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20141305%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMolitor%26aufirst%3DT.%2BP.%26aulast%3DLangston%26aufirst%3DJ.%2BW.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26atitle%3DLRRK2%2520Dephosphorylation%2520Increases%2520Its%2520Ubiquitination%26jtitle%3DBiochem.%2520J.%26date%3D2015%26volume%3D469%26issue%3D1%26spage%3D107%26epage%3D120%26doi%3D10.1042%2FBJ20141305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobbestael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greggio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span> <span> </span><span class="NLM_article-title">Pharmacological LRRK2 Kinase Inhibition Induces LRRK2 Protein Destabilization and Proteasomal Degradation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">33897</span>, <span class="refDoi"> DOI: 10.1038/srep33897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fsrep33897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27658356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOnurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=33897&author=E.+Lobbestaelauthor=L.+Civieroauthor=T.+De+Witauthor=J.+M.+Taymansauthor=E.+Greggioauthor=V.+Baekelandt&title=Pharmacological+LRRK2+Kinase+Inhibition+Induces+LRRK2+Protein+Destabilization+and+Proteasomal+Degradation&doi=10.1038%2Fsrep33897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation</span></div><div class="casAuthors">Lobbestael, E.; Civiero, L.; De Wit, T.; Taymans, J.-M.; Greggio, E.; Baekelandt, V.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33897</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S, and is known to play a role in Parkinson's disease (PD) pathobiol.  This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one of the most prevailing disease-modifying therapeutic PD strategies.  Although several lines of evidence support beneficial effects of LRRK2 kinase inhibitors, many questions need to be answered before clin. applications can be envisaged.  Using six different LRRK2 kinase inhibitors, we show that LRRK2 kinase inhibition induces LRRK2 dephosphorylation and can reduce LRRK2 protein levels of overexpressed wild type and G2019S, but not A2016T or K1906M, LRRK2 as well as endogenous LRRK2 in mouse brain, lung and kidney.  The inhibitor-induced redn. in LRRK2 levels could be reversed by proteasomal inhibition, but not by lysosomal inhibition, while mRNA levels remained unaffected.  In addn., using LRRK2 S910A and S935A phosphorylation mutants, we show that dephosphorylation of these sites is not required for LRRK2 degrdn.  Increasing our insight in the mol. and cellular consequences of LRRK2 kinase inhibition will be crucial in the further development of LRRK2-based PD therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW4s9pKBobXLVg90H21EOLACvtfcHk0livc6G6m9DAxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOnurzJ&md5=0693de5d80cd9826b59ed113a204ad7b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsrep33897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep33897%26sid%3Dliteratum%253Aachs%26aulast%3DLobbestael%26aufirst%3DE.%26aulast%3DCiviero%26aufirst%3DL.%26aulast%3DDe%2BWit%26aufirst%3DT.%26aulast%3DTaymans%26aufirst%3DJ.%2BM.%26aulast%3DGreggio%26aufirst%3DE.%26aulast%3DBaekelandt%26aufirst%3DV.%26atitle%3DPharmacological%2520LRRK2%2520Kinase%2520Inhibition%2520Induces%2520LRRK2%2520Protein%2520Destabilization%2520and%2520Proteasomal%2520Degradation%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D33897%26doi%3D10.1038%2Fsrep33897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persohn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmelen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grevot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Putten, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span> <span> </span><span class="NLM_article-title">LRRK2 Protein Levels Are Determined by Kinase Function and Are Crucial for Kidney and Lung Homeostasis in Mice</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4209</span>– <span class="NLM_lpage">4223</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddr348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1093%2Fhmg%2Fddr348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21828077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=4209-4223&issue=21&author=M.+C.+Herzigauthor=C.+Kollyauthor=E.+Persohnauthor=D.+Theilauthor=T.+Schweizerauthor=T.+Hafnerauthor=C.+Stemmelenauthor=T.+J.+Troxlerauthor=P.+Schmidauthor=S.+Dannerauthor=C.+R.+Schnellauthor=M.+Muellerauthor=B.+Kinzelauthor=A.+Grevotauthor=F.+Bolognaniauthor=M.+Stirnauthor=R.+R.+Kuhnauthor=K.+Kaupmannauthor=P.+H.+van+der%0APuttenauthor=G.+Rovelliauthor=D.+R.+Shimshek&title=LRRK2+Protein+Levels+Are+Determined+by+Kinase+Function+and+Are+Crucial+for+Kidney+and+Lung+Homeostasis+in+Mice&doi=10.1093%2Fhmg%2Fddr348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice</span></div><div class="casAuthors">Herzig, Martin C.; Kolly, Carine; Persohn, Elke; Theil, Diethilde; Schweizer, Tatjana; Hafner, Thomas; Stemmelen, Christine; Troxler, Thomas J.; Schmid, Peter; Danner, Simone; Schnell, Christian R.; Mueller, Matthias; Kinzel, Bernd; Grevot, Armelle; Bolognani, Federico; Stirn, Martina; Kuhn, Rainer R.; Kaupmann, Klemens; van der Putten, P. Herman; Rovelli, Giorgio; Shimshek, Derya R.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4209-4223</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset Parkinson's disease (PD), but the underlying pathophysiol. mechanisms and the normal function of this large multidomain protein remain speculative.  To address the role of this protein in vivo, we generated three different LRRK2 mutant mouse lines.  Mice completely lacking the LRRK2 protein (knock-out, KO) showed an early-onset (age 6 wk) marked increase in no. and size of secondary lysosomes in kidney proximal tubule cells and lamellar bodies in lung type II cells.  Mice expressing a LRRK2 kinase-dead (KD) mutant from the endogenous locus displayed similar early-onset pathophysiol. changes in kidney but not lung.  KD mutants had dramatically reduced full-length LRRK2 protein levels in the kidney and this genetic effect was mimicked pharmacol. in wild-type mice treated with a LRRK2-selective kinase inhibitor.  Knock-in (KI) mice expressing the G2019S PD-assocd. mutation that increases LRRK2 kinase activity showed none of the LRRK2 protein level and histopathol. changes obsd. in KD and KO mice.  The autophagy marker LC3 remained unchanged but kidney mTOR and TCS2 protein levels decreased in KD and increased in KO and KI mice.  Unexpectedly, KO and KI mice suffered from diastolic hypertension opposed to normal blood pressure in KD mice.  Our findings demonstrate a role for LRRK2 in kidney and lung physiol. and further show that LRRK2 kinase function affects LRRK2 protein steady-state levels thereby altering putative scaffold/GTPase activity.  These novel aspects of peripheral LRRK2 biol. critically impact ongoing attempts to develop LRRK2 selective kinase inhibitors as therapeutics for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol714w-ZIM5rVg90H21EOLACvtfcHk0lgsqwS7pWjIXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI&md5=9c7935965c8f21e13b42bdc9e794cde0</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddr348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddr348%26sid%3Dliteratum%253Aachs%26aulast%3DHerzig%26aufirst%3DM.%2BC.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DPersohn%26aufirst%3DE.%26aulast%3DTheil%26aufirst%3DD.%26aulast%3DSchweizer%26aufirst%3DT.%26aulast%3DHafner%26aufirst%3DT.%26aulast%3DStemmelen%26aufirst%3DC.%26aulast%3DTroxler%26aufirst%3DT.%2BJ.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DDanner%26aufirst%3DS.%26aulast%3DSchnell%26aufirst%3DC.%2BR.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DB.%26aulast%3DGrevot%26aufirst%3DA.%26aulast%3DBolognani%26aufirst%3DF.%26aulast%3DStirn%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DR.%2BR.%26aulast%3DKaupmann%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BPutten%26aufirst%3DP.%2BH.%26aulast%3DRovelli%26aufirst%3DG.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26atitle%3DLRRK2%2520Protein%2520Levels%2520Are%2520Determined%2520by%2520Kinase%2520Function%2520and%2520Are%2520Crucial%2520for%2520Kidney%2520and%2520Lung%2520Homeostasis%2520in%2520Mice%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26issue%3D21%26spage%3D4209%26epage%3D4223%26doi%3D10.1093%2Fhmg%2Fddr348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katavolos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roose-Girma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urkowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warming, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaylaoglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span> <span> </span><span class="NLM_article-title">Effect of Selective LRRK2 Kinase Inhibition on Nonhuman Primate Lung</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">273</span>),  <span class="NLM_fpage">273ra15</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa3634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscitranslmed.aaa3634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25653221" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=273ra15&issue=273&author=R.+N.+Fujiauthor=M.+Flagellaauthor=M.+Bacaauthor=M.+A.+S.+Baptistaauthor=J.+Brodbeckauthor=B.+K.+Chanauthor=B.+K.+Fiskeauthor=L.+Honigbergauthor=A.+M.+Jubbauthor=P.+Katavolosauthor=D.+W.+Leeauthor=S.-C.+Lewin-Kohauthor=T.+Linauthor=X.+Liuauthor=S.+Liuauthor=J.+P.+Lyssikatosauthor=J.+O%E2%80%99Mahonyauthor=M.+Reicheltauthor=M.+Roose-Girmaauthor=Z.+Shengauthor=T.+Shererauthor=A.+Smithauthor=M.+Solonauthor=Z.+K.+Sweeneyauthor=J.+Tarrantauthor=A.+Urkowitzauthor=S.+Warmingauthor=M.+Yaylaogluauthor=S.+Zhangauthor=H.+Zhuauthor=A.+A.+Estradaauthor=R.+J.+Watts&title=Effect+of+Selective+LRRK2+Kinase+Inhibition+on+Nonhuman+Primate+Lung&doi=10.1126%2Fscitranslmed.aaa3634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa3634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa3634%26sid%3Dliteratum%253Aachs%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DBaca%26aufirst%3DM.%26aulast%3DBaptista%26aufirst%3DM.%2BA.%2BS.%26aulast%3DBrodbeck%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26aulast%3DHonigberg%26aufirst%3DL.%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DKatavolos%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DJ.%26aulast%3DReichelt%26aufirst%3DM.%26aulast%3DRoose-Girma%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSherer%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSolon%26aufirst%3DM.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DUrkowitz%26aufirst%3DA.%26aulast%3DWarming%26aufirst%3DS.%26aulast%3DYaylaoglu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26atitle%3DEffect%2520of%2520Selective%2520LRRK2%2520Kinase%2520Inhibition%2520on%2520Nonhuman%2520Primate%2520Lung%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D273%26spage%3D273ra15%26doi%3D10.1126%2Fscitranslmed.aaa3634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greeley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varsho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshul, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span> <span> </span><span class="NLM_article-title">Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e80705</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0080705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1371%2Fjournal.pone.0080705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24244710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e80705&issue=11&author=M.+A.+S.+Baptistaauthor=K.+D.+Daveauthor=M.+A.+Frasierauthor=T.+B.+Shererauthor=M.+Greeleyauthor=M.+J.+Beckauthor=J.+S.+Varshoauthor=G.+A.+Parkerauthor=C.+Mooreauthor=M.+J.+Churchillauthor=C.+K.+Meshulauthor=B.+K.+Fiske&title=Loss+of+Leucine-Rich+Repeat+Kinase+2+%28LRRK2%29+in+Rats+Leads+to+Progressive+Abnormal+Phenotypes+in+Peripheral+Organs&doi=10.1371%2Fjournal.pone.0080705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of leucine-rich repeat kinase 2 (LRKK2) in rats leads to progressive abnormal phenotypes in peripheral organs</span></div><div class="casAuthors">Baptista, Marco A. S.; Dave, Kuldip D.; Frasier, Mark A.; Sherer, Todd B.; Greeley, Melanie; Beck, Melissa J.; Varsho, Julie S.; Parker, George A.; Moore, Cindy; Churchill, Madeline J.; Meshul, Charles K.; Fiske, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e80705/1-e80705/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate the pathol. time course of the LRRK2 knockout rat model of Parkinson's disease at 1-, 2-, 4-, 8-, 12-, and 16-mo of age.  The evaluation consisted of histopathol. and ultrastructure examn. of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematol., serum, and urine anal.  The LRRK2 knockout rat, starting at 2-mo of age, displayed abnormal kidney staining patterns and/or morphol. changes that were assocd. with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat.  Urinalysis indicated pronounced changes in LRRK2 knockout rats in urine sp. gr., total vol., urine potassium, creatinine, sodium, and chloride that started as early as 1- to 2-mo of age.  Electron microscopy of 16-mo old LRRK2 knockout rats displayed an abnormal kidney, lung, and liver phenotype.  In contrast, there were equivocal or no differences in the heart and spleen of LRRK2 wild-type and knockout rats.  These findings partially replicate data from a recent study in 4-mo old LRRK2 knockout rats and expand the anal. to demonstrate that the renal and possibly lung and liver abnormalities progress with age.  The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0nBkK8AbyV7Vg90H21EOLACvtfcHk0lhgeWb4EHUKmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D&md5=f10ad0059276bf1b2894df72772a8151</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0080705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0080705%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DM.%2BA.%2BS.%26aulast%3DDave%26aufirst%3DK.%2BD.%26aulast%3DFrasier%26aufirst%3DM.%2BA.%26aulast%3DSherer%26aufirst%3DT.%2BB.%26aulast%3DGreeley%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DM.%2BJ.%26aulast%3DVarsho%26aufirst%3DJ.%2BS.%26aulast%3DParker%26aufirst%3DG.%2BA.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DChurchill%26aufirst%3DM.%2BJ.%26aulast%3DMeshul%26aufirst%3DC.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26atitle%3DLoss%2520of%2520Leucine-Rich%2520Repeat%2520Kinase%25202%2520%2528LRRK2%2529%2520in%2520Rats%2520Leads%2520to%2520Progressive%2520Abnormal%2520Phenotypes%2520in%2520Peripheral%2520Organs%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D11%26spage%3De80705%26doi%3D10.1371%2Fjournal.pone.0080705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheewatrakoolpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMong, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgraf, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulet, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, J. A.</span></span> <span> </span><span class="NLM_article-title">MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.227587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1124%2Fjpet.115.227587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26407721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=397-409&issue=3&author=M.+J.+Fellauthor=C.+Mirescuauthor=K.+Basuauthor=B.+Cheewatrakoolpongauthor=D.+E.+DeMongauthor=J.+M.+Ellisauthor=L.+A.+Hydeauthor=Y.+Linauthor=C.+G.+Markgrafauthor=H.+Meiauthor=M.+Millerauthor=F.+M.+Pouletauthor=J.+D.+Scottauthor=M.+D.+Smithauthor=Z.+Yinauthor=X.+Zhouauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=J.+A.+Morrow&title=MLi-2%2C+a+Potent%2C+Selective%2C+and+Centrally+Active+Compound+for+Exploring+the+Therapeutic+Potential+and+Safety+of+LRRK2+Kinase+Inhibition&doi=10.1124%2Fjpet.115.227587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition</span></div><div class="casAuthors">Fell, Matthew J.; Mirescu, Christian; Basu, Kallol; Cheewatrakoolpong, Boonlert; DeMong, Duane E.; Ellis, J. Michael; Hyde, Lynn A.; Lin, Yinghui; Markgraf, Carrie G.; Mei, Hong; Miller, Michael; Poulet, Frederique M.; Scott, Jack D.; Smith, Michelle D.; Yin, Zhizhang; Zhou, Xiaoping; Parker, Eric M.; Kennedy, Matthew E.; Morrow, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of familial and sporadic Parkinson's disease (PD).  That the most prevalent mutation, G2019S, leads to increased kinase activity has led to a concerted effort to identify LRRK2 kinase inhibitors as a potential disease-modifying therapy for PD.  An internal medicinal chem. effort identified several potent and highly selective compds. with favorable drug-like properties.  Here, we characterize the pharmacol. properties of cis-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine (MLi-2), a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.  MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).  MLi-2 has greater than 295-fold selectivity for over 300 kinases in addn. to a diverse panel of receptors and ion channels.  Acute oral and subchronic dosing in MLi-2 mice resulted in dose-dependent central and peripheral target inhibition over a 24-h period as measured by dephosphorylation of pSer935 LRRK2.  Treatment of MitoPark mice with MLi-2 was well tolerated over a 15-wk period at brain and plasma exposures >100× the in vivo plasma IC50 for LRRK2 kinase inhibition as measured by pSer935 dephosphorylation.  Morphol. changes in the lung, consistent with enlarged type II pneumocytes, were obsd. in MLi-2-treated MitoPark mice.  These data demonstrate the suitability of MLi-2 as a compd. to explore LRRK2 biol. in cellular and animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpot402TvUrkbVg90H21EOLACvtfcHk0lj6F964lUg5zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D&md5=83c68f7bb731bef2fa9db880196dbabe</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227587%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DMirescu%26aufirst%3DC.%26aulast%3DBasu%26aufirst%3DK.%26aulast%3DCheewatrakoolpong%26aufirst%3DB.%26aulast%3DDeMong%26aufirst%3DD.%2BE.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DMarkgraf%26aufirst%3DC.%2BG.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPoulet%26aufirst%3DF.%2BM.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DMorrow%26aufirst%3DJ.%2BA.%26atitle%3DMLi-2%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Centrally%2520Active%2520Compound%2520for%2520Exploring%2520the%2520Therapeutic%2520Potential%2520and%2520Safety%2520of%2520LRRK2%2520Kinase%2520Inhibition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26issue%3D3%26spage%3D397%26epage%3D409%26doi%3D10.1124%2Fjpet.115.227587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skibinski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cookson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkbeiner, S.</span></span> <span> </span><span class="NLM_article-title">Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein but Not Kinase Activity or Inclusion Bodies</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2712-13.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1523%2FJNEUROSCI.2712-13.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24403142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Wqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=418-433&issue=2&author=G.+Skibinskiauthor=K.+Nakamuraauthor=M.+R.+Cooksonauthor=S.+Finkbeiner&title=Mutant+LRRK2+Toxicity+in+Neurons+Depends+on+LRRK2+Levels+and+Synuclein+but+Not+Kinase+Activity+or+Inclusion+Bodies&doi=10.1523%2FJNEUROSCI.2712-13.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies</span></div><div class="casAuthors">Skibinski, Gaia; Nakamura, Ken; Cookson, Mark R.; Finkbeiner, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-433</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">By combining exptl. neuron models and math. tools, we developed a "systems" approach to deconvolve cellular mechanisms of neurodegeneration underlying the most common known cause of Parkinson's disease (PD), mutations in leucine-rich repeat kinase 2 (LRRK2).  Neurons ectopically expressing mutant LRRK2 formed inclusion bodies (IBs), retracted neurites, accumulated synuclein, and died prematurely, recapitulating key features of PD.  Degeneration was predicted from the levels of diffuse mutant LRRK2 that each neuron contained, but IB formation was neither necessary nor sufficient for death.  Genetic or pharmacol. blockade of its kinase activity destabilized LRRK2 and lowered its levels enough to account for the moderate redn. in LRRK2 toxicity that ensued.  By contrast, targeting synuclein, including neurons made from PD patient-derived induced pluripotent cells, dramatically reduced LRRK2-dependent neurodegeneration and LRRK2 levels.  These findings suggest that LRRK2 levels are more important than kinase activity per se in predicting toxicity and implicate synuclein as a major mediator of LRRK2-induced neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdgp6jm-zdrVg90H21EOLACvtfcHk0lj6F964lUg5zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Wqug%253D%253D&md5=a4f8d3935fe3c9be47e691d728d23e7d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2712-13.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2712-13.2014%26sid%3Dliteratum%253Aachs%26aulast%3DSkibinski%26aufirst%3DG.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DCookson%26aufirst%3DM.%2BR.%26aulast%3DFinkbeiner%26aufirst%3DS.%26atitle%3DMutant%2520LRRK2%2520Toxicity%2520in%2520Neurons%2520Depends%2520on%2520LRRK2%2520Levels%2520and%2520Synuclein%2520but%2520Not%2520Kinase%2520Activity%2520or%2520Inclusion%2520Bodies%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26issue%3D2%26spage%3D418%26epage%3D433%26doi%3D10.1523%2FJNEUROSCI.2712-13.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzamko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of a Selective Inhibitor of the Parkinson’s Disease Kinase LRRK2</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1038/nchembio.538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnchembio.538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21378983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVKqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=203-205&issue=4&author=X.+Dengauthor=N.+Dzamkoauthor=A.+Prescottauthor=P.+Daviesauthor=Q.+Liuauthor=Q.+Yangauthor=J.-D.+Leeauthor=M.+P.+Patricelliauthor=T.+K.+Nomanbhoyauthor=D.+R.+Alessiauthor=N.+S.+Gray&title=Characterization+of+a+Selective+Inhibitor+of+the+Parkinson%E2%80%99s+Disease+Kinase+LRRK2&doi=10.1038%2Fnchembio.538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2</span></div><div class="casAuthors">Deng, Xianming; Dzamko, Nicolas; Prescott, Alan; Davies, Paul; Liu, Qingsong; Yang, Qingkai; Lee, Jiing-Dwan; Patricelli, Matthew P.; Nomanbhoy, Tyzoon K.; Alessi, Dario R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">203-205</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly assocd. with late-onset autosomal dominant Parkinson's disease.  We employed a new, parallel, compd.-centric approach to identify a potent and selective LRRK2 inhibitor, LRRK2-IN-1, and demonstrated that inhibition of LRRK2 induces dephosphorylation of Ser910 and Ser935 and accumulation of LRRK2 within aggregate structures.  LRRK2-IN-1 will serve as a versatile tool to pharmacol. interrogate LRRK2 biol. and study its role in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwLpGURHqDULVg90H21EOLACvtfcHk0lhBtARTOBhnzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVKqsL0%253D&md5=9f48f74cad9988e3ea8bb7af280473c1</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.538%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDzamko%26aufirst%3DN.%26aulast%3DPrescott%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.-D.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DCharacterization%2520of%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Parkinson%25E2%2580%2599s%2520Disease%2520Kinase%2520LRRK2%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26issue%3D4%26spage%3D203%26epage%3D205%26doi%3D10.1038%2Fnchembio.538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The Phosphoinositide 3-Kinase Pathway</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span> (<span class="NLM_issue">5573</span>),  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1126/science.296.5573.1655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&issue=5573&author=L.+C.+Cantley&title=The+Phosphoinositide+3-Kinase+Pathway&doi=10.1126%2Fscience.296.5573.1655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0lhBtARTOBhnzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Phosphoinositide%25203-Kinase%2520Pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26issue%3D5573%26spage%3D1655%26epage%3D1657%26doi%3D10.1126%2Fscience.296.5573.1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Kittler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rago, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huso, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">Mutant PIK3CA Promotes Cell Growth and Invasion of Human Cancer Cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2005.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15950905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslCgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=561-573&issue=6&author=Y.+Samuelsauthor=L.+A.+Diazauthor=O.+Schmidt-Kittlerauthor=J.+M.+Cumminsauthor=L.+Delongauthor=I.+Cheongauthor=C.+Ragoauthor=D.+L.+Husoauthor=C.+Lengauerauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=Mutant+PIK3CA+Promotes+Cell+Growth+and+Invasion+of+Human+Cancer+Cells&doi=10.1016%2Fj.ccr.2005.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant PIK3CA promotes cell growth and invasion of human cancer cells</span></div><div class="casAuthors">Samuels, Yardena; Diaz, Luis A., Jr.; Schmidt-Kittler, Oleg; Cummins, Jordan M.; DeLong, Laura; Cheong, Ian; Rago, Carlo; Huso, David L.; Lengauer, Christoph; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">561-573</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PIK3CA is mutated in diverse human cancers, but the functional effects of these mutations have not been defined.  To evaluate the consequences of PIK3CA alterations, the two most common mutations were inactivated by gene targeting in colorectal cancer (CRC) cells.  Biochem. analyses of these cells showed that mutant PIK3CA selectively regulated the phosphorylation of AKT and the forkhead transcription factors FKHR and FKHRL1.  PIK3CA mutations had little effect on growth under std. conditions, but reduced cellular dependence on growth factors.  PIK3CA mutations resulted in attenuation of apoptosis and facilitated tumor invasion.  Treatment with the PI3K inhibitor LY294002 abrogated PIK3CA signaling and preferentially inhibited growth of PIK3CA mutant cells.  These data have important implications for therapy of cancers harboring PIK3CA alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAqbiIItFxwLVg90H21EOLACvtfcHk0ljYOpFdUZyKyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslCgsrY%253D&md5=3f9399e100d35a817dd052254765fa12</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DSchmidt-Kittler%26aufirst%3DO.%26aulast%3DCummins%26aufirst%3DJ.%2BM.%26aulast%3DDelong%26aufirst%3DL.%26aulast%3DCheong%26aufirst%3DI.%26aulast%3DRago%26aufirst%3DC.%26aulast%3DHuso%26aufirst%3DD.%2BL.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DMutant%2520PIK3CA%2520Promotes%2520Cell%2520Growth%2520and%2520Invasion%2520of%2520Human%2520Cancer%2520Cells%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26issue%3D6%26spage%3D561%26epage%3D573%26doi%3D10.1016%2Fj.ccr.2005.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&issue=7&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+Phosphatidylinositol+3-Kinase+AKT+Pathway+in+Human+Cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0ljYOpFdUZyKyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520Phosphatidylinositol%25203-Kinase%2520AKT%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26issue%3D7%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saal, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memeo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmström, P.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansukhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enoksson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibshoosh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R.</span></span> <span> </span><span class="NLM_article-title">PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1158/0008-5472-CAN-04-3913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472-CAN-04-3913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15805248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVeqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=2554-2559&issue=7&author=L.+H.+Saalauthor=K.+Holmauthor=M.+Maurerauthor=L.+Memeoauthor=T.+Suauthor=X.+Wangauthor=J.+S.+Yuauthor=P.-O.+Malmstr%C3%B6mauthor=M.+Mansukhaniauthor=J.+Enokssonauthor=H.+Hibshooshauthor=A.+Borgauthor=R.+Parsons&title=PIK3CA+Mutations+Correlate+with+Hormone+Receptors%2C+Node+Metastasis%2C+and+ERBB2%2C+and+Are+Mutually+Exclusive+with+PTEN+Loss+in+Human+Breast+Carcinoma&doi=10.1158%2F0008-5472-CAN-04-3913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma</span></div><div class="casAuthors">Saal, Lao H.; Holm, Karolina; Maurer, Matthew; Memeo, Lorenzo; Su, Tao; Wang, Xiaomei; Yu, Jennifer S.; Malmstroem, Per-Olof; Mansukhani, Mahesh; Enoksson, Jens; Hibshoosh, Hanina; Borg, Ake; Parsons, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2554-2559</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway either through loss of PTEN or mutation of the catalytic subunit α of PI3K (PIK3CA) occurs frequently in human cancer.  We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV.  To investigate the relationship between PTEN and PIK3CA, we generated a cohort of tumors that had lost PTEN expression and compared it with a matched control set that had retained PTEN.  A highly significant assocn. between PIK3CA mutations and retention of PTEN protein expression was obsd.  In addn., PIK3CA mutations were assocd. with expression of estrogen and progesterone receptors (ER/PR), lymph node metastasis, and ERBB2 overexpression.  The fact that PIK3CA mutations and PTEN loss are nearly mutually exclusive implies that deregulated phosphatidylinositol-3,4,5-triphosphate (PIP3) is crit. for tumorigenesis in a significant fraction of breast cancers and that loss of PIP3 homeostasis by abrogation of either PIK3CA or PTEN relieves selective pressure for targeting of the other gene.  The correlation of PIK3CA mutation to ER/PR-pos. tumors and PTEN loss to ER/PR-neg. tumors argues for disparate branches of tumor evolution.  Furthermore, the assocn. between ERBB2 overexpression and PIK3CA mutation implies that more than one input activating the PI3K/AKT pathway may be required to overcome intact PTEN.  Thus, mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAU1nSRyBQNLVg90H21EOLACvtfcHk0liOa4OlnKkxwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVeqsrc%253D&md5=3e912dbd897f720b7ddd5ae3f32cd1e9</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F0008-5472-CAN-04-3913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472-CAN-04-3913%26sid%3Dliteratum%253Aachs%26aulast%3DSaal%26aufirst%3DL.%2BH.%26aulast%3DHolm%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DMemeo%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%2BS.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DP.-O.%26aulast%3DMansukhani%26aufirst%3DM.%26aulast%3DEnoksson%26aufirst%3DJ.%26aulast%3DHibshoosh%26aufirst%3DH.%26aulast%3DBorg%26aufirst%3DA.%26aulast%3DParsons%26aufirst%3DR.%26atitle%3DPIK3CA%2520Mutations%2520Correlate%2520with%2520Hormone%2520Receptors%252C%2520Node%2520Metastasis%252C%2520and%2520ERBB2%252C%2520and%2520Are%2520Mutually%2520Exclusive%2520with%2520PTEN%2520Loss%2520in%2520Human%2520Breast%2520Carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D7%26spage%3D2554%26epage%3D2559%26doi%3D10.1158%2F0008-5472-CAN-04-3913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stemke-Hale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmans, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolden, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlings, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de
Vijver, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span> <span> </span><span class="NLM_article-title">An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6084</span>– <span class="NLM_lpage">6091</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-07-6854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18676830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1SqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=6084-6091&issue=15&author=K.+Stemke-Haleauthor=A.+M.+Gonzalez-Anguloauthor=A.+Lluchauthor=R.+M.+Neveauthor=W.-L.+Kuoauthor=M.+Daviesauthor=M.+Careyauthor=Z.+Huauthor=Y.+Guanauthor=A.+Sahinauthor=W.+F.+Symmansauthor=L.+Pusztaiauthor=L.+K.+Noldenauthor=H.+Horlingsauthor=K.+Bernsauthor=M.-C.+Hungauthor=M.+J.+van+de%0AVijverauthor=V.+Valeroauthor=J.+W.+Grayauthor=R.+Bernardsauthor=G.+B.+Millsauthor=B.+T.+Hennessy&title=An+Integrative+Genomic+and+Proteomic+Analysis+of+PIK3CA%2C+PTEN%2C+and+AKT+Mutations+in+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-07-6854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer</span></div><div class="casAuthors">Stemke-Hale, Katherine; Gonzalez-Angulo, Ana Maria; Lluch, Ana; Neve, Richard M.; Kuo, Wen-Lin; Davies, Michael; Carey, Mark; Hu, Zhi; Guan, Yinghui; Sahin, Aysegul; Symmans, W. Fraser; Pusztai, Lajos; Nolden, Laura K.; Horlings, Hugo; Berns, Katrien; Hung, Mien-Chie; van de Vijver, Marc J.; Valero, Vicente; Gray, Joe W.; Bernards, Rene; Mills, Gordon B.; Hennessy, Bryan T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6084-6091</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer.  By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, the authors detd. the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen.  PIK3CA mutations were more common in hormone receptor-pos. (34.5%) and HER2-pos. (22.7%) than in basal-like tumors (8.3%).  AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor-pos. cancers.  Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture.  PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor-pos. breast cancer patients.  PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were assocd. with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines.  PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiol.  PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations.  Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes.  The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW4lGMvEywSbVg90H21EOLACvtfcHk0liOa4OlnKkxwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1SqtLs%253D&md5=687be276321b774ce7cb0f00949c36b4</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6854%26sid%3Dliteratum%253Aachs%26aulast%3DStemke-Hale%26aufirst%3DK.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DKuo%26aufirst%3DW.-L.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DCarey%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DSymmans%26aufirst%3DW.%2BF.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DNolden%26aufirst%3DL.%2BK.%26aulast%3DHorlings%26aufirst%3DH.%26aulast%3DBerns%26aufirst%3DK.%26aulast%3DHung%26aufirst%3DM.-C.%26aulast%3Dvan%2Bde%2BVijver%26aufirst%3DM.%2BJ.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26aulast%3DBernards%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26atitle%3DAn%2520Integrative%2520Genomic%2520and%2520Proteomic%2520Analysis%2520of%2520PIK3CA%252C%2520PTEN%252C%2520and%2520AKT%2520Mutations%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D15%26spage%3D6084%26epage%3D6091%26doi%3D10.1158%2F0008-5472.CAN-07-6854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silliman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, J. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">High Frequency of Mutations of the PIK3CA Gene in Human Cancers</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span> (<span class="NLM_issue">5670</span>),  <span class="NLM_fpage">554</span>, <span class="refDoi"> DOI: 10.1126/science.1096502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1096502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15016963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=554&issue=5670&author=Y.+Samuelsauthor=Z.+Wangauthor=A.+Bardelliauthor=N.+Sillimanauthor=J.+Ptakauthor=S.+Szaboauthor=H.+Yanauthor=A.+Gazdarauthor=S.+M.+Powellauthor=G.+J.+Rigginsauthor=J.+K.+V.+Willsonauthor=S.+Markowitzauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=High+Frequency+of+Mutations+of+the+PIK3CA+Gene+in+Human+Cancers&doi=10.1126%2Fscience.1096502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Brevia: High frequency of mutations of the PIK3Ca gene in human cancers</span></div><div class="casAuthors">Samuels, Yardena; Wang, Zhenghe; Bardelli, Alberto; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Yan, Hai; Gazdar, Adi; Powell, Steven M.; Riggins, Gregory J.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5670</span>),
    <span class="NLM_cas:pages">554</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74Tv7Oo80NbVg90H21EOLACvtfcHk0lgiUKlkvvSjig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D&md5=be8d63bf0c909971c3b7a5f475ce8fab</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096502%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPtak%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DS.%2BM.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DWillson%26aufirst%3DJ.%2BK.%2BV.%26aulast%3DMarkowitz%26aufirst%3DS.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DHigh%2520Frequency%2520of%2520Mutations%2520of%2520the%2520PIK3CA%2520Gene%2520in%2520Human%2520Cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26issue%3D5670%26spage%3D554%26doi%3D10.1126%2Fscience.1096502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Phosphoinositide 3-Kinase Pathway in Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&issue=8&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+Phosphoinositide+3-Kinase+Pathway+in+Cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lgiUKlkvvSjig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520Phosphoinositide%25203-Kinase%2520Pathway%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26issue%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powis, G.</span></span> <span> </span><span class="NLM_article-title">Take Your PIK: Phosphatidylinositol 3-Kinase Inhibitors Race Through the Clinic and Toward Cancer Therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1535-7163.MCT-08-0801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19139107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1-9&issue=1&author=N.+T.+Ihleauthor=G.+Powis&title=Take+Your+PIK%3A+Phosphatidylinositol+3-Kinase+Inhibitors+Race+Through+the+Clinic+and+Toward+Cancer+Therapy&doi=10.1158%2F1535-7163.MCT-08-0801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy</span></div><div class="casAuthors">Ihle, Nathan T.; Powis, Garth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncol.  However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiol. signaling.  Since that time, studies have delineated the roles of these four isoforms in nonpathol. signaling as well as their roles in cancer.  An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer.  These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a no. are in clin. testing.  The agents, their properties, and their mol. targets are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtwozBC-h437Vg90H21EOLACvtfcHk0lgiUKlkvvSjig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D&md5=4bc339da7fdd1dc74e13eadf76ae53ce</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0801%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DN.%2BT.%26aulast%3DPowis%26aufirst%3DG.%26atitle%3DTake%2520Your%2520PIK%253A%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520Race%2520Through%2520the%2520Clinic%2520and%2520Toward%2520Cancer%2520Therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D1%26spage%3D1%26epage%3D9%26doi%3D10.1158%2F1535-7163.MCT-08-0801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&issue=2&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0ljj8WaTBe4KRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span> <span> </span><span class="NLM_article-title">Abstract S6-04: the PI3K Inhibitor, Taselisib, Has Enhanced Potency in PIK3CA Mutant Models Through a Unique Mechanism of Action</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">4, Suppl.</span>),  <span class="NLM_fpage">S6-04</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.SABCS16-S6-04</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.SABCS16-S6-04" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=S6-04&issue=4%2C+Suppl.&author=L.+S.+Friedmanauthor=K.+A.+Edgarauthor=K.+Songauthor=S.+Schmidtauthor=D.+S.+Kirkpatrickauthor=L.+Phuauthor=M.+A.+Nanniniauthor=R.+Hongauthor=E.+Chengauthor=L.+Crockerauthor=A.+Youngauthor=D.+Sampath&title=Abstract+S6-04%3A+the+PI3K+Inhibitor%2C+Taselisib%2C+Has+Enhanced+Potency+in+PIK3CA+Mutant+Models+Through+a+Unique+Mechanism+of+Action&doi=10.1158%2F1538-7445.SABCS16-S6-04"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS16-S6-04&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS16-S6-04%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DPhu%26aufirst%3DL.%26aulast%3DNannini%26aufirst%3DM.%2BA.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DAbstract%2520S6-04%253A%2520the%2520PI3K%2520Inhibitor%252C%2520Taselisib%252C%2520Has%2520Enhanced%2520Potency%2520in%2520PIK3CA%2520Mutant%2520Models%2520Through%2520a%2520Unique%2520Mechanism%2520of%2520Action%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D4%252C%2520Suppl%26spage%3DS6-04%26doi%3D10.1158%2F1538-7445.SABCS16-S6-04" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span> <span> </span><span class="NLM_article-title">Abstract 146: the PI3K Inhibitor, Taselisib, Has a Unique Mechanism of Action That Leads to Enhanced Potency in PIK3CA Mutant Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.AM2017-146" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=146&issue=13%2C+Suppl.&author=K.+W.+Songauthor=K.+A.+Edgarauthor=D.+S.+Kirkpatrickauthor=L.+Phuauthor=S.+Schmidtauthor=M.+Nanniniauthor=R.+Hongauthor=E.+Chengauthor=L.+Crockerauthor=A.+Youngauthor=D.+Sampathauthor=L.+Friedman&title=Abstract+146%3A+the+PI3K+Inhibitor%2C+Taselisib%2C+Has+a+Unique+Mechanism+of+Action+That+Leads+to+Enhanced+Potency+in+PIK3CA+Mutant+Models&doi=10.1158%2F1538-7445.AM2017-146"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-146%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DK.%2BW.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DPhu%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DFriedman%26aufirst%3DL.%26atitle%3DAbstract%2520146%253A%2520the%2520PI3K%2520Inhibitor%252C%2520Taselisib%252C%2520Has%2520a%2520Unique%2520Mechanism%2520of%2520Action%2520That%2520Leads%2520to%2520Enhanced%2520Potency%2520in%2520PIK3CA%2520Mutant%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%252C%2520Suppl%26spage%3D146%26doi%3D10.1158%2F1538-7445.AM2017-146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span> <span> </span><span class="NLM_article-title">Abstract 156: Preclinical Characterization of GDC-0077, a Specific PI3K Alpha Inhibitor in Early Clinical Development</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 Suppl.</span>),  <span class="NLM_fpage">156</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.AM2017-156" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=156&issue=13+Suppl.&author=K.+Edgarauthor=E.+Hananauthor=S.+Stabenauthor=S.+Schmidtauthor=R.+Hongauthor=K.+Songauthor=A.+Youngauthor=P.+Hamiltonauthor=A.+Arrazateauthor=C.+de+la+Cruzauthor=M.+Belvinauthor=M.+Nanniniauthor=L.+S.+Friedmanauthor=D.+Sampath&title=Abstract+156%3A+Preclinical+Characterization+of+GDC-0077%2C+a+Specific+PI3K+Alpha+Inhibitor+in+Early+Clinical+Development&doi=10.1158%2F1538-7445.AM2017-156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-156%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DHanan%26aufirst%3DE.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DHamilton%26aufirst%3DP.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3Dde%2Bla%2BCruz%26aufirst%3DC.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DAbstract%2520156%253A%2520Preclinical%2520Characterization%2520of%2520GDC-0077%252C%2520a%2520Specific%2520PI3K%2520Alpha%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D156%26doi%3D10.1158%2F1538-7445.AM2017-156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steven, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span> <span> </span><span class="NLM_article-title">Abstract PD4-14: GDC-0077 Is a Selective PI3Kalpha Inhibitor That Demonstrates Robust Efficacy in PIK3CA Mutant Breast Cancer Models as a Single Agent and in Combination with Standard of Care Therapies</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">4, Suppl.</span>),  <span class="NLM_fpage">PD4-14</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.SABCS17-PD4-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.SABCS17-PD4-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=PD4-14&issue=4%2C+Suppl.&author=R.+Hongauthor=K.+Edgarauthor=K.+Songauthor=S.+Stevenauthor=A.+Youngauthor=P.+Hamiltonauthor=A.+Arrazateauthor=C.+De+La+Cruzauthor=C.+Chanauthor=J.+Pangauthor=L.+Salphatiauthor=M.+Belvinauthor=M.+Nanniniauthor=S.+Stabenauthor=L.+Friedmanauthor=D.+Sampath&title=Abstract+PD4-14%3A+GDC-0077+Is+a+Selective+PI3Kalpha+Inhibitor+That+Demonstrates+Robust+Efficacy+in+PIK3CA+Mutant+Breast+Cancer+Models+as+a+Single+Agent+and+in+Combination+with+Standard+of+Care+Therapies&doi=10.1158%2F1538-7445.SABCS17-PD4-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS17-PD4-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS17-PD4-14%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DR.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DSteven%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DHamilton%26aufirst%3DP.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DDe%2BLa%2BCruz%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DAbstract%2520PD4-14%253A%2520GDC-0077%2520Is%2520a%2520Selective%2520PI3Kalpha%2520Inhibitor%2520That%2520Demonstrates%2520Robust%2520Efficacy%2520in%2520PIK3CA%2520Mutant%2520Breast%2520Cancer%2520Models%2520as%2520a%2520Single%2520Agent%2520and%2520in%2520Combination%2520with%2520Standard%2520of%2520Care%2520Therapies%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D4%252C%2520Suppl%26spage%3DPD4-14%26doi%3D10.1158%2F1538-7445.SABCS17-PD4-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]Imidazo[1,2-d][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4597</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&issue=11&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-methyl-1H-1%2C2-4-triazol-5-yl%29-5%2C6-dihydrobenzo%5Bf%5DImidazo%5B1%2C2-d%5D%5B1%2C4%5Doxazepin-9-yl%5D-1H-pyrazol-1-yl%7D-2-methylpropanamide+%28GDC-0032%29%3A+a+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Robust+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span></div><div class="casAuthors">Ndubaku, Chudi O.; Heffron, Timothy P.; Staben, Steven T.; Baumgardner, Matthew; Blaquiere, Nicole; Bradley, Erin; Bull, Richard; Do, Steven; Dotson, Jennafer; Dudley, Danette; Edgar, Kyle A.; Friedman, Lori S.; Goldsmith, Richard; Heald, Robert A.; Kolesnikov, Aleksandr; Lee, Leslie; Lewis, Cristina; Nannini, Michelle; Nonomiya, Jim; Pang, Jodie; Price, Steve; Prior, Wei Wei; Salphati, Laurent; Sideris, Steve; Wallin, Jeffery J.; Wang, Lan; Wei, BinQing; Sampath, Deepak; Olivero, Alan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4597-4610</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation.  In the course of the discovery of novel benzoxepin PI3K inhibitors, we obsd. a strong dependency of in vivo antitumor activity on the free-drug exposure.  By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compds. that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.  One of these compds., GDC-0032 (I), was progressed to clin. trials and is currently under phase I evaluation as a potential treatment for human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvaWg9tu7Zv7Vg90H21EOLACvtfcHk0lj3-IzwaYbvdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D&md5=f9c169c99757708a9d327ad0b022fde9</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2-4-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255DImidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2520%2528GDC-0032%2529%253A%2520a%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Robust%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D11%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foukas, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claret, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peskett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">Critical Role for the p110α Phosphoinositide-3-OH Kinase in Growth and Metabolic Regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>441</i></span> (<span class="NLM_issue">7091</span>),  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1038/nature04694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature04694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16625210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28XksleltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2006&pages=366-370&issue=7091&author=L.+C.+Foukasauthor=M.+Claretauthor=W.+Pearceauthor=K.+Okkenhaugauthor=S.+Meekauthor=E.+Peskettauthor=S.+Sanchoauthor=A.+J.+H.+Smithauthor=D.+J.+Withersauthor=B.+Vanhaesebroeck&title=Critical+Role+for+the+p110%CE%B1+Phosphoinositide-3-OH+Kinase+in+Growth+and+Metabolic+Regulation&doi=10.1038%2Fnature04694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation</span></div><div class="casAuthors">Foukas, Lazaros C.; Claret, Marc; Pearce, Wayne; Okkenhaug, Klaus; Meek, Stephen; Peskett, Emma; Sancho, Sara; Smith, Andrew J. H.; Withers, Dominic J.; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">7091</span>),
    <span class="NLM_cas:pages">366-370</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The eight catalytic subunits of the mammalian phosphoinositide-3-OH kinase (PI(3)K) family form the backbone of an evolutionarily conserved signaling pathway; however, the roles of most PI(3)K isoforms in organismal physiol. and disease are unknown.  To delineate the role of p110α, a ubiquitously expressed PI(3)K involved in tyrosine kinase and Ras signaling, here we generated mice carrying a knockin mutation (D933A) that abrogates p110α kinase activity.  Homozygosity for this kinase-dead p110α led to embryonic lethality.  Mice heterozygous for this mutation were viable and fertile, but displayed severely blunted signaling via insulin-receptor substrate (IRS) proteins, key mediators of insulin, insulin-like growth factor-1 and leptin action.  Defective responsiveness to these hormones led to reduced somatic growth, hyperinsulinemia, glucose intolerance, hyperphagia and increased adiposity in mice heterozygous for the D933A mutation.  This signaling function of p110α derives from its highly selective recruitment and activation to IRS signaling complexes compared to p110β, the other broadly expressed PI(3)K isoform, which did not contribute to IRS-assocd. PI(3)K activity.  P110α was the principal IRS-assocd. PI(3)K in cancer cell lines.  These findings demonstrate a crit. role for p110α in growth factor and metabolic signaling and also suggest an explanation for selective mutation or overexpression of p110α in a variety of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOi2VSn94VNLVg90H21EOLACvtfcHk0lj3-IzwaYbvdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksleltL0%253D&md5=4b39bf234e759be7540057e4d9d70e6c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnature04694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04694%26sid%3Dliteratum%253Aachs%26aulast%3DFoukas%26aufirst%3DL.%2BC.%26aulast%3DClaret%26aufirst%3DM.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DMeek%26aufirst%3DS.%26aulast%3DPeskett%26aufirst%3DE.%26aulast%3DSancho%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DWithers%26aufirst%3DD.%2BJ.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DCritical%2520Role%2520for%2520the%2520p110%25CE%25B1%2520Phosphoinositide-3-OH%2520Kinase%2520in%2520Growth%2520and%2520Metabolic%2520Regulation%26jtitle%3DNature%26date%3D2006%26volume%3D441%26issue%3D7091%26spage%3D366%26epage%3D370%26doi%3D10.1038%2Fnature04694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunder, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&issue=4&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+p110%CE%B1+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0ljoZtmT2o1j2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520p110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26issue%3D4%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmoller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLaurentiis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drullinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacot, W.</span></span> <span> </span><span class="NLM_article-title">Phase III Study of Taselisib (GDC-0032) + Fulvestrant (FULV) v FULV in Patients (Pts) with Estrogen Receptor (ER)-Positive, PIK3CA-Mutant (MUT), Locally Advanced or Metastatic Breast Cancer (MBC): Primary Analysis From SANDPIPER</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">18_suppl</span>),  <span class="NLM_fpage">LBA1006</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.18_suppl.LBA1006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1200%2FJCO.2018.36.18_suppl.LBA1006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=LBA1006&issue=18_suppl&author=J.+Baselgaauthor=S.+F.+Dentauthor=J.+Cortesauthor=Y.-H.+Imauthor=V.+Di%C3%A9rasauthor=N.+Harbeckauthor=I.+E.+Kropauthor=S.+Vermaauthor=T.+R.+Wilsonauthor=H.+Jinauthor=L.+Wangauthor=F.+Schimmollerauthor=J.+Y.+Hsuauthor=J.+Heauthor=M.+DeLaurentiisauthor=P.+Drullinskyauthor=W.+Jacot&title=Phase+III+Study+of+Taselisib+%28GDC-0032%29+%2B+Fulvestrant+%28FULV%29+v+FULV+in+Patients+%28Pts%29+with+Estrogen+Receptor+%28ER%29-Positive%2C+PIK3CA-Mutant+%28MUT%29%2C+Locally+Advanced+or+Metastatic+Breast+Cancer+%28MBC%29%3A+Primary+Analysis+From+SANDPIPER&doi=10.1200%2FJCO.2018.36.18_suppl.LBA1006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.18_suppl.LBA1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.18_suppl.LBA1006%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DDent%26aufirst%3DS.%2BF.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DY.-H.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSchimmoller%26aufirst%3DF.%26aulast%3DHsu%26aufirst%3DJ.%2BY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DDeLaurentiis%26aufirst%3DM.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DJacot%26aufirst%3DW.%26atitle%3DPhase%2520III%2520Study%2520of%2520Taselisib%2520%2528GDC-0032%2529%2520%252B%2520Fulvestrant%2520%2528FULV%2529%2520v%2520FULV%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Estrogen%2520Receptor%2520%2528ER%2529-Positive%252C%2520PIK3CA-Mutant%2520%2528MUT%2529%252C%2520Locally%2520Advanced%2520or%2520Metastatic%2520Breast%2520Cancer%2520%2528MBC%2529%253A%2520Primary%2520Analysis%2520From%2520SANDPIPER%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D18_suppl%26spage%3DLBA1006%26doi%3D10.1200%2FJCO.2018.36.18_suppl.LBA1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span> <span> </span><span class="NLM_article-title">The Discovery of Artemisinin (Qinghaosu) and Gifts From Chinese Medicine</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1038/nm.2471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnm.2471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21989013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1217-1220&issue=10&author=Y.+Tu&title=The+Discovery+of+Artemisinin+%28Qinghaosu%29+and+Gifts+From+Chinese+Medicine&doi=10.1038%2Fnm.2471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine</span></div><div class="casAuthors">Tu, Youyou</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1217-1220</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria, caused by Plasmodium falciparum, has been a life-threatening disease for thousands of years.  After the failure of international attempts to eradicate malaria in the 1950s, the disease rebounded, largely due to the emergence of parasites resistant to the existing antimalarial drugs of the time, such as chloroquine.  This created an urgent need for new antimalarial medicines.  In 1967, a national project against malaria was set up in China under the leadership of the Project 523 office.  My institute quickly became involved in the project and appointed me to be the head of a malaria research group comprising both phytochem. and pharmacol. researchers.  Our group of young investigators started working on the extn. and isolation of constituents with possible antimalarial activities from Chinese herbal materials.  During the first stage of our work, we investigated more than 2,000 Chinese herb prepns. and identified 640 hits that had possible antimalarial activities.  More than 380 exts. obtained from ∼200 Chinese herbs were evaluated against a mouse model of malaria.  However, progress was not smooth, and no significant results emerged easily.  The turning point came when an Artemisia annua L. ext. showed a promising degree of inhibition against parasite growth.  However, this observation was not reproducible in subsequent expts. and appeared to be contradictory to what was recorded in the literature.  Seeking an explanation, we carried out an intensive review of the literature.  The only ref. relevant to use of qinghao (the Chinese name of Artemisia annua L.) for alleviating malaria symptoms appeared in Ge Hong's A Handbook of Prescriptions for Emergencies: "A handful of qinghao immersed with 2 L of water, wring out the juice and drink it all" (Fig. 1).  This sentence gave me the idea that the heating involved in the conventional extn. step we had used might have destroyed the active components, and that extn. at a lower temp. might be necessary to preserve antimalarial activity.  Indeed, we obtained much better activity after switching to a lower-temp. procedure.  We subsequently sepd. the ext. into its acidic and neutral portions and, at long last, on 4 Oct. 1971, we obtained a nontoxic, neutral ext. that was 100% effective against parasitemia in mice infected with Plasmodium berghei and in monkeys infected with Plasmodium cynomolgi.  This finding represented the breakthrough in the discovery of artemisinin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPPcf3cZ2WFLVg90H21EOLACvtfcHk0ljoZtmT2o1j2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vK&md5=d751f12196cf4f3d316bdaada5d38e02</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnm.2471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2471%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DY.%26atitle%3DThe%2520Discovery%2520of%2520Artemisinin%2520%2528Qinghaosu%2529%2520and%2520Gifts%2520From%2520Chinese%2520Medicine%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D10%26spage%3D1217%26epage%3D1220%26doi%3D10.1038%2Fnm.2471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.-J.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin Is an Inhibitor of Ovarian Cancer Cell Growth</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1111/j.1745-7254.2007.00612.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1111%2Fj.1745-7254.2007.00612.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17588342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFynsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=1045-1056&issue=7&author=Y.+Jiaoauthor=C.-M.+Geauthor=Q.-H.+Mengauthor=J.-P.+Caoauthor=J.+Tongauthor=S.-J.+Fan&title=Dihydroartemisinin+Is+an+Inhibitor+of+Ovarian+Cancer+Cell+Growth&doi=10.1111%2Fj.1745-7254.2007.00612.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin is an inhibitor of ovarian cancer cell growth</span></div><div class="casAuthors">Jiao, Yang; Ge, Chun-min; Meng, Qing-hui; Cao, Jian-ping; Tong, Jian; Fan, Sai-jun</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1045-1056</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Aim: To investigate the anticancer activity of dihydroartemisinin (DHA), a deriv. of antimalaria drug artemisinin in a panel of human ovarian cancer cell lines.  Methods: Cell growth was detd. by the MTT viability assay.  Apoptosis and cell cycle progression were evaluated by a DNA fragmentation gel electro-phoresis, flow cytometry assay, and TUNEL assay; protein and mRNA expression were analyzed by Western blotting and RT-PCR assay.  Results: Artemisinin and its derivs., including artesunate, arteether, artemether, arteannuin, and DHA, exhibit anticancer growth activities in human ovarian cancer cells.  Among them, DHA is the most effective in inhibiting cell growth.  Ovarian cancer cell lines are more sensitive (5-10-fold) to DHA treatment compared to normal ovarian cell lines.  DHA at micromolar dose levels exhibits a dose- and time-dependent cytotoxicity in ovarian cancer cell lines.  Furthermore, DHA induced apoptosis and G2 cell cycle arrest, accompanied by a decrease of Bcl-xL and Bcl-2 and an increase of Bax and Bad.  Conclusion: The promising results show for the first time that DHA inhibits the growth of human ovarian cancer cells.  The selective inhibition of ovarian cancer cell growth, apoptosis induction, and G2 arrest provide in vitro evidence for further studies of DHA as a possible anticancer drug in the clin. treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY7KMUc-Yf_LVg90H21EOLACvtfcHk0lh-W7X_nYo4Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFynsLs%253D&md5=37e7d3210528e81d521af706a2626266</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1745-7254.2007.00612.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1745-7254.2007.00612.x%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DC.-M.%26aulast%3DMeng%26aufirst%3DQ.-H.%26aulast%3DCao%26aufirst%3DJ.-P.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DS.-J.%26atitle%3DDihydroartemisinin%2520Is%2520an%2520Inhibitor%2520of%2520Ovarian%2520Cancer%2520Cell%2520Growth%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2007%26volume%3D28%26issue%3D7%26spage%3D1045%26epage%3D1056%26doi%3D10.1111%2Fj.1745-7254.2007.00612.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin Induces Apoptosis and Sensitizes Human Ovarian Cancer Cells to Carboplatin Therapy</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2008.00360.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1111%2Fj.1582-4934.2008.00360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18466355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCku7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=1358-1370&issue=7&author=T.+Chenauthor=M.+Liauthor=R.+Zhangauthor=H.+Wang&title=Dihydroartemisinin+Induces+Apoptosis+and+Sensitizes+Human+Ovarian+Cancer+Cells+to+Carboplatin+Therapy&doi=10.1111%2Fj.1582-4934.2008.00360.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy</span></div><div class="casAuthors">Chen, Tao; Li, Mian; Zhang, Ruiwen; Wang, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1358-1370</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The present study was designed to det. the effects of artemisinin (ARS) and its derivs. on human ovarian cancer cells, to evaluate their potential as novel chemotherapeutic agents used alone or in combination with a conventional cancer chemotherapeutic agent, and to investigate their underlying mechanisms of action.  Human ovarian cancer cells (A2780 and OVCAR-3), and immortalized non-tumorigenic human ovarian surface epithelial cells (IOSE144), were exposed to four ARS compds. for cytotoxicity testing.  The in vitro and in vivo antitumor effects and possible underlying mechanisms of action of dihydroartemisinin (DHA), the most effective compd., were further detd. in ovarian cancer cells.  ARS compds. exerted potent cytotoxicity to human ovarian carcinoma cells, with minimal effects on non-tumorigenic ovarian surface epithelial (OSE) cells.  DHA inhibited ovarian cancer cell growth when administered alone or in combination with carboplatin, presumably through the death receptor- and, mitochondrion-mediated caspase-dependent apoptotic pathway.  These effects were also obsd. in in vivo ovarian A2780 and OVCAR-3 xenograft tumor models.  In conclusion, ARS derivs., particularly DHA, exhibit significant anticancer activity against ovarian cancer cells in vitro and in vivo, with minimal toxicity to non-tumorigenic human OSE cells, indicating that they may be promising therapeutic agents for ovarian cancer, either used alone or in combination with conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc2LHhKbSaq7Vg90H21EOLACvtfcHk0lh-W7X_nYo4Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCku7bE&md5=a82778c2d7cff6b7084b3e31c5dcc0a0</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2008.00360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2008.00360.x%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDihydroartemisinin%2520Induces%2520Apoptosis%2520and%2520Sensitizes%2520Human%2520Ovarian%2520Cancer%2520Cells%2520to%2520Carboplatin%2520Therapy%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2009%26volume%3D13%26issue%3D7%26spage%3D1358%26epage%3D1370%26doi%3D10.1111%2Fj.1582-4934.2008.00360.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span> <span> </span><span class="NLM_article-title">Development of Artemisinin Compounds for Cancer Treatment</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9873-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2Fs10637-012-9873-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22935909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=230-246&issue=1&author=H.+C.+Laiauthor=N.+P.+Singhauthor=T.+Sasaki&title=Development+of+Artemisinin+Compounds+for+Cancer+Treatment&doi=10.1007%2Fs10637-012-9873-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Development of artemisinin compounds for cancer treatment</span></div><div class="casAuthors">Lai, Henry C.; Singh, Narendra P.; Sasaki, Tomikazu</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">230-246</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Artemisinin contains an endoperoxide moiety that can react with iron to form cytotoxic free radicals.  Cancer cells contain significantly more intracellular free iron than normal cells and it has been shown that artemisinin and its analogs selectively cause apoptosis in many cancer cell lines.  In addn., artemisinin compds. have been shown to have anti-angiogenic, anti-inflammatory, anti-metastasis, and growth inhibition effects.  These properties make artemisinin compds. attractive cancer chemotherapeutic drug candidates.  However, simple artemisinin analogs are less potent than traditional cancer chemotherapeutic agents and have short plasma half-lives, and would require high dosage and frequent administration to be effective for cancer treatment.  More potent and target-selective artemisinin-compds. are being developed.  These include artemisinin dimers and trimers, artemisinin hybrid compds., and tagging of artemisinin compds. to mols. that are involved in the intracellular iron-delivery mechanism.  These compds. are promising potent anticancer compds. that produce significantly less side effect than traditional chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9pCP2c4F3R7Vg90H21EOLACvtfcHk0lh-W7X_nYo4Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogsrg%253D&md5=5a2bab46c18166ccda727ea2b72141cb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9873-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9873-z%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DH.%2BC.%26aulast%3DSingh%26aufirst%3DN.%2BP.%26aulast%3DSasaki%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520Artemisinin%2520Compounds%2520for%2520Cancer%2520Treatment%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26issue%3D1%26spage%3D230%26epage%3D246%26doi%3D10.1007%2Fs10637-012-9873-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ba, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin Selectively Inhibits PDGFRα-Positive Ovarian Cancer Growth and Metastasis Through Inducing Degradation of PDGFRα Protein</span>. <i>Cell Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">17042</span>, <span class="refDoi"> DOI: 10.1038/celldisc.2017.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fcelldisc.2017.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29387451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVehsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=17042&author=X.+Liauthor=Q.+Baauthor=Y.+Liuauthor=Q.+Yueauthor=P.+Chenauthor=J.+Liauthor=H.+Zhangauthor=H.+Yingauthor=Q.+Dingauthor=H.+Songauthor=H.+Liuauthor=R.+Zhangauthor=H.+Wang&title=Dihydroartemisinin+Selectively+Inhibits+PDGFR%CE%B1-Positive+Ovarian+Cancer+Growth+and+Metastasis+Through+Inducing+Degradation+of+PDGFR%CE%B1+Protein&doi=10.1038%2Fcelldisc.2017.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein</span></div><div class="casAuthors">Li, Xiaoguang; Ba, Qian; Liu, Yanling; Yue, Qingxi; Chen, Peizhan; Li, Jingquan; Zhang, Haibing; Ying, Hao; Ding, Qiurong; Song, Haiyun; Liu, Hong; Zhang, Ruiwen; Wang, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Cell Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17042</span>CODEN:
                <span class="NLM_cas:coden">CDEIBM</span>;
        ISSN:<span class="NLM_cas:issn">2056-5968</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To develop traditional medicines as modern pharmacotherapies, understanding their mol. mechanisms of action can be very helpful.  We have recently reported that Artemisinin and its derivs., which are clin. used anti-malarial drugs, have significant effects against ovarian cancer, but the direct mol. targets and related combination therapy have been unclear.  Herein, we report that dihydroartemisinin, one of the most active derivs. of Artemisinin, directly targets platelet-derived growth factor receptor-alpha (PDGFRα) to inhibit ovarian cancer cell growth and metastasis.  Dihydroartemisinin directly binds to the intercellular domain of PDGFRα, reducing its protein stability by accelerating its ubiquitin-mediated degrdn., which further inactivates downstream phosphoinositide 3-Kinase and mitogen-activated protein kinase pathways and subsequently represses epithelial-mesenchymal transition, inhibiting cell growth and metastasis of PDGFRα-pos. ovarian cancer in vitro and in vivo.  A combinational treatment reveals that dihydroartemisinin sensitizes ovarian cancer cells to PDGFR inhibitors.  Our clin. study also finds that PDGFRα is overexpressed and pos. correlated with high grade and metastasis in human ovarian cancer.  Considering that Artemisinin compds. are currently clin. used drugs with favorable safety profiles, the results from this study will potentiate their use in combination with clin. used PDGFRα inhibitors, leading to maximal therapeutic efficacy with minimal adverse effects in PDGFRα-pos. cancer patients.  These findings also shed high light on future development of novel Artemisinin-based targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi5hLbiBC0-rVg90H21EOLACvtfcHk0liEdJ1MnAJT1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVehsLrL&md5=55c1420c2ca79433d77135a5ed89a59c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fcelldisc.2017.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcelldisc.2017.42%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBa%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYing%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDihydroartemisinin%2520Selectively%2520Inhibits%2520PDGFR%25CE%25B1-Positive%2520Ovarian%2520Cancer%2520Growth%2520and%2520Metastasis%2520Through%2520Inducing%2520Degradation%2520of%2520PDGFR%25CE%25B1%2520Protein%26jtitle%3DCell%2520Discovery%26date%3D2017%26volume%3D3%26spage%3D17042%26doi%3D10.1038%2Fcelldisc.2017.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carden, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span> <span> </span><span class="NLM_article-title">Beyond Chemotherapy: Targeted Therapies in Ovarian Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc2583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19238149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=167-181&issue=3&author=T.+A.+Yapauthor=C.+P.+Cardenauthor=S.+B.+Kaye&title=Beyond+Chemotherapy%3A+Targeted+Therapies+in+Ovarian+Cancer&doi=10.1038%2Fnrc2583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond chemotherapy: targeted therapies in ovarian cancer</span></div><div class="casAuthors">Yap, Timothy A.; Carden, Craig P.; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ovarian cancer is the leading cause of death from gynaecol. malignancies in the Western world.  Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease.  In an age when great advances have been made in understanding the genetics and mol. biol. of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer.  Importantly, such strategies might allow selection of treatments based on the mol. characteristics of tumors and bring us closer to an era of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-IolhZb5BfLVg90H21EOLACvtfcHk0liEdJ1MnAJT1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans74%253D&md5=35c1e2e4171120bc5411b778306929ca</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnrc2583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2583%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DCarden%26aufirst%3DC.%2BP.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DBeyond%2520Chemotherapy%253A%2520Targeted%2520Therapies%2520in%2520Ovarian%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D3%26spage%3D167%26epage%3D181%26doi%3D10.1038%2Fnrc2583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stankov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikov, M.</span></span> <span> </span><span class="NLM_article-title">C-KIT Signaling in Cancer Treatment</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2880</span>, <span class="refDoi"> DOI: 10.2174/13816128113199990593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F13816128113199990593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23944364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Wgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2849-2880&issue=17&author=K.+Stankovauthor=S.+Popovicauthor=M.+Mikov&title=C-KIT+Signaling+in+Cancer+Treatment&doi=10.2174%2F13816128113199990593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">C-KIT signaling in cancer treatment</span></div><div class="casAuthors">Stankov, Karmen; Popovic, Stevan; Mikov, Momir</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2849-2880</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor progression is strongly assocd. with the activity of receptor tyrosine kinases (RTKs) and their intracellular signal transduction pathways, which regulate several cell functions including proliferation, apoptosis, motility, adhesion and angiogenesis.  Detailed structural and functional studies of RTKs, including the stem cell factor receptor c-KIT, revealed the complexity of these receptor systems and contributed to development of targeted clin. approaches with relevance in both prognosis and therapy.  C-KIT signaling network has been the subject of intense research and pharmaceutical strategies to identify novel target-based approaches for cancer treatment.  Evidence that c-KIT signaling promotes cell proliferation and survival, along with the frequency in which this pathway is aberrantly activated in cancer, support the current efforts to identify approaches for its efficient inhibition.  C-KIT mutations are associatied with several human malignancies, such as gastrointestinal stromal tumors, acute myeloid leukemia, mast cell leukemia, and melanoma.  Novel therapies are developed that target some of the identified genetic defects.  It is therefore anticipated that newly-identified genetic markers will acquire a predictive value, i.e., the ability to predict differential efficacy of a therapy.  This review describes the evolving understanding of c-KIT/SCF axis and their downstream signaling in cancer, and the strategies for c-KIT-directed targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKLApMu7v92LVg90H21EOLACvtfcHk0liEdJ1MnAJT1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Wgtr8%253D&md5=d5323ddde193e774455925cc8a1c2b43</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.2174%2F13816128113199990593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13816128113199990593%26sid%3Dliteratum%253Aachs%26aulast%3DStankov%26aufirst%3DK.%26aulast%3DPopovic%26aufirst%3DS.%26aulast%3DMikov%26aufirst%3DM.%26atitle%3DC-KIT%2520Signaling%2520in%2520Cancer%2520Treatment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2014%26volume%3D20%26issue%3D17%26spage%3D2849%26epage%3D2880%26doi%3D10.2174%2F13816128113199990593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbaspour Babaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalidehghan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman Huri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadipour, F.</span></span> <span> </span><span class="NLM_article-title">Receptor Tyrosine Kinase (C-Kit) Inhibitors: a Potential Therapeutic Target in</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2459</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S89114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2147%2FDDDT.S89114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27536065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2443-2459&author=M.+Abbaspour+Babaeiauthor=B.+Kamalidehghanauthor=M.+Saleemauthor=H.+Zaman+Huriauthor=F.+Ahmadipour&title=Receptor+Tyrosine+Kinase+%28C-Kit%29+Inhibitors%3A+a+Potential+Therapeutic+Target+in&doi=10.2147%2FDDDT.S89114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells</span></div><div class="casAuthors">Abbaspour Babaei Maryam; Ahmadipour Fatemeh; Kamalidehghan Behnam; Saleem Mohammad; Huri Hasniza Zaman</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2443-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form of c-Kit plays a crucial role in occurrence of some cancers.  The function of c-Kit has led to the concept that inhibiting c-Kit kinase activity can be a target for cancer therapy.  The promising results of inhibition of c-Kit for treatment of cancers have been observed in some cancers such as gastrointestinal stromal tumor, acute myeloid leukemia, melanoma, and other tumors, and these results have encouraged attempts toward improvement of using c-Kit as a capable target for cancer therapy.  This paper presents the findings of previous studies regarding c-Kit as a receptor tyrosine kinase and an oncogene, as well as its gene targets and signaling pathways in normal and cancer cells.  The c-Kit gene location, protein structure, and the role of c-Kit in normal cell have been discussed.  Comprehending the molecular mechanism underlying c-Kit-mediated tumorogenesis is consequently essential and may lead to the identification of future novel drug targets.  The potential mechanisms by which c-Kit induces cellular transformation have been described.  This study aims to elucidate the function of c-Kit for future cancer therapy.  In addition, it has c-Kit inhibitor drug properties and their functions have been listed in tables and demonstrated in schematic pictures.  This review also has collected previous studies that targeted c-Kit as a novel strategy for cancer therapy.  This paper further emphasizes the advantages of this approach, as well as the limitations that must be addressed in the future.  Finally, although c-Kit is an attractive target for cancer therapy, based on the outcomes of treatment of patients with c-Kit inhibitors, it is unlikely that Kit inhibitors alone can lead to cure.  It seems that c-Kit mutations alone are not sufficient for tumorogenesis, but do play a crucial role in cancer occurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfTnK2L7idhRwLZxei1HN8fW6udTcc2ea2-LxRW_lQvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D&md5=c45d232471e049dc8d42a98fc5aa1d76</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S89114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S89114%26sid%3Dliteratum%253Aachs%26aulast%3DAbbaspour%2BBabaei%26aufirst%3DM.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DSaleem%26aufirst%3DM.%26aulast%3DZaman%2BHuri%26aufirst%3DH.%26aulast%3DAhmadipour%26aufirst%3DF.%26atitle%3DReceptor%2520Tyrosine%2520Kinase%2520%2528C-Kit%2529%2520Inhibitors%253A%2520a%2520Potential%2520Therapeutic%2520Target%2520in%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D2443%26epage%3D2459%26doi%3D10.2147%2FDDDT.S89114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descarpentries, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubreuil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmider, O.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors Induce Down-Regulation of C-Kit by Targeting the ATP Pocket</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e60961</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0060961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1371%2Fjournal.pone.0060961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23637779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVKrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e60961-14&issue=4&author=D.+D%E2%80%99allardauthor=J.+Gayauthor=C.+Descarpentriesauthor=E.+Frisanauthor=K.+Adamauthor=F.+Verdierauthor=C.+Floquetauthor=P.+Dubreuilauthor=C.+Lacombeauthor=M.+Fontenayauthor=P.+Mayeuxauthor=O.+Kosmider&title=Tyrosine+Kinase+Inhibitors+Induce+Down-Regulation+of+C-Kit+by+Targeting+the+ATP+Pocket&doi=10.1371%2Fjournal.pone.0060961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket</span></div><div class="casAuthors">D'Allard, Diane; Gay, Julie; Descarpentries, Clotilde; Frisan, Emilie; Adam, Kevin; Verdier, Frederique; Floquet, Celia; Dubreuil, Patrice; Lacombe, Catherine; Fontenay, Michaela; Mayeux, Patrick; Kosmider, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e60961</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The stem cell factor receptor (SCF) c-Kit plays a pivotal role in regulating cell proliferation and survival in many cell types.  In particular, c-Kit is required for early amplification of erythroid progenitors, while it must disappear from cell surface for the cell entering the final steps of maturation in an erythropoietin-dependent manner.  We initially obsd. that imatinib (IM), an inhibitor targeting the tyrosine kinase activity of c-Kit concomitantly down-regulated the expression of c-Kit and accelerated the Epo-driven differentiation of erythroblasts in the absence of SCF.  We investigated the mechanism by which IM or related masitinib (MA) induce c-Kit down-regulation in the human UT-7/Epo cell line.  We found that the down-regulation of c-Kit in the presence of IM or MA was inhibited by a pre-incubation with methyl-β-cyclodextrin suggesting that c-Kit was internalized in the absence of ligand.  By contrast to SCF, the internalization induced by TKI was independent of the E3 ubiquitin ligase c-Cbl.  Furthermore, c-Kit was degraded through lysosomal, but not proteasomal pathway.  In pulse-chase expts., IM did not modulate c-Kit synthesis or maturation.  Anal. of phosphotyrosine peptides in UT-7/Epo cells treated or not with IM show that IM did not modify overall tyrosine phosphorylation in these cells.  Furthermore, we showed that a T670I mutation preventing the full access of IM to the ATP binding pocket, did not allow the internalization process in the presence of IM.  Altogether these data show that TKI-induced internalization of c-Kit is linked to a modification of the integrity of ATP binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2F1HZL9M3eLVg90H21EOLACvtfcHk0lg4tdJBhxJZOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVKrsrc%253D&md5=4fa572781129c2390df26d200d8481e6</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060961%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599allard%26aufirst%3DD.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DDescarpentries%26aufirst%3DC.%26aulast%3DFrisan%26aufirst%3DE.%26aulast%3DAdam%26aufirst%3DK.%26aulast%3DVerdier%26aufirst%3DF.%26aulast%3DFloquet%26aufirst%3DC.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DFontenay%26aufirst%3DM.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DKosmider%26aufirst%3DO.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors%2520Induce%2520Down-Regulation%2520of%2520C-Kit%2520by%2520Targeting%2520the%2520ATP%2520Pocket%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D4%26spage%3De60961%26epage%3D14%26doi%3D10.1371%2Fjournal.pone.0060961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solheim, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seglen, P. O.</span></span> <span> </span><span class="NLM_article-title">Cellular and Lysosomal Uptake of Methylamine in Isolated Rat Hepatocytes</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>210</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1042/bj2100929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2Fbj2100929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=6870811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaL3sXlslentbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=1983&pages=929-936&issue=3&author=A.+E.+Solheimauthor=P.+O.+Seglen&title=Cellular+and+Lysosomal+Uptake+of+Methylamine+in+Isolated+Rat+Hepatocytes&doi=10.1042%2Fbj2100929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and lysosomal uptake of methylamine in isolated rat hepatocytes</span></div><div class="casAuthors">Solheim, Anne E.; Seglen, Per O.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">929-36</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">Methylamine (I) was accumulated by at least 2 different mechanisms in rat isolated hepatocytes.  These were: (1) a facilitated diffusion subject to trans stimulation and cis inhibition by other amines, nonconcentrative, energy-independent, and operative at 0° and (2) an energy-dependent process inhibited by anoxia and energy inhibitors.  I gradually accumulated in lysosomes, causing them to swell and increasing the total cell vol. by ∼12%.  Lysosomal swelling was abolished by anoxia or energy inhibitors, in spite of there being a high intracellular I concn. resulting from facilitated diffusion.  Hence, lysosomal I accumulation appears to depend on energy-requiring processes (such as continuous proton pumping), and not only on trapping by Donan-equil.-generated protons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0vMb4WsIS5rVg90H21EOLACvtfcHk0lg4tdJBhxJZOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlslentbs%253D&md5=6b3f8e0c7e83f9551bd751394cff08e7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1042%2Fbj2100929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2100929%26sid%3Dliteratum%253Aachs%26aulast%3DSolheim%26aufirst%3DA.%2BE.%26aulast%3DSeglen%26aufirst%3DP.%2BO.%26atitle%3DCellular%2520and%2520Lysosomal%2520Uptake%2520of%2520Methylamine%2520in%2520Isolated%2520Rat%2520Hepatocytes%26jtitle%3DBiochem.%2520J.%26date%3D1983%26volume%3D210%26issue%3D3%26spage%3D929%26epage%3D936%26doi%3D10.1042%2Fbj2100929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skretting, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garred, Ø.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilhardt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Deurs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandvig, K.</span></span> <span> </span><span class="NLM_article-title">Extraction of Cholesterol with Methyl-B-Cyclodextrin Perturbs Formation of Clathrin-Coated Endocytic Vesicles</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1091/mbc.10.4.961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1091%2Fmbc.10.4.961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10198050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXisVGks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=961-974&issue=4&author=S.+K.+Rodalauthor=G.+Skrettingauthor=%C3%98.+Garredauthor=F.+Vilhardtauthor=B.+van+Deursauthor=K.+Sandvig&title=Extraction+of+Cholesterol+with+Methyl-B-Cyclodextrin+Perturbs+Formation+of+Clathrin-Coated+Endocytic+Vesicles&doi=10.1091%2Fmbc.10.4.961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles</span></div><div class="casAuthors">Rodal, Siv Kjersti; Skretting, Grethe; Garred, Oystein; Vilhardt, Frederik; Van Deurs, Bo; Sandvig, Kirsten</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">961-974</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">The importance of cholesterol for endocytosis has been investigated in HEp-2 and other cell lines by using methyl-β-cyclodextrin (MβCD) to selectively ext. cholesterol from the plasma membrane.  MβCD treatment strongly inhibited endocytosis of transferrin and EGF, whereas endocytosis of ricin was less affected.  The inhibition of transferrin endocytosis was completely reversible.  On removal of MβCD it was restored by continued incubation of the cells even in serum-free medium.  The recovery in serum-free medium was inhibited by addn. of lovastatin, which prevents cholesterol synthesis, but endocytosis recovered when a water-sol. form of cholesterol was added together with lovastatin.  Electron microscopical studies of MβCD-treated HEp-2 cells revealed that typical invaginated caveolae were no longer present.  Moreover, the invagination of clathrin-coated pits was strongly inhibited, resulting in accumulation of shallow coated pits.  Quant. immunogold labeling showed that transferrin receptors were concd. in coated pits to the same degree (approx. sevenfold) after MβCD treatment as in control cells.  Our results therefore indicate that although clathrin-independent (and caveolae-independent) endocytosis still operates after removal of cholesterol, cholesterol is essential for the formation of clathrin-coated endocytic vesicles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphvV-Z-RId6bVg90H21EOLACvtfcHk0lg-Zk3alR-phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisVGks7o%253D&md5=a17a986bc0d94dde00ffb87138890e63</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1091%2Fmbc.10.4.961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.10.4.961%26sid%3Dliteratum%253Aachs%26aulast%3DRodal%26aufirst%3DS.%2BK.%26aulast%3DSkretting%26aufirst%3DG.%26aulast%3DGarred%26aufirst%3D%25C3%2598.%26aulast%3DVilhardt%26aufirst%3DF.%26aulast%3Dvan%2BDeurs%26aufirst%3DB.%26aulast%3DSandvig%26aufirst%3DK.%26atitle%3DExtraction%2520of%2520Cholesterol%2520with%2520Methyl-B-Cyclodextrin%2520Perturbs%2520Formation%2520of%2520Clathrin-Coated%2520Endocytic%2520Vesicles%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D1999%26volume%3D10%26issue%3D4%26spage%3D961%26epage%3D974%26doi%3D10.1091%2Fmbc.10.4.961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subtil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobylarz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGraw, T. E.</span></span> <span> </span><span class="NLM_article-title">Acute Cholesterol Depletion Inhibits Clathrin-Coated Pit Budding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">6775</span>– <span class="NLM_lpage">6780</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.12.6775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.96.12.6775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10359788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXks1WksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=6775-6780&issue=12&author=A.+Subtilauthor=I.+Gaidarovauthor=K.+Kobylarzauthor=M.+A.+Lampsonauthor=J.+H.+Keenauthor=T.+E.+McGraw&title=Acute+Cholesterol+Depletion+Inhibits+Clathrin-Coated+Pit+Budding&doi=10.1073%2Fpnas.96.12.6775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Acute cholesterol depletion inhibits clathrin-coated pit budding</span></div><div class="casAuthors">Subtil, Agathe; Gaidarov, Ibragim; Kobylarz, Keith; Lampson, Michael A.; Keen, James H.; McGraw, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6775-6780</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Many biol. important macromols. are internalized into cells by clathrin-coated pit endocytosis.  The mechanism of clathrin-coated pit budding has been investigated intensively, and considerable progress has been made in characterizing the proteins involved in internalization.  Membrane lipid compn. and the lateral organization of lipids and proteins within membranes are believed to play an important role in the regulation of membrane-trafficking processes.  Here we report that membrane cholesterol plays a crit. role in clathrin-coated pit internalization.  We show that acute cholesterol depletion, using β-methyl-cyclodextrin, specifically reduces the rate of internalization of transferrin receptor by more than 85%, without affecting intracellular receptor trafficking back to the cell surface.  The effect on endocytosis is attributable to a failure of coated pits to detach from the plasma membrane, as visualized by using a green fluorescent protein-clathrin conjugate in living cells.  Ultrastructural studies indicate that acute cholesterol depletion causes accumulation of flat-coated membranes and a corresponding decrease in deep-coated pits, consistent with the possibility that flat clathrin lattices are direct precursors of indented pits and endocytic vesicles in intact cells.  We conclude that clathrin is unable to induce curvature in the membrane depleted of cholesterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG2HRLKz6887Vg90H21EOLACvtfcHk0lg-Zk3alR-phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXks1WksLs%253D&md5=a49e9a271451df26f514c302811ccfae</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.12.6775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.12.6775%26sid%3Dliteratum%253Aachs%26aulast%3DSubtil%26aufirst%3DA.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DKobylarz%26aufirst%3DK.%26aulast%3DLampson%26aufirst%3DM.%2BA.%26aulast%3DKeen%26aufirst%3DJ.%2BH.%26aulast%3DMcGraw%26aufirst%3DT.%2BE.%26atitle%3DAcute%2520Cholesterol%2520Depletion%2520Inhibits%2520Clathrin-Coated%2520Pit%2520Budding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26issue%3D12%26spage%3D6775%26epage%3D6780%26doi%3D10.1073%2Fpnas.96.12.6775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corneth, O. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Wolterink, R. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">BTK Signaling in B Cell Differentiation and Autoimmunity</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>393</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1007/82_2015_478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F82_2015_478" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2015&pages=67-105&issue=12&author=O.+B.+J.+Cornethauthor=R.+G.+J.+Klein+Wolterinkauthor=R.+W.+Hendriks&title=BTK+Signaling+in+B+Cell+Differentiation+and+Autoimmunity&doi=10.1007%2F82_2015_478"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1007%2F82_2015_478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F82_2015_478%26sid%3Dliteratum%253Aachs%26aulast%3DCorneth%26aufirst%3DO.%2BB.%2BJ.%26aulast%3DKlein%2BWolterink%26aufirst%3DR.%2BG.%2BJ.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DBTK%2520Signaling%2520in%2520B%2520Cell%2520Differentiation%2520and%2520Autoimmunity%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2015%26volume%3D393%26issue%3D12%26spage%3D67%26epage%3D105%26doi%3D10.1007%2F82_2015_478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolibaba, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients with Relapsed/Refractory B-Cell Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.42.7906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1200%2FJCO.2012.42.7906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23045577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=88-94&issue=1&author=R.+H.+Advaniauthor=J.+J.+Buggyauthor=J.+P.+Sharmanauthor=S.+M.+Smithauthor=T.+E.+Boydauthor=B.+Grantauthor=K.+S.+Kolibabaauthor=R.+R.+Furmanauthor=S.+Rodriguezauthor=B.+Y.+Changauthor=J.+Sukbuntherngauthor=R.+Izumiauthor=A.+Hamdyauthor=E.+Hedrickauthor=N.+H.+Fowler&title=Bruton+Tyrosine+Kinase+Inhibitor+Ibrutinib+%28PCI-32765%29+Has+Significant+Activity+in+Patients+with+Relapsed%2FRefractory+B-Cell+Malignancies&doi=10.1200%2FJCO.2012.42.7906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies</span></div><div class="casAuthors">Advani, Ranjana H.; Buggy, Joseph J.; Sharman, Jeff P.; Smith, Sonali M.; Boyd, Thomas E.; Grant, Barbara; Kolibaba, Kathryn S.; Furman, Richard R.; Rodriguez, Sara; Chang, Betty Y.; Sukbuntherng, Juthamas; Izumi, Raquel; Hamdy, Ahmed; Hedrick, Eric; Fowler, Nathan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-94</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a crit. signaling kinase in this pathway.  We evaluated ibrutinib (PCI-32765), a small-mol. irreversible inhibitor of BTK, in patients with B-cell malignancies.  Patients and Methods Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib.  Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing.  Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe.  Dose escalation proceeded until either the max.-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib.  Response was evaluated every two cycles.  Results Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts.  Most adverse events were grade 1 and 2 in severity and self-limited.  Dose-limiting events were not obsd., even with prolonged dosing.  Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD.  Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 h, consistent with the irreversible mechanism.  Objective response rate in 50 evaluable patients was 60%, including complete response of 16%.  Median progression-free survival in all patients was 13.6 mo.  Conclusion Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqj_UZPM0nBrVg90H21EOLACvtfcHk0lg-Zk3alR-phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D&md5=e955490a02af9a321823033b9e258cb6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.7906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.7906%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DBoyd%26aufirst%3DT.%2BE.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DKolibaba%26aufirst%3DK.%2BS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%2520%2528PCI-32765%2529%2520Has%2520Significant%2520Activity%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B-Cell%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D1%26spage%3D88%26epage%3D94%26doi%3D10.1200%2FJCO.2012.42.7906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The Development of Bruton’s Tyrosine Kinase (BTK) Inhibitors From 2012 to 2017: a Mini-Review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+Development+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+From+2012+to+2017%3A+a+Mini-Review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0ljZjDcUQYd1VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520Development%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520From%25202012%2520to%25202017%253A%2520a%2520Mini-Review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1086</span>– <span class="NLM_lpage">1091</span>, <span class="refDoi"> DOI: 10.1021/cb4008524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4008524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1086-1091&issue=5&author=H.+Wuauthor=W.+Wangauthor=F.+Liuauthor=E.+L.+Weisbergauthor=B.+Tianauthor=Y.+Chenauthor=B.+Liauthor=A.+Wangauthor=B.+Wangauthor=Z.+Zhaoauthor=D.+W.+McMillinauthor=C.+Huauthor=H.+Liauthor=J.+Wangauthor=Y.+Liangauthor=S.+J.+Buhrlageauthor=J.+Liangauthor=J.+Liuauthor=G.+Yangauthor=J.+R.+Brownauthor=S.+P.+Treonauthor=C.+S.+Mitsiadesauthor=J.+D.+Griffinauthor=Q.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+Potent%2C+Covalent+BTK+Inhibitor+for+B-Cell+Lymphoma&doi=10.1021%2Fcb4008524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma</span></div><div class="casAuthors">Wu, Hong; Wang, Wenchao; Liu, Feiyang; Weisberg, Ellen E.; Tian, Bei; Chen, Yongfei; Li, Binhua; Wang, Aoli; Wang, Beilei; Zhao, Zheng; McMillin, Douglas W.; Hu, Chen; Li, Hong; Wang, Jinhua; Liang, Yanke; Buhrlage, Sara J.; Liang, Junting; Liu, Jing; Yang, Guang; Brown, Jennifer R.; Treon, Steven P.; Mitsiades, Constantine S.; Griffin, James; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-1091</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases.  The authors have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible BTK kinase inhibitor, QL47, which covalently modifies Cys 481.  QL47 inhibits BTK kinase activity with an IC50 of 7 nM, inhibits autophosphorylation of BTK on Tyr 223 in cells with an EC50 of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr 759) with an EC50 of 318 nM.  In Ramos cells QL47 induces a G1 cell cycle arrest that is assocd. with pronounced degrdn. of BTK protein.  QL47 inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiyQbTbqIpCbVg90H21EOLACvtfcHk0ljZjDcUQYd1VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D&md5=6cee72676bcd141f79d89d708dea5db2</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fcb4008524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4008524%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMcMillin%26aufirst%3DD.%2BW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Covalent%2520BTK%2520Inhibitor%2520for%2520B-Cell%2520Lymphoma%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26issue%3D5%26spage%3D1086%26epage%3D1091%26doi%3D10.1021%2Fcb4008524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tinworth, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lithgow, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, Z. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muelbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span> <span> </span><span class="NLM_article-title">PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b01094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b01094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1ylsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=342-347&issue=3&author=C.+P.+Tinworthauthor=H.+Lithgowauthor=L.+Dittusauthor=Z.+I.+Bassiauthor=S.+E.+Hughesauthor=M.+Muelbaierauthor=H.+Daiauthor=I.+E.+D.+Smithauthor=W.+J.+Kerrauthor=G.+A.+Burleyauthor=M.+Bantscheffauthor=J.+D.+Harling&title=PROTAC-Mediated+Degradation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Is+Inhibited+by+Covalent+Binding&doi=10.1021%2Facschembio.8b01094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding</span></div><div class="casAuthors">Tinworth, Christopher P.; Lithgow, Hannah; Dittus, Lars; Bassi, Zuni I.; Hughes, Sophie E.; Muelbaier, Marcel; Dai, Han; Smith, Ian E. D.; Kerr, William J.; Burley, Glenn A.; Bantscheff, Marcus; Harling, John D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-347</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The impact of covalent binding on PROTAC-mediated degrdn. of BTK was investigated through the prepn. of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib.  It was detd. that a covalent binding PROTAC inhibited BTK degrdn. despite evidence of target engagement, while BTK degrdn. was obsd. with a reversible binding PROTAC.  These observations were consistently found when PROTACs that were able to recruit either IAP or cereblon E3 ligases were employed.  Proteomics anal. detd. that the use of a covalently bound PROTAC did not result in the degrdn. of covalently bound targets, while degrdn. was obsd. for some reversibly bound targets.  This observation highlights the importance of catalysis for successful PROTAC-mediated degrdn. and highlights a potential caveat for the use of covalent target binders in PROTAC design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTsgJ6eGHCfbVg90H21EOLACvtfcHk0ljZjDcUQYd1VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1ylsLg%253D&md5=7705320a9ffd433ffceec0d67063a599</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b01094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b01094%26sid%3Dliteratum%253Aachs%26aulast%3DTinworth%26aufirst%3DC.%2BP.%26aulast%3DLithgow%26aufirst%3DH.%26aulast%3DDittus%26aufirst%3DL.%26aulast%3DBassi%26aufirst%3DZ.%2BI.%26aulast%3DHughes%26aufirst%3DS.%2BE.%26aulast%3DMuelbaier%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DKerr%26aufirst%3DW.%2BJ.%26aulast%3DBurley%26aufirst%3DG.%2BA.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26atitle%3DPROTAC-Mediated%2520Degradation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Is%2520Inhibited%2520by%2520Covalent%2520Binding%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D342%26epage%3D347%26doi%3D10.1021%2Facschembio.8b01094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span> <span> </span><span class="NLM_article-title">Protein Degradation Through Covalent Inhibitor-Based PROTACs</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1039/C9CC08238G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1039%2FC9CC08238G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31922153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=1521-1524&issue=10&author=G.+Xueauthor=J.+Chenauthor=L.+Liuauthor=D.+Zhouauthor=Y.+Zuoauthor=T.+Fuauthor=Z.+Pan&title=Protein+Degradation+Through+Covalent+Inhibitor-Based+PROTACs&doi=10.1039%2FC9CC08238G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Protein degradation through covalent inhibitor-based PROTACs</span></div><div class="casAuthors">Xue, Gang; Chen, Jiahui; Liu, Lihong; Zhou, Danli; Zuo, Yingying; Fu, Tiancheng; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1521-1524</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Tremendous advancements in proteolysis targeting chimera (PROTAC) technol. have been made in recent years.  However, whether a covalent inhibitor-based PROTAC can be developed remains controversial.  Here, we successfully developed chimeric degraders based on covalent inhibitors to degrade BTK and BLK kinases, demonstrating that covalent inhibitor-based PROTACs are viable and useful tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTxWXFGSqOh7Vg90H21EOLACvtfcHk0li_chZK1amIVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlKgsr8%253D&md5=c240b1ae3c859dbd0dc93a4a7848bfce</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2FC9CC08238G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CC08238G%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZuo%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DProtein%2520Degradation%2520Through%2520Covalent%2520Inhibitor-Based%2520PROTACs%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2020%26volume%3D56%26issue%3D10%26spage%3D1521%26epage%3D1524%26doi%3D10.1039%2FC9CC08238G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scriven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Checkpoint Kinase Chk1 Induces DNA Damage and Cell Death in Human Leukemia and Lymphoma Cells</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">147</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-13-147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1186%2F1476-4598-13-147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24913641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=147&issue=1&author=C.+Bryantauthor=K.+Scrivenauthor=A.+J.+Massey&title=Inhibition+of+the+Checkpoint+Kinase+Chk1+Induces+DNA+Damage+and+Cell+Death+in+Human+Leukemia+and+Lymphoma+Cells&doi=10.1186%2F1476-4598-13-147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells</span></div><div class="casAuthors">Bryant, Christopher; Scriven, Kirsten; Massey, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147/1-147/20, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Chk1 forms a core component of the DNA damage response and small mol. inhibitors are currently being investigated in the clinic as cytotoxic chemotherapy potentiators.  Recent evidence suggests that Chk1 inhibitors may demonstrate significant single agent activity in tumors with specific DNA repair defects, a constitutively activated DNA damage response or oncogene induced replicative stress.  Methods: Growth inhibition induced by the small mol. Chk1 inhibitor V158411 was assessed in a panel of human leukemia and lymphoma cell lines and compared to cancer cell lines derived from solid tumors.  The effects on cell cycle and DNA damage response markers were further evaluated.  Results: Leukemia and lymphoma cell lines were identified as particularly sensitive to the Chk1 inhibitor V158411 (mean GI50 0.17 μM) compared to colon (2.8 μM) or lung (6.9 μM) cancer cell lines.  Chk1 inhibition by V158411 in the leukemia and lymphoma cell lines induced DNA fragmentation and cell death that was both caspase dependent and independent, and prevented cells undergoing mitosis.  An anal. of in vitro pharmacodynamic markers identified a dose dependent decrease in Chk1 and cyclin B1 protein levels and Cdc2 Thr15 phosphorylation along with a concomitant increase in H2AX phosphorylation at Ser139 following V158411 treatment.  Conclusions: These data support the further evaluation of Chk1 inhibitors in hematopoietic cancers as single agents as well as in combination with std. of care cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xm_X9mO2B7Vg90H21EOLACvtfcHk0li_chZK1amIVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWntbo%253D&md5=617eff8bf38666590b093eff96c3dd13</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-13-147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-13-147%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DC.%26aulast%3DScriven%26aufirst%3DK.%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520Checkpoint%2520Kinase%2520Chk1%2520Induces%2520DNA%2520Damage%2520and%2520Cell%2520Death%2520in%2520Human%2520Leukemia%2520and%2520Lymphoma%2520Cells%26jtitle%3DMol.%2520Cancer%26date%3D2014%26volume%3D13%26issue%3D1%26spage%3D147%26doi%3D10.1186%2F1476-4598-13-147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foloppe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiumana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallowfield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel, in Vivo Active Chk1 Inhibitors Utilizing Structure Guided Drug Design</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">35797</span>– <span class="NLM_lpage">35812</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.18632%2Foncotarget.5929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26437226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC283oslGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=35797-35812&issue=34&author=A.+J.+Masseyauthor=S.+Stokesauthor=H.+Browneauthor=N.+Foloppeauthor=A.+Fiumanaauthor=S.+Scraceauthor=M.+Fallowfieldauthor=S.+Bedfordauthor=P.+Webbauthor=L.+Bakerauthor=M.+Christieauthor=M.+J.+Drysdaleauthor=M.+Wood&title=Identification+of+Novel%2C+in+Vivo+Active+Chk1+Inhibitors+Utilizing+Structure+Guided+Drug+Design&doi=10.18632%2Foncotarget.5929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design</span></div><div class="casAuthors">Massey Andrew J; Stokes Stephen; Browne Helen; Foloppe Nicolas; Fiumana Andrea; Scrace Simon; Fallowfield Mandy; Bedford Simon; Webb Paul; Baker Lisa; Drysdale Martin J; Wood Mike; Scrace Simon; Christie Mark; Drysdale Martin J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">35797-812</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chk1 kinase is a critical component of the DNA damage response checkpoint especially in cancer cells and targeting Chk1 is a potential therapeutic opportunity for potentiating the anti-tumor activity of DNA damaging chemotherapy drugs.  Fragment elaboration by structure guided design was utilized to identify and develop a novel series of Chk1 inhibitors culminating in the identification of V158411, a potent ATP-competitive inhibitor of the Chk1 and Chk2 kinases.  V158411 abrogated gemcitabine and camptothecin induced cell cycle checkpoints, resulting in the expected modulation of cell cycle proteins and increased cell death in cancer cells.  V158411 potentiated the cytotoxicity of gemcitabine, cisplatin, SN38 and camptothecin in a variety of p53 deficient human tumor cell lines in vitro, p53 proficient cells were unaffected.  In nude mice, V158411 showed minimal toxicity as a single agent and in combination with irinotecan.  In tumor bearing animals, V158411 was detected at high levels in the tumor with a long elimination half-life; no pharmacologically significant in vivo drug-drug interactions with irinotecan were identified through analysis of the pharmacokinetic profiles.  V158411 potentiated the anti-tumor activity of irinotecan in a variety of human colon tumor xenograft models without additional systemic toxicity.  These results demonstrate the opportunity for combining V158411 with standard of care chemotherapeutic agents to potentiate the therapeutic efficacy of these agents without increasing their toxicity to normal cells.  Thus, V158411 would warrant further clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEUXLTsW9xitXdcedVHT5tfW6udTcc2eb4iqdBY1SA5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283oslGksg%253D%253D&md5=3b3e009bab7d5f0e2a744ed7c261bf14</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5929%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DBrowne%26aufirst%3DH.%26aulast%3DFoloppe%26aufirst%3DN.%26aulast%3DFiumana%26aufirst%3DA.%26aulast%3DScrace%26aufirst%3DS.%26aulast%3DFallowfield%26aufirst%3DM.%26aulast%3DBedford%26aufirst%3DS.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DL.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DWood%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520Novel%252C%2520in%2520Vivo%2520Active%2520Chk1%2520Inhibitors%2520Utilizing%2520Structure%2520Guided%2520Drug%2520Design%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D34%26spage%3D35797%26epage%3D35812%26doi%3D10.18632%2Foncotarget.5929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvesen, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, C. S.</span></span> <span> </span><span class="NLM_article-title">IAP Proteins: Blocking the Road to Death’s Door</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/nrm830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrm830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12042762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=401-410&issue=6&author=G.+S.+Salvesenauthor=C.+S.+Duckett&title=IAP+Proteins%3A+Blocking+the+Road+to+Death%E2%80%99s+Door&doi=10.1038%2Fnrm830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis: IAP proteins: blocking the road to death's door</span></div><div class="casAuthors">Salvesen, Guy S.; Duckett, Colin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">401-410</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'inhibitor of apoptosis' (IAP) gene family, which was discovered less than a decade ago, encodes a group of structurally related proteins that, in addn. to their ability to suppress apoptotic cell death, are involved in an increasing no. of seemingly unrelated cellular functions.  Here, we review the functional and structural properties of this fascinating group of proteins, and of several recently identified IAP-binding factors that regulate IAP function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofMWLW8mAr_LVg90H21EOLACvtfcHk0lj0wLovJNpiww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartL4%253D&md5=0f967aad318a34d988ad40486950ed62</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrm830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm830%26sid%3Dliteratum%253Aachs%26aulast%3DSalvesen%26aufirst%3DG.%2BS.%26aulast%3DDuckett%26aufirst%3DC.%2BS.%26atitle%3DIAP%2520Proteins%253A%2520Blocking%2520the%2520Road%2520to%2520Death%25E2%2580%2599s%2520Door%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26issue%3D6%26spage%3D401%26epage%3D410%26doi%3D10.1038%2Fnrm830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">IAPs, RINGs and Ubiquitylation</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1038/nrm1621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrm1621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15803136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVaktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=287-297&issue=4&author=D.+L.+Vauxauthor=J.+Silke&title=IAPs%2C+RINGs+and+Ubiquitylation&doi=10.1038%2Fnrm1621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">IAPs, RINGs and ubiquitylation</span></div><div class="casAuthors">Vaux, David L.; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Here, the authors review the function of the RING domain of inhibitor of apoptosis proteins (IAPs), provide an overview of the biol. of E3 ubiquitin ligases, the enzymes which conjugate ubiquitin to substrate proteins, and its application to IAPs, and examine evidence for substrate ubiquitination by IAPs and for the importance of these ubiquitination events in the prevention of apoptosis.  The IAPs all contain one or more baculoviral IAP repeat motifs, through which they interact with various other proteins.  Many IAPs also have another Zn-binding motif, the RING domain, which can recruit E2 ubiquitin-conjugating enzymes and catalyze the transfer of ubiquitin onto target proteins.  The no. of targets of IAP-mediated ubiquitination is increasing, and recent results indicate that outcomes following ubiquitination are tantalizingly complex.  As well as regulating other proteins, the IAPs themselves are controlled by ubiquitin-mediated degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8gh0_du1aY7Vg90H21EOLACvtfcHk0lj0wLovJNpiww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVaktb8%253D&md5=4d3040429bbac085dd33b46c8c74d955</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnrm1621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1621%26sid%3Dliteratum%253Aachs%26aulast%3DVaux%26aufirst%3DD.%2BL.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DIAPs%252C%2520RINGs%2520and%2520Ubiquitylation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2005%26volume%3D6%26issue%3D4%26spage%3D287%26epage%3D297%26doi%3D10.1038%2Fnrm1621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCasse, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korneluk, R. G.</span></span> <span> </span><span class="NLM_article-title">The Inhibitors of Apoptosis (IAPs) as Cancer Targets</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1568</span>, <span class="refDoi"> DOI: 10.1007/s10495-007-0087-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2Fs10495-007-0087-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17573556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFWru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1543-1568&issue=9&author=A.+M.+Hunterauthor=E.+C.+LaCasseauthor=R.+G.+Korneluk&title=The+Inhibitors+of+Apoptosis+%28IAPs%29+as+Cancer+Targets&doi=10.1007%2Fs10495-007-0087-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibitors of apoptosis (IAPs) as cancer targets</span></div><div class="casAuthors">Hunter, Allison M.; LaCasse, Eric C.; Korneluk, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1543-1568</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Apoptosis has been accepted as a fundamental component in the pathogenesis of cancer, in addn. to other human diseases including neurodegeneration, coronary disease and diabetes.  The origin of cancer involves deregulated cellular proliferation and the suppression of apoptotic processes, ultimately leading to tumor establishment and growth.  Several lines of evidence point toward the IAP family of proteins playing a role in oncogenesis, via their effective suppression of apoptosis.  The central mechanisms of IAP apoptotic suppression appear to be through direct caspase and pro-caspase inhibition (primarily caspase 3 and 7) and modulation of, and by, the transcription factor NF-kappaB.  Thus, when the IAPs are over-expressed or over-active, as is the case in many cancers, cells are no longer able to die in a physiol. programmed fashion and become increasingly resistant to std. chemo- and radiation therapies.  To date several approaches have been taken to target and eliminate IAP function in an attempt to re-establish sensitivity, reduce toxicity, and improve efficacy of cancer treatment.  In this review, we address IAP proteins as therapeutic targets for the treatment of cancer and emphasize the importance of novel therapeutic approaches for cancer therapy.  Novel targets of IAP function are being identified and include gene therapy strategies and small mol. inhibitors that are based on endogenous IAP antagonists.  As well, mol. mechanistic approaches, such as RNAi to deplete IAP expression, are in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3AD5U2Vmcv7Vg90H21EOLACvtfcHk0lj0wLovJNpiww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFWru7c%253D&md5=69c286dc6604cc97c54c09d7af8fe300</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1007%2Fs10495-007-0087-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-007-0087-3%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DA.%2BM.%26aulast%3DLaCasse%26aufirst%3DE.%2BC.%26aulast%3DKorneluk%26aufirst%3DR.%2BG.%26atitle%3DThe%2520Inhibitors%2520of%2520Apoptosis%2520%2528IAPs%2529%2520as%2520Cancer%2520Targets%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26issue%3D9%26spage%3D1543%26epage%3D1568%26doi%3D10.1007%2Fs10495-007-0087-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvesen, G. S.</span></span> <span> </span><span class="NLM_article-title">Human Caspases: Activation, Specificity, and Regulation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">21777</span>– <span class="NLM_lpage">21781</span>, <span class="refDoi"> DOI: 10.1074/jbc.R800084200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fjbc.R800084200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19473994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFymsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=21777-21781&issue=33&author=C.+Popauthor=G.+S.+Salvesen&title=Human+Caspases%3A+Activation%2C+Specificity%2C+and+Regulation&doi=10.1074%2Fjbc.R800084200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Human Caspases: Activation, Specificity, and Regulation</span></div><div class="casAuthors">Pop, Cristina; Salvesen, Guy S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">21777-21781</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Caspases are intracellular proteases that propagate programmed cell death, proliferation, and inflammation.  Activation of caspases occurs by a conserved mechanism subject to strict cellular regulation.  Once activated by a specific stimulus, caspases execute limited proteolysis of downstream substrates to trigger a cascade of events that culminates in the desired biol. response.  Much has been learned of the mechanisms that govern the activation and regulation of caspases, and this minireview provides an update of these areas.  We also delineate substantial gaps in knowledge of caspase function, which can be approached by techniques and exptl. paradigms that are currently undergoing development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6lC2wmuHJbVg90H21EOLACvtfcHk0lhvA8qqye6ogQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFymsbw%253D&md5=4ac8ce49ca4122e19c1d29c6610e10f6</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R800084200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R800084200%26sid%3Dliteratum%253Aachs%26aulast%3DPop%26aufirst%3DC.%26aulast%3DSalvesen%26aufirst%3DG.%2BS.%26atitle%3DHuman%2520Caspases%253A%2520Activation%252C%2520Specificity%252C%2520and%2520Regulation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26issue%3D33%26spage%3D21777%26epage%3D21781%26doi%3D10.1074%2Fjbc.R800084200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, C.</span></span> <span> </span><span class="NLM_article-title">Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5750</span>– <span class="NLM_lpage">5772</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01668</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01668" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5750-5772&issue=12&author=H.+Congauthor=L.+Xuauthor=Y.+Wuauthor=Z.+Quauthor=T.+Bianauthor=W.+Zhangauthor=C.+Xingauthor=C.+Zhuang&title=Inhibitor+of+Apoptosis+Protein+%28IAP%29+Antagonists+in+Anticancer+Agent+Discovery%3A+Current+Status+and+Perspectives&doi=10.1021%2Facs.jmedchem.8b01668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives</span></div><div class="casAuthors">Cong, Hui; Xu, Lijuan; Wu, Yougen; Qu, Zhuo; Bian, Tengfei; Zhang, Wannian; Xing, Chengguo; Zhuang, Chunlin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5750-5772</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Apoptosis, an important form of programmed cell death (PCD), is a tightly regulated cellular process to eliminate unwanted or damaged cells.  Resistance of apoptosis is a hallmark of cancer cells.  Inhibitor of apoptosis proteins (IAPs) is a class of key apoptosis regulators that promote cancer cell resistant to apoptosis, particularly in cancer treatment.  Disrupting the binding of IAPs with their functional partners therefore is a promising strategy to restore the apoptotic response to proapoptotic stimuli, particularly those introduced by std. cancer therapies.  The most successful example is the use of small mols. to mimic the IAP-binding motif of an endogenous IAP antagonist, second mitochondria-derived activator of caspase (SMAC).  Here we will review the functions of IAPs, the structural interactions of IAPs with SMAC, four generations of SMAC-mimetic IAP antagonists, and representative antagonists in clin. evaluations, focusing on research articles over the past 15 years.  Outlooks and perspectives on the assocd. challenges are provided as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokxBHQlIfyQrVg90H21EOLACvtfcHk0lhvA8qqye6ogQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWksrY%253D&md5=e3a0daceb7979f37d994f55b2323995e</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01668%26sid%3Dliteratum%253Aachs%26aulast%3DCong%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DZhuang%26aufirst%3DC.%26atitle%3DInhibitor%2520of%2520Apoptosis%2520Protein%2520%2528IAP%2529%2520Antagonists%2520in%2520Anticancer%2520Agent%2520Discovery%253A%2520Current%2520Status%2520and%2520Perspectives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5750%26epage%3D5772%26doi%3D10.1021%2Facs.jmedchem.8b01668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varfolomeev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenship, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dynek, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshayes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span> <span> </span><span class="NLM_article-title">IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2007.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18022362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSgurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=669-681&issue=4&author=E.+Varfolomeevauthor=J.+W.+Blankenshipauthor=S.+M.+Waysonauthor=A.+V.+Fedorovaauthor=N.+Kayagakiauthor=P.+Gargauthor=K.+Zobelauthor=J.+N.+Dynekauthor=L.+O.+Elliottauthor=H.+J.+A.+Wallweberauthor=J.+A.+Flygareauthor=W.+J.+Fairbrotherauthor=K.+Deshayesauthor=V.+M.+Dixitauthor=D.+Vucic&title=IAP+Antagonists+Induce+Autoubiquitination+of+c-IAPs%2C+NF-%CE%BAB+Activation%2C+and+TNF%CE%B1-Dependent+Apoptosis&doi=10.1016%2Fj.cell.2007.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis</span></div><div class="casAuthors">Varfolomeev, Eugene; Blankenship, John W.; Wayson, Sarah M.; Fedorova, Anna V.; Kayagaki, Nobuhiko; Garg, Parie; Zobel, Kerry; Dynek, Jasmin N.; Elliott, Linda O.; Wallweber, Heidi J. A.; Flygare, John A.; Fairbrother, Wayne J.; Deshayes, Kurt; Dixit, Vishva M.; Vucic, Domagoj</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">669-681</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibitor of apoptosis (IAP) proteins are antiapoptotic regulators that block cell death in response to diverse stimuli.  They are expressed at elevated levels in human malignancies and are attractive targets for the development of novel cancer therapeutics.  Herein, the authors demonstrate that small-mol. IAP antagonists bind to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of autoubiquitination activity and rapid proteasomal degrdn. of c-IAPs.  The IAP antagonists also induce cell death that is dependent on TNF signaling and de novo protein biosynthesis.  Addnl., the c-IAP proteins were found to function as regulators of NF-κB signaling.  Through their ubiquitin E3 ligase activities c-IAP1 and c-IAP2 promote proteasomal degrdn. of NIK, the central ser/thr kinase in the noncanonical NF-κB pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV7cKeBeR_hrVg90H21EOLACvtfcHk0lhvA8qqye6ogQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSgurzF&md5=c9a255030cc26db0519680d170ba91f9</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DBlankenship%26aufirst%3DJ.%2BW.%26aulast%3DWayson%26aufirst%3DS.%2BM.%26aulast%3DFedorova%26aufirst%3DA.%2BV.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DDynek%26aufirst%3DJ.%2BN.%26aulast%3DElliott%26aufirst%3DL.%2BO.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26aulast%3DVucic%26aufirst%3DD.%26atitle%3DIAP%2520Antagonists%2520Induce%2520Autoubiquitination%2520of%2520c-IAPs%252C%2520NF-%25CE%25BAB%2520Activation%252C%2520and%2520TNF%25CE%25B1-Dependent%2520Apoptosis%26jtitle%3DCell%26date%3D2007%26volume%3D131%26issue%3D4%26spage%3D669%26epage%3D681%26doi%3D10.1016%2Fj.cell.2007.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vince, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benetatos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chunduru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinlay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverkus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tergaonkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callus, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koentgen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.10.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2007.10.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18022363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSgur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=682-693&issue=4&author=J.+E.+Vinceauthor=W.+W.-L.+Wongauthor=N.+Khanauthor=R.+Felthamauthor=D.+Chauauthor=A.+U.+Ahmedauthor=C.+A.+Benetatosauthor=S.+K.+Chunduruauthor=S.+M.+Condonauthor=M.+McKinlayauthor=R.+Brinkauthor=M.+Leverkusauthor=V.+Tergaonkarauthor=P.+Schneiderauthor=B.+A.+Callusauthor=F.+Koentgenauthor=D.+L.+Vauxauthor=J.+Silke&title=IAP+Antagonists+Target+cIAP1+to+Induce+TNF%CE%B1-Dependent+Apoptosis&doi=10.1016%2Fj.cell.2007.10.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis</span></div><div class="casAuthors">Vince, James E.; Wong, W. Wei-Lynn; Khan, Nufail; Feltham, Rebecca; Chau, Diep; Ahmed, Afsar U.; Benetatos, Christopher A.; Chunduru, Srinivas K.; Condon, Stephen M.; McKinlay, Mark; Brink, Robert; Leverkus, Martin; Tergaonkar, Vinay; Schneider, Pascal; Callus, Bernard A.; Koentgen, Frank; Vaux, David L.; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">682-693</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">XIAP prevents apoptosis by binding to and inhibiting caspases, and this inhibition can be relieved by IAP antagonists, such as Smac/DIABLO.  IAP antagonist compds. (IACs) have therefore been designed to inhibit XIAP to kill tumor cells.  Because XIAP inhibits postmitochondrial caspases, caspase 8 inhibitors should not block killing by IACs.  Instead, the authors show that apoptosis caused by an IAC is blocked by the caspase 8 inhibitor crmA and that IAP antagonists activate NF-κB signaling via inhibition of cIAP1.  In sensitive tumor lines, IAP antagonist induced NF-κB-stimulated prodn. of TNFα that killed cells in an autocrine fashion.  Inhibition of NF-κB reduced TNFα prodn., and blocking NF-κB activation or TNFα allowed tumor cells to survive IAC-induced apoptosis.  Cells treated with an IAC, or those in which cIAP1 was deleted, became sensitive to apoptosis induced by exogenous TNFα, suggesting novel uses of these compds. in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqNa8nssRGeLVg90H21EOLACvtfcHk0lhBviIWt5bITw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSgur3N&md5=9e973670c472d0612d947a2ffe688d20</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.037%26sid%3Dliteratum%253Aachs%26aulast%3DVince%26aufirst%3DJ.%2BE.%26aulast%3DWong%26aufirst%3DW.%2BW.-L.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DFeltham%26aufirst%3DR.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DA.%2BU.%26aulast%3DBenetatos%26aufirst%3DC.%2BA.%26aulast%3DChunduru%26aufirst%3DS.%2BK.%26aulast%3DCondon%26aufirst%3DS.%2BM.%26aulast%3DMcKinlay%26aufirst%3DM.%26aulast%3DBrink%26aufirst%3DR.%26aulast%3DLeverkus%26aufirst%3DM.%26aulast%3DTergaonkar%26aufirst%3DV.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DCallus%26aufirst%3DB.%2BA.%26aulast%3DKoentgen%26aufirst%3DF.%26aulast%3DVaux%26aufirst%3DD.%2BL.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DIAP%2520Antagonists%2520Target%2520cIAP1%2520to%2520Induce%2520TNF%25CE%25B1-Dependent%2520Apoptosis%26jtitle%3DCell%26date%3D2007%26volume%3D131%26issue%3D4%26spage%3D682%26epage%3D693%26doi%3D10.1016%2Fj.cell.2007.10.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">COHEN, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshayes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisner, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varfolomeev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WEN, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4101</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1021/jm300060k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300060k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4101-4113&issue=9&author=J.+A.+Flygareauthor=M.+Beresiniauthor=N.+Budhaauthor=H.+Chanauthor=I.+T.+Chanauthor=S.+Cheetiauthor=F.+COHENauthor=K.+Deshayesauthor=K.+Doernerauthor=S.+G.+Eckhardtauthor=L.+O.+Elliottauthor=B.+Fengauthor=M.+C.+Franklinauthor=S.+F.+Reisnerauthor=L.+Gazzardauthor=J.+Halladayauthor=S.+G.+Hymowitzauthor=H.+Laauthor=P.+LoRussoauthor=B.+Maurerauthor=L.+Murrayauthor=E.+Pliseauthor=C.+Quanauthor=J.-P.+Stephanauthor=S.+G.+Youngauthor=J.+Tomauthor=V.+Tsuiauthor=J.+Umauthor=E.+Varfolomeevauthor=D.+Vucicauthor=A.+J.+Wagnerauthor=H.+J.+A.+Wallweberauthor=L.+Wangauthor=J.+Wareauthor=Z.+WENauthor=H.+Wongauthor=J.+M.+Wongauthor=M.+Wongauthor=S.+Wongauthor=R.+Yuauthor=K.+Zobelauthor=W.+J.+Fairbrother&title=Discovery+of+a+Potent+Small-Molecule+Antagonist+of+Inhibitor+of+Apoptosis+%28IAP%29+Proteins+and+Clinical+Candidate+for+the+Treatment+of+Cancer+%28GDC-0152%29&doi=10.1021%2Fjm300060k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)</span></div><div class="casAuthors">Flygare, John A.; Beresini, Maureen; Budha, Nageshwar; Chan, Helen; Chan, Iris T.; Cheeti, Sravanthi; Cohen, Frederick; Deshayes, Kurt; Doerner, Karl; Eckhardt, S. Gail; Elliott, Linda O.; Feng, Bainian; Franklin, Matthew C.; Reisner, Stacy Frankovitz; Gazzard, Lewis; Halladay, Jason; Hymowitz, Sarah G.; La, Hank; LoRusso, Patricia; Maurer, Brigitte; Murray, Lesley; Plise, Emile; Quan, Clifford; Stephan, Jean-Philippe; Young, Shin G.; Tom, Jeffrey; Tsui, Vickie; Um, Joanne; Varfolomeev, Eugene; Vucic, Domagoj; Wagner, Andrew J.; Wallweber, Heidi J. A.; Wang, Lan; Ware, Joseph; Wen, Zhaoyang; Wong, Harvey; Wong, Jonathan M.; Wong, Melisa; Wong, Susan; Yu, Ron; Zobel, Kerry; Fairbrother, Wayne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4101-4113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac.  Compd. (I) (GDC-0152) has the best profile of these compds.; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with Ki values of 28, 14, 17, and 43 nM, resp.  These compds. promote degrdn. of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells.  Compd. I inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model.  Compd. I was advanced to human clin. trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested.  Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the vol. of distribution was 0.6 ± 0.2 L/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZSPNVJ5gVWrVg90H21EOLACvtfcHk0lhBviIWt5bITw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D&md5=19452878ea834d3c324d567b39a78fb2</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm300060k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300060k%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBudha%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DI.%2BT.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DCOHEN%26aufirst%3DF.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DDoerner%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DElliott%26aufirst%3DL.%2BO.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DFranklin%26aufirst%3DM.%2BC.%26aulast%3DReisner%26aufirst%3DS.%2BF.%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DStephan%26aufirst%3DJ.-P.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DTom%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUm%26aufirst%3DJ.%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWare%26aufirst%3DJ.%26aulast%3DWEN%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Small-Molecule%2520Antagonist%2520of%2520Inhibitor%2520of%2520Apoptosis%2520%2528IAP%2529%2520Proteins%2520and%2520Clinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Cancer%2520%2528GDC-0152%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D9%26spage%3D4101%26epage%3D4113%26doi%3D10.1021%2Fjm300060k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolovska-Coleska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A Potent and Orally Active Antagonist (SM-406/at-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2714</span>– <span class="NLM_lpage">2726</span>, <span class="refDoi"> DOI: 10.1021/jm101505d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101505d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvV2hurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2714-2726&issue=8&author=Q.+Caiauthor=H.+Sunauthor=Y.+Pengauthor=J.+Luauthor=Z.+Nikolovska-Coleskaauthor=D.+McEachernauthor=L.+Liuauthor=S.+Qiuauthor=C.-Y.+Yangauthor=R.+Millerauthor=H.+Yiauthor=T.+Zhangauthor=D.+Sunauthor=S.+Kangauthor=M.+Guoauthor=L.+Leopoldauthor=D.+Yangauthor=S.+Wang&title=A+Potent+and+Orally+Active+Antagonist+%28SM-406%2Fat-406%29+of+Multiple+Inhibitor+of+Apoptosis+Proteins+%28IAPs%29+in+Clinical+Development+for+Cancer+Treatment&doi=10.1021%2Fjm101505d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment</span></div><div class="casAuthors">Cai, Qian; Sun, Haiying; Peng, Yuefeng; Lu, Jianfeng; Nikolovska-Coleska, Zaneta; McEachern, Donna; Liu, Liu; Qiu, Su; Yang, Chao-Yie; Miller, Rebecca; Yi, Han; Zhang, Tao; Sun, Duxin; Kang, Sanmao; Guo, Ming; Leopold, Lance; Yang, Dajun; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2714-2726</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the discovery and characterization of SM-406 (compd. 2), a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs).  This compd. binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, resp.  Compd. 2 effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degrdn. of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines.  It has good oral bioavailability in mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth.  Compd. 2 is currently in phase I clin. trials for the treatment of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgYOZBCwfnLrVg90H21EOLACvtfcHk0lgkNxfhcazk2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvV2hurg%253D&md5=5b73a2ea1a5a2a6b3e3f4c978b49706f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm101505d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101505d%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520Potent%2520and%2520Orally%2520Active%2520Antagonist%2520%2528SM-406%252Fat-406%2529%2520of%2520Multiple%2520Inhibitor%2520of%2520Apoptosis%2520Proteins%2520%2528IAPs%2529%2520in%2520Clinical%2520Development%2520for%2520Cancer%2520Treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D8%26spage%3D2714%26epage%3D2726%26doi%3D10.1021%2Fjm101505d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millemaggi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peakman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilsher, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span> <span> </span><span class="NLM_article-title">A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1<i>H</i>,2<i>H</i>,3<i>H</i>-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2<i>R</i>,5<i>R</i>)-5-methyl-2-([(3<i>R</i>)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7314</span>– <span class="NLM_lpage">7329</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00900</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00900" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7314-7329&issue=16&author=C.+N.+Johnsonauthor=J.+S.+Ahnauthor=I.+M.+Buckauthor=E.+Chiarparinauthor=J.+E.+H.+Dayauthor=A.+Hopkinsauthor=S.+Howardauthor=E.+J.+Lewisauthor=V.+Martinsauthor=A.+Millemaggiauthor=J.+M.+Munckauthor=L.+W.+Pageauthor=T.+Peakmanauthor=M.+Readerauthor=S.+J.+Richauthor=G.+Saxtyauthor=T.+Smythauthor=N.+T.+Thompsonauthor=G.+A.+Wardauthor=P.+A.+Williamsauthor=N.+E.+Wilsherauthor=G.+Chessari&title=A+Fragment-Derived+Clinical+Candidate+for+Antagonism+of+X-Linked+and+Cellular+Inhibitor+of+Apoptosis+Proteins%3A+1-%286-%5B%284-Fluorophenyl%29methyl%5D-5-%28hydroxymethyl%29-3%2C3-dimethyl-1H%2C2H%2C3H-pyrrolo%5B3%2C2-b%5Dpyridin-1-yl%29-2-%5B%282R%2C5R%29-5-methyl-2-%28%5B%283R%29-3-methylmorpholin-4-yl%5Dmethyl%29piperazin-1-yl%5Dethan-1-one+%28ASTX660%29&doi=10.1021%2Facs.jmedchem.8b00900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2R,5R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)</span></div><div class="casAuthors">Johnson, Christopher N.; Ahn, Jong Sook; Buck, Ildiko M.; Chiarparin, Elisabetta; Day, James E. H.; Hopkins, Anna; Howard, Steven; Lewis, Edward J.; Martins, Vanessa; Millemaggi, Alessia; Munck, Joanne M.; Page, Lee W.; Peakman, Torren; Reader, Michael; Rich, Sharna J.; Saxty, Gordon; Smyth, Tomoko; Thompson, Neil T.; Ward, George A.; Williams, Pamela A.; Wilsher, Nicola E.; Chessari, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7314-7329</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitor of apoptosis proteins (IAPs) are promising anticancer targets, given their roles in the evasion of apoptosis.  Several peptidomimetic IAP antagonists, with inherent selectivity for cellular IAP (cIAP) over X-linked IAP (XIAP), have been tested in the clinic.  A fragment screening approach followed by structure-based optimization has previously been reported that resulted in a low-nanomolar cIAP1 and XIAP antagonist lead mol. with a more balanced cIAP-XIAP profile.  We now report the further structure-guided optimization of the lead, with a view to improving the metabolic stability and cardiac safety profile, to give the nonpeptidomimetic antagonist clin. candidate (ASTX660), currently being tested in a phase 1/2 clin. trial (NCT02503423).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBj2OOs5EG-7Vg90H21EOLACvtfcHk0lgkNxfhcazk2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtr7P&md5=9c7ca5775f42441c971ad8459bb129c2</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00900%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DBuck%26aufirst%3DI.%2BM.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DDay%26aufirst%3DJ.%2BE.%2BH.%26aulast%3DHopkins%26aufirst%3DA.%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMillemaggi%26aufirst%3DA.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DPage%26aufirst%3DL.%2BW.%26aulast%3DPeakman%26aufirst%3DT.%26aulast%3DReader%26aufirst%3DM.%26aulast%3DRich%26aufirst%3DS.%2BJ.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWard%26aufirst%3DG.%2BA.%26aulast%3DWilliams%26aufirst%3DP.%2BA.%26aulast%3DWilsher%26aufirst%3DN.%2BE.%26aulast%3DChessari%26aufirst%3DG.%26atitle%3DA%2520Fragment-Derived%2520Clinical%2520Candidate%2520for%2520Antagonism%2520of%2520X-Linked%2520and%2520Cellular%2520Inhibitor%2520of%2520Apoptosis%2520Proteins%253A%25201-%25286-%255B%25284-Fluorophenyl%2529methyl%255D-5-%2528hydroxymethyl%2529-3%252C3-dimethyl-1H%252C2H%252C3H-pyrrolo%255B3%252C2-b%255Dpyridin-1-yl%2529-2-%255B%25282R%252C5R%2529-5-methyl-2-%2528%255B%25283R%2529-3-methylmorpholin-4-yl%255Dmethyl%2529piperazin-1-yl%255Dethan-1-one%2520%2528ASTX660%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D16%26spage%3D7314%26epage%3D7329%26doi%3D10.1021%2Facs.jmedchem.8b00900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dueber, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffler, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varfolomeev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshayes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span> <span> </span><span class="NLM_article-title">Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">6054</span>),  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1126/science.1207862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1207862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22021857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlahsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=376-380&issue=6054&author=E.+C.+Dueberauthor=A.+J.+Schoefflerauthor=A.+Lingelauthor=J.+M.+Elliottauthor=A.+V.+Fedorovaauthor=A.+M.+Giannettiauthor=K.+Zobelauthor=B.+Maurerauthor=E.+Varfolomeevauthor=P.+Wuauthor=H.+J.+A.+Wallweberauthor=S.+G.+Hymowitzauthor=K.+Deshayesauthor=D.+Vucicauthor=W.+J.+Fairbrother&title=Antagonists+Induce+a+Conformational+Change+in+cIAP1+That+Promotes+Autoubiquitination&doi=10.1126%2Fscience.1207862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination</span></div><div class="casAuthors">Dueber, Erin C.; Schoeffler, Allyn J.; Lingel, Andreas; Elliott, J. Michael; Fedorova, Anna V.; Giannetti, Anthony M.; Zobel, Kerry; Maurer, Brigitte; Varfolomeev, Eugene; Wu, Ping; Wallweber, Heidi J. A.; Hymowitz, Sarah G.; Deshayes, Kurt; Vucic, Domagoj; Fairbrother, Wayne J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6054</span>),
    <span class="NLM_cas:pages">376-380</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Inhibitor of apoptosis (IAP) proteins are neg. regulators of cell death.  IAP family members contain RING domains that impart E3 ubiquitin ligase activity.  Binding of endogenous or small-mol. antagonists to select baculovirus IAP repeat (BIR) domains within cellular IAP (cIAP) proteins promotes autoubiquitination and proteasomal degrdn. and so releases inhibition of apoptosis mediated by cIAP.  Although the mol. details of antagonist-BIR domain interactions are well understood, it is not clear how this binding event influences the activity of the RING domain.  Here biochem. and structural studies reveal that the unliganded, multidomain cIAP1 sequesters the RING domain within a compact, monomeric structure that prevents RING dimerization.  Antagonist binding induces conformational rearrangements that enable RING dimerization and formation of the active E3 ligase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLt33kw3IgQLVg90H21EOLACvtfcHk0lgkNxfhcazk2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlahsrzJ&md5=eeaaac9b5ad01f6c1f7fc062d54204d0</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1126%2Fscience.1207862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1207862%26sid%3Dliteratum%253Aachs%26aulast%3DDueber%26aufirst%3DE.%2BC.%26aulast%3DSchoeffler%26aufirst%3DA.%2BJ.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DElliott%26aufirst%3DJ.%2BM.%26aulast%3DFedorova%26aufirst%3DA.%2BV.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26atitle%3DAntagonists%2520Induce%2520a%2520Conformational%2520Change%2520in%2520cIAP1%2520That%2520Promotes%2520Autoubiquitination%26jtitle%3DScience%26date%3D2011%26volume%3D334%26issue%3D6054%26spage%3D376%26epage%3D380%26doi%3D10.1126%2Fscience.1207862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span> <span> </span><span class="NLM_article-title">A Covalently Bound Inhibitor Triggers EZH2 Degradation Through CHIP-Mediated Ubiquitination</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.15252/embj.201694058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.15252%2Fembj.201694058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28320739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=1243-1260&issue=9&author=X.+Wangauthor=W.+Caoauthor=J.+Zhangauthor=M.+Yanauthor=Q.+Xuauthor=X.+Wuauthor=L.+Wanauthor=Z.+Zhangauthor=C.+Zhangauthor=X.+Qinauthor=M.+Xiaoauthor=D.+Yeauthor=Y.+Liuauthor=Z.+Hanauthor=S.+Wangauthor=L.+Maoauthor=W.+Weiauthor=W.+Chen&title=A+Covalently+Bound+Inhibitor+Triggers+EZH2+Degradation+Through+CHIP-Mediated+Ubiquitination&doi=10.15252%2Fembj.201694058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination</span></div><div class="casAuthors">Wang, Xu; Cao, Wei; Zhang, Jianjun; Yan, Ming; Xu, Qin; Wu, Xiangbing; Wan, Lixin; Zhang, Zhiyuan; Zhang, Chenping; Qin, Xing; Xiao, Meng; Ye, Dongxia; Liu, Yuyang; Han, Zeguang; Wang, Shaomeng; Mao, Li; Wei, Wenyi; Chen, Wantao</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1243-1260</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2) has been characterized as a crit. oncogene and a promising drug target in human malignant tumors.  The current EZH2 inhibitors strongly suppress the enhanced enzymic function of mutant EZH2 in some lymphomas.  However, the recent identification of a PRC2- and methyltransferase-independent role of EZH2 indicates that a complete suppression of all oncogenic functions of EZH2 is needed.  Here, we report a unique EZH2-targeting strategy by identifying a gambogenic acid (GNA) deriv. as a novel agent that specifically and covalently bound to Cys668 within the EZH2-SET domain, triggering EZH2 degrdn. through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.  This class of inhibitors significantly suppressed H3K27Me3 and effectively reactivated polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes.  Moreover, the novel inhibitors significantly suppressed tumor growth in an EZH2-dependent manner, and tumors bearing a non-GNA-interacting C668S-EZH2 mutation exhibited resistance to the inhibitors.  Together, our results identify the inhibition of the signaling pathway that governs GNA-mediated destruction of EZH2 as a promising anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRQknSdWy5T7Vg90H21EOLACvtfcHk0liWQOVARIU1Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D&md5=b9b8a266537e2922648784d9cd4edf02</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.15252%2Fembj.201694058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201694058%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26atitle%3DA%2520Covalently%2520Bound%2520Inhibitor%2520Triggers%2520EZH2%2520Degradation%2520Through%2520CHIP-Mediated%2520Ubiquitination%26jtitle%3DEMBO%2520J.%26date%3D2017%26volume%3D36%26issue%3D9%26spage%3D1243%26epage%3D1260%26doi%3D10.15252%2Fembj.201694058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Polycomb Group Proteins: Navigators of Lineage Pathways Led Astray in Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrc2736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc2736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19851313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=773-784&issue=11&author=A.+P.+Brackenauthor=K.+Helin&title=Polycomb+Group+Proteins%3A+Navigators+of+Lineage+Pathways+Led+Astray+in+Cancer&doi=10.1038%2Fnrc2736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb group proteins: navigators of lineage pathways led astray in cancer</span></div><div class="casAuthors">Bracken, Adrian P.; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">773-784</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Polycomb group (PcG) proteins are transcriptional repressors that regulate lineage choices during development and differentiation.  Recent studies have advanced our understanding of how the PcG proteins regulate cell fate decisions and how their deregulation potentially contributes to cancer.  In this Review we discuss the emerging roles of long non-coding RNAs (ncRNAs) and a subset of transcription factors, which we call cell fate transcription factors, in the regulation of PcG assocn. with target genes.  We also speculate about how their deregulation contributes to tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJw0rl14G2LVg90H21EOLACvtfcHk0liWQOVARIU1Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtbbE&md5=3c8cdededb7febba1acb0da897c2e8d7</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrc2736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2736%26sid%3Dliteratum%253Aachs%26aulast%3DBracken%26aufirst%3DA.%2BP.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DPolycomb%2520Group%2520Proteins%253A%2520Navigators%2520of%2520Lineage%2520Pathways%2520Led%2520Astray%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D11%26spage%3D773%26epage%3D784%26doi%3D10.1038%2Fnrc2736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5595</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1126/science.1076997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1076997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12351676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1039-1043&issue=5595&author=R.+Caoauthor=L.+Wangauthor=H.+Wangauthor=L.+Xiaauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=R.+S.+Jonesauthor=Y.+Zhang&title=Role+of+Histone+H3+Lysine+27+Methylation+in+Polycomb-Group+Silencing&doi=10.1126%2Fscience.1076997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing</span></div><div class="casAuthors">Cao, Ru; Wang, Liangjun; Wang, Hengbin; Xia, Li; Erdjument-Bromage, Hediye; Tempst, Paul; Jones, Richard S.; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5595</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins play important roles in maintaining the silent state of HOX genes.  Recent studies have implicated histone methylation in long-term gene silencing.  However, a connection between PcG-mediated gene silencing and histone methylation has not been established.  Here the authors report the purifn. and characterization of an EED-EZH2 complex, the human counterpart of the Drosophila ESC-E(Z) complex.  They demonstrate that the complex specifically methylates nucleosomal histone H3 at lysine 27 (H3-K27).  Using chromatin immunopptn. assays, the authors show that H3-K27 methylation colocalizes with, and is dependent on, E(Z) binding at an Ultrabithorax med° (Ubx) Polycomb response element (PRE), and that this methylation correlates with Ubx repression.  Methylation on H3-K27 facilitates binding of Polycomb (PC), a component of the PRC1 complex, to histone H3 amino-terminal tail.  Thus, these studies establish a link between histone methylation and PcG-mediated gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnqusXKZEbLVg90H21EOLACvtfcHk0liWQOVARIU1Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D&md5=8f24c05ec935c9110b2ff85b65911396</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1126%2Fscience.1076997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1076997%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DR.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DRole%2520of%2520Histone%2520H3%2520Lysine%252027%2520Methylation%2520in%2520Polycomb-Group%2520Silencing%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5595%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1076997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ezhkova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasolli, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarakhovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, E.</span></span> <span> </span><span class="NLM_article-title">Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2008.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19303854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=1122-1135&issue=6&author=E.+Ezhkovaauthor=H.+A.+Pasolliauthor=J.+S.+Parkerauthor=N.+Stokesauthor=I.-H.+Suauthor=G.+Hannonauthor=A.+Tarakhovskyauthor=E.+Fuchs&title=Ezh2+Orchestrates+Gene+Expression+for+the+Stepwise+Differentiation+of+Tissue-Specific+Stem+Cells&doi=10.1016%2Fj.cell.2008.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells</span></div><div class="casAuthors">Ezhkova, Elena; Pasolli, H. Amalia; Parker, Joel S.; Stokes, Nicole; Su, I.-hsin; Hannon, Gregory; Tarakhovsky, Alexander; Fuchs, Elaine</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1122-1135</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although in vitro studies of embryonic stem cells have identified polycomb repressor complexes (PRCs) as key regulators of differentiation, it remains unclear as to how PRC-mediated mechanisms control fates of multipotent progenitors in developing tissues.  Here, we show that an essential PRC component, Ezh2, is expressed in epidermal progenitors but diminishes concomitant with embryonic differentiation and with postnatal decline in proliferative activity.  We show that Ezh2 controls proliferative potential of basal progenitors by repressing the Ink4A-Ink4B locus and tempers the developmental rate of differentiation by preventing premature recruitment of AP1 transcriptional activator to the structural genes that are required for epidermal differentiation.  Together, our studies reveal that PRCs control epigenetic modifications temporally and spatially in tissue-restricted stem cells.  They maintain their proliferative potential and globally repressing undesirable differentiation programs while selectively establishing a specific terminal differentiation program in a stepwise fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEXB1DFBAlB7Vg90H21EOLACvtfcHk0liS6BRajbq4tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnt70%253D&md5=0dd92cb7797a1459b766a3b492946995</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DEzhkova%26aufirst%3DE.%26aulast%3DPasolli%26aufirst%3DH.%2BA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DStokes%26aufirst%3DN.%26aulast%3DSu%26aufirst%3DI.-H.%26aulast%3DHannon%26aufirst%3DG.%26aulast%3DTarakhovsky%26aufirst%3DA.%26aulast%3DFuchs%26aufirst%3DE.%26atitle%3DEzh2%2520Orchestrates%2520Gene%2520Expression%2520for%2520the%2520Stepwise%2520Differentiation%2520of%2520Tissue-Specific%2520Stem%2520Cells%26jtitle%3DCell%26date%3D2009%26volume%3D136%26issue%3D6%26spage%3D1122%26epage%3D1135%26doi%3D10.1016%2Fj.cell.2008.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span> <span> </span><span class="NLM_article-title">The Epigenomics of Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2007.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17320506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12ju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=683-692&issue=4&author=P.+A.+Jonesauthor=S.+B.+Baylin&title=The+Epigenomics+of+Cancer&doi=10.1016%2Fj.cell.2007.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The epigenomics of cancer</span></div><div class="casAuthors">Jones, Peter A.; Baylin, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">683-692</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Aberrant gene function and altered patterns of gene expression are key features of cancer.  Growing evidence shows that acquired epigenetic abnormalities participate with genetic alterations to cause this dysregulation.  Here, we review recent advances in understanding how epigenetic alterations participate in the earliest stages of neoplasia, including stem/precursor cell contributions, and discuss the growing implications of these advances for strategies to control cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPBpHNAkcSPbVg90H21EOLACvtfcHk0liS6BRajbq4tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12ju7k%253D&md5=78eac8ecc093f1aed0acbfd578f34717</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BA.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DThe%2520Epigenomics%2520of%2520Cancer%26jtitle%3DCell%26date%3D2007%26volume%3D128%26issue%3D4%26spage%3D683%26epage%3D692%26doi%3D10.1016%2Fj.cell.2007.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleer, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewalt, R. G. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabel, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">EZH2 Is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">11606</span>– <span class="NLM_lpage">11611</span>, <span class="refDoi"> DOI: 10.1073/pnas.1933744100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.1933744100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=14500907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFKmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11606-11611&issue=20&author=C.+G.+Kleerauthor=Q.+Caoauthor=S.+Varamballyauthor=R.+Shenauthor=I.+Otaauthor=S.+A.+Tomlinsauthor=D.+Ghoshauthor=R.+G.+A.+B.+Sewaltauthor=A.+P.+Otteauthor=D.+F.+Hayesauthor=M.+S.+Sabelauthor=D.+Livantauthor=S.+J.+Weissauthor=M.+A.+Rubinauthor=A.+M.+Chinnaiyan&title=EZH2+Is+a+Marker+of+Aggressive+Breast+Cancer+and+Promotes+Neoplastic+Transformation+of+Breast+Epithelial+Cells&doi=10.1073%2Fpnas.1933744100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells</span></div><div class="casAuthors">Kleer, Celina G.; Cao, Qi; Varambally, Sooryanarayana; Shen, Ronglai; Ota, Ichiro; Tomlins, Scott A.; Ghosh, Debashis; Sewalt, Richard G. A. B.; Otte, Arie P.; Hayes, Daniel F.; Sabel, Michael S.; Livant, Donna; Weiss, Stephen J.; Rubin, Mark A.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11606-11611</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer.  Here the authors investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression.  EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia.  Tissue microarray anal., which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly assocd. with breast cancer aggressiveness.  Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion.  EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity.  This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV3vRwhSLDh7Vg90H21EOLACvtfcHk0liS6BRajbq4tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFKmt7g%253D&md5=a362e2d0f3c61c8e8b3afd5cea992255</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1933744100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1933744100%26sid%3Dliteratum%253Aachs%26aulast%3DKleer%26aufirst%3DC.%2BG.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DOta%26aufirst%3DI.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DSewalt%26aufirst%3DR.%2BG.%2BA.%2BB.%26aulast%3DOtte%26aufirst%3DA.%2BP.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DSabel%26aufirst%3DM.%2BS.%26aulast%3DLivant%26aufirst%3DD.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DEZH2%2520Is%2520a%2520Marker%2520of%2520Aggressive%2520Breast%2520Cancer%2520and%2520Promotes%2520Neoplastic%2520Transformation%2520of%2520Breast%2520Epithelial%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26issue%3D20%26spage%3D11606%26epage%3D11611%26doi%3D10.1073%2Fpnas.1933744100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamochi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwabi-Addo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P. J.</span></span> <span> </span><span class="NLM_article-title">Gene Silencing in Cancer by Histone H3 Lysine 27 Trimethylation Independent of Promoter DNA Methylation</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1038/ng.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18488029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVejtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=741-750&issue=6&author=Y.+Kondoauthor=L.+Shenauthor=A.+S.+Chengauthor=S.+Ahmedauthor=Y.+Boumberauthor=C.+Charoauthor=T.+Yamochiauthor=T.+Uranoauthor=K.+Furukawaauthor=B.+Kwabi-Addoauthor=D.+L.+Goldauthor=Y.+Sekidoauthor=T.+H.-M.+Huangauthor=J.-P.+J.+Issa&title=Gene+Silencing+in+Cancer+by+Histone+H3+Lysine+27+Trimethylation+Independent+of+Promoter+DNA+Methylation&doi=10.1038%2Fng.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation</span></div><div class="casAuthors">Kondo, Yutaka; Shen, Lanlan; Cheng, Alfred S.; Ahmed, Saira; Boumber, Yanis; Charo, Chantale; Yamochi, Tadanori; Urano, Takeshi; Furukawa, Koichi; Kwabi-Addo, Bernard; Gold, David L.; Sekido, Yoshitaka; Huang, Tim Hui-Ming; Issa, Jean-Pierre J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">741-750</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic silencing in cancer cells is mediated by at least two distinct histone modifications, polycomb-based histone H3 lysine 27 trimethylation (H3K27triM) and H3K9 dimethylation.  The relationship between DNA hypermethylation and these histone modifications is not completely understood.  Using chromatin immunopptn. microarrays (ChIP-chip) in prostate cancer cells compared to normal prostate, we found that up to 5% of promoters (16% CpG islands and 84% non-CpG islands) were enriched with H3K27triM.  These genes were silenced specifically in prostate cancer, and those CpG islands affected showed low levels of DNA methylation.  Downregulation of the EZH2 histone methyltransferase restored expression of the H3K27triM target genes alone or in synergy with histone deacetylase inhibition, without affecting promoter DNA methylation, and with no effect on the expression of genes silenced by DNA hypermethylation.  These data establish EZH2-mediated H3K27triM as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1sXzleyaabVg90H21EOLACvtfcHk0liFlo_oXoIugQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVejtro%253D&md5=065aada76322ddbc2e8d4b25bd245748</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fng.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.159%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DA.%2BS.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBoumber%26aufirst%3DY.%26aulast%3DCharo%26aufirst%3DC.%26aulast%3DYamochi%26aufirst%3DT.%26aulast%3DUrano%26aufirst%3DT.%26aulast%3DFurukawa%26aufirst%3DK.%26aulast%3DKwabi-Addo%26aufirst%3DB.%26aulast%3DGold%26aufirst%3DD.%2BL.%26aulast%3DSekido%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DT.%2BH.-M.%26aulast%3DIssa%26aufirst%3DJ.-P.%2BJ.%26atitle%3DGene%2520Silencing%2520in%2520Cancer%2520by%2520Histone%2520H3%2520Lysine%252027%2520Trimethylation%2520Independent%2520of%2520Promoter%2520DNA%2520Methylation%26jtitle%3DNat.%2520Genet.%26date%3D2008%26volume%3D40%26issue%3D6%26spage%3D741%26epage%3D750%26doi%3D10.1038%2Fng.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lohuizen, M.</span></span> <span> </span><span class="NLM_article-title">Polycomb Silencers Control Cell Fate, Development and Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1038/nrc1991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc1991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17060944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=846-856&issue=11&author=A.+Sparmannauthor=M.+van+Lohuizen&title=Polycomb+Silencers+Control+Cell+Fate%2C+Development+and+Cancer&doi=10.1038%2Fnrc1991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb silencers control cell fate, development and cancer</span></div><div class="casAuthors">Sparmann, Anke; van Lohuizen, Maarten</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">846-856</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) proteins are epigenetic gene silencers that are implicated in neoplastic development.  Their oncogenic function might be assocd. with their well-established role in the maintenance of embryonic and adult stem cells.  In this review, we discuss new insights into the possible mechanisms by which PcGs regulate cellular identity, and speculate how these functions might be relevant during tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIpKu4D8YBLVg90H21EOLACvtfcHk0liFlo_oXoIugQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bE&md5=6ae0b0ef2360828615cd56872cb0ab3b</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fnrc1991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1991%26sid%3Dliteratum%253Aachs%26aulast%3DSparmann%26aufirst%3DA.%26aulast%3Dvan%2BLohuizen%26aufirst%3DM.%26atitle%3DPolycomb%2520Silencers%2520Control%2520Cell%2520Fate%252C%2520Development%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26issue%3D11%26spage%3D846%26epage%3D856%26doi%3D10.1038%2Fnrc1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunizaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyokawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maejima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponder, B. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, R.</span></span> <span> </span><span class="NLM_article-title">Validation of the Histone Methyltransferase EZH2 as a Therapeutic Target for Various Types of Human Cancer and as a Prognostic Marker</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1298</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2011.01958.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1111%2Fj.1349-7006.2011.01958.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21539681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2011&pages=1298-1305&issue=7&author=M.+Takawaauthor=K.+Masudaauthor=M.+Kunizakiauthor=Y.+Daigoauthor=K.+Takagiauthor=Y.+Iwaiauthor=H.-S.+Choauthor=G.+Toyokawaauthor=Y.+Yamaneauthor=K.+Maejimaauthor=H.+I.+Fieldauthor=T.+Kobayashiauthor=T.+Akasuauthor=M.+Sugiyamaauthor=E.+Tsuchiyaauthor=Y.+Atomiauthor=B.+A.+J.+Ponderauthor=Y.+Nakamuraauthor=R.+Hamamoto&title=Validation+of+the+Histone+Methyltransferase+EZH2+as+a+Therapeutic+Target+for+Various+Types+of+Human+Cancer+and+as+a+Prognostic+Marker&doi=10.1111%2Fj.1349-7006.2011.01958.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker</span></div><div class="casAuthors">Takawa, Masashi; Masuda, Ken; Kunizaki, Masaki; Daigo, Yataro; Takagi, Katsunori; Iwai, Yukiko; Cho, Hyun-Soo; Toyokawa, Gouji; Yamane, Yuka; Maejima, Kazuhiro; Field, Helen I.; Kobayashi, Takaaki; Akasu, Takayuki; Sugiyama, Masanori; Tsuchiya, Eijyu; Atomi, Yutaka; Ponder, Bruce A. J.; Nakamura, Yusuke; Hamamoto, Ryuji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1298-1305</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The emphasis in anticancer drug discovery has always been on finding a drug with great antitumor potential but few side-effects.  This can be achieved if the drug is specific for a mol. site found only in tumor cells.  Here, we find the enhancer of zeste homolog 2 (EZH2) to be highly overexpressed in lung and other cancers, and show that EZH2 is integral to proliferation in cancer cells.  Quant. real-time PCR anal. revealed higher expression of EZH2 in clin. bladder cancer tissues than in corresponding non-neoplastic tissues (P < 0.0001), and we confirmed that a wide range of cancers also overexpress EZH2, using cDNA microarray anal.  Immunohistochem. anal. showed pos. staining for EZH2 in 14 of 29 cases of bladder cancer, 135 of 292 cases of non-small-cell lung cancer (NSCLC), and 214 of 245 cases of colorectal cancer, whereas no significant staining was obsd. in various normal tissues.  We found elevated expression of EZH2 to be assocd. with poor prognosis for patients with NSCLC (P = 0.0239).  In lung and bladder cancer cells overexpressing EZH2, suppression of EZH2 using specific siRNAs inhibited incorporation of BrdU and resulted in significant suppression of cell growth, even though no significant effect was obsd. in the normal cell strain CCD-18Co, which has undetectable EZH2.  Because EZH2 expression was scarcely detectable in all normal tissues we examd., EZH2 shows promise as a tumor-specific therapeutic target.  Furthermore, as elevated levels of EZH2 are assocd. with poor prognosis of patients with NSCLC, its overexpression in resected specimens could prove a useful mol. marker, indicating the necessity for a more extensive follow-up in some lung cancer patients after surgical treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbQobKk1jwgrVg90H21EOLACvtfcHk0liFlo_oXoIugQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSiu74%253D&md5=52f1ab04ee004f5cef50db8d1297facf</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2011.01958.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2011.01958.x%26sid%3Dliteratum%253Aachs%26aulast%3DTakawa%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DKunizaki%26aufirst%3DM.%26aulast%3DDaigo%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DK.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.-S.%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DYamane%26aufirst%3DY.%26aulast%3DMaejima%26aufirst%3DK.%26aulast%3DField%26aufirst%3DH.%2BI.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAkasu%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTsuchiya%26aufirst%3DE.%26aulast%3DAtomi%26aufirst%3DY.%26aulast%3DPonder%26aufirst%3DB.%2BA.%2BJ.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DHamamoto%26aufirst%3DR.%26atitle%3DValidation%2520of%2520the%2520Histone%2520Methyltransferase%2520EZH2%2520as%2520a%2520Therapeutic%2520Target%2520for%2520Various%2520Types%2520of%2520Human%2520Cancer%2520and%2520as%2520a%2520Prognostic%2520Marker%26jtitle%3DCancer%2520Sci.%26date%3D2011%26volume%3D102%26issue%3D7%26spage%3D1298%26epage%3D1305%26doi%3D10.1111%2Fj.1349-7006.2011.01958.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasekaran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrette, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar-Sinha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewalt, R. G. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">The Polycomb Group Protein EZH2 Is Involved in Progression of Prostate Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>419</i></span> (<span class="NLM_issue">6907</span>),  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1038/nature01075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature01075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12374981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38Xns1Ontrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=419&publication_year=2002&pages=624-629&issue=6907&author=S.+Varamballyauthor=S.+M.+Dhanasekaranauthor=M.+Zhouauthor=T.+R.+Barretteauthor=C.+Kumar-Sinhaauthor=M.+G.+Sandaauthor=D.+Ghoshauthor=K.+J.+Pientaauthor=R.+G.+A.+B.+Sewaltauthor=A.+P.+Otteauthor=M.+A.+Rubinauthor=A.+M.+Chinnaiyan&title=The+Polycomb+Group+Protein+EZH2+Is+Involved+in+Progression+of+Prostate+Cancer&doi=10.1038%2Fnature01075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The polycomb group protein EZH2 is involved in progression of prostate cancer</span></div><div class="casAuthors">Varambally, Sooryanarayana; Dhanasekaran, Saravana M.; Zhou, Ming; Barrette, Terrence R.; Kumar-Sinha, Chandan; Sanda, Martin G.; Ghosh, Debashis; Pienta, Kenneth J.; Sewalt, Richard G. A. B.; Otte, Arie P.; Rubin, Mark A.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">419</span>
        (<span class="NLM_cas:issue">6907</span>),
    <span class="NLM_cas:pages">624-629</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Prostate cancer is a leading cause of cancer-related death in males and is second only to lung cancer.  Although effective surgical and radiation treatments exist for clin. localized prostate cancer, metastatic prostate cancer remains essentially incurable.  Here we show, through gene expression profiling, that the polycomb group protein enhancer of zeste homolog 2 (EZH2) is overexpressed in hormone-refractory, metastatic prostate cancer.  Small interfering RNA (siRNA) duplexes targeted against EZH2 reduce the amts. of EZH2 protein present in prostate cells and also inhibit cell proliferation in vitro.  Ectopic expression of EZH2 in prostate cells induces transcriptional repression of a specific cohort of genes.  Gene silencing mediated by EZH2 requires the SET domain and is attenuated by inhibiting histone deacetylase activity.  Amts. of both EZH2 mRNA and EZH2 protein are increased in metastatic prostate cancer; in addn., clin. localized prostate cancers that express higher concns. of EZH2 show a poorer prognosis.  Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression.  Supplementary information on the gene expression profile can be obtained at: http://www.nature.com/nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfW_h7gunzd7Vg90H21EOLACvtfcHk0lgd6sujz3WvTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xns1Ontrk%253D&md5=c38f80915b4183472aa7be4f9f3ecc67</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnature01075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01075%26sid%3Dliteratum%253Aachs%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DDhanasekaran%26aufirst%3DS.%2BM.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBarrette%26aufirst%3DT.%2BR.%26aulast%3DKumar-Sinha%26aufirst%3DC.%26aulast%3DSanda%26aufirst%3DM.%2BG.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DSewalt%26aufirst%3DR.%2BG.%2BA.%2BB.%26aulast%3DOtte%26aufirst%3DA.%2BP.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Polycomb%2520Group%2520Protein%2520EZH2%2520Is%2520Involved%2520in%2520Progression%2520of%2520Prostate%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D419%26issue%3D6907%26spage%3D624%26epage%3D629%26doi%3D10.1038%2Fnature01075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uesugi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter-Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uenaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1535-7163.MCT-13-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24563539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=842-854&issue=4&author=S.+K.+Knutsonauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=N.+M.+Warholicauthor=K.-C.+Huangauthor=Y.+Xiaoauthor=T.+Kadowakiauthor=M.+Uesugiauthor=G.+Kuznetsovauthor=N.+Kumarauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+Porter-Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=T.+Uenakaauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=A.+Yokoiauthor=H.+Keilhack&title=Selective+Inhibition+of+EZH2+by+EPZ-6438+Leads+to+Potent+Antitumor+Activity+in+EZH2-Mutant+Non-Hodgkin+Lymphoma&doi=10.1158%2F1535-7163.MCT-13-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span></div><div class="casAuthors">Knutson, Sarah K.; Kawano, Satoshi; Minoshima, Yukinori; Warholic, Natalie M.; Huang, Kuan-Chun; Xiao, Yonghong; Kadowaki, Tadashi; Uesugi, Mai; Kuznetsov, Galina; Kumar, Namita; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Waters, Nigel J.; Smith, Jesse J.; Porter-Scott, Margaret; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Uenaka, Toshimitsu; Pollock, Roy M.; Kuntz, Kevin W.; Yokoi, Akira; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-854</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL).  These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymic activity in these cancers.  We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small mol. inhibitors of EZH2.  Although both compds. are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals.  Here, we characterize the activity of EPZ-6438 in preclin. models of NHL.  EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concn.- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells.  Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations.  Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues.  Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compd. treatment in two EZH2-mutant xenograft models.  These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers.  Mol Cancer Ther; 13(4); 842-54. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2o1v5F3GzLVg90H21EOLACvtfcHk0lgd6sujz3WvTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D&md5=89354e9453dcd7430978d1a6c5ee5846</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0773%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DHuang%26aufirst%3DK.-C.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DUesugi%26aufirst%3DM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DSelective%2520Inhibition%2520of%2520EZH2%2520by%2520EPZ-6438%2520Leads%2520to%2520Potent%2520Antitumor%2520Activity%2520in%2520EZH2-Mutant%2520Non-Hodgkin%2520Lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D842%26epage%3D854%26doi%3D10.1158%2F1535-7163.MCT-13-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span> <span> </span><span class="NLM_article-title">Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9928</span>– <span class="NLM_lpage">9941</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9928-9941&issue=21&author=R.+G.+Vaswaniauthor=V.+S.+Gehlingauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=N.+Cantoneauthor=R.+T.+Cummingsauthor=E.+Normantauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=J.-C.+Harmangeauthor=P.+Trojerauthor=J.+E.+Audiaauthor=Y.+Zhangauthor=N.+Justinauthor=S.+Chenauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Identification+of+%28R%29-N-%28%284-Methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-2-methyl-1-%281-%281-%282%2C2%2C2-trifluoroethyl%29piperidin-4-yl%29ethyl%29-1H-indole-3-carboxamide+%28CPI-1205%29%2C+a+Potent+and+Selective+Inhibitor+of+Histone+Methyltransferase+EZH2%2C+Suitable+for+Phase+I+Clinical+Trials+for+B-Cell+Lymphomas&doi=10.1021%2Facs.jmedchem.6b01315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span></div><div class="casAuthors">Vaswani, Rishi G.; Gehling, Victor S.; Dakin, Les A.; Cook, Andrew S.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Cantone, Nico; Cummings, Richard T.; Normant, Emmanuel; Bellon, Steven F.; Albrecht, Brian K.; Harmange, Jean-Christophe; Trojer, Patrick; Audia, James E.; Zhang, Ying; Justin, Neil; Chen, Shuyang; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9928-9941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3.  Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis.  EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncol. target for pharmacol. intervention.  Here we report the optimization of our indole-based EZH2 inhibitor series that led to the identification of CPI-1205, a highly potent (biochem. IC50 = 0.002 μM, cellular EC50 = 0.032 μM) and selective inhibitor of EZH2.  This compd. demonstrates robust antitumor effects in a Karpas-422 xenograft model when dosed at 160 mg/kg BID and is currently in Phase I clin. trials.  Addnl., we disclose the co-crystal structure of our inhibitor series bound to the human PRC2 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqnfg3FGdE7Vg90H21EOLACvtfcHk0ljFvaCgl8eHag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I&md5=4096fa91399fef88a7ec8aabb5aaee13</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01315%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DIdentification%2520of%2520%2528R%2529-N-%2528%25284-Methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-2-methyl-1-%25281-%25281-%25282%252C2%252C2-trifluoroethyl%2529piperidin-4-yl%2529ethyl%2529-1H-indole-3-carboxamide%2520%2528CPI-1205%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Histone%2520Methyltransferase%2520EZH2%252C%2520Suitable%2520for%2520Phase%2520I%2520Clinical%2520Trials%2520for%2520B-Cell%2520Lymphomas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9928%26epage%3D9941%26doi%3D10.1021%2Facs.jmedchem.6b01315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsherniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haswell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walensky, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. W. M.</span></span> <span> </span><span class="NLM_article-title">SWI/SNF-Mutant Cancers Depend on Catalytic and Non-Catalytic Activity of EZH2</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1038/nm.3968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnm.3968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26552009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1491-1496&issue=12&author=K.+H.+Kimauthor=W.+Kimauthor=T.+P.+Howardauthor=F.+Vazquezauthor=A.+Tsherniakauthor=J.+N.+Wuauthor=W.+Wangauthor=J.+R.+Haswellauthor=L.+D.+Walenskyauthor=W.+C.+Hahnauthor=S.+H.+Orkinauthor=C.+W.+M.+Roberts&title=SWI%2FSNF-Mutant+Cancers+Depend+on+Catalytic+and+Non-Catalytic+Activity+of+EZH2&doi=10.1038%2Fnm.3968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span></div><div class="casAuthors">Kim, Kimberly H.; Kim, Woojin; Howard, Thomas P.; Vazquez, Francisca; Tsherniak, Aviad; Wu, Jennifer N.; Wang, Weishan; Haswell, Jeffrey R.; Walensky, Loren D.; Hahn, William C.; Orkin, Stuart H.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1496</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex have been shown to have bona fide tumor suppressor activity.  However, whether mutations in SWI/SNF subunits result in shared dependencies is unknown.  Here we show that EZH2, a catalytic subunit of the polycomb repressive complex 2 (PRC2), is essential in all tested cancer cell lines and xenografts harboring mutations of the SWI/SNF subunits ARID1A, PBRM1, and SMARCA4, which are several of the most frequently mutated SWI/SNF subunits in human cancer, but that co-occurrence of a Ras pathway mutation is correlated with abrogation of this dependence.  Notably, we demonstrate that SWI/SNF-mutant cancer cells are primarily dependent on a non-catalytic role of EZH2 in the stabilization of the PRC2 complex, and that they are only partially dependent on EZH2 histone methyltransferase activity.  These results not only reveal a shared dependency of cancers with genetic alterations in SWI/SNF subunits, but also suggest that EZH2 enzymic inhibitors now in clin. development may not fully suppress the oncogenic activity of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjhQKP01U5bVg90H21EOLACvtfcHk0ljFvaCgl8eHag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK&md5=a30c11fe7ce3c20e982e824105b8d640</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnm.3968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3968%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHoward%26aufirst%3DT.%2BP.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHaswell%26aufirst%3DJ.%2BR.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%2BM.%26atitle%3DSWI%252FSNF-Mutant%2520Cancers%2520Depend%2520on%2520Catalytic%2520and%2520Non-Catalytic%2520Activity%2520of%2520EZH2%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D1491%26epage%3D1496%26doi%3D10.1038%2Fnm.3968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessella, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montironi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magi-Galluzzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantoff, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>338</i></span> (<span class="NLM_issue">6113</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1469</span>, <span class="refDoi"> DOI: 10.1126/science.1227604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1227604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23239736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2012&pages=1465-1469&issue=6113&author=K.+Xuauthor=Z.+J.+Wuauthor=A.+C.+Gronerauthor=H.+H.+Heauthor=C.+Caiauthor=R.+T.+Lisauthor=X.+Wuauthor=E.+C.+Stackauthor=M.+Lodaauthor=T.+Liuauthor=H.+Xuauthor=L.+Catoauthor=J.+E.+Thorntonauthor=R.+I.+Gregoryauthor=C.+Morrisseyauthor=R.+L.+Vessellaauthor=R.+Montironiauthor=C.+Magi-Galluzziauthor=P.+W.+Kantoffauthor=S.+P.+Balkauthor=X.+S.+Liuauthor=M.+Brown&title=EZH2+Oncogenic+Activity+in+Castration-Resistant+Prostate+Cancer+Cells+Is+Polycomb-Independent&doi=10.1126%2Fscience.1227604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent</span></div><div class="casAuthors">Xu, Kexin; Wu, Zhenhua Jeremy; Groner, Anna C.; He, Housheng Hansen; Cai, Changmeng; Lis, Rosina T.; Wu, Xiaoqiu; Stack, Edward C.; Loda, Massimo; Liu, Tao; Xu, Han; Cato, Laura; Thornton, James E.; Gregory, Richard I.; Morrissey, Colm; Vessella, Robert L.; Montironi, Rodolfo; Magi-Galluzzi, Cristina; Kantoff, Philip W.; Balk, Steven P.; Liu, X. Shirley; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">6113</span>),
    <span class="NLM_cas:pages">1465-1469</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Epigenetic regulators represent a promising new class of therapeutic targets for cancer.  Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity.  We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor.  Instead, it involves the ability of EZH2 to act as a coactivator for crit. transcription factors including the androgen receptor.  This functional switch is dependent on phosphorylation of EZH2 and requires an intact methyltransferase domain.  Hence, targeting the non-PRC2 function of EZH2 may have therapeutic efficacy for treating metastatic, hormone-refractory prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOB2b-7A-UaLVg90H21EOLACvtfcHk0li5HlegPwnOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF&md5=98399f2e6a4c9b07121059772650d2d3</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1126%2Fscience.1227604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1227604%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DZ.%2BJ.%26aulast%3DGroner%26aufirst%3DA.%2BC.%26aulast%3DHe%26aufirst%3DH.%2BH.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DLis%26aufirst%3DR.%2BT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DStack%26aufirst%3DE.%2BC.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCato%26aufirst%3DL.%26aulast%3DThornton%26aufirst%3DJ.%2BE.%26aulast%3DGregory%26aufirst%3DR.%2BI.%26aulast%3DMorrissey%26aufirst%3DC.%26aulast%3DVessella%26aufirst%3DR.%2BL.%26aulast%3DMontironi%26aufirst%3DR.%26aulast%3DMagi-Galluzzi%26aufirst%3DC.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DEZH2%2520Oncogenic%2520Activity%2520in%2520Castration-Resistant%2520Prostate%2520Cancer%2520Cells%2520Is%2520Polycomb-Independent%26jtitle%3DScience%26date%3D2012%26volume%3D338%26issue%3D6113%26spage%3D1465%26epage%3D1469%26doi%3D10.1126%2Fscience.1227604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, J. L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, S.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W.-J.</span></span> <span> </span><span class="NLM_article-title">EZH2 Overexpression in Natural Killer/T-Cell Lymphoma Confers Growth Advantage Independently of Histone Methyltransferase Activity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4512</span>– <span class="NLM_lpage">4520</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-08-450494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1182%2Fblood-2012-08-450494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23529930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFGrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=4512-4520&issue=22&author=J.+Yanauthor=S.-B.+Ngauthor=J.+L.-S.+Tayauthor=B.+Linauthor=T.+L.+Kohauthor=J.+Tanauthor=V.+Selvarajanauthor=S.-C.+Liuauthor=C.+Biauthor=S.+Wangauthor=S.-N.+Chooauthor=N.+Shimizuauthor=G.+Huangauthor=Q.+Yuauthor=W.-J.+Chng&title=EZH2+Overexpression+in+Natural+Killer%2FT-Cell+Lymphoma+Confers+Growth+Advantage+Independently+of+Histone+Methyltransferase+Activity&doi=10.1182%2Fblood-2012-08-450494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity</span></div><div class="casAuthors">Yan, Junli; Ng, Siok-Bian; Tay, Jim Liang-Seah; Lin, Baohong; Koh, Tze Loong; Tan, Joy; Selvarajan, Viknesvaran; Liu, Shaw-Cheng; Bi, Chonglei; Wang, Shi; Choo, Shoa-Nian; Shimizu, Norio; Huang, Gaofeng; Yu, Qiang; Chng, Wee-Joo</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4512-4520</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The role of enhancer of zeste homolog 2 (EZH2) in cancer is complex and may vary depending on the cellular context.  We found that EZH2 is aberrantly overexpressed in the majority of natural killer/T-cell lymphoma (NKTL), an aggressive lymphoid malignancy with very poor prognosis.  We show that EZH2 upregulation is mediated by MYC-induced repression of its regulatory micro RNAs and EZH2 exerts oncogenic properties in NKTL.  Ectopic expression of EZH2 in both primary NK cells and NKTL cell lines leads to a significant growth advantage.  Conversely, knock-down of EZH2 in NKTL cell lines results in cell growth inhibition.  Intriguingly, ectopic EZH2 mutant deficient for histone methyltransferase activity is also able to confer growth advantage and rescue growth inhibition on endogenous EZH2 depletion in NKTL cells, indicating an oncogenic role of EZH2 independent of its gene-silencing activity.  Mechanistically, we show that EZH2 directly promotes the transcription of cyclin D1 and this effect is independent of its enzymic activity.  Furthermore, depletion of EZH2 using a PRC2 inhibitor 3-deazaneplanocin A significantly inhibits growth of NK tumor cells.  Therefore, our study uncovers an oncogenic role of EZH2 independent of its methyltransferase activity in NKTL and suggests that targeting EZH2 may have therapeutic usefulness in this lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocRlqv_dn0TrVg90H21EOLACvtfcHk0li5HlegPwnOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFGrs7c%253D&md5=ae998d8ef1d728645988fe7e8ca5fe74</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-08-450494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-08-450494%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DS.-B.%26aulast%3DTay%26aufirst%3DJ.%2BL.-S.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DKoh%26aufirst%3DT.%2BL.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DSelvarajan%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DS.-C.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChoo%26aufirst%3DS.-N.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DChng%26aufirst%3DW.-J.%26atitle%3DEZH2%2520Overexpression%2520in%2520Natural%2520Killer%252FT-Cell%2520Lymphoma%2520Confers%2520Growth%2520Advantage%2520Independently%2520of%2520Histone%2520Methyltransferase%2520Activity%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26issue%3D22%26spage%3D4512%26epage%3D4520%26doi%3D10.1182%2Fblood-2012-08-450494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bate-Eya, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gierman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versteeg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolman, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenaar, J. J.</span></span> <span> </span><span class="NLM_article-title">Enhancer of Zeste Homologue 2 Plays an Important Role in Neuroblastoma Cell Survival Independent of Its Histone Methyltransferase Activity</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejca.2016.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28214660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1eru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2017&pages=63-72&author=L.+T.+Bate-Eyaauthor=H.+J.+Giermanauthor=M.+E.+Ebusauthor=J.+Kosterauthor=H.+N.+Caronauthor=R.+Versteegauthor=M.+E.+M.+Dolmanauthor=J.+J.+Molenaar&title=Enhancer+of+Zeste+Homologue+2+Plays+an+Important+Role+in+Neuroblastoma+Cell+Survival+Independent+of+Its+Histone+Methyltransferase+Activity&doi=10.1016%2Fj.ejca.2016.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity</span></div><div class="casAuthors">Bate-Eya, Laurel T.; Gierman, Hinco J.; Ebus, Marli E.; Koster, Jan; Caron, Huib N.; Versteeg, Rogier; Dolman, M. Emmy M.; Molenaar, Jan J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Neuroblastoma is predominantly characterized by chromosomal rearrangements.  Next to V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) amplification, chromosome 7 and 17q gains are frequently obsd.  We identified a neuroblastoma patient with a regional 7q36 gain, encompassing the enhancer of zeste homolog 2 (EZH2) gene.  EZH2 is the histone methyltransferase of lysine 27 of histone H3 (H3K27me3) that forms the catalytic subunit of the polycomb repressive complex 2.  H3K27me3 is commonly assocd. with the silencing of genes involved in cellular processes such as cell cycle regulation, cellular differentiation and cancer.  High EZH2 expression correlated with poor prognosis and overall survival independent of MYCN amplification status.  Unexpectedly, treatment of 3 EZH2-high expressing neuroblastoma cell lines (IMR32, CHP134 and NMB), with EZH2-specific inhibitors (GSK126 and EPZ6438) resulted in only a slight G1 arrest, despite max. histone methyltransferase activity inhibition.  Furthermore, colony formation in cell lines treated with the inhibitors was reduced only at concns. much higher than necessary for complete inhibition of EZH2 histone methyltransferase activity.  Knockdown of the complete protein with three independent shRNAs resulted in a strong apoptotic response and decreased cyclin D1 levels.  This apoptotic response could be rescued by overexpressing EZH2ΔSET, a truncated form of wild-type EZH2 lacking the SET transactivation domain necessary for histone methyltransferase activity.  Our findings suggest that high EZH2 expression, at least in neuroblastoma, has a survival function independent of its methyltransferase activity.  This important finding highlights the need for studies on EZH2 beyond its methyltransferase function and the requirement for compds. that will target EZH2 as a complete protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPeYIEEK1oFLVg90H21EOLACvtfcHk0lhpQ7VLZt6DJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1eru70%253D&md5=65cbff2c51dc7c1af9d96cbeaf12cf11</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DBate-Eya%26aufirst%3DL.%2BT.%26aulast%3DGierman%26aufirst%3DH.%2BJ.%26aulast%3DEbus%26aufirst%3DM.%2BE.%26aulast%3DKoster%26aufirst%3DJ.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DVersteeg%26aufirst%3DR.%26aulast%3DDolman%26aufirst%3DM.%2BE.%2BM.%26aulast%3DMolenaar%26aufirst%3DJ.%2BJ.%26atitle%3DEnhancer%2520of%2520Zeste%2520Homologue%25202%2520Plays%2520an%2520Important%2520Role%2520in%2520Neuroblastoma%2520Cell%2520Survival%2520Independent%2520of%2520Its%2520Histone%2520Methyltransferase%2520Activity%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D75%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.ejca.2016.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Gambogenic Acid Mediated Apoptosis Through the Mitochondrial Oxidative Stress and Inactivation of Akt Signaling Pathway in Human Nasopharyngeal Carcinoma CNE-1 Cells</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>652</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejphar.2010.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21118682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1KjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=652&publication_year=2011&pages=23-32&issue=1%E2%80%933&author=F.+Yanauthor=M.+Wangauthor=H.+Chenauthor=J.+Suauthor=X.+Wangauthor=F.+Wangauthor=L.+Xiaauthor=Q.+Li&title=Gambogenic+Acid+Mediated+Apoptosis+Through+the+Mitochondrial+Oxidative+Stress+and+Inactivation+of+Akt+Signaling+Pathway+in+Human+Nasopharyngeal+Carcinoma+CNE-1+Cells&doi=10.1016%2Fj.ejphar.2010.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Gambogenic acid mediated apoptosis through the mitochondrial oxidative stress and inactivation of Akt signaling pathway in human nasopharyngeal carcinoma CNE-1 cells</span></div><div class="casAuthors">Yan, Fenggen; Wang, Mei; Chen, Hui; Su, Jingjing; Wang, Xiaoshan; Wang, Fei; Xia, Lunzhu; Li, Qinglin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">652</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">23-32</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the present study, Gambogenic acid exhibits potential anti-tumor activity in several cancer cell lines.  However, Gambogenic acid-induced apoptosis mechanism is not well understood.  Here, we report that Gambogenic acid was capable to induce CNE-1 cells apoptosis and caused mitochondrial and endoplasmic reticulum injury, analyzed via transmission electron microscopy and acridine orange/ethidium bromide (AO/EB) double staining.  To quant. analyze apoptosis, through the propidium iodide (PI)/Annexin V-FITC double staining to detect cell apoptosis, PI staining of the cell cycle distribution.  To further explore the potential mechanism of Gambogenic acid mediated apoptosis in CNE-1 cells, we also examd. mitochondrial oxidative stress in the levels of reactive oxygen species, the release of cytochrome c, intracellular Ca2+ concn. and mitochondrial membrane potential by flow cytometry.  Moreover, Gambogenic acid could result in a time and concn.-dependent decrease in Phospho-Akt expression, basal expression levels of Akt change was not obvious.  In addn., we detected Bcl-2 family including Bcl-2, Bax and Bad expression in mRNA level.  His resulted in a decrease of Bcl-2 and Bad increased in CNE-1 cells after Gambogenic acid treatment.  These results indicated that Gambogenic acid mediated apoptosis through inactivation of Akt, accompanied with mitochondrial oxidative stress and cross-talk with Bcl-2 family in the process of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG-m-NbeyCqbVg90H21EOLACvtfcHk0lhpQ7VLZt6DJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1KjtA%253D%253D&md5=748af88184d75b0a5d2bbcf8dba5f12c</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DGambogenic%2520Acid%2520Mediated%2520Apoptosis%2520Through%2520the%2520Mitochondrial%2520Oxidative%2520Stress%2520and%2520Inactivation%2520of%2520Akt%2520Signaling%2520Pathway%2520in%2520Human%2520Nasopharyngeal%2520Carcinoma%2520CNE-1%2520Cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D652%26issue%3D1%25E2%2580%25933%26spage%3D23%26epage%3D32%26doi%3D10.1016%2Fj.ejphar.2010.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.-B.</span></span> <span> </span><span class="NLM_article-title">Gambogenic Acid Induces G1 Arrest via GSK3β-Dependent Cyclin D1 Degradation and Triggers Autophagy in Lung Cancer Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>322</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2012.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.canlet.2012.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22410463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlWktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2012&pages=185-194&issue=2&author=X.-J.+Yuauthor=Q.-B.+Hanauthor=Z.-S.+Wenauthor=L.+Maauthor=J.+Gaoauthor=G.-B.+Zhou&title=Gambogenic+Acid+Induces+G1+Arrest+via+GSK3%CE%B2-Dependent+Cyclin+D1+Degradation+and+Triggers+Autophagy+in+Lung+Cancer+Cells&doi=10.1016%2Fj.canlet.2012.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells</span></div><div class="casAuthors">Yu, Xian-Jun; Han, Quan-Bin; Wen, Zhe-Sheng; Ma, Liang; Gao, Jin; Zhou, Guang-Biao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-194</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cyclin D1, an oncogenic G1 cyclin which can be induced by environmental carcinogens and whose over-expression may cause dysplasia and carcinoma, has been shown to be a target for cancer chemoprevention and therapy.  In this study, we investigated the effects and underlying mechanisms of action of a polyprenylated xanthone, gambogenic acid (GEA) on gefitinib-sensitive and -resistant lung cancer cells.  We found that GEA inhibited proliferation, caused G1 arrest and repressed colony-forming activity of lung cancer cells.  GEA induced degrdn. of cyclin D1 via the proteasome pathway, and triggered dephosphorylation of GSK3β which was required for cyclin D1 turnover, because GSK3β inactivation by its inhibitor or specific siRNA markedly attenuated GEA-caused cyclin D1 catabolism.  GEA induced autophagy of lung cancer cells, possibly due to activation of GSK3β and inactivation of AKT/mTOR signal pathway.  These results indicate that GEA is a cyclin D1 inhibitor and a GSK3β activator which may have chemopreventive and therapeutic potential for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUmIKBcLV1Y7Vg90H21EOLACvtfcHk0lhpQ7VLZt6DJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlWktr8%253D&md5=f48a013835a7f7296534d418f3109d58</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DX.-J.%26aulast%3DHan%26aufirst%3DQ.-B.%26aulast%3DWen%26aufirst%3DZ.-S.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DG.-B.%26atitle%3DGambogenic%2520Acid%2520Induces%2520G1%2520Arrest%2520via%2520GSK3%25CE%25B2-Dependent%2520Cyclin%2520D1%2520Degradation%2520and%2520Triggers%2520Autophagy%2520in%2520Lung%2520Cancer%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D322%26issue%3D2%26spage%3D185%26epage%3D194%26doi%3D10.1016%2Fj.canlet.2012.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pietra, A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquenne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span> <span> </span><span class="NLM_article-title">EZH2 Inhibition as a Therapeutic Strategy for Lymphoma with EZH2-Activating Mutations</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span> (<span class="NLM_issue">7427</span>),  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/nature11606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature11606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23051747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=108-112&issue=7427&author=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+Ganjiauthor=S.+Korenchukauthor=C.+Thompsonauthor=G.+S.+Van+Allerauthor=Y.+Liuauthor=A.+P.+Gravesauthor=A.+Della+Pietraauthor=E.+Diazauthor=L.+V.+LaFranceauthor=M.+Mellingerauthor=C.+Duquenneauthor=X.+Tianauthor=R.+G.+Krugerauthor=C.+F.+McHughauthor=M.+Brandtauthor=W.+H.+Millerauthor=D.+Dhanakauthor=S.+K.+Vermaauthor=P.+J.+Tumminoauthor=C.+L.+Creasy&title=EZH2+Inhibition+as+a+Therapeutic+Strategy+for+Lymphoma+with+EZH2-Activating+Mutations&doi=10.1038%2Fnature11606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span></div><div class="casAuthors">McCabe, Michael T.; Ott, Heidi M.; Ganji, Gopinath; Korenchuk, Susan; Thompson, Christine; Van Aller, Glenn S.; Liu, Yan; Graves, Alan P.; Della Pietra, Anthony , III; Diaz, Elsie; LaFrance, Louis V.; Mellinger, Mark; Duquenne, Celine; Tian, Xinrong; Kruger, Ryan G.; McHugh, Charles F.; Brandt, Martin; Miller, William H.; Dhanak, Dashyant; Verma, Sharad K.; Tummino, Peter J.; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7427</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In eukaryotes, post-translational modification of histones is crit. for regulation of chromatin structure and gene expression.  EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).  EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumor types.  Addnl., somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.  The Y641 residue is the most frequently mutated residue, with up to 22% of germinal center B-cell DLBCL and follicular lymphoma harbouring mutations at this site.  These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes.  However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas.  Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-mol. inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.  GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice.  Together, these data demonstrate that pharmacol. inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxw5cLmW3Lc7Vg90H21EOLACvtfcHk0lhmcrN77bVZOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL&md5=a1dff99556de004c48aae88bc45dffab</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnature11606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11606%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DMellinger%26aufirst%3DM.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DEZH2%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Lymphoma%2520with%2520EZH2-Activating%2520Mutations%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7427%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature11606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grantner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamphavong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01375</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01375" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=650-665&issue=3&author=P.-P.+Kungauthor=P.+Binghamauthor=A.+Broounauthor=M.+Collinsauthor=Y.-L.+Dengauthor=D.+Dinhauthor=C.+Fanauthor=K.+S.+Gajiwalaauthor=R.+Grantnerauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=R.+Kaniaauthor=S.+E.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=P.+Khamphavongauthor=M.+Krausauthor=W.+Liuauthor=K.+A.+Maegleyauthor=L.+Nguyenauthor=S.+Renauthor=D.+Richterauthor=R.+A.+Rollinsauthor=N.+Sachauthor=S.+Sharmaauthor=J.+Sherrillauthor=J.+Spanglerauthor=A.+E.+Stewartauthor=S.+Suttonauthor=S.+Uryuauthor=D.+Verhelleauthor=H.+Wangauthor=S.+Wangauthor=M.+Wythesauthor=S.+Xinauthor=S.+Yamazakiauthor=H.+Zhuauthor=J.+Zhuauthor=L.+Zehnderauthor=M.+Edwards&title=Optimization+of+Orally+Bioavailable+Enhancer+of+Zeste+Homolog+2+%28EZH2%29+Inhibitors+Using+Ligand+and+Property-Based+Design+Strategies%3A+Identification+of+Development+Candidate+%28R%29-5%2C8-Dichloro-7-%28methoxy%28oxetan-3-yl%29methyl%29-2-%28%284-methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-3%2C4-dihydroisoquinolin-1%282H%29-one+%28PF-06821497%29&doi=10.1021%2Facs.jmedchem.7b01375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)</span></div><div class="casAuthors">Kung, Pei-Pei; Bingham, Patrick; Brooun, Alexei; Collins, Michael; Deng, Ya-Li; Dinh, Dac; Fan, Connie; Gajiwala, Ketan S.; Grantner, Rita; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kania, Robert; Kephart, Susan E.; Krivacic, Cody; Kumpf, Robert A.; Khamphavong, Penney; Kraus, Manfred; Liu, Wei; Maegley, Karen A.; Nguyen, Lisa; Ren, Shijian; Richter, Dan; Rollins, Robert A.; Sach, Neal; Sharma, Shikhar; Sherrill, John; Spangler, Jillian; Stewart, Albert E.; Sutton, Scott; Uryu, Sean; Verhelle, Dominique; Wang, Hui; Wang, Shuiwang; Wythes, Martin; Xin, Shuibo; Yamazaki, Shinji; Zhu, Huichun; Zhu, JinJiang; Zehnder, Luke; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochem.-property-based strategies to address metabolic stability and thermodn. soly. issues assocd. with previous lead compd. (I).  The new inhibitors incorporated an Sp3 hybridized carbon atom at the 7-position of the lactam moiety present in lead compd. (I) as a replacement for a dimethylisoxazole group.  This transformation enabled optimization of the physicochem. properties and potency compared to compd. (I).  Anal. of relationships between calcd. log D (clogD) values and in vitro metabolic stability and permeability parameters identified a clogD range that afforded an increased probability of achieving favorable ADME data in a single mol.  Compd. 23a (5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one) exhibited the best overlap of potency and pharmaceutical properties as well as robust tumor growth inhibition in vivo and was therefore advanced as a development candidate (PF-06821497).  A crystal structure of 23a in complex with the three-protein PRC2 complex enabled understanding of the key structural features required for optimal binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro0-Aa0AZgXLVg90H21EOLACvtfcHk0lhmcrN77bVZOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF&md5=96ff75b96f5eea2dc82013a6bad8096b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01375%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DGrantner%26aufirst%3DR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DKhamphavong%26aufirst%3DP.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSherrill%26aufirst%3DJ.%26aulast%3DSpangler%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520Orally%2520Bioavailable%2520Enhancer%2520of%2520Zeste%2520Homolog%25202%2520%2528EZH2%2529%2520Inhibitors%2520Using%2520Ligand%2520and%2520Property-Based%2520Design%2520Strategies%253A%2520Identification%2520of%2520Development%2520Candidate%2520%2528R%2529-5%252C8-Dichloro-7-%2528methoxy%2528oxetan-3-yl%2529methyl%2529-2-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2520%2528PF-06821497%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1021%2Facs.jmedchem.7b01375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, J. M.</span></span> <span> </span><span class="NLM_article-title">Amplification of N-Myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>224</i></span> (<span class="NLM_issue">4653</span>),  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1126/science.6719137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.6719137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=6719137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADyaL2c7ps1Chtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1984&pages=1121-1124&issue=4653&author=G.+M.+Brodeurauthor=R.+C.+Seegerauthor=M.+Schwabauthor=H.+E.+Varmusauthor=J.+M.+Bishop&title=Amplification+of+N-Myc+in+Untreated+Human+Neuroblastomas+Correlates+with+Advanced+Disease+Stage&doi=10.1126%2Fscience.6719137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage</span></div><div class="casAuthors">Brodeur G M; Seeger R C; Schwab M; Varmus H E; Bishop J M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">4653</span>),
    <span class="NLM_cas:pages">1121-4</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A domain of DNA designated N-myc is amplified 20- to 140-fold in human neuroblastoma cell lines but not in cell lines from other tumor types.  N-myc has now been found to be amplified in neuroblastoma tissue from 24 of 63 untreated patients (38 percent).  The extent of amplification appears to be bimodal, with amplification of 100- to 300-fold in 12 cases and 3- to 10-fold in 10 others.  Amplification was found in 0 of 15 patients with stage 1 or 2 disease, whereas 24 of 48 cases (50 percent) with stage 3 or 4 had evidence of N-myc amplification.  These data indicate that N-myc amplification is a common event in untreated human neuroblastomas.  Furthermore, N-myc amplification is highly correlated with advanced stages of disease (P less than 0.001) and with the ability to grow in vitro as an established cell line, both of which are associated with a poor prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ87Kw6s8IBfftos8R3JUhXfW6udTcc2eZDCZY7gjgWO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7ps1Chtw%253D%253D&md5=8920f3fcf76f0f8ae977a839a36c04b0</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1126%2Fscience.6719137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6719137%26sid%3Dliteratum%253Aachs%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DSeeger%26aufirst%3DR.%2BC.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26aulast%3DBishop%26aufirst%3DJ.%2BM.%26atitle%3DAmplification%2520of%2520N-Myc%2520in%2520Untreated%2520Human%2520Neuroblastomas%2520Correlates%2520with%2520Advanced%2520Disease%2520Stage%26jtitle%3DScience%26date%3D1984%26volume%3D224%26issue%3D4653%26spage%3D1121%26epage%3D1124%26doi%3D10.1126%2Fscience.6719137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Boussard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibshirani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span> <span> </span><span class="NLM_article-title">Combined Microarray Analysis of Small Cell Lung Cancer Reveals Altered Apoptotic Balance and Distinct Expression Signatures of MYC Family Gene Amplification</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fsj.onc.1208997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16116477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1aqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=130-138&issue=1&author=Y.+H.+Kimauthor=L.+Girardauthor=C.+P.+Giacominiauthor=P.+Wangauthor=T.+Hernandez-Boussardauthor=R.+Tibshiraniauthor=J.+D.+Minnaauthor=J.+R.+Pollack&title=Combined+Microarray+Analysis+of+Small+Cell+Lung+Cancer+Reveals+Altered+Apoptotic+Balance+and+Distinct+Expression+Signatures+of+MYC+Family+Gene+Amplification&doi=10.1038%2Fsj.onc.1208997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification</span></div><div class="casAuthors">Kim, Y. H.; Girard, L.; Giacomini, C. P.; Wang, P.; Hernandez-Boussard, T.; Tibshirani, R.; Minna, J. D.; Pollack, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNA amplifications and deletions frequently contribute to the development and progression of lung cancer.  To identify such novel alterations in small cell lung cancer (SCLC), we performed comparative genomic hybridization on a set of 24 SCLC cell lines, using cDNA microarrays representing ∼22 000 human genes (providing an av. mapping resoln. of <70 kb).  We identified localized DNA amplifications corresponding to oncogenes known to be amplified in SCLC, including MYC (8q24), MYCN (2p24) and MYCL1 (1p34).  Addnl. highly localized DNA amplifications suggested candidate oncogenes not previously identified as amplified in SCLC, including the antiapoptotic genes TNFRSF4 (1p36), DAD1 (14q11), BCL2L1 (20q11) and BCL2L2 (14q11).  Likewise, newly discovered PCR-validated homozygous deletions suggested candidate tumor-suppressor genes, including the proapoptotic genes MAPK10 (4q21) and TNFRSF6 (10q23).  To characterize the effect of DNA amplification on gene expression patterns, we performed expression profiling using the same microarray platform.  Among our findings, we identified sets of genes whose expression correlated with MYC, MYCN or MYCL1 amplification, with surprisingly little overlap among gene sets.  While both MYC and MYCN amplification were assocd. with increased and decreased expression of known MYC upregulated and downregulated targets, resp., MYCL1 amplification was assocd. only with the latter.  Our findings support a role of altered apoptotic balance in the pathogenesis of SCLC, and suggest that MYC family genes might affect oncogenesis through distinct sets of targets, in particular implicating the importance of transcriptional repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3f-J9j1ltm7Vg90H21EOLACvtfcHk0lhhJkUFSbVzVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1aqtA%253D%253D&md5=daf5611f8a6112ed9fee6732bc34a670</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208997%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DGiacomini%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DHernandez-Boussard%26aufirst%3DT.%26aulast%3DTibshirani%26aufirst%3DR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26atitle%3DCombined%2520Microarray%2520Analysis%2520of%2520Small%2520Cell%2520Lung%2520Cancer%2520Reveals%2520Altered%2520Apoptotic%2520Balance%2520and%2520Distinct%2520Expression%2520Signatures%2520of%2520MYC%2520Family%2520Gene%2520Amplification%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26issue%3D1%26spage%3D130%26epage%3D138%26doi%3D10.1038%2Fsj.onc.1208997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, H.</span></span> <span> </span><span class="NLM_article-title">The N-Myc Oncogene: Maximizing Its Targets, Regulation, and Therapeutic Potential</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-13-0536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1541-7786.MCR-13-0536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24589438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1CnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=815-822&issue=6&author=H.+Beltran&title=The+N-Myc+Oncogene%3A+Maximizing+Its+Targets%2C+Regulation%2C+and+Therapeutic+Potential&doi=10.1158%2F1541-7786.MCR-13-0536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential</span></div><div class="casAuthors">Beltran, Himisha</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">815-822</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  N-myc (MYCN), a member of the Myc family of basic-helix-loop-helix-zipper (bHLHZ) transcription factors, is a central regulator of many vital cellular processes.  As such, N-myc is well recognized for its classic oncogenic activity and assocn. with human neuroblastoma.  Amplification and overexpression of N-myc has been described in other tumor types, particularly those of neural origin and neuroendocrine tumors.  This review outlines N-myc's contribution to normal development and oncogenic progression.  In addn., it highlights relevant transcriptional targets and mechanisms of regulation.  Finally, the clin. implications of N-Myc as a biomarker and potential as a target using novel therapeutic approaches are discussed.  Mol Cancer Res; 12(6); 815-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx2j7fn-LpjbVg90H21EOLACvtfcHk0lhhJkUFSbVzVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1CnsLs%253D&md5=7fb6fcb690297043775e378e1a5b7c00</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-13-0536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-13-0536%26sid%3Dliteratum%253Aachs%26aulast%3DBeltran%26aufirst%3DH.%26atitle%3DThe%2520N-Myc%2520Oncogene%253A%2520Maximizing%2520Its%2520Targets%252C%2520Regulation%252C%2520and%2520Therapeutic%2520Potential%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2014%26volume%3D12%26issue%3D6%26spage%3D815%26epage%3D822%26doi%3D10.1158%2F1541-7786.MCR-13-0536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span> <span> </span><span class="NLM_article-title">Myc Proteins as Therapeutic Targets</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fonc.2009.512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20101214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=1249-1259&issue=9&author=W.+C.+Gustafsonauthor=W.+A.+Weiss&title=Myc+Proteins+as+Therapeutic+Targets&doi=10.1038%2Fonc.2009.512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Myc proteins as therapeutic targets</span></div><div class="casAuthors">Gustafson, W. C.; Weiss, W. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1249-1259</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Myc proteins (c-myc, Mycn and Mycl) target proliferative and apoptotic pathways vital for progression in cancer.  Amplification of the MYCN gene has emerged as one of the clearest indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the most common extracranial solid tumor of childhood.  Phosphorylation and ubiquitin-mediated modulation of Myc protein influence stability and represent potential targets for therapeutic intervention.  Phosphorylation of Myc proteins is controlled in-part by the receptor tyrosine kinase/phosphatidylinositol 3-kinase/Akt/mTOR signaling, with addnl. contributions from Aurora A kinase.  Myc proteins regulate apoptosis in part through interactions with the p53/Mdm2/Arf signaling pathway.  Mutation in p53 is commonly obsd. in patients with relapsed neuroblastoma, contributing to both biol. and therapeutic resistance.  This review examines Myc function and regulation in neuroblastoma, and discusses emerging therapies that target Mycn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0CvK5-9-gzbVg90H21EOLACvtfcHk0lhhJkUFSbVzVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yltr0%253D&md5=e6c015a47fb88c9735b78057d9f7adb3</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.512%26sid%3Dliteratum%253Aachs%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DMyc%2520Proteins%2520as%2520Therapeutic%2520Targets%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26issue%3D9%26spage%3D1249%26epage%3D1259%26doi%3D10.1038%2Fonc.2009.512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitfield, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodir, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massó-Vallés, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnezis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swigart, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evan, G. I.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Myc Family Proteins Eradicates KRas-Driven Lung Cancer in Mice</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1101/gad.205542.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1101%2Fgad.205542.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23475959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVKkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=504-513&issue=5&author=L.+Soucekauthor=J.+R.+Whitfieldauthor=N.+M.+Sodirauthor=D.+Mass%C3%B3-Vall%C3%A9sauthor=E.+Serranoauthor=A.+N.+Karnezisauthor=L.+B.+Swigartauthor=G.+I.+Evan&title=Inhibition+of+Myc+Family+Proteins+Eradicates+KRas-Driven+Lung+Cancer+in+Mice&doi=10.1101%2Fgad.205542.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice</span></div><div class="casAuthors">Soucek, Laura; Whitfield, Jonathan R.; Sodir, Nicole M.; Masso-Valles, Daniel; Serrano, Erika; Karnezis, Anthony N.; Swigart, Lamorna Brown; Evan, Gerard I.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">504-513</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The principal reason for failure of targeted cancer therapies is the emergence of resistant clones that regenerate the tumor.  Therapeutic efficacy therefore depends on not only how effectively a drug inhibits its target, but also the innate or adaptive functional redundancy of that target and its attendant pathway.  In this regard, the Myc transcription factors are intriguing therapeutic targets because they serve the unique and irreplaceable role of coordinating expression of the many diverse genes that, together, are required for somatic cell proliferation.  Furthermore, Myc expression is deregulated in most-perhaps all-cancers, underscoring its irreplaceable role in proliferation.  We previously showed in a preclin. mouse model of non-small-cell lung cancer that systemic Myc inhibition using the dominant-neg. Myc mutant Omomyc exerts a dramatic therapeutic impact, triggering rapid regression of tumors with only mild and fully reversible side effects.  Using protracted episodic expression of Omomyc, we now demonstrate that metronomic Myc inhibition not only contains Ras-driven lung tumors indefinitely, but also leads to their progressive eradication.  Hence, Myc does indeed serve a unique and nondegenerate role in lung tumor maintenance that cannot be complemented by any adaptive mechanism, even in the most aggressive p53-deficient tumors.  These data endorse Myc as a compelling cancer drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfpivJKOSErbVg90H21EOLACvtfcHk0lhhJkUFSbVzVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVKkurY%253D&md5=0fc5aa1a0223f4b09da3e7bf114bdc56</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1101%2Fgad.205542.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.205542.112%26sid%3Dliteratum%253Aachs%26aulast%3DSoucek%26aufirst%3DL.%26aulast%3DWhitfield%26aufirst%3DJ.%2BR.%26aulast%3DSodir%26aufirst%3DN.%2BM.%26aulast%3DMass%25C3%25B3-Vall%25C3%25A9s%26aufirst%3DD.%26aulast%3DSerrano%26aufirst%3DE.%26aulast%3DKarnezis%26aufirst%3DA.%2BN.%26aulast%3DSwigart%26aufirst%3DL.%2BB.%26aulast%3DEvan%26aufirst%3DG.%2BI.%26atitle%3DInhibition%2520of%2520Myc%2520Family%2520Proteins%2520Eradicates%2520KRas-Driven%2520Lung%2520Cancer%2520in%2520Mice%26jtitle%3DGenes%2520Dev.%26date%3D2013%26volume%3D27%26issue%3D5%26spage%3D504%26epage%3D513%26doi%3D10.1101%2Fgad.205542.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Myc</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1177/1947601910377494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1177%2F1947601910377494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21132100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyisb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=650-659&issue=6&author=E.+V.+Prochownikauthor=P.+K.+Vogt&title=Therapeutic+Targeting+of+Myc&doi=10.1177%2F1947601910377494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Myc</span></div><div class="casAuthors">Prochownik, Edward V.; Vogt, Peter K.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-659</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions between members of the Myc transcription factor network are potential targets of small mol. inhibitors and stabilizers.  Diverse screening strategies-including fluorescence resonance energy transfer, fluorescence polarization, 2-hybrid, and protein complementation assays-have identified several lead compds. that inhibit Myc-Max dimerization and one compd. that stabilizes the Max homodimer.  Representative compds. interfere with Myc-induced transcriptional activation, Myc-mediated oncogenic transformation, Myc-driven cellular replication, and DNA binding of Myc.  For the best-characterized compds., specific binding sites have been detd., and mol. mechanisms of action have been documented.  This knowledge of small mol.-protein interaction is currently applied to highly targeted approaches to identify novel compds. with improved potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYWOjlKJxaTLVg90H21EOLACvtfcHk0lgQNuMkH1NjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyisb7O&md5=25cac1ccda841463f58131a7c385b095</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1177%2F1947601910377494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910377494%26sid%3Dliteratum%253Aachs%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Myc%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26issue%3D6%26spage%3D650%26epage%3D659%26doi%3D10.1177%2F1947601910377494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjostrom, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowitch, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, A. M.</span></span> <span> </span><span class="NLM_article-title">The Cdk1 Complex Plays a Prime Role in Regulating N-Myc Phosphorylation and Turnover in Neural Precursors</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2005.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.devcel.2005.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16139224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVert77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=327-338&issue=3&author=S.+K.+Sjostromauthor=G.+Finnauthor=W.+C.+Hahnauthor=D.+H.+Rowitchauthor=A.+M.+Kenney&title=The+Cdk1+Complex+Plays+a+Prime+Role+in+Regulating+N-Myc+Phosphorylation+and+Turnover+in+Neural+Precursors&doi=10.1016%2Fj.devcel.2005.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors</span></div><div class="casAuthors">Sjostrom, Sarah K.; Finn, Greg; Hahn, William C.; Rowitch, David H.; Kenney, Anna Marie</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-338</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Myc family transcription factors are destabilized by phosphorylation of a conserved amino-terminal GSK-3β motif.  In proliferating cerebellar granule neuron precursors (CGNPs), Sonic hedgehog signaling induces N-myc expression, and N-myc protein is stabilized by insulin-like growth factor-mediated suppression of GSK-3β.  N-myc phosphorylation-mediated degrdn. is a prerequisite for CGNP growth arrest and differentiation.  We investigated whether N-myc phosphorylation and turnover are thus linked to cell cycle exit in primary mouse CGNP cultures and the developing cerebellum.  We report that phosphorylation-induced turnover of endogenous N-myc protein in CGNPs increases during mitosis, due to increased priming phosphorylation of N-myc for GSK-3β.  The priming phosphorylation requires the Cdk1 complex, whose cyclin subunits are indirect Sonic hedgehog targets.  These findings provide a mechanism for promoting growth arrest in the final cycle of neural precursor proliferation competency, or for resetting the cell cycle in the G1 phase, by destabilizing N-myc in mitosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE2jHlwpZfZLVg90H21EOLACvtfcHk0lgQNuMkH1NjsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVert77O&md5=d64628f5d9e5b5c3de55a64d34a2c355</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2005.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2005.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DSjostrom%26aufirst%3DS.%2BK.%26aulast%3DFinn%26aufirst%3DG.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DRowitch%26aufirst%3DD.%2BH.%26aulast%3DKenney%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Cdk1%2520Complex%2520Plays%2520a%2520Prime%2520Role%2520in%2520Regulating%2520N-Myc%2520Phosphorylation%2520and%2520Turnover%2520in%2520Neural%2520Precursors%26jtitle%3DDev.%2520Cell%26date%3D2005%26volume%3D9%26issue%3D3%26spage%3D327%26epage%3D338%26doi%3D10.1016%2Fj.devcel.2005.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Barrueco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, J.</span></span> <span> </span><span class="NLM_article-title">MYC Is a Critical Target of FBXW7</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">3292</span>– <span class="NLM_lpage">3305</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.18632%2Foncotarget.3203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25669969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrktlymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=3292-3305&issue=5&author=M.+Satoauthor=R.+Rodriguez-Barruecoauthor=J.+Yuauthor=C.+Doauthor=J.+M.+Silvaauthor=J.+Gautier&title=MYC+Is+a+Critical+Target+of+FBXW7&doi=10.18632%2Foncotarget.3203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">MYC is a critical target of FBXW7</span></div><div class="casAuthors">Sato Mai; Silva Jose M; Sato Mai; Rodriguez-Barrueco Ruth; Do Catherine; Silva Jose M; Gautier Jean; Rodriguez-Barrueco Ruth; Silva Jose M; Yu Jiyang; Gautier Jean</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3292-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MYC deregulation is a driver of many human cancers.  Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumorigenic phenotype.  While direct targeting of MYC is difficult, specific genetic vulnerabilities of MYC-deregulated cells could be exploited to selectively inhibit their growth.  Using a genome-wide shRNA screen, we identified 78 candidate genes, which are required for survival of human mammary epithelial cells with elevated MYC levels.  Among the candidates, we validated and characterized FBXW7, a component of the SCF-like ubiquitin ligase complex that targets MYC for proteasomal degradation.  Down-regulation of FBXW7 leads to synergistic accumulation of cellular and active chromatin-bound MYC, while protein levels of other FBXW7 targets appear unaffected.  Over a four-week time course, continuous FBXW7 down-regulation and MYC activation together cause an accumulation of cells in S-phase and G2/M-phase of the cell cycle.  Under these conditions, we also observe elevated chromatin-bound levels of CDC45, suggesting increased DNA replication stress.  Consistent with these results, FBXW7 down-regulation alone decreases the survival of T47D breast cancer cells.  These results establish that FBXW7 down-regulation is synthetic lethal with MYC, and that MYC is a critical target of FBXW7 in breast epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbGTerAThFYJQHPYJuLg8TfW6udTcc2eZvRI_hOQVaXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrktlymsg%253D%253D&md5=106e6e5dc6d87b8b637bfd334b30a475</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3203%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%26aulast%3DRodriguez-Barrueco%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DJ.%2BM.%26aulast%3DGautier%26aufirst%3DJ.%26atitle%3DMYC%2520Is%2520a%2520Critical%2520Target%2520of%2520FBXW7%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D3292%26epage%3D3305%26doi%3D10.18632%2Foncotarget.3203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüttrumpf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berwanger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span> <span> </span><span class="NLM_article-title">Stabilization of N-Myc Is a Critical Function of Aurora a in Human Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2008.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19111882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=67-78&issue=1&author=T.+Ottoauthor=S.+Hornauthor=M.+Brockmannauthor=U.+Eilersauthor=L.+Sch%C3%BCttrumpfauthor=N.+Popovauthor=A.+M.+Kenneyauthor=J.+H.+Schulteauthor=R.+Beijersbergenauthor=H.+Christiansenauthor=B.+Berwangerauthor=M.+Eilers&title=Stabilization+of+N-Myc+Is+a+Critical+Function+of+Aurora+a+in+Human+Neuroblastoma&doi=10.1016%2Fj.ccr.2008.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma</span></div><div class="casAuthors">Otto, Tobias; Horn, Sebastian; Brockmann, Markus; Eilers, Ursula; Schuettrumpf, Lars; Popov, Nikita; Kenney, Anna Marie; Schulte, Johannes H.; Beijersbergen, Roderick; Christiansen, Holger; Berwanger, Bernd; Eilers, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-78</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">In human neuroblastoma, amplification of the MYCN gene predicts poor prognosis and resistance to therapy.  In a shRNA screen of genes that are highly expressed in MYCN-amplified tumors, the authors have identified AURKA as a gene that is required for the growth of MYCN-amplified neuroblastoma cells but largely dispensable for cells lacking amplified MYCN.  Aurora A has a crit. function in regulating turnover of the N-Myc protein.  Degrdn. of N-Myc requires sequential phosphorylation by cyclin B/Cdk1 and Gsk3.  N-Myc is therefore degraded during mitosis in response to low levels of PI3-kinase activity.  Aurora A interacts with both N-Myc and the SCFFbxw7 ubiquitin ligase that ubiquitinates N-Myc and counteracts degrdn. of N-Myc, thereby uncoupling N-Myc stability from growth factor-dependent signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7Wf4DMtd3SLVg90H21EOLACvtfcHk0ljkaRC9nr-mdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptVKjsw%253D%253D&md5=954b16742a6a512725a003e602add047</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DT.%26aulast%3DHorn%26aufirst%3DS.%26aulast%3DBrockmann%26aufirst%3DM.%26aulast%3DEilers%26aufirst%3DU.%26aulast%3DSch%25C3%25BCttrumpf%26aufirst%3DL.%26aulast%3DPopov%26aufirst%3DN.%26aulast%3DKenney%26aufirst%3DA.%2BM.%26aulast%3DSchulte%26aufirst%3DJ.%2BH.%26aulast%3DBeijersbergen%26aufirst%3DR.%26aulast%3DChristiansen%26aufirst%3DH.%26aulast%3DBerwanger%26aufirst%3DB.%26aulast%3DEilers%26aufirst%3DM.%26atitle%3DStabilization%2520of%2520N-Myc%2520Is%2520a%2520Critical%2520Function%2520of%2520Aurora%2520a%2520in%2520Human%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D15%26issue%3D1%26spage%3D67%26epage%3D78%26doi%3D10.1016%2Fj.ccr.2008.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brockmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rycak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roels, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Aurora-a Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2013.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23792191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVymurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=75-89&issue=1&author=M.+Brockmannauthor=E.+Poonauthor=T.+Berryauthor=A.+Carstensenauthor=H.+E.+Deubzerauthor=L.+Rycakauthor=Y.+Jaminauthor=K.+Thwayauthor=S.+P.+Robinsonauthor=F.+Roelsauthor=O.+Wittauthor=M.+Fischerauthor=L.+Cheslerauthor=M.+Eilers&title=Small+Molecule+Inhibitors+of+Aurora-a+Induce+Proteasomal+Degradation+of+N-Myc+in+Childhood+Neuroblastoma&doi=10.1016%2Fj.ccr.2013.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma</span></div><div class="casAuthors">Brockmann, Markus; Poon, Evon; Berry, Teeara; Carstensen, Anne; Deubzer, Hedwig E.; Rycak, Lukas; Jamin, Yann; Thway, Khin; Robinson, Simon P.; Roels, Frederik; Witt, Olaf; Fischer, Matthias; Chesler, Louis; Eilers, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-89</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors, including neuroblastoma.  No small mols. that target N-Myc, the protein encoded by MYCN, are clin. available.  N-Myc forms a complex with the Aurora-A kinase, which protects N-Myc from proteasomal degrdn.  Although stabilization of N-Myc does not require the catalytic activity of Aurora-A, we show here that 2 Aurora-A inhibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-Myc complex and promote degrdn. of N-Myc mediated by the Fbxw7 ubiquitin ligase.  Disruption of the Aurora-A/N-Myc complex inhibits N-Myc-dependent transcription, correlating with tumor regression and prolonged survival in a mouse model of MYCN-driven neuroblastoma.  We conclude that Aurora-A is an accessible target that makes destabilization of N-Myc a viable therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09vD68WUraLVg90H21EOLACvtfcHk0ljkaRC9nr-mdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVymurY%253D&md5=0b53df3d2aaaad8c9a46c07e06227b2c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBrockmann%26aufirst%3DM.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DBerry%26aufirst%3DT.%26aulast%3DCarstensen%26aufirst%3DA.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DRycak%26aufirst%3DL.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DThway%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DRoels%26aufirst%3DF.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DEilers%26aufirst%3DM.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Aurora-a%2520Induce%2520Proteasomal%2520Degradation%2520of%2520N-Myc%2520in%2520Childhood%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D24%26issue%3D1%26spage%3D75%26epage%3D89%26doi%3D10.1016%2Fj.ccr.2013.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecsedy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meetze, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balani, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burenkova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeRoy, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sells, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysong, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of MLN8054, an Orally Active Small-Molecule Inhibitor of Aurora a Kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4106</span>– <span class="NLM_lpage">4111</span>, <span class="refDoi"> DOI: 10.1073/pnas.0608798104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.0608798104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17360485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=4106-4111&issue=10&author=M.+G.+Manfrediauthor=J.+A.+Ecsedyauthor=K.+A.+Meetzeauthor=S.+K.+Balaniauthor=O.+Burenkovaauthor=W.+Chenauthor=K.+M.+Galvinauthor=K.+M.+Hoarauthor=J.+J.+Huckauthor=P.+J.+LeRoyauthor=E.+T.+Rayauthor=T.+B.+Sellsauthor=B.+Stringerauthor=S.+G.+Stroudauthor=T.+J.+Vosauthor=G.+S.+Weatherheadauthor=D.+R.+Wysongauthor=M.+Zhangauthor=J.+B.+Bolenauthor=C.+F.+Claiborne&title=Antitumor+Activity+of+MLN8054%2C+an+Orally+Active+Small-Molecule+Inhibitor+of+Aurora+a+Kinase&doi=10.1073%2Fpnas.0608798104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase</span></div><div class="casAuthors">Manfredi, Mark G.; Ecsedy, Jeffrey A.; Meetze, Kristan A.; Balani, Suresh K.; Burenkova, Olga; Chen, Wei; Galvin, Katherine M.; Hoar, Kara M.; Huck, Jessica J.; LeRoy, Patrick J.; Ray, Emily T.; Sells, Todd B.; Stringer, Bradley; Stroud, Stephen G.; Vos, Tricia J.; Weatherhead, Gabriel S.; Wysong, Deborah R.; Zhang, Mengkun; Bolen, Joseph B.; Claiborne, Christopher F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4106-4111</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Increased Aurora A expression occurs in a variety of human cancers and induces chromosomal abnormalities during mitosis assocd. with tumor initiation and progression.  MLN8054 is a selective small-mol. Aurora A kinase inhibitor that has entered Phase I clin. trials for advanced solid tumors.  MLN8054 inhibits recombinant Aurora A kinase activity in vitro and is selective for Aurora A over the family member Aurora B in cultured cells.  MLN8054 treatment results in G2/M accumulation and spindle defects and inhibits proliferation in multiple cultured human tumor cells lines.  Growth of human tumor xenografts in nude mice was dramatically inhibited after oral administration of MLN8054 at well tolerated doses.  Moreover, the tumor growth inhibition was sustained after discontinuing MLN8054 treatment.  In human tumor xenografts, MLN8054 induced mitotic accumulation and apoptosis, phenotypes consistent with inhibition of Aurora A.  MLN8054 is a selective inhibitor of Aurora A kinase that robustly inhibits growth of human tumor xenografts and represents an attractive modality for therapeutic intervention of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLXnsHNqFuS7Vg90H21EOLACvtfcHk0ljkaRC9nr-mdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12nu7o%253D&md5=1c0cace58d13fa5ea5e3c0340a7c7f36</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0608798104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0608798104%26sid%3Dliteratum%253Aachs%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DEcsedy%26aufirst%3DJ.%2BA.%26aulast%3DMeetze%26aufirst%3DK.%2BA.%26aulast%3DBalani%26aufirst%3DS.%2BK.%26aulast%3DBurenkova%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DGalvin%26aufirst%3DK.%2BM.%26aulast%3DHoar%26aufirst%3DK.%2BM.%26aulast%3DHuck%26aufirst%3DJ.%2BJ.%26aulast%3DLeRoy%26aufirst%3DP.%2BJ.%26aulast%3DRay%26aufirst%3DE.%2BT.%26aulast%3DSells%26aufirst%3DT.%2BB.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DStroud%26aufirst%3DS.%2BG.%26aulast%3DVos%26aufirst%3DT.%2BJ.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DWysong%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26atitle%3DAntitumor%2520Activity%2520of%2520MLN8054%252C%2520an%2520Orally%2520Active%2520Small-Molecule%2520Inhibitor%2520of%2520Aurora%2520a%2520Kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26issue%3D10%26spage%3D4106%26epage%3D4111%26doi%3D10.1073%2Fpnas.0608798104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sloane, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikic, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M. L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M. B. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span> <span> </span><span class="NLM_article-title">Drug-Resistant Aurora a Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1021/cb100053q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100053q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVaktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=563-576&issue=6&author=D.+A.+Sloaneauthor=M.+Z.+Trikicauthor=M.+L.+H.+Chuauthor=M.+B.+A.+C.+Lamersauthor=C.+S.+Masonauthor=I.+Muellerauthor=W.+J.+Savoryauthor=D.+H.+Williamsauthor=P.+A.+Eyers&title=Drug-Resistant+Aurora+a+Mutants+for+Cellular+Target+Validation+of+the+Small+Molecule+Kinase+Inhibitors+MLN8054+and+MLN8237&doi=10.1021%2Fcb100053q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237</span></div><div class="casAuthors">Sloane, Dominic A.; Trikic, Michael Z.; Chu, Matthew L. H.; Lamers, Maria B. A. C.; Mason, Clive S.; Mueller, Ilka; Savory, Wendy J.; Williams, David H.; Eyers, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">563-576</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Aurora kinases regulate multiple aspects of mitotic progression, and their overexpression in diverse tumor types makes them appealing oncol. targets.  An intensive research effort over the past decade has led to the discovery of chem. distinct families of small mol. Aurora kinase inhibitors, many of which have demonstrated therapeutic potential in model systems.  These agents are also important tools to help dissect signaling pathways that are orchestrated by Aurora kinases, and the antiproliferative target of pan-Aurora inhibitors such as VX-680 has been validated using chem. genetic techniques.  In many cases the nonspecific nature of Aurora inhibitors toward unrelated kinases is well established, potentially broadening the spectrum of cancers to which these compds. might be applied.  However, unambiguously demonstrating the mol. target(s) for clin. kinase inhibitors is an important challenge, one that is absolutely crit. for deciphering the mol. basis of compd. specificity, resistance, and efficacy.  In this paper, we have investigated amino acid requirements for Aurora A sensitivity to the benzazepine-based Aurora inhibitor MLN8054 and the close analog MLN8237, a second-generation compd. that is in phase II clin. trials.  A crystallog. anal. facilitated the design and biochem. investigation of a panel of resistant Aurora A mutants, a subset of which were then selected as candidate drug-resistance targets for further evaluation.  Using inducible human cell lines, we show that cells expressing near-physiol. levels of a functional but partially drug-resistant Aurora A T217D mutant survive in the presence of MLN8054 or MLN8237, authenticating Aurora A as a crit. antiproliferative target of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjg-t6yjgWhLVg90H21EOLACvtfcHk0lijWWFQIR5vHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVaktbs%253D&md5=f20bc2f2f827fd8f640570078d6505c6</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fcb100053q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100053q%26sid%3Dliteratum%253Aachs%26aulast%3DSloane%26aufirst%3DD.%2BA.%26aulast%3DTrikic%26aufirst%3DM.%2BZ.%26aulast%3DChu%26aufirst%3DM.%2BL.%2BH.%26aulast%3DLamers%26aufirst%3DM.%2BB.%2BA.%2BC.%26aulast%3DMason%26aufirst%3DC.%2BS.%26aulast%3DMueller%26aufirst%3DI.%26aulast%3DSavory%26aufirst%3DW.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26atitle%3DDrug-Resistant%2520Aurora%2520a%2520Mutants%2520for%2520Cellular%2520Target%2520Validation%2520of%2520the%2520Small%2520Molecule%2520Kinase%2520Inhibitors%2520MLN8054%2520and%2520MLN8237%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2010%26volume%3D5%26issue%3D6%26spage%3D563%26epage%3D576%26doi%3D10.1021%2Fcb100053q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrash, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavetsias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of an Aurora-a Mutant That Mimics Aurora-B Bound to MLN8054: Insights Into Selectivity and Drug Design</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>427</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1042/BJ20091530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBJ20091530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20067443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2010&pages=19-28&issue=1&author=C.+A.+Dodsonauthor=M.+Kosmopoulouauthor=M.+W.+Richardsauthor=B.+Atrashauthor=V.+Bavetsiasauthor=J.+Blaggauthor=R.+Bayliss&title=Crystal+Structure+of+an+Aurora-a+Mutant+That+Mimics+Aurora-B+Bound+to+MLN8054%3A+Insights+Into+Selectivity+and+Drug+Design&doi=10.1042%2FBJ20091530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design</span></div><div class="casAuthors">Dodson, Charlotte A.; Kosmopoulou, Magda; Richards, Mark W.; Atrash, Butrus; Bavetsias, Vassilios; Blagg, Julian; Bayliss, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">427</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-28</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The prodn. of selective protein kinase inhibitors is often frustrated by the similarity of the enzyme active sites.  For this reason, it is challenging to design inhibitors that discriminate between the three Aurora kinases, which are important targets in cancer drug discovery.  We have used a triple-point mutant of Aurora-A (AurAx3) which mimics the active site of Aurora-B to investigate the structural basis of MLN8054 selectivity.  The bias toward Aurora-A inhibition by MLN8054 is fully recapitulated by AurAx3 in vitro.  X-ray crystal structures of the complex suggest that the basis for the discrimination is electrostatic repulsion due to the T217E substitution, which we have confirmed using a single-point mutant.  The activation loop of Aurora-A in the AurAx3-MLN8054 complex exhibits an unusual conformation in which Asp274 and Phe275 side chains point into the interior of the protein.  There is to our knowledge no documented precedent for this conformation, which we have termed DFG-up.  The sequence requirements of the DFG-up conformation suggest that it might be accessible to only a fraction of kinases.  MLN8054 thus circumvents the problem of highly homologous active sites.  Binding of MLN8054 to Aurora-A switches the character of a pocket within the active site from polar to a hydrophobic pocket, similar to what is obsd. in the structure of Aurora-A bound to a compd. that induces DFG-out.  We propose that targeting this pocket may be a productive route in the design of selective kinase inhibitors and describe the structural basis for the rational design of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdJs5KY2VkabVg90H21EOLACvtfcHk0lijWWFQIR5vHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyntr8%253D&md5=fdf1a176a5fdf5fcd71fd57c3ef92817</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1042%2FBJ20091530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20091530%26sid%3Dliteratum%253Aachs%26aulast%3DDodson%26aufirst%3DC.%2BA.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DRichards%26aufirst%3DM.%2BW.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520an%2520Aurora-a%2520Mutant%2520That%2520Mimics%2520Aurora-B%2520Bound%2520to%2520MLN8054%253A%2520Insights%2520Into%2520Selectivity%2520and%2520Drug%2520Design%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D427%26issue%3D1%26spage%3D19%26epage%3D28%26doi%3D10.1042%2FBJ20091530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerowitz, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekritz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonds, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthay, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertz, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span> <span> </span><span class="NLM_article-title">Drugging MYCN Through an Allosteric Transition in Aurora Kinase a</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2014.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25175806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKmsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=414-427&issue=3&author=W.+C.+Gustafsonauthor=J.+G.+Meyerowitzauthor=E.+A.+Nekritzauthor=J.+Chenauthor=C.+Benesauthor=E.+Charronauthor=E.+F.+Simondsauthor=R.+Seegerauthor=K.+K.+Matthayauthor=N.+T.+Hertzauthor=M.+Eilersauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=Drugging+MYCN+Through+an+Allosteric+Transition+in+Aurora+Kinase+a&doi=10.1016%2Fj.ccr.2014.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging MYCN through an Allosteric Transition in Aurora Kinase A</span></div><div class="casAuthors">Gustafson, William Clay; Meyerowitz, Justin Gabriel; Nekritz, Erin A.; Chen, Justin; Benes, Cyril; Charron, Elise; Simonds, Erin F.; Seeger, Robert; Matthay, Katherine K.; Hertz, Nicholas T.; Eilers, Martin; Shokat, Kevan M.; Weiss, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">414-427</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">MYC proteins are major drivers of cancer, yet are considered undruggable because their DNA binding domains are composed of two extended alpha helixes with no apparent surfaces for small-mol. binding.  Proteolytic degrdn. of MYCN protein is regulated in part by a kinase-independent function of Aurora A.  We describe a class of inhibitors that disrupts the native conformation of Aurora A and drives the degrdn. of MYCN protein across MYCN-driven cancers.  Comparison of cocrystal structures with structure-activity relationships across multiple inhibitors and chemotypes, coupled with mechanistic studies and biochem. assays, delineates an Aurora A conformation-specific effect on proteolytic degrdn. of MYCN, rather than simple nanomolar-level inhibition of Aurora A kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8At2LNPE-ubVg90H21EOLACvtfcHk0lgops78L5Dr3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKmsLnJ&md5=20944894851fe5466422c149a0a0b266</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26aulast%3DMeyerowitz%26aufirst%3DJ.%2BG.%26aulast%3DNekritz%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DCharron%26aufirst%3DE.%26aulast%3DSimonds%26aufirst%3DE.%2BF.%26aulast%3DSeeger%26aufirst%3DR.%26aulast%3DMatthay%26aufirst%3DK.%2BK.%26aulast%3DHertz%26aufirst%3DN.%2BT.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DDrugging%2520MYCN%2520Through%2520an%2520Allosteric%2520Transition%2520in%2520Aurora%2520Kinase%2520a%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D3%26spage%3D414%26epage%3D427%26doi%3D10.1016%2Fj.ccr.2014.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, L. H.</span></span> <span> </span><span class="NLM_article-title">The Design, Synthesis, and Evaluation of 8 Hybrid DFG-Out Allosteric Kinase Inhibitors: a Structural Analysis of the Binding Interactions of Gleevec, Nexavar, and BIRB-796</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5738</span>– <span class="NLM_lpage">5748</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmc.2010.05.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20621496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5738-5748&issue=15&author=J.+Dietrichauthor=C.+Hulmeauthor=L.+H.+Hurley&title=The+Design%2C+Synthesis%2C+and+Evaluation+of+8+Hybrid+DFG-Out+Allosteric+Kinase+Inhibitors%3A+a+Structural+Analysis+of+the+Binding+Interactions+of+Gleevec%2C+Nexavar%2C+and+BIRB-796&doi=10.1016%2Fj.bmc.2010.05.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796</span></div><div class="casAuthors">Dietrich, Justin; Hulme, Christopher; Hurley, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5738-5748</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The majority of kinase inhibitors developed to date are competitive inhibitors that target the ATP binding site; however, recent crystal structures of Gleevec (imatinib mesylate, STI571, PDB: 1IEP), Nexavar (Sorafenib tosylate, BAY 43-9006, PDB: 1UWJ), and BIRB-796 (PDB: 1KV2) have revealed a secondary binding site adjacent to the ATP binding site known as the DFG-out allosteric binding site.  The recent successes of Gleevec and Nexavar for the treatment of chronic myeloid leukemia and renal cell carcinoma has generated great interest in the development of other kinase inhibitors that target this secondary binding site.  Here, we present a structural comparison of the important and similar interactions necessary for Gleevec, Nexavar, and BIRB-796 to bind to their resp. DFG-out allosteric binding pockets and the selectivity of each with respect to c-Abl, B-Raf, and p38α.  A structural anal. of their selectivity profiles has been generated from the synthesis and evaluation of 8 addnl. DFG-out allosteric inhibitors that were developed directly from fragments of these successful scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuTXCEZCwd0bVg90H21EOLACvtfcHk0lgops78L5Dr3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGhu7s%253D&md5=430e5d3c95213441b17030a931f6e2ad</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.063%26sid%3Dliteratum%253Aachs%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DHulme%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DThe%2520Design%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%25208%2520Hybrid%2520DFG-Out%2520Allosteric%2520Kinase%2520Inhibitors%253A%2520a%2520Structural%2520Analysis%2520of%2520the%2520Binding%2520Interactions%2520of%2520Gleevec%252C%2520Nexavar%252C%2520and%2520BIRB-796%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D15%26spage%3D5738%26epage%3D5748%26doi%3D10.1016%2Fj.bmc.2010.05.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filomia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rienzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menziani, M. C.</span></span> <span> </span><span class="NLM_article-title">Insights Into MAPK p38α DFG Flip Mechanism by Accelerated Molecular Dynamics</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">6805</span>– <span class="NLM_lpage">6812</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmc.2010.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20724167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamt7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6805-6812&issue=18&author=F.+Filomiaauthor=F.+De+Rienzoauthor=M.+C.+Menziani&title=Insights+Into+MAPK+p38%CE%B1+DFG+Flip+Mechanism+by+Accelerated+Molecular+Dynamics&doi=10.1016%2Fj.bmc.2010.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into MAPK p38α DFG flip mechanism by accelerated molecular dynamics</span></div><div class="casAuthors">Filomia, Federico; De Rienzo, Francesca; Menziani, M. Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6805-6812</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The DFG motif at the beginning of the activation loop of the MAPK p38α undergoes a local structural reorganization upon binding of allosteric type-II and type-III inhibitors, which causes the residue F169 to move from a buried conformation (defined as DFG-in) to a solvent exposed conformation (defined as DFG-out).  Although both exptl. and computer simulation studies had been performed with the aim of unveiling the details of the DFG-in to DFG-out transition, the mol. mechanism is still far from being unequivocally depicted.  Here, the accelerated mol. dynamics (AMD) technique has been applied to model the active loop flexibility of p38α and sample special protein conformations which can be accessible only in some conditions or time periods.  Starting from the assumption of an exptl. known initial and final state of the protein, the study allowed the description of the interaction network and the structural intermediates which lead the protein to change its loop conformation and active site accessibility.  Besides a few important hydrogen bond interactions, a primary role seems to be played by cation-π interactions, involving the DFG-loop residue F169, which participate in the stabilization of an intermediate conformation and in its consequent transition to the DFG-out conformation.  From this study, insights which may prove useful for inhibitor design and/or site directed mutagenesis studies are derived.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJP0YSfTC6D7Vg90H21EOLACvtfcHk0lgops78L5Dr3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamt7%252FJ&md5=f938ad724335525311f9531ba4528e77</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DFilomia%26aufirst%3DF.%26aulast%3DDe%2BRienzo%26aufirst%3DF.%26aulast%3DMenziani%26aufirst%3DM.%2BC.%26atitle%3DInsights%2520Into%2520MAPK%2520p38%25CE%25B1%2520DFG%2520Flip%2520Mechanism%2520by%2520Accelerated%2520Molecular%2520Dynamics%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D18%26spage%3D6805%26epage%3D6812%26doi%3D10.1016%2Fj.bmc.2010.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyerowitz, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span> <span> </span><span class="NLM_article-title">A New “Angle” on Kinase Inhibitor Design: Prioritizing Amphosteric Activity Above Kinase Inhibition</span>. <i>Mol. Cell. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e975641</span>, <span class="refDoi"> DOI: 10.4161/23723556.2014.975641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.4161%2F23723556.2014.975641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27308435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=e975641&issue=2&author=J.+G.+Meyerowitzauthor=W.+A.+Weissauthor=W.+C.+Gustafson&title=A+New+%E2%80%9CAngle%E2%80%9D+on+Kinase+Inhibitor+Design%3A+Prioritizing+Amphosteric+Activity+Above+Kinase+Inhibition&doi=10.4161%2F23723556.2014.975641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above Aurora kinase A inhibition</span></div><div class="casAuthors">Meyerowitz, Justin G.; Weiss, William A.; Gustafson, W. Clay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e975641/1-e975641/3</span>CODEN:
                <span class="NLM_cas:coden">MCOOCO</span>;
        ISSN:<span class="NLM_cas:issn">2372-3556</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The MYCN oncoprotein has remained an elusive target for decades.  We recently reported a new class of kinase inhibitors designed to disrupt the conformation of Aurora kinase A enough to block its kinase-independent interaction with MYCN, resulting in potent degrdn. of MYCN.  These studies provide proof-of-principle for a new method of targeting enzyme activity-independent functions of kinases and other enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT0fnQuBQMpbVg90H21EOLACvtfcHk0lgops78L5Dr3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWqu7w%253D&md5=46174a42a5bb5e2ce73b69c7f030bcde</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.4161%2F23723556.2014.975641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F23723556.2014.975641%26sid%3Dliteratum%253Aachs%26aulast%3DMeyerowitz%26aufirst%3DJ.%2BG.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26atitle%3DA%2520New%2520%25E2%2580%259CAngle%25E2%2580%259D%2520on%2520Kinase%2520Inhibitor%2520Design%253A%2520Prioritizing%2520Amphosteric%2520Activity%2520Above%2520Kinase%2520Inhibition%26jtitle%3DMol.%2520Cell.%2520Oncol.%26date%3D2015%26volume%3D2%26issue%3D2%26spage%3De975641%26doi%3D10.4161%2F23723556.2014.975641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerres, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischerauer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flotzinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kölle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancia, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischerikow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mück, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peinsipp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varecka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss-Puxbaum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span> <span> </span><span class="NLM_article-title">Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2860</span>– <span class="NLM_lpage">2875</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.08.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.celrep.2017.08.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28930682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=2860-2875&issue=12&author=N.+Kerresauthor=S.+Steurerauthor=S.+Schlagerauthor=G.+Baderauthor=H.+Bergerauthor=M.+Caligiuriauthor=C.+Dankauthor=J.+R.+Engenauthor=P.+Ettmayerauthor=B.+Fischerauerauthor=G.+Flotzingerauthor=D.+Gerlachauthor=T.+Gerstbergerauthor=T.+Gmaschitzauthor=P.+Grebauthor=B.+Hanauthor=E.+Heyesauthor=R.+E.+Iacobauthor=D.+Kesslerauthor=H.+K%C3%B6lleauthor=L.+Lamarreauthor=D.+R.+Lanciaauthor=S.+Lucasauthor=M.+Mayerauthor=K.+Mayrauthor=N.+Mischerikowauthor=K.+M%C3%BCckauthor=C.+Peinsippauthor=O.+Petermannauthor=U.+Reiserauthor=D.+Rudolphauthor=K.+Rumpelauthor=C.+Salomonauthor=D.+Scharnauthor=R.+Schnitzerauthor=A.+Schrenkauthor=N.+Schweiferauthor=D.+Thompsonauthor=E.+Traxlerauthor=R.+Vareckaauthor=T.+Vossauthor=A.+Weiss-Puxbaumauthor=S.+Winklerauthor=X.+Zhengauthor=A.+Zoephelauthor=N.+Krautauthor=D.+McConnellauthor=M.+Pearsonauthor=M.+Koegl&title=Chemically+Induced+Degradation+of+the+Oncogenic+Transcription+Factor+BCL6&doi=10.1016%2Fj.celrep.2017.08.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6</span></div><div class="casAuthors">Kerres, Nina; Steurer, Steffen; Schlager, Stefanie; Bader, Gerd; Berger, Helmut; Caligiuri, Maureen; Dank, Christian; Engen, John R.; Ettmayer, Peter; Fischerauer, Bernhard; Flotzinger, Gerlinde; Gerlach, Daniel; Gerstberger, Thomas; Gmaschitz, Teresa; Greb, Peter; Han, Bingsong; Heyes, Elizabeth; Iacob, Roxana E.; Kessler, Dirk; Koelle, Heike; Lamarre, Lyne; Lancia, David R.; Lucas, Simon; Mayer, Moriz; Mayr, Katharina; Mischerikow, Nikolai; Mueck, Katja; Peinsipp, Christoph; Petermann, Oliver; Reiser, Ulrich; Rudolph, Dorothea; Rumpel, Klaus; Salomon, Carina; Scharn, Dirk; Schnitzer, Renate; Schrenk, Andreas; Schweifer, Norbert; Thompson, Diane; Traxler, Elisabeth; Varecka, Roland; Voss, Tilman; Weiss-Puxbaum, Alexander; Winkler, Sandra; Zheng, Xiaozhang; Zoephel, Andreas; Kraut, Norbert; McConnell, Darryl; Pearson, Mark; Koegl, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2860-2875</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL).  Disruption of its interaction with transcriptional repressors interferes with the oncogenic effects of BCL6.  We used a structure-based drug design to develop highly potent compds. that block this interaction.  A subset of these inhibitors also causes rapid ubiquitylation and degrdn. of BCL6 in cells.  These compds. display significantly stronger induction of expression of BCL6-repressed genes and anti-proliferative effects than compds. that merely inhibit co-repressor interactions.  This work establishes the BTB domain as a highly druggable structure, paving the way for the use of other members of this protein family as drug targets.  The magnitude of effects elicited by this class of BCL6-degrading compds. exceeds that of our equipotent non-degrading inhibitors, suggesting opportunities for the development of BCL6-based lymphoma therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfmjxa_7LnrVg90H21EOLACvtfcHk0liA1jOSfy4J1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsrfK&md5=45b538db6643abbd5b8f3fa04770a772</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.08.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.08.081%26sid%3Dliteratum%253Aachs%26aulast%3DKerres%26aufirst%3DN.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DSchlager%26aufirst%3DS.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFischerauer%26aufirst%3DB.%26aulast%3DFlotzinger%26aufirst%3DG.%26aulast%3DGerlach%26aufirst%3DD.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHeyes%26aufirst%3DE.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DKessler%26aufirst%3DD.%26aulast%3DK%25C3%25B6lle%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLancia%26aufirst%3DD.%2BR.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DMayr%26aufirst%3DK.%26aulast%3DMischerikow%26aufirst%3DN.%26aulast%3DM%25C3%25BCck%26aufirst%3DK.%26aulast%3DPeinsipp%26aufirst%3DC.%26aulast%3DPetermann%26aufirst%3DO.%26aulast%3DReiser%26aufirst%3DU.%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DRumpel%26aufirst%3DK.%26aulast%3DSalomon%26aufirst%3DC.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DVarecka%26aufirst%3DR.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DWeiss-Puxbaum%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DMcConnell%26aufirst%3DD.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DKoegl%26aufirst%3DM.%26atitle%3DChemically%2520Induced%2520Degradation%2520of%2520the%2520Oncogenic%2520Transcription%2520Factor%2520BCL6%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D20%26issue%3D12%26spage%3D2860%26epage%3D2875%26doi%3D10.1016%2Fj.celrep.2017.08.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purushottamachar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbole, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gediya, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasaitis, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwegyir-Afful, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ates-Alagoz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njar, V. C. O.</span></span> <span> </span><span class="NLM_article-title">Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone to Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4880</span>– <span class="NLM_lpage">4898</span>, <span class="refDoi"> DOI: 10.1021/jm400048v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400048v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVeis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4880-4898&issue=12&author=P.+Purushottamacharauthor=A.+M.+Godboleauthor=L.+K.+Gediyaauthor=M.+S.+Martinauthor=T.+S.+Vasaitisauthor=A.+K.+Kwegyir-Affulauthor=S.+Ramalingamauthor=Z.+Ates-Alagozauthor=V.+C.+O.+Njar&title=Systematic+Structure+Modifications+of+Multitarget+Prostate+Cancer+Drug+Candidate+Galeterone+to+Produce+Novel+Androgen+Receptor+Down-Regulating+Agents+as+an+Approach+to+Treatment+of+Advanced+Prostate+Cancer&doi=10.1021%2Fjm400048v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer</span></div><div class="casAuthors">Purushottamachar, Puranik; Godbole, Abhijit M.; Gediya, Lalji K.; Martin, Marlena S.; Vasaitis, Tadas S.; Kwegyir-Afful, Andrew K.; Ramalingam, Senthilmurugan; Ates-Alagoz, Zeynep; Njar, Vincent C. O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4880-4898</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of the authors' program to explore the influence of small structural modifications of the authors' drug candidate 3β-(hydroxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (galeterone) on the modulation of the androgen receptor (AR), the authors have prepd. and evaluated a series of novel C-3, C-16, and C-17 analogs.  Using structure activity anal., the authors established that the benzimidazole moiety at C-17 is essential and optimal and also that hydrophilic and heteroarom. groups at C-3 enhance both antiproliferative (AP) and AR degrading (ARD) activities.  The most potent antiproliferative compds. were 3β-(1H-imidazole-1-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene, 3-((EZ)-hydroximino)-17-(1H-benzimidazol-1-yl)androsta-4,16-diene, and 3β-(pyridine-4-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene, with GIC50 values of 0.87, 1.91, and 2.57 μM, resp.  Compared to galeterone, 3β-(1H-imidazole-1-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene was 4- and 8-fold more potent with respect to AP and ARD activities, resp.  Importantly, the authors also discovered that the compds. listed above could degrade both full-length and truncated ARs in CWR22rv1 human prostate cancer cells.  With these activities, they have potential for development as new drugs for the treatment of all forms of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0mOnJvfkXYbVg90H21EOLACvtfcHk0liA1jOSfy4J1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVeis7s%253D&md5=b54990d661614231dc8c3b10f8b6f804</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Fjm400048v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400048v%26sid%3Dliteratum%253Aachs%26aulast%3DPurushottamachar%26aufirst%3DP.%26aulast%3DGodbole%26aufirst%3DA.%2BM.%26aulast%3DGediya%26aufirst%3DL.%2BK.%26aulast%3DMartin%26aufirst%3DM.%2BS.%26aulast%3DVasaitis%26aufirst%3DT.%2BS.%26aulast%3DKwegyir-Afful%26aufirst%3DA.%2BK.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DAtes-Alagoz%26aufirst%3DZ.%26aulast%3DNjar%26aufirst%3DV.%2BC.%2BO.%26atitle%3DSystematic%2520Structure%2520Modifications%2520of%2520Multitarget%2520Prostate%2520Cancer%2520Drug%2520Candidate%2520Galeterone%2520to%2520Produce%2520Novel%2520Androgen%2520Receptor%2520Down-Regulating%2520Agents%2520as%2520an%2520Approach%2520to%2520Treatment%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D12%26spage%3D4880%26epage%3D4898%26doi%3D10.1021%2Fjm400048v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purushottamachar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwegyir-Afful, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamurthy, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njar, V. C. O.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00137</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00137" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xotl2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=708-713&issue=7&author=P.+Purushottamacharauthor=A.+K.+Kwegyir-Affulauthor=M.+S.+Martinauthor=V.+P.+Ramamurthyauthor=S.+Ramalingamauthor=V.+C.+O.+Njar&title=Identification+of+Novel+Steroidal+Androgen+Receptor+Degrading+Agents+Inspired+by+Galeterone+3%CE%B2-Imidazole+Carbamate&doi=10.1021%2Facsmedchemlett.6b00137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate</span></div><div class="casAuthors">Purushottamachar, Puranik; Kwegyir-Afful, Andrew K.; Martin, Marlena S.; Ramamurthy, Vidya P.; Ramalingam, Senthilmurugan; Njar, Vincent C. O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">708-713</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Degrdn. of all forms of androgen receptors (ARs) is emerging as an advantageous therapeutic paradigm for the effective treatment of prostate cancer.  In continuation of our program to identify and develop improved efficacious novel small-mol. agents designed to disrupt AR signaling through enhanced AR degrdn., we have designed, synthesized, and evaluated novel C-3 modified analogs of our phase 3 clin. agent, galeterone I.  Concerns of potential in vivo stability of our recently discovered more efficacious galeterone 3β-imidazole carbamate II led to the design and synthesis of new steroidal compds.  Two of the 11 compds., 3β-pyridyl ether III and 3β-imidazole IV with antiproliferative GI50 values of 3.24 and 2.54 μM against CWR22Rv1 prostate cancer cell, are 2.75- and 3.5-fold superior to I.  In addn., compds. III and IV possess improved (∼4-fold) AR-V7 degrading activities.  Importantly, these two compds. are expected to be metabolically stable, making them suitable for further development as new therapeutics against all forms of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowF_M83EYRpLVg90H21EOLACvtfcHk0lhsqo6XGwM57Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xotl2qu7k%253D&md5=5f07c9f57ea1fd65b8775ed2d774c863</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00137%26sid%3Dliteratum%253Aachs%26aulast%3DPurushottamachar%26aufirst%3DP.%26aulast%3DKwegyir-Afful%26aufirst%3DA.%2BK.%26aulast%3DMartin%26aufirst%3DM.%2BS.%26aulast%3DRamamurthy%26aufirst%3DV.%2BP.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DNjar%26aufirst%3DV.%2BC.%2BO.%26atitle%3DIdentification%2520of%2520Novel%2520Steroidal%2520Androgen%2520Receptor%2520Degrading%2520Agents%2520Inspired%2520by%2520Galeterone%25203%25CE%25B2-Imidazole%2520Carbamate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D7%26spage%3D708%26epage%3D713%26doi%3D10.1021%2Facsmedchemlett.6b00137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coss, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selth, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagadala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wake, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledbetter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldoveanu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span> <span> </span><span class="NLM_article-title">Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6282</span>– <span class="NLM_lpage">6298</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-17-0976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28978635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6282-6298&issue=22&author=S.+Ponnusamyauthor=C.+C.+Cossauthor=T.+Thiyagarajanauthor=K.+Wattsauthor=D.-J.+Hwangauthor=Y.+Heauthor=L.+A.+Selthauthor=I.+J.+McEwanauthor=C.+B.+Dukeauthor=J.+Pagadalaauthor=G.+Singhauthor=R.+W.+Wakeauthor=C.+Ledbetterauthor=W.+D.+Tilleyauthor=T.+Moldoveanuauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=R.+Narayanan&title=Novel+Selective+Agents+for+the+Degradation+of+Androgen+Receptor+Variants+to+Treat+Castration-Resistant+Prostate+Cancer&doi=10.1158%2F0008-5472.CAN-17-0976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer</span></div><div class="casAuthors">Ponnusamy, Suriyan; Coss, Christopher C.; Thiyagarajan, Thirumagal; Watts, Kate; Hwang, Dong-Jin; He, Yali; Selth, Luke A.; McEwan, Iain J.; Duke, Charles B.; Pagadala, Jayaprakash; Singh, Geetika; Wake, Robert W.; Ledbetter, Christopher; Tilley, Wayne D.; Moldoveanu, Tudor; Dalton, James T.; Miller, Duane D.; Narayanan, Ramesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6282-6298</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease.  AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubiquitinated and degraded by proteasomes after ligand binding.  Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy.  Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses.  Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degrdn. previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain.  Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists.  Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer.  Cancer Res; 77(22); 6282-98. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUU2nKdVBuLVg90H21EOLACvtfcHk0lhsqo6XGwM57Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur%252FI&md5=683c849987ed758177664b949dcc98ea</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0976%26sid%3Dliteratum%253Aachs%26aulast%3DPonnusamy%26aufirst%3DS.%26aulast%3DCoss%26aufirst%3DC.%2BC.%26aulast%3DThiyagarajan%26aufirst%3DT.%26aulast%3DWatts%26aufirst%3DK.%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DSelth%26aufirst%3DL.%2BA.%26aulast%3DMcEwan%26aufirst%3DI.%2BJ.%26aulast%3DDuke%26aufirst%3DC.%2BB.%26aulast%3DPagadala%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DWake%26aufirst%3DR.%2BW.%26aulast%3DLedbetter%26aufirst%3DC.%26aulast%3DTilley%26aufirst%3DW.%2BD.%26aulast%3DMoldoveanu%26aufirst%3DT.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DNarayanan%26aufirst%3DR.%26atitle%3DNovel%2520Selective%2520Agents%2520for%2520the%2520Degradation%2520of%2520Androgen%2520Receptor%2520Variants%2520to%2520Treat%2520Castration-Resistant%2520Prostate%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D22%26spage%3D6282%26epage%3D6298%26doi%3D10.1158%2F0008-5472.CAN-17-0976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00973</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00973" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=491-511&issue=2&author=D.-J.+Hwangauthor=Y.+Heauthor=S.+Ponnusamyauthor=M.+L.+Mohlerauthor=T.+Thiyagarajanauthor=I.+J.+McEwanauthor=R.+Narayananauthor=D.+D.+Miller&title=New+Generation+of+Selective+Androgen+Receptor+Degraders%3A+Our+Initial+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+New+Compounds+with+Enzalutamide-Resistant+Prostate+Cancer+Activity&doi=10.1021%2Facs.jmedchem.8b00973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity</span></div><div class="casAuthors">Hwang, Dong-Jin; He, Yali; Ponnusamy, Suriyan; Mohler, Michael L.; Thiyagarajan, Thirumagal; McEwan, Iain J.; Narayanan, Ramesh; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">491-511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to find small-mol. treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs).  Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability.  Cyclization to II and III produced submicromolar AR antagonism and protein degrdn. selective to AR and AR splice variant (AR SV).  II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs.  Design, synthesis, and biol. activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr10pfDXlGf9bVg90H21EOLACvtfcHk0liHPoNa1oQ_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjE&md5=c65b48e592c8746ca821726f007f7b6f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00973%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DPonnusamy%26aufirst%3DS.%26aulast%3DMohler%26aufirst%3DM.%2BL.%26aulast%3DThiyagarajan%26aufirst%3DT.%26aulast%3DMcEwan%26aufirst%3DI.%2BJ.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DNew%2520Generation%2520of%2520Selective%2520Androgen%2520Receptor%2520Degraders%253A%2520Our%2520Initial%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520New%2520Compounds%2520with%2520Enzalutamide-Resistant%2520Prostate%2520Cancer%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D491%26epage%3D511%26doi%3D10.1021%2Facs.jmedchem.8b00973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lack, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennie, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherkasov, A.</span></span> <span> </span><span class="NLM_article-title">Small Molecule-Induced Degradation of the Full Length and V7 Truncated Variant Forms of Human Androgen Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejmech.2018.08.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30193215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=1164-1173&author=K.+Dalalauthor=H.+Morinauthor=F.+Banauthor=A.+Shepherdauthor=M.+Fernandezauthor=K.+J.+Tamauthor=H.+Liauthor=E.+LeBlancauthor=N.+Lackauthor=H.+Prinzauthor=P.+S.+Rennieauthor=A.+Cherkasov&title=Small+Molecule-Induced+Degradation+of+the+Full+Length+and+V7+Truncated+Variant+Forms+of+Human+Androgen+Receptor&doi=10.1016%2Fj.ejmech.2018.08.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor</span></div><div class="casAuthors">Dalal, Kush; Morin, Helene; Ban, Fuqiang; Shepherd, Ashley; Fernandez, Michael; Tam, Kevin J.; Li, Huifang; LeBlanc, Eric; Lack, Nathan; Prinz, Helge; Rennie, Paul S.; Cherkasov, Artem</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1164-1173</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets.  Currently clin. approved small mol. inhibitors of AR, such as enzalutamide, are built upon a common chem. scaffold that interacts with the AR by the same mechanism of action.  These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease.  The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, esp. since AR signalling remains important even in late-stage advanced PCa.  Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degrdn. and display some ability to block recruitment of hormones to the receptor.  In the current work, we extended the anal. of the lead compds., and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivs. capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor.  Importantly, the developed compds. efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD8u9wCiR-ZLVg90H21EOLACvtfcHk0liHPoNa1oQ_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GksLbP&md5=e0fe03ffa376ce03c03fb475ac755b20</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.059%26sid%3Dliteratum%253Aachs%26aulast%3DDalal%26aufirst%3DK.%26aulast%3DMorin%26aufirst%3DH.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DShepherd%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DM.%26aulast%3DTam%26aufirst%3DK.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLeBlanc%26aufirst%3DE.%26aulast%3DLack%26aufirst%3DN.%26aulast%3DPrinz%26aufirst%3DH.%26aulast%3DRennie%26aufirst%3DP.%2BS.%26aulast%3DCherkasov%26aufirst%3DA.%26atitle%3DSmall%2520Molecule-Induced%2520Degradation%2520of%2520the%2520Full%2520Length%2520and%2520V7%2520Truncated%2520Variant%2520Forms%2520of%2520Human%2520Androgen%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D1164%26epage%3D1173%26doi%3D10.1016%2Fj.ejmech.2018.08.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girdwood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortlock, A. A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Androgen Receptor Downregulators as an Approach to Treatment of Advanced Prostate Cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5442</span>– <span class="NLM_lpage">5445</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.06.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2011.06.122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21782422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKis7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5442-5445&issue=18&author=R.+H.+Bradburyauthor=N.+J.+Halesauthor=A.+A.+Rabowauthor=G.+E.+Walkerauthor=D.+G.+Actonauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=N.+A.+N.+Brooksauthor=N.+Colcloughauthor=A.+Girdwoodauthor=U.+J.+Hancoxauthor=O.+Jonesauthor=D.+Judeauthor=S.+A.+Loddickauthor=A.+A.+Mortlock&title=Small-Molecule+Androgen+Receptor+Downregulators+as+an+Approach+to+Treatment+of+Advanced+Prostate+Cancer&doi=10.1016%2Fj.bmcl.2011.06.122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer</span></div><div class="casAuthors">Bradbury, Robert H.; Hales, Neil J.; Rabow, Alfred A.; Walker, Graeme E.; Acton, David G.; Andrews, David M.; Ballard, Peter; Brooks, Nigel A. N.; Colclough, Nicola; Girdwood, Alan; Hancox, Urs J.; Jones, Owen; Jude, David; Loddick, Sarah A.; Mortlock, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5442-5445</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chem. starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer.  Although prototypic steroidal downregulators such as 6a designed for i.m. administration showed insufficient cellular potency, a medicinal chem. program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine (10b), for which high plasma levels following oral administration in a preclin. model compensate for moderate cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDCeGpPNTfxLVg90H21EOLACvtfcHk0liHPoNa1oQ_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKis7nM&md5=dfd44749a6307b772c75920cb3814b7b</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.06.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.06.122%26sid%3Dliteratum%253Aachs%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DHales%26aufirst%3DN.%2BJ.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%2BN.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DGirdwood%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DU.%2BJ.%26aulast%3DJones%26aufirst%3DO.%26aulast%3DJude%26aufirst%3DD.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMortlock%26aufirst%3DA.%2BA.%26atitle%3DSmall-Molecule%2520Androgen%2520Receptor%2520Downregulators%2520as%2520an%2520Approach%2520to%2520Treatment%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D18%26spage%3D5442%26epage%3D5445%26doi%3D10.1016%2Fj.bmcl.2011.06.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parveen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma-Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD3514, a Small-Molecule Androgen Receptor Downregulator for Treatment of Advanced Prostate Cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1945</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2013.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23466225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1Cit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1945-1948&issue=7&author=R.+H.+Bradburyauthor=D.+G.+Actonauthor=N.+L.+Broadbentauthor=A.+N.+Brooksauthor=G.+R.+Carrauthor=G.+Hatterauthor=B.+R.+Hayterauthor=K.+J.+Hillauthor=N.+J.+Howeauthor=R.+D.+O.+Jonesauthor=D.+Judeauthor=S.+G.+Lamontauthor=S.+A.+Loddickauthor=H.+L.+McFarlandauthor=Z.+Parveenauthor=A.+A.+Rabowauthor=G.+Sharma-Singhauthor=N.+C.+Strattonauthor=A.+G.+Thomasonauthor=D.+Truemanauthor=G.+E.+Walkerauthor=S.+L.+Wellsauthor=J.+Wilsonauthor=J.+M.+Wood&title=Discovery+of+AZD3514%2C+a+Small-Molecule+Androgen+Receptor+Downregulator+for+Treatment+of+Advanced+Prostate+Cancer&doi=10.1016%2Fj.bmcl.2013.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer</span></div><div class="casAuthors">Bradbury, Robert H.; Acton, David G.; Broadbent, Nicola L.; Brooks, A. Nigel; Carr, Gregory R.; Hatter, Glenn; Hayter, Barry R.; Hill, Kathryn J.; Howe, Nicholas J.; Jones, Rhys D. O.; Jude, David; Lamont, Scott G.; Loddick, Sarah A.; McFarland, Heather L.; Parveen, Zaieda; Rabow, Alfred A.; Sharma-Singh, Gorkhn; Stratton, Natalie C.; Thomason, Andrew G.; Trueman, Dawn; Walker, Graeme E.; Wells, Stuart L.; Wilson, Joanne; Wood, J. Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1945-1948</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial redn. of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine (1) addressed hERG and phys. property issues, and led to clin. candidate 6-(4-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}piperidin-1-yl)-3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clin. trial in patients with castrate-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaxgJ1mG7VBLVg90H21EOLACvtfcHk0liBKdJqi1rcSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1Cit78%253D&md5=a7b1ebac3f7d412fa78e0188dceec42d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DBroadbent%26aufirst%3DN.%2BL.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DCarr%26aufirst%3DG.%2BR.%26aulast%3DHatter%26aufirst%3DG.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHill%26aufirst%3DK.%2BJ.%26aulast%3DHowe%26aufirst%3DN.%2BJ.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DJude%26aufirst%3DD.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DParveen%26aufirst%3DZ.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DSharma-Singh%26aufirst%3DG.%26aulast%3DStratton%26aufirst%3DN.%2BC.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DTrueman%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWells%26aufirst%3DS.%2BL.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520of%2520AZD3514%252C%2520a%2520Small-Molecule%2520Androgen%2520Receptor%2520Downregulator%2520for%2520Treatment%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D7%26spage%3D1945%26epage%3D1948%26doi%3D10.1016%2Fj.bmcl.2013.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omlin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelman, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clack, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alumkal, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malone, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, T.</span></span> <span> </span><span class="NLM_article-title">A First-in-Human Study of the Oral Selective Androgen Receptor Down-Regulating Drug (SARD) AZD3514 in Patients with Castration-Resistant Prostate Cancer (CRPC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">4511</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.31.15_suppl.4511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1200%2Fjco.2013.31.15_suppl.4511" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=4511&issue=15_suppl&author=A.+G.+Omlinauthor=R.+J.+Jonesauthor=R.+van+der+Nollauthor=J.+Grahamauthor=M.+Ongauthor=R.+D.+Finkelmanauthor=J.+H.+Schellensauthor=A.+Ziviauthor=M.+Crespoauthor=G.+Clackauthor=J.+J.+Alumkalauthor=A.+Dymondauthor=A.+Dickinsonauthor=M.+Ransonauthor=M.+D.+Maloneauthor=J.+S.+De+Bonoauthor=T.+Elliott&title=A+First-in-Human+Study+of+the+Oral+Selective+Androgen+Receptor+Down-Regulating+Drug+%28SARD%29+AZD3514+in+Patients+with+Castration-Resistant+Prostate+Cancer+%28CRPC%29&doi=10.1200%2Fjco.2013.31.15_suppl.4511"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1200%2Fjco.2013.31.15_suppl.4511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2013.31.15_suppl.4511%26sid%3Dliteratum%253Aachs%26aulast%3DOmlin%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DM.%26aulast%3DFinkelman%26aufirst%3DR.%2BD.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DZivi%26aufirst%3DA.%26aulast%3DCrespo%26aufirst%3DM.%26aulast%3DClack%26aufirst%3DG.%26aulast%3DAlumkal%26aufirst%3DJ.%2BJ.%26aulast%3DDymond%26aufirst%3DA.%26aulast%3DDickinson%26aufirst%3DA.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DMalone%26aufirst%3DM.%2BD.%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DElliott%26aufirst%3DT.%26atitle%3DA%2520First-in-Human%2520Study%2520of%2520the%2520Oral%2520Selective%2520Androgen%2520Receptor%2520Down-Regulating%2520Drug%2520%2528SARD%2529%2520AZD3514%2520in%2520Patients%2520with%2520Castration-Resistant%2520Prostate%2520Cancer%2520%2528CRPC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D15_suppl%26spage%3D4511%26doi%3D10.1200%2Fjco.2013.31.15_suppl.4511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunkley, T. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brave, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouchet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumberbatch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaughan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedge, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span> <span> </span><span class="NLM_article-title">AZD3514: a Small Molecule That Modulates Androgen Receptor Signaling and Function in Vitro and in Vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1535-7163.MCT-12-1174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23861347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1715-1727&issue=9&author=S.+A.+Loddickauthor=S.+J.+Rossauthor=A.+G.+Thomasonauthor=D.+M.+Robinsonauthor=G.+E.+Walkerauthor=T.+P.+J.+Dunkleyauthor=S.+R.+Braveauthor=N.+Broadbentauthor=N.+C.+Strattonauthor=D.+Truemanauthor=E.+Mouchetauthor=F.+S.+Shaheenauthor=V.+N.+Jacobsauthor=M.+Cumberbatchauthor=J.+Wilsonauthor=R.+D.+O.+Jonesauthor=R.+H.+Bradburyauthor=A.+Rabowauthor=L.+Gaughanauthor=C.+Womackauthor=S.+T.+Barryauthor=C.+N.+Robsonauthor=S.+E.+Critchlowauthor=S.+R.+Wedgeauthor=A.+N.+Brooks&title=AZD3514%3A+a+Small+Molecule+That+Modulates+Androgen+Receptor+Signaling+and+Function+in+Vitro+and+in+Vivo&doi=10.1158%2F1535-7163.MCT-12-1174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo</span></div><div class="casAuthors">Loddick, Sarah A.; Ross, Sarah J.; Thomason, Andrew G.; Robinson, David M.; Walker, Graeme E.; Dunkley, Tom P. J.; Brave, Sandra R.; Broadbent, Nicola; Stratton, Natalie C.; Trueman, Dawn; Mouchet, Elizabeth; Shaheen, Fadhel S.; Jacobs, Vivien N.; Cumberbatch, Marie; Wilson, Joanne; Jones, Rhys D. O.; Bradbury, Robert H.; Rabow, Alfred; Gaughan, Luke; Womack, Chris; Barry, Simon T.; Robson, Craig N.; Critchlow, Susan E.; Wedge, Stephen R.; Brooks, A. Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1715-1727</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressive disease.  Here, we describe the biol. characterization of AZD3514, an orally bioavailable drug that inhibits androgen-dependent and -independent AR signaling.  AZD3514 modulates AR signaling through two distinct mechanisms, an inhibition of ligand-driven nuclear translocation of AR and a downregulation of receptor levels, both of which were obsd. in vitro and in vivo.  AZD3514 inhibited testosterone-driven seminal vesicle development in juvenile male rats and the growth of androgen-dependent Dunning R3327H prostate tumors in adult rats.  Furthermore, this class of compd. showed antitumor activity in the HID28 mouse model of CRPC in vivo.  AZD3514 is currently in phase I clin. evaluation.  Mol Cancer Ther; 12(9); 1715-27. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUjB28XcSVrVg90H21EOLACvtfcHk0liBKdJqi1rcSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI&md5=553f0953189e9e5982a08c7933566ce0</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1174%26sid%3Dliteratum%253Aachs%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DRobinson%26aufirst%3DD.%2BM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DDunkley%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DBroadbent%26aufirst%3DN.%26aulast%3DStratton%26aufirst%3DN.%2BC.%26aulast%3DTrueman%26aufirst%3DD.%26aulast%3DMouchet%26aufirst%3DE.%26aulast%3DShaheen%26aufirst%3DF.%2BS.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DCumberbatch%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DGaughan%26aufirst%3DL.%26aulast%3DWomack%26aufirst%3DC.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26atitle%3DAZD3514%253A%2520a%2520Small%2520Molecule%2520That%2520Modulates%2520Androgen%2520Receptor%2520Signaling%2520and%2520Function%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26issue%3D9%26spage%3D1715%26epage%3D1727%26doi%3D10.1158%2F1535-7163.MCT-12-1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merenbakh-Lamin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Baruch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeheskel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span> <span> </span><span class="NLM_article-title">D538G Mutation in Estrogen Receptor-A: a Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6856</span>– <span class="NLM_lpage">6864</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-13-1197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24217577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKhurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6856-6864&issue=23&author=K.+Merenbakh-Laminauthor=N.+Ben-Baruchauthor=A.+Yeheskelauthor=A.+Dvirauthor=L.+Soussan-Gutmanauthor=R.+Jeselsohnauthor=R.+Yelenskyauthor=M.+Brownauthor=V.+A.+Millerauthor=D.+Saridauthor=S.+Rizelauthor=B.+Kleinauthor=T.+Rubinekauthor=I.+Wolf&title=D538G+Mutation+in+Estrogen+Receptor-A%3A+a+Novel+Mechanism+for+Acquired+Endocrine+Resistance+in+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-13-1197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer</span></div><div class="casAuthors">Merenbakh-Lamin, Keren; Ben-Baruch, Noa; Yeheskel, Adva; Dvir, Addie; Soussan-Gutman, Lior; Jeselsohn, Rinath; Yelensky, Roman; Brown, Myles; Miller, Vincent A.; Sarid, David; Rizel, Shulamith; Klein, Baruch; Rubinek, Tami; Wolf, Ido</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6856-6864</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to endocrine therapy occurs in virtually all patients with estrogen receptor a (ERa)-pos. metastatic breast cancer, and is attributed to various mechanisms including loss of ERα expression, altered activity of coregulators, and cross-talk between the ERa and growth factor signaling pathways.  To our knowledge, acquired mutations of the ERα have not been described as mediating endocrine resistance.  Samples of 13 patients with metastatic breast cancer were analyzed for mutations in cancer-related genes.  In five patients who developed resistance to hormonal therapy, a mutation of A to G at position 1,613 of ERα, resulting in a substitution of aspartic acid at position 538 to glycine (D538G), was identified in liver metastases.  Importantly, the mutation was not detected in the primary tumors obtained prior to endocrine treatment.  Structural modeling indicated that D538G substitution leads to a conformational change in the ligand-binding domain, which mimics the conformation of activated ligand-bound receptor and alters binding of tamoxifen.  Indeed, expts. in breast cancer cells indicated constitutive, ligand-independent transcriptional activity of the D538G receptor, and overexpression of it enhanced proliferation and conferred resistance to tamoxifen.  These data indicate a novel mechanism of acquired endocrine resistance in breast cancer.  Further studies are needed to assess the frequency of D538G-ERα among patients with breast cancer and explore ways to inhibit its activity and restore endocrine sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWljQ_odNNUrVg90H21EOLACvtfcHk0lgmkW1e7cwfOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKhurfN&md5=6dca8ee6cdb77bfc8a94d02fe5630ea8</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1197%26sid%3Dliteratum%253Aachs%26aulast%3DMerenbakh-Lamin%26aufirst%3DK.%26aulast%3DBen-Baruch%26aufirst%3DN.%26aulast%3DYeheskel%26aufirst%3DA.%26aulast%3DDvir%26aufirst%3DA.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DSarid%26aufirst%3DD.%26aulast%3DRizel%26aufirst%3DS.%26aulast%3DKlein%26aufirst%3DB.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DI.%26atitle%3DD538G%2520Mutation%2520in%2520Estrogen%2520Receptor-A%253A%2520a%2520Novel%2520Mechanism%2520for%2520Acquired%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D23%26spage%3D6856%26epage%3D6864%26doi%3D10.1158%2F0008-5472.CAN-13-1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiken, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saied, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuntoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phommaly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSchryver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&issue=6&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-Therapy-Resistant+ESR1+Variants+Revealed+by+Genomic+Characterization+of+Breast-Cancer-Derived+Xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0lgmkW1e7cwfOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-Therapy-Resistant%2520ESR1%2520Variants%2520Revealed%2520by%2520Genomic%2520Characterization%2520of%2520Breast-Cancer-Derived%2520Xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vats, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyana-Sundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Poznak, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunju, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Activating ESR1 Mutations in Hormone-Resistant Metastatic Breast Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1446</span>– <span class="NLM_lpage">1451</span>, <span class="refDoi"> DOI: 10.1038/ng.2823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.2823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24185510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1446-1451&issue=12&author=D.+R.+Robinsonauthor=Y.-M.+Wuauthor=P.+Vatsauthor=F.+Suauthor=R.+J.+Lonigroauthor=X.+Caoauthor=S.+Kalyana-Sundaramauthor=R.+Wangauthor=Y.+Ningauthor=L.+Hodgesauthor=A.+Gurskyauthor=J.+Siddiquiauthor=S.+A.+Tomlinsauthor=S.+Roychowdhuryauthor=K.+J.+Pientaauthor=S.+Y.+Kimauthor=J.+S.+Robertsauthor=J.+M.+Raeauthor=C.+H.+Van+Poznakauthor=D.+F.+Hayesauthor=R.+Chughauthor=L.+P.+Kunjuauthor=M.+Talpazauthor=A.+F.+Schottauthor=A.+M.+Chinnaiyan&title=Activating+ESR1+Mutations+in+Hormone-Resistant+Metastatic+Breast+Cancer&doi=10.1038%2Fng.2823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Vats, Pankaj; Su, Fengyun; Lonigro, Robert J.; Cao, Xuhong; Kalyana-Sundaram, Shanker; Wang, Rui; Ning, Yu; Hodges, Lynda; Gursky, Amy; Siddiqui, Javed; Tomlins, Scott A.; Roychowdhury, Sameek; Pienta, Kenneth J.; Kim, Scott Y.; Roberts, J. Scott; Rae, James M.; Van Poznak, Catherine H.; Hayes, Daniel F.; Chugh, Rashmi; Kunju, Lakshmi P.; Talpaz, Moshe; Schott, Anne F.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer is the most prevalent cancer in women, and over two-thirds of cases express estrogen receptor-α (ER-α, encoded by ESR1).  Through a prospective clin. sequencing program for advanced cancers, we enrolled 11 patients with ER-pos. metastatic breast cancer.  Whole-exome and transcriptome anal. showed that six cases harbored mutations of ESR1 affecting its ligand-binding domain (LBD), all of whom had been treated with anti-estrogens and estrogen deprivation therapies.  A survey of The Cancer Genome Atlas (TCGA) identified four endometrial cancers with similar mutations of ESR1.  The five new LBD-localized ESR1 mutations identified here (encoding p.Leu536Gln, p.Tyr537Ser, p.Tyr537Cys, p.Tyr537Asn and p.Asp538Gly) were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.  Taken together, these studies suggest that activating mutations in ESR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQSL6mlhMOrVg90H21EOLACvtfcHk0lglY7SJq52ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN&md5=af9e69d6064726af238fe74dad7d2204</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fng.2823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2823%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DGursky%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DRae%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BPoznak%26aufirst%3DC.%2BH.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DActivating%2520ESR1%2520Mutations%2520in%2520Hormone-Resistant%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fng.2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">ESR1 Ligand-Binding Domain Mutations in Hormone-Resistant Breast Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1038/ng.2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24185512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1439-1445&issue=12&author=W.+Toyauthor=Y.+Shenauthor=H.+Wonauthor=B.+Greenauthor=R.+A.+Sakrauthor=M.+Willauthor=Z.+Liauthor=K.+Galaauthor=S.+Fanningauthor=T.+A.+Kingauthor=C.+Hudisauthor=D.+Chenauthor=T.+Taranauthor=G.+Hortobagyiauthor=G.+Greeneauthor=M.+Bergerauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=ESR1+Ligand-Binding+Domain+Mutations+in+Hormone-Resistant+Breast+Cancer&doi=10.1038%2Fng.2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span></div><div class="casAuthors">Toy, Weiyi; Shen, Yang; Won, Helen; Green, Bradley; Sakr, Rita A.; Will, Marie; Li, Zhiqiang; Gala, Kinisha; Fanning, Sean; King, Tari A.; Hudis, Clifford; Chen, David; Taran, Tetiana; Hortobagyi, Gabriel; Greene, Geoffrey; Berger, Michael; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition.  However, many such tumors for unknown reasons become refractory to inhibition of estrogen action in the metastatic setting.  We conducted a comprehensive genetic anal. of two independent cohorts of metastatic ER-pos. breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases.  These included highly recurrent mutations encoding p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations.  Mol. dynamics simulations suggest that the structures of the Tyr537Ser and Asp538Gly mutants involve hydrogen bonding of the mutant amino acids with Asp351, thus favoring the agonist conformation of the receptor.  Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.  These data implicate LBD-mutant forms of ER in mediating clin. resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KQLxyqE3lrVg90H21EOLACvtfcHk0lglY7SJq52ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ&md5=1f7c247e079d08a463db4e20ec0f9d17</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1038%2Fng.2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2822%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DSakr%26aufirst%3DR.%2BA.%26aulast%3DWill%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DGala%26aufirst%3DK.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DESR1%2520Ligand-Binding%2520Domain%2520Mutations%2520in%2520Hormone-Resistant%2520Breast%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1439%26epage%3D1445%26doi%3D10.1038%2Fng.2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">The Search for ESR1 Mutations in Breast Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1416</span>, <span class="refDoi"> DOI: 10.1038/ng.2831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.2831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24270445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVaitL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1415-1416&issue=12&author=S.+Oesterreichauthor=N.+E.+Davidson&title=The+Search+for+ESR1+Mutations+in+Breast+Cancer&doi=10.1038%2Fng.2831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">The search for ESR1 mutations in breast cancer</span></div><div class="casAuthors">Oesterreich, Steffi; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1415-1416</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Two new studies report the identification of activating ESR1 gene mutations in aromatase inhibitor-resistant metastatic breast cancers.  This insight into therapeutic resistance suggests new approaches that may be useful in the management of endocrine-resistant breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFpXltTLXBR7Vg90H21EOLACvtfcHk0lglY7SJq52ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVaitL7P&md5=e9cf29471564b577f3f8bcb1ee83f7b7</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fng.2831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2831%26sid%3Dliteratum%253Aachs%26aulast%3DOesterreich%26aufirst%3DS.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DThe%2520Search%2520for%2520ESR1%2520Mutations%2520in%2520Breast%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1415%26epage%3D1416%26doi%3D10.1038%2Fng.2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span> <span> </span><span class="NLM_article-title">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4887</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&issue=12&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+Selective+Estrogen+Receptor+Downregulators+%28SERDs%29%2C+a+Breakthrough+Endocrine+Therapy+for+Breast+Cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0ljwYMYq32yYZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520Selective%2520Estrogen%2520Receptor%2520Downregulators%2520%2528SERDs%2529%252C%2520a%2520Breakthrough%2520Endocrine%2520Therapy%2520for%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">A Potent Specific Pure Antiestrogen with Clinical Potential</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3867</span>– <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&issue=15&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+Potent+Specific+Pure+Antiestrogen+with+Clinical+Potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0ljwYMYq32yYZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520Potent%2520Specific%2520Pure%2520Antiestrogen%2520with%2520Clinical%2520Potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D15%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Kruchten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaudemans, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lanschot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Faassen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kema, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospers, G. A.</span></span> <span> </span><span class="NLM_article-title">Measuring Residual Estrogen Receptor Availability During Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&issue=1&author=M.+van%0AKruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schroderauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+Residual+Estrogen+Receptor+Availability+During+Fulvestrant+Therapy+in+Patients+with+Metastatic+Breast+Cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0ljwYMYq32yYZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchroder%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520Residual%2520Estrogen%2520Receptor%2520Availability%2520During%2520Fulvestrant%2520Therapy%2520in%2520Patients%2520with%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D1%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerstrom, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripnikova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannuti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant-3 Boronic Acid (ZB716): an Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8134</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00753</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00753" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8134-8140&issue=17&author=J.+Liuauthor=S.+Zhengauthor=V.+L.+Akerstromauthor=C.+Yuanauthor=Y.+Maauthor=Q.+Zhongauthor=C.+Zhangauthor=Q.+Zhangauthor=S.+Guoauthor=P.+Maauthor=E.+V.+Skripnikovaauthor=M.+R.+Brattonauthor=A.+Pannutiauthor=L.+Mieleauthor=T.+E.+Wieseauthor=G.+Wang&title=Fulvestrant-3+Boronic+Acid+%28ZB716%29%3A+an+Orally+Bioavailable+Selective+Estrogen+Receptor+Downregulator+%28SERD%29&doi=10.1021%2Facs.jmedchem.6b00753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)</span></div><div class="casAuthors">Liu, Jiawang; Zheng, Shilong; Akerstrom, Victoria L.; Yuan, Chester; Ma, Youning; Zhong, Qiu; Zhang, Changde; Zhang, Qiang; Guo, Shanchun; Ma, Peng; Skripnikova, Elena V.; Bratton, Melyssa R.; Pannuti, Antonio; Miele, Lucio; Wiese, Thomas E.; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8134-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Orally bioavailable SERDs may offer greater systemic drug exposure, improved clin. efficacy, and more durable treatment outcome for patients with ER-pos. endocrine-resistant breast cancer.  We report the design and synthesis of a boronic acid modified fulvestrant (ZB716), which binds to ERα competitively (IC50=4.1 nM) and effectively downregulates ERα in both tamoxifen-sensitive and tamoxifen-resistant breast cancer cells.  Furthermore, it has superior oral bioavailability (AUC=2547.1 ng•h/mL) in mice, indicating its promising clin. utility as an oral SERD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjvM1bnXTzLVg90H21EOLACvtfcHk0lgppOQDmRetpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI&md5=d8c398dc337357fe36a387266a51d5ec</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00753%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DAkerstrom%26aufirst%3DV.%2BL.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DSkripnikova%26aufirst%3DE.%2BV.%26aulast%3DBratton%26aufirst%3DM.%2BR.%26aulast%3DPannuti%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DWiese%26aufirst%3DT.%2BE.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DFulvestrant-3%2520Boronic%2520Acid%2520%2528ZB716%2529%253A%2520an%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Downregulator%2520%2528SERD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D17%26spage%3D8134%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.6b00753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillen, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6336</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6321-6336&issue=14&author=J.+Minauthor=V.+S.+Guillenauthor=A.+Sharmaauthor=Y.+Zhaoauthor=Y.+Zieglerauthor=P.+Gongauthor=C.+G.+Mayneauthor=S.+Srinivasanauthor=S.+H.+Kimauthor=K.+E.+Carlsonauthor=K.+W.+Nettlesauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Adamantyl+Antiestrogens+with+Novel+Side+Chains+Reveal+a+Spectrum+of+Activities+in+Suppressing+Estrogen+Receptor+Mediated+Activities+in+Breast+Cancer+Cells&doi=10.1021%2Facs.jmedchem.7b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells</span></div><div class="casAuthors">Min, Jian; Guillen, Valeria Sanabria; Sharma, Abhishek; Zhao, Yuechao; Ziegler, Yvonne; Gong, Ping; Mayne, Christopher G.; Srinivasan, Sathish; Kim, Sung Hoon; Carlson, Kathryn E.; Nettles, Kendall W.; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6321-6336</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens.  To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochem. issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs.  All compds. were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-down-regulating agents.  There were large differences in activity between compds. having minor structural changes, but antiproliferative and ERα-down-regulating efficacies generally paralleled one another.  Some compds. with side chain polar groups had particularly high affinities.  The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression.  This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUZF-YO3F3uLVg90H21EOLACvtfcHk0lgppOQDmRetpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP&md5=a22b96675e183041d48f7fb62e560f75</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00585%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DGuillen%26aufirst%3DV.%2BS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZiegler%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAdamantyl%2520Antiestrogens%2520with%2520Novel%2520Side%2520Chains%2520Reveal%2520a%2520Spectrum%2520of%2520Activities%2520in%2520Suppressing%2520Estrogen%2520Receptor%2520Mediated%2520Activities%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D6321%26epage%3D6336%26doi%3D10.1021%2Facs.jmedchem.7b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&issue=7&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+Acrylic+Acid+Based+Tetrahydroisoquinoline+as+an+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+for+ER%CE%B1%2B+Breast+Cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span></div><div class="casAuthors">Burks, Heather E.; Abrams, Tinya; Kirby, Christina A.; Baird, Jason; Fekete, Alexander; Hamann, Lawrence G.; Kim, Sunkyu; Lombardo, Franco; Loo, Alice; Lubicka, Danuta; Macchi, Kaitlin; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Saran, Chitra; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2790-2818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.  We outline the discovery and chem. optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclin. species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N78pDzgcpLVg90H21EOLACvtfcHk0lgppOQDmRetpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D&md5=51ce5c93fb6dcaebb3e81fbb3ca67657</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520Acrylic%2520Acid%2520Based%2520Tetrahydroisoquinoline%2520as%2520an%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520for%2520ER%25CE%25B1%252B%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D7%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&issue=20&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+Novel+Binding+Motif+to+%28E%29-3-%283%2C5-Difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+Acid+%28AZD9496%29%2C+a+Potent+and+Orally+Bioavailable+Selective+Estrogen+Receptor+Downregulator+and+Antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0lhl5nCi83OBxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520Novel%2520Binding%2520Motif%2520to%2520%2528E%2529-3-%25283%252C5-Difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520Acid%2520%2528AZD9496%2529%252C%2520a%2520Potent%2520and%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Downregulator%2520and%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span> <span> </span><span class="NLM_article-title">Tricyclic Indazoles—a Novel Class of Selective Estrogen Receptor Degrader Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1593-1608&issue=3&author=J.+S.+Scottauthor=A.+Baileyauthor=D.+Buttarauthor=R.+J.+Carbajoauthor=J.+Curwenauthor=P.+R.+J.+Daveyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=C.+Donaldauthor=E.+Ganglauthor=R.+Greenwoodauthor=S.+D.+Groombridgeauthor=T.+Johnsonauthor=S.+Lamontauthor=M.+Lawsonauthor=A.+Listerauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=J.+H.+Pinkauthor=R.+Polanski&title=Tricyclic+Indazoles%E2%80%94a+Novel+Class+of+Selective+Estrogen+Receptor+Degrader+Antagonists&doi=10.1021%2Facs.jmedchem.8b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Buttar, David; Carbajo, Rodrigo J.; Curwen, Jon; Davey, Paul R. J.; Davies, Robert D. M.; Degorce, Sebastien L.; Donald, Craig; Gangl, Eric; Greenwood, Ryan; Groombridge, Sam D.; Johnson, Tony; Lamont, Scott; Lawson, Mandy; Lister, Andrew; Morrow, Christopher J.; Moss, Thomas A.; Pink, Jennifer H.; Polanski, Radoslaw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1593-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tricyclic tetrahydropyridoindazoles such as I were prepd. as estrogen receptor degrader antagonists for potential use in the treatment of ERα-dependent breast cancer; the indazole moiety was prepd. as a replacement for a phenol moiety in a tetrahydroisoquinolinol which generated reactive metabolites in a glutathione trapping assay.  The structure of a nonracemic tetrahydropyridoindazole bound to an ERα ligand binding domain fragment was detd. by X-ray crystallog.  I demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhswxQKXWq7Vg90H21EOLACvtfcHk0lhl5nCi83OBxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D&md5=753ed2af89e482d9d9e8aa0f49a54ddb</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDonald%26aufirst%3DC.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPolanski%26aufirst%3DR.%26atitle%3DTricyclic%2520Indazoles%25E2%2580%2594a%2520Novel%2520Class%2520of%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D3%26spage%3D1593%26epage%3D1608%26doi%3D10.1021%2Facs.jmedchem.8b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&issue=7&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.+L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+Potent%2C+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+%28SERD%29+for+the+Treatment+of+Estrogen+Receptor+Positive+Breast+Cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0ljrn9sv0j7jEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.%2BL.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520Potent%252C%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520for%2520the%2520Treatment%2520of%2520Estrogen%2520Receptor%2520Positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&issue=12&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+%28SERD%29+That+Demonstrates+Robust+Activity+in+Tamoxifen-Resistant+Breast+Cancer+Xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0ljrn9sv0j7jEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520That%2520Demonstrates%2520Robust%2520Activity%2520in%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Selective Estrogen Receptor Degraders with Novel Structural Motifs Induce Regression in a Tamoxifen-Resistant Breast Cancer Xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2018.12.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30587451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFynurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=367-372&issue=3&author=S.+P.+Govekauthor=C.+Bonnefousauthor=J.+D.+Julienauthor=J.+Y.+Nagasawaauthor=M.+Kahramanauthor=A.+G.+Laiauthor=K.+L.+Douglasauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.+J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Selective+Estrogen+Receptor+Degraders+with+Novel+Structural+Motifs+Induce+Regression+in+a+Tamoxifen-Resistant+Breast+Cancer+Xenograft&doi=10.1016%2Fj.bmcl.2018.12.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Bonnefous, Celine; Julien, Jackaline D.; Nagasawa, Johnny Y.; Kahraman, Mehmet; Lai, Andiliy G.; Douglas, Karensa L.; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-372</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Potent estrogen receptor ligands typically contain a phenolic hydrogen-bond donor.  The indazole of the selective estrogen receptor degrader (SERD) ARN-810 is believed to mimic this.  Disclosed herein is the discovery of ARN-810 analogs which lack this hydrogen-bond donor.  These SERDs induced tumor regression in a tamoxifen-resistant breast cancer xenograft, demonstrating that the indazole NH is not necessary for robust ER-modulation and antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUfIVe9l_ey7Vg90H21EOLACvtfcHk0lhxVgxCHvof7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFynurzO&md5=25f4c3838d63c8abe9166c3295c28926</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%2BD.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DSelective%2520Estrogen%2520Receptor%2520Degraders%2520with%2520Novel%2520Structural%2520Motifs%2520Induce%2520Regression%2520in%2520a%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D367%26epage%3D372%26doi%3D10.1016%2Fj.bmcl.2018.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges-Gallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span> <span> </span><span class="NLM_article-title">Specific Stereochemistry of OP-1074 Disrupts Estrogen Receptor Alpha Helix 12 and Confers Pure Antiestrogenic Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2368</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41467-018-04413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29915250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2368&issue=1&author=S.+W.+Fanningauthor=L.+Hodges-Gallagherauthor=D.+C.+Mylesauthor=R.+Sunauthor=C.+E.+Fowlerauthor=I.+N.+Plantauthor=B.+D.+Greenauthor=C.+L.+Harmonauthor=G.+L.+Greeneauthor=P.+J.+Kushner&title=Specific+Stereochemistry+of+OP-1074+Disrupts+Estrogen+Receptor+Alpha+Helix+12+and+Confers+Pure+Antiestrogenic+Activity&doi=10.1038%2Fs41467-018-04413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span></div><div class="casAuthors">Fanning S W; Fowler C E; Green B D; Greene G L; Hodges-Gallagher L; Myles D C; Sun R; Harmon C L; Kushner P J; Plant I N</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer.  Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates.  Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay.  We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model.  Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYJ5LDE5uCtbjnyZkbE8yXfW6udTcc2ebJU1J98zHJxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D&md5=a381a76b8363cda16ac9ac5ec0c702d8</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04413-3%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW.%26aulast%3DHodges-Gallagher%26aufirst%3DL.%26aulast%3DMyles%26aufirst%3DD.%2BC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DC.%2BE.%26aulast%3DPlant%26aufirst%3DI.%2BN.%26aulast%3DGreen%26aufirst%3DB.%2BD.%26aulast%3DHarmon%26aufirst%3DC.%2BL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26atitle%3DSpecific%2520Stereochemistry%2520of%2520OP-1074%2520Disrupts%2520Estrogen%2520Receptor%2520Alpha%2520Helix%252012%2520and%2520Confers%2520Pure%2520Antiestrogenic%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D2368%26doi%3D10.1038%2Fs41467-018-04413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&issue=17&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+Orally+Bioavailable+Chromene-Based+Selective+Estrogen+Receptor+Degrader+%28SERD%29+That+Demonstrates+Robust+Activity+in+a+Model+of+Tamoxifen-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0lge9P6cfNlo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520Orally%2520Bioavailable%2520Chromene-Based%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520That%2520Demonstrates%2520Robust%2520Activity%2520in%2520a%2520Model%2520of%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-A Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&issue=1&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-A+Degradation+Maximizes+Activity+in+a+Tamoxifen-Resistant+Breast+Cancer+Model%3A+Identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0lge9P6cfNlo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-A%2520Degradation%2520Maximizes%2520Activity%2520in%2520a%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Model%253A%2520Identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmazeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courjaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginesty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic Acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=512-528&issue=2&author=Y.+El-Ahmadauthor=M.+Tabartauthor=F.+Halleyauthor=V.+Certalauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=F.+Gruss-Leleuauthor=C.+Mullerauthor=M.+Brolloauthor=L.+Fabienauthor=V.+Loyauauthor=L.+Bertinauthor=P.+Richepinauthor=F.+Pilorgeauthor=P.+Desmazeauauthor=C.+Girardetauthor=S.+Beccariauthor=A.+Louboutinauthor=G.+Lebourgauthor=J.+Le-Rouxauthor=C.+Terrierauthor=F.+Vall%C3%A9eauthor=V.+Steierauthor=M.+Mathieuauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=P.+Vicatauthor=T.+Benardauthor=M.+Bouaboulaauthor=F.+Sunauthor=M.+Shomaliauthor=A.+Hebertauthor=M.+Levitauthor=H.+Chengauthor=A.+Courjaudauthor=C.+Ginestyauthor=C.+Perraultauthor=C.+Garcia-Echeverriaauthor=G.+McCortauthor=L.+Schio&title=Discovery+of+6-%282%2C4-Dichlorophenyl%29-5-%5B4-%5B%283S%29-1-%283-fluoropropyl%29pyrrolidin-3-yl%5Doxyphenyl%5D-8%2C9-dihydro-7H-benzo%5B7%5Dannulene-2-carboxylic+Acid+%28SAR439859%29%2C+a+Potent+and+Selective+Estrogen+Receptor+Degrader+%28SERD%29+for+the+Treatment+of+Estrogen-Receptor-Positive+Breast+Cancer&doi=10.1021%2Facs.jmedchem.9b01293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span></div><div class="casAuthors">El-Ahmad Youssef; Tabart Michel; Halley Frank; Certal Victor; Thompson Fabienne; Filoche-Romme Bruno; Gruss-Leleu Florence; Muller Claire; Brollo Maurice; Fabien Laurence; Loyau Veronique; Bertin Luc; Richepin Patrick; Pilorge Fabienne; Desmazeau Pascal; Girardet Chrystelle; Beccari Sylvie; Louboutin Audrey; Lebourg Gilles; Le-Roux Jacques; Terrier Corinne; Vallee Francois; Steier Valerie; Mathieu Magali; Rak Alexey; Abecassis Pierre-Yves; Vicat Pascale; Benard Tsiala; Courjaud Albane; Ginesty Celine; Perrault Christelle; Garcia-Echeverria Carlos; McCort Gary; Schio Laurent; Bouaboula Monsif; Sun Fangxian; Shomali Maysoun; Hebert Andrew; Levit Mikhail; Cheng Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients.  Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective.  Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy.  However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections.  This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgG8wK4xhUykloaUqgkFHkfW6udTcc2eYhFJJfsBlAd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D&md5=40732bc5b74a05cf8551ad5baea64217</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DTabart%26aufirst%3DM.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DFabien%26aufirst%3DL.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDesmazeau%26aufirst%3DP.%26aulast%3DGirardet%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DS.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DLe-Roux%26aufirst%3DJ.%26aulast%3DTerrier%26aufirst%3DC.%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DSteier%26aufirst%3DV.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DVicat%26aufirst%3DP.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DHebert%26aufirst%3DA.%26aulast%3DLevit%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCourjaud%26aufirst%3DA.%26aulast%3DGinesty%26aufirst%3DC.%26aulast%3DPerrault%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DMcCort%26aufirst%3DG.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-Dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2520Acid%2520%2528SAR439859%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520for%2520the%2520Treatment%2520of%2520Estrogen-Receptor-Positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D2%26spage%3D512%26epage%3D528%26doi%3D10.1021%2Facs.jmedchem.9b01293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&issue=4&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+Ligands+Antagonize+Estrogen+Receptor+Function+by+Impairing+Its+Mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0ljabXA3abL-Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520Ligands%2520Antagonize%2520Estrogen%2520Receptor%2520Function%2520by%2520Impairing%2520Its%2520Mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26issue%3D4%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Agostino, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span> <span> </span><span class="NLM_article-title">Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1592</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGjtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1592-1602&issue=12&author=P.+P.+Chamberlainauthor=L.+A.+D%E2%80%99Agostinoauthor=J.+M.+Ellisauthor=J.+D.+Hansenauthor=M.+E.+Matyskielaauthor=J.+J.+McDonaldauthor=J.+R.+Riggsauthor=L.+G.+Hamann&title=Evolution+of+Cereblon-Mediated+Protein+Degradation+as+a+Therapeutic+Modality&doi=10.1021%2Facsmedchemlett.9b00425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality</span></div><div class="casAuthors">Chamberlain, Philip P.; DAgostino, Laura A.; Ellis, J. Michael; Hansen, Joshua D.; Matyskiela, Mary E.; McDonald, Joseph J.; Riggs, Jennifer R.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1592-1602</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many cellular processes and pathways are mediated by the regulation of protein-protein complexes.  For example, E3 ubiquitin ligases recruit substrate proteins and transfer an ubiquitin tag to target those proteins for destruction by the proteasome.  It has now been shown that this cellular process for protein destruction can be redirected by small mols. in both lab. and clin. settings.  This presents a new paradigm in drug discovery, enabling the rapid removal of target proteins linked to disease.  In this review we will describe the work done on cereblon as a case study on the different strategies available for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppPyGPfBStwrVg90H21EOLACvtfcHk0ljabXA3abL-Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGjtL%252FL&md5=ee2c72a8f8e11216a491442165916237</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00425%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DL.%2BA.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DEvolution%2520of%2520Cereblon-Mediated%2520Protein%2520Degradation%2520as%2520a%2520Therapeutic%2520Modality%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D12%26spage%3D1592%26epage%3D1602%26doi%3D10.1021%2Facsmedchemlett.9b00425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a Primary Target of Thalidomide Teratogenicity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span> (<span class="NLM_issue">5971</span>),  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1126/science.1177319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1177319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20223979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1345-1350&issue=5971&author=T.+Itoauthor=H.+Andoauthor=T.+Suzukiauthor=T.+Oguraauthor=K.+Hottaauthor=Y.+Imamuraauthor=Y.+Yamaguchiauthor=H.+Handa&title=Identification+of+a+Primary+Target+of+Thalidomide+Teratogenicity&doi=10.1126%2Fscience.1177319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Primary Target of Thalidomide Teratogenicity</span></div><div class="casAuthors">Ito, Takumi; Ando, Hideki; Suzuki, Takayuki; Ogura, Toshihiko; Hotta, Kentaro; Imamura, Yoshimasa; Yamaguchi, Yuki; Handa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5971</span>),
    <span class="NLM_cas:pages">1345-1350</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects.  Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown.  Here, we identified cereblon (CRBN) as a thalidomide-binding protein.  CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.  Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the assocd. ubiquitin ligase activity.  This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivs. without teratogenic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPC_7RXLkfabVg90H21EOLACvtfcHk0lgCHWpkLubB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D&md5=4565a67837e0ec34ede2c93c1036f312</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1126%2Fscience.1177319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1177319%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Primary%2520Target%2520of%2520Thalidomide%2520Teratogenicity%26jtitle%3DScience%26date%3D2010%26volume%3D327%26issue%3D5971%26spage%3D1345%26epage%3D1350%26doi%3D10.1126%2Fscience.1177319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampaio, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galilly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>173</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1084/jem.173.3.699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1084%2Fjem.173.3.699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1997652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFKku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=1991&pages=699-703&issue=3&author=E.+P.+Sampaioauthor=E.+N.+Sarnoauthor=R.+Galillyauthor=Z.+A.+Cohnauthor=G.+Kaplan&title=Thalidomide+Selectively+Inhibits+Tumor+Necrosis+Factor+Alpha+Production+by+Stimulated+Human+Monocytes&doi=10.1084%2Fjem.173.3.699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes</span></div><div class="casAuthors">Sampaio, Elizabeth P.; Sarno, Euzenir N.; Galilly, Ruth; Cohn, Zanvil A.; Kaplan, Gilla</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">699-703</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">Thalidomide selectively inhibits the prodn. of human monocyte tumor necrosis factor-α (TNF-α) when these cells are triggered with lipopolysaccharide and other agonists in culture.  A 40% inhibition occurs at the clin. achievable concn. of 1 μg/mL.  The amt. of total protein and individual proteins labeled with [35S]methionine detected by SDS-PAGE are not affected by thalidomide.  The amts. of interleukin 1β (IL-1β), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered.  The selectivity of this drug may be useful in detg. the role of TNF-α in vivo and modulating its toxic effects in a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvBdYHP7onbVg90H21EOLACvtfcHk0lgCHWpkLubB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFKku70%253D&md5=a33ea2da47d0845627665a96a1fd3688</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1084%2Fjem.173.3.699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.173.3.699%26sid%3Dliteratum%253Aachs%26aulast%3DSampaio%26aufirst%3DE.%2BP.%26aulast%3DSarno%26aufirst%3DE.%2BN.%26aulast%3DGalilly%26aufirst%3DR.%26aulast%3DCohn%26aufirst%3DZ.%2BA.%26aulast%3DKaplan%26aufirst%3DG.%26atitle%3DThalidomide%2520Selectively%2520Inhibits%2520Tumor%2520Necrosis%2520Factor%2520Alpha%2520Production%2520by%2520Stimulated%2520Human%2520Monocytes%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1991%26volume%3D173%26issue%3D3%26spage%3D699%26epage%3D703%26doi%3D10.1084%2Fjem.173.3.699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haslett, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>187</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1892</span>, <span class="refDoi"> DOI: 10.1084/jem.187.11.1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1084%2Fjem.187.11.1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=9607928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1cXjs1eht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1998&pages=1885-1892&issue=11&author=P.+A.+Haslettauthor=L.+G.+Corralauthor=M.+Albertauthor=G.+Kaplan&title=Thalidomide+Costimulates+Primary+Human+T+Lymphocytes%2C+Preferentially+Inducing+Proliferation%2C+Cytokine+Production%2C+and+Cytotoxic+Responses+in+the+CD8%2B+Subset&doi=10.1084%2Fjem.187.11.1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset</span></div><div class="casAuthors">Haslett, Patrick A. J.; Corral, Laura G.; Albert, Matthew; Kaplan, Gilla</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1885-1892</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The efficacy of thalidomide (α-phthalimidoglutarimide) therapy in leprosy patients with erythema nodosum leprosum is thought to be due to inhibition of tumor necrosis factor α.  In other diseases reported to respond to thalidomide, the mechanism of action of the drug is unclear.  We show that thalidomide is a potent costimulator of primary human T cells in vitro, synergizing with stimulation via the T cell receptor complex to increase interleukin 2-mediated T cell proliferation and interferon γ prodn.  The costimulatory effect is greater on the CD8+ than the CD4+ T cell subset.  The drug also increases the primary CD8+ cytotoxic T cell response induced by allogeneic dendritic cells in the absence of CD4+ T cells.  Therefore, human T cell costimulation can be achieved pharmacol. with thalidomide, and preferentially in the CD8+ T cell subset.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlxTfsUapj-bVg90H21EOLACvtfcHk0lgCHWpkLubB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjs1eht7k%253D&md5=799f1ac43b794a37bb057f330a0ac5a7</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1084%2Fjem.187.11.1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.187.11.1885%26sid%3Dliteratum%253Aachs%26aulast%3DHaslett%26aufirst%3DP.%2BA.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DAlbert%26aufirst%3DM.%26aulast%3DKaplan%26aufirst%3DG.%26atitle%3DThalidomide%2520Costimulates%2520Primary%2520Human%2520T%2520Lymphocytes%252C%2520Preferentially%2520Inducing%2520Proliferation%252C%2520Cytokine%2520Production%252C%2520and%2520Cytotoxic%2520Responses%2520in%2520the%2520CD8%252B%2520Subset%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D187%26issue%3D11%26spage%3D1885%26epage%3D1892%26doi%3D10.1084%2Fjem.187.11.1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughnan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkman, J.</span></span> <span> </span><span class="NLM_article-title">Thalidomide Is an Inhibitor of Angiogenesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4082</span>– <span class="NLM_lpage">4085</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.9.4082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.91.9.4082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=7513432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFGmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=4082-4085&issue=9&author=R.+J.+D%E2%80%99Amatoauthor=M.+S.+Loughnanauthor=E.+Flynnauthor=J.+Folkman&title=Thalidomide+Is+an+Inhibitor+of+Angiogenesis&doi=10.1073%2Fpnas.91.9.4082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide is an inhibitor of angiogenesis</span></div><div class="casAuthors">D'Amato, Robert J.; Loughnan, Michael S.; Flynn, Evelyn; Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4082-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans.  The authors have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay.  Expts. including the anal. of thalidomide analogs revealed that the antiangiogenic activity correlated with the teratogenicity but not with the sedative or the mild immunosuppressive properties of thalidomide.  Electron microscopic examn. of the corneal neovascularization of thalidomide-treated rabbits revealed specific ultrastructural changes similar to those seen in the deformed limb bud vasculature of thalidomide-treated embryos.  These expts. shed light on the mechanism of thalidomide's teratogenicity and hold promise for the potential use of thalidomide as an orally administered drug for the treatment of many diverse diseases dependent on angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6LACOyP9P7Vg90H21EOLACvtfcHk0lim_DZv2wc7BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFGmsrY%253D&md5=e715297759cd4e5a8e1ec0c7b95f4540</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.9.4082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.9.4082%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DR.%2BJ.%26aulast%3DLoughnan%26aufirst%3DM.%2BS.%26aulast%3DFlynn%26aufirst%3DE.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DThalidomide%2520Is%2520an%2520Inhibitor%2520of%2520Angiogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D9%26spage%3D4082%26epage%3D4085%26doi%3D10.1073%2Fpnas.91.9.4082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span> <span> </span><span class="NLM_article-title">Amino-Substituted Thalidomide Analogs: Potent Inhibitors of TNF-Alpha Production</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1630</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00250-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS0960-894X%2899%2900250-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10386948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVKisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=1625-1630&issue=11&author=G.+W.+Mullerauthor=R.+Chenauthor=S.+Y.+Huangauthor=L.+G.+Corralauthor=L.+M.+Wongauthor=R.+T.+Pattersonauthor=Y.+Chenauthor=G.+Kaplanauthor=D.+I.+Stirling&title=Amino-Substituted+Thalidomide+Analogs%3A+Potent+Inhibitors+of+TNF-Alpha+Production&doi=10.1016%2FS0960-894X%2899%2900250-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production</span></div><div class="casAuthors">Muller, George W.; Chen, Roger; Huang, Shaei-Yun; Corral, Laura G.; Wong, Lu Min; Patterson, Rebecca T.; Chen, Yuxi; Kaplan, Gilla; Stirling, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1625-1630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Thalidomide is a known inhibitor of TNF-α release in LPS stimulated human PBMC.  Herein we describe the TNF-α inhibitory activity of amino substituted analogs of thalidomide and its isoindolin-1-one analog, EM-12.  The 4-amino substituted analogs were found to be potent inhibitors of TNF-α release in LPS stimulated human PBMC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-73DeaMOeK7Vg90H21EOLACvtfcHk0lim_DZv2wc7BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVKisbs%253D&md5=770d1a9078c6ffc93d743d6f59290dc6</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900250-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900250-4%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DG.%2BW.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DPatterson%26aufirst%3DR.%2BT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26atitle%3DAmino-Substituted%2520Thalidomide%2520Analogs%253A%2520Potent%2520Inhibitors%2520of%2520TNF-Alpha%2520Production%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D11%26spage%3D1625%26epage%3D1630%26doi%3D10.1016%2FS0960-894X%2899%2900250-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarlo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span> (<span class="NLM_issue">6168</span>),  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1126/science.1244851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1244851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24292625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=301-305&issue=6168&author=J.+Kr%C3%B6nkeauthor=N.+D.+Udeshiauthor=A.+Narlaauthor=P.+Graumanauthor=S.+N.+Hurstauthor=M.+McConkeyauthor=T.+Svinkinaauthor=D.+Hecklauthor=E.+Comerauthor=X.+Liauthor=C.+Ciarloauthor=E.+Hartmanauthor=N.+Munshiauthor=M.+Schenoneauthor=S.+L.+Schreiberauthor=S.+A.+Carrauthor=B.+L.+Ebert&title=Lenalidomide+Causes+Selective+Degradation+of+IKZF1+and+IKZF3+in+Multiple+Myeloma+Cells&doi=10.1126%2Fscience.1244851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span></div><div class="casAuthors">Kronke Jan; Udeshi Namrata D; Narla Anupama; Grauman Peter; Hurst Slater N; McConkey Marie; Svinkina Tanya; Heckl Dirk; Comer Eamon; Li Xiaoyu; Ciarlo Christie; Hartman Emily; Munshi Nikhil; Schenone Monica; Schreiber Stuart L; Carr Steven A; Ebert Benjamin L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown.  Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.  IKZF1 and IKZF3 are essential transcription factors in multiple myeloma.  A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth.  Similarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion of IKZF1 and IKZF3.  These findings reveal a previously unknown mechanism of action for a therapeutic agent: alteration of the activity of an E3 ubiquitin ligase, leading to selective degradation of specific targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiiGR0Yx7nuYFEOhA_Im3cfW6udTcc2eZyxzY8vGm5ZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D&md5=8cae3e554399308493aa38f0d05ed610</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244851%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DNarla%26aufirst%3DA.%26aulast%3DGrauman%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DHeckl%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCiarlo%26aufirst%3DC.%26aulast%3DHartman%26aufirst%3DE.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520Causes%2520Selective%2520Degradation%2520of%2520IKZF1%2520and%2520IKZF3%2520in%2520Multiple%2520Myeloma%2520Cells%26jtitle%3DScience%26date%3D2014%26volume%3D343%26issue%3D6168%26spage%3D301%26epage%3D305%26doi%3D10.1126%2Fscience.1244851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naniong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaelin, W. G.</span></span> <span> </span><span class="NLM_article-title">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span> (<span class="NLM_issue">6168</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&issue=6168&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.-K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+Myeloma+Drug+Lenalidomide+Promotes+the+Cereblon-Dependent+Destruction+of+Ikaros+Proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0lhuEgwVNlWVEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520Myeloma%2520Drug%2520Lenalidomide%2520Promotes%2520the%2520Cereblon-Dependent%2520Destruction%2520of%2520Ikaros%2520Proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26issue%3D6168%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chie-Leon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakoshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span> <span> </span><span class="NLM_article-title">Structure of the Human Cereblon-DDB1-Lenalidomide Complex Reveals Basis for Responsiveness to Thalidomide Analogs</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnsmb.2874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25108355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=803-810&issue=9&author=P.+P.+Chamberlainauthor=A.+Lopez-Gironaauthor=K.+Millerauthor=G.+Carmelauthor=B.+Pagariganauthor=B.+Chie-Leonauthor=E.+Rychakauthor=L.+G.+Corralauthor=Y.+J.+Renauthor=M.+Wangauthor=M.+Rileyauthor=S.+L.+Delkerauthor=T.+Itoauthor=H.+Andoauthor=T.+Moriauthor=Y.+Hiranoauthor=H.+Handaauthor=T.+Hakoshimaauthor=T.+O.+Danielauthor=B.+E.+Cathers&title=Structure+of+the+Human+Cereblon-DDB1-Lenalidomide+Complex+Reveals+Basis+for+Responsiveness+to+Thalidomide+Analogs&doi=10.1038%2Fnsmb.2874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs</span></div><div class="casAuthors">Chamberlain, Philip P.; Lopez-Girona, Antonia; Miller, Karen; Carmel, Gilles; Pagarigan, Barbra; Chie-Leon, Barbara; Rychak, Emily; Corral, Laura G.; Ren, Yan J.; Wang, Maria; Riley, Mariko; Delker, Silvia L.; Ito, Takumi; Ando, Hideki; Mori, Tomoyuki; Hirano, Yoshinori; Handa, Hiroshi; Hakoshima, Toshio; Daniel, Thomas O.; Cathers, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">803-809</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is the target of thalidomide, lenalidomide and pomalidomide, therapeutically important drugs for multiple myeloma and other B-cell malignancies.  These drugs directly bind Cereblon (CRBN) and promote the recruitment of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading to substrate ubiquitination and degrdn.  Here we present the crystal structure of human CRBN bound to DDB1 and the drug lenalidomide.  A hydrophobic pocket in the thalidomide-binding domain (TBD) of CRBN accommodates the glutarimide moiety of lenalidomide, whereas the isoindolinone ring is exposed to solvent.  We also solved the structures of the mouse TBD in the apo state and with thalidomide or pomalidomide.  Site-directed mutagenesis in lentiviral-expression myeloma models showed that key drug-binding residues are crit. for antiproliferative effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtN-ZCacB1m7Vg90H21EOLACvtfcHk0lhuEgwVNlWVEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI&md5=627fc3c8eae320059ca1cdc173bb56ed</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2874%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DChie-Leon%26aufirst%3DB.%26aulast%3DRychak%26aufirst%3DE.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DRen%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DDelker%26aufirst%3DS.%2BL.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHirano%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DHakoshima%26aufirst%3DT.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26atitle%3DStructure%2520of%2520the%2520Human%2520Cereblon-DDB1-Lenalidomide%2520Complex%2520Reveals%2520Basis%2520for%2520Responsiveness%2520to%2520Thalidomide%2520Analogs%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D9%26spage%3D803%26epage%3D810%26doi%3D10.1038%2Fnsmb.2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacBeth, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järås, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide Induces Ubiquitination and Degradation of CK1α in Del(5q) MDS</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>523</i></span> (<span class="NLM_issue">7559</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nature14610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature14610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26131937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=523&publication_year=2015&pages=183-188&issue=7559&author=J.+Kr%C3%B6nkeauthor=E.+C.+Finkauthor=P.+W.+Hollenbachauthor=K.+J.+MacBethauthor=S.+N.+Hurstauthor=N.+D.+Udeshiauthor=P.+P.+Chamberlainauthor=D.+R.+Maniauthor=H.-W.+Manauthor=A.+K.+Gandhiauthor=T.+Svinkinaauthor=R.+K.+Schneiderauthor=M.+McConkeyauthor=M.+J%C3%A4r%C3%A5sauthor=E.+Griffithsauthor=M.+Wetzlerauthor=L.+Bullingerauthor=B.+E.+Cathersauthor=S.+A.+Carrauthor=R.+Chopraauthor=B.+L.+Ebert&title=Lenalidomide+Induces+Ubiquitination+and+Degradation+of+CK1%CE%B1+in+Del%285q%29+MDS&doi=10.1038%2Fnature14610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS</span></div><div class="casAuthors">Kronke, Jan; Fink, Emma C.; Hollenbach, Paul W.; MacBeth, Kyle J.; Hurst, Slater N.; Udeshi, Namrata D.; Chamberlain, Philip P.; Mani, D. R.; Man, Hon Wah; Gandhi, Anita K.; Svinkina, Tanya; Schneider, Rebekka K.; McConkey, Marie; Jaras, Marcus; Griffiths, Elizabeth; Wetzler, Meir; Bullinger, Lars; Cathers, Brian E.; Carr, Steven A.; Chopra, Rajesh; Ebert, Benjamin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">523</span>
        (<span class="NLM_cas:issue">7559</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)).  Lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1α) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN), resulting in CK1α degrdn.  CK1α is encoded by a gene within the common deleted region for del(5q) MDS and haplo-insufficient expression sensitizes cells to lenalidomide therapy, providing a mechanistic basis for the therapeutic window of lenalidomide in del(5q) MDS.  The authors found that mouse cells are resistant to lenalidomide but that changing a single amino acid in mouse Crbn to the corresponding human residue enables lenalidomide-dependent degrdn. of CK1α.  The authors further demonstrate that minor side chain modifications in thalidomide and a novel analog, CC-122, can modulate the spectrum of substrates targeted by CRL4CRBN.  These findings have implications for the clin. activity of lenalidomide and related compds., and demonstrate the therapeutic potential of novel modulators of E3 ubiquitin ligases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLiHx3FKesbVg90H21EOLACvtfcHk0lhuEgwVNlWVEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN&md5=9b20a91c13e888e6569223ffa25af2cd</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1038%2Fnature14610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14610%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DFink%26aufirst%3DE.%2BC.%26aulast%3DHollenbach%26aufirst%3DP.%2BW.%26aulast%3DMacBeth%26aufirst%3DK.%2BJ.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DMani%26aufirst%3DD.%2BR.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DR.%2BK.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DJ%25C3%25A4r%25C3%25A5s%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DE.%26aulast%3DWetzler%26aufirst%3DM.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520Induces%2520Ubiquitination%2520and%2520Degradation%2520of%2520CK1%25CE%25B1%2520in%2520Del%25285q%2529%2520MDS%26jtitle%3DNature%26date%3D2015%26volume%3D523%26issue%3D7559%26spage%3D183%26epage%3D188%26doi%3D10.1038%2Fnature14610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Lenalidomide-Induced CK1α Degradation by the CRL4(CRBN) Ubiquitin Ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span> (<span class="NLM_issue">7597</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature16979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature16979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26909574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=127-130&issue=7597&author=G.+Petzoldauthor=E.+S.+Fischerauthor=N.+H.+Thom%C3%A4&title=Structural+Basis+of+Lenalidomide-Induced+CK1%CE%B1+Degradation+by+the+CRL4%28CRBN%29+Ubiquitin+Ligase&doi=10.1038%2Fnature16979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Petzold, Georg; Fischer, Eric S.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7597</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thalidomide and its derivs., lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of hematol. malignancies.  IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates.  Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degrdn.  Lenalidomide induces degrdn. of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clin. efficacy in the treatment of multiple myeloma and 5q-deletion assocd. myelodysplastic syndrome (del(5q) MDS), resp.  How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive.  Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α.  CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe.  We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD.  Binding of IKZF1 to CRBN similarly requires the compd. and both, IKZF1 and CK1α, use a related binding mode.  Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy.  We anticipate that high-affinity protein-protein interactions induced by small mols. will provide opportunities for drug development, particularly for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs4FxWriI1ObVg90H21EOLACvtfcHk0lggh6-T6snX5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D&md5=320fc6ff811da335fa8e02feab2d702d</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1038%2Fnature16979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16979%26sid%3Dliteratum%253Aachs%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructural%2520Basis%2520of%2520Lenalidomide-Induced%2520CK1%25CE%25B1%2520Degradation%2520by%2520the%2520CRL4%2528CRBN%2529%2520Ubiquitin%2520Ligase%26jtitle%3DNature%26date%3D2016%26volume%3D532%26issue%3D7597%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fnature16979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorklund, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havens, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amantangelo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourdehnad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakurta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span> <span> </span><span class="NLM_article-title">CC-122, a Pleiotropic Pathway Modifier, Mimics an Interferon Response and Has Antitumor Activity in DLBCL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-02-628669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1182%2Fblood-2015-02-628669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26002965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFahtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=779-789&issue=6&author=P.+R.+Hagnerauthor=H.-W.+Manauthor=C.+Fontanilloauthor=M.+Wangauthor=S.+Coutoauthor=M.+Breiderauthor=C.+Bjorklundauthor=C.+G.+Havensauthor=G.+Luauthor=E.+Rychakauthor=H.+Raymonauthor=R.+K.+Narlaauthor=L.+Barnesauthor=G.+Khambattaauthor=H.+Chiuauthor=J.+Kosekauthor=J.+Kangauthor=M.+D.+Amantangeloauthor=M.+Waldmanauthor=A.+Lopez-Gironaauthor=T.+Caiauthor=M.+Pourdehnadauthor=M.+Trotterauthor=T.+O.+Danielauthor=P.+H.+Schaferauthor=A.+Klippelauthor=A.+Thakurtaauthor=R.+Chopraauthor=A.+K.+Gandhi&title=CC-122%2C+a+Pleiotropic+Pathway+Modifier%2C+Mimics+an+Interferon+Response+and+Has+Antitumor+Activity+in+DLBCL&doi=10.1182%2Fblood-2015-02-628669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL</span></div><div class="casAuthors">Hagner, Patrick R.; Man, Hon-Wah; Fontanillo, Celia; Wang, Maria; Couto, Suzana; Breider, Mike; Bjorklund, Chad; Havens, Courtney G.; Lu, Gang; Rychak, Emily; Raymon, Heather; Narla, Rama Krishna; Barnes, Leo; Khambatta, Gody; Chiu, Hsiling; Kosek, Jolanta; Kang, Jian; Amantangelo, Michael D.; Waldman, Michelle; Lopez-Girona, Antonia; Cai, Ti; Pourdehnad, Michael; Trotter, Matthew; Daniel, Thomas O.; Schafer, Peter H.; Klippel, Anke; Thakurta, Anjan; Chopra, Rajesh; Gandhi, Anita K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-789</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.  Recently, it was demonstrated that binding of these drugs to CRBN promotes the ubiquitination and subsequent degrdn. of 2 common substrates, transcription factors Aiolos and Ikaros.  Here we report that CC-122, a new chem. entity termed pleiotropic pathway modifier, binds CRBN and promotes degrdn. of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo, and in patients, resulting in both cell autonomous as well as immunostimulatory effects.  In DLBCL cell lines, CC-122-induced degrdn. or short hairpin RNA-mediated knockdown of Aiolos and Ikaros correlates with increased transcription of interferon (IFN)-stimulated genes independent of IFN-α, -β, and -γ prodn. and/or secretion and results in apoptosis in both activated B-cell (ABC) and germinal center B-cell DLBCL cell lines.  Our results provide mechanistic insight into the cell-of-origin independent antilymphoma activity of CC-122, in contrast to the ABC subtype selective activity of lenalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Ayj7KrKYWrVg90H21EOLACvtfcHk0lggh6-T6snX5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFahtL7K&md5=786ea247e42ebc90dec67fc6f7a4e48b</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-02-628669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-02-628669%26sid%3Dliteratum%253Aachs%26aulast%3DHagner%26aufirst%3DP.%2BR.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DFontanillo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCouto%26aufirst%3DS.%26aulast%3DBreider%26aufirst%3DM.%26aulast%3DBjorklund%26aufirst%3DC.%26aulast%3DHavens%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DRychak%26aufirst%3DE.%26aulast%3DRaymon%26aufirst%3DH.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBarnes%26aufirst%3DL.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DChiu%26aufirst%3DH.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DAmantangelo%26aufirst%3DM.%2BD.%26aulast%3DWaldman%26aufirst%3DM.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DPourdehnad%26aufirst%3DM.%26aulast%3DTrotter%26aufirst%3DM.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DKlippel%26aufirst%3DA.%26aulast%3DThakurta%26aufirst%3DA.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26atitle%3DCC-122%252C%2520a%2520Pleiotropic%2520Pathway%2520Modifier%252C%2520Mimics%2520an%2520Interferon%2520Response%2520and%2520Has%2520Antitumor%2520Activity%2520in%2520DLBCL%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26issue%3D6%26spage%3D779%26epage%3D789%26doi%3D10.1182%2Fblood-2015-02-628669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baculi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBrun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=535-542&issue=2&author=M.+E.+Matyskielaauthor=W.+Zhangauthor=H.-W.+Manauthor=G.+Mullerauthor=G.+Khambattaauthor=F.+Baculiauthor=M.+Hickmanauthor=L.+LeBrunauthor=B.+Pagariganauthor=G.+Carmelauthor=C.-C.+Luauthor=G.+Luauthor=M.+Rileyauthor=Y.+Satohauthor=P.+Schaferauthor=T.+O.+Danielauthor=J.+Carmichaelauthor=B.+E.+Cathersauthor=P.+P.+Chamberlain&title=A+Cereblon+Modulator+%28CC-220%29+with+Improved+Degradation+of+Ikaros+and+Aiolos&doi=10.1021%2Facs.jmedchem.6b01921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span></div><div class="casAuthors">Matyskiela, Mary E.; Zhang, Weihong; Man, Hon-Wah; Muller, George; Khambatta, Godrej; Baculi, Frans; Hickman, Matthew; LeBrun, Laurie; Pagarigan, Barbra; Carmel, Gilles; Lu, Chin-Chun; Lu, Gang; Riley, Mariko; Satoh, Yoshitaka; Schafer, Peter; Daniel, Thomas O.; Carmichael, James; Cathers, Brian E.; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the CRL4-CRBN E3 ligase toward the transcription factors Ikaros and Aiolos to cause their ubiquitination and degrdn.  Here we describe CC-220 (compd. 6), a cereblon modulator in clin. development for systemic lupus erythematosis and relapsed/refractory multiple myeloma.  Compd. 6 binds cereblon with a higher affinity than lenalidomide or pomalidomide.  Consistent with this, the cellular degrdn. of Ikaros and Aiolos is more potent and the extent of substrate depletion is greater.  The crystal structure of cereblon in complex with DDB1 and compd. 6 reveals that the increase in potency correlates with increased contacts between compd. 6 and cereblon away from the modeled binding site for Ikaros/Aiolos.  These results describe a new cereblon modulator which achieves greater substrate degrdn. via tighter binding to the cereblon E3 ligase and provides an example of the effect of E3 ligase binding affinity with relevance to other drug discovery efforts in targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropbvYIxr5j7Vg90H21EOLACvtfcHk0liJmVRMR4WbPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D&md5=8358ae8563f8f2c09dbf68683e5e4008</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01921%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBaculi%26aufirst%3DF.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DLeBrun%26aufirst%3DL.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520Cereblon%2520Modulator%2520%2528CC-220%2529%2520with%2520Improved%2520Degradation%2520of%2520Ikaros%2520and%2520Aiolos%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D535%26epage%3D542%26doi%3D10.1021%2Facs.jmedchem.6b01921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchelman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A Novel Cereblon Modulator Recruits GSPT1 to the CRL4(CRBN) Ubiquitin Ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span> (<span class="NLM_issue">7611</span>),  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1038/nature18611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature18611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=252-257&issue=7611&author=M.+E.+Matyskielaauthor=G.+Luauthor=T.+Itoauthor=B.+Pagariganauthor=C.-C.+Luauthor=K.+Millerauthor=W.+Fangauthor=N.-Y.+Wangauthor=D.+Nguyenauthor=J.+Houstonauthor=G.+Carmelauthor=T.+Tranauthor=M.+Rileyauthor=L.+Nosakaauthor=G.+C.+Landerauthor=S.+Gaidarovaauthor=S.+Xuauthor=A.+L.+Ruchelmanauthor=H.+Handaauthor=J.+Carmichaelauthor=T.+O.+Danielauthor=B.+E.+Cathersauthor=A.+Lopez-Gironaauthor=P.+P.+Chamberlain&title=A+Novel+Cereblon+Modulator+Recruits+GSPT1+to+the+CRL4%28CRBN%29+Ubiquitin+Ligase&doi=10.1038%2Fnature18611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Matyskiela, Mary E.; Lu, Gang; Ito, Takumi; Pagarigan, Barbra; Lu, Chin-Chun; Miller, Karen; Fang, Wei; Wang, Nai-Yu; Nguyen, Derek; Houston, Jack; Carmel, Gilles; Tran, Tam; Riley, Mariko; Nosaka, Lyn'Al; Lander, Gabriel C.; Gaidarova, Svetlana; Xu, Shuichan; Ruchelman, Alexander L.; Handa, Hiroshi; Carmichael, James; Daniel, Thomas O.; Cathers, Brian E.; Lopez-Girona, Antonia; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7611</span>),
    <span class="NLM_cas:pages">252-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4CRBN E3 ubiquitin ligase.  Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumor activity.  The anti-tumor activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degrdn. of the translation termination factor GSPT1.  Patient-derived acute myeloid leukemia tumor cells exhibit high sensitivity to CC-885, indicating the clin. potential of this mechanism.  Crystallog. studies of the CRBN-DDB1-CC-885-GSPT1 complex reveal that GSPT1 binds to cereblon through a surface turn contg. a glycine residue at a key position, interacting with both CC-885 and a 'hotspot' on the cereblon surface.  Although GSPT1 possesses no obvious structural, sequence or functional homol. to previously known cereblon substrates, mutational anal. and modeling indicate that the cereblon substrate Ikaros uses a similar structural feature to bind cereblon, suggesting a common motif for substrate recruitment.  These findings define a structural degron underlying cereblon 'neosubstrate' selectivity, and identify an anti-tumor target rendered druggable by cereblon modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgAWiXdlJgYLVg90H21EOLACvtfcHk0liJmVRMR4WbPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI&md5=1d4e340416aa0b08fc0f123faf638c3f</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1038%2Fnature18611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18611%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DN.-Y.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DHouston%26aufirst%3DJ.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DNosaka%26aufirst%3DL.%26aulast%3DLander%26aufirst%3DG.%2BC.%26aulast%3DGaidarova%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DRuchelman%26aufirst%3DA.%2BL.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520Novel%2520Cereblon%2520Modulator%2520Recruits%2520GSPT1%2520to%2520the%2520CRL4%2528CRBN%2529%2520Ubiquitin%2520Ligase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26issue%3D7611%26spage%3D252%26epage%3D257%26doi%3D10.1038%2Fnature18611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goralski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaskill, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capota, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhawan, D.</span></span> <span> </span><span class="NLM_article-title">Anticancer Sulfonamides Target Splicing by Inducing RBM39 Degradation via Recruitment to DCAF15</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">6336</span>),  <span class="NLM_fpage">eaal3755</span>, <span class="refDoi"> DOI: 10.1126/science.aal3755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.aal3755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28302793" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2017&pages=eaal3755&issue=6336&author=T.+Hanauthor=M.+Goralskiauthor=N.+Gaskillauthor=E.+Capotaauthor=J.+Kimauthor=T.+C.+Tingauthor=Y.+Xieauthor=N.+S.+Williamsauthor=D.+Nijhawan&title=Anticancer+Sulfonamides+Target+Splicing+by+Inducing+RBM39+Degradation+via+Recruitment+to+DCAF15&doi=10.1126%2Fscience.aal3755"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1126%2Fscience.aal3755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aal3755%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DT.%26aulast%3DGoralski%26aufirst%3DM.%26aulast%3DGaskill%26aufirst%3DN.%26aulast%3DCapota%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DTing%26aufirst%3DT.%2BC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DN.%2BS.%26aulast%3DNijhawan%26aufirst%3DD.%26atitle%3DAnticancer%2520Sulfonamides%2520Target%2520Splicing%2520by%2520Inducing%2520RBM39%2520Degradation%2520via%2520Recruitment%2520to%2520DCAF15%26jtitle%3DScience%26date%3D2017%26volume%3D356%26issue%3D6336%26spage%3Deaal3755%26doi%3D10.1126%2Fscience.aal3755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okauchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimatsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugi, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyanagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitoh, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3789</span>– <span class="NLM_lpage">3799</span>, <span class="refDoi"> DOI: 10.1021/jm9902638</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9902638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXltlyqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3789-3799&issue=19&author=T.+Owaauthor=H.+Yoshinoauthor=T.+Okauchiauthor=K.+Yoshimatsuauthor=Y.+Ozawaauthor=N.+H.+Sugiauthor=T.+Nagasuauthor=N.+Koyanagiauthor=K.+Kitoh&title=Discovery+of+Novel+Antitumor+Sulfonamides+Targeting+G1+Phase+of+the+Cell+Cycle&doi=10.1021%2Fjm9902638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle</span></div><div class="casAuthors">Owa, Takashi; Yoshino, Hiroshi; Okauchi, Tatsuo; Yoshimatsu, Kentaro; Ozawa, Yoichi; Sugi, Naoko Hata; Nagasu, Takeshi; Koyanagi, Nozomu; Kitoh, Kyosuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3789-3799</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein is the discovery of a novel series of antitumor sulfonamides targeting G1 phase of the cell cycle.  Cell cycle control in G1 phase has attracted considerable attention in recent cancer research, because many of the important proteins involved in G1 progression or G1/S transition have been found to play a crucial role in proliferation, differentiation, transformation, and programmed cell death (apoptosis).  We previously reported our first antitumor sulfonamide E7010 as a novel tubulin polymn. inhibitor.  Interestingly enough, continuous research on structurally related compds. led us to the finding of another class of antitumor sulfonamides that block cell cycle progression of P388 murine leukemia cells in G1 phase, but not in M phase.  Of the compds. examd., N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide (E7070) showed significant antitumor activity against HCT116 human colon carcinoma both in vitro (IC50 0.11 μg/mL in cell proliferation assay) and in vivo (not only growth suppression but also a marked redn. of tumor size in nude mice).  Because of its promising efficacy against human tumor xenografts and its unique mode of action, E7070 is currently undergoing phase I clin. trials in European countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJHw-oFWkEIbVg90H21EOLACvtfcHk0lhyYVdMtDH7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltlyqurY%253D&md5=5019173efb40da605c495fc0dd77475a</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1021%2Fjm9902638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9902638%26sid%3Dliteratum%253Aachs%26aulast%3DOwa%26aufirst%3DT.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DOkauchi%26aufirst%3DT.%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DOzawa%26aufirst%3DY.%26aulast%3DSugi%26aufirst%3DN.%2BH.%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DKoyanagi%26aufirst%3DN.%26aulast%3DKitoh%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520Novel%2520Antitumor%2520Sulfonamides%2520Targeting%2520G1%2520Phase%2520of%2520the%2520Cell%2520Cycle%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26issue%3D19%26spage%3D3789%26epage%3D3799%26doi%3D10.1021%2Fjm9902638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkov, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhawan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span> <span> </span><span class="NLM_article-title">Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1633</span>, <span class="refDoi"> DOI: 10.1016/j.str.2019.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.str.2019.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31693911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFant7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1625-1633&issue=11&author=X.+Duauthor=O.+A.+Volkovauthor=R.+M.+Czerwinskiauthor=H.+Tanauthor=C.+Huertaauthor=E.+R.+Mortonauthor=J.+P.+Rizziauthor=P.+M.+Wehnauthor=R.+Xuauthor=D.+Nijhawanauthor=E.+M.+Wallace&title=Structural+Basis+and+Kinetic+Pathway+of+RBM39+Recruitment+to+DCAF15+by+a+Sulfonamide+Molecular+Glue+E7820&doi=10.1016%2Fj.str.2019.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820</span></div><div class="casAuthors">Du, Xinlin; Volkov, Oleg A.; Czerwinski, Robert M.; Tan, HuiLing; Huerta, Carlos; Morton, Emily R.; Rizzi, Jim P.; Wehn, Paul M.; Xu, Rui; Nijhawan, Deepak; Wallace, Eli M.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1625-1633.e3</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">E7820 and indisulam are two examples of aryl sulfonamides that recruit RBM39 to Rbx-Cul4-DDA1-DDB1-DCAF15 E3 ligase complex, leading to its ubiquitination and degrdn. by the proteasome.  To understand their mechanism of action, we performed kinetic anal. on the recruitment of RBM39 to DCAF15 and solved a crystal structure of DDA1-DDB1-DCAF15 in complex with E7820 and the RRM2 domain of RBM39.  E7820 packs in a shallow pocket on the surface of DCAF15 and the resulting modified interface binds RBM39 through the α1 helix of the RRM2 domain.  Our kinetic studies revealed that aryl sulfonamide and RBM39 bind to DCAF15 in a synergistic manner.  The structural and kinetic studies confirm aryl sulfonamides as mol. glues in the recruitment of RBM39 and provide a framework for future efforts to utilize DCAF15 to degrade other proteins of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptVt-FWWkhhrVg90H21EOLACvtfcHk0lhyYVdMtDH7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFant7fJ&md5=295a6f13e258e6fffc4a6a0ff8c773b9</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2019.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2019.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DX.%26aulast%3DVolkov%26aufirst%3DO.%2BA.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DHuerta%26aufirst%3DC.%26aulast%3DMorton%26aufirst%3DE.%2BR.%26aulast%3DRizzi%26aufirst%3DJ.%2BP.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DNijhawan%26aufirst%3DD.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26atitle%3DStructural%2520Basis%2520and%2520Kinetic%2520Pathway%2520of%2520RBM39%2520Recruitment%2520to%2520DCAF15%2520by%2520a%2520Sulfonamide%2520Molecular%2520Glue%2520E7820%26jtitle%3DStructure%26date%3D2019%26volume%3D27%26issue%3D11%26spage%3D1625%26epage%3D1633%26doi%3D10.1016%2Fj.str.2019.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="note"><p class="first last">The SciFinder database was searched in May 2019 to enumerate the heterodimeric compounds in the following manner. The search was initiated using the keyword “PROTAC”. CRBN-directed compounds were identified by substructure sorting on the key 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione and 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione pharmacophores. VHL-directed compounds were identified by sorting on the most commonly used 1-(2-amino-3,3-dimethylbutanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide ligand. In both cases, compounds were manually removed that were not designed to be heterodimeric degraders. In both cases, compounds were included even if there were no activity data reported. A sdf file containing these structures and associated calculated properties is included as a supplemental to this perspective.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lhyYVdMtDH7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoull, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petteruti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmusson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raubo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricchiuto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span> <span> </span><span class="NLM_article-title">Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC to Provide Insight Into Small Molecule Targeting of BCL6</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3131</span>– <span class="NLM_lpage">3141</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaisrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=3131-3141&issue=11&author=W.+McCoullauthor=T.+Cheungauthor=E.+Andersonauthor=P.+Bartonauthor=J.+Burgessauthor=K.+Bythauthor=Q.+Caoauthor=M.+P.+Castaldiauthor=H.+Chenauthor=E.+Chiarparinauthor=R.+J.+Carbajoauthor=E.+Codeauthor=S.+Cowanauthor=P.+R.+Daveyauthor=A.+D.+Fergusonauthor=S.+Filleryauthor=N.+O.+Fullerauthor=N.+Gaoauthor=D.+Hargreavesauthor=M.+R.+Howardauthor=J.+Huauthor=A.+Kawatkarauthor=P.+D.+Kemmittauthor=E.+Leoauthor=D.+M.+Molinaauthor=N.+O%E2%80%99Connellauthor=P.+Petterutiauthor=T.+Rasmussonauthor=P.+Rauboauthor=P.+B.+Rawlinsauthor=P.+Ricchiutoauthor=G.+R.+Robbauthor=M.+Schenoneauthor=M.+J.+Waringauthor=M.+Zindaauthor=S.+Fawellauthor=D.+M.+Wilson&title=Development+of+a+Novel+B-Cell+Lymphoma+6+%28BCL6%29+PROTAC+to+Provide+Insight+Into+Small+Molecule+Targeting+of+BCL6&doi=10.1021%2Facschembio.8b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6</span></div><div class="casAuthors">McCoull, William; Cheung, Tony; Anderson, Erica; Barton, Peter; Burgess, Jonathan; Byth, Kate; Cao, Qing; Castaldi, M. Paola; Chen, Huawei; Chiarparin, Elisabetta; Carbajo, Rodrigo J.; Code, Erin; Cowan, Suzanna; Davey, Paul R.; Ferguson, Andrew D.; Fillery, Shaun; Fuller, Nathan O.; Gao, Ning; Hargreaves, David; Howard, Martin R.; Hu, Jun; Kawatkar, Aarti; Kemmitt, Paul D.; Leo, Elisabetta; Molina, Daniel M.; O'Connell, Nichole; Petteruti, Philip; Rasmusson, Timothy; Raubo, Piotr; Rawlins, Philip B.; Ricchiuto, Piero; Robb, Graeme R.; Schenone, Monica; Waring, Michael J.; Zinda, Michael; Fawell, Stephen; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3131-3141</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">B-cell lymphoma 6 (BCL6) inhibition is a promising mechanism for treating hematol. cancers but high quality chem. probes are necessary to evaluate its therapeutic potential.  Here we report potent BCL6 inhibitors that demonstrate cellular target engagement and exhibit exquisite selectivity for BCL6 based on mass spectrometry analyses following chem. proteomic pull down.  Importantly, a proteolysis-targeting chimera, 4-((R)-25-Chloro-41-methyl-42-oxo-41,42,43,44-tetrahydro-5,8-dioxa-3-aza-4(6,8)-quinolina2(2,4)-pyrimidina-1(1,2)-piperazinacyclononaphane-14-yl)-N-(3-(2-(2-((2-((S)-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)propyl)-4-oxobutanamide trifluoroacetate, (PROTAC, 15) was also developed and shown to significantly degrade BCL6 in a no. of diffuse large B-cell lymphoma (DLBCL) cell lines, but neither BCL6 inhibition nor degrdn. selectively induced marked phenotypic response.  To investigate, we monitored PROTAC directed BCL6 degrdn. in DLBCL OCI-Ly1 cells by immunofluorescence and discovered a residual BCL6 population.  Anal. of subcellular fractions also showed incomplete BCL6 degrdn. in all fractions despite having measurable PROTAC concns., together providing a rationale for the weak antiproliferative response seen with both BCL6 inhibitor and degrader.  In summary, we have developed potent and selective BCL6 inhibitors and a BCL6 PROTAC that effectively degraded BCL6, but both modalities failed to induce a significant phenotypic response in DLBCL despite achieving cellular concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEe9aUjqcaHLVg90H21EOLACvtfcHk0lh7xIFM87eM7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaisrnF&md5=3d2c2d8acf143f05babee6ebdabddc8c</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00698%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoull%26aufirst%3DW.%26aulast%3DCheung%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBurgess%26aufirst%3DJ.%26aulast%3DByth%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DCastaldi%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCode%26aufirst%3DE.%26aulast%3DCowan%26aufirst%3DS.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DN.%2BO.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DHargreaves%26aufirst%3DD.%26aulast%3DHoward%26aufirst%3DM.%2BR.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKemmitt%26aufirst%3DP.%2BD.%26aulast%3DLeo%26aufirst%3DE.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DN.%26aulast%3DPetteruti%26aufirst%3DP.%26aulast%3DRasmusson%26aufirst%3DT.%26aulast%3DRaubo%26aufirst%3DP.%26aulast%3DRawlins%26aufirst%3DP.%2BB.%26aulast%3DRicchiuto%26aufirst%3DP.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520Novel%2520B-Cell%2520Lymphoma%25206%2520%2528BCL6%2529%2520PROTAC%2520to%2520Provide%2520Insight%2520Into%2520Small%2520Molecule%2520Targeting%2520of%2520BCL6%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D11%26spage%3D3131%26epage%3D3141%26doi%3D10.1021%2Facschembio.8b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span>; <span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Siu, K.</span>; <span class="NLM_string-name">Ferraro, C.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Qian, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for the Targeted Degradation of Androgen Receptor</span>. World Intellectual Property Organization, <span class="NLM_patent">WO2016118666 A1</span>, Jul 28, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jin%2C+M.%3B+Crew%2C+A.+P.%3B+Dong%2C+H.%3B+Wang%2C+J.%3B+Siu%2C+K.%3B+Ferraro%2C+C.%3B+Chen%2C+X.%3B+Qian%2C+Y.+Compounds+and+Methods+for+the+Targeted+Degradation+of+Androgen+Receptor.+World+Intellectual+Property+Organization%2C+WO2016118666+A1%2C+Jul+28%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520the%2520Targeted%2520Degradation%2520of%2520Androgen%2520Receptor" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Berlin, M.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Homberger, K. R.</span>; <span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">Snyder, L. B.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Zimmermann, K.</span></span> <span> </span><span class="NLM_article-title">Cereblon Ligands and Bifunctional Compounds Comprising the Same</span>. United States Patent Application Publication, <span class="NLM_patent">US20180215731</span>, Aug 2, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Crew%2C+A.+P.%3B+Berlin%2C+M.%3B+Dong%2C+H.%3B+Homberger%2C+K.+R.%3B+Qian%2C+Y.%3B+Snyder%2C+L.+B.%3B+Wang%2C+J.%3B+Zimmermann%2C+K.+Cereblon+Ligands+and+Bifunctional+Compounds+Comprising+the+Same.+United+States+Patent+Application+Publication%2C+US20180215731%2C+Aug+2%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrew%26aufirst%3DA.%2BP.%26atitle%3DCereblon%2520Ligands%2520and%2520Bifunctional%2520Compounds%2520Comprising%2520the%2520Same" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Crews, C. M.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Hornberger, K. R.</span>; <span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Modulators of Estrogen Receptor Proteolysis and Associated Methods of Use</span>. World Intellectual Property Organization, <span class="NLM_patent">WO2018140809</span>, Aug 2, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Qian%2C+Y.%3B+Crew%2C+A.+P.%3B+Crews%2C+C.+M.%3B+Dong%2C+H.%3B+Hornberger%2C+K.+R.%3B+Wang%2C+J.+Modulators+of+Estrogen+Receptor+Proteolysis+and+Associated+Methods+of+Use.+World+Intellectual+Property+Organization%2C+WO2018140809%2C+Aug+2%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26atitle%3DModulators%2520of%2520Estrogen%2520Receptor%2520Proteolysis%2520and%2520Associated%2520Methods%2520of%2520Use" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzer, P.</span></span> <span> </span><span class="NLM_article-title">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3714</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&issue=20&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+Calculation+of+Molecular+Polar+Surface+Area+as+a+Sum+of+Fragment-Based+Contributions+and+Its+Application+to+the+Prediction+of+Drug+Transport+Properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0lh7xIFM87eM7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520Calculation%2520of%2520Molecular%2520Polar%2520Surface%2520Area%2520as%2520a%2520Sum%2520of%2520Fragment-Based%2520Contributions%2520and%2520Its%2520Application%2520to%2520the%2520Prediction%2520of%2520Drug%2520Transport%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D20%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':[],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Frances P. Rodriguez-Rivera, <span class="NLM_string-name hlFld-ContribAuthor">Samuel M. Levi</span>. </span><span class="cited-content_cbyCitation_article-title">Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2021,</strong> <em>7 </em>
                                    (7)
                                     , 1117-1125. <a href="https://doi.org/10.1021/acscentsci.1c00389" title="DOI URL">https://doi.org/10.1021/acscentsci.1c00389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.1c00389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.1c00389%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DUnifying%252BCatalysis%252BFramework%252Bto%252BDissect%252BProteasomal%252BDegradation%252BParadigms%26aulast%3DRodriguez-Rivera%26aufirst%3DFrances%2BP.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27032021%26date%3D16062021%26volume%3D7%26issue%3D7%26spage%3D1117%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Willem den Besten, Kshitij Verma, Sayumi Yamazoe, Nicole Blaquiere, Wilson Phung, Anita Izrael-Tomasevic, Melinda M. Mulvihill, Elizabeth Helgason, Sumit Prakash, Tatiana Goncharov, Domagoj Vucic, Erin Dueber, Wayne J. Fairbrother, Ingrid Wertz, Kebing Yu, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Primary Amine Tethered Small Molecules Promote the Degradation of X-Linked Inhibitor of Apoptosis Protein. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (28)
                                     , 10571-10575. <a href="https://doi.org/10.1021/jacs.1c05269" title="DOI URL">https://doi.org/10.1021/jacs.1c05269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c05269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c05269%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPrimary%252BAmine%252BTethered%252BSmall%252BMolecules%252BPromote%252Bthe%252BDegradation%252Bof%252BX-Linked%252BInhibitor%252Bof%252BApoptosis%252BProtein%26aulast%3DBesten%26aufirst%3DWillem%2Bden%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D26052021%26date%3D08072021%26volume%3D143%26issue%3D28%26spage%3D10571%26epage%3D10575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jessica N. Spradlin, Erika Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Daniel K. Nomura</span>. </span><span class="cited-content_cbyCitation_article-title">Reimagining Druggability Using Chemoproteomic Platforms. </span><span class="cited-content_cbyCitation_journal-name">Accounts of Chemical Research</span><span> <strong>2021,</strong> <em>54 </em>
                                    (7)
                                     , 1801-1813. <a href="https://doi.org/10.1021/acs.accounts.1c00065" title="DOI URL">https://doi.org/10.1021/acs.accounts.1c00065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.accounts.1c00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.accounts.1c00065%26sid%3Dliteratum%253Aachs%26jtitle%3DAccounts%2520of%2520Chemical%2520Research%26atitle%3DReimagining%252BDruggability%252BUsing%252BChemoproteomic%252BPlatforms%26aulast%3DSpradlin%26aufirst%3DJessica%2BN.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D29012021%26date%3D18032021%26volume%3D54%26issue%3D7%26spage%3D1801%26epage%3D1813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nico Zinn, Thilo Werner, Carola Doce, Toby Mathieson, Christine Boecker, Gavain Sweetman, Christian Fufezan, <span class="NLM_string-name hlFld-ContribAuthor">Marcus Bantscheff</span>. </span><span class="cited-content_cbyCitation_article-title">Improved Proteomics-Based Drug Mechanism-of-Action Studies Using 16-Plex Isobaric Mass Tags. </span><span class="cited-content_cbyCitation_journal-name">Journal of Proteome Research</span><span> <strong>2021,</strong> <em>20 </em>
                                    (3)
                                     , 1792-1801. <a href="https://doi.org/10.1021/acs.jproteome.0c00900" title="DOI URL">https://doi.org/10.1021/acs.jproteome.0c00900</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jproteome.0c00900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jproteome.0c00900%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Proteome%2520Research%26atitle%3DImproved%252BProteomics-Based%252BDrug%252BMechanism-of-Action%252BStudies%252BUsing%252B16-Plex%252BIsobaric%252BMass%252BTags%26aulast%3DZinn%26aufirst%3DNico%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D23022021%26volume%3D20%26issue%3D3%26spage%3D1792%26epage%3D1801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hengmiao Cheng, Suvi T. M. Orr, Simon Bailey, Alexei Brooun, Ping Chen, Judith G. Deal, Yali L. Deng, Martin P. Edwards, Gary M. Gallego, Neil Grodsky, Buwen Huang, Mehran Jalaie, Stephen Kaiser, Robert S. Kania, Susan E. Kephart, Jennifer Lafontaine, Martha A. Ornelas, Mason Pairish, Simon Planken, Hong Shen, Scott Sutton, Luke Zehnder, Chau D. Almaden, Shubha Bagrodia, Matthew D. Falk, Hovhannes J. Gukasyan, Caroline Ho, Xiaolin Kang, Rachel E. Kosa, Ling Liu, Mary E. Spilker, Sergei Timofeevski, Ravi Visswanathan, Zhenxiong Wang, Fanxiu Meng, Shijian Ren, Li Shao, Feng Xu, <span class="NLM_string-name hlFld-ContribAuthor">John C. Kath</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 644-661. <a href="https://doi.org/10.1021/acs.jmedchem.0c01652" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDrug%252BDesign%252Band%252BSynthesis%252Bof%252BPI3K%2525CE%2525B1-Selective%252BInhibitor%252B%252528PF-06843195%252529%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D21092020%26date%3D24122020%26volume%3D64%26issue%3D1%26spage%3D644%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalie S.  Scholes</span>, <span class="hlFld-ContribAuthor ">Cristina  Mayor-Ruiz</span>, <span class="hlFld-ContribAuthor ">Georg E.  Winter</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and selectivity profiling of small-molecule degraders via multi-omics approaches. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (7)
                                     , 1048-1060. <a href="https://doi.org/10.1016/j.chembiol.2021.03.007" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.03.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.03.007%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DIdentification%252Band%252Bselectivity%252Bprofiling%252Bof%252Bsmall-molecule%252Bdegraders%252Bvia%252Bmulti-omics%252Bapproaches%26aulast%3DScholes%26aufirst%3DNatalie%2BS.%26date%3D2021%26volume%3D28%26issue%3D7%26spage%3D1048%26epage%3D1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zuzanna  Kozicka</span>, <span class="hlFld-ContribAuthor ">Nicolas Holger  Thomä</span>. </span><span class="cited-content_cbyCitation_article-title">Haven't got a glue: Protein surface variation for the design of molecular glue degraders. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (7)
                                     , 1032-1047. <a href="https://doi.org/10.1016/j.chembiol.2021.04.009" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DHaven%252527t%252Bgot%252Ba%252Bglue%25253A%252BProtein%252Bsurface%252Bvariation%252Bfor%252Bthe%252Bdesign%252Bof%252Bmolecular%252Bglue%252Bdegraders%26aulast%3DKozicka%26aufirst%3DZuzanna%26date%3D2021%26volume%3D28%26issue%3D7%26spage%3D1032%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marton  Siklos</span>, <span class="hlFld-ContribAuthor ">Stefan  Kubicek</span>. </span><span class="cited-content_cbyCitation_article-title">T
              herapeutic targeting of chromatin: status and opportunities. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1111/febs.15966" title="DOI URL">https://doi.org/10.1111/febs.15966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.15966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.15966%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DT%252Bherapeutic%252Btargeting%252Bof%252Bchromatin%25253A%252Bstatus%252Band%252Bopportunities%26aulast%3DSiklos%26aufirst%3DMarton%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew J.  Henley</span>, <span class="hlFld-ContribAuthor ">Angela N.  Koehler</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in targeting ‘undruggable’ transcription factors with small molecules. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>172 </em><a href="https://doi.org/10.1038/s41573-021-00199-0" title="DOI URL">https://doi.org/10.1038/s41573-021-00199-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-021-00199-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-021-00199-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DAdvances%252Bin%252Btargeting%252B%2525E2%252580%252598undruggable%2525E2%252580%252599%252Btranscription%252Bfactors%252Bwith%252Bsmall%252Bmolecules%26aulast%3DHenley%26aufirst%3DMatthew%2BJ.%26date%3D2021%26date%3D2021%26volume%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joachim  Rudolph</span>, <span class="hlFld-ContribAuthor ">Jeff  Settleman</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2021,</strong> <em>11 </em>
                                    (4)
                                     , 815-821. <a href="https://doi.org/10.1158/2159-8290.CD-21-0260" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-21-0260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-21-0260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-21-0260%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DEmerging%252BTrends%252Bin%252BCancer%252BDrug%252BDiscovery%2525E2%252580%252594From%252BDrugging%252Bthe%252B%2525E2%252580%25259CUndruggable%2525E2%252580%25259D%252Bto%252BOvercoming%252BResistance%26aulast%3DRudolph%26aufirst%3DJoachim%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D4%26spage%3D815%26epage%3D821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Maneiro</span>, <span class="hlFld-ContribAuthor ">E.  De Vita</span>, <span class="hlFld-ContribAuthor ">D.  Conole</span>, <span class="hlFld-ContribAuthor ">C.S.  Kounde</span>, <span class="hlFld-ContribAuthor ">Q.  Zhang</span>, <span class="hlFld-ContribAuthor ">E.W.  Tate</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/bs.pmch.2021.01.002" title="DOI URL">https://doi.org/10.1016/bs.pmch.2021.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmch.2021.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmch.2021.01.002%26sid%3Dliteratum%253Aachs%26atitle%3DPROTACs%25252C%252Bmolecular%252Bglues%252Band%252Bbifunctionals%252Bfrom%252Bbench%252Bto%252Bbedside%25253A%252BUnlocking%252Bthe%252Bclinical%252Bpotential%252Bof%252Bcatalytic%252Bdrugs%26aulast%3DManeiro%26aufirst%3DM.%26date%3D2021%26pub%3DElsevier%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas M.  Leissing</span>, <span class="hlFld-ContribAuthor ">Laura M.  Luh</span>, <span class="hlFld-ContribAuthor ">Philipp M.  Cromm</span>. </span><span class="cited-content_cbyCitation_article-title">Structure driven compound optimization in targeted protein degradation. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2020,</strong> <em>61 </em><a href="https://doi.org/10.1016/j.ddtec.2020.11.005" title="DOI URL">https://doi.org/10.1016/j.ddtec.2020.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2020.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2020.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DStructure%252Bdriven%252Bcompound%252Boptimization%252Bin%252Btargeted%252Bprotein%252Bdegradation%26aulast%3DLeissing%26aufirst%3DThomas%2BM.%26date%3D2020%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Willem  den Besten</span>, <span class="hlFld-ContribAuthor ">J. Russell  Lipford</span>. </span><span class="cited-content_cbyCitation_article-title">Prospecting for molecular glues. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (11)
                                     , 1157-1158. <a href="https://doi.org/10.1038/s41589-020-0620-z" title="DOI URL">https://doi.org/10.1038/s41589-020-0620-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41589-020-0620-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41589-020-0620-z%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DProspecting%252Bfor%252Bmolecular%252Bglues%26aulast%3Dden%2BBesten%26aufirst%3DWillem%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D11%26spage%3D1157%26epage%3D1158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew G.  Reidenbach</span>, <span class="hlFld-ContribAuthor ">Michael F.  Mesleh</span>, <span class="hlFld-ContribAuthor ">Dominick  Casalena</span>, <span class="hlFld-ContribAuthor ">Sonia M.  Vallabh</span>, <span class="hlFld-ContribAuthor ">Jayme L.  Dahlin</span>, <span class="hlFld-ContribAuthor ">Alison J.  Leed</span>, <span class="hlFld-ContribAuthor ">Alix I.  Chan</span>, <span class="hlFld-ContribAuthor ">Dmitry L.  Usanov</span>, <span class="hlFld-ContribAuthor ">Jenna B.  Yehl</span>, <span class="hlFld-ContribAuthor ">Christopher T.  Lemke</span>, <span class="hlFld-ContribAuthor ">Arthur J.  Campbell</span>, <span class="hlFld-ContribAuthor ">Rishi N.  Shah</span>, <span class="hlFld-ContribAuthor ">Om K.  Shrestha</span>, <span class="hlFld-ContribAuthor ">Joshua R.  Sacher</span>, <span class="hlFld-ContribAuthor ">Victor L.  Rangel</span>, <span class="hlFld-ContribAuthor ">Jamie A.  Moroco</span>, <span class="hlFld-ContribAuthor ">Murugappan  Sathappa</span>, <span class="hlFld-ContribAuthor ">Maria Cristina  Nonato</span>, <span class="hlFld-ContribAuthor ">Kong T.  Nguyen</span>, <span class="hlFld-ContribAuthor ">S. Kirk  Wright</span>, <span class="hlFld-ContribAuthor ">David R.  Liu</span>, <span class="hlFld-ContribAuthor ">Florence F.  Wagner</span>, <span class="hlFld-ContribAuthor ">Virendar K.  Kaushik</span>, <span class="hlFld-ContribAuthor ">Douglas S.  Auld</span>, <span class="hlFld-ContribAuthor ">Stuart L.  Schreiber</span>, <span class="hlFld-ContribAuthor ">Eric Vallabh  Minikel</span>. </span><span class="cited-content_cbyCitation_article-title">Multimodal small-molecule screening for human prion protein binders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (39)
                                     , 13516-13531. <a href="https://doi.org/10.1074/jbc.RA120.014905" title="DOI URL">https://doi.org/10.1074/jbc.RA120.014905</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA120.014905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA120.014905%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DMultimodal%252Bsmall-molecule%252Bscreening%252Bfor%252Bhuman%252Bprion%252Bprotein%252Bbinders%26aulast%3DReidenbach%26aufirst%3DAndrew%2BG.%26date%3D2020%26volume%3D295%26issue%3D39%26spage%3D13516%26epage%3D13531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claire  Whitworth</span>, <span class="hlFld-ContribAuthor ">Alessio  Ciulli</span>. </span><span class="cited-content_cbyCitation_article-title">New class of molecule targets proteins outside cells for degradation. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2020,</strong> <em>584 </em>
                                    (7820)
                                     , 193-194. <a href="https://doi.org/10.1038/d41586-020-02211-w" title="DOI URL">https://doi.org/10.1038/d41586-020-02211-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/d41586-020-02211-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fd41586-020-02211-w%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DNew%252Bclass%252Bof%252Bmolecule%252Btargets%252Bproteins%252Boutside%252Bcells%252Bfor%252Bdegradation%26aulast%3DWhitworth%26aufirst%3DClaire%26date%3D2020%26date%3D2020%26volume%3D584%26issue%3D7820%26spage%3D193%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Methods of measuring protein degradation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The graph depicts the relative change in estrogen receptor α (ERα) protein levels caused by selective estrogen receptor modulators and degraders (SERMs and SERDs) in MCF7 breast cancer cells, measured using quantitative fluorescence imaging (previously unpublished data). Each of the drugs results in the reduction of ERα to a new steady state level that represents the maximum percentage degradation that is achievable by each drug in this cell type and these assay conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0022.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Tool compounds to aid in mechanistic experiments for targeted protein degraders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0023.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) A composition model of CDK4/Cdc37/HSP90 cryo-EM structures (CDK4 cyan, Cdc37 orange, HSP90 salmon/mauve) displayed from PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWK">5FWK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWP">5FWP</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWM">5FWM</a>. (b) CDK4 from the complex with Cdc37/HSP90 compared to a normal closed state (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96">2W96</a>, cyclin-D removed for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0024.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinase inhibitors reported to promote degradation of associated targets through a mechanism that includes chaperone deprivation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0025.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and biochemical potency of compounds <b>17</b> and <b>18</b>.<a onclick="showRef(event, 'ref64 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref64 ref70 ref71">(64,70,71)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0026.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures and biochemical activity for selected LRRK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0027.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Clinical inhibitors of PI3Kα that induce selective degradation of mutant p110α.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0028.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structure of dihydroartemisinin (DHA, <b>26</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Downregulators of c-Kit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compounds reported to promote loss of BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chk1 downregulator V158411 (<b>32</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (a) Structures of representative BIR3-binding IAP antagonists: GDC-0152 (<b>33</b>), SM-406 (<b>34</b>), ASTX660 (<b>35</b>), and MV1 (<b>36</b>). (b) Crystal structure of cIAP-BIR3 (gray) in complex with <b>33</b> (cyan), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UW4">3UW4</a>.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Proposed mechanism for IAP-antagonist induced ubiquitylation of cIAP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures and activity of compounds <b>37</b> and <b>38</b> and structure of GSK126 (<b>39</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures and activity of selected Aurora-A inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0009.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures and activity of compounds <b>44</b> and <b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0010.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Steroidal antagonists and degraders of androgen receptor (AR).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0011.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Nonsteroidal antagonists and degraders of androgen receptor (AR).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0013.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Steroidal antagonists and degraders of ERα.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0014.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Representative nonsteroidal antagonists and degraders of ERα.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0015.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. X-ray structure of LSZ102 (cyan, <b>61</b>) bound to the LBD of ERα (gray) [PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F">6B0F</a>]. The ligand is tightly enclosed by a series of α helices.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0016.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. (a) Assembled subunits that make up the active E3 ligase CRL4<sup>CRBN</sup>; CRBN = cereblon, DDB1 = DNA damage-binding protein 1, CUL4A = Cullin 4A, RBX1 = RING box protein 1, E2/Ub = ubiquitin charged ubiquitin-conjugating enzyme. (b) Structures of the original immunomodulatory drugs (“IMiDs”): thalidomide (<b>66</b>), pomalidomide (<b>67</b>), and lenalidomide (<b>68</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0017.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (a) Simplified model of IMiD induced degradation mechanism of action. Additional CRL4<sup>CRBN</sup> subunits are omitted for clarity. (b) Crystal structure of <b>68</b> bound to human CRBN-DDB1 highlighting key interactions with the thalidomide-binding-domain (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TZ4">4TZ4</a>). (c) Crystal structure of the CRBN (cyan)–<b>68</b> (orange)–CK1α (magenta) complex (DDB1 ommitted for clarity) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FQD">5FQD</a>). (d) Key interactions between CRBN surface residues and CK1α β-hairpin loop residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0018.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Later generation IMiDs from scientists at Celgene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0019.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures of splicing inhibitor sulfonamides (“SPLAMs”).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0020.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Calculated properties of CRBN-directed heterodimeric compounds (<i>n</i> = 488), VHL-directed heterodimeric compounds (<i>n</i> = 344), and representative monomeric compounds from this Perspective (<i>n</i> = 39, 1–3 per target protein discussed): (a) molecular weight comparison; (b) number of rotatable bonds comparison, prediction of rotatable bonds using the standard methods implemented in the Open Eye software package; (c) TPSA comparison, showing calculated topological polar surface area estimated using the standard methods implemented in the Open Eye software package;<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> (d) calculated log <i>D</i> at pH = 7.4, showing the logarithm of the distribution coefficient calculated using MoKa (Molecular Discovery, version 2.6.4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/medium/jm0c00093_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0021.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Representative AR, ERα, and Bcl6 targeted modalities that promote degradation. Calculations for properties were done using the same software as in <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00093/20201019/images/large/jm0c00093_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00093&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37251" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37251" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 224 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span> <span> </span><span class="NLM_article-title">Development of Targeted Protein Degradation Therapeutics</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0362-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41589-019-0362-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31527835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslygur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=937-944&issue=10&author=P.+P.+Chamberlainauthor=L.+G.+Hamann&title=Development+of+Targeted+Protein+Degradation+Therapeutics&doi=10.1038%2Fs41589-019-0362-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Development of targeted protein degradation therapeutics</span></div><div class="casAuthors">Chamberlain, Philip P.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">937-944</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted protein degrdn. as a therapeutic modality has seen dramatic progress and massive investment in recent years because of the convergence of two key scientific breakthroughs: optimization of first-generation peptidic proteolysis-targeted chimeras (PROTACs) into more drug-like mols. able to support in vivo proof of concept and the discovery that clin. mols. function as degraders by binding and repurposing the proteins cereblon and DCAF15.  This provided clin. validation for the general approach through the cereblon modulator class of drugs and provided highly drug-like and ligand-efficient E3 ligase binders upon which to tether target-binding moieties.  Increasingly rational and systematic approaches including biophys. and structural studies on ternary complexes are being leveraged as the field advances.  In this Perspective we summarize the discoveries that have laid the foundation for future degrdn. therapeutics, focusing on those classes of small mols. that redirect E3 ubiquitin ligases to non-native substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfcIEwVR-Xq7Vg90H21EOLACvtfcHk0lhm3EPaOowlZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslygur%252FF&md5=468e3fd87ba2b21607dac8b495e5ecf6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0362-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0362-y%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DDevelopment%2520of%2520Targeted%2520Protein%2520Degradation%2520Therapeutics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26issue%3D10%26spage%3D937%26epage%3D944%26doi%3D10.1038%2Fs41589-019-0362-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maniaci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Bifunctional Chemical Probes Inducing Protein-Protein Interactions</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cbpa.2019.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31419624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=145-156&author=C.+Maniaciauthor=A.+Ciulli&title=Bifunctional+Chemical+Probes+Inducing+Protein-Protein+Interactions&doi=10.1016%2Fj.cbpa.2019.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional chemical probes inducing protein-protein interactions</span></div><div class="casAuthors">Maniaci, Chiara; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145-156</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inducing biomol. interactions with synthetic mols. to impact biol. function is a concept of enormous appeal.  Recent years have seen a resurgence of interest in designing bispecific mols. that serve as bridging agents to bring proteins together.  Pioneering structural and biophys. investigation of ternary complexes formed by mono-functional and bifunctional ligands highlights that proximity-induced stabilization or de novo formation of protein-protein interactions is a common feature of their mol. recognition.  In this review, we illustrate these concepts and advances with representative case studies, and highlight progress over the past three years, with particular focus on recruitment to E3 ubiquitin ligases by 'mol. glues' and chimeric dimerizers (PROTACs) for targeted protein degrdn.  This approach promises to significantly expand the range of tractable targets for chem. biol. and therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobXJM1PThHPbVg90H21EOLACvtfcHk0lhm3EPaOowlZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyltbjF&md5=4302bb010003177f4f5e5c3d4a401dc9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DManiaci%26aufirst%3DC.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DBifunctional%2520Chemical%2520Probes%2520Inducing%2520Protein-Protein%2520Interactions%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D52%26spage%3D145%26epage%3D156%26doi%3D10.1016%2Fj.cbpa.2019.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">PROteolysis TArgeting Chimeras (PROTACs) - Past, Present and Future</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2019.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ddtec.2019.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31200855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BB3M3mvFWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=15-27&author=M.+Petterssonauthor=C.+M.+Crews&title=PROteolysis+TArgeting+Chimeras+%28PROTACs%29+-+Past%2C+Present+and+Future&doi=10.1016%2Fj.ddtec.2019.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future</span></div><div class="casAuthors">Pettersson Mariell; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The majority of currently used therapeutics are small molecule-based and utilize occupancy-driven pharmacology as the mode of action (MOA), in which the protein function is modulated via temporary inhibition.  New modalities that operate using alternative MOAs are essential for tapping into the "undruggable" proteome.  The PROteolysis Targeting Chimera (PROTAC) technology provides an attractive new approach that utilizes an event-driven MOA.  Small molecule-based heterobifunctional PROTACs modulate protein target levels by hijacking the ubiquitin-proteasome system to induce degradation of the target.  Here, we address important milestones in the development of the PROTAC technology, as well as emphasize key findings from this previous year and highlight future directions of this promising drug discovery modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCRHissLLXoRfKb6ELK8t0fW6udTcc2ebcfYj_8OHXiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mvFWkuw%253D%253D&md5=c629f3128321e136f1f247e05ee6f182</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2019.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2019.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DPettersson%26aufirst%3DM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DPROteolysis%2520TArgeting%2520Chimeras%2520%2528PROTACs%2529%2520-%2520Past%252C%2520Present%2520and%2520Future%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2019%26volume%3D31%26spage%3D15%26epage%3D27%26doi%3D10.1016%2Fj.ddtec.2019.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallan, C.</span></span> <span> </span><span class="NLM_article-title">Proteolysis Targeting Chimeras (PROTACs) in “Beyond Rule-of-Five” Chemical Space: Recent Progress and Future Challenges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2019.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31047748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1555-1564&issue=13&author=S.+D.+Edmondsonauthor=B.+Yangauthor=C.+Fallan&title=Proteolysis+Targeting+Chimeras+%28PROTACs%29+in+%E2%80%9CBeyond+Rule-of-Five%E2%80%9D+Chemical+Space%3A+Recent+Progress+and+Future+Challenges&doi=10.1016%2Fj.bmcl.2019.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges</span></div><div class="casAuthors">Edmondson, Scott D.; Yang, Bin; Fallan, Charlene</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional compds. with mol. wts. and other properties that lie outside the classic 'rule-of-five' space.  Consequently, PROTACs have unique challenges assocd. with their development as potential therapeutic agents.  This review summarizes and analyzes a representative set of recent PROTACs and highlights some of the potential future challenges facing this promising modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcS0gIul-K7Vg90H21EOLACvtfcHk0lj9SZ7K1K0cWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12gs74%253D&md5=62a74500178bd711b1ddaa33d731b960</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DFallan%26aufirst%3DC.%26atitle%3DProteolysis%2520Targeting%2520Chimeras%2520%2528PROTACs%2529%2520in%2520%25E2%2580%259CBeyond%2520Rule-of-Five%25E2%2580%259D%2520Chemical%2520Space%253A%2520Recent%2520Progress%2520and%2520Future%2520Challenges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D13%26spage%3D1555%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2019.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Towbin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staehelin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, J.</span></span> <span> </span><span class="NLM_article-title">Immunoblotting in the Clinical Laboratory</span>. <i>J. Clin. Chem. Clin. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=2681521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaL1MXlslShtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1989&pages=495-501&issue=8&author=H.+Towbinauthor=T.+Staehelinauthor=J.+Gordon&title=Immunoblotting+in+the+Clinical+Laboratory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoblotting in the clinical laboratory</span></div><div class="casAuthors">Towbin, H.; Staehelin, T.; Gordon, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Chemistry and Clinical Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">495-501</span>CODEN:
                <span class="NLM_cas:coden">JCCBDT</span>;
        ISSN:<span class="NLM_cas:issn">0340-076X</span>.
    </div><div class="casAbstract">A review with 42 refs.  The basic principles of protein blotting are outlined and illustrated with some examples related to clin. applications, and differences between these and classical methods are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9f_ADICvAbVg90H21EOLACvtfcHk0lj9SZ7K1K0cWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlslShtbo%253D&md5=3d7dccbca1f6a24019126b2e48e7a4e1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTowbin%26aufirst%3DH.%26aulast%3DStaehelin%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DJ.%26atitle%3DImmunoblotting%2520in%2520the%2520Clinical%2520Laboratory%26jtitle%3DJ.%2520Clin.%2520Chem.%2520Clin.%2520Biochem.%26date%3D1989%26volume%3D27%26issue%3D8%26spage%3D495%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span> <span> </span><span class="NLM_article-title">Immunodetection of Proteins by Western Blotting</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1385/0-89603-204-3:221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1385%2F0-89603-204-3%3A221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23150313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK38XmsVyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=221-233&author=C.+J.+Hendersonauthor=C.+R.+Wolf&title=Immunodetection+of+Proteins+by+Western+Blotting&doi=10.1385%2F0-89603-204-3%3A221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Immunodetection of proteins by Western blotting</span></div><div class="casAuthors">Henderson, Colin J.; Wolf, C. Roland</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">Immunochem. Protoc.</span>),
    <span class="NLM_cas:pages">221-33</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">The procedure for Western blotting of peptides and proteins sepd. on a denaturing polyacrylamide gel system is detailed.  This procedure is used routinely for the anal. of peptides from a variety of subcellular fractions of whole tissue and cell lines and has evolved over a no. of years.  Many different immunoblotting procedures are currently available; details of variations from the 125I-protein-A method described here are given, as are brief amendments covering electrotransfer from 2-dimensional and isoelec. focusing systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgOh5AQrx9vbVg90H21EOLACvtfcHk0lh4iDLKSYS3ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVyjtrk%253D&md5=1ed6ce4801b7ba594430512239348129</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1385%2F0-89603-204-3%3A221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F0-89603-204-3%253A221%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DC.%2BJ.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26atitle%3DImmunodetection%2520of%2520Proteins%2520by%2520Western%2520Blotting%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D1992%26volume%3D10%26spage%3D221%26epage%3D233%26doi%3D10.1385%2F0-89603-204-3%3A221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, V. M.</span></span> <span> </span><span class="NLM_article-title">Protein Detection by Simple Western Analysis</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1312</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-2694-7_47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F978-1-4939-2694-7_47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26044028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbgs1Oksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1312&publication_year=2015&pages=465-468&author=V.+M.+Harris&title=Protein+Detection+by+Simple+Western+Analysis&doi=10.1007%2F978-1-4939-2694-7_47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Protein detection by Simple Western® analysis</span></div><div class="casAuthors">Harris Valerie M</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1312</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">465-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein Simple© has taken a well-known protein detection method, the western blot, and revolutionized it.  The Simple Western® system uses capillary electrophoresis to identify and quantitate a protein of interest.  Protein Simple© provides multiple detection apparatuses (Wes, Sally Sue, or Peggy Sue) that are suggested to save scientists valuable time by allowing the researcher to prepare the protein sample, load it along with necessary antibodies and substrates, and walk away.  Within 3-5 h the protein will be separated by size, or charge, immuno-detection of target protein will be accurately quantitated, and results will be immediately made available.  Using the Peggy Sue instrument, one study recently examined changes in MAPK signaling proteins in the sex-determining stage of gonadal development.  Here the methodology is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq2usTPByFh2HOrQ6qeX-mfW6udTcc2eYsICXjHFCqvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbgs1Oksw%253D%253D&md5=243a3117c68541fb2b53950eb743e270</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2694-7_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-2694-7_47%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DV.%2BM.%26atitle%3DProtein%2520Detection%2520by%2520Simple%2520Western%2520Analysis%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2015%26volume%3D1312%26spage%3D465%26epage%3D468%26doi%3D10.1007%2F978-1-4939-2694-7_47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katunuma, N.</span></span> <span> </span><span class="NLM_article-title">Use of Rabbit Antibody IgG Bound Onto Plain and Aminoalkylsilyl Glass Surface for the Enzyme-Linked Sandwich Immunoassay</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1093/oxfordjournals.jbchem.a131678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1093%2Foxfordjournals.jbchem.a131678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=408341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaE2sXltVSgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1977&pages=261-266&issue=1&author=K.+Katoauthor=Y.+Hamaguchiauthor=S.+Okawaauthor=E.+Ishikawaauthor=K.+Kobayashiauthor=N.+Katunuma&title=Use+of+Rabbit+Antibody+IgG+Bound+Onto+Plain+and+Aminoalkylsilyl+Glass+Surface+for+the+Enzyme-Linked+Sandwich+Immunoassay&doi=10.1093%2Foxfordjournals.jbchem.a131678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Use of rabbit antibody IgG bound onto plain and aminoalkylsilyl glass surface for the enzyme-linked sandwich immunoassay</span></div><div class="casAuthors">Kato, Kanefusa; Hamaguchi, Yoshitaka; Okawa, Sachiyo; Ishikawa, Eiji; Kobayashi, Keiko; Katunuma, Nobuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">261-6</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">Rabbit antibody IgG was bound onto aminoalkylsilyl or plain glass rods by simple adsorption.  For comparison, rabbit antibody IgG was also bound onto glutaraldehyde-activated aminoalkylsilyl glass rods.  These antibody-glass rods were tested by the sandwich procedure using Fab' fragments of rabbit antibody conjugated with β-D-galactosidase from Escherichia coli.  The glutaraldehyde-activated aminoalkylsilyl glass showed the largest capacity to bind antigen and the plain glass showed the smallest.  However, the antibody-glass rods prepd. by simple adsorption were as useful for the sandwich immunoassay of macromol. antigens as those prepd. with glutaraldehyde.  With all the antibody-glass rods prepd., 0.1-10 fmol of ornithine δ-aminotransferase from rat liver and 2,4-dinitrophenyl human IgG were measurable.  More than 10 fmol of the antigens may be measurable with larger amts. of the antibody-β-D-galactosidase complexes, although the non-specific binding of the complexes to the solid phase increases to limit the sensitivity of the immunoassay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJIgjGujt-RLVg90H21EOLACvtfcHk0lgKpQJgqHXVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXltVSgu7w%253D&md5=13a3a9e2b33543e30672ee3adb9f0879</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a131678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a131678%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DY.%26aulast%3DOkawa%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DE.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DKatunuma%26aufirst%3DN.%26atitle%3DUse%2520of%2520Rabbit%2520Antibody%2520IgG%2520Bound%2520Onto%2520Plain%2520and%2520Aminoalkylsilyl%2520Glass%2520Surface%2520for%2520the%2520Enzyme-Linked%2520Sandwich%2520Immunoassay%26jtitle%3DJ.%2520Biochem.%26date%3D1977%26volume%3D82%26issue%3D1%26spage%3D261%26epage%3D266%26doi%3D10.1093%2Foxfordjournals.jbchem.a131678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornbeck, P. V.</span></span> <span> </span><span class="NLM_article-title">Enzyme-Linked Immunosorbent Assays</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2.1.1</span>– <span class="NLM_lpage">2.1.23</span>, <span class="refDoi"> DOI: 10.1002/0471142735.im0201s110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2F0471142735.im0201s110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2015&pages=2.1.1-2.1.23&issue=1&author=P.+V.+Hornbeck&title=Enzyme-Linked+Immunosorbent+Assays&doi=10.1002%2F0471142735.im0201s110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F0471142735.im0201s110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471142735.im0201s110%26sid%3Dliteratum%253Aachs%26aulast%3DHornbeck%26aufirst%3DP.%2BV.%26atitle%3DEnzyme-Linked%2520Immunosorbent%2520Assays%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2015%26volume%3D110%26issue%3D1%26spage%3D2.1.1%26epage%3D2.1.23%26doi%3D10.1002%2F0471142735.im0201s110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aydin, S.</span></span> <span> </span><span class="NLM_article-title">A Short History, Principles, and Types of ELISA, and Our Laboratory Experience with Peptide/Protein Analyses Using ELISA</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2015.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.peptides.2015.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25908411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1Sruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=4-15&author=S.+Aydin&title=A+Short+History%2C+Principles%2C+and+Types+of+ELISA%2C+and+Our+Laboratory+Experience+with+Peptide%2FProtein+Analyses+Using+ELISA&doi=10.1016%2Fj.peptides.2015.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA</span></div><div class="casAuthors">Aydin, Suleyman</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4-15</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Playing a crit. role in the metabolic homeostasis of living systems, the circulating concns. of peptides/proteins are influenced by a variety of patho-physiol. events.  These peptide/protein concns. in biol. fluids were measured using various methods, the most common of which is enzymic immunoassay EIA/ELISA and which guide the clinicians in diagnosing and monitoring diseases that inflict biol. systems.  All the techniques where enzymes were employed to show antigen-antibody reactions are generally referred to as enzymic immunoassay EIA/ELISA method.  The basic principles of EIA and ELISA are the same.  The main objective of this review is to present an overview of the historical journey that had led to the invention of EIA/ELISA, an indispensible method for medical and research labs., types of ELISA developed after its invention [direct (the first ELISA method invented), indirect, sandwich and competitive methods], problems encountered during peptide/protein analyses (pre-anal., anal. and post-anal.), rules to be followed to prevent these problems, and the authors' lab. experience of >15 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruTnWISClXpbVg90H21EOLACvtfcHk0lgKpQJgqHXVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1Sruro%253D&md5=9db04530496e40dc07254ebd31f98ac5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2015.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2015.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DAydin%26aufirst%3DS.%26atitle%3DA%2520Short%2520History%252C%2520Principles%252C%2520and%2520Types%2520of%2520ELISA%252C%2520and%2520Our%2520Laboratory%2520Experience%2520with%2520Peptide%252FProtein%2520Analyses%2520Using%2520ELISA%26jtitle%3DPeptides%26date%3D2015%26volume%3D72%26spage%3D4%26epage%3D15%26doi%3D10.1016%2Fj.peptides.2015.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span> <span> </span><span class="NLM_article-title">A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides</span>. <i>Curr. Chem. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.2174/1875397300802010040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F1875397300802010040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20161842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVWhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=40-47&issue=1&author=Y.+Duauthor=F.+R.+Khuriauthor=H.+Fu&title=A+Homogenous+Luminescent+Proximity+Assay+for+14-3-3+Interactions+with+Both+Phosphorylated+and+Nonphosphorylated+Client+Peptides&doi=10.2174%2F1875397300802010040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A homogenous luminescent proximity assay for 14-3-3 interactions with both phosphorylated and nonphosphorylated client peptides</span></div><div class="casAuthors">Du, Yuhong; Khuri, Fadlo R.; Fu, Haian</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The 14-3-3 proteins are a family of dimeric eukaryotic proteins that mediate both phosphorylation-dependent and -independent protein-protein interactions.  Through these interactions, 14-3-3 proteins participate in the regulation of a wide range of cellular processes, including cell proliferation, cell cycle progression, and apoptosis.  Because of their fundamental importance, 14-3-3 proteins have also been implicated in a variety of diseases, including cancer and neurodegenerative disorders.  In order to monitor 14-3-3/client protein interactions for the discovery of small mol. 14-3-3 modulators, we have designed and optimized 14-3-3 protein binding assays based on the amplified luminescent proximity homogeneous assay (AlphaScreen) technol.  Using the interaction of 14-3-3 with a phosphorylated Raf-1 peptide and a nonphosphorylated R18 peptide as model systems, we have established homogenous "add-and-measure" high-throughput screening assays.  Both assays achieved robust performance with S/B ratios above 7 and Z' factors above 0.7.  Application of the known antagonistic peptides in our studies further validated the assay for screening of chem. compd. libraries to identify small mols. that can modulate 14-3-3 protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6cZFi3G3hbVg90H21EOLACvtfcHk0lgKpQJgqHXVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVWhurs%253D&md5=3317b19dd61113832e0b6d249fcb6cae</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1875397300802010040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397300802010040%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DY.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DFu%26aufirst%3DH.%26atitle%3DA%2520Homogenous%2520Luminescent%2520Proximity%2520Assay%2520for%252014-3-3%2520Interactions%2520with%2520Both%2520Phosphorylated%2520and%2520Nonphosphorylated%2520Client%2520Peptides%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2008%26volume%3D2%26issue%3D1%26spage%3D40%26epage%3D47%26doi%3D10.2174%2F1875397300802010040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eglen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouleau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielefeld, M.</span></span> <span> </span><span class="NLM_article-title">The Use of AlphaScreen Technology in HTS: Current Status</span>. <i>Curr. Chem. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.2174/1875397300801010002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F1875397300801010002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20161822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=2-10&issue=1&author=R.+M.+Eglenauthor=T.+Reisineauthor=P.+Robyauthor=N.+Rouleauauthor=C.+Illyauthor=R.+Boss%C3%A9author=M.+Bielefeld&title=The+Use+of+AlphaScreen+Technology+in+HTS%3A+Current+Status&doi=10.2174%2F1875397300801010002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The use of AlphaScreen technology in HTS: Current status</span></div><div class="casAuthors">Eglen, Richard M.; Reisine, Terry; Roby, Philippe; Rouleau, Nathalie; Illy, Chantal; Bosse, Roger; Bielefeld, Martina</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-10</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay Screen) is versatile assay technol. developed to measuring analytes using a homogeneous protocol.  This technol. is an example of a bead-based proximity assay and was developed from a diagnostic assay technol. known as LOCI (Luminescent Oxygen Channeling Assay).  Here, singlet oxygen mols., generated by high energy irradn. of Donor beads, travel over a constrained distance (approx. 200 nm) to Acceptor beads.  This results in excitation of a cascading series of chem. reactions, ultimately causing generation of a chemiluminescent signal.  In the past decade, a wide variety of applications has been reported, ranging from detection of analytes involved in cell signaling, including protein:protein, protein:peptide, protein:small mol. or peptide:peptide interactions.  Numerous homogeneous HTS-optimized assays have been reported using the approach, including generation of second messengers (such as accumulation of cAMP, cyclic GMP, inositol [1, 4, 5] trisphosphate or phosphorylated ERK) from liganded GPCRs or tyrosine kinase receptors, post-translational modification of proteins (such as proteolytic cleavage, phosphorylation, ubiquitination and sumoylation) as well as protein-protein and protein-nucleic acid interactions.  Recently, the basic AlphaScreen technol. was extended in that the chem. of the Acceptor bead was modified such that emitted light is more intense and spectrally defined, thereby markedly reducing interference from biol. fluid matrixes (such as trace hemolysis in serum and plasma).  In this format, referred to as AlphaLISA, it provides an alternative technol. to classical ELISA assays and is suitable for high throughput automated fluid dispensing and detection systems.  Collectively, AlphaScreen and AlphaLISA technologies provide a facile assay platform with which one can quantitate complex cellular processes using simple no-wash microtiter plate based assays.  They provide the means by which large compd. libraries can be screened in a high throughput fashion at a diverse range of therapeutically important targets, often not readily undertaken using other homogeneous assay technologies.  This review assesses the current status of the technol. in drug discovery, in general, and high throughput screening (HTS), in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4coo45wvUbbVg90H21EOLACvtfcHk0lgeOdNPhDBS1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D&md5=4d35f83091184d6eb4d1b76444754707</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F1875397300801010002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397300801010002%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.%2BM.%26aulast%3DReisine%26aufirst%3DT.%26aulast%3DRoby%26aufirst%3DP.%26aulast%3DRouleau%26aufirst%3DN.%26aulast%3DIlly%26aufirst%3DC.%26aulast%3DBoss%25C3%25A9%26aufirst%3DR.%26aulast%3DBielefeld%26aufirst%3DM.%26atitle%3DThe%2520Use%2520of%2520AlphaScreen%2520Technology%2520in%2520HTS%253A%2520Current%2520Status%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2008%26volume%3D1%26issue%3D1%26spage%3D2%26epage%3D10%26doi%3D10.2174%2F1875397300801010002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span> <span> </span><span class="NLM_article-title">Cellular Screening Assays Using Fluorescence Microscopy</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1016/S1471-4892(01)00092-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS1471-4892%2801%2900092-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=11764781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFOisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=533-539&issue=5&author=R.+A.+Blake&title=Cellular+Screening+Assays+Using+Fluorescence+Microscopy&doi=10.1016%2FS1471-4892%2801%2900092-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular screening assays using fluorescence microscopy</span></div><div class="casAuthors">Blake, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-539</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  The recent development of automated fluorescence imaging systems has enabled fluorescence microscopy to be used for the purposes of compd. screening.  This information-rich technique has found various applications, including screening for the effect of kinase inhibitors on the cytoskeleton, agonist-stimulated receptor internalization, and protein phosphorylation and acetylation.  The discovery of novel fluorescent proteins and new fluorescent dyes will find many applications in multichannel fluorescence imaging assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvnw-vrC-qJbVg90H21EOLACvtfcHk0lgeOdNPhDBS1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFOisr0%253D&md5=1ec689b223b9d83d3f68b4055cbb6c4a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1471-4892%2801%2900092-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4892%252801%252900092-3%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DR.%2BA.%26atitle%3DCellular%2520Screening%2520Assays%2520Using%2520Fluorescence%2520Microscopy%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2001%26volume%3D1%26issue%3D5%26spage%3D533%26epage%3D539%26doi%3D10.1016%2FS1471-4892%2801%2900092-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span> <span> </span><span class="NLM_article-title">High-Content Analysis in Preclinical Drug Discovery</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.2174/138620708783877780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F138620708783877780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18336214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslCisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=216-230&issue=3&author=P.+Dennerauthor=J.+Schmalowskyauthor=S.+Prechtl&title=High-Content+Analysis+in+Preclinical+Drug+Discovery&doi=10.2174%2F138620708783877780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">High-content analysis in preclinical drug discovery</span></div><div class="casAuthors">Denner, Philip; Schmalowsky, Janine; Prechtl, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-230</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  High-Content Anal. (HCA) has developed into an established tool and is used in a wide range of academic labs. and pharmaceutical research groups.  HCA is now routinely proving to be effective in providing functionally relevant results.  It is essential to select the appropriate HCA application with regard to the targeted compd.'s cellular function.  The cellular impact and compd. specificity as revealed by HCA anal. facilitates reaching definitive conclusions at an early stage in the drug discovery process.  This technol. therefore has the potential to substantially improve the efficiency of pharmaceutical research.  Recent advances in fluorescent probes have significantly boosted the success of HCA.  Auto-fluorescent proteins which minimally hinder the functioning of the living cell were playing a decisive role in cell biol. research.  For companies the severely restricted license conditions regarding auto-fluorescent proteins hamper their general use in pharmaceutical research.  This has opened the field for other solns. such as self-labeling protein technol., which could potentially replace the well established methods that utilize auto-fluorescent proteins.  In addn., direct labeling techniques have improved considerably and may supersede many of the approaches based on fusion proteins.  Following sample prepn., treated cells are imaged and the resulting multiple fluorescent signals are subjected to contextual and statistical anal.  The extraordinary advantage of HCA is that it enables the large-scale and simultaneous quantification and correlation of multiple phenotypic responses and physiol. reactions using sophisticated software solns. that permit assay-specific image anal.  Hence, HCA once more has demonstrated its outstanding potential to significantly support establishing effective pharmaceutical research processes to both advance research projects and cut costs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAmqzHcxZ0rLVg90H21EOLACvtfcHk0lhsR3NcEUs74Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslCisL8%253D&md5=528fa42c18fb54e0945ea318dfdd8b92</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F138620708783877780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620708783877780%26sid%3Dliteratum%253Aachs%26aulast%3DDenner%26aufirst%3DP.%26aulast%3DSchmalowsky%26aufirst%3DJ.%26aulast%3DPrechtl%26aufirst%3DS.%26atitle%3DHigh-Content%2520Analysis%2520in%2520Preclinical%2520Drug%2520Discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26issue%3D3%26spage%3D216%26epage%3D230%26doi%3D10.2174%2F138620708783877780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, N.</span></span> <span> </span><span class="NLM_article-title">Fluorescent Proteins and Engineered Cell Lines</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1385/1-59745-217-3:165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1385%2F1-59745-217-3%3A165" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2006&pages=165-187&author=N.+Thomas&title=Fluorescent+Proteins+and+Engineered+Cell+Lines&doi=10.1385%2F1-59745-217-3%3A165"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1385%2F1-59745-217-3%3A165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59745-217-3%253A165%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DN.%26atitle%3DFluorescent%2520Proteins%2520and%2520Engineered%2520Cell%2520Lines%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2006%26volume%3D356%26spage%3D165%26epage%3D187%26doi%3D10.1385%2F1-59745-217-3%3A165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D.</span></span> <span> </span><span class="NLM_article-title">Attaching Suspension Cells to Slides Using a Cytocentrifuge</span>. <i>Cold Spring Harbor Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">pdb.prot4291</span>, <span class="refDoi"> DOI: 10.1101/pdb.prot4291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1101%2Fpdb.prot4291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=pdb.prot4291&author=E.+Harlowauthor=D.+Lane&title=Attaching+Suspension+Cells+to+Slides+Using+a+Cytocentrifuge&doi=10.1101%2Fpdb.prot4291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1101%2Fpdb.prot4291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fpdb.prot4291%26sid%3Dliteratum%253Aachs%26aulast%3DHarlow%26aufirst%3DE.%26aulast%3DLane%26aufirst%3DD.%26atitle%3DAttaching%2520Suspension%2520Cells%2520to%2520Slides%2520Using%2520a%2520Cytocentrifuge%26jtitle%3DCold%2520Spring%2520Harbor%2520Protoc.%26date%3D2006%26spage%3Dpdb.prot4291%26doi%3D10.1101%2Fpdb.prot4291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D.</span></span> <span> </span><span class="NLM_article-title">Attaching Suspension Cells to Slides Using Chemical Linkers</span>. <i>Cold Spring Harbor Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">pdb.prot4292</span>, <span class="refDoi"> DOI: 10.1101/pdb.prot4292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1101%2Fpdb.prot4292" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=pdb.prot4292&author=E.+Harlowauthor=D.+Lane&title=Attaching+Suspension+Cells+to+Slides+Using+Chemical+Linkers&doi=10.1101%2Fpdb.prot4292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1101%2Fpdb.prot4292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fpdb.prot4292%26sid%3Dliteratum%253Aachs%26aulast%3DHarlow%26aufirst%3DE.%26aulast%3DLane%26aufirst%3DD.%26atitle%3DAttaching%2520Suspension%2520Cells%2520to%2520Slides%2520Using%2520Chemical%2520Linkers%26jtitle%3DCold%2520Spring%2520Harbor%2520Protoc.%26date%3D2006%26spage%3Dpdb.prot4292%26doi%3D10.1101%2Fpdb.prot4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teramura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekdahl, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, B.</span></span> <span> </span><span class="NLM_article-title">Cell Adhesion Induced Using Surface Modification with Cell-Penetrating Peptide-Conjugated Poly(Ethylene Glycol)-Lipid: a New Cell Glue for 3D Cell-Based Structures</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b14584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b14584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyrt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=244-254&issue=1&author=Y.+Teramuraauthor=S.+Asifauthor=K.+N.+Ekdahlauthor=E.+Gustafsonauthor=B.+Nilsson&title=Cell+Adhesion+Induced+Using+Surface+Modification+with+Cell-Penetrating+Peptide-Conjugated+Poly%28Ethylene+Glycol%29-Lipid%3A+a+New+Cell+Glue+for+3D+Cell-Based+Structures&doi=10.1021%2Facsami.6b14584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Adhesion Induced Using Surface Modification with Cell-Penetrating Peptide-Conjugated Poly(ethylene glycol)-Lipid: A New Cell Glue for 3D Cell-Based Structures</span></div><div class="casAuthors">Teramura, Yuji; Asif, Sana; Ekdahl, Kristina N.; Gustafson, Elisabet; Nilsson, Bo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">244-254</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We synthesized a novel material, cell-penetrating peptide-conjugated poly(ethylene glycol)-lipid (CPP-PEG-lipid), that can induce the adhesion of floating cells.  Firm cell adhesion with spreading could be induced by cell surface modification with the CPP-PEG-lipids.  Cell adhesion was induced by CPPs but not by any other cationic short peptides we tested.  Here, we demonstrated adherence using the floating cell line CCRF-CEM as well as primary human T cells, B cells, erythrocytes, and hepatocytes.  As compared to cells grown in suspension, adherent cells were more rapidly induced to attach to substrates with the cell-surface modification.  The crit. factor for attachment was localization of CPPs at the cell membrane by PEG-lipids with PEG > 20 kDa.  These cationic CPPs on PEG chains were able to interact with substrate surfaces such as polystyrene (PS) surfaces, glass surfaces, and PS microfibers that are neg. charged, inducing firm cell adhesion and cell spreading.  Also, as opposed to normal cationic peptides that interact strongly with cell membranes, CPPs were less interactive with the cell surfaces because of their cell-penetrating property, making them more available for adhering cells to the substrate surface.  No effects on cell viability or cell proliferation were obsd. after the induction of cell adhesion.  With this technique, cells could be easily immobilized onto PS microfibers, an important step in fabricating 3D cell-based structures.  Cells immobilized onto 3D PS microfibers were alive, and human hepatocytes showed normal prodn. of urea and albumin on the microfibers.  This method is novel in inducing firm cell adhesion via a one-step treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLoWYxS2RPXbVg90H21EOLACvtfcHk0lhsR3NcEUs74Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyrt7vE&md5=8ae54e2cc42ad0446334fd487fcfa19f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b14584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b14584%26sid%3Dliteratum%253Aachs%26aulast%3DTeramura%26aufirst%3DY.%26aulast%3DAsif%26aufirst%3DS.%26aulast%3DEkdahl%26aufirst%3DK.%2BN.%26aulast%3DGustafson%26aufirst%3DE.%26aulast%3DNilsson%26aufirst%3DB.%26atitle%3DCell%2520Adhesion%2520Induced%2520Using%2520Surface%2520Modification%2520with%2520Cell-Penetrating%2520Peptide-Conjugated%2520Poly%2528Ethylene%2520Glycol%2529-Lipid%253A%2520a%2520New%2520Cell%2520Glue%2520for%25203D%2520Cell-Based%2520Structures%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2017%26volume%3D9%26issue%3D1%26spage%3D244%26epage%3D254%26doi%3D10.1021%2Facsami.6b14584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quah, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, C. R.</span></span> <span> </span><span class="NLM_article-title">Monitoring Lymphocyte Proliferation in Vitro and in Vivo with the Intracellular Fluorescent Dye Carboxyfluorescein Diacetate Succinimidyl Ester</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2049</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnprot.2007.296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17853860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2049-2056&issue=9&author=B.+J.+Quahauthor=H.+S.+Warrenauthor=C.+R.+Parish&title=Monitoring+Lymphocyte+Proliferation+in+Vitro+and+in+Vivo+with+the+Intracellular+Fluorescent+Dye+Carboxyfluorescein+Diacetate+Succinimidyl+Ester&doi=10.1038%2Fnprot.2007.296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester</span></div><div class="casAuthors">Quah, Ben J. C.; Warren, Hilary S.; Parish, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2049-2056</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol outlines the carboxyfluorescein diacetate succinimidyl ester (CFSE) method for following the proliferation of human lymphocytes in vitro and mouse lymphocytes both in vitro and in vivo.  The method relies on the ability of CFSE to covalently label long-lived intracellular mols. with the highly fluorescent dye, carboxyfluorescein.  Following each cell division, the equal distribution of these fluorescent mols. to progeny cells results in a halving of the fluorescence of daughter cells.  The CFSE labeling protocol described, which typically takes <1 h to perform, allows the detection of up to eight cell divisions before CFSE fluorescence is decreased to the background fluorescence of unlabeled cells.  Protocols are outlined for labeling large and small nos. of human and mouse lymphocytes, labeling conditions being identified that minimize CFSE toxicity but maximize the no. of cell divisions detected.  An important feature of the technique is that division-dependent changes in the expression of cell-surface markers and intracellular proteins are easily quantified by flow cytometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop6vkbNREW8rVg90H21EOLACvtfcHk0lgTw16RS3glEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FL&md5=201f688e3fe9b95681d418001dc80a32</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.296%26sid%3Dliteratum%253Aachs%26aulast%3DQuah%26aufirst%3DB.%2BJ.%26aulast%3DWarren%26aufirst%3DH.%2BS.%26aulast%3DParish%26aufirst%3DC.%2BR.%26atitle%3DMonitoring%2520Lymphocyte%2520Proliferation%2520in%2520Vitro%2520and%2520in%2520Vivo%2520with%2520the%2520Intracellular%2520Fluorescent%2520Dye%2520Carboxyfluorescein%2520Diacetate%2520Succinimidyl%2520Ester%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26issue%3D9%26spage%3D2049%26epage%3D2056%26doi%3D10.1038%2Fnprot.2007.296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchser, W.</span>; <span class="NLM_string-name">Collins, M.</span>; <span class="NLM_string-name">Garyantes, T.</span>; <span class="NLM_string-name">Guha, R.</span>; <span class="NLM_string-name">Haney, S.</span>; <span class="NLM_string-name">Lemmon, V.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Trask, O. J.</span></span> <span> </span><span class="NLM_article-title">Assay Development Guidelines for Image-Based High Content Screening, High Content Analysis and High Content Imaging</span>. In  <i>Assay Guidance Manual</i> [Online]; <span class="NLM_contrib-group"><span class="NLM_string-name">Sittampalam, G. S.</span>, <span class="NLM_string-name">Coussens, N. P.</span>, <span class="NLM_string-name">Brimacombe, K.</span>, <span class="NLM_string-name">Grossman, A.</span>, <span class="NLM_string-name">Arkin, M.</span>, <span class="NLM_string-name">Auld, D.</span>, <span class="NLM_string-name">Austin, C.</span>, <span class="NLM_string-name">Baell, J.</span>, <span class="NLM_string-name">Bejcek, B.</span>, <span class="NLM_string-name">Caaveiro, J. M. M.</span>, <span class="NLM_string-name">Chung, T. D. Y.</span>, <span class="NLM_string-name">Dahlin, J. L.</span>, <span class="NLM_string-name">Devanaryan, V.</span>, <span class="NLM_string-name">Foley, T. L.</span>, <span class="NLM_string-name">Glicksman, M.</span>, <span class="NLM_string-name">Hall, M. D.</span>, <span class="NLM_string-name">Haas, J. V.</span>, <span class="NLM_string-name">Inglese, J.</span>, <span class="NLM_string-name">Iversen, P. W.</span>, <span class="NLM_string-name">Kahl, S. D.</span>, <span class="NLM_string-name">Kales, S. C.</span>, <span class="NLM_string-name">Lal-Nag, M.</span>, <span class="NLM_string-name">Li, Z.</span>, <span class="NLM_string-name">McGee, J.</span>, <span class="NLM_string-name">McManus, O.</span>, <span class="NLM_string-name">Riss, T.</span>, <span class="NLM_string-name">Trask, O. J. J.</span>, <span class="NLM_string-name">Weidner, J. R.</span>, <span class="NLM_string-name">Wildey, M. J.</span>, <span class="NLM_string-name">Xia, M.</span>, <span class="NLM_string-name">Xu, X.</span></span>, Eds.; <span class="NLM_publisher-name">Eli Lilly & Company and the National Center for Advancing Translational Sciences</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2004</span>; <a href="https://www.ncbi.nlm.nih.gov/books/NBK53196/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK53196/</a> (accessed March 20, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=W.+Buchser&author=M.+Collins&author=T.+Garyantes&author=R.+Guha&author=S.+Haney&author=V.+Lemmon&author=Z.+Li&author=O.+J.+Traskauthor=G.+S.+Sittampalam&author=N.+P.+Coussens&author=K.+Brimacombe&author=A.+Grossman&author=M.+Arkin&author=D.+Auld&author=C.+Austin&author=J.+Baell&author=B.+Bejcek&author=J.+M.+M.+Caaveiro&author=T.+D.+Y.+Chung&author=J.+L.+Dahlin&author=V.+Devanaryan&author=T.+L.+Foley&author=M.+Glicksman&author=M.+D.+Hall&author=J.+V.+Haas&author=J.+Inglese&author=P.+W.+Iversen&author=S.+D.+Kahl&author=S.+C.+Kales&author=M.+Lal-Nag&author=Z.+Li&author=J.+McGee&author=O.+McManus&author=T.+Riss&author=O.+J.+J.+Trask&author=J.+R.+Weidner&author=M.+J.+Wildey&author=M.+Xia&author=X.+Xu&title=Assay+Guidance+Manual"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBuchser%26aufirst%3DW.%26atitle%3DAssay%2520Development%2520Guidelines%2520for%2520Image-Based%2520High%2520Content%2520Screening%252C%2520High%2520Content%2520Analysis%2520and%2520High%2520Content%2520Imaging%26btitle%3DAssay%2520Guidance%2520Manual%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%26pub%3DEli%2520Lilly%2520%2526%2520Company%2520and%2520the%2520National%2520Center%2520for%2520Advancing%2520Translational%2520Sciences%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandavilli, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. S.</span></span> <span> </span><span class="NLM_article-title">General Staining and Segmentation Procedures for High Content Imaging and Analysis</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1683</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7357-6_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F978-1-4939-7357-6_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29082484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaitbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1683&publication_year=2018&pages=21-31&author=K.+M.+Chambersauthor=B.+S.+Mandavilliauthor=N.+J.+Dolmanauthor=M.+S.+Janes&title=General+Staining+and+Segmentation+Procedures+for+High+Content+Imaging+and+Analysis&doi=10.1007%2F978-1-4939-7357-6_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">General staining and segmentation procedures for high content imaging and analysis</span></div><div class="casAuthors">Chambers, Kevin M.; Mandavilli, Bhaskar S.; Dolman, Nick J.; Janes, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1683</span>
        (<span class="NLM_cas:issue">High Content Screening</span>),
    <span class="NLM_cas:pages">21-31</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Automated quant. fluorescence microscopy, also known as high content imaging (HCI), is a rapidly growing anal. approach in cell biol.  Because automated image anal. relies heavily on robust demarcation of cells and subcellular regions, reliable methods for labeling cells is a crit. component of the HCI workflow.  Labeling of cells for image segmentation is typically performed with fluorescent probes that bind DNA for nuclear-based cell demarcation or with those which react with proteins for image anal. based on whole cell staining.  These reagents, along with instrument and software settings, play an important role in the successful segmentation of cells in a population for automated and quant. image anal.  In this chapter, we describe std. procedures for labeling and image segmentation in both live and fixed cell samples.  The chapter will also provide troubleshooting guidelines for some of the common problems assocd. with these aspects of HCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYzCb2juHZCrVg90H21EOLACvtfcHk0ljU_gJ9vJPAJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaitbfE&md5=e15d3716e8a8015b503dd0421a92576e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7357-6_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7357-6_2%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DK.%2BM.%26aulast%3DMandavilli%26aufirst%3DB.%2BS.%26aulast%3DDolman%26aufirst%3DN.%2BJ.%26aulast%3DJanes%26aufirst%3DM.%2BS.%26atitle%3DGeneral%2520Staining%2520and%2520Segmentation%2520Procedures%2520for%2520High%2520Content%2520Imaging%2520and%2520Analysis%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2018%26volume%3D1683%26spage%3D21%26epage%3D31%26doi%3D10.1007%2F978-1-4939-7357-6_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, F.</span></span> <span> </span><span class="NLM_article-title">New Developments and Novel Applications in High Throughput and High Content Imaging</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1002/cyto.a.22921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcyto.a.22921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27564063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2szkvVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=705-707&issue=8&author=M.+E.+Calvertauthor=A.+M.+Wardauthor=G.+D.+Wrightauthor=F.+Bard&title=New+Developments+and+Novel+Applications+in+High+Throughput+and+High+Content+Imaging&doi=10.1002%2Fcyto.a.22921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New developments and novel applications in high throughput and high content imaging</span></div><div class="casAuthors">Calvert Meredith E K; Ward Alex M; Wright Graham D; Bard Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry. Part A : the journal of the International Society for Analytical Cytology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">705-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrL0J-xPHBpZggzHGM8X5CfW6udTcc2eZgEvC1eToMUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szkvVegtg%253D%253D&md5=191afb75328b91554530fb2990545109</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.22921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.22921%26sid%3Dliteratum%253Aachs%26aulast%3DCalvert%26aufirst%3DM.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BM.%26aulast%3DWright%26aufirst%3DG.%2BD.%26aulast%3DBard%26aufirst%3DF.%26atitle%3DNew%2520Developments%2520and%2520Novel%2520Applications%2520in%2520High%2520Throughput%2520and%2520High%2520Content%2520Imaging%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2016%26volume%3D89%26issue%3D8%26spage%3D705%26epage%3D707%26doi%3D10.1002%2Fcyto.a.22921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, M. E.</span></span> <span> </span><span class="NLM_article-title">Pushing the Boundaries of High Content Imaging</span>. <i>Cytometry, Part A</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1002/cyto.a.23063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcyto.a.23063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28222254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ptVyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=113-114&issue=2&author=G.+D.+Wrightauthor=A.+M.+Wardauthor=F.+Bardauthor=M.+E.+Calvert&title=Pushing+the+Boundaries+of+High+Content+Imaging&doi=10.1002%2Fcyto.a.23063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pushing the boundaries of high content imaging</span></div><div class="casAuthors">Wright Graham D; Ward Alex M; Bard Frederic; Calvert Meredith E K</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry. Part A : the journal of the International Society for Analytical Cytology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-114</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3fLYiHvqnzZdYoSR9eyvsfW6udTcc2eZgEvC1eToMUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ptVyrsw%253D%253D&md5=6c00b6b4ed088093f9209e504a248f55</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.23063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.23063%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DG.%2BD.%26aulast%3DWard%26aufirst%3DA.%2BM.%26aulast%3DBard%26aufirst%3DF.%26aulast%3DCalvert%26aufirst%3DM.%2BE.%26atitle%3DPushing%2520the%2520Boundaries%2520of%2520High%2520Content%2520Imaging%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2017%26volume%3D91%26issue%3D2%26spage%3D113%26epage%3D114%26doi%3D10.1002%2Fcyto.a.23063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizada, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiraz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalbant, A.</span></span> <span> </span><span class="NLM_article-title">Flow Cytometry: Basic Principles and Applications</span>. <i>Crit. Rev. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.3109/07388551.2015.1128876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.3109%2F07388551.2015.1128876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26767547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=163-176&issue=2&author=A.+Adanauthor=G.+Alizadaauthor=Y.+Kirazauthor=Y.+Baranauthor=A.+Nalbant&title=Flow+Cytometry%3A+Basic+Principles+and+Applications&doi=10.3109%2F07388551.2015.1128876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Flow cytometry: basic principles and applications</span></div><div class="casAuthors">Adan, Aysun; Alizada, Gunel; Kiraz, Yagmur; Baran, Yusuf; Nalbant, Ayten</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biotechnology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-176</span>CODEN:
                <span class="NLM_cas:coden">CRBTE5</span>;
        ISSN:<span class="NLM_cas:issn">0738-8551</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Flow cytometry is a sophisticated instrument measuring multiple phys. characteristics of a single cell such as size and granularity simultaneously as the cell flows in suspension through a measuring device.  Its working depends on the light scattering features of the cells under investigation, which may be derived from dyes or monoclonal antibodies targeting either extracellular mols. located on the surface or intracellular mols. inside the cell.  This approach makes flow cytometry a powerful tool for detailed anal. of complex populations in a short period of time.  This review covers the general principles and selected applications of flow cytometry such as immunophenotyping of peripheral blood cells, anal. of apoptosis and detection of cytokines.  Addnl., this report provides a basic understanding of flow cytometry technol. essential for all users as well as the methods used to analyze and interpret the data.  Moreover, recent progresses in flow cytometry have been discussed in order to give an opinion about the future importance of this technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgb2jCpKQ5LVg90H21EOLACvtfcHk0lgdyPgjemDSPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKhsL4%253D&md5=bea04538a4b554e8502fbe2030f58c99</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3109%2F07388551.2015.1128876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07388551.2015.1128876%26sid%3Dliteratum%253Aachs%26aulast%3DAdan%26aufirst%3DA.%26aulast%3DAlizada%26aufirst%3DG.%26aulast%3DKiraz%26aufirst%3DY.%26aulast%3DBaran%26aufirst%3DY.%26aulast%3DNalbant%26aufirst%3DA.%26atitle%3DFlow%2520Cytometry%253A%2520Basic%2520Principles%2520and%2520Applications%26jtitle%3DCrit.%2520Rev.%2520Biotechnol.%26date%3D2017%26volume%3D37%26issue%3D2%26spage%3D163%26epage%3D176%26doi%3D10.3109%2F07388551.2015.1128876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspersson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelle, C.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Flow Cytometry for Drug Discovery: Principles, Applications, and Case Studies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1844</span>– <span class="NLM_lpage">1850</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.drudis.2017.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28916303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1844-1850&issue=12&author=M.+Dingauthor=K.+Kasperssonauthor=D.+Murrayauthor=C.+Bardelle&title=High-Throughput+Flow+Cytometry+for+Drug+Discovery%3A+Principles%2C+Applications%2C+and+Case+Studies&doi=10.1016%2Fj.drudis.2017.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput flow cytometry for drug discovery: principles, applications, and case studies</span></div><div class="casAuthors">Ding, Mei; Kaspersson, Karin; Murray, David; Bardelle, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1844-1850</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Flow cytometry is a technol. providing multiparametric anal. of single cells or other suspension particles.  High-throughput (HT) flow cytometry has become an attractive screening platform for drug discovery.  In this review, we highlight the recent HT flow cytometry applications, and then focus on HT flow cytometry deployment at AstraZeneca (AZ).  Practical considerations for successful HT flow cytometry assay development and screening are provided based on experience from four project case studies at AZ.  We provide an overview of the scientific rationale, explain why HT flow cytometry was chosen and how HT flow cytometry assays deliver new ways to support the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVkzNwaV50drVg90H21EOLACvtfcHk0lgdyPgjemDSPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsbbK&md5=7c7684d096a2b343b3c5baa0dc121b69</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DM.%26aulast%3DKaspersson%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DD.%26aulast%3DBardelle%26aufirst%3DC.%26atitle%3DHigh-Throughput%2520Flow%2520Cytometry%2520for%2520Drug%2520Discovery%253A%2520Principles%252C%2520Applications%252C%2520and%2520Case%2520Studies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26issue%3D12%26spage%3D1844%26epage%3D1850%26doi%3D10.1016%2Fj.drudis.2017.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitson-Salazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prussin, C.</span></span> <span> </span><span class="NLM_article-title">Detection of Intracellular Cytokines by Flow Cytometry</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">6.24.1</span>– <span class="NLM_lpage">6.24.18</span>, <span class="refDoi"> DOI: 10.1002/0471142735.im0624s110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2F0471142735.im0624s110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2015&pages=6.24.1-6.24.18&author=Y.+Yinauthor=A.+Mitson-Salazarauthor=C.+Prussin&title=Detection+of+Intracellular+Cytokines+by+Flow+Cytometry&doi=10.1002%2F0471142735.im0624s110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2F0471142735.im0624s110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471142735.im0624s110%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DY.%26aulast%3DMitson-Salazar%26aufirst%3DA.%26aulast%3DPrussin%26aufirst%3DC.%26atitle%3DDetection%2520of%2520Intracellular%2520Cytokines%2520by%2520Flow%2520Cytometry%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2015%26volume%3D110%26spage%3D6.24.1%26epage%3D6.24.18%26doi%3D10.1002%2F0471142735.im0624s110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maciorowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chattopadhyay, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P.</span></span> <span> </span><span class="NLM_article-title">Basic Multicolor Flow Cytometry</span>. <i>Curr. Protoc. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">5.4.1</span>– <span class="NLM_lpage">5.4.38</span>, <span class="refDoi"> DOI: 10.1002/cpim.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcpim.26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=5.4.1-5.4.38&author=Z.+Maciorowskiauthor=P.+K.+Chattopadhyayauthor=P.+Jain&title=Basic+Multicolor+Flow+Cytometry&doi=10.1002%2Fcpim.26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcpim.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpim.26%26sid%3Dliteratum%253Aachs%26aulast%3DMaciorowski%26aufirst%3DZ.%26aulast%3DChattopadhyay%26aufirst%3DP.%2BK.%26aulast%3DJain%26aufirst%3DP.%26atitle%3DBasic%2520Multicolor%2520Flow%2520Cytometry%26jtitle%3DCurr.%2520Protoc.%2520Immunol.%26date%3D2017%26volume%3D117%26spage%3D5.4.1%26epage%3D5.4.38%26doi%3D10.1002%2Fcpim.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, W. G.</span></span> <span> </span><span class="NLM_article-title">Fluorescent Proteins for Flow Cytometry</span>. <i>Curr. Protoc. Cytom.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">9.12.1</span>– <span class="NLM_lpage">9.12.20</span>, <span class="refDoi"> DOI: 10.1002/cpcy.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2Fcpcy.17" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2017&pages=9.12.1-9.12.20&issue=1&author=T.+S.+Hawleyauthor=R.+G.+Hawleyauthor=W.+G.+Telford&title=Fluorescent+Proteins+for+Flow+Cytometry&doi=10.1002%2Fcpcy.17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcpcy.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpcy.17%26sid%3Dliteratum%253Aachs%26aulast%3DHawley%26aufirst%3DT.%2BS.%26aulast%3DHawley%26aufirst%3DR.%2BG.%26aulast%3DTelford%26aufirst%3DW.%2BG.%26atitle%3DFluorescent%2520Proteins%2520for%2520Flow%2520Cytometry%26jtitle%3DCurr.%2520Protoc.%2520Cytom.%26date%3D2017%26volume%3D80%26issue%3D1%26spage%3D9.12.1%26epage%3D9.12.20%26doi%3D10.1002%2Fcpcy.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duc, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span> <span> </span><span class="NLM_article-title">Labelling HaloTag Fusion Proteins with HaloTag Ligand in Living Cells</span>. <i>Bio-Protoc</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">e2526</span>, <span class="refDoi"> DOI: 10.21769/BioProtoc.2526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.21769%2FBioProtoc.2526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28966948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlGktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e2526&issue=17&author=H.+N.+Ducauthor=X.+Ren&title=Labelling+HaloTag+Fusion+Proteins+with+HaloTag+Ligand+in+Living+Cells&doi=10.21769%2FBioProtoc.2526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Labelling HaloTag fusion proteins with HaloTag ligand in living cells</span></div><div class="casAuthors">Duc, Huy Nguyen; Ren, Xiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Bio-Protocol</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2526/1-2526/8</span>CODEN:
                <span class="NLM_cas:coden">BIOPCG</span>;
        ISSN:<span class="NLM_cas:issn">2331-8325</span>.
    
            (<span class="NLM_cas:orgname">Bio-Protocol LLC</span>)
        </div><div class="casAbstract">HaloTag has been widely used to label proteins in vitro and in vivo.  In this protocol, we describe labeling HaloTag-Cbx fusion proteins by HaloTag ligands for live-cell single-mol. imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq4vqfXFZvErVg90H21EOLACvtfcHk0ljUQgmKjYt1yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlGktLc%253D&md5=53ef81ff0d936149e13b4ced06b5c225</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.21769%2FBioProtoc.2526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21769%252FBioProtoc.2526%26sid%3Dliteratum%253Aachs%26aulast%3DDuc%26aufirst%3DH.%2BN.%26aulast%3DRen%26aufirst%3DX.%26atitle%3DLabelling%2520HaloTag%2520Fusion%2520Proteins%2520with%2520HaloTag%2520Ligand%2520in%2520Living%2520Cells%26jtitle%3DBio-Protoc%26date%3D2017%26volume%3D7%26issue%3D17%26spage%3De2526%26doi%3D10.21769%2FBioProtoc.2526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riching, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDougall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasta, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span> <span> </span><span class="NLM_article-title">Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2758</span>– <span class="NLM_lpage">2770</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00692</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00692" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOrtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2758-2770&issue=9&author=K.+M.+Richingauthor=S.+Mahanauthor=C.+R.+Coronaauthor=M.+McDougallauthor=J.+D.+Vastaauthor=M.+B.+Robersauthor=M.+Urhauthor=D.+L.+Daniels&title=Quantitative+Live-Cell+Kinetic+Degradation+and+Mechanistic+Profiling+of+PROTAC+Mode+of+Action&doi=10.1021%2Facschembio.8b00692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action</span></div><div class="casAuthors">Riching, Kristin M.; Mahan, Sarah; Corona, Cesear R.; McDougall, Mark; Vasta, James D.; Robers, Matthew B.; Urh, Marjeta; Daniels, Danette L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2758-2770</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new generation of heterobifunctional small mols., termed proteolysis targeting chimeras (PROTACs), targets proteins for degrdn. through recruitment to E3 ligases and holds significant therapeutic potential.  Despite numerous successful examples, PROTAC small mol. development remains laborious and unpredictable, involving testing compds. for end-point degrdn. activity at fixed times and concns. without resolving or optimizing for the important biol. steps required for the process.  Given the complexity of the ubiquitin proteasomal pathway, technologies that enable real-time characterization of PROTAC efficacy and mechanism of action are crit. for accelerating compd. development, profiling, and improving guidance of chem. structure-activity relationship.  Here, the authors present an innovative, modular live-cell platform utilizing endogenous tagging technologies and apply it to monitoring PROTAC-mediated degrdn. of the bromodomain and extra-terminal family members.  The authors show comprehensive real-time degrdn. and recovery profiles for each target, precisely quantifying degrdn. rates, maximal levels of degrdn. (Dmax), and time frame at Dmax.  These degrdn. metrics show specific PROTAC and family member-dependent responses that are closely assocd. with the key cellular protein interactions required for the process.  Kinetic studies show cellular ternary complex stability influences potency and degrdn. efficacy.  Meanwhile, the level of ubiquitination is highly correlated to degrdn. rate, indicating ubiquitination stemming from productive ternary complex formation is the main driver of the degrdn. rate.  The approaches applied here highlight the steps at which the choice of E3 ligase handle can elicit different outcomes and discern individual parameters required for degrdn., ultimately enabling chem. design strategies and rank ordering of potential therapeutic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnkETO-K622bVg90H21EOLACvtfcHk0ljUQgmKjYt1yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOrtbbM&md5=9a2a3162dd930ac04622db6990c0d748</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00692%26sid%3Dliteratum%253Aachs%26aulast%3DRiching%26aufirst%3DK.%2BM.%26aulast%3DMahan%26aufirst%3DS.%26aulast%3DCorona%26aufirst%3DC.%2BR.%26aulast%3DMcDougall%26aufirst%3DM.%26aulast%3DVasta%26aufirst%3DJ.%2BD.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DUrh%26aufirst%3DM.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26atitle%3DQuantitative%2520Live-Cell%2520Kinetic%2520Degradation%2520and%2520Mechanistic%2520Profiling%2520of%2520PROTAC%2520Mode%2520of%2520Action%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D2758%26epage%3D2770%26doi%3D10.1021%2Facschembio.8b00692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwinn, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encell, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkowski, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=467-474&issue=2&author=M.+K.+Schwinnauthor=T.+Machleidtauthor=K.+Zimmermanauthor=C.+T.+Eggersauthor=A.+S.+Dixonauthor=R.+Hurstauthor=M.+P.+Hallauthor=L.+P.+Encellauthor=B.+F.+Binkowskiauthor=K.+V.+Wood&title=CRISPR-Mediated+Tagging+of+Endogenous+Proteins+with+a+Luminescent+Peptide&doi=10.1021%2Facschembio.7b00549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide</span></div><div class="casAuthors">Schwinn, Marie K.; Machleidt, Thomas; Zimmerman, Kris; Eggers, Christopher T.; Dixon, Andrew S.; Hurst, Robin; Hall, Mary P.; Encell, Lance P.; Binkowski, Brock F.; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">467-474</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Intracellular signaling pathways are mediated by changes in protein abundance and post-translational modifications.  A common approach for investigating signaling mechanisms and the effects induced by synthetic compds. is through overexpression of recombinant reporter genes.  Genome editing with CRISPR/Cas9 offers a means to better preserve native biol. by appending reporters directly onto the endogenous genes.  An optimal reporter for this purpose would be small to negligibly influence intracellular processes, be readily linked to the endogenous genes with minimal exptl. effort, and be sensitive enough to detect low expressing proteins.  HiBiT is a 1.3 kDa peptide (11 amino acids) capable of producing bright and quant. luminescence through high affinity complementation (KD = 700 pM) with an 18 kDa subunit derived from NanoLuc (LgBiT).  Using CRISPR/Cas9, we demonstrate that HiBiT can be rapidly and efficiently integrated into the genome to serve as a reporter tag for endogenous proteins.  Without requiring clonal isolation of the edited cells, we were able to quantify changes in abundance of the hypoxia inducible factor 1A (HIF1α) and several of its downstream transcriptional targets in response to various stimuli.  In combination with fluorescent antibodies, we further used HiBiT to directly correlate HIF1α levels with the hydroxyproline modification that mediates its degrdn.  These results demonstrate the ability to efficiently tag endogenous proteins with a small luminescent peptide, allowing sensitive quantitation of the response dynamics in their regulated expression and covalent modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzCZoXuuYB37Vg90H21EOLACvtfcHk0ljNsV-CJoF8mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKmur7I&md5=0d02aa711b02f68a5a54b72b968f6292</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00549%26sid%3Dliteratum%253Aachs%26aulast%3DSchwinn%26aufirst%3DM.%2BK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DEggers%26aufirst%3DC.%2BT.%26aulast%3DDixon%26aufirst%3DA.%2BS.%26aulast%3DHurst%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DM.%2BP.%26aulast%3DEncell%26aufirst%3DL.%2BP.%26aulast%3DBinkowski%26aufirst%3DB.%2BF.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DCRISPR-Mediated%2520Tagging%2520of%2520Endogenous%2520Proteins%2520with%2520a%2520Luminescent%2520Peptide%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D2%26spage%3D467%26epage%3D474%26doi%3D10.1021%2Facschembio.7b00549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkowski, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valley, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidugiris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benink, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggers, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenheimer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaubert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encell, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">Engineered Luciferase Reporter From a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1857</span>, <span class="refDoi"> DOI: 10.1021/cb3002478</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb3002478" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Smu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1848-1857&issue=11&author=M.+P.+Hallauthor=J.+Unchauthor=B.+F.+Binkowskiauthor=M.+P.+Valleyauthor=B.+L.+Butlerauthor=M.+G.+Woodauthor=P.+Ottoauthor=K.+Zimmermanauthor=G.+Vidugirisauthor=T.+Machleidtauthor=M.+B.+Robersauthor=H.+A.+Beninkauthor=C.+T.+Eggersauthor=M.+R.+Slaterauthor=P.+L.+Meisenheimerauthor=D.+H.+Klaubertauthor=F.+Fanauthor=L.+P.+Encellauthor=K.+V.+Wood&title=Engineered+Luciferase+Reporter+From+a+Deep+Sea+Shrimp+Utilizing+a+Novel+Imidazopyrazinone+Substrate&doi=10.1021%2Fcb3002478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate</span></div><div class="casAuthors">Hall, Mary P.; Unch, James; Binkowski, Brock F.; Valley, Michael P.; Butler, Braeden L.; Wood, Monika G.; Otto, Paul; Zimmerman, Kristopher; Vidugiris, Gediminas; Machleidt, Thomas; Robers, Matthew B.; Benink, Helene A.; Eggers, Christopher T.; Slater, Michael R.; Meisenheimer, Poncho L.; Klaubert, Dieter H.; Fan, Frank; Encell, Lance P.; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioluminescence methodologies have been extraordinarily useful due to their high sensitivity, broad dynamic range, and operational simplicity.  These capabilities have been realized largely through incremental adaptations of native enzymes and substrates, originating from luminous organisms of diverse evolutionary lineages.  We engineered both an enzyme and substrate in combination to create a novel bioluminescence system capable of more efficient light emission with superior biochem. and phys. characteristics.  Using a small luciferase subunit (19 kDa) from the deep sea shrimp Oplophorus gracilirostris, we have improved luminescence expression in mammalian cells ∼2.5 million-fold by merging optimization of protein structure with development of a novel imidazopyrazinone substrate (furimazine).  The new luciferase, NanoLuc, produces glow-type luminescence (signal half-life >2 h) with a specific activity ∼150-fold greater than that of either firefly (Photinus pyralis) or Renilla luciferases similarly configured for glow-type assays.  In mammalian cells, NanoLuc shows no evidence of post-translational modifications or subcellular partitioning.  The enzyme exhibits high phys. stability, retaining activity with incubation up to 55 °C or in culture medium for >15 h at 37 °C.  As a genetic reporter, NanoLuc may be configured for high sensitivity or for response dynamics by appending a degrdn. sequence to reduce intracellular accumulation.  Appending a signal sequence allows NanoLuc to be exported to the culture medium, where reporter expression can be measured without cell lysis.  Fusion onto other proteins allows luminescent assays of their metab. or localization within cells.  Reporter quantitation is achievable even at very low expression levels to facilitate more reliable coupling with endogenous cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlTT1m2z_bZLVg90H21EOLACvtfcHk0ljNsV-CJoF8mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Smu7%252FN&md5=0581a7e44935671471577ade1ff538eb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcb3002478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb3002478%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BP.%26aulast%3DUnch%26aufirst%3DJ.%26aulast%3DBinkowski%26aufirst%3DB.%2BF.%26aulast%3DValley%26aufirst%3DM.%2BP.%26aulast%3DButler%26aufirst%3DB.%2BL.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DVidugiris%26aufirst%3DG.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DBenink%26aufirst%3DH.%2BA.%26aulast%3DEggers%26aufirst%3DC.%2BT.%26aulast%3DSlater%26aufirst%3DM.%2BR.%26aulast%3DMeisenheimer%26aufirst%3DP.%2BL.%26aulast%3DKlaubert%26aufirst%3DD.%2BH.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DEncell%26aufirst%3DL.%2BP.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DEngineered%2520Luciferase%2520Reporter%2520From%2520a%2520Deep%2520Sea%2520Shrimp%2520Utilizing%2520a%2520Novel%2520Imidazopyrazinone%2520Substrate%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26issue%3D11%26spage%3D1848%26epage%3D1857%26doi%3D10.1021%2Fcb3002478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rauniyar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.,  3.</span></span> <span> </span><span class="NLM_article-title">Isobaric Labeling-Based Relative Quantification in Shotgun Proteomics</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5293</span>– <span class="NLM_lpage">5309</span>, <span class="refDoi"> DOI: 10.1021/pr500880b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr500880b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyrsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=5293-5309&issue=12&author=N.+Rauniyarauthor=J.+R.+Yates&title=Isobaric+Labeling-Based+Relative+Quantification+in+Shotgun+Proteomics&doi=10.1021%2Fpr500880b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Isobaric Labeling-Based Relative Quantification in Shotgun Proteomics</span></div><div class="casAuthors">Rauniyar, Navin; Yates, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5293-5309</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Mass spectrometry plays a key role in relative quant. comparisons of proteins to understand their functional role in biol. systems upon perturbation.  The authors review studies that examine different aspects of isobaric labeling-based relative quantification for shotgun proteomic anal.  In particular, the authors focus on different types of isobaric reagents and their reaction chem. (e.g., amine-, carbonyl-, and sulfhydryl-reactive).  Various factors, such as ratio compression, reporter ion dynamic range, and others, cause an underestimation of changes in relative abundance of proteins across samples, undermining the ability of the isobaric labeling approach to be truly quant.  These factors that affect quantification and the suggested combinations of exptl. design and optimal data acquisition methods to increase the precision and accuracy of the measurements are discussed.  Finally, the extended application of isobaric labeling-based approach in hyperplexing strategy, targeted quantification, and phosphopeptide anal. were also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAnWzL7zw5bVg90H21EOLACvtfcHk0lgscxWRA8huwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyrsbzE&md5=5a5286bac4061c3026d978a39e73319d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fpr500880b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr500880b%26sid%3Dliteratum%253Aachs%26aulast%3DRauniyar%26aufirst%3DN.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26atitle%3DIsobaric%2520Labeling-Based%2520Relative%2520Quantification%2520in%2520Shotgun%2520Proteomics%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2014%26volume%3D13%26issue%3D12%26spage%3D5293%26epage%3D5309%26doi%3D10.1021%2Fpr500880b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakalarski, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span> <span> </span><span class="NLM_article-title">A Biologist’s Field Guide to Multiplexed Quantitative Proteomics</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1074/mcp.O115.056986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fmcp.O115.056986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26873251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFOrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1489-1497&issue=5&author=C.+E.+Bakalarskiauthor=D.+S.+Kirkpatrick&title=A+Biologist%E2%80%99s+Field+Guide+to+Multiplexed+Quantitative+Proteomics&doi=10.1074%2Fmcp.O115.056986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A Biologist's Field Guide to Multiplexed Quantitative Proteomics</span></div><div class="casAuthors">Bakalarski, Corey E.; Kirkpatrick, Donald S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1489-1497</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">High-throughput genomic and proteomic studies have generated near-comprehensive catalogs of biol. constituents within many model systems.  Nevertheless, static catalogs are often insufficient to fully describe the dynamic processes that drive biol.  Quant. proteomic techniques address this need by providing insight into closely related biol. states such as the stages of a therapeutic response or cellular differentiation.  The maturation of quant. proteomics in recent years has brought about a variety of technologies, each with their own strengths and weaknesses.  It can be difficult for those unfamiliar with this evolving landscape to match the expt. at hand with the best tool for the job.  Here, we outline quant. methods for proteomic mass spectrometry and discuss their benefits and weaknesses from the perspective of the biologist aiming to generate meaningful data and address mechanistic questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyZP47hxg6ybVg90H21EOLACvtfcHk0lgscxWRA8huwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFOrt7s%253D&md5=d9dfb4544b22488b0465f6d71f39b60e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fmcp.O115.056986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.O115.056986%26sid%3Dliteratum%253Aachs%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26atitle%3DA%2520Biologist%25E2%2580%2599s%2520Field%2520Guide%2520to%2520Multiplexed%2520Quantitative%2520Proteomics%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2016%26volume%3D15%26issue%3D5%26spage%3D1489%26epage%3D1497%26doi%3D10.1074%2Fmcp.O115.056986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D. W.</span></span> <span> </span><span class="NLM_article-title">Quantitative Comparisons of Large Numbers of Human Plasma Samples Using TMT10plex Labeling</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1619</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7057-5_22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F978-1-4939-7057-5_22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28674894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2isLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1619&publication_year=2017&pages=319-337&author=P.+Liuauthor=L.+A.+Beerauthor=B.+Kyauthor=K.+T.+Barnhartauthor=D.+W.+Speicher&title=Quantitative+Comparisons+of+Large+Numbers+of+Human+Plasma+Samples+Using+TMT10plex+Labeling&doi=10.1007%2F978-1-4939-7057-5_22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative comparisons of large numbers of human plasma samples using TMT10plex labeling</span></div><div class="casAuthors">Liu, Pengyuan; Beer, Lynn A.; Ky, Bonnie; Barnhart, Kurt T.; Speicher, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1619</span>
        (<span class="NLM_cas:issue">Serum/Plasma Proteomics</span>),
    <span class="NLM_cas:pages">319-337</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">One strategy for improving the throughput of human plasma proteomic discovery anal. while maintaining good depth of anal. is to multiplex using isobaric tags.  At present, the greatest multiplexing that is com. available uses the TMT10plex kit.  As an example of this approach, we describe efficient shotgun discovery proteomics of large nos. of human plasma to identify potential biomarkers.  In the anal. strategy, a common pooled ref. was used to enable comparisons across multiple expts.  Duplicate samples showed excellent overall reproducibility across different TMT expts.  Data filters that improved the quality of individual peptide and protein quantitation included using a filter for purity of the targeted precursor ion in the isolation window and using only unique peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYRfEefoIV_rVg90H21EOLACvtfcHk0lgscxWRA8huwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2isLjI&md5=c0bf757ada5b9a03eb2b82c3c2a42887</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7057-5_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7057-5_22%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBeer%26aufirst%3DL.%2BA.%26aulast%3DKy%26aufirst%3DB.%26aulast%3DBarnhart%26aufirst%3DK.%2BT.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26atitle%3DQuantitative%2520Comparisons%2520of%2520Large%2520Numbers%2520of%2520Human%2520Plasma%2520Samples%2520Using%2520TMT10plex%2520Labeling%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2017%26volume%3D1619%26spage%3D319%26epage%3D337%26doi%3D10.1007%2F978-1-4939-7057-5_22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClatchy, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkallah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.,  3.</span></span> <span> </span><span class="NLM_article-title">Quantitative Analysis of Newly Synthesized Proteins</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1744</span>– <span class="NLM_lpage">1762</span>, <span class="refDoi"> DOI: 10.1038/s41596-018-0012-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41596-018-0012-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30038347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOis7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1744-1762&issue=8&author=Y.+Maauthor=D.+B.+McClatchyauthor=S.+Barkallahauthor=W.+W.+Woodauthor=J.+R.+Yates&title=Quantitative+Analysis+of+Newly+Synthesized+Proteins&doi=10.1038%2Fs41596-018-0012-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of newly synthesized proteins</span></div><div class="casAuthors">Ma, Yuanhui; McClatchy, Daniel B.; Barkallah, Salim; Wood, William W.; Yates, III, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1744-1762</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Measuring proteome response to perturbations is crit. for understanding the underlying mechanisms involved.  Traditional quant. proteomic methods are limited by the large nos. of proteins in the proteome and the mass spectrometer's dynamic range.  A previous method uses the biorthogonal reagent azidohomoalanine (AHA), a methionine analog, for labeling, enrichment and detection of newly synthesized proteins (NSPs).  Newly synthesized AHA proteins can be coupled to biotin via CuAAC-mediated click chem. and enriched using avidin-based affinity purifn.  The combination of AHA-mediated NSP labeling with metabolic stable isotope labeling allows quantitation of low-abundant, newly secreted proteins by mass spectrometry (MS).  However, the resulting multiplicity of labeling complicates NSP anal.  We developed a new NSP quantification strategy, called HILAQ (heavy isotope-labeled azidohomoalanine quantification), that uses a heavy isotope-labeled AHA mol. to enable NSP labeling, enrichment, identification and quantification.  In addn., the AHA-peptide enrichment used in HILAQ improves both the identification and quantification of NSPs over AHA-protein enrichment.  Here, we provide a description of the HILAQ method that includes procedures for (i) pulse-labeling and harvesting NSPs; (ii) addn. of biotin by click reaction; (iii) protein pptn.; (iv) protein digestion; (v) enrichment of AHA-biotin peptides by NeutrAvidin beads and four-step elution; (vi) MS anal.; and (vii) data anal. for the identification and quantification of NSPs by ProLuCID and pQuant.  We demonstrate our HILAQ approach by identifying NSPs from cell cultures, but we anticipate that it can be adapted for applications in animal models.  The whole protocol takes ∼6 d to complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHtHGCDdsc47Vg90H21EOLACvtfcHk0liSULwxftALqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOis7rO&md5=a93767e88af5b979057b4d02e10c39de</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41596-018-0012-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41596-018-0012-y%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMcClatchy%26aufirst%3DD.%2BB.%26aulast%3DBarkallah%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DW.%2BW.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26atitle%3DQuantitative%2520Analysis%2520of%2520Newly%2520Synthesized%2520Proteins%26jtitle%3DNat.%2520Protoc.%26date%3D2018%26volume%3D13%26issue%3D8%26spage%3D1744%26epage%3D1762%26doi%3D10.1038%2Fs41596-018-0012-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.,  3.</span></span> <span> </span><span class="NLM_article-title">Proteomics and Pulse Azidohomoalanine Labeling of Newly Synthesized Proteins: What Are the Potential Applications?</span>. <i>Expert Rev. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1080/14789450.2018.1500902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1080%2F14789450.2018.1500902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30005169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=545-554&issue=7&author=Y.+Maauthor=J.+R.+Yates&title=Proteomics+and+Pulse+Azidohomoalanine+Labeling+of+Newly+Synthesized+Proteins%3A+What+Are+the+Potential+Applications%3F&doi=10.1080%2F14789450.2018.1500902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomics and pulse azidohomoalanine labeling of newly synthesized proteins: what are the potential applications?</span></div><div class="casAuthors">Ma, Yuanhui; Yates, John R. III</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Proteomics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">545-554</span>CODEN:
                <span class="NLM_cas:coden">ERPXA3</span>;
        ISSN:<span class="NLM_cas:issn">1478-9450</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Measuring the immediate changes in cells that arise from changing environmental conditions is crucial to understanding the underlying mechanisms involved.  These changes can be measured with metabolic stable isotope fully labeled proteomes, but requires looking for changes in the midst of a large background.  In addn., labeling efficiency can be an issue in primary and fully differentiated cells.  Azidohomoalanine (AHA), an analog of methionine, can be accepted by cellular translational machinery and incorporated into newly synthesized proteins (NSPs).  AHA-NSPs can be coupled to biotin via CuAAC-mediated click-chem. and enriched using avidin-based affinity purifn.  Thus, AHA-contg. proteins or peptides can be enriched and efficiently sepd. from the whole proteome.  In this review, we describe the development of mass spectrometry (MS) based AHA strategies and discuss their potential to measure proteins involved in immune response, secretome, gut microbiome, and proteostasis as well as their potential for clin. uses.  AHA strategies have been used to identify synthesis activity and to compare two biol. conditions in various biol. model organisms.  In combination with instrument development, improved sample prepn. and fractionation strategies, MS-based AHA strategies have the potential for broad application, and the methods should translate into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0XqsmQfzr4LVg90H21EOLACvtfcHk0liSULwxftALqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtrjM&md5=e48f427e02d7956dfdaf3416b05e5dbe</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F14789450.2018.1500902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14789450.2018.1500902%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26atitle%3DProteomics%2520and%2520Pulse%2520Azidohomoalanine%2520Labeling%2520of%2520Newly%2520Synthesized%2520Proteins%253A%2520What%2520Are%2520the%2520Potential%2520Applications%253F%26jtitle%3DExpert%2520Rev.%2520Proteomics%26date%3D2018%26volume%3D15%26issue%3D7%26spage%3D545%26epage%3D554%26doi%3D10.1080%2F14789450.2018.1500902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. M.</span></span> <span> </span><span class="NLM_article-title">Nonradioactive Quantification of Autophagic Protein Degradation with L-Azidohomoalanine Labeling</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1038/nprot.2016.160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnprot.2016.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28079880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=279-288&issue=2&author=J.+Wangauthor=J.+Zhangauthor=Y.+M.+Leeauthor=S.+Ngauthor=Y.+Shiauthor=Z.+C.+Huaauthor=Q.+Linauthor=H.+M.+Shen&title=Nonradioactive+Quantification+of+Autophagic+Protein+Degradation+with+L-Azidohomoalanine+Labeling&doi=10.1038%2Fnprot.2016.160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Nonradioactive quantification of autophagic protein degradation with L-azidohomoalanine labeling</span></div><div class="casAuthors">Wang, Jigang; Zhang, Jianbin; Lee, Yew Mun; Ng, Shukie; Shi, Yin; Hua, Zi-Chun; Lin, Qingsong; Shen, Han-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-288</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">At present, several assays that use radioisotope labeling to quantify the degrdn. of long-lived proteins have been developed to measure autophagic flux.  Here, we describe a nonradioactive pulse-chase protocol using L-azidohomoalanine (AHA) labeling to quantify long-lived protein degrdn. during autophagy.  AHA is used as a surrogate for L-methionine, and, when added to cultured cells grown in methionine-free medium, AHA is incorporated into proteins during de novo protein synthesis.  After a chase period to remove short-lived proteins, autophagy is induced by starvation or other stimuli.  Cells then undergo a 'click' reaction between the azide group of AHA and a fluorescently tagged alkyne probe.  The AHA-contg. proteins can then be detected by flow cytometry.  This protocol is nonradioactive, sensitive and quant., and it is easy to perform.  It is also applicable to various cell culture systems.  The whole protocol is estd. to take 4-5 d to complete.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCPShpR6gY7LVg90H21EOLACvtfcHk0lgA4NW0tlH4BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVSjsQ%253D%253D&md5=40ebc7715edbfaf52bd7a001d2695b26</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2016.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2016.160%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BM.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DHua%26aufirst%3DZ.%2BC.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DH.%2BM.%26atitle%3DNonradioactive%2520Quantification%2520of%2520Autophagic%2520Protein%2520Degradation%2520with%2520L-Azidohomoalanine%2520Labeling%26jtitle%3DNat.%2520Protoc.%26date%3D2017%26volume%3D12%26issue%3D2%26spage%3D279%26epage%3D288%26doi%3D10.1038%2Fnprot.2016.160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tom
Dieck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nehring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartnik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieterich, D. C.</span></span> <span> </span><span class="NLM_article-title">Metabolic Labeling with Noncanonical Amino Acids and Visualization by Chemoselective Fluorescent Tagging</span>. <i>Curr. Protoc. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7.11.1</span>– <span class="NLM_lpage">7.11.29</span>, <span class="refDoi"> DOI: 10.1002/0471143030.cb0711s56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1002%2F0471143030.cb0711s56" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=7.11.1-7.11.29&author=S.+Tom%0ADieckauthor=A.+M%C3%BCllerauthor=A.+Nehringauthor=F.+I.+Hinzauthor=I.+Bartnikauthor=E.+M.+Schumanauthor=D.+C.+Dieterich&title=Metabolic+Labeling+with+Noncanonical+Amino+Acids+and+Visualization+by+Chemoselective+Fluorescent+Tagging&doi=10.1002%2F0471143030.cb0711s56"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2F0471143030.cb0711s56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471143030.cb0711s56%26sid%3Dliteratum%253Aachs%26aulast%3DTom%2BDieck%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DNehring%26aufirst%3DA.%26aulast%3DHinz%26aufirst%3DF.%2BI.%26aulast%3DBartnik%26aufirst%3DI.%26aulast%3DSchuman%26aufirst%3DE.%2BM.%26aulast%3DDieterich%26aufirst%3DD.%2BC.%26atitle%3DMetabolic%2520Labeling%2520with%2520Noncanonical%2520Amino%2520Acids%2520and%2520Visualization%2520by%2520Chemoselective%2520Fluorescent%2520Tagging%26jtitle%3DCurr.%2520Protoc.%2520Cell%2520Biol.%26date%3D2012%26volume%3D56%26spage%3D7.11.1%26epage%3D7.11.29%26doi%3D10.1002%2F0471143030.cb0711s56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+Protein+Degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lgA4NW0tlH4BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&issue=2&author=I.+Churcher&title=Protac-Induced+Protein+Degradation+in+Drug+Discovery%3A+Breaking+the+Rules+or+Just+Making+New+Ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0ljbNwcw6dqO6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-Induced%2520Protein%2520Degradation%2520in%2520Drug%2520Discovery%253A%2520Breaking%2520the%2520Rules%2520or%2520Just%2520Making%2520New%2520Ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Kinase Downregulators</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.chembiol.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29174540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=30-35&issue=1&author=L.+H.+Jones&title=Small-Molecule+Kinase+Downregulators&doi=10.1016%2Fj.chembiol.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Kinase Downregulators</span></div><div class="casAuthors">Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-35</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">New opportunities to advance small-mol. kinase ligands that downregulate their cognate target binding proteins are discussed.  Rationally designed heterobifunctional kinase degraders are compared with ATP site ligands that were serendipitously found to cause kinase downregulation.  These approaches could be particularly useful in the treatment of cancers since many kinases are known to remodel pro-oncogenic protein-protein interactions, which could be destroyed by small-mol.-mediated kinase depletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbltft5F3cs7Vg90H21EOLACvtfcHk0ljbNwcw6dqO6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfO&md5=b3d575658b082f1f879651ea296ce58f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSmall-Molecule%2520Kinase%2520Downregulators%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D30%26epage%3D35%26doi%3D10.1016%2Fj.chembiol.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantawy, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span> <span> </span><span class="NLM_article-title">The Selective Estrogen Receptor Downregulator GDC-0810 Is Efficacious in Diverse Models of ER+ Breast Cancer</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e15828</span>, <span class="refDoi"> DOI: 10.7554/eLife.15828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.7554%2FeLife.15828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27410477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e15828&author=J.+D.+Josephauthor=B.+Darimontauthor=W.+Zhouauthor=A.+Arrazateauthor=A.+Youngauthor=E.+Ingallaauthor=K.+Walterauthor=R.+A.+Blakeauthor=J.+Nonomiyaauthor=Z.+Guanauthor=L.+Kategayaauthor=S.+P.+Govekauthor=A.+G.+Laiauthor=M.+Kahramanauthor=D.+Brighamauthor=J.+Sensintaffarauthor=N.+Luauthor=G.+Shaoauthor=J.+Qianauthor=K.+Grillotauthor=M.+Moonauthor=R.+Prudenteauthor=E.+Bischoffauthor=K.-J.+Leeauthor=C.+Bonnefousauthor=K.+L.+Douglasauthor=J.+D.+Julienauthor=J.+Y.+Nagasawaauthor=A.+Aparicioauthor=J.+Kaufmanauthor=B.+Haleyauthor=J.+M.+Giltnaneauthor=I.+E.+Wertzauthor=M.+R.+Lacknerauthor=M.+A.+Nanniniauthor=D.+Sampathauthor=L.+Schwarzauthor=H.+C.+Manningauthor=M.+N.+Tantawyauthor=C.+L.+Arteagaauthor=R.+A.+Heymanauthor=P.+J.+Rixauthor=L.+Friedmanauthor=N.+D.+Smithauthor=C.+Metcalfeauthor=J.+H.+Hager&title=The+Selective+Estrogen+Receptor+Downregulator+GDC-0810+Is+Efficacious+in+Diverse+Models+of+ER%2B+Breast+Cancer&doi=10.7554%2FeLife.15828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span></div><div class="casAuthors">Joseph, James D.; Darimont, Beatrice; Zhou, Wei; Arrazate, Alfonso; Young, Amy; Ingalla, Ellen; Walter, Kimberly; Blake, Robert A.; Nonomiya, Jim; Guan, Zhengyu; Kategaya, Lorna; Govek, Steven P.; Lai, Andiliy G.; Kahraman, Mehmet; Brigham, Dan; Sensintaffar, John; Lu, Nhin; Shao, Gang; Qian, Jing; Grillot, Kate; Moon, Michael; Prudente, Rene; Bischoff, Eric; Lee, Kyoung-Jin; Bonnefous, Celine; Douglas, Karensa L.; Julien, Jackaline D.; Nagasawa, Johnny Y.; Aparicio, Anna; Kaufman, Josh; Haley, Benjamin; Giltnane, Jennifer M.; Wertz, Ingrid E.; Lackner, Mark R.; Nannini, Michelle A.; Sampath, Deepak; Schwarz, Luis; Manning, Henry Charles; Tantawy, Mohammed Noor; Arteaga, Carlos L.; Heyman, Richard A.; Rix, Peter J.; Friedman, Lori; Smith, Nicholas D.; Metcalfe, Ciara; Hager, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e15828/1-e15828/34</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies.  The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERa signaling, and provides a strong rationale for continued targeting of ERa.  Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERa degrdn., antagonism and pharmacokinetic properties.  GDC-0810 induces a distinct ERa conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action.  GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERa mutations.  GDC-0810 is currently being evaluated in Phase II clin. studies in women with ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML4fZixufB7Vg90H21EOLACvtfcHk0lhbacS2EQleDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D&md5=cfdf9624f8b260a732b92caab0bb2d58</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.7554%2FeLife.15828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.15828%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DZ.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DJulien%26aufirst%3DJ.%2BD.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DNannini%26aufirst%3DM.%2BA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSchwarz%26aufirst%3DL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26aulast%3DTantawy%26aufirst%3DM.%2BN.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520Selective%2520Estrogen%2520Receptor%2520Downregulator%2520GDC-0810%2520Is%2520Efficacious%2520in%2520Diverse%2520Models%2520of%2520ER%252B%2520Breast%2520Cancer%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26spage%3De15828%26doi%3D10.7554%2FeLife.15828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Poetsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyler, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1038/nchembio.304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnchembio.304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20118940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=209-217&issue=3&author=T.+Schneider-Poetschauthor=J.+Juauthor=D.+E.+Eylerauthor=Y.+Dangauthor=S.+Bhatauthor=W.+C.+Merrickauthor=R.+Greenauthor=B.+Shenauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+Elongation+by+Cycloheximide+and+Lactimidomycin&doi=10.1038%2Fnchembio.304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin</span></div><div class="casAuthors">Schneider-Poetsch, Tilman; Ju, Jianhua; Eyler, Daniel E.; Dang, Yongjun; Bhat, Shridhar; Merrick, William C.; Green, Rachel; Shen, Ben; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-217</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the protein synthesis inhibitor cycloheximide (CHX) has been known for decades, its precise mechanism of action remains incompletely understood.  The glutarimide portion of CHX is seen in a family of structurally related natural products including migrastatin, isomigrastatin, and lactimidomycin (LTM).  We found that LTM, isomigrastatin, and analogs have a potent antiproliferative effect on tumor cell lines and selectively inhibit translation.  A systematic comparative study of the effects of CHX and LTM on protein synthesis revealed both similarities and differences between the two inhibitors.  Both LTM and CHX were found to block the translocation step in elongation.  Footprinting expts. revealed protection of a single cytidine nucleotide (C3993) in the E-site of the 60S ribosomal subunit, thus defining a common binding pocket for the two inhibitors in the ribosome.  These results shed new light on the mol. mechanism of inhibition of translation elongation by both CHX and LTM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsVhn_TkyD-LVg90H21EOLACvtfcHk0lg0LEtxSzwdKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D&md5=77e621c87b496cd697f77299623b9f06</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.304%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider-Poetsch%26aufirst%3DT.%26aulast%3DJu%26aufirst%3DJ.%26aulast%3DEyler%26aufirst%3DD.%2BE.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520Elongation%2520by%2520Cycloheximide%2520and%2520Lactimidomycin%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26issue%3D3%26spage%3D209%26epage%3D217%26doi%3D10.1038%2Fnchembio.304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, Y.</span></span> <span> </span><span class="NLM_article-title">Synthetic Study of Peptide Aldehydes</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3106</span>– <span class="NLM_lpage">3113</span>, <span class="refDoi"> DOI: 10.1248/cpb.23.3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1248%2Fcpb.23.3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaE28XptVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1975&pages=3106-3113&issue=12&author=A.+Itoauthor=R.+Takahashiauthor=C.+Miuraauthor=Y.+Baba&title=Synthetic+Study+of+Peptide+Aldehydes&doi=10.1248%2Fcpb.23.3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic study of peptide aldehydes</span></div><div class="casAuthors">Ito, Akira; Takahashi, Rieko; Miura, Chieko; Baba, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3106-13</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">Ac-Leu-Leu-R [R = L- or D-NHCH(CH2Ph)CHO, L-NHCH(CH2C6H4OH-4)CHO, L-NHCH(CH2R1)CHO, R1 = 3-indolyl] were prepd. from benzyloxycarbonyl-α-aminoaldehyde semicarbazones derived from benzyloxycarbonyl amino acid esters by redn. with (Me2CHCH2)2AlH.  The racemization of the aldehyde of the purified analogs was examined using the analytical ion exchange chromatog. of diastereomers produced by the condensation of L-aspartic acid with aminoalcohols, which were obtained by the NaBH4 redn. of the synthesized peptide aldehydes followed by acid hydrolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSRjA5l9vB7Vg90H21EOLACvtfcHk0lg0LEtxSzwdKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XptVGksA%253D%253D&md5=cbd5b79f0fc52c5092c022622c6f8fe6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1248%2Fcpb.23.3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.23.3106%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DMiura%26aufirst%3DC.%26aulast%3DBaba%26aufirst%3DY.%26atitle%3DSynthetic%2520Study%2520of%2520Peptide%2520Aldehydes%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1975%26volume%3D23%26issue%3D12%26spage%3D3106%26epage%3D3113%26doi%3D10.1248%2Fcpb.23.3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Proteasome Block the Degradation of Most Cell Proteins and the Generation of Peptides Presented on MHC Class I Molecules</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(94)90462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS0092-8674%2894%2990462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=8087844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=761-771&issue=5&author=K.+L.+Rockauthor=C.+Grammauthor=L.+Rothsteinauthor=K.+Clarkauthor=R.+Steinauthor=L.+Dickauthor=D.+Hwangauthor=A.+L.+Goldberg&title=Inhibitors+of+the+Proteasome+Block+the+Degradation+of+Most+Cell+Proteins+and+the+Generation+of+Peptides+Presented+on+MHC+Class+I+Molecules&doi=10.1016%2FS0092-8674%2894%2990462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules</span></div><div class="casAuthors">Rock, Kenneth L.; Gramm, Colette; Rothstein, Lisa; Clark, Karen; Stein, Ross; Dick, Lawrence; Hwang, Daniel; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">761-71</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Reagents that inhibit the ubiquitin-proteasome proteolytic pathway in cells have not been available.  Peptide aldehydes that inhibit major peptidase activities of the 20S and 26S proteasomes are shown to reduce the degrdn. of protein and ubiquitinated protein substrates by 26S particles.  Unlike inhibitors of lysosomal proteolysis, these compds. inhibit the degrdn. of not only abnormal and short-lived polypeptides but also long-lived proteins in intact cells.  The authors used these agents to test the importance of the proteasome in antigen presentation.  When ovalbumin is introduced into the cytosol of lymphoblasts, these inhibitors block the presentation on MHC class I mols. of an ovalbumin-derived peptide by preventing its proteolytic generation.  By preventing peptide prodn. from cell proteins, these inhibitors block the assembly of class I mols.  Therefore, the proteasome catalyzes the degrdn. of the vast majority of cell proteins and generates most peptides presented on MHC class I mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVw5InxABShLVg90H21EOLACvtfcHk0litAFj_fMF8iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D&md5=2960e350aedb5a0d9e04d672f96f9c4f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2894%2990462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252894%252990462-6%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DGramm%26aufirst%3DC.%26aulast%3DRothstein%26aufirst%3DL.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DInhibitors%2520of%2520the%2520Proteasome%2520Block%2520the%2520Degradation%2520of%2520Most%2520Cell%2520Proteins%2520and%2520the%2520Generation%2520of%2520Peptides%2520Presented%2520on%2520MHC%2520Class%2520I%2520Molecules%26jtitle%3DCell%26date%3D1994%26volume%3D78%26issue%3D5%26spage%3D761%26epage%3D771%26doi%3D10.1016%2FS0092-8674%2894%2990462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, H. N.</span></span> <span> </span><span class="NLM_article-title">Evidence That a Rapidly Turning Over Protein, Normally Degraded by Proteasomes, Regulates Hsp72 Gene Transcription in HepG2 Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span> (<span class="NLM_issue">40</span>),  <span class="NLM_fpage">24769</span>– <span class="NLM_lpage">24775</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.40.24769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fjbc.271.40.24769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=8798747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK28XmtFegs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=24769-24775&issue=40&author=M.+Zhouauthor=X.+Wuauthor=H.+N.+Ginsberg&title=Evidence+That+a+Rapidly+Turning+Over+Protein%2C+Normally+Degraded+by+Proteasomes%2C+Regulates+Hsp72+Gene+Transcription+in+HepG2+Cells&doi=10.1074%2Fjbc.271.40.24769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells</span></div><div class="casAuthors">Zhou, Mingyue; Wu, Xujun; Ginsberg, Henry N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24769-24775</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Heat shock protein 72/73 (Hsp70) is a cytosolic mol. chaperone that carries out fundamental roles under both normal and stress situations.  There is great interest in delineating the mechanisms whereby Hsp70 levels are regulated.  We obsd. that N-acetyl-leucyl-leucyl-norleucinal (ALLN), a synthetic aldehydic tripeptide that inhibits proteasomes, markedly induced Hsp70 levels (up to 30-fold above base line in HepG2 cells and human endothelial cells).  Induction of Hsp70 by ALLN was dose-dependent and not related to cell toxicity.  ALLN selectively increased Hsp70 levels without affecting Hsp25, Hsp27, Hsp60, Hsp86, Hsp90, Hsp104, or Bip (Ig heavy chain binding protein) in HepG2 cells.  ALLN induced Hsp70 not only by stabilizing the protein but also by dramatically increasing its synthesis.  The modulation of Hsp70 synthesis by ALLN resulted from a rapid and marked increase in transcription of the hsp72 gene, since the induction of hsp72 mRNA was blocked in cells co-treated with actinomycin D. hsp72 mRNA levels were affected in a time-dependent manner by exposure to ALLN; significant elevations occurred within 60 min of treatment, and a decline to background levels was obsd. by 7 h of recovery.  The ALLN-induced increase in hsp72 gene expression was assocd. with trimerization of the heat shock transcriptional factor (HSF1).  ALLN did not affect the steady-state level of HSF1 protein.  The effects of ALLN appeared to require de novo protein synthesis, since the induction of both HSF1 trimerization and hsp72 transcription was blocked by co-treatment with cycloheximide.  When we tested a series of protease inhibitors, only the related aldehydic tripeptides, N-acetyl-leucyl-leucyl-methioninal and the proteasome inhibitor, Cbz-leucyl-leucyl-leucinal, induced Hsp70 levels.  The specific proteasome inhibitor, lactacystin, which has a different structure, also induced Hsp70 levels.  Overall, our results suggest that a rapidly turning over protein that is normally degraded by proteasomes may be involved in the regulation of Hsp70 synthesis via effects on the hsp70 transcriptional factor, HSF1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_XJac9ixawrVg90H21EOLACvtfcHk0litAFj_fMF8iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtFegs7Y%253D&md5=98f05922d79f91f8d5bc12bea411dfa7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.40.24769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.40.24769%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGinsberg%26aufirst%3DH.%2BN.%26atitle%3DEvidence%2520That%2520a%2520Rapidly%2520Turning%2520Over%2520Protein%252C%2520Normally%2520Degraded%2520by%2520Proteasomes%252C%2520Regulates%2520Hsp72%2520Gene%2520Transcription%2520in%2520HepG2%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26issue%3D40%26spage%3D24769%26epage%3D24775%26doi%3D10.1074%2Fjbc.271.40.24769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dajee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidig, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallone, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molineaux, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6383</span>– <span class="NLM_lpage">6391</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-06-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17616698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6383-6391&issue=13&author=S.+D.+Demoauthor=C.+J.+Kirkauthor=M.+A.+Aujayauthor=T.+J.+Buchholzauthor=M.+Dajeeauthor=M.+N.+Hoauthor=J.+Jiangauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=F.+Parlatiauthor=K.+D.+Shenkauthor=M.+S.+Smythauthor=C.+M.+Sunauthor=M.+K.+Valloneauthor=T.+M.+Wooauthor=C.+J.+Molineauxauthor=M.+K.+Bennett&title=Antitumor+Activity+of+PR-171%2C+a+Novel+Irreversible+Inhibitor+of+the+Proteasome&doi=10.1158%2F0008-5472.CAN-06-4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span></div><div class="casAuthors">Demo, Susan D.; Kirk, Christopher J.; Aujay, Monette A.; Buchholz, Tonia J.; Dajee, Maya; Ho, Mark N.; Jiang, Jing; Laidig, Guy J.; Lewis, Evan R.; Parlati, Francesco; Shenk, Kevin D.; Smyth, Mark S.; Sun, Congcong M.; Vallone, Marcy K.; Woo, Tina M.; Molineaux, Christopher J.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6383-6391</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma.  However, significant toxicities have restricted the intensity of bortezomib dosing.  Here we describe the antitumor activity of PR-171, a novel epoxyketone-based irreversible proteasome inhibitor that is currently in clin. development.  In comparison to bortezomib, PR-171 exhibits equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome.  In cell culture, PR-171 is more cytotoxic than bortezomib following brief treatments that mimic the in vivo pharmacokinetics of both mols.  Hematol. tumor cells exhibit the greatest sensitivity to brief exposure, whereas solid tumor cells and nontransformed cell types are less sensitive to such treatments.  Cellular consequences of PR-171 treatment include the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.  Administration of PR-171 to animals results in the dose-dependent inhibition of the chymotrypsin-like proteasome activity in all tissues examd. with the exception of the brain.  PR-171 is well tolerated when administered for either 2 or 5 consecutive days at doses resulting in >80% proteasome inhibition in blood and most tissues.  In human tumor xenograft models, PR-171 mediates an antitumor response that is both dose and schedule dependent.  The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clin. dosing schedule.  These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clin. testing of PR-171 in the treatment of hematol. malignancies using dose-intensive schedules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzP-VJ4DNRbVg90H21EOLACvtfcHk0lhoyVxndXL96A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D&md5=301bcab3e60cbfd518b2f88fb479fa79</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4086%26sid%3Dliteratum%253Aachs%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DVallone%26aufirst%3DM.%2BK.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DMolineaux%26aufirst%3DC.%2BJ.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520Activity%2520of%2520PR-171%252C%2520a%2520Novel%2520Irreversible%2520Inhibitor%2520of%2520the%2520Proteasome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D13%26spage%3D6383%26epage%3D6391%26doi%3D10.1158%2F0008-5472.CAN-06-4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">The Proteasome Inhibitor PS-341 in Cancer Therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10499643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFyjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=2638-2645&issue=9&author=B.+A.+Teicherauthor=G.+Araauthor=R.+Herbstauthor=V.+J.+Palombellaauthor=J.+Adams&title=The+Proteasome+Inhibitor+PS-341+in+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor PS-341 in cancer therapy</span></div><div class="casAuthors">Teicher, Beverly A.; Ara, Gulshan; Herbst, Roy; Palombella, Vito J.; Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The anticancer activity of the boronic acid dipeptide proteasome inhibitor PS-341 was examd. in vitro and in vivo.  PS-341 was a potent cytotoxic agent toward MCF-7 human breast carcinoma cells in culture, producing an IC90 of 0.05 μM on 24 h of exposure to the drug.  In the EMT-6 tumor cell survival assay, PS-341 was equally cytotoxic administered p.o. or by i.p. injection up to a dose of 2 mg/kg.  PS-341 was also toxic to the bone marrow colony-forming unit-granulocyte macrophage.  PS-341 increased the tumor cell killing of radiation therapy, cyclophosphamide, and cisplatin in the EMT-6/Parent tumor, but was not able to overcome the in vivo resistance of the EMT-6/CTX and EMT-6/CDDP tumors.  In the tumor growth delay assay, PS-341 administered p.o. had antitumor activity against the Lewis lung carcinoma, both primary and metastatic disease.  In combination, regimens with 5-fluorouracil, cisplatin, Taxol and adriamycin, PS-341 seemed to produce primarily additive tumor growth delays against the s.c. tumor and was highly effective against disease metastatic to the lungs.  The proteasome is an interesting new target for cancer therapy, and the proteasome inhibitor PS-341 warrants continued investigation in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1t9w6rX80frVg90H21EOLACvtfcHk0lhoyVxndXL96A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFyjtro%253D&md5=585dee69fcb728c0e9a50d1d65ebfc2e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DAra%26aufirst%3DG.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520Proteasome%2520Inhibitor%2520PS-341%2520in%2520Cancer%2520Therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26issue%3D9%26spage%3D2638%26epage%3D2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahlberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenstam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaumann, H.</span></span> <span> </span><span class="NLM_article-title">Degradation of Short and Long Lived Proteins in Isolated Rat Liver Lysosomes. Effects of pH, Temperature, and Proteolytic Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">5847</span>– <span class="NLM_lpage">5854</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=3988775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaL2MXktVChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=5847-5854&issue=9&author=J.+Ahlbergauthor=A.+Berkenstamauthor=F.+Henellauthor=H.+Glaumann&title=Degradation+of+Short+and+Long+Lived+Proteins+in+Isolated+Rat+Liver+Lysosomes.+Effects+of+pH%2C+Temperature%2C+and+Proteolytic+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of short and long lived proteins in isolated rat liver lysosomes.  Effects of pH, temperature, and proteolytic inhibitors</span></div><div class="casAuthors">Ahlberg, Jeanne; Berkenstam, Anders; Henell, Fredrik; Glaumann, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5847-54</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Various inhibitors of proteolysis were tested on lysosomes isolated from livers of rats injected with [14C]leucine 15 min (short labeling time) and 16 h (long labeling time) before killing.  Intact lysosomes were incubated with different inhibitors (leupeptin, propylamine, E-64, pepstatin, and chloroquine) in increasing concns.  None of these caused >40-75% inhibition of proteolysis irresp. of labeling protocol.  Chloroquine was the most effective inhibitor, followed by leupeptin, propylamine, E-64, and pepstatin.  When lysosomes were incubated with various combinations of inhibitors, including a weak base and an enzyme inhibitor, a somewhat higher inhibition (86%) was obtained.  To assess if lysosomes are active in the degrdn. of both short- and long-lived proteins, lysosomes were isolated from livers of rats labeled with [14C]leucine for various time intervals.  The highest fractional proteolytic rates were seen for short lived proteins.  If the recovery of the isolated lysosomes is taken into consideration, ∼80% (short labeling time) and 90% (long labeling time) of the total proteolysis in the homogenate could be accounted for by lysosomes.  Isolated Golgi, mitochondrial, and microsomal fractions displayed negligible proteolytic activities.  The cytosol contributed 20% of the total protein breakdown of short lived proteins, whereas insignificant proteolysis was recovered in the cytosolic fraction following long time labeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtbFLpBXmi17Vg90H21EOLACvtfcHk0li-n4hIEi7MiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktVChsr8%253D&md5=19d82fa8e2fa9b47c33229e0428640c3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAhlberg%26aufirst%3DJ.%26aulast%3DBerkenstam%26aufirst%3DA.%26aulast%3DHenell%26aufirst%3DF.%26aulast%3DGlaumann%26aufirst%3DH.%26atitle%3DDegradation%2520of%2520Short%2520and%2520Long%2520Lived%2520Proteins%2520in%2520Isolated%2520Rat%2520Liver%2520Lysosomes.%2520Effects%2520of%2520pH%252C%2520Temperature%252C%2520and%2520Proteolytic%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26issue%3D9%26spage%3D5847%26epage%3D5854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaravadi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span> <span> </span><span class="NLM_article-title">Lys05: a New Lysosomal Autophagy Inhibitor</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi"> DOI: 10.4161/auto.20958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.4161%2Fauto.20958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22878685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=1383-1384&issue=9&author=R.+K.+Amaravadiauthor=J.+D.+Winkler&title=Lys05%3A+a+New+Lysosomal+Autophagy+Inhibitor&doi=10.4161%2Fauto.20958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Lys05: a new lysosomal autophagy inhibitor</span></div><div class="casAuthors">Amaravadi, Ravi K.; Winkler, Jeffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1383-1384</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Lys05 is a previously undescribed dimeric chloroquine which more potently accumulates in the lysosome and blocks autophagy compared with HCQ.  Lys05 produced more potent antitumor activity as a single agent both in vitro and in vivo in multiple human cancer cell lines and xenograft models compared with HCQ.  Initial structure-activity relationship studies demonstrated that the increased activity assocd. with Lys05 was due to the bivalent aminoquinoline rings, C7-Chlorine, and a short triamine linker.  While lower doses of Lys05 were well tolerated and assocd. with anti-tumor activity, at the highest dose tested, Lys05 produced Paneth cell dysfunction and intestinal toxicity, similar to what can be obsd. in mice and humans with genetic defects in the autophagy gene ATG16L1.  Lys05 is therefore a new lysosomal autophagy inhibitor that has potential to be developed further into a drug for cancer and other medical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnTN3s5fp9bVg90H21EOLACvtfcHk0li-n4hIEi7MiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ktLk%253D&md5=174288b34f302deec1374b00e6688195</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.4161%2Fauto.20958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.20958%26sid%3Dliteratum%253Aachs%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26atitle%3DLys05%253A%2520a%2520New%2520Lysosomal%2520Autophagy%2520Inhibitor%26jtitle%3DAutophagy%26date%3D2012%26volume%3D8%26issue%3D9%26spage%3D1383%26epage%3D1384%26doi%3D10.4161%2Fauto.20958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schopf, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biebl, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, J.</span></span> <span> </span><span class="NLM_article-title">The HSP90 Chaperone Machinery</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrm.2017.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28429788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2mtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=345-360&issue=6&author=F.+H.+Schopfauthor=M.+M.+Bieblauthor=J.+Buchner&title=The+HSP90+Chaperone+Machinery&doi=10.1038%2Fnrm.2017.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The HSP90 chaperone machinery</span></div><div class="casAuthors">Schopf, Florian H.; Biebl, Maximilian M.; Buchner, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">345-360</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The heat shock protein 90 (HSP90) chaperone machinery is a key regulator of proteostasis under both physiol. and stress conditions in eukaryotic cells.  As HSP90 has several hundred protein substrates (or 'clients'), it is involved in many cellular processes beyond protein folding, which include DNA repair, development, the immune response and neurodegenerative disease.  A large no. of co-chaperones interact with HSP90 and regulate the ATPase-assocd. conformational changes of the HSP90 dimer that occur during the processing of clients.  Recent progress has allowed the interactions of clients with HSP90 and its co-chaperones to be defined.  Owing to the importance of HSP90 in the regulation of many cellular proteins, it has become a promising drug target for the treatment of several diseases, which include cancer and diseases assocd. with protein misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGQAAfluC3NbVg90H21EOLACvtfcHk0li69dTtVrk4GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2mtbw%253D&md5=65931b74cf0a4fb5e60c936177829bd4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.20%26sid%3Dliteratum%253Aachs%26aulast%3DSchopf%26aufirst%3DF.%2BH.%26aulast%3DBiebl%26aufirst%3DM.%2BM.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DThe%2520HSP90%2520Chaperone%2520Machinery%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26issue%3D6%26spage%3D345%26epage%3D360%26doi%3D10.1038%2Fnrm.2017.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimnaugh, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Heat Shock Protein HSP90-Pp60v-Src Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8324</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.18.8324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.91.18.8324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=8078881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8324-8328&issue=18&author=L.+Whitesellauthor=E.+G.+Mimnaughauthor=B.+De+Costaauthor=C.+E.+Myersauthor=L.+M.+Neckers&title=Inhibition+of+Heat+Shock+Protein+HSP90-Pp60v-Src+Heteroprotein+Complex+Formation+by+Benzoquinone+Ansamycins%3A+Essential+Role+for+Stress+Proteins+in+Oncogenic+Transformation&doi=10.1073%2Fpnas.91.18.8324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation</span></div><div class="casAuthors">Whitesell, Luke; Mimnaugh, Edward G.; De Costa, Brian; Myers, Charles E.; Neckers, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8324-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanisms by which oncogenic tyrosine kinases induce cellular transformation are unclear.  Herbimycin A, geldanamycin, and certain other benzoquinone ansamycins display an unusual capacity to revert tyrosine kinase-induced oncogenic transformation.  As an approach to the study of v-src-mediated transformation, the authors examd. ansamycin action in transformed cells and found that drug-induced reversion could be achieved without direct inhibition of src phosphorylating activity.  To identify mechanisms other than kinase inhibition for drug-mediated reversion, the authors prepd. a solid phase-immobilized geldanamycin deriv. and affinity pptd. the mol. targets with which the drug interacted.  In a range of cell lines, immobilized geldanamycin bound elements of a major class of heat shock protein (HSP90) in a stable and pharmacol. specific manner.  Consistent with these binding data, the authors found that sol. geldanamycin and herbimycin A inhibited specifically the formation of a previously described src-HSP90 heteroprotein complex.  A related benzoquinone ansamycin that failed to revert transformed cells did not inhibit the formation of this complex.  These results demonstrate that HSP participation in multimol. complex formation is required for src-mediated transformation and can provide a target for drug modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfTW8DJOglQLVg90H21EOLACvtfcHk0li69dTtVrk4GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlslKnsLw%253D&md5=18f1cad01698df44adaa05ef3da9f850</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.18.8324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.18.8324%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DMimnaugh%26aufirst%3DE.%2BG.%26aulast%3DDe%2BCosta%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DNeckers%26aufirst%3DL.%2BM.%26atitle%3DInhibition%2520of%2520Heat%2520Shock%2520Protein%2520HSP90-Pp60v-Src%2520Heteroprotein%2520Complex%2520Formation%2520by%2520Benzoquinone%2520Ansamycins%253A%2520Essential%2520Role%2520for%2520Stress%2520Proteins%2520in%2520Oncogenic%2520Transformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D18%26spage%3D8324%26epage%3D8328%26doi%3D10.1073%2Fpnas.91.18.8324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Development of Heat Shock Protein (Hsp90) Inhibitors to Combat Resistance to Tyrosine Kinase Inhibitors Through Hsp90-Kinase Interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5563</span>– <span class="NLM_lpage">5586</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5563-5586&issue=12&author=M.+Wangauthor=A.+Shenauthor=C.+Zhangauthor=Z.+Songauthor=J.+Aiauthor=H.+Liuauthor=L.+Sunauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Development+of+Heat+Shock+Protein+%28Hsp90%29+Inhibitors+to+Combat+Resistance+to+Tyrosine+Kinase+Inhibitors+Through+Hsp90-Kinase+Interactions&doi=10.1021%2Facs.jmedchem.5b01106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions</span></div><div class="casAuthors">Wang, Meining; Shen, Aijun; Zhang, Chi; Song, Zilan; Ai, Jing; Liu, Hongchun; Sun, Liping; Ding, Jian; Geng, Meiyu; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5563-5586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a ubiquitous chaperone of all of the oncogenic tyrosine kinases.  Many Hsp90 inhibitors, alone or in combination, have shown significant antitumor efficacy against the kinase-pos. na.ovrddot.ive and mutant models.  However, clin. trials of these inhibitors are unsuccessful due to insufficient clin. benefits and nonoptimal safety profiles.  Recently, much progress has been reported on the Hsp90-cochaperone-client complex, which will undoubtedly assist in the understanding of the interactions between Hsp90 and its clients.  Meanwhile, Hsp90 inhibitors have shown promise against patients' resistance caused by early generation tyrosine kinase inhibitors (TKIs), and at least 13 Hsp90 inhibitors are being reevaluated in the clinic.  In this regard, the objectives of the current perspective are to summarize the structure and function of the Hsp90-cochaperone-client complex, to analyze the structural and functional insights into the Hsp90-client interactions to address several existing unresolved problems with Hsp90 inhibitors, and to highlight the preclin. and clin. studies of Hsp90 inhibitors as an effective treatment against resistance to tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogrgsVY9MSMrVg90H21EOLACvtfcHk0lhGs1pm106Brw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOls7s%253D&md5=2408b273b2a00136223ff21709c7ae2d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01106%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Heat%2520Shock%2520Protein%2520%2528Hsp90%2529%2520Inhibitors%2520to%2520Combat%2520Resistance%2520to%2520Tyrosine%2520Kinase%2520Inhibitors%2520Through%2520Hsp90-Kinase%2520Interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D12%26spage%3D5563%26epage%3D5586%26doi%3D10.1021%2Facs.jmedchem.5b01106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Studies of Substrate-Assisted Inhibition of Ubiquitin-Activating Enzyme by Adenosine Sulfamate Analogues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">40867</span>– <span class="NLM_lpage">40877</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.279984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fjbc.M111.279984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21969368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=40867-40877&issue=47&author=J.+J.+Chenauthor=C.+A.+Tsuauthor=J.+M.+Gavinauthor=M.+A.+Milhollenauthor=F.+J.+Bruzzeseauthor=W.+D.+Mallenderauthor=M.+D.+Sintchakauthor=N.+J.+Bumpauthor=X.+Yangauthor=J.+Maauthor=H.-K.+Lokeauthor=Q.+Xuauthor=P.+Liauthor=N.+F.+Benceauthor=J.+E.+Brownellauthor=L.+R.+Dick&title=Mechanistic+Studies+of+Substrate-Assisted+Inhibition+of+Ubiquitin-Activating+Enzyme+by+Adenosine+Sulfamate+Analogues&doi=10.1074%2Fjbc.M111.279984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues</span></div><div class="casAuthors">Chen, Jesse J.; Tsu, Christopher A.; Gavin, James M.; Milhollen, Michael A.; Bruzzese, Frank J.; Mallender, William D.; Sintchak, Michael D.; Bump, Nancy J.; Yang, Xiaofeng; Ma, Jingya; Loke, Huay-Keng; Xu, Qing; Li, Ping; Bence, Neil F.; Brownell, James E.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">40867-40877</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin-activating enzyme (UAE or E1) activates ubiquitin via an adenylate intermediate and catalyzes its transfer to a ubiquitin-conjugating enzyme (E2).  MLN4924 is an adenosine sulfamate analog that was identified as a selective, mechanism-based inhibitor of NEDD8-activating enzyme (NAE), another E1 enzyme, by forming a NEDD8-MLN4924 adduct that tightly binds at the active site of NAE, a novel mechanism termed substrate-assisted inhibition.  In the present study, substrate-assisted inhibition of human UAE (Ube1) by another adenosine sulfamate analog, 5'-O-sulfamoyl-N6-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine (Compd. I), a nonselective E1 inhibitor, was characterized.  Compd. I inhibited UAE-dependent ATP-PPi exchange activity, caused loss of UAE thioester, and inhibited E1-E2 transthiolation in a dose-dependent manner.  Mechanistic studies on Compd. I and its purified ubiquitin adduct demonstrate that the proposed substrate-assisted inhibition via covalent adduct formation is entirely consistent with the three-step ubiquitin activation process and that the adduct is formed via nucleophilic attack of UAE thioester by the sulfamate group of Compd. I after completion of step 2.  Kinetic and affinity anal. of Compd. I, MLN4924, and their purified ubiquitin adducts suggest that both the rate of adduct formation and the affinity between the adduct and E1 contribute to the overall potency.  Because all E1s are thought to use a similar mechanism to activate their cognate ubiquitin-like proteins, the substrate-assisted inhibition by adenosine sulfamate analogs represents a promising strategy to develop potent and selective E1 inhibitors that can modulate diverse biol. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiclhUT_b-7Vg90H21EOLACvtfcHk0lhGs1pm106Brw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE&md5=2362ac83bb8acf0de63162bac731c6e7</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.279984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.279984%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.-K.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBence%26aufirst%3DN.%2BF.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DMechanistic%2520Studies%2520of%2520Substrate-Assisted%2520Inhibition%2520of%2520Ubiquitin-Activating%2520Enzyme%2520by%2520Adenosine%2520Sulfamate%2520Analogues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D47%26spage%3D40867%26epage%3D40877%26doi%3D10.1074%2Fjbc.M111.279984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Inhibitor of the Ubiquitin Activating Enzyme for Cancer Treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nm.4474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnm.4474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29334375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=186-193&issue=2&author=M.+L.+Hyerauthor=M.+A.+Milhollenauthor=J.+Ciavarriauthor=P.+Flemingauthor=T.+Traoreauthor=D.+Sappalauthor=J.+Huckauthor=J.+Shiauthor=J.+Gavinauthor=J.+Brownellauthor=Y.+Yangauthor=B.+Stringerauthor=R.+Griffinauthor=F.+Bruzzeseauthor=T.+Soucyauthor=J.+Duffyauthor=C.+Rabinoauthor=J.+Ricebergauthor=K.+Hoarauthor=A.+Lublinskyauthor=S.+Menonauthor=M.+Sintchakauthor=N.+Bumpauthor=S.+M.+Pulukuriauthor=S.+Langstonauthor=S.+Tirrellauthor=M.+Kurandaauthor=P.+Veibyauthor=J.+Newcombauthor=P.+Liauthor=J.+T.+Wuauthor=J.+Poweauthor=L.+R.+Dickauthor=P.+Greenspanauthor=K.+Galvinauthor=M.+Manfrediauthor=C.+Claiborneauthor=B.+S.+Amidonauthor=N.+F.+Bence&title=A+Small-Molecule+Inhibitor+of+the+Ubiquitin+Activating+Enzyme+for+Cancer+Treatment&doi=10.1038%2Fnm.4474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span></div><div class="casAuthors">Hyer, Marc L.; Milhollen, Michael A.; Ciavarri, Jeff; Fleming, Paul; Traore, Tary; Sappal, Darshan; Huck, Jessica; Shi, Judy; Gavin, James; Brownell, Jim; Yang, Yu; Stringer, Bradley; Griffin, Robert; Bruzzese, Frank; Soucy, Teresa; Duffy, Jennifer; Rabino, Claudia; Riceberg, Jessica; Hoar, Kara; Lublinsky, Anya; Menon, Saurabh; Sintchak, Michael; Bump, Nancy; Pulukuri, Sai M.; Langston, Steve; Tirrell, Stephen; Kuranda, Mike; Veiby, Petter; Newcomb, John; Li, Ping; Wu, Jing Tao; Powe, Josh; Dick, Lawrence R.; Greenspan, Paul; Galvin, Katherine; Manfredi, Mark; Claiborne, Chris; Amidon, Benjamin S.; Bence, Neil F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis.  The therapeutic potential of this pathway has been validated by the clin. successes of a no. of UPS modulators, including proteasome inhibitors and immunomodulatory imide drugs (IMiDs).  Here we identified TAK-243 (formerly known as MLN7243) as a potent, mechanism-based small-mol. inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade.  TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways.  TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses.  Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biol. and for assessment of UAE inhibition as a new approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GCsna-MdUrVg90H21EOLACvtfcHk0lgqx5UkQDHpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D&md5=06010b7eb1cc59cf3687b9c52844eb96</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnm.4474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4474%26sid%3Dliteratum%253Aachs%26aulast%3DHyer%26aufirst%3DM.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DCiavarri%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DSappal%26aufirst%3DD.%26aulast%3DHuck%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DGavin%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DHoar%26aufirst%3DK.%26aulast%3DLublinsky%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DKuranda%26aufirst%3DM.%26aulast%3DVeiby%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DPowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGreenspan%26aufirst%3DP.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DClaiborne%26aufirst%3DC.%26aulast%3DAmidon%26aufirst%3DB.%2BS.%26aulast%3DBence%26aufirst%3DN.%2BF.%26atitle%3DA%2520Small-Molecule%2520Inhibitor%2520of%2520the%2520Ubiquitin%2520Activating%2520Enzyme%2520for%2520Cancer%2520Treatment%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D2%26spage%3D186%26epage%3D193%26doi%3D10.1038%2Fnm.4474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talreja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of NEDD8-Activating Enzyme as a New Approach to Treat Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span> (<span class="NLM_issue">7239</span>),  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1038/nature07884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature07884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19360080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=732-736&issue=7239&author=T.+A.+Soucyauthor=P.+G.+Smithauthor=M.+A.+Milhollenauthor=A.+J.+Bergerauthor=J.+M.+Gavinauthor=S.+Adhikariauthor=J.+E.+Brownellauthor=K.+E.+Burkeauthor=D.+P.+Cardinauthor=S.+Critchleyauthor=C.+A.+Cullisauthor=A.+Doucetteauthor=J.+J.+Garnseyauthor=J.+L.+Gaulinauthor=R.+E.+Gershmanauthor=A.+R.+Lublinskyauthor=A.+McDonaldauthor=H.+Mizutaniauthor=U.+Narayananauthor=E.+J.+Olhavaauthor=S.+Pelusoauthor=M.+Rezaeiauthor=M.+D.+Sintchakauthor=T.+Talrejaauthor=M.+P.+Thomasauthor=T.+Traoreauthor=S.+Vyskocilauthor=G.+S.+Weatherheadauthor=J.+Yuauthor=J.+Zhangauthor=L.+R.+Dickauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=S.+P.+Langston&title=An+Inhibitor+of+NEDD8-Activating+Enzyme+as+a+New+Approach+to+Treat+Cancer&doi=10.1038%2Fnature07884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span></div><div class="casAuthors">Soucy, Teresa A.; Smith, Peter G.; Milhollen, Michael A.; Berger, Allison J.; Gavin, James M.; Adhikari, Sharmila; Brownell, James E.; Burke, Kristine E.; Cardin, David P.; Critchley, Stephen; Cullis, Courtney A.; Doucette, Amanda; Garnsey, James J.; Gaulin, Jeffrey L.; Gershman, Rachel E.; Lublinsky, Anna R.; McDonald, Alice; Mizutani, Hirotake; Narayanan, Usha; Olhava, Edward J.; Peluso, Stephane; Rezaei, Mansoureh; Sintchak, Michael D.; Talreja, Tina; Thomas, Michael P.; Traore, Tary; Vyskocil, Stepan; Weatherhead, Gabriel S.; Yu, Jie; Zhang, Julie; Dick, Lawrence R.; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Langston, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7239</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. development of an inhibitor of cellular proteasome function suggests that compds. targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies.  NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome.  Substrates of cullin-RING ligases have important roles in cellular processes assocd. with cancer cell growth and survival pathways.  Here we describe MLN4924, a potent and selective inhibitor of NAE.  MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells by a new mechanism of action, the deregulation of S-phase DNA synthesis.  MLN4924 suppressed the growth of human tumor xenografts in mice at compd. exposures that were well tolerated.  Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8fx7OnZtYjbVg90H21EOLACvtfcHk0lg5yo_rNYPwHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D&md5=365d4b4feac3994849050e00f1aae5e0</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature07884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07884%26sid%3Dliteratum%253Aachs%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCardin%26aufirst%3DD.%2BP.%26aulast%3DCritchley%26aufirst%3DS.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DDoucette%26aufirst%3DA.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DGaulin%26aufirst%3DJ.%2BL.%26aulast%3DGershman%26aufirst%3DR.%2BE.%26aulast%3DLublinsky%26aufirst%3DA.%2BR.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DTalreja%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26atitle%3DAn%2520Inhibitor%2520of%2520NEDD8-Activating%2520Enzyme%2520as%2520a%2520New%2520Approach%2520to%2520Treat%2520Cancer%26jtitle%3DNature%26date%3D2009%26volume%3D458%26issue%3D7239%26spage%3D732%26epage%3D736%26doi%3D10.1038%2Fnature07884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duda, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, B. A.</span></span> <span> </span><span class="NLM_article-title">Structural Insights Into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>134</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2008.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18805092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sns7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2008&pages=995-1006&issue=6&author=D.+M.+Dudaauthor=L.+A.+Borgauthor=D.+C.+Scottauthor=H.+W.+Huntauthor=M.+Hammelauthor=B.+A.+Schulman&title=Structural+Insights+Into+NEDD8+Activation+of+Cullin-RING+Ligases%3A+Conformational+Control+of+Conjugation&doi=10.1016%2Fj.cell.2008.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into NEDD8 activation of Cullin-RING ligases: conformational control of conjugation</span></div><div class="casAuthors">Duda, David M.; Borg, Laura A.; Scott, Daniel C.; Hunt, Harold W.; Hammel, Michal; Schulman, Brenda A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">995-1006</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cullin-RING ligases (CRLs) comprise the largest ubiquitin E3 subclass, in which a central cullin subunit links a substrate-binding adaptor with an E2-binding RING.  Covalent attachment of the ubiquitin-like protein NEDD8 to a conserved C-terminal domain (ctd) lysine stimulates CRL ubiquitination activity and prevents binding of the inhibitor CAND1.  Here we report striking conformational rearrangements in the crystal structure of NEDD8∼Cul5ctd-Rbx1 and SAXS anal. of NEDD8∼Cul1ctd-Rbx1 relative to their unmodified counterparts.  In NEDD8ylated CRL structures, the cullin WHB and Rbx1 RING subdomains are dramatically reoriented, eliminating a CAND1-binding site and imparting multiple potential catalytic geometries to an assocd. E2.  Biochem. analyses indicate that the structural malleability is important for both CRL NEDD8ylation and subsequent ubiquitination activities.  Thus, our results point to a conformational control of CRL activity, with ligation of NEDD8 shifting equil. to disfavor inactive CAND1-bound closed architectures, and favor dynamic, open forms that promote polyubiquitination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmwB4M6C7dU7Vg90H21EOLACvtfcHk0lg5yo_rNYPwHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sns7rN&md5=379107aaeb4c0824f9fa352e4aa34edb</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DD.%2BM.%26aulast%3DBorg%26aufirst%3DL.%2BA.%26aulast%3DScott%26aufirst%3DD.%2BC.%26aulast%3DHunt%26aufirst%3DH.%2BW.%26aulast%3DHammel%26aufirst%3DM.%26aulast%3DSchulman%26aufirst%3DB.%2BA.%26atitle%3DStructural%2520Insights%2520Into%2520NEDD8%2520Activation%2520of%2520Cullin-RING%2520Ligases%253A%2520Conformational%2520Control%2520of%2520Conjugation%26jtitle%3DCell%26date%3D2008%26volume%3D134%26issue%3D6%26spage%3D995%26epage%3D1006%26doi%3D10.1016%2Fj.cell.2008.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span> <span> </span><span class="NLM_article-title">How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">811</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.tibs.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28784328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1entLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=799-811&issue=10&author=K.+A.+Verbaauthor=D.+A.+Agard&title=How+Hsp90+and+Cdc37+Lubricate+Kinase+Molecular+Switches&doi=10.1016%2Fj.tibs.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches</span></div><div class="casAuthors">Verba, Kliment A.; Agard, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">799-811</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Hsp90/Cdc37 chaperone system interacts with and supports 60% of the human kinome.  Not only are Hsp90 and Cdc37 generally required for initial folding, but many kinases rely on the Hsp90/Cdc37 throughout their lifetimes.  A large fraction of these 'client' kinases are key oncoproteins, and their interactions with the Hsp90/Cdc37 machinery are crucial for both their normal and malignant activity.  Recently, advances in single-particle cryo-electron microscopy (cryoEM) and biochem. strategies have provided the first key mol. insights into kinase-chaperone interactions.  The surprising results suggest a re-evaluation of the role of chaperones in the kinase lifecycle, and suggest that such interactions potentially allow kinases to more rapidly respond to key signals while simultaneously protecting unstable kinases from degrdn. and suppressing unwanted basal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGaSubzxlym7Vg90H21EOLACvtfcHk0lhEDza3t0hYtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1entLvF&md5=34a329cf822ebbb8776b9e03451f0e6b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26atitle%3DHow%2520Hsp90%2520and%2520Cdc37%2520Lubricate%2520Kinase%2520Molecular%2520Switches%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26issue%3D10%26spage%3D799%26epage%3D811%26doi%3D10.1016%2Fj.tibs.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoraki, M. A.</span></span> <span> </span><span class="NLM_article-title">Molecular Chaperones and Protein Kinase Quality Control</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2006.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.tcb.2006.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17184992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1Sms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=87-92&issue=2&author=A.+J.+Caplanauthor=A.+K.+Mandalauthor=M.+A.+Theodoraki&title=Molecular+Chaperones+and+Protein+Kinase+Quality+Control&doi=10.1016%2Fj.tcb.2006.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular chaperones and protein kinase quality control</span></div><div class="casAuthors">Caplan, Avrom J.; Mandal, Atin K.; Theodoraki, Maria A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Hsp90-Cdc37 chaperone pair has special responsibility for folding of protein kinases.  This function has made Hsp90 a target for new chemotherapeutic approaches, and several compds. are currently being tested for their ability to inhibit many different kinases simultaneously.  Not all kinases are sensitive to these inhibitors, however, and this difference might depend on how each kinase interacts with Hsp90 and Cdc37 during folding of the nascent chain and thereafter.  Indeed, several kinases require the persistent presence of both chaperones after initial folding and some of these kinases seem to be particularly sensitive to Hsp90 inhibitors.  This requirement might relate to conformational changes that take place during the protein kinase activity cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYJvSw0DtYnLVg90H21EOLACvtfcHk0lhEDza3t0hYtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1Sms7s%253D&md5=6595e47928ff70cd6d1686364ffde72e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2006.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2006.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DCaplan%26aufirst%3DA.%2BJ.%26aulast%3DMandal%26aufirst%3DA.%2BK.%26aulast%3DTheodoraki%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520Chaperones%2520and%2520Protein%2520Kinase%2520Quality%2520Control%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2007%26volume%3D17%26issue%3D2%26spage%3D87%26epage%3D92%26doi%3D10.1016%2Fj.tcb.2006.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keramisanou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasantha Kumar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Vaart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelis, I.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation Induced Cochaperone Unfolding Promotes Kinase Recruitment and Client Class-Specific Hsp90 Phosphorylation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">265</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02711-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41467-017-02711-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29343704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvhs12muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=265&issue=1&author=A.+B.+Bachmanauthor=D.+Keramisanouauthor=W.+Xuauthor=K.+Beebeauthor=M.+A.+Mosesauthor=M.+V.+Vasantha+Kumarauthor=G.+Grayauthor=R.+E.+Noorauthor=A.+van+der%0AVaartauthor=L.+Neckersauthor=I.+Gelis&title=Phosphorylation+Induced+Cochaperone+Unfolding+Promotes+Kinase+Recruitment+and+Client+Class-Specific+Hsp90+Phosphorylation&doi=10.1038%2Fs41467-017-02711-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation induced cochaperone unfolding promotes kinase recruitment and client class-specific Hsp90 phosphorylation</span></div><div class="casAuthors">Bachman Ashleigh B; Keramisanou Dimitra; Vasantha Kumar M V; Gray Geoffrey; Noor Radwan Ebna; van der Vaart Arjan; Gelis Ioannis; Xu Wanping; Beebe Kristin; Moses Michael A; Neckers Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During the Hsp90-mediated chaperoning of protein kinases, the core components of the machinery, Hsp90 and the cochaperone Cdc37, recycle between different phosphorylation states that regulate progression of the chaperone cycle.  We show that Cdc37 phosphorylation at Y298 results in partial unfolding of the C-terminal domain and the population of folding intermediates.  Unfolding facilitates Hsp90 phosphorylation at Y197 by unmasking a phosphopeptide sequence, which serves as a docking site to recruit non-receptor tyrosine kinases to the chaperone complex via their SH2 domains.  In turn, Hsp90 phosphorylation at Y197 specifically regulates its interaction with Cdc37 and thus affects the chaperoning of only protein kinase clients.  In summary, we find that by providing client class specificity, Hsp90 cochaperones such as Cdc37 do not merely assist in client recruitment but also shape the post-translational modification landscape of Hsp90 in a client class-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7izekEYEuoxLDWw4HIq2sfW6udTcc2eZVWmsP7taAsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvhs12muw%253D%253D&md5=7bdc49c613d47135b952650239f031a2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02711-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02711-w%26sid%3Dliteratum%253Aachs%26aulast%3DBachman%26aufirst%3DA.%2BB.%26aulast%3DKeramisanou%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26aulast%3DVasantha%2BKumar%26aufirst%3DM.%2BV.%26aulast%3DGray%26aufirst%3DG.%26aulast%3DNoor%26aufirst%3DR.%2BE.%26aulast%3Dvan%2Bder%2BVaart%26aufirst%3DA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DGelis%26aufirst%3DI.%26atitle%3DPhosphorylation%2520Induced%2520Cochaperone%2520Unfolding%2520Promotes%2520Kinase%2520Recruitment%2520and%2520Client%2520Class-Specific%2520Hsp90%2520Phosphorylation%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D265%26doi%3D10.1038%2Fs41467-017-02711-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samant, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span> <span> </span><span class="NLM_article-title">ATP-Competitive Inhibitors Block Protein Kinase Recruitment to the Hsp90-Cdc37 System</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnchembio.1212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23502424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVKgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=307-312&issue=5&author=S.+Polierauthor=R.+S.+Samantauthor=P.+A.+Clarkeauthor=P.+Workmanauthor=C.+Prodromouauthor=L.+H.+Pearl&title=ATP-Competitive+Inhibitors+Block+Protein+Kinase+Recruitment+to+the+Hsp90-Cdc37+System&doi=10.1038%2Fnchembio.1212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system</span></div><div class="casAuthors">Polier, Sigrun; Samant, Rahul S.; Clarke, Paul A.; Workman, Paul; Prodromou, Chrisostomos; Pearl, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">307-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinase clients are recruited to the Hsp90 mol. chaperone system via Cdc37, which simultaneously binds Hsp90 and kinases and regulates the Hsp90 chaperone cycle.  Pharmacol. inhibition of Hsp90 in vivo results in degrdn. of kinase clients, with a therapeutic effect in dependent tumors.  We show here that Cdc37 directly antagonizes ATP binding to client kinases, suggesting a role for the Hsp90-Cdc37 complex in controlling kinase activity.  Unexpectedly, we find that Cdc37 binding to protein kinases is itself antagonized by ATP-competitive kinase inhibitors, including vemurafenib and lapatinib.  In cancer cells, these inhibitors deprive oncogenic kinases such as B-Raf and ErbB2 of access to the Hsp90-Cdc37 complex, leading to their degrdn.  Our results suggest that at least part of the efficacy of ATP-competitive inhibitors of Hsp90-dependent kinases in tumor cells may be due to targeted chaperone deprivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopGiAehQefXbVg90H21EOLACvtfcHk0lj-YcppCLGK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVKgtLw%253D&md5=628085339cdaae95e62644d66b3b03a6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1212%26sid%3Dliteratum%253Aachs%26aulast%3DPolier%26aufirst%3DS.%26aulast%3DSamant%26aufirst%3DR.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26atitle%3DATP-Competitive%2520Inhibitors%2520Block%2520Protein%2520Kinase%2520Recruitment%2520to%2520the%2520Hsp90-Cdc37%2520System%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D5%26spage%3D307%26epage%3D312%26doi%3D10.1038%2Fnchembio.1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Neratinib Induces ErbB2 Ubiquitylation and Endocytic Degradation via HSP90 Dissociation in Breast Cancer Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.canlet.2016.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27597738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2016&pages=176-185&issue=2&author=Y.+Zhangauthor=J.+Zhangauthor=C.+Liuauthor=S.+Duauthor=L.+Fengauthor=X.+Luanauthor=Y.+Zhangauthor=Y.+Shiauthor=T.+Wangauthor=Y.+Wuauthor=W.+Chengauthor=S.+Mengauthor=M.+Liauthor=H.+Liu&title=Neratinib+Induces+ErbB2+Ubiquitylation+and+Endocytic+Degradation+via+HSP90+Dissociation+in+Breast+Cancer+Cells&doi=10.1016%2Fj.canlet.2016.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells</span></div><div class="casAuthors">Zhang, Yingqiu; Zhang, Jinrui; Liu, Congcong; Du, Sha; Feng, Lu; Luan, Xuelin; Zhang, Yayun; Shi, Yulin; Wang, Taishu; Wu, Yue; Cheng, Wei; Meng, Songshu; Li, Man; Liu, Han</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-185</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase ErbB2/HER2 is frequently obsd. to be overexpressed in human cancers, leading to over activation of downstream signaling modules.  HER2 pos. is a major type of breast cancer for which ErbB2 targeting is already proving to be an effective therapeutic strategy.  Apart from antibodies against ErbB2, the small mol. tyrosine kinase inhibitor lapatinib has had successful clin. outcomes, and other inhibitors such as neratinib are currently undergoing clin. investigations.  In this study we report the effects of lapatinib and neratinib on the mRNA and protein levels of the ErbB2 receptor.  We provide evidence that neratinib-induced down regulation of ErbB2 occurs through ubiquitin-mediated endocytic sorting and lysosomal degrdn.  At the mechanistic level, neratinib treatment leads to HSP90 release from ErbB2 and its subsequent ubiquitylation and endocytic degrdn.  Our findings provide novel insights into the mechanism of ErbB2 inhibition by neratinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvWoy_iFPS7bVg90H21EOLACvtfcHk0lj-YcppCLGK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqtbnJ&md5=cfa019e3fd86f1cdd43b7d39053bcbfc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DLuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DMeng%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DNeratinib%2520Induces%2520ErbB2%2520Ubiquitylation%2520and%2520Endocytic%2520Degradation%2520via%2520HSP90%2520Dissociation%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D382%26issue%3D2%26spage%3D176%26epage%3D185%26doi%3D10.1016%2Fj.canlet.2016.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshinsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaux, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span> <span> </span><span class="NLM_article-title">The Specificity of JAK3 Kinase Inhibitors</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-09-115030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1182%2Fblood-2007-09-115030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18094329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2155-2157&issue=4&author=P.+S.+Changelianauthor=D.+Moshinskyauthor=C.+F.+Kuhnauthor=M.+E.+Flanaganauthor=M.+J.+Munchhofauthor=T.+M.+Harrisauthor=D.+A.+Whippleauthor=J.+L.+Dotyauthor=J.+Sunauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=D.+G.+Perregauxauthor=P.+S.+Sawyerauthor=E.+M.+Kudlacz&title=The+Specificity+of+JAK3+Kinase+Inhibitors&doi=10.1182%2Fblood-2007-09-115030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The specificity of JAK3 kinase inhibitors</span></div><div class="casAuthors">Changelian, Paul S.; Moshinsky, Deborah; Kuhn, Cyrille F.; Flanagan, Mark E.; Munchhof, Michael J.; Harris, Thomas M.; Doty, Jonathan L.; Sun, Jianmin; Kent, Craig R.; Magnuson, Kelly S.; Perregaux, David G.; Sawyer, Perry S.; Kudlacz, Elizabeth M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2155-2157</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compd. being evaluated in clin. trials for rheumatoid arthritis and prevention of allograft rejection.  PF-956980 was evaluated against a panel of 30 kinases, and found to have nanomolar potency against only JAK3.  Cellular and whole blood activity of this compd. parallels its potency and selectivity in enzyme assays.  It was effective in vivo at inhibiting the delayed type hypersensitivity reaction in mice.  We compared 2 com. available JAK3 inhibitors (WHI-P131 and WHI-P154) in the same panel of biochem. and cellular assays and found them to be neither potent nor selective for JAK3.  Both were found to be nanomolar inhibitors of the EGF receptor family of kinases.  As these compds. were used in numerous publications in the transplant and autoimmune disease literature, their specificity should be considered when interpreting these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-xhj-I5327Vg90H21EOLACvtfcHk0lj-YcppCLGK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVeitrw%253D&md5=bbcf27a841692f796d1fcdc382745bc3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-09-115030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-09-115030%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DMoshinsky%26aufirst%3DD.%26aulast%3DKuhn%26aufirst%3DC.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26atitle%3DThe%2520Specificity%2520of%2520JAK3%2520Kinase%2520Inhibitors%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26issue%3D4%26spage%3D2155%26epage%3D2157%26doi%3D10.1182%2Fblood-2007-09-115030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive Pan-JAK Inhibitor</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1183</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVyrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1183-1187&issue=5&author=S.+D.+Fieldauthor=J.+Arkinauthor=J.+Liauthor=L.+H.+Jones&title=Selective+Downregulation+of+JAK2+and+JAK3+by+an+ATP-Competitive+Pan-JAK+Inhibitor&doi=10.1021%2Facschembio.7b00116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor</span></div><div class="casAuthors">Field, S. Denise; Arkin, Jacob; Li, Jing; Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1183-1187</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-956980 has been used previously as a JAK3-selective chem. probe in numerous cell-based expts.  Here, we report that not only is PF-956980 a pan-JAK ATP-competitive inhibitor but it also causes selective redn. of endogenous JAK2 and JAK3 protein levels in human primary immune cells (in a time-dependent manner), leaving the other JAK family members (JAK1 and TYK2) unchanged.  We found that PF-956980 selectively downregulated JAK2 and JAK3 mRNA, corresponding to changes obsd. at the protein level.  This work highlights therapeutic opportunities for the development of pharmacol. inhibitors that also modulate the expression of their cognate binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolA7-3oHqu-LVg90H21EOLACvtfcHk0lh5_C18UKBhfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVyrs78%253D&md5=8c38a7120b8c401047b9b298ff602748</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00116%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DS.%2BD.%26aulast%3DArkin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSelective%2520Downregulation%2520of%2520JAK2%2520and%2520JAK3%2520by%2520an%2520ATP-Competitive%2520Pan-JAK%2520Inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26issue%3D5%26spage%3D1183%26epage%3D1187%26doi%3D10.1021%2Facschembio.7b00116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and Consequences of Jak-STAT Signaling in the Immune System</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/ni.3691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fni.3691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28323260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=374-384&issue=4&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+and+Consequences+of+Jak-STAT+Signaling+in+the+Immune+System&doi=10.1038%2Fni.3691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and consequences of Jak-STAT signaling in the immune system</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">374-384</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases of the Jak ('Janus kinase') family and transcription factors (TFs) of the STAT ('signal transducer and activator of transcription') family constitute a rapid membrane-to-nucleus signaling module that affects every aspect of the mammalian immune system.  Research on this paradigmatic pathway has experienced breakneck growth in the quarter century since its discovery and has yielded a stream of basic and clin. insights that have profoundly influenced modern understanding of human health and disease, exemplified by the bench-to-bedside success of Jak inhibitors ('jakinibs') and pathway-targeting drugs.  Here we review recent advances in Jak-STAT biol., focusing on immune cell function, disease etiol. and therapeutic intervention, as well as broader principles of gene regulation and signal-dependent TFs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUlP3emd5BrVg90H21EOLACvtfcHk0lh5_C18UKBhfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D&md5=b50a88aee2b64fcb85c9a64d4ec1724e</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fni.3691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3691%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520and%2520Consequences%2520of%2520Jak-STAT%2520Signaling%2520in%2520the%2520Immune%2520System%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26issue%3D4%26spage%3D374%26epage%3D384%26doi%3D10.1038%2Fni.3691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&issue=1&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+Pathway%3A+Impact+on+Human+Disease+and+Therapeutic+Intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0lh5_C18UKBhfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520Pathway%253A%2520Impact%2520on%2520Human%2520Disease%2520and%2520Therapeutic%2520Intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26issue%3D1%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&issue=12&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lhISyWydbUd4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3212</span>– <span class="NLM_lpage">3217</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1078-0432.CCR-12-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22544377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3212-3217&issue=12&author=A.+Deisserothauthor=E.+Kaminskasauthor=J.+Grilloauthor=W.+Chenauthor=H.+Saberauthor=H.+L.+Luauthor=M.+D.+Rothmannauthor=S.+Brarauthor=J.+Wangauthor=C.+Garnettauthor=J.+Bullockauthor=L.+B.+Burkeauthor=A.+Rahmanauthor=R.+Sridharaauthor=A.+Farrellauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+Approval%3A+Ruxolitinib+for+the+Treatment+of+Patients+with+Intermediate+and+High-Risk+Myelofibrosis&doi=10.1158%2F1078-0432.CCR-12-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span></div><div class="casAuthors">Deisseroth, Albert; Kaminskas, Edvardas; Grillo, Joseph; Chen, Wei; Saber, Haleh; Lu, Hong L.; Rothmann, Mark D.; Brar, Satjit; Wang, Jian; Garnett, Christine; Bullock, Julie; Burke, Laurie B.; Rahman, Atiqur; Sridhara, Rajeshwari; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3212-3217</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the U.S.  Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.  This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2).  The primary efficacy endpoint was the proportion of patients who experienced a redn. in spleen vol. of ≥35% at 24 wk (study 1) or 48 wk (study 2).  The key secondary endpoint in study 1 was the proportion of patients who experienced a ≥50% improvement from baseline in myelofibrosis total symptom score at 24 wk.  The results of these studies showed that a greater proportion of patients treated with ruxolitinib experienced a ≥35% redn. in spleen vol. as compared with those treated with placebo (42% vs. 1%, P < 0.0001) or best available therapy (29% vs. 0%, P < 0.0001).  A greater proportion of patients in study 1 experienced a ≥50% redn. in the myelofibrosis total symptom score during treatment with ruxolitinib than with placebo (46% vs. 5%, P < 0.0001).  Ruxolitinib treatment was assocd. with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia.  This is the first drug approved for myelofibrosis.  Clin Cancer Res; 18(12); 3212-7. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44NYcMOixiLVg90H21EOLACvtfcHk0lhISyWydbUd4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D&md5=6ed7731730708b8a8cbdc5d766065ddb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0653%26sid%3Dliteratum%253Aachs%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%2BL.%26aulast%3DRothmann%26aufirst%3DM.%2BD.%26aulast%3DBrar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DL.%2BB.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520Approval%253A%2520Ruxolitinib%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Intermediate%2520and%2520High-Risk%2520Myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D12%26spage%3D3212%26epage%3D3217%26doi%3D10.1158%2F1078-0432.CCR-12-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&issue=24&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+Potent+and+Selective+Janus+Kinase+%28JAK%29+Inhibitor+for+the+Treatment+of+Autoimmune+Diseases+and+Organ+Transplant+Rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lhISyWydbUd4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%2520and%2520Organ%2520Transplant%2520Rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elrick, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funckes-Shippy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saabye, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. L.</span></span> <span> </span><span class="NLM_article-title">Anti-Inflammatory Activity and Neutrophil Reductions Mediated by the JAK1/JAK3 Inhibitor, CP-690,550, in Rat Adjuvant-Induced Arthritis</span>. <i>J. Inflammation (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1186/1476-9255-7-41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20701804" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41-53&issue=1&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-Inflammatory+Activity+and+Neutrophil+Reductions+Mediated+by+the+JAK1%2FJAK3+Inhibitor%2C+CP-690%2C550%2C+in+Rat+Adjuvant-Induced+Arthritis&doi=10.1186%2F1476-9255-7-41"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-Inflammatory%2520Activity%2520and%2520Neutrophil%2520Reductions%2520Mediated%2520by%2520the%2520JAK1%252FJAK3%2520Inhibitor%252C%2520CP-690%252C550%252C%2520in%2520Rat%2520Adjuvant-Induced%2520Arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26issue%3D1%26spage%3D41%26epage%3D53%26doi%3D10.1186%2F1476-9255-7-41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greggio, E.</span></span> <span> </span><span class="NLM_article-title">LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/1570159X13666151030102847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F1570159X13666151030102847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26517051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlCgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=214-225&issue=3&author=J.-M.+Taymansauthor=E.+Greggio&title=LRRK2+Kinase+Inhibition+as+a+Therapeutic+Strategy+for+Parkinson%E2%80%99s+Disease%2C+Where+Do+We+Stand%3F&doi=10.2174%2F1570159X13666151030102847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?</span></div><div class="casAuthors">Taymans, Jean-Marc; Greggio, Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-225</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">One of the most promising therapeutic targets for potential disease modifying treatment of Parkinson's disease (PD) is leucine-rich repeat kinase 2 (LRRK2).  Specifically, targeting LRRK2's kinase function has generated a lot of interest from both industry and academia.  This work has yielded several published studies showing the feasibility of developing potent, selective and brain permeable LRRK2 kinase inhibitors.  The availability of these exptl. drugs is contributing to filling in the gaps in our knowledge on the safety and efficacy of LRRK2 kinase inhibition.  Recent studies of LRRK2 kinase inhibition in preclin. models point to potential undesired effects in peripheral tissues such as lung and kidney.  Also, while strategies are now emerging to measure target engagement of LRRK2 inhibitors, there remains an important need to expand efficacy studies in preclin. models of progressive PD.  Future work in the LRRK2 inhibition field must therefore be directed towards developing mols. and treatment regimens which demonstrate efficacy in mammalian models of disease in conditions where safety liabilities are reduced to a min.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrE-1Rx3Jzh7Vg90H21EOLACvtfcHk0lidV1OX48JFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlCgu74%253D&md5=f68fc6814e2add4836aefe53321d1199</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F1570159X13666151030102847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X13666151030102847%26sid%3Dliteratum%253Aachs%26aulast%3DTaymans%26aufirst%3DJ.-M.%26aulast%3DGreggio%26aufirst%3DE.%26atitle%3DLRRK2%2520Kinase%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%252C%2520Where%2520Do%2520We%2520Stand%253F%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2016%26volume%3D14%26issue%3D3%26spage%3D214%26epage%3D225%26doi%3D10.2174%2F1570159X13666151030102847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gloeckner, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zweydorf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarioglu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueffing, M.</span></span> <span> </span><span class="NLM_article-title">Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1745</span>, <span class="refDoi"> DOI: 10.1021/pr9008578</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr9008578" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFejt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1738-1745&issue=4&author=C.+J.+Gloecknerauthor=K.+Boldtauthor=F.+von+Zweydorfauthor=S.+Helmauthor=L.+Wiesentauthor=H.+Sariogluauthor=M.+Ueffing&title=Phosphopeptide+Analysis+Reveals+Two+Discrete+Clusters+of+Phosphorylation+in+the+N-Terminus+and+the+Roc+Domain+of+the+Parkinson-Disease+Associated+Protein+Kinase+LRRK2&doi=10.1021%2Fpr9008578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2</span></div><div class="casAuthors">Gloeckner, Christian Johannes; Boldt, Karsten; von Zweydorf, Felix; Helm, Sandra; Wiesent, Ludwig; Sarioglu, Hakan; Ueffing, Marius</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1738-1745</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) that increase its kinase activity assoc. with familial forms of Parkinson disease (PD).  As phosphorylation dets. the functional state of most protein kinases, we systematically mapped LRRK2 phosphorylation sites by mass spectrometry.  Our anal. revealed a high degree of constitutive phosphorylation in a narrow serine-rich region preceding the LRR-domain.  Allowing de novo autophosphorylation of purified LRRK2 in an in vitro autokinase assay prior to mass spectrometric anal., we discovered multiple sites of autophosphorylation.  Solely serine and threonine residues were found phosphorylated suggesting LRRK2 as a true serine threonine kinase.  Autophosphorylation mainly targets the ROC GTPase domain and its clustering around the GTP binding pocket of ROC suggests cross-regulatory activity between kinase and Roc domain.  In conclusion, the phosphoprotein LRRK2 functions as an autocatalytically active serine threonine kinase.  Clustering of phosphosites within two discrete domains suggest that phosphorylation may regulate its biol. functions in a yet unknown fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu6BAiUXeTVbVg90H21EOLACvtfcHk0lidV1OX48JFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFejt7g%253D&md5=c20f1e8a727b8fc5f2d33b685f808725</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fpr9008578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr9008578%26sid%3Dliteratum%253Aachs%26aulast%3DGloeckner%26aufirst%3DC.%2BJ.%26aulast%3DBoldt%26aufirst%3DK.%26aulast%3Dvon%2BZweydorf%26aufirst%3DF.%26aulast%3DHelm%26aufirst%3DS.%26aulast%3DWiesent%26aufirst%3DL.%26aulast%3DSarioglu%26aufirst%3DH.%26aulast%3DUeffing%26aufirst%3DM.%26atitle%3DPhosphopeptide%2520Analysis%2520Reveals%2520Two%2520Discrete%2520Clusters%2520of%2520Phosphorylation%2520in%2520the%2520N-Terminus%2520and%2520the%2520Roc%2520Domain%2520of%2520the%2520Parkinson-Disease%2520Associated%2520Protein%2520Kinase%2520LRRK2%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2010%26volume%3D9%26issue%3D4%26spage%3D1738%26epage%3D1745%26doi%3D10.1021%2Fpr9008578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobbestael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J.-M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of LRRK2: From Kinase to Substrate</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1042/BST20120128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBST20120128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22988873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOjurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1102-1110&issue=5&author=E.+Lobbestaelauthor=V.+Baekelandtauthor=J.-M.+Taymans&title=Phosphorylation+of+LRRK2%3A+From+Kinase+to+Substrate&doi=10.1042%2FBST20120128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of LRRK2: from kinase to substrate</span></div><div class="casAuthors">Lobbestael, Evy; Baekelandt, Veerle; Taymans, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1102-1110</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The PD (Parkinson's disease) protein LRRK2 (leucine-rich repeat kinase 2) occurs in cells as a highly phosphorylated protein, with the majority of phosphosites clustering in the region between the ankyrin repeat and leucine-rich repeat domains.  The observation that several pathogenic variants of LRRK2 display strongly reduced cellular phosphorylation suggests that phosphorylation of LRRK2 is involved in the PD pathol. process.  Furthermore, treatment of cells with inhibitors of LRRK2 kinase activity, which are currently considered as potential disease-modifying therapeutics for PD, leads to a rapid decrease in the phosphorylation levels of LRRK2.  For these reasons, understanding the cellular role and regulation of LRRK2 as a kinase and as a substrate has become the focus of intense investigation.  In the present review, we discuss what is currently known about the cellular phosphorylation of LRRK2 and how this relates to its function and dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFV1_upRIH2bVg90H21EOLACvtfcHk0lg5LpOw2f8dtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOjurzN&md5=013ec8ec8243d2a08b01a4bf01b80f08</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1042%2FBST20120128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20120128%26sid%3Dliteratum%253Aachs%26aulast%3DLobbestael%26aufirst%3DE.%26aulast%3DBaekelandt%26aufirst%3DV.%26aulast%3DTaymans%26aufirst%3DJ.-M.%26atitle%3DPhosphorylation%2520of%2520LRRK2%253A%2520From%2520Kinase%2520to%2520Substrate%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2012%26volume%3D40%26issue%3D5%26spage%3D1102%26epage%3D1110%26doi%3D10.1042%2FBST20120128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzamko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of LRRK2 Kinase Activity Leads to Dephosphorylation of Ser(910)/Ser(935), Disruption of 14-3-3 Binding and Altered Cytoplasmic Localization</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1042/BJ20100784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBJ20100784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20659021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=405-413&issue=3&author=N.+Dzamkoauthor=M.+Deakauthor=F.+Hentatiauthor=A.+D.+Reithauthor=A.+R.+Prescottauthor=D.+R.+Alessiauthor=R.+J.+Nichols&title=Inhibition+of+LRRK2+Kinase+Activity+Leads+to+Dephosphorylation+of+Ser%28910%29%2FSer%28935%29%2C+Disruption+of+14-3-3+Binding+and+Altered+Cytoplasmic+Localization&doi=10.1042%2FBJ20100784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization</span></div><div class="casAuthors">Dzamko, Nicolas; Deak, Maria; Hentati, Faycal; Reith, Alastair D.; Prescott, Alan R.; Alessi, Dario R.; Nichols, R. Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant no. of Parkinson's disease patients.  Since a common mutation that replaces Gly2019 with a serine residue enhances kinase catalytic activity, small-mol. LRRK2 inhibitors might have utility in treating Parkinson's disease.  However, the effectiveness of inhibitors is difficult to assess, as no physiol. substrates or downstream effectors have been identified that could be exploited to develop a robust cell-based assay.  The authors recently established that LRRK2 bound 14-3-3 protein isoforms via its phosphorylation of Ser910 and Ser935.  In the present study they show that treatment of Swiss 3T3 cells or lymphoblastoid cells derived from control or a Parkinson's disease patient harboring a homozygous LRRK2(G2019S) mutation with two structurally unrelated inhibitors of LRRK2 (H-1152 or sunitinib) induced dephosphorylation of endogenous LRRK2 at Ser910 and Ser935, thereby disrupting 14-3-3 interaction.  The results suggest that H-1152 and sunitinib induce dephosphorylation of Ser910 and Ser935 by inhibiting LRRK2 kinase activity, as these compds. failed to induce significant dephosphorylation of a drug-resistant LRRK2(A2016T) mutant.  Moreover, consistent with the finding that non-14-3-3-binding mutants of LRRK2 accumulated within discrete cytoplasmic pools resembling inclusion bodies, the authors obsd. that H-1152 causes LRRK2 to accumulate within inclusion bodies.  These findings indicate that dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and/or monitoring LRRK2 cytoplasmic localization can be used as an assay to assess the relative activity of LRRK2 inhibitors in vivo.  These results will aid the elaboration and evaluation of LRRK2 inhibitors.  They will also stimulate further research to understand how phosphorylation of Ser910 and Ser935 is controlled by LRRK2, and establish any relationship to development of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwgToKFLmVu7Vg90H21EOLACvtfcHk0lg5LpOw2f8dtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL&md5=f14dd622d2b2fa3f7495c990e65bbbfc</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1042%2FBJ20100784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100784%26sid%3Dliteratum%253Aachs%26aulast%3DDzamko%26aufirst%3DN.%26aulast%3DDeak%26aufirst%3DM.%26aulast%3DHentati%26aufirst%3DF.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26atitle%3DInhibition%2520of%2520LRRK2%2520Kinase%2520Activity%2520Leads%2520to%2520Dephosphorylation%2520of%2520Ser%2528910%2529%252FSer%2528935%2529%252C%2520Disruption%2520of%252014-3-3%2520Binding%2520and%2520Altered%2520Cytoplasmic%2520Localization%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26issue%3D3%26spage%3D405%26epage%3D413%26doi%3D10.1042%2FBJ20100784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vancraenenbroeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Raeymaecker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobbestael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Maeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J.-M.</span></span> <span> </span><span class="NLM_article-title">In Silico, in Vitro and Cellular Analysis with a Kinome-Wide Inhibitor Panel Correlates Cellular LRRK2 Dephosphorylation to Inhibitor Activity on LRRK2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.3389%2Ffnmol.2014.00051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24917786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVChsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=51&author=R.+Vancraenenbroeckauthor=J.+De+Raeymaeckerauthor=E.+Lobbestaelauthor=F.+Gaoauthor=M.+De+Maeyerauthor=A.+Voetauthor=V.+Baekelandtauthor=J.-M.+Taymans&title=In+Silico%2C+in+Vitro+and+Cellular+Analysis+with+a+Kinome-Wide+Inhibitor+Panel+Correlates+Cellular+LRRK2+Dephosphorylation+to+Inhibitor+Activity+on+LRRK2&doi=10.3389%2Ffnmol.2014.00051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2</span></div><div class="casAuthors">Vancraenenbroeck, Renee; De Raeymaecker, Joren; Lobbestael, Evy; Gao, Fangye; De Maeyer, Marc; Voet, Arnout; Baekelandt, Veerle; Taymans, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Leucine-rich repeat kinase 2 (LRRK2) is a complex, multidomain protein which is considered a valuable target for potential disease-modifying therapeutic strategies for Parkinson's disease (PD).  In mammalian cells and brain, LRRK2 is phosphorylated and treatment of cells with inhibitors of LRRK2 kinase activity can induce LRRK2 dephosphorylation at a cluster of serines including Ser910/935/955/973.  It has been suggested that phosphorylation levels at these sites reflect LRRK2 kinase activity, however kinase-dead variants of LRRK2 or kinase activating variants do not display altered Ser935 phosphorylation levels compared to wild type.  Furthermore, Ser910/935/955/973 are not autophosphorylation sites, therefore, it is unclear if inhibitor induced dephosphorylation depends on the activity of compds. on LRRK2 or on yet to be identified upstream kinases.  Here we used a panel of 160 ATP competitive and cell permeable kinase inhibitors directed against all branches of the kinome and tested their activity on LRRK2 in vitro using a peptide-substrate-based kinase assay.  In neuronal SH-SY5Y cells overexpressing LRRK2 we used compd.-induced dephosphorylation of Ser935 as readout.  In silico docking of selected compds. was performed using a modeled LRRK2 kinase structure.  Receiver operating characteristic plots demonstrated that the obtained docking scores to the LRRK2 ATP binding site correlated with in vitro and cellular compd. activity.  We also found that in vitro potency showed a high degree of correlation to cellular compd. induced LRRK2 dephosphorylation activity across multiple compd. classes.  Therefore, acute LRRK2 dephosphorylation at Ser935 in inhibitor treated cells involves a strong component of inhibitor activity on LRRK2 itself, without excluding a role for upstream kinases.  Understanding the regulation of LRRK2 phosphorylation by kinase inhibitors aids our understanding of LRRK2 signaling and may lead to development of new classes of LRRK2 kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOkDJX9D3umrVg90H21EOLACvtfcHk0lj3D7iL0G44Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVChsb%252FK&md5=e489943d1d2337897ddb460ff21f9cb7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00051%26sid%3Dliteratum%253Aachs%26aulast%3DVancraenenbroeck%26aufirst%3DR.%26aulast%3DDe%2BRaeymaecker%26aufirst%3DJ.%26aulast%3DLobbestael%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DDe%2BMaeyer%26aufirst%3DM.%26aulast%3DVoet%26aufirst%3DA.%26aulast%3DBaekelandt%26aufirst%3DV.%26aulast%3DTaymans%26aufirst%3DJ.-M.%26atitle%3DIn%2520Silico%252C%2520in%2520Vitro%2520and%2520Cellular%2520Analysis%2520with%2520a%2520Kinome-Wide%2520Inhibitor%2520Panel%2520Correlates%2520Cellular%2520LRRK2%2520Dephosphorylation%2520to%2520Inhibitor%2520Activity%2520on%2520LRRK2%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D51%26doi%3D10.3389%2Ffnmol.2014.00051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molitor, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span> <span> </span><span class="NLM_article-title">LRRK2 Dephosphorylation Increases Its Ubiquitination</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>469</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1042/BJ20141305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBJ20141305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25939886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12itr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2015&pages=107-120&issue=1&author=J.+Zhaoauthor=T.+P.+Molitorauthor=J.+W.+Langstonauthor=R.+J.+Nichols&title=LRRK2+Dephosphorylation+Increases+Its+Ubiquitination&doi=10.1042%2FBJ20141305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 dephosphorylation increases its ubiquitination</span></div><div class="casAuthors">Zhao, Jing; Molitor, Tyler P.; Langston, J. William; Nichols, R. Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Activating mutations in the leucine rich repeat protein kinase 2 (LRRK2) gene are the most common cause of inherited Parkinson's disease (PD).  LRRK2 is phosphorylated on a cluster of phosphosites including Ser-910, Ser-935, Ser-955 and Ser-973, which are dephosphorylated in several PD-related LRRK2 mutants (N1437H, R1441C/G, Y1699C and I2020T) linking the regulation of these sites to PD.  These serine residues are also dephosphorylated after kinase inhibition and lose 14-3-3 binding, which serves as a pharmacodynamic marker for inhibited LRRK2.  Loss of 14-3-3 binding is well established, but the consequences of dephosphorylation are only now being uncovered.  Potent and selective inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser-935 then ubiquitination and degrdn. of a significant fraction of LRRK2.  GNE1023 treatment decreased the phosphorylation and stability of LRRK2 in expression systems and endogenous LRRK2 in A549 cells and in mouse dosing studies.  The authors next established that LRRK2 is ubiquitinated through at least Lys-48 and Lys-63 ubiquitin linkages in response to inhibition.  To study the link between dephosphorylation induced by inhibitor treatment and LRRK2 ubiquitination, the authors studied LRRK2 in conditions where it is dephosphorylated such as expression of PD mutants [R1441G, Y1699C and I2020T] or by blocking 14-3-3 binding to LRRK2 via difopein expression, and found LRRK2 is hyper-ubiquitinated.  Calyculin A treatment prevents inhibitor and PD mutant induced dephosphorylation and reverts LRRK2 to a lesser ubiquitinated species, thus directly implicating phosphatase activity in LRRK2 ubiquitination.  This dynamic dephosphorylation-ubiquitination cycle could explain detrimental loss-of-function phenotypes found in peripheral tissues of LRRK2 kinase inactive mutants, LRRK2 KO (knockout) animals and following LRRK2 inhibitor administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxqm5oSlvVrbVg90H21EOLACvtfcHk0lj3D7iL0G44Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12itr7J&md5=6b343827aa9df5dab3c83fbd745491c0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1042%2FBJ20141305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20141305%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMolitor%26aufirst%3DT.%2BP.%26aulast%3DLangston%26aufirst%3DJ.%2BW.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26atitle%3DLRRK2%2520Dephosphorylation%2520Increases%2520Its%2520Ubiquitination%26jtitle%3DBiochem.%2520J.%26date%3D2015%26volume%3D469%26issue%3D1%26spage%3D107%26epage%3D120%26doi%3D10.1042%2FBJ20141305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobbestael, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taymans, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greggio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baekelandt, V.</span></span> <span> </span><span class="NLM_article-title">Pharmacological LRRK2 Kinase Inhibition Induces LRRK2 Protein Destabilization and Proteasomal Degradation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">33897</span>, <span class="refDoi"> DOI: 10.1038/srep33897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fsrep33897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27658356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOnurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=33897&author=E.+Lobbestaelauthor=L.+Civieroauthor=T.+De+Witauthor=J.+M.+Taymansauthor=E.+Greggioauthor=V.+Baekelandt&title=Pharmacological+LRRK2+Kinase+Inhibition+Induces+LRRK2+Protein+Destabilization+and+Proteasomal+Degradation&doi=10.1038%2Fsrep33897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation</span></div><div class="casAuthors">Lobbestael, E.; Civiero, L.; De Wit, T.; Taymans, J.-M.; Greggio, E.; Baekelandt, V.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33897</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S, and is known to play a role in Parkinson's disease (PD) pathobiol.  This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one of the most prevailing disease-modifying therapeutic PD strategies.  Although several lines of evidence support beneficial effects of LRRK2 kinase inhibitors, many questions need to be answered before clin. applications can be envisaged.  Using six different LRRK2 kinase inhibitors, we show that LRRK2 kinase inhibition induces LRRK2 dephosphorylation and can reduce LRRK2 protein levels of overexpressed wild type and G2019S, but not A2016T or K1906M, LRRK2 as well as endogenous LRRK2 in mouse brain, lung and kidney.  The inhibitor-induced redn. in LRRK2 levels could be reversed by proteasomal inhibition, but not by lysosomal inhibition, while mRNA levels remained unaffected.  In addn., using LRRK2 S910A and S935A phosphorylation mutants, we show that dephosphorylation of these sites is not required for LRRK2 degrdn.  Increasing our insight in the mol. and cellular consequences of LRRK2 kinase inhibition will be crucial in the further development of LRRK2-based PD therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW4s9pKBobXLVg90H21EOLACvtfcHk0lj3D7iL0G44Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOnurzJ&md5=0693de5d80cd9826b59ed113a204ad7b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsrep33897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep33897%26sid%3Dliteratum%253Aachs%26aulast%3DLobbestael%26aufirst%3DE.%26aulast%3DCiviero%26aufirst%3DL.%26aulast%3DDe%2BWit%26aufirst%3DT.%26aulast%3DTaymans%26aufirst%3DJ.%2BM.%26aulast%3DGreggio%26aufirst%3DE.%26aulast%3DBaekelandt%26aufirst%3DV.%26atitle%3DPharmacological%2520LRRK2%2520Kinase%2520Inhibition%2520Induces%2520LRRK2%2520Protein%2520Destabilization%2520and%2520Proteasomal%2520Degradation%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D33897%26doi%3D10.1038%2Fsrep33897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persohn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmelen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grevot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Putten, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span> <span> </span><span class="NLM_article-title">LRRK2 Protein Levels Are Determined by Kinase Function and Are Crucial for Kidney and Lung Homeostasis in Mice</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">4209</span>– <span class="NLM_lpage">4223</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddr348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1093%2Fhmg%2Fddr348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21828077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=4209-4223&issue=21&author=M.+C.+Herzigauthor=C.+Kollyauthor=E.+Persohnauthor=D.+Theilauthor=T.+Schweizerauthor=T.+Hafnerauthor=C.+Stemmelenauthor=T.+J.+Troxlerauthor=P.+Schmidauthor=S.+Dannerauthor=C.+R.+Schnellauthor=M.+Muellerauthor=B.+Kinzelauthor=A.+Grevotauthor=F.+Bolognaniauthor=M.+Stirnauthor=R.+R.+Kuhnauthor=K.+Kaupmannauthor=P.+H.+van+der%0APuttenauthor=G.+Rovelliauthor=D.+R.+Shimshek&title=LRRK2+Protein+Levels+Are+Determined+by+Kinase+Function+and+Are+Crucial+for+Kidney+and+Lung+Homeostasis+in+Mice&doi=10.1093%2Fhmg%2Fddr348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice</span></div><div class="casAuthors">Herzig, Martin C.; Kolly, Carine; Persohn, Elke; Theil, Diethilde; Schweizer, Tatjana; Hafner, Thomas; Stemmelen, Christine; Troxler, Thomas J.; Schmid, Peter; Danner, Simone; Schnell, Christian R.; Mueller, Matthias; Kinzel, Bernd; Grevot, Armelle; Bolognani, Federico; Stirn, Martina; Kuhn, Rainer R.; Kaupmann, Klemens; van der Putten, P. Herman; Rovelli, Giorgio; Shimshek, Derya R.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4209-4223</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset Parkinson's disease (PD), but the underlying pathophysiol. mechanisms and the normal function of this large multidomain protein remain speculative.  To address the role of this protein in vivo, we generated three different LRRK2 mutant mouse lines.  Mice completely lacking the LRRK2 protein (knock-out, KO) showed an early-onset (age 6 wk) marked increase in no. and size of secondary lysosomes in kidney proximal tubule cells and lamellar bodies in lung type II cells.  Mice expressing a LRRK2 kinase-dead (KD) mutant from the endogenous locus displayed similar early-onset pathophysiol. changes in kidney but not lung.  KD mutants had dramatically reduced full-length LRRK2 protein levels in the kidney and this genetic effect was mimicked pharmacol. in wild-type mice treated with a LRRK2-selective kinase inhibitor.  Knock-in (KI) mice expressing the G2019S PD-assocd. mutation that increases LRRK2 kinase activity showed none of the LRRK2 protein level and histopathol. changes obsd. in KD and KO mice.  The autophagy marker LC3 remained unchanged but kidney mTOR and TCS2 protein levels decreased in KD and increased in KO and KI mice.  Unexpectedly, KO and KI mice suffered from diastolic hypertension opposed to normal blood pressure in KD mice.  Our findings demonstrate a role for LRRK2 in kidney and lung physiol. and further show that LRRK2 kinase function affects LRRK2 protein steady-state levels thereby altering putative scaffold/GTPase activity.  These novel aspects of peripheral LRRK2 biol. critically impact ongoing attempts to develop LRRK2 selective kinase inhibitors as therapeutics for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol714w-ZIM5rVg90H21EOLACvtfcHk0lgFfm3z8GcEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI&md5=9c7935965c8f21e13b42bdc9e794cde0</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddr348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddr348%26sid%3Dliteratum%253Aachs%26aulast%3DHerzig%26aufirst%3DM.%2BC.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DPersohn%26aufirst%3DE.%26aulast%3DTheil%26aufirst%3DD.%26aulast%3DSchweizer%26aufirst%3DT.%26aulast%3DHafner%26aufirst%3DT.%26aulast%3DStemmelen%26aufirst%3DC.%26aulast%3DTroxler%26aufirst%3DT.%2BJ.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DDanner%26aufirst%3DS.%26aulast%3DSchnell%26aufirst%3DC.%2BR.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DB.%26aulast%3DGrevot%26aufirst%3DA.%26aulast%3DBolognani%26aufirst%3DF.%26aulast%3DStirn%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DR.%2BR.%26aulast%3DKaupmann%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BPutten%26aufirst%3DP.%2BH.%26aulast%3DRovelli%26aufirst%3DG.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26atitle%3DLRRK2%2520Protein%2520Levels%2520Are%2520Determined%2520by%2520Kinase%2520Function%2520and%2520Are%2520Crucial%2520for%2520Kidney%2520and%2520Lung%2520Homeostasis%2520in%2520Mice%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26issue%3D21%26spage%3D4209%26epage%3D4223%26doi%3D10.1093%2Fhmg%2Fddr348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katavolos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roose-Girma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urkowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warming, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaylaoglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span> <span> </span><span class="NLM_article-title">Effect of Selective LRRK2 Kinase Inhibition on Nonhuman Primate Lung</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">273</span>),  <span class="NLM_fpage">273ra15</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa3634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscitranslmed.aaa3634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25653221" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=273ra15&issue=273&author=R.+N.+Fujiauthor=M.+Flagellaauthor=M.+Bacaauthor=M.+A.+S.+Baptistaauthor=J.+Brodbeckauthor=B.+K.+Chanauthor=B.+K.+Fiskeauthor=L.+Honigbergauthor=A.+M.+Jubbauthor=P.+Katavolosauthor=D.+W.+Leeauthor=S.-C.+Lewin-Kohauthor=T.+Linauthor=X.+Liuauthor=S.+Liuauthor=J.+P.+Lyssikatosauthor=J.+O%E2%80%99Mahonyauthor=M.+Reicheltauthor=M.+Roose-Girmaauthor=Z.+Shengauthor=T.+Shererauthor=A.+Smithauthor=M.+Solonauthor=Z.+K.+Sweeneyauthor=J.+Tarrantauthor=A.+Urkowitzauthor=S.+Warmingauthor=M.+Yaylaogluauthor=S.+Zhangauthor=H.+Zhuauthor=A.+A.+Estradaauthor=R.+J.+Watts&title=Effect+of+Selective+LRRK2+Kinase+Inhibition+on+Nonhuman+Primate+Lung&doi=10.1126%2Fscitranslmed.aaa3634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa3634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa3634%26sid%3Dliteratum%253Aachs%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DBaca%26aufirst%3DM.%26aulast%3DBaptista%26aufirst%3DM.%2BA.%2BS.%26aulast%3DBrodbeck%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26aulast%3DHonigberg%26aufirst%3DL.%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DKatavolos%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DJ.%26aulast%3DReichelt%26aufirst%3DM.%26aulast%3DRoose-Girma%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSherer%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSolon%26aufirst%3DM.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DUrkowitz%26aufirst%3DA.%26aulast%3DWarming%26aufirst%3DS.%26aulast%3DYaylaoglu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26atitle%3DEffect%2520of%2520Selective%2520LRRK2%2520Kinase%2520Inhibition%2520on%2520Nonhuman%2520Primate%2520Lung%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D273%26spage%3D273ra15%26doi%3D10.1126%2Fscitranslmed.aaa3634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greeley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varsho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshul, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span> <span> </span><span class="NLM_article-title">Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e80705</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0080705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1371%2Fjournal.pone.0080705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24244710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e80705&issue=11&author=M.+A.+S.+Baptistaauthor=K.+D.+Daveauthor=M.+A.+Frasierauthor=T.+B.+Shererauthor=M.+Greeleyauthor=M.+J.+Beckauthor=J.+S.+Varshoauthor=G.+A.+Parkerauthor=C.+Mooreauthor=M.+J.+Churchillauthor=C.+K.+Meshulauthor=B.+K.+Fiske&title=Loss+of+Leucine-Rich+Repeat+Kinase+2+%28LRRK2%29+in+Rats+Leads+to+Progressive+Abnormal+Phenotypes+in+Peripheral+Organs&doi=10.1371%2Fjournal.pone.0080705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of leucine-rich repeat kinase 2 (LRKK2) in rats leads to progressive abnormal phenotypes in peripheral organs</span></div><div class="casAuthors">Baptista, Marco A. S.; Dave, Kuldip D.; Frasier, Mark A.; Sherer, Todd B.; Greeley, Melanie; Beck, Melissa J.; Varsho, Julie S.; Parker, George A.; Moore, Cindy; Churchill, Madeline J.; Meshul, Charles K.; Fiske, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e80705/1-e80705/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate the pathol. time course of the LRRK2 knockout rat model of Parkinson's disease at 1-, 2-, 4-, 8-, 12-, and 16-mo of age.  The evaluation consisted of histopathol. and ultrastructure examn. of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematol., serum, and urine anal.  The LRRK2 knockout rat, starting at 2-mo of age, displayed abnormal kidney staining patterns and/or morphol. changes that were assocd. with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat.  Urinalysis indicated pronounced changes in LRRK2 knockout rats in urine sp. gr., total vol., urine potassium, creatinine, sodium, and chloride that started as early as 1- to 2-mo of age.  Electron microscopy of 16-mo old LRRK2 knockout rats displayed an abnormal kidney, lung, and liver phenotype.  In contrast, there were equivocal or no differences in the heart and spleen of LRRK2 wild-type and knockout rats.  These findings partially replicate data from a recent study in 4-mo old LRRK2 knockout rats and expand the anal. to demonstrate that the renal and possibly lung and liver abnormalities progress with age.  The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0nBkK8AbyV7Vg90H21EOLACvtfcHk0lgFfm3z8GcEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D&md5=f10ad0059276bf1b2894df72772a8151</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0080705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0080705%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DM.%2BA.%2BS.%26aulast%3DDave%26aufirst%3DK.%2BD.%26aulast%3DFrasier%26aufirst%3DM.%2BA.%26aulast%3DSherer%26aufirst%3DT.%2BB.%26aulast%3DGreeley%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DM.%2BJ.%26aulast%3DVarsho%26aufirst%3DJ.%2BS.%26aulast%3DParker%26aufirst%3DG.%2BA.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DChurchill%26aufirst%3DM.%2BJ.%26aulast%3DMeshul%26aufirst%3DC.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26atitle%3DLoss%2520of%2520Leucine-Rich%2520Repeat%2520Kinase%25202%2520%2528LRRK2%2529%2520in%2520Rats%2520Leads%2520to%2520Progressive%2520Abnormal%2520Phenotypes%2520in%2520Peripheral%2520Organs%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D11%26spage%3De80705%26doi%3D10.1371%2Fjournal.pone.0080705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheewatrakoolpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMong, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgraf, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulet, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, J. A.</span></span> <span> </span><span class="NLM_article-title">MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.227587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1124%2Fjpet.115.227587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26407721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=397-409&issue=3&author=M.+J.+Fellauthor=C.+Mirescuauthor=K.+Basuauthor=B.+Cheewatrakoolpongauthor=D.+E.+DeMongauthor=J.+M.+Ellisauthor=L.+A.+Hydeauthor=Y.+Linauthor=C.+G.+Markgrafauthor=H.+Meiauthor=M.+Millerauthor=F.+M.+Pouletauthor=J.+D.+Scottauthor=M.+D.+Smithauthor=Z.+Yinauthor=X.+Zhouauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=J.+A.+Morrow&title=MLi-2%2C+a+Potent%2C+Selective%2C+and+Centrally+Active+Compound+for+Exploring+the+Therapeutic+Potential+and+Safety+of+LRRK2+Kinase+Inhibition&doi=10.1124%2Fjpet.115.227587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition</span></div><div class="casAuthors">Fell, Matthew J.; Mirescu, Christian; Basu, Kallol; Cheewatrakoolpong, Boonlert; DeMong, Duane E.; Ellis, J. Michael; Hyde, Lynn A.; Lin, Yinghui; Markgraf, Carrie G.; Mei, Hong; Miller, Michael; Poulet, Frederique M.; Scott, Jack D.; Smith, Michelle D.; Yin, Zhizhang; Zhou, Xiaoping; Parker, Eric M.; Kennedy, Matthew E.; Morrow, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of familial and sporadic Parkinson's disease (PD).  That the most prevalent mutation, G2019S, leads to increased kinase activity has led to a concerted effort to identify LRRK2 kinase inhibitors as a potential disease-modifying therapy for PD.  An internal medicinal chem. effort identified several potent and highly selective compds. with favorable drug-like properties.  Here, we characterize the pharmacol. properties of cis-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine (MLi-2), a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.  MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).  MLi-2 has greater than 295-fold selectivity for over 300 kinases in addn. to a diverse panel of receptors and ion channels.  Acute oral and subchronic dosing in MLi-2 mice resulted in dose-dependent central and peripheral target inhibition over a 24-h period as measured by dephosphorylation of pSer935 LRRK2.  Treatment of MitoPark mice with MLi-2 was well tolerated over a 15-wk period at brain and plasma exposures >100× the in vivo plasma IC50 for LRRK2 kinase inhibition as measured by pSer935 dephosphorylation.  Morphol. changes in the lung, consistent with enlarged type II pneumocytes, were obsd. in MLi-2-treated MitoPark mice.  These data demonstrate the suitability of MLi-2 as a compd. to explore LRRK2 biol. in cellular and animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpot402TvUrkbVg90H21EOLACvtfcHk0lg30tpAi76vww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D&md5=83c68f7bb731bef2fa9db880196dbabe</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227587%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DMirescu%26aufirst%3DC.%26aulast%3DBasu%26aufirst%3DK.%26aulast%3DCheewatrakoolpong%26aufirst%3DB.%26aulast%3DDeMong%26aufirst%3DD.%2BE.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DMarkgraf%26aufirst%3DC.%2BG.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPoulet%26aufirst%3DF.%2BM.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DMorrow%26aufirst%3DJ.%2BA.%26atitle%3DMLi-2%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Centrally%2520Active%2520Compound%2520for%2520Exploring%2520the%2520Therapeutic%2520Potential%2520and%2520Safety%2520of%2520LRRK2%2520Kinase%2520Inhibition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26issue%3D3%26spage%3D397%26epage%3D409%26doi%3D10.1124%2Fjpet.115.227587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skibinski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cookson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkbeiner, S.</span></span> <span> </span><span class="NLM_article-title">Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein but Not Kinase Activity or Inclusion Bodies</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2712-13.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1523%2FJNEUROSCI.2712-13.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24403142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Wqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=418-433&issue=2&author=G.+Skibinskiauthor=K.+Nakamuraauthor=M.+R.+Cooksonauthor=S.+Finkbeiner&title=Mutant+LRRK2+Toxicity+in+Neurons+Depends+on+LRRK2+Levels+and+Synuclein+but+Not+Kinase+Activity+or+Inclusion+Bodies&doi=10.1523%2FJNEUROSCI.2712-13.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies</span></div><div class="casAuthors">Skibinski, Gaia; Nakamura, Ken; Cookson, Mark R.; Finkbeiner, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-433</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">By combining exptl. neuron models and math. tools, we developed a "systems" approach to deconvolve cellular mechanisms of neurodegeneration underlying the most common known cause of Parkinson's disease (PD), mutations in leucine-rich repeat kinase 2 (LRRK2).  Neurons ectopically expressing mutant LRRK2 formed inclusion bodies (IBs), retracted neurites, accumulated synuclein, and died prematurely, recapitulating key features of PD.  Degeneration was predicted from the levels of diffuse mutant LRRK2 that each neuron contained, but IB formation was neither necessary nor sufficient for death.  Genetic or pharmacol. blockade of its kinase activity destabilized LRRK2 and lowered its levels enough to account for the moderate redn. in LRRK2 toxicity that ensued.  By contrast, targeting synuclein, including neurons made from PD patient-derived induced pluripotent cells, dramatically reduced LRRK2-dependent neurodegeneration and LRRK2 levels.  These findings suggest that LRRK2 levels are more important than kinase activity per se in predicting toxicity and implicate synuclein as a major mediator of LRRK2-induced neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdgp6jm-zdrVg90H21EOLACvtfcHk0lg30tpAi76vww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Wqug%253D%253D&md5=a4f8d3935fe3c9be47e691d728d23e7d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2712-13.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2712-13.2014%26sid%3Dliteratum%253Aachs%26aulast%3DSkibinski%26aufirst%3DG.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DCookson%26aufirst%3DM.%2BR.%26aulast%3DFinkbeiner%26aufirst%3DS.%26atitle%3DMutant%2520LRRK2%2520Toxicity%2520in%2520Neurons%2520Depends%2520on%2520LRRK2%2520Levels%2520and%2520Synuclein%2520but%2520Not%2520Kinase%2520Activity%2520or%2520Inclusion%2520Bodies%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26issue%3D2%26spage%3D418%26epage%3D433%26doi%3D10.1523%2FJNEUROSCI.2712-13.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzamko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of a Selective Inhibitor of the Parkinson’s Disease Kinase LRRK2</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1038/nchembio.538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnchembio.538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21378983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVKqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=203-205&issue=4&author=X.+Dengauthor=N.+Dzamkoauthor=A.+Prescottauthor=P.+Daviesauthor=Q.+Liuauthor=Q.+Yangauthor=J.-D.+Leeauthor=M.+P.+Patricelliauthor=T.+K.+Nomanbhoyauthor=D.+R.+Alessiauthor=N.+S.+Gray&title=Characterization+of+a+Selective+Inhibitor+of+the+Parkinson%E2%80%99s+Disease+Kinase+LRRK2&doi=10.1038%2Fnchembio.538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2</span></div><div class="casAuthors">Deng, Xianming; Dzamko, Nicolas; Prescott, Alan; Davies, Paul; Liu, Qingsong; Yang, Qingkai; Lee, Jiing-Dwan; Patricelli, Matthew P.; Nomanbhoy, Tyzoon K.; Alessi, Dario R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">203-205</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly assocd. with late-onset autosomal dominant Parkinson's disease.  We employed a new, parallel, compd.-centric approach to identify a potent and selective LRRK2 inhibitor, LRRK2-IN-1, and demonstrated that inhibition of LRRK2 induces dephosphorylation of Ser910 and Ser935 and accumulation of LRRK2 within aggregate structures.  LRRK2-IN-1 will serve as a versatile tool to pharmacol. interrogate LRRK2 biol. and study its role in Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwLpGURHqDULVg90H21EOLACvtfcHk0licw6nnHsD1yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVKqsL0%253D&md5=9f48f74cad9988e3ea8bb7af280473c1</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.538%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDzamko%26aufirst%3DN.%26aulast%3DPrescott%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.-D.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DCharacterization%2520of%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Parkinson%25E2%2580%2599s%2520Disease%2520Kinase%2520LRRK2%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26issue%3D4%26spage%3D203%26epage%3D205%26doi%3D10.1038%2Fnchembio.538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The Phosphoinositide 3-Kinase Pathway</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span> (<span class="NLM_issue">5573</span>),  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1126/science.296.5573.1655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.296.5573.1655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12040186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=1655-1657&issue=5573&author=L.+C.+Cantley&title=The+Phosphoinositide+3-Kinase+Pathway&doi=10.1126%2Fscience.296.5573.1655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase pathway</span></div><div class="casAuthors">Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5573</span>),
    <span class="NLM_cas:pages">1655-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 8 refs.  Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components.  The role of phosphoinositide 3-kinase (PI3K), which catalyzes the prodn. of phosphatidylinositol 3,4,5-trisphosphate, in cell survival pathways; the regulation of gene expression and cell metab.; and cytoskeletal rearrangements are highlighted.  The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9pxSplxmS1rVg90H21EOLACvtfcHk0licw6nnHsD1yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlChu7s%253D&md5=110c8a351448aed6ab938b9ccf90a655</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1126%2Fscience.296.5573.1655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.296.5573.1655%26sid%3Dliteratum%253Aachs%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520Phosphoinositide%25203-Kinase%2520Pathway%26jtitle%3DScience%26date%3D2002%26volume%3D296%26issue%3D5573%26spage%3D1655%26epage%3D1657%26doi%3D10.1126%2Fscience.296.5573.1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Kittler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rago, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huso, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">Mutant PIK3CA Promotes Cell Growth and Invasion of Human Cancer Cells</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2005.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15950905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslCgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=561-573&issue=6&author=Y.+Samuelsauthor=L.+A.+Diazauthor=O.+Schmidt-Kittlerauthor=J.+M.+Cumminsauthor=L.+Delongauthor=I.+Cheongauthor=C.+Ragoauthor=D.+L.+Husoauthor=C.+Lengauerauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=Mutant+PIK3CA+Promotes+Cell+Growth+and+Invasion+of+Human+Cancer+Cells&doi=10.1016%2Fj.ccr.2005.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant PIK3CA promotes cell growth and invasion of human cancer cells</span></div><div class="casAuthors">Samuels, Yardena; Diaz, Luis A., Jr.; Schmidt-Kittler, Oleg; Cummins, Jordan M.; DeLong, Laura; Cheong, Ian; Rago, Carlo; Huso, David L.; Lengauer, Christoph; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">561-573</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PIK3CA is mutated in diverse human cancers, but the functional effects of these mutations have not been defined.  To evaluate the consequences of PIK3CA alterations, the two most common mutations were inactivated by gene targeting in colorectal cancer (CRC) cells.  Biochem. analyses of these cells showed that mutant PIK3CA selectively regulated the phosphorylation of AKT and the forkhead transcription factors FKHR and FKHRL1.  PIK3CA mutations had little effect on growth under std. conditions, but reduced cellular dependence on growth factors.  PIK3CA mutations resulted in attenuation of apoptosis and facilitated tumor invasion.  Treatment with the PI3K inhibitor LY294002 abrogated PIK3CA signaling and preferentially inhibited growth of PIK3CA mutant cells.  These data have important implications for therapy of cancers harboring PIK3CA alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAqbiIItFxwLVg90H21EOLACvtfcHk0licw6nnHsD1yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslCgsrY%253D&md5=3f9399e100d35a817dd052254765fa12</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DSchmidt-Kittler%26aufirst%3DO.%26aulast%3DCummins%26aufirst%3DJ.%2BM.%26aulast%3DDelong%26aufirst%3DL.%26aulast%3DCheong%26aufirst%3DI.%26aulast%3DRago%26aufirst%3DC.%26aulast%3DHuso%26aufirst%3DD.%2BL.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DMutant%2520PIK3CA%2520Promotes%2520Cell%2520Growth%2520and%2520Invasion%2520of%2520Human%2520Cancer%2520Cells%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26issue%3D6%26spage%3D561%26epage%3D573%26doi%3D10.1016%2Fj.ccr.2005.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivanco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1038/nrc839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&issue=7&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+Phosphatidylinositol+3-Kinase+AKT+Pathway+in+Human+Cancer&doi=10.1038%2Fnrc839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0licw6nnHsD1yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520Phosphatidylinositol%25203-Kinase%2520AKT%2520Pathway%2520in%2520Human%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26issue%3D7%26spage%3D489%26epage%3D501%26doi%3D10.1038%2Fnrc839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saal, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memeo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmström, P.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansukhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enoksson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibshoosh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R.</span></span> <span> </span><span class="NLM_article-title">PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1158/0008-5472-CAN-04-3913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472-CAN-04-3913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15805248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVeqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=2554-2559&issue=7&author=L.+H.+Saalauthor=K.+Holmauthor=M.+Maurerauthor=L.+Memeoauthor=T.+Suauthor=X.+Wangauthor=J.+S.+Yuauthor=P.-O.+Malmstr%C3%B6mauthor=M.+Mansukhaniauthor=J.+Enokssonauthor=H.+Hibshooshauthor=A.+Borgauthor=R.+Parsons&title=PIK3CA+Mutations+Correlate+with+Hormone+Receptors%2C+Node+Metastasis%2C+and+ERBB2%2C+and+Are+Mutually+Exclusive+with+PTEN+Loss+in+Human+Breast+Carcinoma&doi=10.1158%2F0008-5472-CAN-04-3913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma</span></div><div class="casAuthors">Saal, Lao H.; Holm, Karolina; Maurer, Matthew; Memeo, Lorenzo; Su, Tao; Wang, Xiaomei; Yu, Jennifer S.; Malmstroem, Per-Olof; Mansukhani, Mahesh; Enoksson, Jens; Hibshoosh, Hanina; Borg, Ake; Parsons, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2554-2559</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway either through loss of PTEN or mutation of the catalytic subunit α of PI3K (PIK3CA) occurs frequently in human cancer.  We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV.  To investigate the relationship between PTEN and PIK3CA, we generated a cohort of tumors that had lost PTEN expression and compared it with a matched control set that had retained PTEN.  A highly significant assocn. between PIK3CA mutations and retention of PTEN protein expression was obsd.  In addn., PIK3CA mutations were assocd. with expression of estrogen and progesterone receptors (ER/PR), lymph node metastasis, and ERBB2 overexpression.  The fact that PIK3CA mutations and PTEN loss are nearly mutually exclusive implies that deregulated phosphatidylinositol-3,4,5-triphosphate (PIP3) is crit. for tumorigenesis in a significant fraction of breast cancers and that loss of PIP3 homeostasis by abrogation of either PIK3CA or PTEN relieves selective pressure for targeting of the other gene.  The correlation of PIK3CA mutation to ER/PR-pos. tumors and PTEN loss to ER/PR-neg. tumors argues for disparate branches of tumor evolution.  Furthermore, the assocn. between ERBB2 overexpression and PIK3CA mutation implies that more than one input activating the PI3K/AKT pathway may be required to overcome intact PTEN.  Thus, mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAU1nSRyBQNLVg90H21EOLACvtfcHk0ljhV-cJYYXPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVeqsrc%253D&md5=3e912dbd897f720b7ddd5ae3f32cd1e9</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F0008-5472-CAN-04-3913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472-CAN-04-3913%26sid%3Dliteratum%253Aachs%26aulast%3DSaal%26aufirst%3DL.%2BH.%26aulast%3DHolm%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DMemeo%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%2BS.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DP.-O.%26aulast%3DMansukhani%26aufirst%3DM.%26aulast%3DEnoksson%26aufirst%3DJ.%26aulast%3DHibshoosh%26aufirst%3DH.%26aulast%3DBorg%26aufirst%3DA.%26aulast%3DParsons%26aufirst%3DR.%26atitle%3DPIK3CA%2520Mutations%2520Correlate%2520with%2520Hormone%2520Receptors%252C%2520Node%2520Metastasis%252C%2520and%2520ERBB2%252C%2520and%2520Are%2520Mutually%2520Exclusive%2520with%2520PTEN%2520Loss%2520in%2520Human%2520Breast%2520Carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D7%26spage%3D2554%26epage%3D2559%26doi%3D10.1158%2F0008-5472-CAN-04-3913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stemke-Hale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmans, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolden, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlings, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de
Vijver, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span> <span> </span><span class="NLM_article-title">An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6084</span>– <span class="NLM_lpage">6091</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-07-6854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18676830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1SqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=6084-6091&issue=15&author=K.+Stemke-Haleauthor=A.+M.+Gonzalez-Anguloauthor=A.+Lluchauthor=R.+M.+Neveauthor=W.-L.+Kuoauthor=M.+Daviesauthor=M.+Careyauthor=Z.+Huauthor=Y.+Guanauthor=A.+Sahinauthor=W.+F.+Symmansauthor=L.+Pusztaiauthor=L.+K.+Noldenauthor=H.+Horlingsauthor=K.+Bernsauthor=M.-C.+Hungauthor=M.+J.+van+de%0AVijverauthor=V.+Valeroauthor=J.+W.+Grayauthor=R.+Bernardsauthor=G.+B.+Millsauthor=B.+T.+Hennessy&title=An+Integrative+Genomic+and+Proteomic+Analysis+of+PIK3CA%2C+PTEN%2C+and+AKT+Mutations+in+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-07-6854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer</span></div><div class="casAuthors">Stemke-Hale, Katherine; Gonzalez-Angulo, Ana Maria; Lluch, Ana; Neve, Richard M.; Kuo, Wen-Lin; Davies, Michael; Carey, Mark; Hu, Zhi; Guan, Yinghui; Sahin, Aysegul; Symmans, W. Fraser; Pusztai, Lajos; Nolden, Laura K.; Horlings, Hugo; Berns, Katrien; Hung, Mien-Chie; van de Vijver, Marc J.; Valero, Vicente; Gray, Joe W.; Bernards, Rene; Mills, Gordon B.; Hennessy, Bryan T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6084-6091</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer.  By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, the authors detd. the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen.  PIK3CA mutations were more common in hormone receptor-pos. (34.5%) and HER2-pos. (22.7%) than in basal-like tumors (8.3%).  AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor-pos. cancers.  Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture.  PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor-pos. breast cancer patients.  PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were assocd. with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines.  PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiol.  PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations.  Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes.  The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW4lGMvEywSbVg90H21EOLACvtfcHk0ljhV-cJYYXPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1SqtLs%253D&md5=687be276321b774ce7cb0f00949c36b4</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6854%26sid%3Dliteratum%253Aachs%26aulast%3DStemke-Hale%26aufirst%3DK.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DKuo%26aufirst%3DW.-L.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DCarey%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DSymmans%26aufirst%3DW.%2BF.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DNolden%26aufirst%3DL.%2BK.%26aulast%3DHorlings%26aufirst%3DH.%26aulast%3DBerns%26aufirst%3DK.%26aulast%3DHung%26aufirst%3DM.-C.%26aulast%3Dvan%2Bde%2BVijver%26aufirst%3DM.%2BJ.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26aulast%3DBernards%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26atitle%3DAn%2520Integrative%2520Genomic%2520and%2520Proteomic%2520Analysis%2520of%2520PIK3CA%252C%2520PTEN%252C%2520and%2520AKT%2520Mutations%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D15%26spage%3D6084%26epage%3D6091%26doi%3D10.1158%2F0008-5472.CAN-07-6854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silliman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, J. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span> <span> </span><span class="NLM_article-title">High Frequency of Mutations of the PIK3CA Gene in Human Cancers</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span> (<span class="NLM_issue">5670</span>),  <span class="NLM_fpage">554</span>, <span class="refDoi"> DOI: 10.1126/science.1096502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1096502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15016963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=554&issue=5670&author=Y.+Samuelsauthor=Z.+Wangauthor=A.+Bardelliauthor=N.+Sillimanauthor=J.+Ptakauthor=S.+Szaboauthor=H.+Yanauthor=A.+Gazdarauthor=S.+M.+Powellauthor=G.+J.+Rigginsauthor=J.+K.+V.+Willsonauthor=S.+Markowitzauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=V.+E.+Velculescu&title=High+Frequency+of+Mutations+of+the+PIK3CA+Gene+in+Human+Cancers&doi=10.1126%2Fscience.1096502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Brevia: High frequency of mutations of the PIK3Ca gene in human cancers</span></div><div class="casAuthors">Samuels, Yardena; Wang, Zhenghe; Bardelli, Alberto; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Yan, Hai; Gazdar, Adi; Powell, Steven M.; Riggins, Gregory J.; Willson, James K. V.; Markowitz, Sanford; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5670</span>),
    <span class="NLM_cas:pages">554</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74Tv7Oo80NbVg90H21EOLACvtfcHk0li0T436R5wWDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGmsbk%253D&md5=be8d63bf0c909971c3b7a5f475ce8fab</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1126%2Fscience.1096502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1096502%26sid%3Dliteratum%253Aachs%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DSilliman%26aufirst%3DN.%26aulast%3DPtak%26aufirst%3DJ.%26aulast%3DSzabo%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DS.%2BM.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DWillson%26aufirst%3DJ.%2BK.%2BV.%26aulast%3DMarkowitz%26aufirst%3DS.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26atitle%3DHigh%2520Frequency%2520of%2520Mutations%2520of%2520the%2520PIK3CA%2520Gene%2520in%2520Human%2520Cancers%26jtitle%3DScience%26date%3D2004%26volume%3D304%26issue%3D5670%26spage%3D554%26doi%3D10.1126%2Fscience.1096502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Phosphoinositide 3-Kinase Pathway in Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&issue=8&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+Phosphoinositide+3-Kinase+Pathway+in+Cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0li0T436R5wWDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520Phosphoinositide%25203-Kinase%2520Pathway%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26issue%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powis, G.</span></span> <span> </span><span class="NLM_article-title">Take Your PIK: Phosphatidylinositol 3-Kinase Inhibitors Race Through the Clinic and Toward Cancer Therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1535-7163.MCT-08-0801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19139107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1-9&issue=1&author=N.+T.+Ihleauthor=G.+Powis&title=Take+Your+PIK%3A+Phosphatidylinositol+3-Kinase+Inhibitors+Race+Through+the+Clinic+and+Toward+Cancer+Therapy&doi=10.1158%2F1535-7163.MCT-08-0801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy</span></div><div class="casAuthors">Ihle, Nathan T.; Powis, Garth</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncol.  However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiol. signaling.  Since that time, studies have delineated the roles of these four isoforms in nonpathol. signaling as well as their roles in cancer.  An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer.  These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a no. are in clin. testing.  The agents, their properties, and their mol. targets are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtwozBC-h437Vg90H21EOLACvtfcHk0li0T436R5wWDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFSntA%253D%253D&md5=4bc339da7fdd1dc74e13eadf76ae53ce</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0801%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DN.%2BT.%26aulast%3DPowis%26aufirst%3DG.%26atitle%3DTake%2520Your%2520PIK%253A%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520Race%2520Through%2520the%2520Clinic%2520and%2520Toward%2520Cancer%2520Therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D1%26spage%3D1%26epage%3D9%26doi%3D10.1158%2F1535-7163.MCT-08-0801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&issue=2&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0li0T436R5wWDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span> <span> </span><span class="NLM_article-title">Abstract S6-04: the PI3K Inhibitor, Taselisib, Has Enhanced Potency in PIK3CA Mutant Models Through a Unique Mechanism of Action</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">4, Suppl.</span>),  <span class="NLM_fpage">S6-04</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.SABCS16-S6-04</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.SABCS16-S6-04" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=S6-04&issue=4%2C+Suppl.&author=L.+S.+Friedmanauthor=K.+A.+Edgarauthor=K.+Songauthor=S.+Schmidtauthor=D.+S.+Kirkpatrickauthor=L.+Phuauthor=M.+A.+Nanniniauthor=R.+Hongauthor=E.+Chengauthor=L.+Crockerauthor=A.+Youngauthor=D.+Sampath&title=Abstract+S6-04%3A+the+PI3K+Inhibitor%2C+Taselisib%2C+Has+Enhanced+Potency+in+PIK3CA+Mutant+Models+Through+a+Unique+Mechanism+of+Action&doi=10.1158%2F1538-7445.SABCS16-S6-04"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS16-S6-04&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS16-S6-04%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DPhu%26aufirst%3DL.%26aulast%3DNannini%26aufirst%3DM.%2BA.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DAbstract%2520S6-04%253A%2520the%2520PI3K%2520Inhibitor%252C%2520Taselisib%252C%2520Has%2520Enhanced%2520Potency%2520in%2520PIK3CA%2520Mutant%2520Models%2520Through%2520a%2520Unique%2520Mechanism%2520of%2520Action%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D4%252C%2520Suppl%26spage%3DS6-04%26doi%3D10.1158%2F1538-7445.SABCS16-S6-04" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span> <span> </span><span class="NLM_article-title">Abstract 146: the PI3K Inhibitor, Taselisib, Has a Unique Mechanism of Action That Leads to Enhanced Potency in PIK3CA Mutant Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">146</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.AM2017-146" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=146&issue=13%2C+Suppl.&author=K.+W.+Songauthor=K.+A.+Edgarauthor=D.+S.+Kirkpatrickauthor=L.+Phuauthor=S.+Schmidtauthor=M.+Nanniniauthor=R.+Hongauthor=E.+Chengauthor=L.+Crockerauthor=A.+Youngauthor=D.+Sampathauthor=L.+Friedman&title=Abstract+146%3A+the+PI3K+Inhibitor%2C+Taselisib%2C+Has+a+Unique+Mechanism+of+Action+That+Leads+to+Enhanced+Potency+in+PIK3CA+Mutant+Models&doi=10.1158%2F1538-7445.AM2017-146"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-146%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DK.%2BW.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DPhu%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DFriedman%26aufirst%3DL.%26atitle%3DAbstract%2520146%253A%2520the%2520PI3K%2520Inhibitor%252C%2520Taselisib%252C%2520Has%2520a%2520Unique%2520Mechanism%2520of%2520Action%2520That%2520Leads%2520to%2520Enhanced%2520Potency%2520in%2520PIK3CA%2520Mutant%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%252C%2520Suppl%26spage%3D146%26doi%3D10.1158%2F1538-7445.AM2017-146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span> <span> </span><span class="NLM_article-title">Abstract 156: Preclinical Characterization of GDC-0077, a Specific PI3K Alpha Inhibitor in Early Clinical Development</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13 Suppl.</span>),  <span class="NLM_fpage">156</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.AM2017-156" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=156&issue=13+Suppl.&author=K.+Edgarauthor=E.+Hananauthor=S.+Stabenauthor=S.+Schmidtauthor=R.+Hongauthor=K.+Songauthor=A.+Youngauthor=P.+Hamiltonauthor=A.+Arrazateauthor=C.+de+la+Cruzauthor=M.+Belvinauthor=M.+Nanniniauthor=L.+S.+Friedmanauthor=D.+Sampath&title=Abstract+156%3A+Preclinical+Characterization+of+GDC-0077%2C+a+Specific+PI3K+Alpha+Inhibitor+in+Early+Clinical+Development&doi=10.1158%2F1538-7445.AM2017-156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-156%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DHanan%26aufirst%3DE.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DHamilton%26aufirst%3DP.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3Dde%2Bla%2BCruz%26aufirst%3DC.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DAbstract%2520156%253A%2520Preclinical%2520Characterization%2520of%2520GDC-0077%252C%2520a%2520Specific%2520PI3K%2520Alpha%2520Inhibitor%2520in%2520Early%2520Clinical%2520Development%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D156%26doi%3D10.1158%2F1538-7445.AM2017-156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steven, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span> <span> </span><span class="NLM_article-title">Abstract PD4-14: GDC-0077 Is a Selective PI3Kalpha Inhibitor That Demonstrates Robust Efficacy in PIK3CA Mutant Breast Cancer Models as a Single Agent and in Combination with Standard of Care Therapies</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">4, Suppl.</span>),  <span class="NLM_fpage">PD4-14</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.SABCS17-PD4-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1538-7445.SABCS17-PD4-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=PD4-14&issue=4%2C+Suppl.&author=R.+Hongauthor=K.+Edgarauthor=K.+Songauthor=S.+Stevenauthor=A.+Youngauthor=P.+Hamiltonauthor=A.+Arrazateauthor=C.+De+La+Cruzauthor=C.+Chanauthor=J.+Pangauthor=L.+Salphatiauthor=M.+Belvinauthor=M.+Nanniniauthor=S.+Stabenauthor=L.+Friedmanauthor=D.+Sampath&title=Abstract+PD4-14%3A+GDC-0077+Is+a+Selective+PI3Kalpha+Inhibitor+That+Demonstrates+Robust+Efficacy+in+PIK3CA+Mutant+Breast+Cancer+Models+as+a+Single+Agent+and+in+Combination+with+Standard+of+Care+Therapies&doi=10.1158%2F1538-7445.SABCS17-PD4-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS17-PD4-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS17-PD4-14%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DR.%26aulast%3DEdgar%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DSteven%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DHamilton%26aufirst%3DP.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DDe%2BLa%2BCruz%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26atitle%3DAbstract%2520PD4-14%253A%2520GDC-0077%2520Is%2520a%2520Selective%2520PI3Kalpha%2520Inhibitor%2520That%2520Demonstrates%2520Robust%2520Efficacy%2520in%2520PIK3CA%2520Mutant%2520Breast%2520Cancer%2520Models%2520as%2520a%2520Single%2520Agent%2520and%2520in%2520Combination%2520with%2520Standard%2520of%2520Care%2520Therapies%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D4%252C%2520Suppl%26spage%3DPD4-14%26doi%3D10.1158%2F1538-7445.SABCS17-PD4-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]Imidazo[1,2-d][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4597</span>– <span class="NLM_lpage">4610</span>, <span class="refDoi"> DOI: 10.1021/jm4003632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4003632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4597-4610&issue=11&author=C.+O.+Ndubakuauthor=T.+P.+Heffronauthor=S.+T.+Stabenauthor=M.+Baumgardnerauthor=N.+Blaquiereauthor=E.+Bradleyauthor=R.+Bullauthor=S.+Doauthor=J.+Dotsonauthor=D.+Dudleyauthor=K.+A.+Edgarauthor=L.+S.+Friedmanauthor=R.+Goldsmithauthor=R.+A.+Healdauthor=A.+Kolesnikovauthor=L.+Leeauthor=C.+Lewisauthor=M.+Nanniniauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=W.+W.+Priorauthor=L.+Salphatiauthor=S.+Siderisauthor=J.+J.+Wallinauthor=L.+Wangauthor=B.+Weiauthor=D.+Sampathauthor=A.+G.+Olivero&title=Discovery+of+2-%7B3-%5B2-%281-Isopropyl-3-methyl-1H-1%2C2-4-triazol-5-yl%29-5%2C6-dihydrobenzo%5Bf%5DImidazo%5B1%2C2-d%5D%5B1%2C4%5Doxazepin-9-yl%5D-1H-pyrazol-1-yl%7D-2-methylpropanamide+%28GDC-0032%29%3A+a+%CE%B2-Sparing+Phosphoinositide+3-Kinase+Inhibitor+with+High+Unbound+Exposure+and+Robust+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm4003632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity</span></div><div class="casAuthors">Ndubaku, Chudi O.; Heffron, Timothy P.; Staben, Steven T.; Baumgardner, Matthew; Blaquiere, Nicole; Bradley, Erin; Bull, Richard; Do, Steven; Dotson, Jennafer; Dudley, Danette; Edgar, Kyle A.; Friedman, Lori S.; Goldsmith, Richard; Heald, Robert A.; Kolesnikov, Aleksandr; Lee, Leslie; Lewis, Cristina; Nannini, Michelle; Nonomiya, Jim; Pang, Jodie; Price, Steve; Prior, Wei Wei; Salphati, Laurent; Sideris, Steve; Wallin, Jeffery J.; Wang, Lan; Wei, BinQing; Sampath, Deepak; Olivero, Alan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4597-4610</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation.  In the course of the discovery of novel benzoxepin PI3K inhibitors, we obsd. a strong dependency of in vivo antitumor activity on the free-drug exposure.  By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compds. that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.  One of these compds., GDC-0032 (I), was progressed to clin. trials and is currently under phase I evaluation as a potential treatment for human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvaWg9tu7Zv7Vg90H21EOLACvtfcHk0liWcBOz6mPBYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWjur8%253D&md5=f9c169c99757708a9d327ad0b022fde9</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm4003632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4003632%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%2BO.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-%257B3-%255B2-%25281-Isopropyl-3-methyl-1H-1%252C2-4-triazol-5-yl%2529-5%252C6-dihydrobenzo%255Bf%255DImidazo%255B1%252C2-d%255D%255B1%252C4%255Doxazepin-9-yl%255D-1H-pyrazol-1-yl%257D-2-methylpropanamide%2520%2528GDC-0032%2529%253A%2520a%2520%25CE%25B2-Sparing%2520Phosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520High%2520Unbound%2520Exposure%2520and%2520Robust%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D11%26spage%3D4597%26epage%3D4610%26doi%3D10.1021%2Fjm4003632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foukas, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claret, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peskett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">Critical Role for the p110α Phosphoinositide-3-OH Kinase in Growth and Metabolic Regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>441</i></span> (<span class="NLM_issue">7091</span>),  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1038/nature04694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature04694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16625210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28XksleltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2006&pages=366-370&issue=7091&author=L.+C.+Foukasauthor=M.+Claretauthor=W.+Pearceauthor=K.+Okkenhaugauthor=S.+Meekauthor=E.+Peskettauthor=S.+Sanchoauthor=A.+J.+H.+Smithauthor=D.+J.+Withersauthor=B.+Vanhaesebroeck&title=Critical+Role+for+the+p110%CE%B1+Phosphoinositide-3-OH+Kinase+in+Growth+and+Metabolic+Regulation&doi=10.1038%2Fnature04694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation</span></div><div class="casAuthors">Foukas, Lazaros C.; Claret, Marc; Pearce, Wayne; Okkenhaug, Klaus; Meek, Stephen; Peskett, Emma; Sancho, Sara; Smith, Andrew J. H.; Withers, Dominic J.; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">7091</span>),
    <span class="NLM_cas:pages">366-370</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The eight catalytic subunits of the mammalian phosphoinositide-3-OH kinase (PI(3)K) family form the backbone of an evolutionarily conserved signaling pathway; however, the roles of most PI(3)K isoforms in organismal physiol. and disease are unknown.  To delineate the role of p110α, a ubiquitously expressed PI(3)K involved in tyrosine kinase and Ras signaling, here we generated mice carrying a knockin mutation (D933A) that abrogates p110α kinase activity.  Homozygosity for this kinase-dead p110α led to embryonic lethality.  Mice heterozygous for this mutation were viable and fertile, but displayed severely blunted signaling via insulin-receptor substrate (IRS) proteins, key mediators of insulin, insulin-like growth factor-1 and leptin action.  Defective responsiveness to these hormones led to reduced somatic growth, hyperinsulinemia, glucose intolerance, hyperphagia and increased adiposity in mice heterozygous for the D933A mutation.  This signaling function of p110α derives from its highly selective recruitment and activation to IRS signaling complexes compared to p110β, the other broadly expressed PI(3)K isoform, which did not contribute to IRS-assocd. PI(3)K activity.  P110α was the principal IRS-assocd. PI(3)K in cancer cell lines.  These findings demonstrate a crit. role for p110α in growth factor and metabolic signaling and also suggest an explanation for selective mutation or overexpression of p110α in a variety of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOi2VSn94VNLVg90H21EOLACvtfcHk0liWcBOz6mPBYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksleltL0%253D&md5=4b39bf234e759be7540057e4d9d70e6c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnature04694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04694%26sid%3Dliteratum%253Aachs%26aulast%3DFoukas%26aufirst%3DL.%2BC.%26aulast%3DClaret%26aufirst%3DM.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DMeek%26aufirst%3DS.%26aulast%3DPeskett%26aufirst%3DE.%26aulast%3DSancho%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DWithers%26aufirst%3DD.%2BJ.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DCritical%2520Role%2520for%2520the%2520p110%25CE%25B1%2520Phosphoinositide-3-OH%2520Kinase%2520in%2520Growth%2520and%2520Metabolic%2520Regulation%26jtitle%3DNature%26date%3D2006%26volume%3D441%26issue%3D7091%26spage%3D366%26epage%3D370%26doi%3D10.1038%2Fnature04694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunder, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&issue=4&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+p110%CE%B1+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0liWcBOz6mPBYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520p110%25CE%25B1%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26issue%3D4%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmoller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLaurentiis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drullinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacot, W.</span></span> <span> </span><span class="NLM_article-title">Phase III Study of Taselisib (GDC-0032) + Fulvestrant (FULV) v FULV in Patients (Pts) with Estrogen Receptor (ER)-Positive, PIK3CA-Mutant (MUT), Locally Advanced or Metastatic Breast Cancer (MBC): Primary Analysis From SANDPIPER</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">18_suppl</span>),  <span class="NLM_fpage">LBA1006</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.18_suppl.LBA1006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1200%2FJCO.2018.36.18_suppl.LBA1006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=LBA1006&issue=18_suppl&author=J.+Baselgaauthor=S.+F.+Dentauthor=J.+Cortesauthor=Y.-H.+Imauthor=V.+Di%C3%A9rasauthor=N.+Harbeckauthor=I.+E.+Kropauthor=S.+Vermaauthor=T.+R.+Wilsonauthor=H.+Jinauthor=L.+Wangauthor=F.+Schimmollerauthor=J.+Y.+Hsuauthor=J.+Heauthor=M.+DeLaurentiisauthor=P.+Drullinskyauthor=W.+Jacot&title=Phase+III+Study+of+Taselisib+%28GDC-0032%29+%2B+Fulvestrant+%28FULV%29+v+FULV+in+Patients+%28Pts%29+with+Estrogen+Receptor+%28ER%29-Positive%2C+PIK3CA-Mutant+%28MUT%29%2C+Locally+Advanced+or+Metastatic+Breast+Cancer+%28MBC%29%3A+Primary+Analysis+From+SANDPIPER&doi=10.1200%2FJCO.2018.36.18_suppl.LBA1006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.18_suppl.LBA1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.18_suppl.LBA1006%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DDent%26aufirst%3DS.%2BF.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DY.-H.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSchimmoller%26aufirst%3DF.%26aulast%3DHsu%26aufirst%3DJ.%2BY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DDeLaurentiis%26aufirst%3DM.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DJacot%26aufirst%3DW.%26atitle%3DPhase%2520III%2520Study%2520of%2520Taselisib%2520%2528GDC-0032%2529%2520%252B%2520Fulvestrant%2520%2528FULV%2529%2520v%2520FULV%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Estrogen%2520Receptor%2520%2528ER%2529-Positive%252C%2520PIK3CA-Mutant%2520%2528MUT%2529%252C%2520Locally%2520Advanced%2520or%2520Metastatic%2520Breast%2520Cancer%2520%2528MBC%2529%253A%2520Primary%2520Analysis%2520From%2520SANDPIPER%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D18_suppl%26spage%3DLBA1006%26doi%3D10.1200%2FJCO.2018.36.18_suppl.LBA1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span> <span> </span><span class="NLM_article-title">The Discovery of Artemisinin (Qinghaosu) and Gifts From Chinese Medicine</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1038/nm.2471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnm.2471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21989013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1217-1220&issue=10&author=Y.+Tu&title=The+Discovery+of+Artemisinin+%28Qinghaosu%29+and+Gifts+From+Chinese+Medicine&doi=10.1038%2Fnm.2471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine</span></div><div class="casAuthors">Tu, Youyou</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1217-1220</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria, caused by Plasmodium falciparum, has been a life-threatening disease for thousands of years.  After the failure of international attempts to eradicate malaria in the 1950s, the disease rebounded, largely due to the emergence of parasites resistant to the existing antimalarial drugs of the time, such as chloroquine.  This created an urgent need for new antimalarial medicines.  In 1967, a national project against malaria was set up in China under the leadership of the Project 523 office.  My institute quickly became involved in the project and appointed me to be the head of a malaria research group comprising both phytochem. and pharmacol. researchers.  Our group of young investigators started working on the extn. and isolation of constituents with possible antimalarial activities from Chinese herbal materials.  During the first stage of our work, we investigated more than 2,000 Chinese herb prepns. and identified 640 hits that had possible antimalarial activities.  More than 380 exts. obtained from ∼200 Chinese herbs were evaluated against a mouse model of malaria.  However, progress was not smooth, and no significant results emerged easily.  The turning point came when an Artemisia annua L. ext. showed a promising degree of inhibition against parasite growth.  However, this observation was not reproducible in subsequent expts. and appeared to be contradictory to what was recorded in the literature.  Seeking an explanation, we carried out an intensive review of the literature.  The only ref. relevant to use of qinghao (the Chinese name of Artemisia annua L.) for alleviating malaria symptoms appeared in Ge Hong's A Handbook of Prescriptions for Emergencies: "A handful of qinghao immersed with 2 L of water, wring out the juice and drink it all" (Fig. 1).  This sentence gave me the idea that the heating involved in the conventional extn. step we had used might have destroyed the active components, and that extn. at a lower temp. might be necessary to preserve antimalarial activity.  Indeed, we obtained much better activity after switching to a lower-temp. procedure.  We subsequently sepd. the ext. into its acidic and neutral portions and, at long last, on 4 Oct. 1971, we obtained a nontoxic, neutral ext. that was 100% effective against parasitemia in mice infected with Plasmodium berghei and in monkeys infected with Plasmodium cynomolgi.  This finding represented the breakthrough in the discovery of artemisinin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPPcf3cZ2WFLVg90H21EOLACvtfcHk0lgD7ja9MuHrcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12iu7vK&md5=d751f12196cf4f3d316bdaada5d38e02</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnm.2471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2471%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DY.%26atitle%3DThe%2520Discovery%2520of%2520Artemisinin%2520%2528Qinghaosu%2529%2520and%2520Gifts%2520From%2520Chinese%2520Medicine%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D10%26spage%3D1217%26epage%3D1220%26doi%3D10.1038%2Fnm.2471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.-J.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin Is an Inhibitor of Ovarian Cancer Cell Growth</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1111/j.1745-7254.2007.00612.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1111%2Fj.1745-7254.2007.00612.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17588342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFynsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=1045-1056&issue=7&author=Y.+Jiaoauthor=C.-M.+Geauthor=Q.-H.+Mengauthor=J.-P.+Caoauthor=J.+Tongauthor=S.-J.+Fan&title=Dihydroartemisinin+Is+an+Inhibitor+of+Ovarian+Cancer+Cell+Growth&doi=10.1111%2Fj.1745-7254.2007.00612.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin is an inhibitor of ovarian cancer cell growth</span></div><div class="casAuthors">Jiao, Yang; Ge, Chun-min; Meng, Qing-hui; Cao, Jian-ping; Tong, Jian; Fan, Sai-jun</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1045-1056</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Aim: To investigate the anticancer activity of dihydroartemisinin (DHA), a deriv. of antimalaria drug artemisinin in a panel of human ovarian cancer cell lines.  Methods: Cell growth was detd. by the MTT viability assay.  Apoptosis and cell cycle progression were evaluated by a DNA fragmentation gel electro-phoresis, flow cytometry assay, and TUNEL assay; protein and mRNA expression were analyzed by Western blotting and RT-PCR assay.  Results: Artemisinin and its derivs., including artesunate, arteether, artemether, arteannuin, and DHA, exhibit anticancer growth activities in human ovarian cancer cells.  Among them, DHA is the most effective in inhibiting cell growth.  Ovarian cancer cell lines are more sensitive (5-10-fold) to DHA treatment compared to normal ovarian cell lines.  DHA at micromolar dose levels exhibits a dose- and time-dependent cytotoxicity in ovarian cancer cell lines.  Furthermore, DHA induced apoptosis and G2 cell cycle arrest, accompanied by a decrease of Bcl-xL and Bcl-2 and an increase of Bax and Bad.  Conclusion: The promising results show for the first time that DHA inhibits the growth of human ovarian cancer cells.  The selective inhibition of ovarian cancer cell growth, apoptosis induction, and G2 arrest provide in vitro evidence for further studies of DHA as a possible anticancer drug in the clin. treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY7KMUc-Yf_LVg90H21EOLACvtfcHk0liSYyxuc5baGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFynsLs%253D&md5=37e7d3210528e81d521af706a2626266</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1745-7254.2007.00612.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1745-7254.2007.00612.x%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DC.-M.%26aulast%3DMeng%26aufirst%3DQ.-H.%26aulast%3DCao%26aufirst%3DJ.-P.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DS.-J.%26atitle%3DDihydroartemisinin%2520Is%2520an%2520Inhibitor%2520of%2520Ovarian%2520Cancer%2520Cell%2520Growth%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2007%26volume%3D28%26issue%3D7%26spage%3D1045%26epage%3D1056%26doi%3D10.1111%2Fj.1745-7254.2007.00612.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin Induces Apoptosis and Sensitizes Human Ovarian Cancer Cells to Carboplatin Therapy</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2008.00360.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1111%2Fj.1582-4934.2008.00360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18466355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCku7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=1358-1370&issue=7&author=T.+Chenauthor=M.+Liauthor=R.+Zhangauthor=H.+Wang&title=Dihydroartemisinin+Induces+Apoptosis+and+Sensitizes+Human+Ovarian+Cancer+Cells+to+Carboplatin+Therapy&doi=10.1111%2Fj.1582-4934.2008.00360.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy</span></div><div class="casAuthors">Chen, Tao; Li, Mian; Zhang, Ruiwen; Wang, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1358-1370</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The present study was designed to det. the effects of artemisinin (ARS) and its derivs. on human ovarian cancer cells, to evaluate their potential as novel chemotherapeutic agents used alone or in combination with a conventional cancer chemotherapeutic agent, and to investigate their underlying mechanisms of action.  Human ovarian cancer cells (A2780 and OVCAR-3), and immortalized non-tumorigenic human ovarian surface epithelial cells (IOSE144), were exposed to four ARS compds. for cytotoxicity testing.  The in vitro and in vivo antitumor effects and possible underlying mechanisms of action of dihydroartemisinin (DHA), the most effective compd., were further detd. in ovarian cancer cells.  ARS compds. exerted potent cytotoxicity to human ovarian carcinoma cells, with minimal effects on non-tumorigenic ovarian surface epithelial (OSE) cells.  DHA inhibited ovarian cancer cell growth when administered alone or in combination with carboplatin, presumably through the death receptor- and, mitochondrion-mediated caspase-dependent apoptotic pathway.  These effects were also obsd. in in vivo ovarian A2780 and OVCAR-3 xenograft tumor models.  In conclusion, ARS derivs., particularly DHA, exhibit significant anticancer activity against ovarian cancer cells in vitro and in vivo, with minimal toxicity to non-tumorigenic human OSE cells, indicating that they may be promising therapeutic agents for ovarian cancer, either used alone or in combination with conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc2LHhKbSaq7Vg90H21EOLACvtfcHk0lh8-bMWzmn0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCku7bE&md5=a82778c2d7cff6b7084b3e31c5dcc0a0</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2008.00360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2008.00360.x%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDihydroartemisinin%2520Induces%2520Apoptosis%2520and%2520Sensitizes%2520Human%2520Ovarian%2520Cancer%2520Cells%2520to%2520Carboplatin%2520Therapy%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2009%26volume%3D13%26issue%3D7%26spage%3D1358%26epage%3D1370%26doi%3D10.1111%2Fj.1582-4934.2008.00360.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span> <span> </span><span class="NLM_article-title">Development of Artemisinin Compounds for Cancer Treatment</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9873-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2Fs10637-012-9873-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22935909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=230-246&issue=1&author=H.+C.+Laiauthor=N.+P.+Singhauthor=T.+Sasaki&title=Development+of+Artemisinin+Compounds+for+Cancer+Treatment&doi=10.1007%2Fs10637-012-9873-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Development of artemisinin compounds for cancer treatment</span></div><div class="casAuthors">Lai, Henry C.; Singh, Narendra P.; Sasaki, Tomikazu</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">230-246</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Artemisinin contains an endoperoxide moiety that can react with iron to form cytotoxic free radicals.  Cancer cells contain significantly more intracellular free iron than normal cells and it has been shown that artemisinin and its analogs selectively cause apoptosis in many cancer cell lines.  In addn., artemisinin compds. have been shown to have anti-angiogenic, anti-inflammatory, anti-metastasis, and growth inhibition effects.  These properties make artemisinin compds. attractive cancer chemotherapeutic drug candidates.  However, simple artemisinin analogs are less potent than traditional cancer chemotherapeutic agents and have short plasma half-lives, and would require high dosage and frequent administration to be effective for cancer treatment.  More potent and target-selective artemisinin-compds. are being developed.  These include artemisinin dimers and trimers, artemisinin hybrid compds., and tagging of artemisinin compds. to mols. that are involved in the intracellular iron-delivery mechanism.  These compds. are promising potent anticancer compds. that produce significantly less side effect than traditional chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9pCP2c4F3R7Vg90H21EOLACvtfcHk0lh8-bMWzmn0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogsrg%253D&md5=5a2bab46c18166ccda727ea2b72141cb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9873-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9873-z%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DH.%2BC.%26aulast%3DSingh%26aufirst%3DN.%2BP.%26aulast%3DSasaki%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520Artemisinin%2520Compounds%2520for%2520Cancer%2520Treatment%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26issue%3D1%26spage%3D230%26epage%3D246%26doi%3D10.1007%2Fs10637-012-9873-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ba, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin Selectively Inhibits PDGFRα-Positive Ovarian Cancer Growth and Metastasis Through Inducing Degradation of PDGFRα Protein</span>. <i>Cell Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">17042</span>, <span class="refDoi"> DOI: 10.1038/celldisc.2017.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fcelldisc.2017.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29387451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVehsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=17042&author=X.+Liauthor=Q.+Baauthor=Y.+Liuauthor=Q.+Yueauthor=P.+Chenauthor=J.+Liauthor=H.+Zhangauthor=H.+Yingauthor=Q.+Dingauthor=H.+Songauthor=H.+Liuauthor=R.+Zhangauthor=H.+Wang&title=Dihydroartemisinin+Selectively+Inhibits+PDGFR%CE%B1-Positive+Ovarian+Cancer+Growth+and+Metastasis+Through+Inducing+Degradation+of+PDGFR%CE%B1+Protein&doi=10.1038%2Fcelldisc.2017.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein</span></div><div class="casAuthors">Li, Xiaoguang; Ba, Qian; Liu, Yanling; Yue, Qingxi; Chen, Peizhan; Li, Jingquan; Zhang, Haibing; Ying, Hao; Ding, Qiurong; Song, Haiyun; Liu, Hong; Zhang, Ruiwen; Wang, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Cell Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17042</span>CODEN:
                <span class="NLM_cas:coden">CDEIBM</span>;
        ISSN:<span class="NLM_cas:issn">2056-5968</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To develop traditional medicines as modern pharmacotherapies, understanding their mol. mechanisms of action can be very helpful.  We have recently reported that Artemisinin and its derivs., which are clin. used anti-malarial drugs, have significant effects against ovarian cancer, but the direct mol. targets and related combination therapy have been unclear.  Herein, we report that dihydroartemisinin, one of the most active derivs. of Artemisinin, directly targets platelet-derived growth factor receptor-alpha (PDGFRα) to inhibit ovarian cancer cell growth and metastasis.  Dihydroartemisinin directly binds to the intercellular domain of PDGFRα, reducing its protein stability by accelerating its ubiquitin-mediated degrdn., which further inactivates downstream phosphoinositide 3-Kinase and mitogen-activated protein kinase pathways and subsequently represses epithelial-mesenchymal transition, inhibiting cell growth and metastasis of PDGFRα-pos. ovarian cancer in vitro and in vivo.  A combinational treatment reveals that dihydroartemisinin sensitizes ovarian cancer cells to PDGFR inhibitors.  Our clin. study also finds that PDGFRα is overexpressed and pos. correlated with high grade and metastasis in human ovarian cancer.  Considering that Artemisinin compds. are currently clin. used drugs with favorable safety profiles, the results from this study will potentiate their use in combination with clin. used PDGFRα inhibitors, leading to maximal therapeutic efficacy with minimal adverse effects in PDGFRα-pos. cancer patients.  These findings also shed high light on future development of novel Artemisinin-based targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi5hLbiBC0-rVg90H21EOLACvtfcHk0lh8-bMWzmn0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVehsLrL&md5=55c1420c2ca79433d77135a5ed89a59c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fcelldisc.2017.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcelldisc.2017.42%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBa%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYing%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDihydroartemisinin%2520Selectively%2520Inhibits%2520PDGFR%25CE%25B1-Positive%2520Ovarian%2520Cancer%2520Growth%2520and%2520Metastasis%2520Through%2520Inducing%2520Degradation%2520of%2520PDGFR%25CE%25B1%2520Protein%26jtitle%3DCell%2520Discovery%26date%3D2017%26volume%3D3%26spage%3D17042%26doi%3D10.1038%2Fcelldisc.2017.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carden, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span> <span> </span><span class="NLM_article-title">Beyond Chemotherapy: Targeted Therapies in Ovarian Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc2583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19238149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=167-181&issue=3&author=T.+A.+Yapauthor=C.+P.+Cardenauthor=S.+B.+Kaye&title=Beyond+Chemotherapy%3A+Targeted+Therapies+in+Ovarian+Cancer&doi=10.1038%2Fnrc2583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond chemotherapy: targeted therapies in ovarian cancer</span></div><div class="casAuthors">Yap, Timothy A.; Carden, Craig P.; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ovarian cancer is the leading cause of death from gynaecol. malignancies in the Western world.  Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease.  In an age when great advances have been made in understanding the genetics and mol. biol. of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer.  Importantly, such strategies might allow selection of treatments based on the mol. characteristics of tumors and bring us closer to an era of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-IolhZb5BfLVg90H21EOLACvtfcHk0liccmok5IVq-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans74%253D&md5=35c1e2e4171120bc5411b778306929ca</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnrc2583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2583%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DCarden%26aufirst%3DC.%2BP.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DBeyond%2520Chemotherapy%253A%2520Targeted%2520Therapies%2520in%2520Ovarian%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D3%26spage%3D167%26epage%3D181%26doi%3D10.1038%2Fnrc2583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stankov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikov, M.</span></span> <span> </span><span class="NLM_article-title">C-KIT Signaling in Cancer Treatment</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2880</span>, <span class="refDoi"> DOI: 10.2174/13816128113199990593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2174%2F13816128113199990593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23944364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Wgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2849-2880&issue=17&author=K.+Stankovauthor=S.+Popovicauthor=M.+Mikov&title=C-KIT+Signaling+in+Cancer+Treatment&doi=10.2174%2F13816128113199990593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">C-KIT signaling in cancer treatment</span></div><div class="casAuthors">Stankov, Karmen; Popovic, Stevan; Mikov, Momir</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2849-2880</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor progression is strongly assocd. with the activity of receptor tyrosine kinases (RTKs) and their intracellular signal transduction pathways, which regulate several cell functions including proliferation, apoptosis, motility, adhesion and angiogenesis.  Detailed structural and functional studies of RTKs, including the stem cell factor receptor c-KIT, revealed the complexity of these receptor systems and contributed to development of targeted clin. approaches with relevance in both prognosis and therapy.  C-KIT signaling network has been the subject of intense research and pharmaceutical strategies to identify novel target-based approaches for cancer treatment.  Evidence that c-KIT signaling promotes cell proliferation and survival, along with the frequency in which this pathway is aberrantly activated in cancer, support the current efforts to identify approaches for its efficient inhibition.  C-KIT mutations are associatied with several human malignancies, such as gastrointestinal stromal tumors, acute myeloid leukemia, mast cell leukemia, and melanoma.  Novel therapies are developed that target some of the identified genetic defects.  It is therefore anticipated that newly-identified genetic markers will acquire a predictive value, i.e., the ability to predict differential efficacy of a therapy.  This review describes the evolving understanding of c-KIT/SCF axis and their downstream signaling in cancer, and the strategies for c-KIT-directed targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKLApMu7v92LVg90H21EOLACvtfcHk0liccmok5IVq-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Wgtr8%253D&md5=d5323ddde193e774455925cc8a1c2b43</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.2174%2F13816128113199990593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13816128113199990593%26sid%3Dliteratum%253Aachs%26aulast%3DStankov%26aufirst%3DK.%26aulast%3DPopovic%26aufirst%3DS.%26aulast%3DMikov%26aufirst%3DM.%26atitle%3DC-KIT%2520Signaling%2520in%2520Cancer%2520Treatment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2014%26volume%3D20%26issue%3D17%26spage%3D2849%26epage%3D2880%26doi%3D10.2174%2F13816128113199990593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbaspour Babaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalidehghan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman Huri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadipour, F.</span></span> <span> </span><span class="NLM_article-title">Receptor Tyrosine Kinase (C-Kit) Inhibitors: a Potential Therapeutic Target in</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2459</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S89114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.2147%2FDDDT.S89114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27536065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2443-2459&author=M.+Abbaspour+Babaeiauthor=B.+Kamalidehghanauthor=M.+Saleemauthor=H.+Zaman+Huriauthor=F.+Ahmadipour&title=Receptor+Tyrosine+Kinase+%28C-Kit%29+Inhibitors%3A+a+Potential+Therapeutic+Target+in&doi=10.2147%2FDDDT.S89114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells</span></div><div class="casAuthors">Abbaspour Babaei Maryam; Ahmadipour Fatemeh; Kamalidehghan Behnam; Saleem Mohammad; Huri Hasniza Zaman</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2443-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form of c-Kit plays a crucial role in occurrence of some cancers.  The function of c-Kit has led to the concept that inhibiting c-Kit kinase activity can be a target for cancer therapy.  The promising results of inhibition of c-Kit for treatment of cancers have been observed in some cancers such as gastrointestinal stromal tumor, acute myeloid leukemia, melanoma, and other tumors, and these results have encouraged attempts toward improvement of using c-Kit as a capable target for cancer therapy.  This paper presents the findings of previous studies regarding c-Kit as a receptor tyrosine kinase and an oncogene, as well as its gene targets and signaling pathways in normal and cancer cells.  The c-Kit gene location, protein structure, and the role of c-Kit in normal cell have been discussed.  Comprehending the molecular mechanism underlying c-Kit-mediated tumorogenesis is consequently essential and may lead to the identification of future novel drug targets.  The potential mechanisms by which c-Kit induces cellular transformation have been described.  This study aims to elucidate the function of c-Kit for future cancer therapy.  In addition, it has c-Kit inhibitor drug properties and their functions have been listed in tables and demonstrated in schematic pictures.  This review also has collected previous studies that targeted c-Kit as a novel strategy for cancer therapy.  This paper further emphasizes the advantages of this approach, as well as the limitations that must be addressed in the future.  Finally, although c-Kit is an attractive target for cancer therapy, based on the outcomes of treatment of patients with c-Kit inhibitors, it is unlikely that Kit inhibitors alone can lead to cure.  It seems that c-Kit mutations alone are not sufficient for tumorogenesis, but do play a crucial role in cancer occurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfTnK2L7idhRwLZxei1HN8fW6udTcc2eZfM2JcEe7INrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szhvV2guw%253D%253D&md5=c45d232471e049dc8d42a98fc5aa1d76</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S89114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S89114%26sid%3Dliteratum%253Aachs%26aulast%3DAbbaspour%2BBabaei%26aufirst%3DM.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DSaleem%26aufirst%3DM.%26aulast%3DZaman%2BHuri%26aufirst%3DH.%26aulast%3DAhmadipour%26aufirst%3DF.%26atitle%3DReceptor%2520Tyrosine%2520Kinase%2520%2528C-Kit%2529%2520Inhibitors%253A%2520a%2520Potential%2520Therapeutic%2520Target%2520in%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D2443%26epage%3D2459%26doi%3D10.2147%2FDDDT.S89114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descarpentries, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubreuil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmider, O.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors Induce Down-Regulation of C-Kit by Targeting the ATP Pocket</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e60961</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0060961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1371%2Fjournal.pone.0060961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23637779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVKrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e60961-14&issue=4&author=D.+D%E2%80%99allardauthor=J.+Gayauthor=C.+Descarpentriesauthor=E.+Frisanauthor=K.+Adamauthor=F.+Verdierauthor=C.+Floquetauthor=P.+Dubreuilauthor=C.+Lacombeauthor=M.+Fontenayauthor=P.+Mayeuxauthor=O.+Kosmider&title=Tyrosine+Kinase+Inhibitors+Induce+Down-Regulation+of+C-Kit+by+Targeting+the+ATP+Pocket&doi=10.1371%2Fjournal.pone.0060961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket</span></div><div class="casAuthors">D'Allard, Diane; Gay, Julie; Descarpentries, Clotilde; Frisan, Emilie; Adam, Kevin; Verdier, Frederique; Floquet, Celia; Dubreuil, Patrice; Lacombe, Catherine; Fontenay, Michaela; Mayeux, Patrick; Kosmider, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e60961</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The stem cell factor receptor (SCF) c-Kit plays a pivotal role in regulating cell proliferation and survival in many cell types.  In particular, c-Kit is required for early amplification of erythroid progenitors, while it must disappear from cell surface for the cell entering the final steps of maturation in an erythropoietin-dependent manner.  We initially obsd. that imatinib (IM), an inhibitor targeting the tyrosine kinase activity of c-Kit concomitantly down-regulated the expression of c-Kit and accelerated the Epo-driven differentiation of erythroblasts in the absence of SCF.  We investigated the mechanism by which IM or related masitinib (MA) induce c-Kit down-regulation in the human UT-7/Epo cell line.  We found that the down-regulation of c-Kit in the presence of IM or MA was inhibited by a pre-incubation with methyl-β-cyclodextrin suggesting that c-Kit was internalized in the absence of ligand.  By contrast to SCF, the internalization induced by TKI was independent of the E3 ubiquitin ligase c-Cbl.  Furthermore, c-Kit was degraded through lysosomal, but not proteasomal pathway.  In pulse-chase expts., IM did not modulate c-Kit synthesis or maturation.  Anal. of phosphotyrosine peptides in UT-7/Epo cells treated or not with IM show that IM did not modify overall tyrosine phosphorylation in these cells.  Furthermore, we showed that a T670I mutation preventing the full access of IM to the ATP binding pocket, did not allow the internalization process in the presence of IM.  Altogether these data show that TKI-induced internalization of c-Kit is linked to a modification of the integrity of ATP binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2F1HZL9M3eLVg90H21EOLACvtfcHk0lhwybmD-yWKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVKrsrc%253D&md5=4fa572781129c2390df26d200d8481e6</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060961%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599allard%26aufirst%3DD.%26aulast%3DGay%26aufirst%3DJ.%26aulast%3DDescarpentries%26aufirst%3DC.%26aulast%3DFrisan%26aufirst%3DE.%26aulast%3DAdam%26aufirst%3DK.%26aulast%3DVerdier%26aufirst%3DF.%26aulast%3DFloquet%26aufirst%3DC.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DFontenay%26aufirst%3DM.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DKosmider%26aufirst%3DO.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors%2520Induce%2520Down-Regulation%2520of%2520C-Kit%2520by%2520Targeting%2520the%2520ATP%2520Pocket%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D4%26spage%3De60961%26epage%3D14%26doi%3D10.1371%2Fjournal.pone.0060961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solheim, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seglen, P. O.</span></span> <span> </span><span class="NLM_article-title">Cellular and Lysosomal Uptake of Methylamine in Isolated Rat Hepatocytes</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>210</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1042/bj2100929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2Fbj2100929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=6870811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaL3sXlslentbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=1983&pages=929-936&issue=3&author=A.+E.+Solheimauthor=P.+O.+Seglen&title=Cellular+and+Lysosomal+Uptake+of+Methylamine+in+Isolated+Rat+Hepatocytes&doi=10.1042%2Fbj2100929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and lysosomal uptake of methylamine in isolated rat hepatocytes</span></div><div class="casAuthors">Solheim, Anne E.; Seglen, Per O.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">929-36</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">Methylamine (I) was accumulated by at least 2 different mechanisms in rat isolated hepatocytes.  These were: (1) a facilitated diffusion subject to trans stimulation and cis inhibition by other amines, nonconcentrative, energy-independent, and operative at 0° and (2) an energy-dependent process inhibited by anoxia and energy inhibitors.  I gradually accumulated in lysosomes, causing them to swell and increasing the total cell vol. by ∼12%.  Lysosomal swelling was abolished by anoxia or energy inhibitors, in spite of there being a high intracellular I concn. resulting from facilitated diffusion.  Hence, lysosomal I accumulation appears to depend on energy-requiring processes (such as continuous proton pumping), and not only on trapping by Donan-equil.-generated protons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0vMb4WsIS5rVg90H21EOLACvtfcHk0lhwybmD-yWKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlslentbs%253D&md5=6b3f8e0c7e83f9551bd751394cff08e7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1042%2Fbj2100929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2100929%26sid%3Dliteratum%253Aachs%26aulast%3DSolheim%26aufirst%3DA.%2BE.%26aulast%3DSeglen%26aufirst%3DP.%2BO.%26atitle%3DCellular%2520and%2520Lysosomal%2520Uptake%2520of%2520Methylamine%2520in%2520Isolated%2520Rat%2520Hepatocytes%26jtitle%3DBiochem.%2520J.%26date%3D1983%26volume%3D210%26issue%3D3%26spage%3D929%26epage%3D936%26doi%3D10.1042%2Fbj2100929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skretting, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garred, Ø.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilhardt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Deurs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandvig, K.</span></span> <span> </span><span class="NLM_article-title">Extraction of Cholesterol with Methyl-B-Cyclodextrin Perturbs Formation of Clathrin-Coated Endocytic Vesicles</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1091/mbc.10.4.961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1091%2Fmbc.10.4.961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10198050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXisVGks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=961-974&issue=4&author=S.+K.+Rodalauthor=G.+Skrettingauthor=%C3%98.+Garredauthor=F.+Vilhardtauthor=B.+van+Deursauthor=K.+Sandvig&title=Extraction+of+Cholesterol+with+Methyl-B-Cyclodextrin+Perturbs+Formation+of+Clathrin-Coated+Endocytic+Vesicles&doi=10.1091%2Fmbc.10.4.961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles</span></div><div class="casAuthors">Rodal, Siv Kjersti; Skretting, Grethe; Garred, Oystein; Vilhardt, Frederik; Van Deurs, Bo; Sandvig, Kirsten</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">961-974</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">The importance of cholesterol for endocytosis has been investigated in HEp-2 and other cell lines by using methyl-β-cyclodextrin (MβCD) to selectively ext. cholesterol from the plasma membrane.  MβCD treatment strongly inhibited endocytosis of transferrin and EGF, whereas endocytosis of ricin was less affected.  The inhibition of transferrin endocytosis was completely reversible.  On removal of MβCD it was restored by continued incubation of the cells even in serum-free medium.  The recovery in serum-free medium was inhibited by addn. of lovastatin, which prevents cholesterol synthesis, but endocytosis recovered when a water-sol. form of cholesterol was added together with lovastatin.  Electron microscopical studies of MβCD-treated HEp-2 cells revealed that typical invaginated caveolae were no longer present.  Moreover, the invagination of clathrin-coated pits was strongly inhibited, resulting in accumulation of shallow coated pits.  Quant. immunogold labeling showed that transferrin receptors were concd. in coated pits to the same degree (approx. sevenfold) after MβCD treatment as in control cells.  Our results therefore indicate that although clathrin-independent (and caveolae-independent) endocytosis still operates after removal of cholesterol, cholesterol is essential for the formation of clathrin-coated endocytic vesicles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphvV-Z-RId6bVg90H21EOLACvtfcHk0lhwybmD-yWKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisVGks7o%253D&md5=a17a986bc0d94dde00ffb87138890e63</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1091%2Fmbc.10.4.961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.10.4.961%26sid%3Dliteratum%253Aachs%26aulast%3DRodal%26aufirst%3DS.%2BK.%26aulast%3DSkretting%26aufirst%3DG.%26aulast%3DGarred%26aufirst%3D%25C3%2598.%26aulast%3DVilhardt%26aufirst%3DF.%26aulast%3Dvan%2BDeurs%26aufirst%3DB.%26aulast%3DSandvig%26aufirst%3DK.%26atitle%3DExtraction%2520of%2520Cholesterol%2520with%2520Methyl-B-Cyclodextrin%2520Perturbs%2520Formation%2520of%2520Clathrin-Coated%2520Endocytic%2520Vesicles%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D1999%26volume%3D10%26issue%3D4%26spage%3D961%26epage%3D974%26doi%3D10.1091%2Fmbc.10.4.961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subtil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobylarz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGraw, T. E.</span></span> <span> </span><span class="NLM_article-title">Acute Cholesterol Depletion Inhibits Clathrin-Coated Pit Budding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">6775</span>– <span class="NLM_lpage">6780</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.12.6775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.96.12.6775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10359788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXks1WksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=6775-6780&issue=12&author=A.+Subtilauthor=I.+Gaidarovauthor=K.+Kobylarzauthor=M.+A.+Lampsonauthor=J.+H.+Keenauthor=T.+E.+McGraw&title=Acute+Cholesterol+Depletion+Inhibits+Clathrin-Coated+Pit+Budding&doi=10.1073%2Fpnas.96.12.6775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Acute cholesterol depletion inhibits clathrin-coated pit budding</span></div><div class="casAuthors">Subtil, Agathe; Gaidarov, Ibragim; Kobylarz, Keith; Lampson, Michael A.; Keen, James H.; McGraw, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6775-6780</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Many biol. important macromols. are internalized into cells by clathrin-coated pit endocytosis.  The mechanism of clathrin-coated pit budding has been investigated intensively, and considerable progress has been made in characterizing the proteins involved in internalization.  Membrane lipid compn. and the lateral organization of lipids and proteins within membranes are believed to play an important role in the regulation of membrane-trafficking processes.  Here we report that membrane cholesterol plays a crit. role in clathrin-coated pit internalization.  We show that acute cholesterol depletion, using β-methyl-cyclodextrin, specifically reduces the rate of internalization of transferrin receptor by more than 85%, without affecting intracellular receptor trafficking back to the cell surface.  The effect on endocytosis is attributable to a failure of coated pits to detach from the plasma membrane, as visualized by using a green fluorescent protein-clathrin conjugate in living cells.  Ultrastructural studies indicate that acute cholesterol depletion causes accumulation of flat-coated membranes and a corresponding decrease in deep-coated pits, consistent with the possibility that flat clathrin lattices are direct precursors of indented pits and endocytic vesicles in intact cells.  We conclude that clathrin is unable to induce curvature in the membrane depleted of cholesterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG2HRLKz6887Vg90H21EOLACvtfcHk0lhwybmD-yWKng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXks1WksLs%253D&md5=a49e9a271451df26f514c302811ccfae</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.12.6775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.12.6775%26sid%3Dliteratum%253Aachs%26aulast%3DSubtil%26aufirst%3DA.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DKobylarz%26aufirst%3DK.%26aulast%3DLampson%26aufirst%3DM.%2BA.%26aulast%3DKeen%26aufirst%3DJ.%2BH.%26aulast%3DMcGraw%26aufirst%3DT.%2BE.%26atitle%3DAcute%2520Cholesterol%2520Depletion%2520Inhibits%2520Clathrin-Coated%2520Pit%2520Budding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26issue%3D12%26spage%3D6775%26epage%3D6780%26doi%3D10.1073%2Fpnas.96.12.6775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corneth, O. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Wolterink, R. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">BTK Signaling in B Cell Differentiation and Autoimmunity</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>393</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1007/82_2015_478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2F82_2015_478" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2015&pages=67-105&issue=12&author=O.+B.+J.+Cornethauthor=R.+G.+J.+Klein+Wolterinkauthor=R.+W.+Hendriks&title=BTK+Signaling+in+B+Cell+Differentiation+and+Autoimmunity&doi=10.1007%2F82_2015_478"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1007%2F82_2015_478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F82_2015_478%26sid%3Dliteratum%253Aachs%26aulast%3DCorneth%26aufirst%3DO.%2BB.%2BJ.%26aulast%3DKlein%2BWolterink%26aufirst%3DR.%2BG.%2BJ.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DBTK%2520Signaling%2520in%2520B%2520Cell%2520Differentiation%2520and%2520Autoimmunity%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2015%26volume%3D393%26issue%3D12%26spage%3D67%26epage%3D105%26doi%3D10.1007%2F82_2015_478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolibaba, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients with Relapsed/Refractory B-Cell Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.42.7906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1200%2FJCO.2012.42.7906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23045577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=88-94&issue=1&author=R.+H.+Advaniauthor=J.+J.+Buggyauthor=J.+P.+Sharmanauthor=S.+M.+Smithauthor=T.+E.+Boydauthor=B.+Grantauthor=K.+S.+Kolibabaauthor=R.+R.+Furmanauthor=S.+Rodriguezauthor=B.+Y.+Changauthor=J.+Sukbuntherngauthor=R.+Izumiauthor=A.+Hamdyauthor=E.+Hedrickauthor=N.+H.+Fowler&title=Bruton+Tyrosine+Kinase+Inhibitor+Ibrutinib+%28PCI-32765%29+Has+Significant+Activity+in+Patients+with+Relapsed%2FRefractory+B-Cell+Malignancies&doi=10.1200%2FJCO.2012.42.7906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies</span></div><div class="casAuthors">Advani, Ranjana H.; Buggy, Joseph J.; Sharman, Jeff P.; Smith, Sonali M.; Boyd, Thomas E.; Grant, Barbara; Kolibaba, Kathryn S.; Furman, Richard R.; Rodriguez, Sara; Chang, Betty Y.; Sukbuntherng, Juthamas; Izumi, Raquel; Hamdy, Ahmed; Hedrick, Eric; Fowler, Nathan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-94</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a crit. signaling kinase in this pathway.  We evaluated ibrutinib (PCI-32765), a small-mol. irreversible inhibitor of BTK, in patients with B-cell malignancies.  Patients and Methods Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib.  Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing.  Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe.  Dose escalation proceeded until either the max.-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib.  Response was evaluated every two cycles.  Results Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts.  Most adverse events were grade 1 and 2 in severity and self-limited.  Dose-limiting events were not obsd., even with prolonged dosing.  Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD.  Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 h, consistent with the irreversible mechanism.  Objective response rate in 50 evaluable patients was 60%, including complete response of 16%.  Median progression-free survival in all patients was 13.6 mo.  Conclusion Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqj_UZPM0nBrVg90H21EOLACvtfcHk0lgujkrDftqB-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D&md5=e955490a02af9a321823033b9e258cb6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.7906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.7906%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DBoyd%26aufirst%3DT.%2BE.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DKolibaba%26aufirst%3DK.%2BS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%2520%2528PCI-32765%2529%2520Has%2520Significant%2520Activity%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B-Cell%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D1%26spage%3D88%26epage%3D94%26doi%3D10.1200%2FJCO.2012.42.7906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The Development of Bruton’s Tyrosine Kinase (BTK) Inhibitors From 2012 to 2017: a Mini-Review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+Development+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+From+2012+to+2017%3A+a+Mini-Review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0lgujkrDftqB-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520Development%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520From%25202012%2520to%25202017%253A%2520a%2520Mini-Review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1086</span>– <span class="NLM_lpage">1091</span>, <span class="refDoi"> DOI: 10.1021/cb4008524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb4008524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1086-1091&issue=5&author=H.+Wuauthor=W.+Wangauthor=F.+Liuauthor=E.+L.+Weisbergauthor=B.+Tianauthor=Y.+Chenauthor=B.+Liauthor=A.+Wangauthor=B.+Wangauthor=Z.+Zhaoauthor=D.+W.+McMillinauthor=C.+Huauthor=H.+Liauthor=J.+Wangauthor=Y.+Liangauthor=S.+J.+Buhrlageauthor=J.+Liangauthor=J.+Liuauthor=G.+Yangauthor=J.+R.+Brownauthor=S.+P.+Treonauthor=C.+S.+Mitsiadesauthor=J.+D.+Griffinauthor=Q.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+Potent%2C+Covalent+BTK+Inhibitor+for+B-Cell+Lymphoma&doi=10.1021%2Fcb4008524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma</span></div><div class="casAuthors">Wu, Hong; Wang, Wenchao; Liu, Feiyang; Weisberg, Ellen E.; Tian, Bei; Chen, Yongfei; Li, Binhua; Wang, Aoli; Wang, Beilei; Zhao, Zheng; McMillin, Douglas W.; Hu, Chen; Li, Hong; Wang, Jinhua; Liang, Yanke; Buhrlage, Sara J.; Liang, Junting; Liu, Jing; Yang, Guang; Brown, Jennifer R.; Treon, Steven P.; Mitsiades, Constantine S.; Griffin, James; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-1091</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases.  The authors have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible BTK kinase inhibitor, QL47, which covalently modifies Cys 481.  QL47 inhibits BTK kinase activity with an IC50 of 7 nM, inhibits autophosphorylation of BTK on Tyr 223 in cells with an EC50 of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr 759) with an EC50 of 318 nM.  In Ramos cells QL47 induces a G1 cell cycle arrest that is assocd. with pronounced degrdn. of BTK protein.  QL47 inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiyQbTbqIpCbVg90H21EOLACvtfcHk0lh_QAvie5vTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFWgt7o%253D&md5=6cee72676bcd141f79d89d708dea5db2</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fcb4008524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4008524%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DTian%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMcMillin%26aufirst%3DD.%2BW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520Potent%252C%2520Covalent%2520BTK%2520Inhibitor%2520for%2520B-Cell%2520Lymphoma%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26issue%3D5%26spage%3D1086%26epage%3D1091%26doi%3D10.1021%2Fcb4008524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tinworth, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lithgow, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, Z. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muelbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span> <span> </span><span class="NLM_article-title">PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b01094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b01094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1ylsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=342-347&issue=3&author=C.+P.+Tinworthauthor=H.+Lithgowauthor=L.+Dittusauthor=Z.+I.+Bassiauthor=S.+E.+Hughesauthor=M.+Muelbaierauthor=H.+Daiauthor=I.+E.+D.+Smithauthor=W.+J.+Kerrauthor=G.+A.+Burleyauthor=M.+Bantscheffauthor=J.+D.+Harling&title=PROTAC-Mediated+Degradation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Is+Inhibited+by+Covalent+Binding&doi=10.1021%2Facschembio.8b01094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding</span></div><div class="casAuthors">Tinworth, Christopher P.; Lithgow, Hannah; Dittus, Lars; Bassi, Zuni I.; Hughes, Sophie E.; Muelbaier, Marcel; Dai, Han; Smith, Ian E. D.; Kerr, William J.; Burley, Glenn A.; Bantscheff, Marcus; Harling, John D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-347</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The impact of covalent binding on PROTAC-mediated degrdn. of BTK was investigated through the prepn. of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib.  It was detd. that a covalent binding PROTAC inhibited BTK degrdn. despite evidence of target engagement, while BTK degrdn. was obsd. with a reversible binding PROTAC.  These observations were consistently found when PROTACs that were able to recruit either IAP or cereblon E3 ligases were employed.  Proteomics anal. detd. that the use of a covalently bound PROTAC did not result in the degrdn. of covalently bound targets, while degrdn. was obsd. for some reversibly bound targets.  This observation highlights the importance of catalysis for successful PROTAC-mediated degrdn. and highlights a potential caveat for the use of covalent target binders in PROTAC design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTsgJ6eGHCfbVg90H21EOLACvtfcHk0lh_QAvie5vTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1ylsLg%253D&md5=7705320a9ffd433ffceec0d67063a599</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b01094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b01094%26sid%3Dliteratum%253Aachs%26aulast%3DTinworth%26aufirst%3DC.%2BP.%26aulast%3DLithgow%26aufirst%3DH.%26aulast%3DDittus%26aufirst%3DL.%26aulast%3DBassi%26aufirst%3DZ.%2BI.%26aulast%3DHughes%26aufirst%3DS.%2BE.%26aulast%3DMuelbaier%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DKerr%26aufirst%3DW.%2BJ.%26aulast%3DBurley%26aufirst%3DG.%2BA.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26atitle%3DPROTAC-Mediated%2520Degradation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Is%2520Inhibited%2520by%2520Covalent%2520Binding%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D342%26epage%3D347%26doi%3D10.1021%2Facschembio.8b01094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span> <span> </span><span class="NLM_article-title">Protein Degradation Through Covalent Inhibitor-Based PROTACs</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1039/C9CC08238G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1039%2FC9CC08238G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31922153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=1521-1524&issue=10&author=G.+Xueauthor=J.+Chenauthor=L.+Liuauthor=D.+Zhouauthor=Y.+Zuoauthor=T.+Fuauthor=Z.+Pan&title=Protein+Degradation+Through+Covalent+Inhibitor-Based+PROTACs&doi=10.1039%2FC9CC08238G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Protein degradation through covalent inhibitor-based PROTACs</span></div><div class="casAuthors">Xue, Gang; Chen, Jiahui; Liu, Lihong; Zhou, Danli; Zuo, Yingying; Fu, Tiancheng; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1521-1524</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Tremendous advancements in proteolysis targeting chimera (PROTAC) technol. have been made in recent years.  However, whether a covalent inhibitor-based PROTAC can be developed remains controversial.  Here, we successfully developed chimeric degraders based on covalent inhibitors to degrade BTK and BLK kinases, demonstrating that covalent inhibitor-based PROTACs are viable and useful tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTxWXFGSqOh7Vg90H21EOLACvtfcHk0lh_QAvie5vTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlKgsr8%253D&md5=c240b1ae3c859dbd0dc93a4a7848bfce</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2FC9CC08238G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CC08238G%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZuo%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DProtein%2520Degradation%2520Through%2520Covalent%2520Inhibitor-Based%2520PROTACs%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2020%26volume%3D56%26issue%3D10%26spage%3D1521%26epage%3D1524%26doi%3D10.1039%2FC9CC08238G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scriven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Checkpoint Kinase Chk1 Induces DNA Damage and Cell Death in Human Leukemia and Lymphoma Cells</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">147</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-13-147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1186%2F1476-4598-13-147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24913641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=147&issue=1&author=C.+Bryantauthor=K.+Scrivenauthor=A.+J.+Massey&title=Inhibition+of+the+Checkpoint+Kinase+Chk1+Induces+DNA+Damage+and+Cell+Death+in+Human+Leukemia+and+Lymphoma+Cells&doi=10.1186%2F1476-4598-13-147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells</span></div><div class="casAuthors">Bryant, Christopher; Scriven, Kirsten; Massey, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147/1-147/20, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Chk1 forms a core component of the DNA damage response and small mol. inhibitors are currently being investigated in the clinic as cytotoxic chemotherapy potentiators.  Recent evidence suggests that Chk1 inhibitors may demonstrate significant single agent activity in tumors with specific DNA repair defects, a constitutively activated DNA damage response or oncogene induced replicative stress.  Methods: Growth inhibition induced by the small mol. Chk1 inhibitor V158411 was assessed in a panel of human leukemia and lymphoma cell lines and compared to cancer cell lines derived from solid tumors.  The effects on cell cycle and DNA damage response markers were further evaluated.  Results: Leukemia and lymphoma cell lines were identified as particularly sensitive to the Chk1 inhibitor V158411 (mean GI50 0.17 μM) compared to colon (2.8 μM) or lung (6.9 μM) cancer cell lines.  Chk1 inhibition by V158411 in the leukemia and lymphoma cell lines induced DNA fragmentation and cell death that was both caspase dependent and independent, and prevented cells undergoing mitosis.  An anal. of in vitro pharmacodynamic markers identified a dose dependent decrease in Chk1 and cyclin B1 protein levels and Cdc2 Thr15 phosphorylation along with a concomitant increase in H2AX phosphorylation at Ser139 following V158411 treatment.  Conclusions: These data support the further evaluation of Chk1 inhibitors in hematopoietic cancers as single agents as well as in combination with std. of care cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xm_X9mO2B7Vg90H21EOLACvtfcHk0lig9Vy3OFIHJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWntbo%253D&md5=617eff8bf38666590b093eff96c3dd13</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-13-147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-13-147%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DC.%26aulast%3DScriven%26aufirst%3DK.%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520Checkpoint%2520Kinase%2520Chk1%2520Induces%2520DNA%2520Damage%2520and%2520Cell%2520Death%2520in%2520Human%2520Leukemia%2520and%2520Lymphoma%2520Cells%26jtitle%3DMol.%2520Cancer%26date%3D2014%26volume%3D13%26issue%3D1%26spage%3D147%26doi%3D10.1186%2F1476-4598-13-147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foloppe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiumana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallowfield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel, in Vivo Active Chk1 Inhibitors Utilizing Structure Guided Drug Design</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">35797</span>– <span class="NLM_lpage">35812</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.18632%2Foncotarget.5929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26437226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC283oslGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=35797-35812&issue=34&author=A.+J.+Masseyauthor=S.+Stokesauthor=H.+Browneauthor=N.+Foloppeauthor=A.+Fiumanaauthor=S.+Scraceauthor=M.+Fallowfieldauthor=S.+Bedfordauthor=P.+Webbauthor=L.+Bakerauthor=M.+Christieauthor=M.+J.+Drysdaleauthor=M.+Wood&title=Identification+of+Novel%2C+in+Vivo+Active+Chk1+Inhibitors+Utilizing+Structure+Guided+Drug+Design&doi=10.18632%2Foncotarget.5929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design</span></div><div class="casAuthors">Massey Andrew J; Stokes Stephen; Browne Helen; Foloppe Nicolas; Fiumana Andrea; Scrace Simon; Fallowfield Mandy; Bedford Simon; Webb Paul; Baker Lisa; Drysdale Martin J; Wood Mike; Scrace Simon; Christie Mark; Drysdale Martin J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">35797-812</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chk1 kinase is a critical component of the DNA damage response checkpoint especially in cancer cells and targeting Chk1 is a potential therapeutic opportunity for potentiating the anti-tumor activity of DNA damaging chemotherapy drugs.  Fragment elaboration by structure guided design was utilized to identify and develop a novel series of Chk1 inhibitors culminating in the identification of V158411, a potent ATP-competitive inhibitor of the Chk1 and Chk2 kinases.  V158411 abrogated gemcitabine and camptothecin induced cell cycle checkpoints, resulting in the expected modulation of cell cycle proteins and increased cell death in cancer cells.  V158411 potentiated the cytotoxicity of gemcitabine, cisplatin, SN38 and camptothecin in a variety of p53 deficient human tumor cell lines in vitro, p53 proficient cells were unaffected.  In nude mice, V158411 showed minimal toxicity as a single agent and in combination with irinotecan.  In tumor bearing animals, V158411 was detected at high levels in the tumor with a long elimination half-life; no pharmacologically significant in vivo drug-drug interactions with irinotecan were identified through analysis of the pharmacokinetic profiles.  V158411 potentiated the anti-tumor activity of irinotecan in a variety of human colon tumor xenograft models without additional systemic toxicity.  These results demonstrate the opportunity for combining V158411 with standard of care chemotherapeutic agents to potentiate the therapeutic efficacy of these agents without increasing their toxicity to normal cells.  Thus, V158411 would warrant further clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEUXLTsW9xitXdcedVHT5tfW6udTcc2ebR6ns_A2shSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283oslGksg%253D%253D&md5=3b3e009bab7d5f0e2a744ed7c261bf14</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5929%26sid%3Dliteratum%253Aachs%26aulast%3DMassey%26aufirst%3DA.%2BJ.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DBrowne%26aufirst%3DH.%26aulast%3DFoloppe%26aufirst%3DN.%26aulast%3DFiumana%26aufirst%3DA.%26aulast%3DScrace%26aufirst%3DS.%26aulast%3DFallowfield%26aufirst%3DM.%26aulast%3DBedford%26aufirst%3DS.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DL.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DWood%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520Novel%252C%2520in%2520Vivo%2520Active%2520Chk1%2520Inhibitors%2520Utilizing%2520Structure%2520Guided%2520Drug%2520Design%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D34%26spage%3D35797%26epage%3D35812%26doi%3D10.18632%2Foncotarget.5929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvesen, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, C. S.</span></span> <span> </span><span class="NLM_article-title">IAP Proteins: Blocking the Road to Death’s Door</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/nrm830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrm830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12042762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=401-410&issue=6&author=G.+S.+Salvesenauthor=C.+S.+Duckett&title=IAP+Proteins%3A+Blocking+the+Road+to+Death%E2%80%99s+Door&doi=10.1038%2Fnrm830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis: IAP proteins: blocking the road to death's door</span></div><div class="casAuthors">Salvesen, Guy S.; Duckett, Colin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">401-410</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'inhibitor of apoptosis' (IAP) gene family, which was discovered less than a decade ago, encodes a group of structurally related proteins that, in addn. to their ability to suppress apoptotic cell death, are involved in an increasing no. of seemingly unrelated cellular functions.  Here, we review the functional and structural properties of this fascinating group of proteins, and of several recently identified IAP-binding factors that regulate IAP function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofMWLW8mAr_LVg90H21EOLACvtfcHk0lig9Vy3OFIHJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartL4%253D&md5=0f967aad318a34d988ad40486950ed62</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrm830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm830%26sid%3Dliteratum%253Aachs%26aulast%3DSalvesen%26aufirst%3DG.%2BS.%26aulast%3DDuckett%26aufirst%3DC.%2BS.%26atitle%3DIAP%2520Proteins%253A%2520Blocking%2520the%2520Road%2520to%2520Death%25E2%2580%2599s%2520Door%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26issue%3D6%26spage%3D401%26epage%3D410%26doi%3D10.1038%2Fnrm830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">IAPs, RINGs and Ubiquitylation</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1038/nrm1621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrm1621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=15803136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVaktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=287-297&issue=4&author=D.+L.+Vauxauthor=J.+Silke&title=IAPs%2C+RINGs+and+Ubiquitylation&doi=10.1038%2Fnrm1621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">IAPs, RINGs and ubiquitylation</span></div><div class="casAuthors">Vaux, David L.; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Here, the authors review the function of the RING domain of inhibitor of apoptosis proteins (IAPs), provide an overview of the biol. of E3 ubiquitin ligases, the enzymes which conjugate ubiquitin to substrate proteins, and its application to IAPs, and examine evidence for substrate ubiquitination by IAPs and for the importance of these ubiquitination events in the prevention of apoptosis.  The IAPs all contain one or more baculoviral IAP repeat motifs, through which they interact with various other proteins.  Many IAPs also have another Zn-binding motif, the RING domain, which can recruit E2 ubiquitin-conjugating enzymes and catalyze the transfer of ubiquitin onto target proteins.  The no. of targets of IAP-mediated ubiquitination is increasing, and recent results indicate that outcomes following ubiquitination are tantalizingly complex.  As well as regulating other proteins, the IAPs themselves are controlled by ubiquitin-mediated degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8gh0_du1aY7Vg90H21EOLACvtfcHk0lgnz6XftOt-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVaktb8%253D&md5=4d3040429bbac085dd33b46c8c74d955</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnrm1621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1621%26sid%3Dliteratum%253Aachs%26aulast%3DVaux%26aufirst%3DD.%2BL.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DIAPs%252C%2520RINGs%2520and%2520Ubiquitylation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2005%26volume%3D6%26issue%3D4%26spage%3D287%26epage%3D297%26doi%3D10.1038%2Fnrm1621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCasse, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korneluk, R. G.</span></span> <span> </span><span class="NLM_article-title">The Inhibitors of Apoptosis (IAPs) as Cancer Targets</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1568</span>, <span class="refDoi"> DOI: 10.1007/s10495-007-0087-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1007%2Fs10495-007-0087-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17573556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFWru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1543-1568&issue=9&author=A.+M.+Hunterauthor=E.+C.+LaCasseauthor=R.+G.+Korneluk&title=The+Inhibitors+of+Apoptosis+%28IAPs%29+as+Cancer+Targets&doi=10.1007%2Fs10495-007-0087-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibitors of apoptosis (IAPs) as cancer targets</span></div><div class="casAuthors">Hunter, Allison M.; LaCasse, Eric C.; Korneluk, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1543-1568</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Apoptosis has been accepted as a fundamental component in the pathogenesis of cancer, in addn. to other human diseases including neurodegeneration, coronary disease and diabetes.  The origin of cancer involves deregulated cellular proliferation and the suppression of apoptotic processes, ultimately leading to tumor establishment and growth.  Several lines of evidence point toward the IAP family of proteins playing a role in oncogenesis, via their effective suppression of apoptosis.  The central mechanisms of IAP apoptotic suppression appear to be through direct caspase and pro-caspase inhibition (primarily caspase 3 and 7) and modulation of, and by, the transcription factor NF-kappaB.  Thus, when the IAPs are over-expressed or over-active, as is the case in many cancers, cells are no longer able to die in a physiol. programmed fashion and become increasingly resistant to std. chemo- and radiation therapies.  To date several approaches have been taken to target and eliminate IAP function in an attempt to re-establish sensitivity, reduce toxicity, and improve efficacy of cancer treatment.  In this review, we address IAP proteins as therapeutic targets for the treatment of cancer and emphasize the importance of novel therapeutic approaches for cancer therapy.  Novel targets of IAP function are being identified and include gene therapy strategies and small mol. inhibitors that are based on endogenous IAP antagonists.  As well, mol. mechanistic approaches, such as RNAi to deplete IAP expression, are in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3AD5U2Vmcv7Vg90H21EOLACvtfcHk0lgnz6XftOt-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFWru7c%253D&md5=69c286dc6604cc97c54c09d7af8fe300</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1007%2Fs10495-007-0087-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-007-0087-3%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DA.%2BM.%26aulast%3DLaCasse%26aufirst%3DE.%2BC.%26aulast%3DKorneluk%26aufirst%3DR.%2BG.%26atitle%3DThe%2520Inhibitors%2520of%2520Apoptosis%2520%2528IAPs%2529%2520as%2520Cancer%2520Targets%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26issue%3D9%26spage%3D1543%26epage%3D1568%26doi%3D10.1007%2Fs10495-007-0087-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvesen, G. S.</span></span> <span> </span><span class="NLM_article-title">Human Caspases: Activation, Specificity, and Regulation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">21777</span>– <span class="NLM_lpage">21781</span>, <span class="refDoi"> DOI: 10.1074/jbc.R800084200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1074%2Fjbc.R800084200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19473994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFymsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=21777-21781&issue=33&author=C.+Popauthor=G.+S.+Salvesen&title=Human+Caspases%3A+Activation%2C+Specificity%2C+and+Regulation&doi=10.1074%2Fjbc.R800084200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Human Caspases: Activation, Specificity, and Regulation</span></div><div class="casAuthors">Pop, Cristina; Salvesen, Guy S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">21777-21781</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Caspases are intracellular proteases that propagate programmed cell death, proliferation, and inflammation.  Activation of caspases occurs by a conserved mechanism subject to strict cellular regulation.  Once activated by a specific stimulus, caspases execute limited proteolysis of downstream substrates to trigger a cascade of events that culminates in the desired biol. response.  Much has been learned of the mechanisms that govern the activation and regulation of caspases, and this minireview provides an update of these areas.  We also delineate substantial gaps in knowledge of caspase function, which can be approached by techniques and exptl. paradigms that are currently undergoing development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6lC2wmuHJbVg90H21EOLACvtfcHk0lgnz6XftOt-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFymsbw%253D&md5=4ac8ce49ca4122e19c1d29c6610e10f6</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R800084200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R800084200%26sid%3Dliteratum%253Aachs%26aulast%3DPop%26aufirst%3DC.%26aulast%3DSalvesen%26aufirst%3DG.%2BS.%26atitle%3DHuman%2520Caspases%253A%2520Activation%252C%2520Specificity%252C%2520and%2520Regulation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26issue%3D33%26spage%3D21777%26epage%3D21781%26doi%3D10.1074%2Fjbc.R800084200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, C.</span></span> <span> </span><span class="NLM_article-title">Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5750</span>– <span class="NLM_lpage">5772</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01668</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01668" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5750-5772&issue=12&author=H.+Congauthor=L.+Xuauthor=Y.+Wuauthor=Z.+Quauthor=T.+Bianauthor=W.+Zhangauthor=C.+Xingauthor=C.+Zhuang&title=Inhibitor+of+Apoptosis+Protein+%28IAP%29+Antagonists+in+Anticancer+Agent+Discovery%3A+Current+Status+and+Perspectives&doi=10.1021%2Facs.jmedchem.8b01668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives</span></div><div class="casAuthors">Cong, Hui; Xu, Lijuan; Wu, Yougen; Qu, Zhuo; Bian, Tengfei; Zhang, Wannian; Xing, Chengguo; Zhuang, Chunlin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5750-5772</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Apoptosis, an important form of programmed cell death (PCD), is a tightly regulated cellular process to eliminate unwanted or damaged cells.  Resistance of apoptosis is a hallmark of cancer cells.  Inhibitor of apoptosis proteins (IAPs) is a class of key apoptosis regulators that promote cancer cell resistant to apoptosis, particularly in cancer treatment.  Disrupting the binding of IAPs with their functional partners therefore is a promising strategy to restore the apoptotic response to proapoptotic stimuli, particularly those introduced by std. cancer therapies.  The most successful example is the use of small mols. to mimic the IAP-binding motif of an endogenous IAP antagonist, second mitochondria-derived activator of caspase (SMAC).  Here we will review the functions of IAPs, the structural interactions of IAPs with SMAC, four generations of SMAC-mimetic IAP antagonists, and representative antagonists in clin. evaluations, focusing on research articles over the past 15 years.  Outlooks and perspectives on the assocd. challenges are provided as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokxBHQlIfyQrVg90H21EOLACvtfcHk0lgnz6XftOt-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWksrY%253D&md5=e3a0daceb7979f37d994f55b2323995e</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01668%26sid%3Dliteratum%253Aachs%26aulast%3DCong%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DZhuang%26aufirst%3DC.%26atitle%3DInhibitor%2520of%2520Apoptosis%2520Protein%2520%2528IAP%2529%2520Antagonists%2520in%2520Anticancer%2520Agent%2520Discovery%253A%2520Current%2520Status%2520and%2520Perspectives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5750%26epage%3D5772%26doi%3D10.1021%2Facs.jmedchem.8b01668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varfolomeev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenship, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dynek, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshayes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span> <span> </span><span class="NLM_article-title">IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2007.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18022362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSgurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=669-681&issue=4&author=E.+Varfolomeevauthor=J.+W.+Blankenshipauthor=S.+M.+Waysonauthor=A.+V.+Fedorovaauthor=N.+Kayagakiauthor=P.+Gargauthor=K.+Zobelauthor=J.+N.+Dynekauthor=L.+O.+Elliottauthor=H.+J.+A.+Wallweberauthor=J.+A.+Flygareauthor=W.+J.+Fairbrotherauthor=K.+Deshayesauthor=V.+M.+Dixitauthor=D.+Vucic&title=IAP+Antagonists+Induce+Autoubiquitination+of+c-IAPs%2C+NF-%CE%BAB+Activation%2C+and+TNF%CE%B1-Dependent+Apoptosis&doi=10.1016%2Fj.cell.2007.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis</span></div><div class="casAuthors">Varfolomeev, Eugene; Blankenship, John W.; Wayson, Sarah M.; Fedorova, Anna V.; Kayagaki, Nobuhiko; Garg, Parie; Zobel, Kerry; Dynek, Jasmin N.; Elliott, Linda O.; Wallweber, Heidi J. A.; Flygare, John A.; Fairbrother, Wayne J.; Deshayes, Kurt; Dixit, Vishva M.; Vucic, Domagoj</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">669-681</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibitor of apoptosis (IAP) proteins are antiapoptotic regulators that block cell death in response to diverse stimuli.  They are expressed at elevated levels in human malignancies and are attractive targets for the development of novel cancer therapeutics.  Herein, the authors demonstrate that small-mol. IAP antagonists bind to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of autoubiquitination activity and rapid proteasomal degrdn. of c-IAPs.  The IAP antagonists also induce cell death that is dependent on TNF signaling and de novo protein biosynthesis.  Addnl., the c-IAP proteins were found to function as regulators of NF-κB signaling.  Through their ubiquitin E3 ligase activities c-IAP1 and c-IAP2 promote proteasomal degrdn. of NIK, the central ser/thr kinase in the noncanonical NF-κB pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV7cKeBeR_hrVg90H21EOLACvtfcHk0lhY2jW39t_oug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSgurzF&md5=c9a255030cc26db0519680d170ba91f9</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DBlankenship%26aufirst%3DJ.%2BW.%26aulast%3DWayson%26aufirst%3DS.%2BM.%26aulast%3DFedorova%26aufirst%3DA.%2BV.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DDynek%26aufirst%3DJ.%2BN.%26aulast%3DElliott%26aufirst%3DL.%2BO.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26aulast%3DVucic%26aufirst%3DD.%26atitle%3DIAP%2520Antagonists%2520Induce%2520Autoubiquitination%2520of%2520c-IAPs%252C%2520NF-%25CE%25BAB%2520Activation%252C%2520and%2520TNF%25CE%25B1-Dependent%2520Apoptosis%26jtitle%3DCell%26date%3D2007%26volume%3D131%26issue%3D4%26spage%3D669%26epage%3D681%26doi%3D10.1016%2Fj.cell.2007.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vince, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benetatos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chunduru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinlay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverkus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tergaonkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callus, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koentgen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.10.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2007.10.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18022363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSgur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=682-693&issue=4&author=J.+E.+Vinceauthor=W.+W.-L.+Wongauthor=N.+Khanauthor=R.+Felthamauthor=D.+Chauauthor=A.+U.+Ahmedauthor=C.+A.+Benetatosauthor=S.+K.+Chunduruauthor=S.+M.+Condonauthor=M.+McKinlayauthor=R.+Brinkauthor=M.+Leverkusauthor=V.+Tergaonkarauthor=P.+Schneiderauthor=B.+A.+Callusauthor=F.+Koentgenauthor=D.+L.+Vauxauthor=J.+Silke&title=IAP+Antagonists+Target+cIAP1+to+Induce+TNF%CE%B1-Dependent+Apoptosis&doi=10.1016%2Fj.cell.2007.10.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis</span></div><div class="casAuthors">Vince, James E.; Wong, W. Wei-Lynn; Khan, Nufail; Feltham, Rebecca; Chau, Diep; Ahmed, Afsar U.; Benetatos, Christopher A.; Chunduru, Srinivas K.; Condon, Stephen M.; McKinlay, Mark; Brink, Robert; Leverkus, Martin; Tergaonkar, Vinay; Schneider, Pascal; Callus, Bernard A.; Koentgen, Frank; Vaux, David L.; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">682-693</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">XIAP prevents apoptosis by binding to and inhibiting caspases, and this inhibition can be relieved by IAP antagonists, such as Smac/DIABLO.  IAP antagonist compds. (IACs) have therefore been designed to inhibit XIAP to kill tumor cells.  Because XIAP inhibits postmitochondrial caspases, caspase 8 inhibitors should not block killing by IACs.  Instead, the authors show that apoptosis caused by an IAC is blocked by the caspase 8 inhibitor crmA and that IAP antagonists activate NF-κB signaling via inhibition of cIAP1.  In sensitive tumor lines, IAP antagonist induced NF-κB-stimulated prodn. of TNFα that killed cells in an autocrine fashion.  Inhibition of NF-κB reduced TNFα prodn., and blocking NF-κB activation or TNFα allowed tumor cells to survive IAC-induced apoptosis.  Cells treated with an IAC, or those in which cIAP1 was deleted, became sensitive to apoptosis induced by exogenous TNFα, suggesting novel uses of these compds. in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqNa8nssRGeLVg90H21EOLACvtfcHk0lhY2jW39t_oug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSgur3N&md5=9e973670c472d0612d947a2ffe688d20</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.037%26sid%3Dliteratum%253Aachs%26aulast%3DVince%26aufirst%3DJ.%2BE.%26aulast%3DWong%26aufirst%3DW.%2BW.-L.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DFeltham%26aufirst%3DR.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DA.%2BU.%26aulast%3DBenetatos%26aufirst%3DC.%2BA.%26aulast%3DChunduru%26aufirst%3DS.%2BK.%26aulast%3DCondon%26aufirst%3DS.%2BM.%26aulast%3DMcKinlay%26aufirst%3DM.%26aulast%3DBrink%26aufirst%3DR.%26aulast%3DLeverkus%26aufirst%3DM.%26aulast%3DTergaonkar%26aufirst%3DV.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DCallus%26aufirst%3DB.%2BA.%26aulast%3DKoentgen%26aufirst%3DF.%26aulast%3DVaux%26aufirst%3DD.%2BL.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DIAP%2520Antagonists%2520Target%2520cIAP1%2520to%2520Induce%2520TNF%25CE%25B1-Dependent%2520Apoptosis%26jtitle%3DCell%26date%3D2007%26volume%3D131%26issue%3D4%26spage%3D682%26epage%3D693%26doi%3D10.1016%2Fj.cell.2007.10.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">COHEN, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshayes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisner, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varfolomeev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WEN, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4101</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1021/jm300060k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300060k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4101-4113&issue=9&author=J.+A.+Flygareauthor=M.+Beresiniauthor=N.+Budhaauthor=H.+Chanauthor=I.+T.+Chanauthor=S.+Cheetiauthor=F.+COHENauthor=K.+Deshayesauthor=K.+Doernerauthor=S.+G.+Eckhardtauthor=L.+O.+Elliottauthor=B.+Fengauthor=M.+C.+Franklinauthor=S.+F.+Reisnerauthor=L.+Gazzardauthor=J.+Halladayauthor=S.+G.+Hymowitzauthor=H.+Laauthor=P.+LoRussoauthor=B.+Maurerauthor=L.+Murrayauthor=E.+Pliseauthor=C.+Quanauthor=J.-P.+Stephanauthor=S.+G.+Youngauthor=J.+Tomauthor=V.+Tsuiauthor=J.+Umauthor=E.+Varfolomeevauthor=D.+Vucicauthor=A.+J.+Wagnerauthor=H.+J.+A.+Wallweberauthor=L.+Wangauthor=J.+Wareauthor=Z.+WENauthor=H.+Wongauthor=J.+M.+Wongauthor=M.+Wongauthor=S.+Wongauthor=R.+Yuauthor=K.+Zobelauthor=W.+J.+Fairbrother&title=Discovery+of+a+Potent+Small-Molecule+Antagonist+of+Inhibitor+of+Apoptosis+%28IAP%29+Proteins+and+Clinical+Candidate+for+the+Treatment+of+Cancer+%28GDC-0152%29&doi=10.1021%2Fjm300060k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)</span></div><div class="casAuthors">Flygare, John A.; Beresini, Maureen; Budha, Nageshwar; Chan, Helen; Chan, Iris T.; Cheeti, Sravanthi; Cohen, Frederick; Deshayes, Kurt; Doerner, Karl; Eckhardt, S. Gail; Elliott, Linda O.; Feng, Bainian; Franklin, Matthew C.; Reisner, Stacy Frankovitz; Gazzard, Lewis; Halladay, Jason; Hymowitz, Sarah G.; La, Hank; LoRusso, Patricia; Maurer, Brigitte; Murray, Lesley; Plise, Emile; Quan, Clifford; Stephan, Jean-Philippe; Young, Shin G.; Tom, Jeffrey; Tsui, Vickie; Um, Joanne; Varfolomeev, Eugene; Vucic, Domagoj; Wagner, Andrew J.; Wallweber, Heidi J. A.; Wang, Lan; Ware, Joseph; Wen, Zhaoyang; Wong, Harvey; Wong, Jonathan M.; Wong, Melisa; Wong, Susan; Yu, Ron; Zobel, Kerry; Fairbrother, Wayne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4101-4113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac.  Compd. (I) (GDC-0152) has the best profile of these compds.; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with Ki values of 28, 14, 17, and 43 nM, resp.  These compds. promote degrdn. of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells.  Compd. I inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model.  Compd. I was advanced to human clin. trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested.  Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the vol. of distribution was 0.6 ± 0.2 L/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZSPNVJ5gVWrVg90H21EOLACvtfcHk0liQK1WdoPMcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D&md5=19452878ea834d3c324d567b39a78fb2</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm300060k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300060k%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBudha%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DI.%2BT.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DCOHEN%26aufirst%3DF.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DDoerner%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DElliott%26aufirst%3DL.%2BO.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DFranklin%26aufirst%3DM.%2BC.%26aulast%3DReisner%26aufirst%3DS.%2BF.%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DStephan%26aufirst%3DJ.-P.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DTom%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUm%26aufirst%3DJ.%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWare%26aufirst%3DJ.%26aulast%3DWEN%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Small-Molecule%2520Antagonist%2520of%2520Inhibitor%2520of%2520Apoptosis%2520%2528IAP%2529%2520Proteins%2520and%2520Clinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Cancer%2520%2528GDC-0152%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D9%26spage%3D4101%26epage%3D4113%26doi%3D10.1021%2Fjm300060k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolovska-Coleska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A Potent and Orally Active Antagonist (SM-406/at-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2714</span>– <span class="NLM_lpage">2726</span>, <span class="refDoi"> DOI: 10.1021/jm101505d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101505d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvV2hurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2714-2726&issue=8&author=Q.+Caiauthor=H.+Sunauthor=Y.+Pengauthor=J.+Luauthor=Z.+Nikolovska-Coleskaauthor=D.+McEachernauthor=L.+Liuauthor=S.+Qiuauthor=C.-Y.+Yangauthor=R.+Millerauthor=H.+Yiauthor=T.+Zhangauthor=D.+Sunauthor=S.+Kangauthor=M.+Guoauthor=L.+Leopoldauthor=D.+Yangauthor=S.+Wang&title=A+Potent+and+Orally+Active+Antagonist+%28SM-406%2Fat-406%29+of+Multiple+Inhibitor+of+Apoptosis+Proteins+%28IAPs%29+in+Clinical+Development+for+Cancer+Treatment&doi=10.1021%2Fjm101505d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment</span></div><div class="casAuthors">Cai, Qian; Sun, Haiying; Peng, Yuefeng; Lu, Jianfeng; Nikolovska-Coleska, Zaneta; McEachern, Donna; Liu, Liu; Qiu, Su; Yang, Chao-Yie; Miller, Rebecca; Yi, Han; Zhang, Tao; Sun, Duxin; Kang, Sanmao; Guo, Ming; Leopold, Lance; Yang, Dajun; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2714-2726</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the discovery and characterization of SM-406 (compd. 2), a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs).  This compd. binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, resp.  Compd. 2 effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degrdn. of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines.  It has good oral bioavailability in mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth.  Compd. 2 is currently in phase I clin. trials for the treatment of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgYOZBCwfnLrVg90H21EOLACvtfcHk0liQK1WdoPMcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvV2hurg%253D&md5=5b73a2ea1a5a2a6b3e3f4c978b49706f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm101505d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101505d%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520Potent%2520and%2520Orally%2520Active%2520Antagonist%2520%2528SM-406%252Fat-406%2529%2520of%2520Multiple%2520Inhibitor%2520of%2520Apoptosis%2520Proteins%2520%2528IAPs%2529%2520in%2520Clinical%2520Development%2520for%2520Cancer%2520Treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D8%26spage%3D2714%26epage%3D2726%26doi%3D10.1021%2Fjm101505d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millemaggi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peakman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilsher, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span> <span> </span><span class="NLM_article-title">A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1<i>H</i>,2<i>H</i>,3<i>H</i>-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2<i>R</i>,5<i>R</i>)-5-methyl-2-([(3<i>R</i>)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7314</span>– <span class="NLM_lpage">7329</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00900</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00900" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7314-7329&issue=16&author=C.+N.+Johnsonauthor=J.+S.+Ahnauthor=I.+M.+Buckauthor=E.+Chiarparinauthor=J.+E.+H.+Dayauthor=A.+Hopkinsauthor=S.+Howardauthor=E.+J.+Lewisauthor=V.+Martinsauthor=A.+Millemaggiauthor=J.+M.+Munckauthor=L.+W.+Pageauthor=T.+Peakmanauthor=M.+Readerauthor=S.+J.+Richauthor=G.+Saxtyauthor=T.+Smythauthor=N.+T.+Thompsonauthor=G.+A.+Wardauthor=P.+A.+Williamsauthor=N.+E.+Wilsherauthor=G.+Chessari&title=A+Fragment-Derived+Clinical+Candidate+for+Antagonism+of+X-Linked+and+Cellular+Inhibitor+of+Apoptosis+Proteins%3A+1-%286-%5B%284-Fluorophenyl%29methyl%5D-5-%28hydroxymethyl%29-3%2C3-dimethyl-1H%2C2H%2C3H-pyrrolo%5B3%2C2-b%5Dpyridin-1-yl%29-2-%5B%282R%2C5R%29-5-methyl-2-%28%5B%283R%29-3-methylmorpholin-4-yl%5Dmethyl%29piperazin-1-yl%5Dethan-1-one+%28ASTX660%29&doi=10.1021%2Facs.jmedchem.8b00900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2R,5R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)</span></div><div class="casAuthors">Johnson, Christopher N.; Ahn, Jong Sook; Buck, Ildiko M.; Chiarparin, Elisabetta; Day, James E. H.; Hopkins, Anna; Howard, Steven; Lewis, Edward J.; Martins, Vanessa; Millemaggi, Alessia; Munck, Joanne M.; Page, Lee W.; Peakman, Torren; Reader, Michael; Rich, Sharna J.; Saxty, Gordon; Smyth, Tomoko; Thompson, Neil T.; Ward, George A.; Williams, Pamela A.; Wilsher, Nicola E.; Chessari, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7314-7329</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitor of apoptosis proteins (IAPs) are promising anticancer targets, given their roles in the evasion of apoptosis.  Several peptidomimetic IAP antagonists, with inherent selectivity for cellular IAP (cIAP) over X-linked IAP (XIAP), have been tested in the clinic.  A fragment screening approach followed by structure-based optimization has previously been reported that resulted in a low-nanomolar cIAP1 and XIAP antagonist lead mol. with a more balanced cIAP-XIAP profile.  We now report the further structure-guided optimization of the lead, with a view to improving the metabolic stability and cardiac safety profile, to give the nonpeptidomimetic antagonist clin. candidate (ASTX660), currently being tested in a phase 1/2 clin. trial (NCT02503423).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBj2OOs5EG-7Vg90H21EOLACvtfcHk0lhmB9uUB9wsFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKhtr7P&md5=9c7ca5775f42441c971ad8459bb129c2</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00900%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DBuck%26aufirst%3DI.%2BM.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DDay%26aufirst%3DJ.%2BE.%2BH.%26aulast%3DHopkins%26aufirst%3DA.%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMillemaggi%26aufirst%3DA.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DPage%26aufirst%3DL.%2BW.%26aulast%3DPeakman%26aufirst%3DT.%26aulast%3DReader%26aufirst%3DM.%26aulast%3DRich%26aufirst%3DS.%2BJ.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSmyth%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWard%26aufirst%3DG.%2BA.%26aulast%3DWilliams%26aufirst%3DP.%2BA.%26aulast%3DWilsher%26aufirst%3DN.%2BE.%26aulast%3DChessari%26aufirst%3DG.%26atitle%3DA%2520Fragment-Derived%2520Clinical%2520Candidate%2520for%2520Antagonism%2520of%2520X-Linked%2520and%2520Cellular%2520Inhibitor%2520of%2520Apoptosis%2520Proteins%253A%25201-%25286-%255B%25284-Fluorophenyl%2529methyl%255D-5-%2528hydroxymethyl%2529-3%252C3-dimethyl-1H%252C2H%252C3H-pyrrolo%255B3%252C2-b%255Dpyridin-1-yl%2529-2-%255B%25282R%252C5R%2529-5-methyl-2-%2528%255B%25283R%2529-3-methylmorpholin-4-yl%255Dmethyl%2529piperazin-1-yl%255Dethan-1-one%2520%2528ASTX660%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D16%26spage%3D7314%26epage%3D7329%26doi%3D10.1021%2Facs.jmedchem.8b00900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dueber, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffler, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varfolomeev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshayes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span> <span> </span><span class="NLM_article-title">Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">6054</span>),  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1126/science.1207862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1207862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22021857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlahsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=376-380&issue=6054&author=E.+C.+Dueberauthor=A.+J.+Schoefflerauthor=A.+Lingelauthor=J.+M.+Elliottauthor=A.+V.+Fedorovaauthor=A.+M.+Giannettiauthor=K.+Zobelauthor=B.+Maurerauthor=E.+Varfolomeevauthor=P.+Wuauthor=H.+J.+A.+Wallweberauthor=S.+G.+Hymowitzauthor=K.+Deshayesauthor=D.+Vucicauthor=W.+J.+Fairbrother&title=Antagonists+Induce+a+Conformational+Change+in+cIAP1+That+Promotes+Autoubiquitination&doi=10.1126%2Fscience.1207862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination</span></div><div class="casAuthors">Dueber, Erin C.; Schoeffler, Allyn J.; Lingel, Andreas; Elliott, J. Michael; Fedorova, Anna V.; Giannetti, Anthony M.; Zobel, Kerry; Maurer, Brigitte; Varfolomeev, Eugene; Wu, Ping; Wallweber, Heidi J. A.; Hymowitz, Sarah G.; Deshayes, Kurt; Vucic, Domagoj; Fairbrother, Wayne J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6054</span>),
    <span class="NLM_cas:pages">376-380</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Inhibitor of apoptosis (IAP) proteins are neg. regulators of cell death.  IAP family members contain RING domains that impart E3 ubiquitin ligase activity.  Binding of endogenous or small-mol. antagonists to select baculovirus IAP repeat (BIR) domains within cellular IAP (cIAP) proteins promotes autoubiquitination and proteasomal degrdn. and so releases inhibition of apoptosis mediated by cIAP.  Although the mol. details of antagonist-BIR domain interactions are well understood, it is not clear how this binding event influences the activity of the RING domain.  Here biochem. and structural studies reveal that the unliganded, multidomain cIAP1 sequesters the RING domain within a compact, monomeric structure that prevents RING dimerization.  Antagonist binding induces conformational rearrangements that enable RING dimerization and formation of the active E3 ligase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLt33kw3IgQLVg90H21EOLACvtfcHk0lhmB9uUB9wsFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlahsrzJ&md5=eeaaac9b5ad01f6c1f7fc062d54204d0</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1126%2Fscience.1207862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1207862%26sid%3Dliteratum%253Aachs%26aulast%3DDueber%26aufirst%3DE.%2BC.%26aulast%3DSchoeffler%26aufirst%3DA.%2BJ.%26aulast%3DLingel%26aufirst%3DA.%26aulast%3DElliott%26aufirst%3DJ.%2BM.%26aulast%3DFedorova%26aufirst%3DA.%2BV.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26atitle%3DAntagonists%2520Induce%2520a%2520Conformational%2520Change%2520in%2520cIAP1%2520That%2520Promotes%2520Autoubiquitination%26jtitle%3DScience%26date%3D2011%26volume%3D334%26issue%3D6054%26spage%3D376%26epage%3D380%26doi%3D10.1126%2Fscience.1207862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span> <span> </span><span class="NLM_article-title">A Covalently Bound Inhibitor Triggers EZH2 Degradation Through CHIP-Mediated Ubiquitination</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.15252/embj.201694058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.15252%2Fembj.201694058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28320739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=1243-1260&issue=9&author=X.+Wangauthor=W.+Caoauthor=J.+Zhangauthor=M.+Yanauthor=Q.+Xuauthor=X.+Wuauthor=L.+Wanauthor=Z.+Zhangauthor=C.+Zhangauthor=X.+Qinauthor=M.+Xiaoauthor=D.+Yeauthor=Y.+Liuauthor=Z.+Hanauthor=S.+Wangauthor=L.+Maoauthor=W.+Weiauthor=W.+Chen&title=A+Covalently+Bound+Inhibitor+Triggers+EZH2+Degradation+Through+CHIP-Mediated+Ubiquitination&doi=10.15252%2Fembj.201694058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination</span></div><div class="casAuthors">Wang, Xu; Cao, Wei; Zhang, Jianjun; Yan, Ming; Xu, Qin; Wu, Xiangbing; Wan, Lixin; Zhang, Zhiyuan; Zhang, Chenping; Qin, Xing; Xiao, Meng; Ye, Dongxia; Liu, Yuyang; Han, Zeguang; Wang, Shaomeng; Mao, Li; Wei, Wenyi; Chen, Wantao</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1243-1260</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Enhancer of zeste homolog 2 (EZH2) has been characterized as a crit. oncogene and a promising drug target in human malignant tumors.  The current EZH2 inhibitors strongly suppress the enhanced enzymic function of mutant EZH2 in some lymphomas.  However, the recent identification of a PRC2- and methyltransferase-independent role of EZH2 indicates that a complete suppression of all oncogenic functions of EZH2 is needed.  Here, we report a unique EZH2-targeting strategy by identifying a gambogenic acid (GNA) deriv. as a novel agent that specifically and covalently bound to Cys668 within the EZH2-SET domain, triggering EZH2 degrdn. through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.  This class of inhibitors significantly suppressed H3K27Me3 and effectively reactivated polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes.  Moreover, the novel inhibitors significantly suppressed tumor growth in an EZH2-dependent manner, and tumors bearing a non-GNA-interacting C668S-EZH2 mutation exhibited resistance to the inhibitors.  Together, our results identify the inhibition of the signaling pathway that governs GNA-mediated destruction of EZH2 as a promising anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRQknSdWy5T7Vg90H21EOLACvtfcHk0lhmB9uUB9wsFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksFSisr0%253D&md5=b9b8a266537e2922648784d9cd4edf02</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.15252%2Fembj.201694058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201694058%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26atitle%3DA%2520Covalently%2520Bound%2520Inhibitor%2520Triggers%2520EZH2%2520Degradation%2520Through%2520CHIP-Mediated%2520Ubiquitination%26jtitle%3DEMBO%2520J.%26date%3D2017%26volume%3D36%26issue%3D9%26spage%3D1243%26epage%3D1260%26doi%3D10.15252%2Fembj.201694058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, K.</span></span> <span> </span><span class="NLM_article-title">Polycomb Group Proteins: Navigators of Lineage Pathways Led Astray in Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrc2736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc2736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19851313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=773-784&issue=11&author=A.+P.+Brackenauthor=K.+Helin&title=Polycomb+Group+Proteins%3A+Navigators+of+Lineage+Pathways+Led+Astray+in+Cancer&doi=10.1038%2Fnrc2736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb group proteins: navigators of lineage pathways led astray in cancer</span></div><div class="casAuthors">Bracken, Adrian P.; Helin, Kristian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">773-784</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Polycomb group (PcG) proteins are transcriptional repressors that regulate lineage choices during development and differentiation.  Recent studies have advanced our understanding of how the PcG proteins regulate cell fate decisions and how their deregulation potentially contributes to cancer.  In this Review we discuss the emerging roles of long non-coding RNAs (ncRNAs) and a subset of transcription factors, which we call cell fate transcription factors, in the regulation of PcG assocn. with target genes.  We also speculate about how their deregulation contributes to tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJw0rl14G2LVg90H21EOLACvtfcHk0lhop2kWwnQRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtbbE&md5=3c8cdededb7febba1acb0da897c2e8d7</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrc2736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2736%26sid%3Dliteratum%253Aachs%26aulast%3DBracken%26aufirst%3DA.%2BP.%26aulast%3DHelin%26aufirst%3DK.%26atitle%3DPolycomb%2520Group%2520Proteins%253A%2520Navigators%2520of%2520Lineage%2520Pathways%2520Led%2520Astray%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D11%26spage%3D773%26epage%3D784%26doi%3D10.1038%2Fnrc2736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5595</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1126/science.1076997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1076997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12351676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1039-1043&issue=5595&author=R.+Caoauthor=L.+Wangauthor=H.+Wangauthor=L.+Xiaauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=R.+S.+Jonesauthor=Y.+Zhang&title=Role+of+Histone+H3+Lysine+27+Methylation+in+Polycomb-Group+Silencing&doi=10.1126%2Fscience.1076997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing</span></div><div class="casAuthors">Cao, Ru; Wang, Liangjun; Wang, Hengbin; Xia, Li; Erdjument-Bromage, Hediye; Tempst, Paul; Jones, Richard S.; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5595</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Polycomb group (PcG) proteins play important roles in maintaining the silent state of HOX genes.  Recent studies have implicated histone methylation in long-term gene silencing.  However, a connection between PcG-mediated gene silencing and histone methylation has not been established.  Here the authors report the purifn. and characterization of an EED-EZH2 complex, the human counterpart of the Drosophila ESC-E(Z) complex.  They demonstrate that the complex specifically methylates nucleosomal histone H3 at lysine 27 (H3-K27).  Using chromatin immunopptn. assays, the authors show that H3-K27 methylation colocalizes with, and is dependent on, E(Z) binding at an Ultrabithorax med° (Ubx) Polycomb response element (PRE), and that this methylation correlates with Ubx repression.  Methylation on H3-K27 facilitates binding of Polycomb (PC), a component of the PRC1 complex, to histone H3 amino-terminal tail.  Thus, these studies establish a link between histone methylation and PcG-mediated gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnqusXKZEbLVg90H21EOLACvtfcHk0lhop2kWwnQRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12rs7g%253D&md5=8f24c05ec935c9110b2ff85b65911396</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1126%2Fscience.1076997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1076997%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DR.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DRole%2520of%2520Histone%2520H3%2520Lysine%252027%2520Methylation%2520in%2520Polycomb-Group%2520Silencing%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5595%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1076997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ezhkova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasolli, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarakhovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, E.</span></span> <span> </span><span class="NLM_article-title">Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2008.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19303854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=1122-1135&issue=6&author=E.+Ezhkovaauthor=H.+A.+Pasolliauthor=J.+S.+Parkerauthor=N.+Stokesauthor=I.-H.+Suauthor=G.+Hannonauthor=A.+Tarakhovskyauthor=E.+Fuchs&title=Ezh2+Orchestrates+Gene+Expression+for+the+Stepwise+Differentiation+of+Tissue-Specific+Stem+Cells&doi=10.1016%2Fj.cell.2008.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells</span></div><div class="casAuthors">Ezhkova, Elena; Pasolli, H. Amalia; Parker, Joel S.; Stokes, Nicole; Su, I.-hsin; Hannon, Gregory; Tarakhovsky, Alexander; Fuchs, Elaine</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1122-1135</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although in vitro studies of embryonic stem cells have identified polycomb repressor complexes (PRCs) as key regulators of differentiation, it remains unclear as to how PRC-mediated mechanisms control fates of multipotent progenitors in developing tissues.  Here, we show that an essential PRC component, Ezh2, is expressed in epidermal progenitors but diminishes concomitant with embryonic differentiation and with postnatal decline in proliferative activity.  We show that Ezh2 controls proliferative potential of basal progenitors by repressing the Ink4A-Ink4B locus and tempers the developmental rate of differentiation by preventing premature recruitment of AP1 transcriptional activator to the structural genes that are required for epidermal differentiation.  Together, our studies reveal that PRCs control epigenetic modifications temporally and spatially in tissue-restricted stem cells.  They maintain their proliferative potential and globally repressing undesirable differentiation programs while selectively establishing a specific terminal differentiation program in a stepwise fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEXB1DFBAlB7Vg90H21EOLACvtfcHk0lhop2kWwnQRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnt70%253D&md5=0dd92cb7797a1459b766a3b492946995</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DEzhkova%26aufirst%3DE.%26aulast%3DPasolli%26aufirst%3DH.%2BA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DStokes%26aufirst%3DN.%26aulast%3DSu%26aufirst%3DI.-H.%26aulast%3DHannon%26aufirst%3DG.%26aulast%3DTarakhovsky%26aufirst%3DA.%26aulast%3DFuchs%26aufirst%3DE.%26atitle%3DEzh2%2520Orchestrates%2520Gene%2520Expression%2520for%2520the%2520Stepwise%2520Differentiation%2520of%2520Tissue-Specific%2520Stem%2520Cells%26jtitle%3DCell%26date%3D2009%26volume%3D136%26issue%3D6%26spage%3D1122%26epage%3D1135%26doi%3D10.1016%2Fj.cell.2008.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span> <span> </span><span class="NLM_article-title">The Epigenomics of Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2007.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17320506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12ju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=683-692&issue=4&author=P.+A.+Jonesauthor=S.+B.+Baylin&title=The+Epigenomics+of+Cancer&doi=10.1016%2Fj.cell.2007.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The epigenomics of cancer</span></div><div class="casAuthors">Jones, Peter A.; Baylin, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">683-692</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Aberrant gene function and altered patterns of gene expression are key features of cancer.  Growing evidence shows that acquired epigenetic abnormalities participate with genetic alterations to cause this dysregulation.  Here, we review recent advances in understanding how epigenetic alterations participate in the earliest stages of neoplasia, including stem/precursor cell contributions, and discuss the growing implications of these advances for strategies to control cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPBpHNAkcSPbVg90H21EOLACvtfcHk0likP-7cM73H-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12ju7k%253D&md5=78eac8ecc093f1aed0acbfd578f34717</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BA.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DThe%2520Epigenomics%2520of%2520Cancer%26jtitle%3DCell%26date%3D2007%26volume%3D128%26issue%3D4%26spage%3D683%26epage%3D692%26doi%3D10.1016%2Fj.cell.2007.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleer, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewalt, R. G. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabel, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">EZH2 Is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">11606</span>– <span class="NLM_lpage">11611</span>, <span class="refDoi"> DOI: 10.1073/pnas.1933744100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.1933744100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=14500907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFKmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11606-11611&issue=20&author=C.+G.+Kleerauthor=Q.+Caoauthor=S.+Varamballyauthor=R.+Shenauthor=I.+Otaauthor=S.+A.+Tomlinsauthor=D.+Ghoshauthor=R.+G.+A.+B.+Sewaltauthor=A.+P.+Otteauthor=D.+F.+Hayesauthor=M.+S.+Sabelauthor=D.+Livantauthor=S.+J.+Weissauthor=M.+A.+Rubinauthor=A.+M.+Chinnaiyan&title=EZH2+Is+a+Marker+of+Aggressive+Breast+Cancer+and+Promotes+Neoplastic+Transformation+of+Breast+Epithelial+Cells&doi=10.1073%2Fpnas.1933744100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells</span></div><div class="casAuthors">Kleer, Celina G.; Cao, Qi; Varambally, Sooryanarayana; Shen, Ronglai; Ota, Ichiro; Tomlins, Scott A.; Ghosh, Debashis; Sewalt, Richard G. A. B.; Otte, Arie P.; Hayes, Daniel F.; Sabel, Michael S.; Livant, Donna; Weiss, Stephen J.; Rubin, Mark A.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11606-11611</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer.  Here the authors investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression.  EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia.  Tissue microarray anal., which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly assocd. with breast cancer aggressiveness.  Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion.  EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity.  This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV3vRwhSLDh7Vg90H21EOLACvtfcHk0likP-7cM73H-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFKmt7g%253D&md5=a362e2d0f3c61c8e8b3afd5cea992255</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1933744100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1933744100%26sid%3Dliteratum%253Aachs%26aulast%3DKleer%26aufirst%3DC.%2BG.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DOta%26aufirst%3DI.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DSewalt%26aufirst%3DR.%2BG.%2BA.%2BB.%26aulast%3DOtte%26aufirst%3DA.%2BP.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DSabel%26aufirst%3DM.%2BS.%26aulast%3DLivant%26aufirst%3DD.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DEZH2%2520Is%2520a%2520Marker%2520of%2520Aggressive%2520Breast%2520Cancer%2520and%2520Promotes%2520Neoplastic%2520Transformation%2520of%2520Breast%2520Epithelial%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26issue%3D20%26spage%3D11606%26epage%3D11611%26doi%3D10.1073%2Fpnas.1933744100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamochi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwabi-Addo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P. J.</span></span> <span> </span><span class="NLM_article-title">Gene Silencing in Cancer by Histone H3 Lysine 27 Trimethylation Independent of Promoter DNA Methylation</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1038/ng.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=18488029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVejtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=741-750&issue=6&author=Y.+Kondoauthor=L.+Shenauthor=A.+S.+Chengauthor=S.+Ahmedauthor=Y.+Boumberauthor=C.+Charoauthor=T.+Yamochiauthor=T.+Uranoauthor=K.+Furukawaauthor=B.+Kwabi-Addoauthor=D.+L.+Goldauthor=Y.+Sekidoauthor=T.+H.-M.+Huangauthor=J.-P.+J.+Issa&title=Gene+Silencing+in+Cancer+by+Histone+H3+Lysine+27+Trimethylation+Independent+of+Promoter+DNA+Methylation&doi=10.1038%2Fng.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation</span></div><div class="casAuthors">Kondo, Yutaka; Shen, Lanlan; Cheng, Alfred S.; Ahmed, Saira; Boumber, Yanis; Charo, Chantale; Yamochi, Tadanori; Urano, Takeshi; Furukawa, Koichi; Kwabi-Addo, Bernard; Gold, David L.; Sekido, Yoshitaka; Huang, Tim Hui-Ming; Issa, Jean-Pierre J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">741-750</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic silencing in cancer cells is mediated by at least two distinct histone modifications, polycomb-based histone H3 lysine 27 trimethylation (H3K27triM) and H3K9 dimethylation.  The relationship between DNA hypermethylation and these histone modifications is not completely understood.  Using chromatin immunopptn. microarrays (ChIP-chip) in prostate cancer cells compared to normal prostate, we found that up to 5% of promoters (16% CpG islands and 84% non-CpG islands) were enriched with H3K27triM.  These genes were silenced specifically in prostate cancer, and those CpG islands affected showed low levels of DNA methylation.  Downregulation of the EZH2 histone methyltransferase restored expression of the H3K27triM target genes alone or in synergy with histone deacetylase inhibition, without affecting promoter DNA methylation, and with no effect on the expression of genes silenced by DNA hypermethylation.  These data establish EZH2-mediated H3K27triM as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1sXzleyaabVg90H21EOLACvtfcHk0likP-7cM73H-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVejtro%253D&md5=065aada76322ddbc2e8d4b25bd245748</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fng.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.159%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DA.%2BS.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBoumber%26aufirst%3DY.%26aulast%3DCharo%26aufirst%3DC.%26aulast%3DYamochi%26aufirst%3DT.%26aulast%3DUrano%26aufirst%3DT.%26aulast%3DFurukawa%26aufirst%3DK.%26aulast%3DKwabi-Addo%26aufirst%3DB.%26aulast%3DGold%26aufirst%3DD.%2BL.%26aulast%3DSekido%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DT.%2BH.-M.%26aulast%3DIssa%26aufirst%3DJ.-P.%2BJ.%26atitle%3DGene%2520Silencing%2520in%2520Cancer%2520by%2520Histone%2520H3%2520Lysine%252027%2520Trimethylation%2520Independent%2520of%2520Promoter%2520DNA%2520Methylation%26jtitle%3DNat.%2520Genet.%26date%3D2008%26volume%3D40%26issue%3D6%26spage%3D741%26epage%3D750%26doi%3D10.1038%2Fng.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lohuizen, M.</span></span> <span> </span><span class="NLM_article-title">Polycomb Silencers Control Cell Fate, Development and Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1038/nrc1991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnrc1991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17060944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=846-856&issue=11&author=A.+Sparmannauthor=M.+van+Lohuizen&title=Polycomb+Silencers+Control+Cell+Fate%2C+Development+and+Cancer&doi=10.1038%2Fnrc1991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Polycomb silencers control cell fate, development and cancer</span></div><div class="casAuthors">Sparmann, Anke; van Lohuizen, Maarten</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">846-856</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polycomb group (PcG) proteins are epigenetic gene silencers that are implicated in neoplastic development.  Their oncogenic function might be assocd. with their well-established role in the maintenance of embryonic and adult stem cells.  In this review, we discuss new insights into the possible mechanisms by which PcGs regulate cellular identity, and speculate how these functions might be relevant during tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGIpKu4D8YBLVg90H21EOLACvtfcHk0lg4-AfV5-7IzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bE&md5=6ae0b0ef2360828615cd56872cb0ab3b</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fnrc1991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1991%26sid%3Dliteratum%253Aachs%26aulast%3DSparmann%26aufirst%3DA.%26aulast%3Dvan%2BLohuizen%26aufirst%3DM.%26atitle%3DPolycomb%2520Silencers%2520Control%2520Cell%2520Fate%252C%2520Development%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26issue%3D11%26spage%3D846%26epage%3D856%26doi%3D10.1038%2Fnrc1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunizaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyokawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maejima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponder, B. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, R.</span></span> <span> </span><span class="NLM_article-title">Validation of the Histone Methyltransferase EZH2 as a Therapeutic Target for Various Types of Human Cancer and as a Prognostic Marker</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1298</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2011.01958.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1111%2Fj.1349-7006.2011.01958.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21539681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2011&pages=1298-1305&issue=7&author=M.+Takawaauthor=K.+Masudaauthor=M.+Kunizakiauthor=Y.+Daigoauthor=K.+Takagiauthor=Y.+Iwaiauthor=H.-S.+Choauthor=G.+Toyokawaauthor=Y.+Yamaneauthor=K.+Maejimaauthor=H.+I.+Fieldauthor=T.+Kobayashiauthor=T.+Akasuauthor=M.+Sugiyamaauthor=E.+Tsuchiyaauthor=Y.+Atomiauthor=B.+A.+J.+Ponderauthor=Y.+Nakamuraauthor=R.+Hamamoto&title=Validation+of+the+Histone+Methyltransferase+EZH2+as+a+Therapeutic+Target+for+Various+Types+of+Human+Cancer+and+as+a+Prognostic+Marker&doi=10.1111%2Fj.1349-7006.2011.01958.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker</span></div><div class="casAuthors">Takawa, Masashi; Masuda, Ken; Kunizaki, Masaki; Daigo, Yataro; Takagi, Katsunori; Iwai, Yukiko; Cho, Hyun-Soo; Toyokawa, Gouji; Yamane, Yuka; Maejima, Kazuhiro; Field, Helen I.; Kobayashi, Takaaki; Akasu, Takayuki; Sugiyama, Masanori; Tsuchiya, Eijyu; Atomi, Yutaka; Ponder, Bruce A. J.; Nakamura, Yusuke; Hamamoto, Ryuji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1298-1305</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The emphasis in anticancer drug discovery has always been on finding a drug with great antitumor potential but few side-effects.  This can be achieved if the drug is specific for a mol. site found only in tumor cells.  Here, we find the enhancer of zeste homolog 2 (EZH2) to be highly overexpressed in lung and other cancers, and show that EZH2 is integral to proliferation in cancer cells.  Quant. real-time PCR anal. revealed higher expression of EZH2 in clin. bladder cancer tissues than in corresponding non-neoplastic tissues (P < 0.0001), and we confirmed that a wide range of cancers also overexpress EZH2, using cDNA microarray anal.  Immunohistochem. anal. showed pos. staining for EZH2 in 14 of 29 cases of bladder cancer, 135 of 292 cases of non-small-cell lung cancer (NSCLC), and 214 of 245 cases of colorectal cancer, whereas no significant staining was obsd. in various normal tissues.  We found elevated expression of EZH2 to be assocd. with poor prognosis for patients with NSCLC (P = 0.0239).  In lung and bladder cancer cells overexpressing EZH2, suppression of EZH2 using specific siRNAs inhibited incorporation of BrdU and resulted in significant suppression of cell growth, even though no significant effect was obsd. in the normal cell strain CCD-18Co, which has undetectable EZH2.  Because EZH2 expression was scarcely detectable in all normal tissues we examd., EZH2 shows promise as a tumor-specific therapeutic target.  Furthermore, as elevated levels of EZH2 are assocd. with poor prognosis of patients with NSCLC, its overexpression in resected specimens could prove a useful mol. marker, indicating the necessity for a more extensive follow-up in some lung cancer patients after surgical treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbQobKk1jwgrVg90H21EOLACvtfcHk0lg4-AfV5-7IzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSiu74%253D&md5=52f1ab04ee004f5cef50db8d1297facf</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2011.01958.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2011.01958.x%26sid%3Dliteratum%253Aachs%26aulast%3DTakawa%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DKunizaki%26aufirst%3DM.%26aulast%3DDaigo%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DK.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.-S.%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DYamane%26aufirst%3DY.%26aulast%3DMaejima%26aufirst%3DK.%26aulast%3DField%26aufirst%3DH.%2BI.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAkasu%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTsuchiya%26aufirst%3DE.%26aulast%3DAtomi%26aufirst%3DY.%26aulast%3DPonder%26aufirst%3DB.%2BA.%2BJ.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DHamamoto%26aufirst%3DR.%26atitle%3DValidation%2520of%2520the%2520Histone%2520Methyltransferase%2520EZH2%2520as%2520a%2520Therapeutic%2520Target%2520for%2520Various%2520Types%2520of%2520Human%2520Cancer%2520and%2520as%2520a%2520Prognostic%2520Marker%26jtitle%3DCancer%2520Sci.%26date%3D2011%26volume%3D102%26issue%3D7%26spage%3D1298%26epage%3D1305%26doi%3D10.1111%2Fj.1349-7006.2011.01958.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varambally, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasekaran, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrette, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar-Sinha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewalt, R. G. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">The Polycomb Group Protein EZH2 Is Involved in Progression of Prostate Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>419</i></span> (<span class="NLM_issue">6907</span>),  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1038/nature01075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature01075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=12374981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD38Xns1Ontrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=419&publication_year=2002&pages=624-629&issue=6907&author=S.+Varamballyauthor=S.+M.+Dhanasekaranauthor=M.+Zhouauthor=T.+R.+Barretteauthor=C.+Kumar-Sinhaauthor=M.+G.+Sandaauthor=D.+Ghoshauthor=K.+J.+Pientaauthor=R.+G.+A.+B.+Sewaltauthor=A.+P.+Otteauthor=M.+A.+Rubinauthor=A.+M.+Chinnaiyan&title=The+Polycomb+Group+Protein+EZH2+Is+Involved+in+Progression+of+Prostate+Cancer&doi=10.1038%2Fnature01075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The polycomb group protein EZH2 is involved in progression of prostate cancer</span></div><div class="casAuthors">Varambally, Sooryanarayana; Dhanasekaran, Saravana M.; Zhou, Ming; Barrette, Terrence R.; Kumar-Sinha, Chandan; Sanda, Martin G.; Ghosh, Debashis; Pienta, Kenneth J.; Sewalt, Richard G. A. B.; Otte, Arie P.; Rubin, Mark A.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">419</span>
        (<span class="NLM_cas:issue">6907</span>),
    <span class="NLM_cas:pages">624-629</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Prostate cancer is a leading cause of cancer-related death in males and is second only to lung cancer.  Although effective surgical and radiation treatments exist for clin. localized prostate cancer, metastatic prostate cancer remains essentially incurable.  Here we show, through gene expression profiling, that the polycomb group protein enhancer of zeste homolog 2 (EZH2) is overexpressed in hormone-refractory, metastatic prostate cancer.  Small interfering RNA (siRNA) duplexes targeted against EZH2 reduce the amts. of EZH2 protein present in prostate cells and also inhibit cell proliferation in vitro.  Ectopic expression of EZH2 in prostate cells induces transcriptional repression of a specific cohort of genes.  Gene silencing mediated by EZH2 requires the SET domain and is attenuated by inhibiting histone deacetylase activity.  Amts. of both EZH2 mRNA and EZH2 protein are increased in metastatic prostate cancer; in addn., clin. localized prostate cancers that express higher concns. of EZH2 show a poorer prognosis.  Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression.  Supplementary information on the gene expression profile can be obtained at: http://www.nature.com/nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfW_h7gunzd7Vg90H21EOLACvtfcHk0lg4-AfV5-7IzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xns1Ontrk%253D&md5=c38f80915b4183472aa7be4f9f3ecc67</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnature01075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01075%26sid%3Dliteratum%253Aachs%26aulast%3DVarambally%26aufirst%3DS.%26aulast%3DDhanasekaran%26aufirst%3DS.%2BM.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBarrette%26aufirst%3DT.%2BR.%26aulast%3DKumar-Sinha%26aufirst%3DC.%26aulast%3DSanda%26aufirst%3DM.%2BG.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DSewalt%26aufirst%3DR.%2BG.%2BA.%2BB.%26aulast%3DOtte%26aufirst%3DA.%2BP.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Polycomb%2520Group%2520Protein%2520EZH2%2520Is%2520Involved%2520in%2520Progression%2520of%2520Prostate%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D419%26issue%3D6907%26spage%3D624%26epage%3D629%26doi%3D10.1038%2Fnature01075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minoshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warholic, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uesugi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter-Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uenaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilhack, H.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1535-7163.MCT-13-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24563539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=842-854&issue=4&author=S.+K.+Knutsonauthor=S.+Kawanoauthor=Y.+Minoshimaauthor=N.+M.+Warholicauthor=K.-C.+Huangauthor=Y.+Xiaoauthor=T.+Kadowakiauthor=M.+Uesugiauthor=G.+Kuznetsovauthor=N.+Kumarauthor=T.+J.+Wigleauthor=C.+R.+Klausauthor=C.+J.+Allainauthor=A.+Raimondiauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+Porter-Scottauthor=R.+Chesworthauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=V.+M.+Richonauthor=T.+Uenakaauthor=R.+M.+Pollockauthor=K.+W.+Kuntzauthor=A.+Yokoiauthor=H.+Keilhack&title=Selective+Inhibition+of+EZH2+by+EPZ-6438+Leads+to+Potent+Antitumor+Activity+in+EZH2-Mutant+Non-Hodgkin+Lymphoma&doi=10.1158%2F1535-7163.MCT-13-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma</span></div><div class="casAuthors">Knutson, Sarah K.; Kawano, Satoshi; Minoshima, Yukinori; Warholic, Natalie M.; Huang, Kuan-Chun; Xiao, Yonghong; Kadowaki, Tadashi; Uesugi, Mai; Kuznetsov, Galina; Kumar, Namita; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Waters, Nigel J.; Smith, Jesse J.; Porter-Scott, Margaret; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Uenaka, Toshimitsu; Pollock, Roy M.; Kuntz, Kevin W.; Yokoi, Akira; Keilhack, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-854</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutations within the catalytic domain of the histone methyltransferase EZH2 have been identified in subsets of patients with non-Hodgkin lymphoma (NHL).  These genetic alterations are hypothesized to confer an oncogenic dependency on EZH2 enzymic activity in these cancers.  We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small mol. inhibitors of EZH2.  Although both compds. are similar with respect to their mechanism of action and selectivity, EPZ-6438 possesses superior potency and drug-like properties, including good oral bioavailability in animals.  Here, we characterize the activity of EPZ-6438 in preclin. models of NHL.  EPZ-6438 selectively inhibits intracellular lysine 27 of histone H3 (H3K27) methylation in a concn.- and time-dependent manner in both EZH2 wild-type and mutant lymphoma cells.  Inhibition of H3K27 trimethylation (H3K27Me3) leads to selective cell killing of human lymphoma cell lines bearing EZH2 catalytic domain point mutations.  Treatment of EZH2-mutant NHL xenograft-bearing mice with EPZ-6438 causes dose-dependent tumor growth inhibition, including complete and sustained tumor regressions with correlative diminution of H3K27Me3 levels in tumors and selected normal tissues.  Mice dosed orally with EPZ-6438 for 28 days remained tumor free for up to 63 days after stopping compd. treatment in two EZH2-mutant xenograft models.  These data confirm the dependency of EZH2-mutant NHL on EZH2 activity and portend the utility of EPZ-6438 as a potential treatment for these genetically defined cancers.  Mol Cancer Ther; 13(4); 842-54. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2o1v5F3GzLVg90H21EOLACvtfcHk0lj-KGX4yiOJUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurw%253D&md5=89354e9453dcd7430978d1a6c5ee5846</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0773%26sid%3Dliteratum%253Aachs%26aulast%3DKnutson%26aufirst%3DS.%2BK.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DMinoshima%26aufirst%3DY.%26aulast%3DWarholic%26aufirst%3DN.%2BM.%26aulast%3DHuang%26aufirst%3DK.-C.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DUesugi%26aufirst%3DM.%26aulast%3DKuznetsov%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKlaus%26aufirst%3DC.%2BR.%26aulast%3DAllain%26aufirst%3DC.%2BJ.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DPorter-Scott%26aufirst%3DM.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DYokoi%26aufirst%3DA.%26aulast%3DKeilhack%26aufirst%3DH.%26atitle%3DSelective%2520Inhibition%2520of%2520EZH2%2520by%2520EPZ-6438%2520Leads%2520to%2520Potent%2520Antitumor%2520Activity%2520in%2520EZH2-Mutant%2520Non-Hodgkin%2520Lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D842%26epage%3D854%26doi%3D10.1158%2F1535-7163.MCT-13-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasveschuk, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span> <span> </span><span class="NLM_article-title">Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9928</span>– <span class="NLM_lpage">9941</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9928-9941&issue=21&author=R.+G.+Vaswaniauthor=V.+S.+Gehlingauthor=L.+A.+Dakinauthor=A.+S.+Cookauthor=C.+G.+Nasveschukauthor=M.+Duplessisauthor=P.+Iyerauthor=S.+Balasubramanianauthor=F.+Zhaoauthor=A.+C.+Goodauthor=R.+Campbellauthor=C.+Leeauthor=N.+Cantoneauthor=R.+T.+Cummingsauthor=E.+Normantauthor=S.+F.+Bellonauthor=B.+K.+Albrechtauthor=J.-C.+Harmangeauthor=P.+Trojerauthor=J.+E.+Audiaauthor=Y.+Zhangauthor=N.+Justinauthor=S.+Chenauthor=J.+R.+Wilsonauthor=S.+J.+Gamblin&title=Identification+of+%28R%29-N-%28%284-Methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-2-methyl-1-%281-%281-%282%2C2%2C2-trifluoroethyl%29piperidin-4-yl%29ethyl%29-1H-indole-3-carboxamide+%28CPI-1205%29%2C+a+Potent+and+Selective+Inhibitor+of+Histone+Methyltransferase+EZH2%2C+Suitable+for+Phase+I+Clinical+Trials+for+B-Cell+Lymphomas&doi=10.1021%2Facs.jmedchem.6b01315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas</span></div><div class="casAuthors">Vaswani, Rishi G.; Gehling, Victor S.; Dakin, Les A.; Cook, Andrew S.; Nasveschuk, Christopher G.; Duplessis, Martin; Iyer, Priyadarshini; Balasubramanian, Srividya; Zhao, Feng; Good, Andrew C.; Campbell, Robert; Lee, Christina; Cantone, Nico; Cummings, Richard T.; Normant, Emmanuel; Bellon, Steven F.; Albrecht, Brian K.; Harmange, Jean-Christophe; Trojer, Patrick; Audia, James E.; Zhang, Ying; Justin, Neil; Chen, Shuyang; Wilson, Jon R.; Gamblin, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9928-9941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3.  Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis.  EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncol. target for pharmacol. intervention.  Here we report the optimization of our indole-based EZH2 inhibitor series that led to the identification of CPI-1205, a highly potent (biochem. IC50 = 0.002 μM, cellular EC50 = 0.032 μM) and selective inhibitor of EZH2.  This compd. demonstrates robust antitumor effects in a Karpas-422 xenograft model when dosed at 160 mg/kg BID and is currently in Phase I clin. trials.  Addnl., we disclose the co-crystal structure of our inhibitor series bound to the human PRC2 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqnfg3FGdE7Vg90H21EOLACvtfcHk0lj-KGX4yiOJUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77I&md5=4096fa91399fef88a7ec8aabb5aaee13</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01315%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DNasveschuk%26aufirst%3DC.%2BG.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCantone%26aufirst%3DN.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DNormant%26aufirst%3DE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJustin%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DJ.%2BR.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26atitle%3DIdentification%2520of%2520%2528R%2529-N-%2528%25284-Methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-2-methyl-1-%25281-%25281-%25282%252C2%252C2-trifluoroethyl%2529piperidin-4-yl%2529ethyl%2529-1H-indole-3-carboxamide%2520%2528CPI-1205%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Histone%2520Methyltransferase%2520EZH2%252C%2520Suitable%2520for%2520Phase%2520I%2520Clinical%2520Trials%2520for%2520B-Cell%2520Lymphomas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9928%26epage%3D9941%26doi%3D10.1021%2Facs.jmedchem.6b01315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsherniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haswell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walensky, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orkin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. W. M.</span></span> <span> </span><span class="NLM_article-title">SWI/SNF-Mutant Cancers Depend on Catalytic and Non-Catalytic Activity of EZH2</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1038/nm.3968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnm.3968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26552009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1491-1496&issue=12&author=K.+H.+Kimauthor=W.+Kimauthor=T.+P.+Howardauthor=F.+Vazquezauthor=A.+Tsherniakauthor=J.+N.+Wuauthor=W.+Wangauthor=J.+R.+Haswellauthor=L.+D.+Walenskyauthor=W.+C.+Hahnauthor=S.+H.+Orkinauthor=C.+W.+M.+Roberts&title=SWI%2FSNF-Mutant+Cancers+Depend+on+Catalytic+and+Non-Catalytic+Activity+of+EZH2&doi=10.1038%2Fnm.3968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2</span></div><div class="casAuthors">Kim, Kimberly H.; Kim, Woojin; Howard, Thomas P.; Vazquez, Francisca; Tsherniak, Aviad; Wu, Jennifer N.; Wang, Weishan; Haswell, Jeffrey R.; Walensky, Loren D.; Hahn, William C.; Orkin, Stuart H.; Roberts, Charles W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1491-1496</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex have been shown to have bona fide tumor suppressor activity.  However, whether mutations in SWI/SNF subunits result in shared dependencies is unknown.  Here we show that EZH2, a catalytic subunit of the polycomb repressive complex 2 (PRC2), is essential in all tested cancer cell lines and xenografts harboring mutations of the SWI/SNF subunits ARID1A, PBRM1, and SMARCA4, which are several of the most frequently mutated SWI/SNF subunits in human cancer, but that co-occurrence of a Ras pathway mutation is correlated with abrogation of this dependence.  Notably, we demonstrate that SWI/SNF-mutant cancer cells are primarily dependent on a non-catalytic role of EZH2 in the stabilization of the PRC2 complex, and that they are only partially dependent on EZH2 histone methyltransferase activity.  These results not only reveal a shared dependency of cancers with genetic alterations in SWI/SNF subunits, but also suggest that EZH2 enzymic inhibitors now in clin. development may not fully suppress the oncogenic activity of EZH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjhQKP01U5bVg90H21EOLACvtfcHk0lg0VdFs8QJNlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7nK&md5=a30c11fe7ce3c20e982e824105b8d640</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnm.3968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3968%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DHoward%26aufirst%3DT.%2BP.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHaswell%26aufirst%3DJ.%2BR.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DOrkin%26aufirst%3DS.%2BH.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%2BM.%26atitle%3DSWI%252FSNF-Mutant%2520Cancers%2520Depend%2520on%2520Catalytic%2520and%2520Non-Catalytic%2520Activity%2520of%2520EZH2%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D1491%26epage%3D1496%26doi%3D10.1038%2Fnm.3968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessella, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montironi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magi-Galluzzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantoff, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>338</i></span> (<span class="NLM_issue">6113</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1469</span>, <span class="refDoi"> DOI: 10.1126/science.1227604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1227604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23239736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2012&pages=1465-1469&issue=6113&author=K.+Xuauthor=Z.+J.+Wuauthor=A.+C.+Gronerauthor=H.+H.+Heauthor=C.+Caiauthor=R.+T.+Lisauthor=X.+Wuauthor=E.+C.+Stackauthor=M.+Lodaauthor=T.+Liuauthor=H.+Xuauthor=L.+Catoauthor=J.+E.+Thorntonauthor=R.+I.+Gregoryauthor=C.+Morrisseyauthor=R.+L.+Vessellaauthor=R.+Montironiauthor=C.+Magi-Galluzziauthor=P.+W.+Kantoffauthor=S.+P.+Balkauthor=X.+S.+Liuauthor=M.+Brown&title=EZH2+Oncogenic+Activity+in+Castration-Resistant+Prostate+Cancer+Cells+Is+Polycomb-Independent&doi=10.1126%2Fscience.1227604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent</span></div><div class="casAuthors">Xu, Kexin; Wu, Zhenhua Jeremy; Groner, Anna C.; He, Housheng Hansen; Cai, Changmeng; Lis, Rosina T.; Wu, Xiaoqiu; Stack, Edward C.; Loda, Massimo; Liu, Tao; Xu, Han; Cato, Laura; Thornton, James E.; Gregory, Richard I.; Morrissey, Colm; Vessella, Robert L.; Montironi, Rodolfo; Magi-Galluzzi, Cristina; Kantoff, Philip W.; Balk, Steven P.; Liu, X. Shirley; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">6113</span>),
    <span class="NLM_cas:pages">1465-1469</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Epigenetic regulators represent a promising new class of therapeutic targets for cancer.  Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity.  We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor.  Instead, it involves the ability of EZH2 to act as a coactivator for crit. transcription factors including the androgen receptor.  This functional switch is dependent on phosphorylation of EZH2 and requires an intact methyltransferase domain.  Hence, targeting the non-PRC2 function of EZH2 may have therapeutic efficacy for treating metastatic, hormone-refractory prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOB2b-7A-UaLVg90H21EOLACvtfcHk0lg0VdFs8QJNlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSktLfF&md5=98399f2e6a4c9b07121059772650d2d3</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1126%2Fscience.1227604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1227604%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DZ.%2BJ.%26aulast%3DGroner%26aufirst%3DA.%2BC.%26aulast%3DHe%26aufirst%3DH.%2BH.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DLis%26aufirst%3DR.%2BT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DStack%26aufirst%3DE.%2BC.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCato%26aufirst%3DL.%26aulast%3DThornton%26aufirst%3DJ.%2BE.%26aulast%3DGregory%26aufirst%3DR.%2BI.%26aulast%3DMorrissey%26aufirst%3DC.%26aulast%3DVessella%26aufirst%3DR.%2BL.%26aulast%3DMontironi%26aufirst%3DR.%26aulast%3DMagi-Galluzzi%26aufirst%3DC.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DEZH2%2520Oncogenic%2520Activity%2520in%2520Castration-Resistant%2520Prostate%2520Cancer%2520Cells%2520Is%2520Polycomb-Independent%26jtitle%3DScience%26date%3D2012%26volume%3D338%26issue%3D6113%26spage%3D1465%26epage%3D1469%26doi%3D10.1126%2Fscience.1227604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, J. L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, S.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W.-J.</span></span> <span> </span><span class="NLM_article-title">EZH2 Overexpression in Natural Killer/T-Cell Lymphoma Confers Growth Advantage Independently of Histone Methyltransferase Activity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4512</span>– <span class="NLM_lpage">4520</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-08-450494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1182%2Fblood-2012-08-450494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23529930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFGrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=4512-4520&issue=22&author=J.+Yanauthor=S.-B.+Ngauthor=J.+L.-S.+Tayauthor=B.+Linauthor=T.+L.+Kohauthor=J.+Tanauthor=V.+Selvarajanauthor=S.-C.+Liuauthor=C.+Biauthor=S.+Wangauthor=S.-N.+Chooauthor=N.+Shimizuauthor=G.+Huangauthor=Q.+Yuauthor=W.-J.+Chng&title=EZH2+Overexpression+in+Natural+Killer%2FT-Cell+Lymphoma+Confers+Growth+Advantage+Independently+of+Histone+Methyltransferase+Activity&doi=10.1182%2Fblood-2012-08-450494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity</span></div><div class="casAuthors">Yan, Junli; Ng, Siok-Bian; Tay, Jim Liang-Seah; Lin, Baohong; Koh, Tze Loong; Tan, Joy; Selvarajan, Viknesvaran; Liu, Shaw-Cheng; Bi, Chonglei; Wang, Shi; Choo, Shoa-Nian; Shimizu, Norio; Huang, Gaofeng; Yu, Qiang; Chng, Wee-Joo</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4512-4520</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The role of enhancer of zeste homolog 2 (EZH2) in cancer is complex and may vary depending on the cellular context.  We found that EZH2 is aberrantly overexpressed in the majority of natural killer/T-cell lymphoma (NKTL), an aggressive lymphoid malignancy with very poor prognosis.  We show that EZH2 upregulation is mediated by MYC-induced repression of its regulatory micro RNAs and EZH2 exerts oncogenic properties in NKTL.  Ectopic expression of EZH2 in both primary NK cells and NKTL cell lines leads to a significant growth advantage.  Conversely, knock-down of EZH2 in NKTL cell lines results in cell growth inhibition.  Intriguingly, ectopic EZH2 mutant deficient for histone methyltransferase activity is also able to confer growth advantage and rescue growth inhibition on endogenous EZH2 depletion in NKTL cells, indicating an oncogenic role of EZH2 independent of its gene-silencing activity.  Mechanistically, we show that EZH2 directly promotes the transcription of cyclin D1 and this effect is independent of its enzymic activity.  Furthermore, depletion of EZH2 using a PRC2 inhibitor 3-deazaneplanocin A significantly inhibits growth of NK tumor cells.  Therefore, our study uncovers an oncogenic role of EZH2 independent of its methyltransferase activity in NKTL and suggests that targeting EZH2 may have therapeutic usefulness in this lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocRlqv_dn0TrVg90H21EOLACvtfcHk0lg0VdFs8QJNlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFGrs7c%253D&md5=ae998d8ef1d728645988fe7e8ca5fe74</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-08-450494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-08-450494%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DS.-B.%26aulast%3DTay%26aufirst%3DJ.%2BL.-S.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DKoh%26aufirst%3DT.%2BL.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DSelvarajan%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DS.-C.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChoo%26aufirst%3DS.-N.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DChng%26aufirst%3DW.-J.%26atitle%3DEZH2%2520Overexpression%2520in%2520Natural%2520Killer%252FT-Cell%2520Lymphoma%2520Confers%2520Growth%2520Advantage%2520Independently%2520of%2520Histone%2520Methyltransferase%2520Activity%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26issue%3D22%26spage%3D4512%26epage%3D4520%26doi%3D10.1182%2Fblood-2012-08-450494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bate-Eya, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gierman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versteeg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolman, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenaar, J. J.</span></span> <span> </span><span class="NLM_article-title">Enhancer of Zeste Homologue 2 Plays an Important Role in Neuroblastoma Cell Survival Independent of Its Histone Methyltransferase Activity</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejca.2016.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28214660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1eru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2017&pages=63-72&author=L.+T.+Bate-Eyaauthor=H.+J.+Giermanauthor=M.+E.+Ebusauthor=J.+Kosterauthor=H.+N.+Caronauthor=R.+Versteegauthor=M.+E.+M.+Dolmanauthor=J.+J.+Molenaar&title=Enhancer+of+Zeste+Homologue+2+Plays+an+Important+Role+in+Neuroblastoma+Cell+Survival+Independent+of+Its+Histone+Methyltransferase+Activity&doi=10.1016%2Fj.ejca.2016.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity</span></div><div class="casAuthors">Bate-Eya, Laurel T.; Gierman, Hinco J.; Ebus, Marli E.; Koster, Jan; Caron, Huib N.; Versteeg, Rogier; Dolman, M. Emmy M.; Molenaar, Jan J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Neuroblastoma is predominantly characterized by chromosomal rearrangements.  Next to V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) amplification, chromosome 7 and 17q gains are frequently obsd.  We identified a neuroblastoma patient with a regional 7q36 gain, encompassing the enhancer of zeste homolog 2 (EZH2) gene.  EZH2 is the histone methyltransferase of lysine 27 of histone H3 (H3K27me3) that forms the catalytic subunit of the polycomb repressive complex 2.  H3K27me3 is commonly assocd. with the silencing of genes involved in cellular processes such as cell cycle regulation, cellular differentiation and cancer.  High EZH2 expression correlated with poor prognosis and overall survival independent of MYCN amplification status.  Unexpectedly, treatment of 3 EZH2-high expressing neuroblastoma cell lines (IMR32, CHP134 and NMB), with EZH2-specific inhibitors (GSK126 and EPZ6438) resulted in only a slight G1 arrest, despite max. histone methyltransferase activity inhibition.  Furthermore, colony formation in cell lines treated with the inhibitors was reduced only at concns. much higher than necessary for complete inhibition of EZH2 histone methyltransferase activity.  Knockdown of the complete protein with three independent shRNAs resulted in a strong apoptotic response and decreased cyclin D1 levels.  This apoptotic response could be rescued by overexpressing EZH2ΔSET, a truncated form of wild-type EZH2 lacking the SET transactivation domain necessary for histone methyltransferase activity.  Our findings suggest that high EZH2 expression, at least in neuroblastoma, has a survival function independent of its methyltransferase activity.  This important finding highlights the need for studies on EZH2 beyond its methyltransferase function and the requirement for compds. that will target EZH2 as a complete protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPeYIEEK1oFLVg90H21EOLACvtfcHk0lgQSfvdP1b10A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1eru70%253D&md5=65cbff2c51dc7c1af9d96cbeaf12cf11</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DBate-Eya%26aufirst%3DL.%2BT.%26aulast%3DGierman%26aufirst%3DH.%2BJ.%26aulast%3DEbus%26aufirst%3DM.%2BE.%26aulast%3DKoster%26aufirst%3DJ.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DVersteeg%26aufirst%3DR.%26aulast%3DDolman%26aufirst%3DM.%2BE.%2BM.%26aulast%3DMolenaar%26aufirst%3DJ.%2BJ.%26atitle%3DEnhancer%2520of%2520Zeste%2520Homologue%25202%2520Plays%2520an%2520Important%2520Role%2520in%2520Neuroblastoma%2520Cell%2520Survival%2520Independent%2520of%2520Its%2520Histone%2520Methyltransferase%2520Activity%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D75%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.ejca.2016.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Gambogenic Acid Mediated Apoptosis Through the Mitochondrial Oxidative Stress and Inactivation of Akt Signaling Pathway in Human Nasopharyngeal Carcinoma CNE-1 Cells</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>652</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejphar.2010.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21118682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1KjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=652&publication_year=2011&pages=23-32&issue=1%E2%80%933&author=F.+Yanauthor=M.+Wangauthor=H.+Chenauthor=J.+Suauthor=X.+Wangauthor=F.+Wangauthor=L.+Xiaauthor=Q.+Li&title=Gambogenic+Acid+Mediated+Apoptosis+Through+the+Mitochondrial+Oxidative+Stress+and+Inactivation+of+Akt+Signaling+Pathway+in+Human+Nasopharyngeal+Carcinoma+CNE-1+Cells&doi=10.1016%2Fj.ejphar.2010.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Gambogenic acid mediated apoptosis through the mitochondrial oxidative stress and inactivation of Akt signaling pathway in human nasopharyngeal carcinoma CNE-1 cells</span></div><div class="casAuthors">Yan, Fenggen; Wang, Mei; Chen, Hui; Su, Jingjing; Wang, Xiaoshan; Wang, Fei; Xia, Lunzhu; Li, Qinglin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">652</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">23-32</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the present study, Gambogenic acid exhibits potential anti-tumor activity in several cancer cell lines.  However, Gambogenic acid-induced apoptosis mechanism is not well understood.  Here, we report that Gambogenic acid was capable to induce CNE-1 cells apoptosis and caused mitochondrial and endoplasmic reticulum injury, analyzed via transmission electron microscopy and acridine orange/ethidium bromide (AO/EB) double staining.  To quant. analyze apoptosis, through the propidium iodide (PI)/Annexin V-FITC double staining to detect cell apoptosis, PI staining of the cell cycle distribution.  To further explore the potential mechanism of Gambogenic acid mediated apoptosis in CNE-1 cells, we also examd. mitochondrial oxidative stress in the levels of reactive oxygen species, the release of cytochrome c, intracellular Ca2+ concn. and mitochondrial membrane potential by flow cytometry.  Moreover, Gambogenic acid could result in a time and concn.-dependent decrease in Phospho-Akt expression, basal expression levels of Akt change was not obvious.  In addn., we detected Bcl-2 family including Bcl-2, Bax and Bad expression in mRNA level.  His resulted in a decrease of Bcl-2 and Bad increased in CNE-1 cells after Gambogenic acid treatment.  These results indicated that Gambogenic acid mediated apoptosis through inactivation of Akt, accompanied with mitochondrial oxidative stress and cross-talk with Bcl-2 family in the process of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG-m-NbeyCqbVg90H21EOLACvtfcHk0lgQSfvdP1b10A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1KjtA%253D%253D&md5=748af88184d75b0a5d2bbcf8dba5f12c</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DGambogenic%2520Acid%2520Mediated%2520Apoptosis%2520Through%2520the%2520Mitochondrial%2520Oxidative%2520Stress%2520and%2520Inactivation%2520of%2520Akt%2520Signaling%2520Pathway%2520in%2520Human%2520Nasopharyngeal%2520Carcinoma%2520CNE-1%2520Cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D652%26issue%3D1%25E2%2580%25933%26spage%3D23%26epage%3D32%26doi%3D10.1016%2Fj.ejphar.2010.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.-B.</span></span> <span> </span><span class="NLM_article-title">Gambogenic Acid Induces G1 Arrest via GSK3β-Dependent Cyclin D1 Degradation and Triggers Autophagy in Lung Cancer Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>322</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2012.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.canlet.2012.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=22410463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlWktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2012&pages=185-194&issue=2&author=X.-J.+Yuauthor=Q.-B.+Hanauthor=Z.-S.+Wenauthor=L.+Maauthor=J.+Gaoauthor=G.-B.+Zhou&title=Gambogenic+Acid+Induces+G1+Arrest+via+GSK3%CE%B2-Dependent+Cyclin+D1+Degradation+and+Triggers+Autophagy+in+Lung+Cancer+Cells&doi=10.1016%2Fj.canlet.2012.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells</span></div><div class="casAuthors">Yu, Xian-Jun; Han, Quan-Bin; Wen, Zhe-Sheng; Ma, Liang; Gao, Jin; Zhou, Guang-Biao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-194</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cyclin D1, an oncogenic G1 cyclin which can be induced by environmental carcinogens and whose over-expression may cause dysplasia and carcinoma, has been shown to be a target for cancer chemoprevention and therapy.  In this study, we investigated the effects and underlying mechanisms of action of a polyprenylated xanthone, gambogenic acid (GEA) on gefitinib-sensitive and -resistant lung cancer cells.  We found that GEA inhibited proliferation, caused G1 arrest and repressed colony-forming activity of lung cancer cells.  GEA induced degrdn. of cyclin D1 via the proteasome pathway, and triggered dephosphorylation of GSK3β which was required for cyclin D1 turnover, because GSK3β inactivation by its inhibitor or specific siRNA markedly attenuated GEA-caused cyclin D1 catabolism.  GEA induced autophagy of lung cancer cells, possibly due to activation of GSK3β and inactivation of AKT/mTOR signal pathway.  These results indicate that GEA is a cyclin D1 inhibitor and a GSK3β activator which may have chemopreventive and therapeutic potential for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUmIKBcLV1Y7Vg90H21EOLACvtfcHk0lgQSfvdP1b10A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlWktr8%253D&md5=f48a013835a7f7296534d418f3109d58</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DX.-J.%26aulast%3DHan%26aufirst%3DQ.-B.%26aulast%3DWen%26aufirst%3DZ.-S.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DG.-B.%26atitle%3DGambogenic%2520Acid%2520Induces%2520G1%2520Arrest%2520via%2520GSK3%25CE%25B2-Dependent%2520Cyclin%2520D1%2520Degradation%2520and%2520Triggers%2520Autophagy%2520in%2520Lung%2520Cancer%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D322%26issue%3D2%26spage%3D185%26epage%3D194%26doi%3D10.1016%2Fj.canlet.2012.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aller, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pietra, A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquenne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, C. L.</span></span> <span> </span><span class="NLM_article-title">EZH2 Inhibition as a Therapeutic Strategy for Lymphoma with EZH2-Activating Mutations</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span> (<span class="NLM_issue">7427</span>),  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/nature11606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature11606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23051747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=108-112&issue=7427&author=M.+T.+McCabeauthor=H.+M.+Ottauthor=G.+Ganjiauthor=S.+Korenchukauthor=C.+Thompsonauthor=G.+S.+Van+Allerauthor=Y.+Liuauthor=A.+P.+Gravesauthor=A.+Della+Pietraauthor=E.+Diazauthor=L.+V.+LaFranceauthor=M.+Mellingerauthor=C.+Duquenneauthor=X.+Tianauthor=R.+G.+Krugerauthor=C.+F.+McHughauthor=M.+Brandtauthor=W.+H.+Millerauthor=D.+Dhanakauthor=S.+K.+Vermaauthor=P.+J.+Tumminoauthor=C.+L.+Creasy&title=EZH2+Inhibition+as+a+Therapeutic+Strategy+for+Lymphoma+with+EZH2-Activating+Mutations&doi=10.1038%2Fnature11606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</span></div><div class="casAuthors">McCabe, Michael T.; Ott, Heidi M.; Ganji, Gopinath; Korenchuk, Susan; Thompson, Christine; Van Aller, Glenn S.; Liu, Yan; Graves, Alan P.; Della Pietra, Anthony , III; Diaz, Elsie; LaFrance, Louis V.; Mellinger, Mark; Duquenne, Celine; Tian, Xinrong; Kruger, Ryan G.; McHugh, Charles F.; Brandt, Martin; Miller, William H.; Dhanak, Dashyant; Verma, Sharad K.; Tummino, Peter J.; Creasy, Caretha L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7427</span>),
    <span class="NLM_cas:pages">108-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In eukaryotes, post-translational modification of histones is crit. for regulation of chromatin structure and gene expression.  EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).  EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumor types.  Addnl., somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.  The Y641 residue is the most frequently mutated residue, with up to 22% of germinal center B-cell DLBCL and follicular lymphoma harbouring mutations at this site.  These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes.  However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas.  Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-mol. inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.  GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice.  Together, these data demonstrate that pharmacol. inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxw5cLmW3Lc7Vg90H21EOLACvtfcHk0lidsiNBqccPBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyktbjL&md5=a1dff99556de004c48aae88bc45dffab</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnature11606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11606%26sid%3Dliteratum%253Aachs%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DOtt%26aufirst%3DH.%2BM.%26aulast%3DGanji%26aufirst%3DG.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGraves%26aufirst%3DA.%2BP.%26aulast%3DDella%2BPietra%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DE.%26aulast%3DLaFrance%26aufirst%3DL.%2BV.%26aulast%3DMellinger%26aufirst%3DM.%26aulast%3DDuquenne%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DVerma%26aufirst%3DS.%2BK.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCreasy%26aufirst%3DC.%2BL.%26atitle%3DEZH2%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Lymphoma%2520with%2520EZH2-Activating%2520Mutations%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7427%26spage%3D108%26epage%3D112%26doi%3D10.1038%2Fnature11606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grantner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gukasyan, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivacic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamphavong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01375</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01375" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=650-665&issue=3&author=P.-P.+Kungauthor=P.+Binghamauthor=A.+Broounauthor=M.+Collinsauthor=Y.-L.+Dengauthor=D.+Dinhauthor=C.+Fanauthor=K.+S.+Gajiwalaauthor=R.+Grantnerauthor=H.+J.+Gukasyanauthor=W.+Huauthor=B.+Huangauthor=R.+Kaniaauthor=S.+E.+Kephartauthor=C.+Krivacicauthor=R.+A.+Kumpfauthor=P.+Khamphavongauthor=M.+Krausauthor=W.+Liuauthor=K.+A.+Maegleyauthor=L.+Nguyenauthor=S.+Renauthor=D.+Richterauthor=R.+A.+Rollinsauthor=N.+Sachauthor=S.+Sharmaauthor=J.+Sherrillauthor=J.+Spanglerauthor=A.+E.+Stewartauthor=S.+Suttonauthor=S.+Uryuauthor=D.+Verhelleauthor=H.+Wangauthor=S.+Wangauthor=M.+Wythesauthor=S.+Xinauthor=S.+Yamazakiauthor=H.+Zhuauthor=J.+Zhuauthor=L.+Zehnderauthor=M.+Edwards&title=Optimization+of+Orally+Bioavailable+Enhancer+of+Zeste+Homolog+2+%28EZH2%29+Inhibitors+Using+Ligand+and+Property-Based+Design+Strategies%3A+Identification+of+Development+Candidate+%28R%29-5%2C8-Dichloro-7-%28methoxy%28oxetan-3-yl%29methyl%29-2-%28%284-methoxy-6-methyl-2-oxo-1%2C2-dihydropyridin-3-yl%29methyl%29-3%2C4-dihydroisoquinolin-1%282H%29-one+%28PF-06821497%29&doi=10.1021%2Facs.jmedchem.7b01375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)</span></div><div class="casAuthors">Kung, Pei-Pei; Bingham, Patrick; Brooun, Alexei; Collins, Michael; Deng, Ya-Li; Dinh, Dac; Fan, Connie; Gajiwala, Ketan S.; Grantner, Rita; Gukasyan, Hovhannes J.; Hu, Wenyue; Huang, Buwen; Kania, Robert; Kephart, Susan E.; Krivacic, Cody; Kumpf, Robert A.; Khamphavong, Penney; Kraus, Manfred; Liu, Wei; Maegley, Karen A.; Nguyen, Lisa; Ren, Shijian; Richter, Dan; Rollins, Robert A.; Sach, Neal; Sharma, Shikhar; Sherrill, John; Spangler, Jillian; Stewart, Albert E.; Sutton, Scott; Uryu, Sean; Verhelle, Dominique; Wang, Hui; Wang, Shuiwang; Wythes, Martin; Xin, Shuibo; Yamazaki, Shinji; Zhu, Huichun; Zhu, JinJiang; Zehnder, Luke; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and physicochem.-property-based strategies to address metabolic stability and thermodn. soly. issues assocd. with previous lead compd. (I).  The new inhibitors incorporated an Sp3 hybridized carbon atom at the 7-position of the lactam moiety present in lead compd. (I) as a replacement for a dimethylisoxazole group.  This transformation enabled optimization of the physicochem. properties and potency compared to compd. (I).  Anal. of relationships between calcd. log D (clogD) values and in vitro metabolic stability and permeability parameters identified a clogD range that afforded an increased probability of achieving favorable ADME data in a single mol.  Compd. 23a (5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one) exhibited the best overlap of potency and pharmaceutical properties as well as robust tumor growth inhibition in vivo and was therefore advanced as a development candidate (PF-06821497).  A crystal structure of 23a in complex with the three-protein PRC2 complex enabled understanding of the key structural features required for optimal binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro0-Aa0AZgXLVg90H21EOLACvtfcHk0lidsiNBqccPBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqtrzF&md5=96ff75b96f5eea2dc82013a6bad8096b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01375%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DGrantner%26aufirst%3DR.%26aulast%3DGukasyan%26aufirst%3DH.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DKrivacic%26aufirst%3DC.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DKhamphavong%26aufirst%3DP.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRollins%26aufirst%3DR.%2BA.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSherrill%26aufirst%3DJ.%26aulast%3DSpangler%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DVerhelle%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZehnder%26aufirst%3DL.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520Orally%2520Bioavailable%2520Enhancer%2520of%2520Zeste%2520Homolog%25202%2520%2528EZH2%2529%2520Inhibitors%2520Using%2520Ligand%2520and%2520Property-Based%2520Design%2520Strategies%253A%2520Identification%2520of%2520Development%2520Candidate%2520%2528R%2529-5%252C8-Dichloro-7-%2528methoxy%2528oxetan-3-yl%2529methyl%2529-2-%2528%25284-methoxy-6-methyl-2-oxo-1%252C2-dihydropyridin-3-yl%2529methyl%2529-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2520%2528PF-06821497%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1021%2Facs.jmedchem.7b01375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, J. M.</span></span> <span> </span><span class="NLM_article-title">Amplification of N-Myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>224</i></span> (<span class="NLM_issue">4653</span>),  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1126/science.6719137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.6719137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=6719137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADyaL2c7ps1Chtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1984&pages=1121-1124&issue=4653&author=G.+M.+Brodeurauthor=R.+C.+Seegerauthor=M.+Schwabauthor=H.+E.+Varmusauthor=J.+M.+Bishop&title=Amplification+of+N-Myc+in+Untreated+Human+Neuroblastomas+Correlates+with+Advanced+Disease+Stage&doi=10.1126%2Fscience.6719137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage</span></div><div class="casAuthors">Brodeur G M; Seeger R C; Schwab M; Varmus H E; Bishop J M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">4653</span>),
    <span class="NLM_cas:pages">1121-4</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A domain of DNA designated N-myc is amplified 20- to 140-fold in human neuroblastoma cell lines but not in cell lines from other tumor types.  N-myc has now been found to be amplified in neuroblastoma tissue from 24 of 63 untreated patients (38 percent).  The extent of amplification appears to be bimodal, with amplification of 100- to 300-fold in 12 cases and 3- to 10-fold in 10 others.  Amplification was found in 0 of 15 patients with stage 1 or 2 disease, whereas 24 of 48 cases (50 percent) with stage 3 or 4 had evidence of N-myc amplification.  These data indicate that N-myc amplification is a common event in untreated human neuroblastomas.  Furthermore, N-myc amplification is highly correlated with advanced stages of disease (P less than 0.001) and with the ability to grow in vitro as an established cell line, both of which are associated with a poor prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ87Kw6s8IBfftos8R3JUhXfW6udTcc2ebq2AIdhPC01bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7ps1Chtw%253D%253D&md5=8920f3fcf76f0f8ae977a839a36c04b0</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1126%2Fscience.6719137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6719137%26sid%3Dliteratum%253Aachs%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DSeeger%26aufirst%3DR.%2BC.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26aulast%3DBishop%26aufirst%3DJ.%2BM.%26atitle%3DAmplification%2520of%2520N-Myc%2520in%2520Untreated%2520Human%2520Neuroblastomas%2520Correlates%2520with%2520Advanced%2520Disease%2520Stage%26jtitle%3DScience%26date%3D1984%26volume%3D224%26issue%3D4653%26spage%3D1121%26epage%3D1124%26doi%3D10.1126%2Fscience.6719137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Boussard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibshirani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span> <span> </span><span class="NLM_article-title">Combined Microarray Analysis of Small Cell Lung Cancer Reveals Altered Apoptotic Balance and Distinct Expression Signatures of MYC Family Gene Amplification</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fsj.onc.1208997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16116477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1aqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=130-138&issue=1&author=Y.+H.+Kimauthor=L.+Girardauthor=C.+P.+Giacominiauthor=P.+Wangauthor=T.+Hernandez-Boussardauthor=R.+Tibshiraniauthor=J.+D.+Minnaauthor=J.+R.+Pollack&title=Combined+Microarray+Analysis+of+Small+Cell+Lung+Cancer+Reveals+Altered+Apoptotic+Balance+and+Distinct+Expression+Signatures+of+MYC+Family+Gene+Amplification&doi=10.1038%2Fsj.onc.1208997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification</span></div><div class="casAuthors">Kim, Y. H.; Girard, L.; Giacomini, C. P.; Wang, P.; Hernandez-Boussard, T.; Tibshirani, R.; Minna, J. D.; Pollack, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNA amplifications and deletions frequently contribute to the development and progression of lung cancer.  To identify such novel alterations in small cell lung cancer (SCLC), we performed comparative genomic hybridization on a set of 24 SCLC cell lines, using cDNA microarrays representing ∼22 000 human genes (providing an av. mapping resoln. of <70 kb).  We identified localized DNA amplifications corresponding to oncogenes known to be amplified in SCLC, including MYC (8q24), MYCN (2p24) and MYCL1 (1p34).  Addnl. highly localized DNA amplifications suggested candidate oncogenes not previously identified as amplified in SCLC, including the antiapoptotic genes TNFRSF4 (1p36), DAD1 (14q11), BCL2L1 (20q11) and BCL2L2 (14q11).  Likewise, newly discovered PCR-validated homozygous deletions suggested candidate tumor-suppressor genes, including the proapoptotic genes MAPK10 (4q21) and TNFRSF6 (10q23).  To characterize the effect of DNA amplification on gene expression patterns, we performed expression profiling using the same microarray platform.  Among our findings, we identified sets of genes whose expression correlated with MYC, MYCN or MYCL1 amplification, with surprisingly little overlap among gene sets.  While both MYC and MYCN amplification were assocd. with increased and decreased expression of known MYC upregulated and downregulated targets, resp., MYCL1 amplification was assocd. only with the latter.  Our findings support a role of altered apoptotic balance in the pathogenesis of SCLC, and suggest that MYC family genes might affect oncogenesis through distinct sets of targets, in particular implicating the importance of transcriptional repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3f-J9j1ltm7Vg90H21EOLACvtfcHk0lh7ucUOQH8POg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1aqtA%253D%253D&md5=daf5611f8a6112ed9fee6732bc34a670</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208997%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DGiacomini%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DHernandez-Boussard%26aufirst%3DT.%26aulast%3DTibshirani%26aufirst%3DR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26atitle%3DCombined%2520Microarray%2520Analysis%2520of%2520Small%2520Cell%2520Lung%2520Cancer%2520Reveals%2520Altered%2520Apoptotic%2520Balance%2520and%2520Distinct%2520Expression%2520Signatures%2520of%2520MYC%2520Family%2520Gene%2520Amplification%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26issue%3D1%26spage%3D130%26epage%3D138%26doi%3D10.1038%2Fsj.onc.1208997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, H.</span></span> <span> </span><span class="NLM_article-title">The N-Myc Oncogene: Maximizing Its Targets, Regulation, and Therapeutic Potential</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-13-0536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1541-7786.MCR-13-0536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24589438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1CnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=815-822&issue=6&author=H.+Beltran&title=The+N-Myc+Oncogene%3A+Maximizing+Its+Targets%2C+Regulation%2C+and+Therapeutic+Potential&doi=10.1158%2F1541-7786.MCR-13-0536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential</span></div><div class="casAuthors">Beltran, Himisha</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">815-822</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  N-myc (MYCN), a member of the Myc family of basic-helix-loop-helix-zipper (bHLHZ) transcription factors, is a central regulator of many vital cellular processes.  As such, N-myc is well recognized for its classic oncogenic activity and assocn. with human neuroblastoma.  Amplification and overexpression of N-myc has been described in other tumor types, particularly those of neural origin and neuroendocrine tumors.  This review outlines N-myc's contribution to normal development and oncogenic progression.  In addn., it highlights relevant transcriptional targets and mechanisms of regulation.  Finally, the clin. implications of N-Myc as a biomarker and potential as a target using novel therapeutic approaches are discussed.  Mol Cancer Res; 12(6); 815-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx2j7fn-LpjbVg90H21EOLACvtfcHk0lh7ucUOQH8POg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1CnsLs%253D&md5=7fb6fcb690297043775e378e1a5b7c00</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-13-0536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-13-0536%26sid%3Dliteratum%253Aachs%26aulast%3DBeltran%26aufirst%3DH.%26atitle%3DThe%2520N-Myc%2520Oncogene%253A%2520Maximizing%2520Its%2520Targets%252C%2520Regulation%252C%2520and%2520Therapeutic%2520Potential%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2014%26volume%3D12%26issue%3D6%26spage%3D815%26epage%3D822%26doi%3D10.1158%2F1541-7786.MCR-13-0536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span> <span> </span><span class="NLM_article-title">Myc Proteins as Therapeutic Targets</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fonc.2009.512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20101214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=1249-1259&issue=9&author=W.+C.+Gustafsonauthor=W.+A.+Weiss&title=Myc+Proteins+as+Therapeutic+Targets&doi=10.1038%2Fonc.2009.512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Myc proteins as therapeutic targets</span></div><div class="casAuthors">Gustafson, W. C.; Weiss, W. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1249-1259</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Myc proteins (c-myc, Mycn and Mycl) target proliferative and apoptotic pathways vital for progression in cancer.  Amplification of the MYCN gene has emerged as one of the clearest indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the most common extracranial solid tumor of childhood.  Phosphorylation and ubiquitin-mediated modulation of Myc protein influence stability and represent potential targets for therapeutic intervention.  Phosphorylation of Myc proteins is controlled in-part by the receptor tyrosine kinase/phosphatidylinositol 3-kinase/Akt/mTOR signaling, with addnl. contributions from Aurora A kinase.  Myc proteins regulate apoptosis in part through interactions with the p53/Mdm2/Arf signaling pathway.  Mutation in p53 is commonly obsd. in patients with relapsed neuroblastoma, contributing to both biol. and therapeutic resistance.  This review examines Myc function and regulation in neuroblastoma, and discusses emerging therapies that target Mycn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0CvK5-9-gzbVg90H21EOLACvtfcHk0lhuwJx3k1h6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yltr0%253D&md5=e6c015a47fb88c9735b78057d9f7adb3</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.512%26sid%3Dliteratum%253Aachs%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DMyc%2520Proteins%2520as%2520Therapeutic%2520Targets%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26issue%3D9%26spage%3D1249%26epage%3D1259%26doi%3D10.1038%2Fonc.2009.512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitfield, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodir, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massó-Vallés, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnezis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swigart, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evan, G. I.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Myc Family Proteins Eradicates KRas-Driven Lung Cancer in Mice</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1101/gad.205542.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1101%2Fgad.205542.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23475959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVKkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=504-513&issue=5&author=L.+Soucekauthor=J.+R.+Whitfieldauthor=N.+M.+Sodirauthor=D.+Mass%C3%B3-Vall%C3%A9sauthor=E.+Serranoauthor=A.+N.+Karnezisauthor=L.+B.+Swigartauthor=G.+I.+Evan&title=Inhibition+of+Myc+Family+Proteins+Eradicates+KRas-Driven+Lung+Cancer+in+Mice&doi=10.1101%2Fgad.205542.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice</span></div><div class="casAuthors">Soucek, Laura; Whitfield, Jonathan R.; Sodir, Nicole M.; Masso-Valles, Daniel; Serrano, Erika; Karnezis, Anthony N.; Swigart, Lamorna Brown; Evan, Gerard I.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">504-513</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The principal reason for failure of targeted cancer therapies is the emergence of resistant clones that regenerate the tumor.  Therapeutic efficacy therefore depends on not only how effectively a drug inhibits its target, but also the innate or adaptive functional redundancy of that target and its attendant pathway.  In this regard, the Myc transcription factors are intriguing therapeutic targets because they serve the unique and irreplaceable role of coordinating expression of the many diverse genes that, together, are required for somatic cell proliferation.  Furthermore, Myc expression is deregulated in most-perhaps all-cancers, underscoring its irreplaceable role in proliferation.  We previously showed in a preclin. mouse model of non-small-cell lung cancer that systemic Myc inhibition using the dominant-neg. Myc mutant Omomyc exerts a dramatic therapeutic impact, triggering rapid regression of tumors with only mild and fully reversible side effects.  Using protracted episodic expression of Omomyc, we now demonstrate that metronomic Myc inhibition not only contains Ras-driven lung tumors indefinitely, but also leads to their progressive eradication.  Hence, Myc does indeed serve a unique and nondegenerate role in lung tumor maintenance that cannot be complemented by any adaptive mechanism, even in the most aggressive p53-deficient tumors.  These data endorse Myc as a compelling cancer drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfpivJKOSErbVg90H21EOLACvtfcHk0lhuwJx3k1h6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVKkurY%253D&md5=0fc5aa1a0223f4b09da3e7bf114bdc56</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1101%2Fgad.205542.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.205542.112%26sid%3Dliteratum%253Aachs%26aulast%3DSoucek%26aufirst%3DL.%26aulast%3DWhitfield%26aufirst%3DJ.%2BR.%26aulast%3DSodir%26aufirst%3DN.%2BM.%26aulast%3DMass%25C3%25B3-Vall%25C3%25A9s%26aufirst%3DD.%26aulast%3DSerrano%26aufirst%3DE.%26aulast%3DKarnezis%26aufirst%3DA.%2BN.%26aulast%3DSwigart%26aufirst%3DL.%2BB.%26aulast%3DEvan%26aufirst%3DG.%2BI.%26atitle%3DInhibition%2520of%2520Myc%2520Family%2520Proteins%2520Eradicates%2520KRas-Driven%2520Lung%2520Cancer%2520in%2520Mice%26jtitle%3DGenes%2520Dev.%26date%3D2013%26volume%3D27%26issue%3D5%26spage%3D504%26epage%3D513%26doi%3D10.1101%2Fgad.205542.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prochownik, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Myc</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1177/1947601910377494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1177%2F1947601910377494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21132100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyisb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=650-659&issue=6&author=E.+V.+Prochownikauthor=P.+K.+Vogt&title=Therapeutic+Targeting+of+Myc&doi=10.1177%2F1947601910377494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Myc</span></div><div class="casAuthors">Prochownik, Edward V.; Vogt, Peter K.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-659</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions between members of the Myc transcription factor network are potential targets of small mol. inhibitors and stabilizers.  Diverse screening strategies-including fluorescence resonance energy transfer, fluorescence polarization, 2-hybrid, and protein complementation assays-have identified several lead compds. that inhibit Myc-Max dimerization and one compd. that stabilizes the Max homodimer.  Representative compds. interfere with Myc-induced transcriptional activation, Myc-mediated oncogenic transformation, Myc-driven cellular replication, and DNA binding of Myc.  For the best-characterized compds., specific binding sites have been detd., and mol. mechanisms of action have been documented.  This knowledge of small mol.-protein interaction is currently applied to highly targeted approaches to identify novel compds. with improved potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYWOjlKJxaTLVg90H21EOLACvtfcHk0lhuwJx3k1h6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyisb7O&md5=25cac1ccda841463f58131a7c385b095</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1177%2F1947601910377494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601910377494%26sid%3Dliteratum%253Aachs%26aulast%3DProchownik%26aufirst%3DE.%2BV.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Myc%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26issue%3D6%26spage%3D650%26epage%3D659%26doi%3D10.1177%2F1947601910377494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjostrom, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowitch, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, A. M.</span></span> <span> </span><span class="NLM_article-title">The Cdk1 Complex Plays a Prime Role in Regulating N-Myc Phosphorylation and Turnover in Neural Precursors</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2005.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.devcel.2005.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=16139224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVert77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=327-338&issue=3&author=S.+K.+Sjostromauthor=G.+Finnauthor=W.+C.+Hahnauthor=D.+H.+Rowitchauthor=A.+M.+Kenney&title=The+Cdk1+Complex+Plays+a+Prime+Role+in+Regulating+N-Myc+Phosphorylation+and+Turnover+in+Neural+Precursors&doi=10.1016%2Fj.devcel.2005.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors</span></div><div class="casAuthors">Sjostrom, Sarah K.; Finn, Greg; Hahn, William C.; Rowitch, David H.; Kenney, Anna Marie</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-338</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Myc family transcription factors are destabilized by phosphorylation of a conserved amino-terminal GSK-3β motif.  In proliferating cerebellar granule neuron precursors (CGNPs), Sonic hedgehog signaling induces N-myc expression, and N-myc protein is stabilized by insulin-like growth factor-mediated suppression of GSK-3β.  N-myc phosphorylation-mediated degrdn. is a prerequisite for CGNP growth arrest and differentiation.  We investigated whether N-myc phosphorylation and turnover are thus linked to cell cycle exit in primary mouse CGNP cultures and the developing cerebellum.  We report that phosphorylation-induced turnover of endogenous N-myc protein in CGNPs increases during mitosis, due to increased priming phosphorylation of N-myc for GSK-3β.  The priming phosphorylation requires the Cdk1 complex, whose cyclin subunits are indirect Sonic hedgehog targets.  These findings provide a mechanism for promoting growth arrest in the final cycle of neural precursor proliferation competency, or for resetting the cell cycle in the G1 phase, by destabilizing N-myc in mitosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE2jHlwpZfZLVg90H21EOLACvtfcHk0lhR-ZQwLaE1cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVert77O&md5=d64628f5d9e5b5c3de55a64d34a2c355</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2005.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2005.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DSjostrom%26aufirst%3DS.%2BK.%26aulast%3DFinn%26aufirst%3DG.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DRowitch%26aufirst%3DD.%2BH.%26aulast%3DKenney%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Cdk1%2520Complex%2520Plays%2520a%2520Prime%2520Role%2520in%2520Regulating%2520N-Myc%2520Phosphorylation%2520and%2520Turnover%2520in%2520Neural%2520Precursors%26jtitle%3DDev.%2520Cell%26date%3D2005%26volume%3D9%26issue%3D3%26spage%3D327%26epage%3D338%26doi%3D10.1016%2Fj.devcel.2005.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Barrueco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, J.</span></span> <span> </span><span class="NLM_article-title">MYC Is a Critical Target of FBXW7</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">3292</span>– <span class="NLM_lpage">3305</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.18632%2Foncotarget.3203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25669969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrktlymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=3292-3305&issue=5&author=M.+Satoauthor=R.+Rodriguez-Barruecoauthor=J.+Yuauthor=C.+Doauthor=J.+M.+Silvaauthor=J.+Gautier&title=MYC+Is+a+Critical+Target+of+FBXW7&doi=10.18632%2Foncotarget.3203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">MYC is a critical target of FBXW7</span></div><div class="casAuthors">Sato Mai; Silva Jose M; Sato Mai; Rodriguez-Barrueco Ruth; Do Catherine; Silva Jose M; Gautier Jean; Rodriguez-Barrueco Ruth; Silva Jose M; Yu Jiyang; Gautier Jean</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3292-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MYC deregulation is a driver of many human cancers.  Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumorigenic phenotype.  While direct targeting of MYC is difficult, specific genetic vulnerabilities of MYC-deregulated cells could be exploited to selectively inhibit their growth.  Using a genome-wide shRNA screen, we identified 78 candidate genes, which are required for survival of human mammary epithelial cells with elevated MYC levels.  Among the candidates, we validated and characterized FBXW7, a component of the SCF-like ubiquitin ligase complex that targets MYC for proteasomal degradation.  Down-regulation of FBXW7 leads to synergistic accumulation of cellular and active chromatin-bound MYC, while protein levels of other FBXW7 targets appear unaffected.  Over a four-week time course, continuous FBXW7 down-regulation and MYC activation together cause an accumulation of cells in S-phase and G2/M-phase of the cell cycle.  Under these conditions, we also observe elevated chromatin-bound levels of CDC45, suggesting increased DNA replication stress.  Consistent with these results, FBXW7 down-regulation alone decreases the survival of T47D breast cancer cells.  These results establish that FBXW7 down-regulation is synthetic lethal with MYC, and that MYC is a critical target of FBXW7 in breast epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbGTerAThFYJQHPYJuLg8TfW6udTcc2eYmtwmOv6t3cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrktlymsg%253D%253D&md5=106e6e5dc6d87b8b637bfd334b30a475</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3203%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%26aulast%3DRodriguez-Barrueco%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DJ.%2BM.%26aulast%3DGautier%26aufirst%3DJ.%26atitle%3DMYC%2520Is%2520a%2520Critical%2520Target%2520of%2520FBXW7%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D3292%26epage%3D3305%26doi%3D10.18632%2Foncotarget.3203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüttrumpf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berwanger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span> <span> </span><span class="NLM_article-title">Stabilization of N-Myc Is a Critical Function of Aurora a in Human Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2008.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=19111882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=67-78&issue=1&author=T.+Ottoauthor=S.+Hornauthor=M.+Brockmannauthor=U.+Eilersauthor=L.+Sch%C3%BCttrumpfauthor=N.+Popovauthor=A.+M.+Kenneyauthor=J.+H.+Schulteauthor=R.+Beijersbergenauthor=H.+Christiansenauthor=B.+Berwangerauthor=M.+Eilers&title=Stabilization+of+N-Myc+Is+a+Critical+Function+of+Aurora+a+in+Human+Neuroblastoma&doi=10.1016%2Fj.ccr.2008.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma</span></div><div class="casAuthors">Otto, Tobias; Horn, Sebastian; Brockmann, Markus; Eilers, Ursula; Schuettrumpf, Lars; Popov, Nikita; Kenney, Anna Marie; Schulte, Johannes H.; Beijersbergen, Roderick; Christiansen, Holger; Berwanger, Bernd; Eilers, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-78</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">In human neuroblastoma, amplification of the MYCN gene predicts poor prognosis and resistance to therapy.  In a shRNA screen of genes that are highly expressed in MYCN-amplified tumors, the authors have identified AURKA as a gene that is required for the growth of MYCN-amplified neuroblastoma cells but largely dispensable for cells lacking amplified MYCN.  Aurora A has a crit. function in regulating turnover of the N-Myc protein.  Degrdn. of N-Myc requires sequential phosphorylation by cyclin B/Cdk1 and Gsk3.  N-Myc is therefore degraded during mitosis in response to low levels of PI3-kinase activity.  Aurora A interacts with both N-Myc and the SCFFbxw7 ubiquitin ligase that ubiquitinates N-Myc and counteracts degrdn. of N-Myc, thereby uncoupling N-Myc stability from growth factor-dependent signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7Wf4DMtd3SLVg90H21EOLACvtfcHk0lhR-ZQwLaE1cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptVKjsw%253D%253D&md5=954b16742a6a512725a003e602add047</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DT.%26aulast%3DHorn%26aufirst%3DS.%26aulast%3DBrockmann%26aufirst%3DM.%26aulast%3DEilers%26aufirst%3DU.%26aulast%3DSch%25C3%25BCttrumpf%26aufirst%3DL.%26aulast%3DPopov%26aufirst%3DN.%26aulast%3DKenney%26aufirst%3DA.%2BM.%26aulast%3DSchulte%26aufirst%3DJ.%2BH.%26aulast%3DBeijersbergen%26aufirst%3DR.%26aulast%3DChristiansen%26aufirst%3DH.%26aulast%3DBerwanger%26aufirst%3DB.%26aulast%3DEilers%26aufirst%3DM.%26atitle%3DStabilization%2520of%2520N-Myc%2520Is%2520a%2520Critical%2520Function%2520of%2520Aurora%2520a%2520in%2520Human%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D15%26issue%3D1%26spage%3D67%26epage%3D78%26doi%3D10.1016%2Fj.ccr.2008.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brockmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rycak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roels, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Aurora-a Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2013.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23792191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVymurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=75-89&issue=1&author=M.+Brockmannauthor=E.+Poonauthor=T.+Berryauthor=A.+Carstensenauthor=H.+E.+Deubzerauthor=L.+Rycakauthor=Y.+Jaminauthor=K.+Thwayauthor=S.+P.+Robinsonauthor=F.+Roelsauthor=O.+Wittauthor=M.+Fischerauthor=L.+Cheslerauthor=M.+Eilers&title=Small+Molecule+Inhibitors+of+Aurora-a+Induce+Proteasomal+Degradation+of+N-Myc+in+Childhood+Neuroblastoma&doi=10.1016%2Fj.ccr.2013.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma</span></div><div class="casAuthors">Brockmann, Markus; Poon, Evon; Berry, Teeara; Carstensen, Anne; Deubzer, Hedwig E.; Rycak, Lukas; Jamin, Yann; Thway, Khin; Robinson, Simon P.; Roels, Frederik; Witt, Olaf; Fischer, Matthias; Chesler, Louis; Eilers, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-89</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors, including neuroblastoma.  No small mols. that target N-Myc, the protein encoded by MYCN, are clin. available.  N-Myc forms a complex with the Aurora-A kinase, which protects N-Myc from proteasomal degrdn.  Although stabilization of N-Myc does not require the catalytic activity of Aurora-A, we show here that 2 Aurora-A inhibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-Myc complex and promote degrdn. of N-Myc mediated by the Fbxw7 ubiquitin ligase.  Disruption of the Aurora-A/N-Myc complex inhibits N-Myc-dependent transcription, correlating with tumor regression and prolonged survival in a mouse model of MYCN-driven neuroblastoma.  We conclude that Aurora-A is an accessible target that makes destabilization of N-Myc a viable therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09vD68WUraLVg90H21EOLACvtfcHk0lgptyru7GXQvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVymurY%253D&md5=0b53df3d2aaaad8c9a46c07e06227b2c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBrockmann%26aufirst%3DM.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DBerry%26aufirst%3DT.%26aulast%3DCarstensen%26aufirst%3DA.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DRycak%26aufirst%3DL.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DThway%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DRoels%26aufirst%3DF.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DEilers%26aufirst%3DM.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Aurora-a%2520Induce%2520Proteasomal%2520Degradation%2520of%2520N-Myc%2520in%2520Childhood%2520Neuroblastoma%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D24%26issue%3D1%26spage%3D75%26epage%3D89%26doi%3D10.1016%2Fj.ccr.2013.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecsedy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meetze, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balani, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burenkova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeRoy, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sells, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysong, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of MLN8054, an Orally Active Small-Molecule Inhibitor of Aurora a Kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4106</span>– <span class="NLM_lpage">4111</span>, <span class="refDoi"> DOI: 10.1073/pnas.0608798104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.0608798104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=17360485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=4106-4111&issue=10&author=M.+G.+Manfrediauthor=J.+A.+Ecsedyauthor=K.+A.+Meetzeauthor=S.+K.+Balaniauthor=O.+Burenkovaauthor=W.+Chenauthor=K.+M.+Galvinauthor=K.+M.+Hoarauthor=J.+J.+Huckauthor=P.+J.+LeRoyauthor=E.+T.+Rayauthor=T.+B.+Sellsauthor=B.+Stringerauthor=S.+G.+Stroudauthor=T.+J.+Vosauthor=G.+S.+Weatherheadauthor=D.+R.+Wysongauthor=M.+Zhangauthor=J.+B.+Bolenauthor=C.+F.+Claiborne&title=Antitumor+Activity+of+MLN8054%2C+an+Orally+Active+Small-Molecule+Inhibitor+of+Aurora+a+Kinase&doi=10.1073%2Fpnas.0608798104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase</span></div><div class="casAuthors">Manfredi, Mark G.; Ecsedy, Jeffrey A.; Meetze, Kristan A.; Balani, Suresh K.; Burenkova, Olga; Chen, Wei; Galvin, Katherine M.; Hoar, Kara M.; Huck, Jessica J.; LeRoy, Patrick J.; Ray, Emily T.; Sells, Todd B.; Stringer, Bradley; Stroud, Stephen G.; Vos, Tricia J.; Weatherhead, Gabriel S.; Wysong, Deborah R.; Zhang, Mengkun; Bolen, Joseph B.; Claiborne, Christopher F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4106-4111</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Increased Aurora A expression occurs in a variety of human cancers and induces chromosomal abnormalities during mitosis assocd. with tumor initiation and progression.  MLN8054 is a selective small-mol. Aurora A kinase inhibitor that has entered Phase I clin. trials for advanced solid tumors.  MLN8054 inhibits recombinant Aurora A kinase activity in vitro and is selective for Aurora A over the family member Aurora B in cultured cells.  MLN8054 treatment results in G2/M accumulation and spindle defects and inhibits proliferation in multiple cultured human tumor cells lines.  Growth of human tumor xenografts in nude mice was dramatically inhibited after oral administration of MLN8054 at well tolerated doses.  Moreover, the tumor growth inhibition was sustained after discontinuing MLN8054 treatment.  In human tumor xenografts, MLN8054 induced mitotic accumulation and apoptosis, phenotypes consistent with inhibition of Aurora A.  MLN8054 is a selective inhibitor of Aurora A kinase that robustly inhibits growth of human tumor xenografts and represents an attractive modality for therapeutic intervention of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLXnsHNqFuS7Vg90H21EOLACvtfcHk0lgptyru7GXQvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12nu7o%253D&md5=1c0cace58d13fa5ea5e3c0340a7c7f36</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0608798104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0608798104%26sid%3Dliteratum%253Aachs%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DEcsedy%26aufirst%3DJ.%2BA.%26aulast%3DMeetze%26aufirst%3DK.%2BA.%26aulast%3DBalani%26aufirst%3DS.%2BK.%26aulast%3DBurenkova%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DGalvin%26aufirst%3DK.%2BM.%26aulast%3DHoar%26aufirst%3DK.%2BM.%26aulast%3DHuck%26aufirst%3DJ.%2BJ.%26aulast%3DLeRoy%26aufirst%3DP.%2BJ.%26aulast%3DRay%26aufirst%3DE.%2BT.%26aulast%3DSells%26aufirst%3DT.%2BB.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DStroud%26aufirst%3DS.%2BG.%26aulast%3DVos%26aufirst%3DT.%2BJ.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DWysong%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26atitle%3DAntitumor%2520Activity%2520of%2520MLN8054%252C%2520an%2520Orally%2520Active%2520Small-Molecule%2520Inhibitor%2520of%2520Aurora%2520a%2520Kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26issue%3D10%26spage%3D4106%26epage%3D4111%26doi%3D10.1073%2Fpnas.0608798104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sloane, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikic, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M. L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M. B. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span> <span> </span><span class="NLM_article-title">Drug-Resistant Aurora a Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1021/cb100053q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100053q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVaktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=563-576&issue=6&author=D.+A.+Sloaneauthor=M.+Z.+Trikicauthor=M.+L.+H.+Chuauthor=M.+B.+A.+C.+Lamersauthor=C.+S.+Masonauthor=I.+Muellerauthor=W.+J.+Savoryauthor=D.+H.+Williamsauthor=P.+A.+Eyers&title=Drug-Resistant+Aurora+a+Mutants+for+Cellular+Target+Validation+of+the+Small+Molecule+Kinase+Inhibitors+MLN8054+and+MLN8237&doi=10.1021%2Fcb100053q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237</span></div><div class="casAuthors">Sloane, Dominic A.; Trikic, Michael Z.; Chu, Matthew L. H.; Lamers, Maria B. A. C.; Mason, Clive S.; Mueller, Ilka; Savory, Wendy J.; Williams, David H.; Eyers, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">563-576</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Aurora kinases regulate multiple aspects of mitotic progression, and their overexpression in diverse tumor types makes them appealing oncol. targets.  An intensive research effort over the past decade has led to the discovery of chem. distinct families of small mol. Aurora kinase inhibitors, many of which have demonstrated therapeutic potential in model systems.  These agents are also important tools to help dissect signaling pathways that are orchestrated by Aurora kinases, and the antiproliferative target of pan-Aurora inhibitors such as VX-680 has been validated using chem. genetic techniques.  In many cases the nonspecific nature of Aurora inhibitors toward unrelated kinases is well established, potentially broadening the spectrum of cancers to which these compds. might be applied.  However, unambiguously demonstrating the mol. target(s) for clin. kinase inhibitors is an important challenge, one that is absolutely crit. for deciphering the mol. basis of compd. specificity, resistance, and efficacy.  In this paper, we have investigated amino acid requirements for Aurora A sensitivity to the benzazepine-based Aurora inhibitor MLN8054 and the close analog MLN8237, a second-generation compd. that is in phase II clin. trials.  A crystallog. anal. facilitated the design and biochem. investigation of a panel of resistant Aurora A mutants, a subset of which were then selected as candidate drug-resistance targets for further evaluation.  Using inducible human cell lines, we show that cells expressing near-physiol. levels of a functional but partially drug-resistant Aurora A T217D mutant survive in the presence of MLN8054 or MLN8237, authenticating Aurora A as a crit. antiproliferative target of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjg-t6yjgWhLVg90H21EOLACvtfcHk0lgptyru7GXQvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVaktbs%253D&md5=f20bc2f2f827fd8f640570078d6505c6</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fcb100053q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100053q%26sid%3Dliteratum%253Aachs%26aulast%3DSloane%26aufirst%3DD.%2BA.%26aulast%3DTrikic%26aufirst%3DM.%2BZ.%26aulast%3DChu%26aufirst%3DM.%2BL.%2BH.%26aulast%3DLamers%26aufirst%3DM.%2BB.%2BA.%2BC.%26aulast%3DMason%26aufirst%3DC.%2BS.%26aulast%3DMueller%26aufirst%3DI.%26aulast%3DSavory%26aufirst%3DW.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26atitle%3DDrug-Resistant%2520Aurora%2520a%2520Mutants%2520for%2520Cellular%2520Target%2520Validation%2520of%2520the%2520Small%2520Molecule%2520Kinase%2520Inhibitors%2520MLN8054%2520and%2520MLN8237%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2010%26volume%3D5%26issue%3D6%26spage%3D563%26epage%3D576%26doi%3D10.1021%2Fcb100053q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrash, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavetsias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of an Aurora-a Mutant That Mimics Aurora-B Bound to MLN8054: Insights Into Selectivity and Drug Design</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>427</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1042/BJ20091530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1042%2FBJ20091530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20067443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2010&pages=19-28&issue=1&author=C.+A.+Dodsonauthor=M.+Kosmopoulouauthor=M.+W.+Richardsauthor=B.+Atrashauthor=V.+Bavetsiasauthor=J.+Blaggauthor=R.+Bayliss&title=Crystal+Structure+of+an+Aurora-a+Mutant+That+Mimics+Aurora-B+Bound+to+MLN8054%3A+Insights+Into+Selectivity+and+Drug+Design&doi=10.1042%2FBJ20091530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design</span></div><div class="casAuthors">Dodson, Charlotte A.; Kosmopoulou, Magda; Richards, Mark W.; Atrash, Butrus; Bavetsias, Vassilios; Blagg, Julian; Bayliss, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">427</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-28</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The prodn. of selective protein kinase inhibitors is often frustrated by the similarity of the enzyme active sites.  For this reason, it is challenging to design inhibitors that discriminate between the three Aurora kinases, which are important targets in cancer drug discovery.  We have used a triple-point mutant of Aurora-A (AurAx3) which mimics the active site of Aurora-B to investigate the structural basis of MLN8054 selectivity.  The bias toward Aurora-A inhibition by MLN8054 is fully recapitulated by AurAx3 in vitro.  X-ray crystal structures of the complex suggest that the basis for the discrimination is electrostatic repulsion due to the T217E substitution, which we have confirmed using a single-point mutant.  The activation loop of Aurora-A in the AurAx3-MLN8054 complex exhibits an unusual conformation in which Asp274 and Phe275 side chains point into the interior of the protein.  There is to our knowledge no documented precedent for this conformation, which we have termed DFG-up.  The sequence requirements of the DFG-up conformation suggest that it might be accessible to only a fraction of kinases.  MLN8054 thus circumvents the problem of highly homologous active sites.  Binding of MLN8054 to Aurora-A switches the character of a pocket within the active site from polar to a hydrophobic pocket, similar to what is obsd. in the structure of Aurora-A bound to a compd. that induces DFG-out.  We propose that targeting this pocket may be a productive route in the design of selective kinase inhibitors and describe the structural basis for the rational design of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdJs5KY2VkabVg90H21EOLACvtfcHk0liwSVS6dAAMVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyntr8%253D&md5=fdf1a176a5fdf5fcd71fd57c3ef92817</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1042%2FBJ20091530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20091530%26sid%3Dliteratum%253Aachs%26aulast%3DDodson%26aufirst%3DC.%2BA.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DRichards%26aufirst%3DM.%2BW.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520an%2520Aurora-a%2520Mutant%2520That%2520Mimics%2520Aurora-B%2520Bound%2520to%2520MLN8054%253A%2520Insights%2520Into%2520Selectivity%2520and%2520Drug%2520Design%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D427%26issue%3D1%26spage%3D19%26epage%3D28%26doi%3D10.1042%2FBJ20091530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerowitz, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekritz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonds, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthay, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertz, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span> <span> </span><span class="NLM_article-title">Drugging MYCN Through an Allosteric Transition in Aurora Kinase a</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ccr.2014.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25175806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKmsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=414-427&issue=3&author=W.+C.+Gustafsonauthor=J.+G.+Meyerowitzauthor=E.+A.+Nekritzauthor=J.+Chenauthor=C.+Benesauthor=E.+Charronauthor=E.+F.+Simondsauthor=R.+Seegerauthor=K.+K.+Matthayauthor=N.+T.+Hertzauthor=M.+Eilersauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=Drugging+MYCN+Through+an+Allosteric+Transition+in+Aurora+Kinase+a&doi=10.1016%2Fj.ccr.2014.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging MYCN through an Allosteric Transition in Aurora Kinase A</span></div><div class="casAuthors">Gustafson, William Clay; Meyerowitz, Justin Gabriel; Nekritz, Erin A.; Chen, Justin; Benes, Cyril; Charron, Elise; Simonds, Erin F.; Seeger, Robert; Matthay, Katherine K.; Hertz, Nicholas T.; Eilers, Martin; Shokat, Kevan M.; Weiss, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">414-427</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">MYC proteins are major drivers of cancer, yet are considered undruggable because their DNA binding domains are composed of two extended alpha helixes with no apparent surfaces for small-mol. binding.  Proteolytic degrdn. of MYCN protein is regulated in part by a kinase-independent function of Aurora A.  We describe a class of inhibitors that disrupts the native conformation of Aurora A and drives the degrdn. of MYCN protein across MYCN-driven cancers.  Comparison of cocrystal structures with structure-activity relationships across multiple inhibitors and chemotypes, coupled with mechanistic studies and biochem. assays, delineates an Aurora A conformation-specific effect on proteolytic degrdn. of MYCN, rather than simple nanomolar-level inhibition of Aurora A kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8At2LNPE-ubVg90H21EOLACvtfcHk0liwSVS6dAAMVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKmsLnJ&md5=20944894851fe5466422c149a0a0b266</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26aulast%3DMeyerowitz%26aufirst%3DJ.%2BG.%26aulast%3DNekritz%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DCharron%26aufirst%3DE.%26aulast%3DSimonds%26aufirst%3DE.%2BF.%26aulast%3DSeeger%26aufirst%3DR.%26aulast%3DMatthay%26aufirst%3DK.%2BK.%26aulast%3DHertz%26aufirst%3DN.%2BT.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DDrugging%2520MYCN%2520Through%2520an%2520Allosteric%2520Transition%2520in%2520Aurora%2520Kinase%2520a%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D3%26spage%3D414%26epage%3D427%26doi%3D10.1016%2Fj.ccr.2014.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, L. H.</span></span> <span> </span><span class="NLM_article-title">The Design, Synthesis, and Evaluation of 8 Hybrid DFG-Out Allosteric Kinase Inhibitors: a Structural Analysis of the Binding Interactions of Gleevec, Nexavar, and BIRB-796</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5738</span>– <span class="NLM_lpage">5748</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmc.2010.05.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20621496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5738-5748&issue=15&author=J.+Dietrichauthor=C.+Hulmeauthor=L.+H.+Hurley&title=The+Design%2C+Synthesis%2C+and+Evaluation+of+8+Hybrid+DFG-Out+Allosteric+Kinase+Inhibitors%3A+a+Structural+Analysis+of+the+Binding+Interactions+of+Gleevec%2C+Nexavar%2C+and+BIRB-796&doi=10.1016%2Fj.bmc.2010.05.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796</span></div><div class="casAuthors">Dietrich, Justin; Hulme, Christopher; Hurley, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5738-5748</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The majority of kinase inhibitors developed to date are competitive inhibitors that target the ATP binding site; however, recent crystal structures of Gleevec (imatinib mesylate, STI571, PDB: 1IEP), Nexavar (Sorafenib tosylate, BAY 43-9006, PDB: 1UWJ), and BIRB-796 (PDB: 1KV2) have revealed a secondary binding site adjacent to the ATP binding site known as the DFG-out allosteric binding site.  The recent successes of Gleevec and Nexavar for the treatment of chronic myeloid leukemia and renal cell carcinoma has generated great interest in the development of other kinase inhibitors that target this secondary binding site.  Here, we present a structural comparison of the important and similar interactions necessary for Gleevec, Nexavar, and BIRB-796 to bind to their resp. DFG-out allosteric binding pockets and the selectivity of each with respect to c-Abl, B-Raf, and p38α.  A structural anal. of their selectivity profiles has been generated from the synthesis and evaluation of 8 addnl. DFG-out allosteric inhibitors that were developed directly from fragments of these successful scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuTXCEZCwd0bVg90H21EOLACvtfcHk0liwSVS6dAAMVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGhu7s%253D&md5=430e5d3c95213441b17030a931f6e2ad</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.063%26sid%3Dliteratum%253Aachs%26aulast%3DDietrich%26aufirst%3DJ.%26aulast%3DHulme%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DThe%2520Design%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%25208%2520Hybrid%2520DFG-Out%2520Allosteric%2520Kinase%2520Inhibitors%253A%2520a%2520Structural%2520Analysis%2520of%2520the%2520Binding%2520Interactions%2520of%2520Gleevec%252C%2520Nexavar%252C%2520and%2520BIRB-796%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D15%26spage%3D5738%26epage%3D5748%26doi%3D10.1016%2Fj.bmc.2010.05.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filomia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rienzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menziani, M. C.</span></span> <span> </span><span class="NLM_article-title">Insights Into MAPK p38α DFG Flip Mechanism by Accelerated Molecular Dynamics</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">6805</span>– <span class="NLM_lpage">6812</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmc.2010.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20724167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamt7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6805-6812&issue=18&author=F.+Filomiaauthor=F.+De+Rienzoauthor=M.+C.+Menziani&title=Insights+Into+MAPK+p38%CE%B1+DFG+Flip+Mechanism+by+Accelerated+Molecular+Dynamics&doi=10.1016%2Fj.bmc.2010.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into MAPK p38α DFG flip mechanism by accelerated molecular dynamics</span></div><div class="casAuthors">Filomia, Federico; De Rienzo, Francesca; Menziani, M. Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6805-6812</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The DFG motif at the beginning of the activation loop of the MAPK p38α undergoes a local structural reorganization upon binding of allosteric type-II and type-III inhibitors, which causes the residue F169 to move from a buried conformation (defined as DFG-in) to a solvent exposed conformation (defined as DFG-out).  Although both exptl. and computer simulation studies had been performed with the aim of unveiling the details of the DFG-in to DFG-out transition, the mol. mechanism is still far from being unequivocally depicted.  Here, the accelerated mol. dynamics (AMD) technique has been applied to model the active loop flexibility of p38α and sample special protein conformations which can be accessible only in some conditions or time periods.  Starting from the assumption of an exptl. known initial and final state of the protein, the study allowed the description of the interaction network and the structural intermediates which lead the protein to change its loop conformation and active site accessibility.  Besides a few important hydrogen bond interactions, a primary role seems to be played by cation-π interactions, involving the DFG-loop residue F169, which participate in the stabilization of an intermediate conformation and in its consequent transition to the DFG-out conformation.  From this study, insights which may prove useful for inhibitor design and/or site directed mutagenesis studies are derived.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJP0YSfTC6D7Vg90H21EOLACvtfcHk0lgkAjTT_bzH5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamt7%252FJ&md5=f938ad724335525311f9531ba4528e77</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DFilomia%26aufirst%3DF.%26aulast%3DDe%2BRienzo%26aufirst%3DF.%26aulast%3DMenziani%26aufirst%3DM.%2BC.%26atitle%3DInsights%2520Into%2520MAPK%2520p38%25CE%25B1%2520DFG%2520Flip%2520Mechanism%2520by%2520Accelerated%2520Molecular%2520Dynamics%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26issue%3D18%26spage%3D6805%26epage%3D6812%26doi%3D10.1016%2Fj.bmc.2010.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyerowitz, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, W. C.</span></span> <span> </span><span class="NLM_article-title">A New “Angle” on Kinase Inhibitor Design: Prioritizing Amphosteric Activity Above Kinase Inhibition</span>. <i>Mol. Cell. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e975641</span>, <span class="refDoi"> DOI: 10.4161/23723556.2014.975641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.4161%2F23723556.2014.975641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27308435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=e975641&issue=2&author=J.+G.+Meyerowitzauthor=W.+A.+Weissauthor=W.+C.+Gustafson&title=A+New+%E2%80%9CAngle%E2%80%9D+on+Kinase+Inhibitor+Design%3A+Prioritizing+Amphosteric+Activity+Above+Kinase+Inhibition&doi=10.4161%2F23723556.2014.975641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above Aurora kinase A inhibition</span></div><div class="casAuthors">Meyerowitz, Justin G.; Weiss, William A.; Gustafson, W. Clay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e975641/1-e975641/3</span>CODEN:
                <span class="NLM_cas:coden">MCOOCO</span>;
        ISSN:<span class="NLM_cas:issn">2372-3556</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The MYCN oncoprotein has remained an elusive target for decades.  We recently reported a new class of kinase inhibitors designed to disrupt the conformation of Aurora kinase A enough to block its kinase-independent interaction with MYCN, resulting in potent degrdn. of MYCN.  These studies provide proof-of-principle for a new method of targeting enzyme activity-independent functions of kinases and other enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT0fnQuBQMpbVg90H21EOLACvtfcHk0lgkAjTT_bzH5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWqu7w%253D&md5=46174a42a5bb5e2ce73b69c7f030bcde</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.4161%2F23723556.2014.975641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F23723556.2014.975641%26sid%3Dliteratum%253Aachs%26aulast%3DMeyerowitz%26aufirst%3DJ.%2BG.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DGustafson%26aufirst%3DW.%2BC.%26atitle%3DA%2520New%2520%25E2%2580%259CAngle%25E2%2580%259D%2520on%2520Kinase%2520Inhibitor%2520Design%253A%2520Prioritizing%2520Amphosteric%2520Activity%2520Above%2520Kinase%2520Inhibition%26jtitle%3DMol.%2520Cell.%2520Oncol.%26date%3D2015%26volume%3D2%26issue%3D2%26spage%3De975641%26doi%3D10.4161%2F23723556.2014.975641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerres, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischerauer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flotzinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kölle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancia, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischerikow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mück, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peinsipp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumpel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varecka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss-Puxbaum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span> <span> </span><span class="NLM_article-title">Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2860</span>– <span class="NLM_lpage">2875</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.08.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.celrep.2017.08.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28930682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=2860-2875&issue=12&author=N.+Kerresauthor=S.+Steurerauthor=S.+Schlagerauthor=G.+Baderauthor=H.+Bergerauthor=M.+Caligiuriauthor=C.+Dankauthor=J.+R.+Engenauthor=P.+Ettmayerauthor=B.+Fischerauerauthor=G.+Flotzingerauthor=D.+Gerlachauthor=T.+Gerstbergerauthor=T.+Gmaschitzauthor=P.+Grebauthor=B.+Hanauthor=E.+Heyesauthor=R.+E.+Iacobauthor=D.+Kesslerauthor=H.+K%C3%B6lleauthor=L.+Lamarreauthor=D.+R.+Lanciaauthor=S.+Lucasauthor=M.+Mayerauthor=K.+Mayrauthor=N.+Mischerikowauthor=K.+M%C3%BCckauthor=C.+Peinsippauthor=O.+Petermannauthor=U.+Reiserauthor=D.+Rudolphauthor=K.+Rumpelauthor=C.+Salomonauthor=D.+Scharnauthor=R.+Schnitzerauthor=A.+Schrenkauthor=N.+Schweiferauthor=D.+Thompsonauthor=E.+Traxlerauthor=R.+Vareckaauthor=T.+Vossauthor=A.+Weiss-Puxbaumauthor=S.+Winklerauthor=X.+Zhengauthor=A.+Zoephelauthor=N.+Krautauthor=D.+McConnellauthor=M.+Pearsonauthor=M.+Koegl&title=Chemically+Induced+Degradation+of+the+Oncogenic+Transcription+Factor+BCL6&doi=10.1016%2Fj.celrep.2017.08.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6</span></div><div class="casAuthors">Kerres, Nina; Steurer, Steffen; Schlager, Stefanie; Bader, Gerd; Berger, Helmut; Caligiuri, Maureen; Dank, Christian; Engen, John R.; Ettmayer, Peter; Fischerauer, Bernhard; Flotzinger, Gerlinde; Gerlach, Daniel; Gerstberger, Thomas; Gmaschitz, Teresa; Greb, Peter; Han, Bingsong; Heyes, Elizabeth; Iacob, Roxana E.; Kessler, Dirk; Koelle, Heike; Lamarre, Lyne; Lancia, David R.; Lucas, Simon; Mayer, Moriz; Mayr, Katharina; Mischerikow, Nikolai; Mueck, Katja; Peinsipp, Christoph; Petermann, Oliver; Reiser, Ulrich; Rudolph, Dorothea; Rumpel, Klaus; Salomon, Carina; Scharn, Dirk; Schnitzer, Renate; Schrenk, Andreas; Schweifer, Norbert; Thompson, Diane; Traxler, Elisabeth; Varecka, Roland; Voss, Tilman; Weiss-Puxbaum, Alexander; Winkler, Sandra; Zheng, Xiaozhang; Zoephel, Andreas; Kraut, Norbert; McConnell, Darryl; Pearson, Mark; Koegl, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2860-2875</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL).  Disruption of its interaction with transcriptional repressors interferes with the oncogenic effects of BCL6.  We used a structure-based drug design to develop highly potent compds. that block this interaction.  A subset of these inhibitors also causes rapid ubiquitylation and degrdn. of BCL6 in cells.  These compds. display significantly stronger induction of expression of BCL6-repressed genes and anti-proliferative effects than compds. that merely inhibit co-repressor interactions.  This work establishes the BTB domain as a highly druggable structure, paving the way for the use of other members of this protein family as drug targets.  The magnitude of effects elicited by this class of BCL6-degrading compds. exceeds that of our equipotent non-degrading inhibitors, suggesting opportunities for the development of BCL6-based lymphoma therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfmjxa_7LnrVg90H21EOLACvtfcHk0lgkAjTT_bzH5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsrfK&md5=45b538db6643abbd5b8f3fa04770a772</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.08.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.08.081%26sid%3Dliteratum%253Aachs%26aulast%3DKerres%26aufirst%3DN.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DSchlager%26aufirst%3DS.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFischerauer%26aufirst%3DB.%26aulast%3DFlotzinger%26aufirst%3DG.%26aulast%3DGerlach%26aufirst%3DD.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHeyes%26aufirst%3DE.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DKessler%26aufirst%3DD.%26aulast%3DK%25C3%25B6lle%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLancia%26aufirst%3DD.%2BR.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DMayr%26aufirst%3DK.%26aulast%3DMischerikow%26aufirst%3DN.%26aulast%3DM%25C3%25BCck%26aufirst%3DK.%26aulast%3DPeinsipp%26aufirst%3DC.%26aulast%3DPetermann%26aufirst%3DO.%26aulast%3DReiser%26aufirst%3DU.%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DRumpel%26aufirst%3DK.%26aulast%3DSalomon%26aufirst%3DC.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DVarecka%26aufirst%3DR.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DWeiss-Puxbaum%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DMcConnell%26aufirst%3DD.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DKoegl%26aufirst%3DM.%26atitle%3DChemically%2520Induced%2520Degradation%2520of%2520the%2520Oncogenic%2520Transcription%2520Factor%2520BCL6%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D20%26issue%3D12%26spage%3D2860%26epage%3D2875%26doi%3D10.1016%2Fj.celrep.2017.08.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purushottamachar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbole, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gediya, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasaitis, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwegyir-Afful, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ates-Alagoz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njar, V. C. O.</span></span> <span> </span><span class="NLM_article-title">Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone to Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4880</span>– <span class="NLM_lpage">4898</span>, <span class="refDoi"> DOI: 10.1021/jm400048v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400048v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVeis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4880-4898&issue=12&author=P.+Purushottamacharauthor=A.+M.+Godboleauthor=L.+K.+Gediyaauthor=M.+S.+Martinauthor=T.+S.+Vasaitisauthor=A.+K.+Kwegyir-Affulauthor=S.+Ramalingamauthor=Z.+Ates-Alagozauthor=V.+C.+O.+Njar&title=Systematic+Structure+Modifications+of+Multitarget+Prostate+Cancer+Drug+Candidate+Galeterone+to+Produce+Novel+Androgen+Receptor+Down-Regulating+Agents+as+an+Approach+to+Treatment+of+Advanced+Prostate+Cancer&doi=10.1021%2Fjm400048v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer</span></div><div class="casAuthors">Purushottamachar, Puranik; Godbole, Abhijit M.; Gediya, Lalji K.; Martin, Marlena S.; Vasaitis, Tadas S.; Kwegyir-Afful, Andrew K.; Ramalingam, Senthilmurugan; Ates-Alagoz, Zeynep; Njar, Vincent C. O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4880-4898</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of the authors' program to explore the influence of small structural modifications of the authors' drug candidate 3β-(hydroxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (galeterone) on the modulation of the androgen receptor (AR), the authors have prepd. and evaluated a series of novel C-3, C-16, and C-17 analogs.  Using structure activity anal., the authors established that the benzimidazole moiety at C-17 is essential and optimal and also that hydrophilic and heteroarom. groups at C-3 enhance both antiproliferative (AP) and AR degrading (ARD) activities.  The most potent antiproliferative compds. were 3β-(1H-imidazole-1-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene, 3-((EZ)-hydroximino)-17-(1H-benzimidazol-1-yl)androsta-4,16-diene, and 3β-(pyridine-4-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene, with GIC50 values of 0.87, 1.91, and 2.57 μM, resp.  Compared to galeterone, 3β-(1H-imidazole-1-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene was 4- and 8-fold more potent with respect to AP and ARD activities, resp.  Importantly, the authors also discovered that the compds. listed above could degrade both full-length and truncated ARs in CWR22rv1 human prostate cancer cells.  With these activities, they have potential for development as new drugs for the treatment of all forms of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0mOnJvfkXYbVg90H21EOLACvtfcHk0lignEMj49iwKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVeis7s%253D&md5=b54990d661614231dc8c3b10f8b6f804</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Fjm400048v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400048v%26sid%3Dliteratum%253Aachs%26aulast%3DPurushottamachar%26aufirst%3DP.%26aulast%3DGodbole%26aufirst%3DA.%2BM.%26aulast%3DGediya%26aufirst%3DL.%2BK.%26aulast%3DMartin%26aufirst%3DM.%2BS.%26aulast%3DVasaitis%26aufirst%3DT.%2BS.%26aulast%3DKwegyir-Afful%26aufirst%3DA.%2BK.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DAtes-Alagoz%26aufirst%3DZ.%26aulast%3DNjar%26aufirst%3DV.%2BC.%2BO.%26atitle%3DSystematic%2520Structure%2520Modifications%2520of%2520Multitarget%2520Prostate%2520Cancer%2520Drug%2520Candidate%2520Galeterone%2520to%2520Produce%2520Novel%2520Androgen%2520Receptor%2520Down-Regulating%2520Agents%2520as%2520an%2520Approach%2520to%2520Treatment%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D12%26spage%3D4880%26epage%3D4898%26doi%3D10.1021%2Fjm400048v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purushottamachar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwegyir-Afful, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamurthy, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njar, V. C. O.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00137</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00137" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xotl2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=708-713&issue=7&author=P.+Purushottamacharauthor=A.+K.+Kwegyir-Affulauthor=M.+S.+Martinauthor=V.+P.+Ramamurthyauthor=S.+Ramalingamauthor=V.+C.+O.+Njar&title=Identification+of+Novel+Steroidal+Androgen+Receptor+Degrading+Agents+Inspired+by+Galeterone+3%CE%B2-Imidazole+Carbamate&doi=10.1021%2Facsmedchemlett.6b00137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate</span></div><div class="casAuthors">Purushottamachar, Puranik; Kwegyir-Afful, Andrew K.; Martin, Marlena S.; Ramamurthy, Vidya P.; Ramalingam, Senthilmurugan; Njar, Vincent C. O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">708-713</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Degrdn. of all forms of androgen receptors (ARs) is emerging as an advantageous therapeutic paradigm for the effective treatment of prostate cancer.  In continuation of our program to identify and develop improved efficacious novel small-mol. agents designed to disrupt AR signaling through enhanced AR degrdn., we have designed, synthesized, and evaluated novel C-3 modified analogs of our phase 3 clin. agent, galeterone I.  Concerns of potential in vivo stability of our recently discovered more efficacious galeterone 3β-imidazole carbamate II led to the design and synthesis of new steroidal compds.  Two of the 11 compds., 3β-pyridyl ether III and 3β-imidazole IV with antiproliferative GI50 values of 3.24 and 2.54 μM against CWR22Rv1 prostate cancer cell, are 2.75- and 3.5-fold superior to I.  In addn., compds. III and IV possess improved (∼4-fold) AR-V7 degrading activities.  Importantly, these two compds. are expected to be metabolically stable, making them suitable for further development as new therapeutics against all forms of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowF_M83EYRpLVg90H21EOLACvtfcHk0lignEMj49iwKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xotl2qu7k%253D&md5=5f07c9f57ea1fd65b8775ed2d774c863</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00137%26sid%3Dliteratum%253Aachs%26aulast%3DPurushottamachar%26aufirst%3DP.%26aulast%3DKwegyir-Afful%26aufirst%3DA.%2BK.%26aulast%3DMartin%26aufirst%3DM.%2BS.%26aulast%3DRamamurthy%26aufirst%3DV.%2BP.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DNjar%26aufirst%3DV.%2BC.%2BO.%26atitle%3DIdentification%2520of%2520Novel%2520Steroidal%2520Androgen%2520Receptor%2520Degrading%2520Agents%2520Inspired%2520by%2520Galeterone%25203%25CE%25B2-Imidazole%2520Carbamate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D7%26spage%3D708%26epage%3D713%26doi%3D10.1021%2Facsmedchemlett.6b00137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coss, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selth, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagadala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wake, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledbetter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldoveanu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span> <span> </span><span class="NLM_article-title">Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6282</span>– <span class="NLM_lpage">6298</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-17-0976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28978635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6282-6298&issue=22&author=S.+Ponnusamyauthor=C.+C.+Cossauthor=T.+Thiyagarajanauthor=K.+Wattsauthor=D.-J.+Hwangauthor=Y.+Heauthor=L.+A.+Selthauthor=I.+J.+McEwanauthor=C.+B.+Dukeauthor=J.+Pagadalaauthor=G.+Singhauthor=R.+W.+Wakeauthor=C.+Ledbetterauthor=W.+D.+Tilleyauthor=T.+Moldoveanuauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=R.+Narayanan&title=Novel+Selective+Agents+for+the+Degradation+of+Androgen+Receptor+Variants+to+Treat+Castration-Resistant+Prostate+Cancer&doi=10.1158%2F0008-5472.CAN-17-0976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer</span></div><div class="casAuthors">Ponnusamy, Suriyan; Coss, Christopher C.; Thiyagarajan, Thirumagal; Watts, Kate; Hwang, Dong-Jin; He, Yali; Selth, Luke A.; McEwan, Iain J.; Duke, Charles B.; Pagadala, Jayaprakash; Singh, Geetika; Wake, Robert W.; Ledbetter, Christopher; Tilley, Wayne D.; Moldoveanu, Tudor; Dalton, James T.; Miller, Duane D.; Narayanan, Ramesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6282-6298</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Androgen receptor (AR) mediates the growth of prostate cancer throughout its course of development, including in abnormal splice variants (AR-SV)-driven advanced stage castration-resistant disease.  AR stabilization by androgens makes it distinct from other steroid receptors, which are typically ubiquitinated and degraded by proteasomes after ligand binding.  Thus, targeting AR in advanced prostate cancer requires the development of agents that can sustainably degrade variant isoforms for effective therapy.  Here we report the discovery and characterization of potent selective AR degraders (SARD) that markedly reduce the activity of wild-type and splice variant isoforms of AR at submicromolar doses.  Three SARDs (UT-69, UT-155, and (R)-UT-155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted for degrdn. previously, with two of these SARD (UT-69 and UT-155) also binding the carboxy-terminal ligand binding domain.  Despite different mechanisms of action, all three SARDs degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the approved AR antagonists.  Collectively, our results introduce a new candidate class of next-generation therapeutics to manage advanced prostate cancer.  Cancer Res; 77(22); 6282-98. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUU2nKdVBuLVg90H21EOLACvtfcHk0lgcc2e0oTpG5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur%252FI&md5=683c849987ed758177664b949dcc98ea</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0976%26sid%3Dliteratum%253Aachs%26aulast%3DPonnusamy%26aufirst%3DS.%26aulast%3DCoss%26aufirst%3DC.%2BC.%26aulast%3DThiyagarajan%26aufirst%3DT.%26aulast%3DWatts%26aufirst%3DK.%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DSelth%26aufirst%3DL.%2BA.%26aulast%3DMcEwan%26aufirst%3DI.%2BJ.%26aulast%3DDuke%26aufirst%3DC.%2BB.%26aulast%3DPagadala%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DWake%26aufirst%3DR.%2BW.%26aulast%3DLedbetter%26aufirst%3DC.%26aulast%3DTilley%26aufirst%3DW.%2BD.%26aulast%3DMoldoveanu%26aufirst%3DT.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DNarayanan%26aufirst%3DR.%26atitle%3DNovel%2520Selective%2520Agents%2520for%2520the%2520Degradation%2520of%2520Androgen%2520Receptor%2520Variants%2520to%2520Treat%2520Castration-Resistant%2520Prostate%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D22%26spage%3D6282%26epage%3D6298%26doi%3D10.1158%2F0008-5472.CAN-17-0976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00973</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00973" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=491-511&issue=2&author=D.-J.+Hwangauthor=Y.+Heauthor=S.+Ponnusamyauthor=M.+L.+Mohlerauthor=T.+Thiyagarajanauthor=I.+J.+McEwanauthor=R.+Narayananauthor=D.+D.+Miller&title=New+Generation+of+Selective+Androgen+Receptor+Degraders%3A+Our+Initial+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+New+Compounds+with+Enzalutamide-Resistant+Prostate+Cancer+Activity&doi=10.1021%2Facs.jmedchem.8b00973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity</span></div><div class="casAuthors">Hwang, Dong-Jin; He, Yali; Ponnusamy, Suriyan; Mohler, Michael L.; Thiyagarajan, Thirumagal; McEwan, Iain J.; Narayanan, Ramesh; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">491-511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to find small-mol. treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs).  Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability.  Cyclization to II and III produced submicromolar AR antagonism and protein degrdn. selective to AR and AR splice variant (AR SV).  II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs.  Design, synthesis, and biol. activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr10pfDXlGf9bVg90H21EOLACvtfcHk0lgcc2e0oTpG5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjE&md5=c65b48e592c8746ca821726f007f7b6f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00973%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DPonnusamy%26aufirst%3DS.%26aulast%3DMohler%26aufirst%3DM.%2BL.%26aulast%3DThiyagarajan%26aufirst%3DT.%26aulast%3DMcEwan%26aufirst%3DI.%2BJ.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DNew%2520Generation%2520of%2520Selective%2520Androgen%2520Receptor%2520Degraders%253A%2520Our%2520Initial%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520New%2520Compounds%2520with%2520Enzalutamide-Resistant%2520Prostate%2520Cancer%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D491%26epage%3D511%26doi%3D10.1021%2Facs.jmedchem.8b00973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lack, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennie, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherkasov, A.</span></span> <span> </span><span class="NLM_article-title">Small Molecule-Induced Degradation of the Full Length and V7 Truncated Variant Forms of Human Androgen Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.ejmech.2018.08.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30193215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GksLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=1164-1173&author=K.+Dalalauthor=H.+Morinauthor=F.+Banauthor=A.+Shepherdauthor=M.+Fernandezauthor=K.+J.+Tamauthor=H.+Liauthor=E.+LeBlancauthor=N.+Lackauthor=H.+Prinzauthor=P.+S.+Rennieauthor=A.+Cherkasov&title=Small+Molecule-Induced+Degradation+of+the+Full+Length+and+V7+Truncated+Variant+Forms+of+Human+Androgen+Receptor&doi=10.1016%2Fj.ejmech.2018.08.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor</span></div><div class="casAuthors">Dalal, Kush; Morin, Helene; Ban, Fuqiang; Shepherd, Ashley; Fernandez, Michael; Tam, Kevin J.; Li, Huifang; LeBlanc, Eric; Lack, Nathan; Prinz, Helge; Rennie, Paul S.; Cherkasov, Artem</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1164-1173</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets.  Currently clin. approved small mol. inhibitors of AR, such as enzalutamide, are built upon a common chem. scaffold that interacts with the AR by the same mechanism of action.  These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease.  The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, esp. since AR signalling remains important even in late-stage advanced PCa.  Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degrdn. and display some ability to block recruitment of hormones to the receptor.  In the current work, we extended the anal. of the lead compds., and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivs. capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor.  Importantly, the developed compds. efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD8u9wCiR-ZLVg90H21EOLACvtfcHk0lgcc2e0oTpG5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GksLbP&md5=e0fe03ffa376ce03c03fb475ac755b20</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.059%26sid%3Dliteratum%253Aachs%26aulast%3DDalal%26aufirst%3DK.%26aulast%3DMorin%26aufirst%3DH.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DShepherd%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DM.%26aulast%3DTam%26aufirst%3DK.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLeBlanc%26aufirst%3DE.%26aulast%3DLack%26aufirst%3DN.%26aulast%3DPrinz%26aufirst%3DH.%26aulast%3DRennie%26aufirst%3DP.%2BS.%26aulast%3DCherkasov%26aufirst%3DA.%26atitle%3DSmall%2520Molecule-Induced%2520Degradation%2520of%2520the%2520Full%2520Length%2520and%2520V7%2520Truncated%2520Variant%2520Forms%2520of%2520Human%2520Androgen%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D1164%26epage%3D1173%26doi%3D10.1016%2Fj.ejmech.2018.08.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girdwood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, U. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortlock, A. A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Androgen Receptor Downregulators as an Approach to Treatment of Advanced Prostate Cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5442</span>– <span class="NLM_lpage">5445</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.06.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2011.06.122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=21782422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKis7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5442-5445&issue=18&author=R.+H.+Bradburyauthor=N.+J.+Halesauthor=A.+A.+Rabowauthor=G.+E.+Walkerauthor=D.+G.+Actonauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=N.+A.+N.+Brooksauthor=N.+Colcloughauthor=A.+Girdwoodauthor=U.+J.+Hancoxauthor=O.+Jonesauthor=D.+Judeauthor=S.+A.+Loddickauthor=A.+A.+Mortlock&title=Small-Molecule+Androgen+Receptor+Downregulators+as+an+Approach+to+Treatment+of+Advanced+Prostate+Cancer&doi=10.1016%2Fj.bmcl.2011.06.122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer</span></div><div class="casAuthors">Bradbury, Robert H.; Hales, Neil J.; Rabow, Alfred A.; Walker, Graeme E.; Acton, David G.; Andrews, David M.; Ballard, Peter; Brooks, Nigel A. N.; Colclough, Nicola; Girdwood, Alan; Hancox, Urs J.; Jones, Owen; Jude, David; Loddick, Sarah A.; Mortlock, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5442-5445</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chem. starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer.  Although prototypic steroidal downregulators such as 6a designed for i.m. administration showed insufficient cellular potency, a medicinal chem. program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine (10b), for which high plasma levels following oral administration in a preclin. model compensate for moderate cellular potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDCeGpPNTfxLVg90H21EOLACvtfcHk0lj33zCFaXY3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKis7nM&md5=dfd44749a6307b772c75920cb3814b7b</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.06.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.06.122%26sid%3Dliteratum%253Aachs%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DHales%26aufirst%3DN.%2BJ.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%2BN.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DGirdwood%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DU.%2BJ.%26aulast%3DJones%26aufirst%3DO.%26aulast%3DJude%26aufirst%3DD.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMortlock%26aufirst%3DA.%2BA.%26atitle%3DSmall-Molecule%2520Androgen%2520Receptor%2520Downregulators%2520as%2520an%2520Approach%2520to%2520Treatment%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D18%26spage%3D5442%26epage%3D5445%26doi%3D10.1016%2Fj.bmcl.2011.06.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parveen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma-Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD3514, a Small-Molecule Androgen Receptor Downregulator for Treatment of Advanced Prostate Cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1945</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2013.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23466225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1Cit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1945-1948&issue=7&author=R.+H.+Bradburyauthor=D.+G.+Actonauthor=N.+L.+Broadbentauthor=A.+N.+Brooksauthor=G.+R.+Carrauthor=G.+Hatterauthor=B.+R.+Hayterauthor=K.+J.+Hillauthor=N.+J.+Howeauthor=R.+D.+O.+Jonesauthor=D.+Judeauthor=S.+G.+Lamontauthor=S.+A.+Loddickauthor=H.+L.+McFarlandauthor=Z.+Parveenauthor=A.+A.+Rabowauthor=G.+Sharma-Singhauthor=N.+C.+Strattonauthor=A.+G.+Thomasonauthor=D.+Truemanauthor=G.+E.+Walkerauthor=S.+L.+Wellsauthor=J.+Wilsonauthor=J.+M.+Wood&title=Discovery+of+AZD3514%2C+a+Small-Molecule+Androgen+Receptor+Downregulator+for+Treatment+of+Advanced+Prostate+Cancer&doi=10.1016%2Fj.bmcl.2013.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer</span></div><div class="casAuthors">Bradbury, Robert H.; Acton, David G.; Broadbent, Nicola L.; Brooks, A. Nigel; Carr, Gregory R.; Hatter, Glenn; Hayter, Barry R.; Hill, Kathryn J.; Howe, Nicholas J.; Jones, Rhys D. O.; Jude, David; Lamont, Scott G.; Loddick, Sarah A.; McFarland, Heather L.; Parveen, Zaieda; Rabow, Alfred A.; Sharma-Singh, Gorkhn; Stratton, Natalie C.; Thomason, Andrew G.; Trueman, Dawn; Walker, Graeme E.; Wells, Stuart L.; Wilson, Joanne; Wood, J. Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1945-1948</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial redn. of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine (1) addressed hERG and phys. property issues, and led to clin. candidate 6-(4-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}piperidin-1-yl)-3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clin. trial in patients with castrate-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaxgJ1mG7VBLVg90H21EOLACvtfcHk0lj33zCFaXY3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1Cit78%253D&md5=a7b1ebac3f7d412fa78e0188dceec42d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DBroadbent%26aufirst%3DN.%2BL.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DCarr%26aufirst%3DG.%2BR.%26aulast%3DHatter%26aufirst%3DG.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHill%26aufirst%3DK.%2BJ.%26aulast%3DHowe%26aufirst%3DN.%2BJ.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DJude%26aufirst%3DD.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DParveen%26aufirst%3DZ.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DSharma-Singh%26aufirst%3DG.%26aulast%3DStratton%26aufirst%3DN.%2BC.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DTrueman%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWells%26aufirst%3DS.%2BL.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520of%2520AZD3514%252C%2520a%2520Small-Molecule%2520Androgen%2520Receptor%2520Downregulator%2520for%2520Treatment%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D7%26spage%3D1945%26epage%3D1948%26doi%3D10.1016%2Fj.bmcl.2013.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omlin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelman, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clack, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alumkal, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malone, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, T.</span></span> <span> </span><span class="NLM_article-title">A First-in-Human Study of the Oral Selective Androgen Receptor Down-Regulating Drug (SARD) AZD3514 in Patients with Castration-Resistant Prostate Cancer (CRPC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">4511</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.31.15_suppl.4511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1200%2Fjco.2013.31.15_suppl.4511" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=4511&issue=15_suppl&author=A.+G.+Omlinauthor=R.+J.+Jonesauthor=R.+van+der+Nollauthor=J.+Grahamauthor=M.+Ongauthor=R.+D.+Finkelmanauthor=J.+H.+Schellensauthor=A.+Ziviauthor=M.+Crespoauthor=G.+Clackauthor=J.+J.+Alumkalauthor=A.+Dymondauthor=A.+Dickinsonauthor=M.+Ransonauthor=M.+D.+Maloneauthor=J.+S.+De+Bonoauthor=T.+Elliott&title=A+First-in-Human+Study+of+the+Oral+Selective+Androgen+Receptor+Down-Regulating+Drug+%28SARD%29+AZD3514+in+Patients+with+Castration-Resistant+Prostate+Cancer+%28CRPC%29&doi=10.1200%2Fjco.2013.31.15_suppl.4511"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1200%2Fjco.2013.31.15_suppl.4511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2013.31.15_suppl.4511%26sid%3Dliteratum%253Aachs%26aulast%3DOmlin%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DM.%26aulast%3DFinkelman%26aufirst%3DR.%2BD.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DZivi%26aufirst%3DA.%26aulast%3DCrespo%26aufirst%3DM.%26aulast%3DClack%26aufirst%3DG.%26aulast%3DAlumkal%26aufirst%3DJ.%2BJ.%26aulast%3DDymond%26aufirst%3DA.%26aulast%3DDickinson%26aufirst%3DA.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DMalone%26aufirst%3DM.%2BD.%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DElliott%26aufirst%3DT.%26atitle%3DA%2520First-in-Human%2520Study%2520of%2520the%2520Oral%2520Selective%2520Androgen%2520Receptor%2520Down-Regulating%2520Drug%2520%2528SARD%2529%2520AZD3514%2520in%2520Patients%2520with%2520Castration-Resistant%2520Prostate%2520Cancer%2520%2528CRPC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D15_suppl%26spage%3D4511%26doi%3D10.1200%2Fjco.2013.31.15_suppl.4511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunkley, T. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brave, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadbent, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouchet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumberbatch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaughan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedge, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span> <span> </span><span class="NLM_article-title">AZD3514: a Small Molecule That Modulates Androgen Receptor Signaling and Function in Vitro and in Vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F1535-7163.MCT-12-1174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=23861347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1715-1727&issue=9&author=S.+A.+Loddickauthor=S.+J.+Rossauthor=A.+G.+Thomasonauthor=D.+M.+Robinsonauthor=G.+E.+Walkerauthor=T.+P.+J.+Dunkleyauthor=S.+R.+Braveauthor=N.+Broadbentauthor=N.+C.+Strattonauthor=D.+Truemanauthor=E.+Mouchetauthor=F.+S.+Shaheenauthor=V.+N.+Jacobsauthor=M.+Cumberbatchauthor=J.+Wilsonauthor=R.+D.+O.+Jonesauthor=R.+H.+Bradburyauthor=A.+Rabowauthor=L.+Gaughanauthor=C.+Womackauthor=S.+T.+Barryauthor=C.+N.+Robsonauthor=S.+E.+Critchlowauthor=S.+R.+Wedgeauthor=A.+N.+Brooks&title=AZD3514%3A+a+Small+Molecule+That+Modulates+Androgen+Receptor+Signaling+and+Function+in+Vitro+and+in+Vivo&doi=10.1158%2F1535-7163.MCT-12-1174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo</span></div><div class="casAuthors">Loddick, Sarah A.; Ross, Sarah J.; Thomason, Andrew G.; Robinson, David M.; Walker, Graeme E.; Dunkley, Tom P. J.; Brave, Sandra R.; Broadbent, Nicola; Stratton, Natalie C.; Trueman, Dawn; Mouchet, Elizabeth; Shaheen, Fadhel S.; Jacobs, Vivien N.; Cumberbatch, Marie; Wilson, Joanne; Jones, Rhys D. O.; Bradbury, Robert H.; Rabow, Alfred; Gaughan, Luke; Womack, Chris; Barry, Simon T.; Robson, Craig N.; Critchlow, Susan E.; Wedge, Stephen R.; Brooks, A. Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1715-1727</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressive disease.  Here, we describe the biol. characterization of AZD3514, an orally bioavailable drug that inhibits androgen-dependent and -independent AR signaling.  AZD3514 modulates AR signaling through two distinct mechanisms, an inhibition of ligand-driven nuclear translocation of AR and a downregulation of receptor levels, both of which were obsd. in vitro and in vivo.  AZD3514 inhibited testosterone-driven seminal vesicle development in juvenile male rats and the growth of androgen-dependent Dunning R3327H prostate tumors in adult rats.  Furthermore, this class of compd. showed antitumor activity in the HID28 mouse model of CRPC in vivo.  AZD3514 is currently in phase I clin. evaluation.  Mol Cancer Ther; 12(9); 1715-27. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUjB28XcSVrVg90H21EOLACvtfcHk0ljcCiOGBhjGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ltbfI&md5=553f0953189e9e5982a08c7933566ce0</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1174%26sid%3Dliteratum%253Aachs%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DRoss%26aufirst%3DS.%2BJ.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DRobinson%26aufirst%3DD.%2BM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DDunkley%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DBroadbent%26aufirst%3DN.%26aulast%3DStratton%26aufirst%3DN.%2BC.%26aulast%3DTrueman%26aufirst%3DD.%26aulast%3DMouchet%26aufirst%3DE.%26aulast%3DShaheen%26aufirst%3DF.%2BS.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DCumberbatch%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DGaughan%26aufirst%3DL.%26aulast%3DWomack%26aufirst%3DC.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26atitle%3DAZD3514%253A%2520a%2520Small%2520Molecule%2520That%2520Modulates%2520Androgen%2520Receptor%2520Signaling%2520and%2520Function%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26issue%3D9%26spage%3D1715%26epage%3D1727%26doi%3D10.1158%2F1535-7163.MCT-12-1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merenbakh-Lamin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Baruch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeheskel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span> <span> </span><span class="NLM_article-title">D538G Mutation in Estrogen Receptor-A: a Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6856</span>– <span class="NLM_lpage">6864</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F0008-5472.CAN-13-1197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24217577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKhurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6856-6864&issue=23&author=K.+Merenbakh-Laminauthor=N.+Ben-Baruchauthor=A.+Yeheskelauthor=A.+Dvirauthor=L.+Soussan-Gutmanauthor=R.+Jeselsohnauthor=R.+Yelenskyauthor=M.+Brownauthor=V.+A.+Millerauthor=D.+Saridauthor=S.+Rizelauthor=B.+Kleinauthor=T.+Rubinekauthor=I.+Wolf&title=D538G+Mutation+in+Estrogen+Receptor-A%3A+a+Novel+Mechanism+for+Acquired+Endocrine+Resistance+in+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-13-1197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer</span></div><div class="casAuthors">Merenbakh-Lamin, Keren; Ben-Baruch, Noa; Yeheskel, Adva; Dvir, Addie; Soussan-Gutman, Lior; Jeselsohn, Rinath; Yelensky, Roman; Brown, Myles; Miller, Vincent A.; Sarid, David; Rizel, Shulamith; Klein, Baruch; Rubinek, Tami; Wolf, Ido</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6856-6864</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to endocrine therapy occurs in virtually all patients with estrogen receptor a (ERa)-pos. metastatic breast cancer, and is attributed to various mechanisms including loss of ERα expression, altered activity of coregulators, and cross-talk between the ERa and growth factor signaling pathways.  To our knowledge, acquired mutations of the ERα have not been described as mediating endocrine resistance.  Samples of 13 patients with metastatic breast cancer were analyzed for mutations in cancer-related genes.  In five patients who developed resistance to hormonal therapy, a mutation of A to G at position 1,613 of ERα, resulting in a substitution of aspartic acid at position 538 to glycine (D538G), was identified in liver metastases.  Importantly, the mutation was not detected in the primary tumors obtained prior to endocrine treatment.  Structural modeling indicated that D538G substitution leads to a conformational change in the ligand-binding domain, which mimics the conformation of activated ligand-bound receptor and alters binding of tamoxifen.  Indeed, expts. in breast cancer cells indicated constitutive, ligand-independent transcriptional activity of the D538G receptor, and overexpression of it enhanced proliferation and conferred resistance to tamoxifen.  These data indicate a novel mechanism of acquired endocrine resistance in breast cancer.  Further studies are needed to assess the frequency of D538G-ERα among patients with breast cancer and explore ways to inhibit its activity and restore endocrine sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWljQ_odNNUrVg90H21EOLACvtfcHk0ljcCiOGBhjGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKhurfN&md5=6dca8ee6cdb77bfc8a94d02fe5630ea8</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1197%26sid%3Dliteratum%253Aachs%26aulast%3DMerenbakh-Lamin%26aufirst%3DK.%26aulast%3DBen-Baruch%26aufirst%3DN.%26aulast%3DYeheskel%26aufirst%3DA.%26aulast%3DDvir%26aufirst%3DA.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DSarid%26aufirst%3DD.%26aulast%3DRizel%26aufirst%3DS.%26aulast%3DKlein%26aufirst%3DB.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DI.%26atitle%3DD538G%2520Mutation%2520in%2520Estrogen%2520Receptor-A%253A%2520a%2520Novel%2520Mechanism%2520for%2520Acquired%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D23%26spage%3D6856%26epage%3D6864%26doi%3D10.1158%2F0008-5472.CAN-13-1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiken, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saied, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuntoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phommaly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSchryver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&issue=6&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-Therapy-Resistant+ESR1+Variants+Revealed+by+Genomic+Characterization+of+Breast-Cancer-Derived+Xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0lgp2h34MUQpNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-Therapy-Resistant%2520ESR1%2520Variants%2520Revealed%2520by%2520Genomic%2520Characterization%2520of%2520Breast-Cancer-Derived%2520Xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vats, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyana-Sundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Poznak, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunju, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Activating ESR1 Mutations in Hormone-Resistant Metastatic Breast Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1446</span>– <span class="NLM_lpage">1451</span>, <span class="refDoi"> DOI: 10.1038/ng.2823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.2823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24185510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1446-1451&issue=12&author=D.+R.+Robinsonauthor=Y.-M.+Wuauthor=P.+Vatsauthor=F.+Suauthor=R.+J.+Lonigroauthor=X.+Caoauthor=S.+Kalyana-Sundaramauthor=R.+Wangauthor=Y.+Ningauthor=L.+Hodgesauthor=A.+Gurskyauthor=J.+Siddiquiauthor=S.+A.+Tomlinsauthor=S.+Roychowdhuryauthor=K.+J.+Pientaauthor=S.+Y.+Kimauthor=J.+S.+Robertsauthor=J.+M.+Raeauthor=C.+H.+Van+Poznakauthor=D.+F.+Hayesauthor=R.+Chughauthor=L.+P.+Kunjuauthor=M.+Talpazauthor=A.+F.+Schottauthor=A.+M.+Chinnaiyan&title=Activating+ESR1+Mutations+in+Hormone-Resistant+Metastatic+Breast+Cancer&doi=10.1038%2Fng.2823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Vats, Pankaj; Su, Fengyun; Lonigro, Robert J.; Cao, Xuhong; Kalyana-Sundaram, Shanker; Wang, Rui; Ning, Yu; Hodges, Lynda; Gursky, Amy; Siddiqui, Javed; Tomlins, Scott A.; Roychowdhury, Sameek; Pienta, Kenneth J.; Kim, Scott Y.; Roberts, J. Scott; Rae, James M.; Van Poznak, Catherine H.; Hayes, Daniel F.; Chugh, Rashmi; Kunju, Lakshmi P.; Talpaz, Moshe; Schott, Anne F.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer is the most prevalent cancer in women, and over two-thirds of cases express estrogen receptor-α (ER-α, encoded by ESR1).  Through a prospective clin. sequencing program for advanced cancers, we enrolled 11 patients with ER-pos. metastatic breast cancer.  Whole-exome and transcriptome anal. showed that six cases harbored mutations of ESR1 affecting its ligand-binding domain (LBD), all of whom had been treated with anti-estrogens and estrogen deprivation therapies.  A survey of The Cancer Genome Atlas (TCGA) identified four endometrial cancers with similar mutations of ESR1.  The five new LBD-localized ESR1 mutations identified here (encoding p.Leu536Gln, p.Tyr537Ser, p.Tyr537Cys, p.Tyr537Asn and p.Asp538Gly) were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.  Taken together, these studies suggest that activating mutations in ESR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQSL6mlhMOrVg90H21EOLACvtfcHk0lgp2h34MUQpNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN&md5=af9e69d6064726af238fe74dad7d2204</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fng.2823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2823%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DGursky%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DRae%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BPoznak%26aufirst%3DC.%2BH.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DActivating%2520ESR1%2520Mutations%2520in%2520Hormone-Resistant%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fng.2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">ESR1 Ligand-Binding Domain Mutations in Hormone-Resistant Breast Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1038/ng.2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24185512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1439-1445&issue=12&author=W.+Toyauthor=Y.+Shenauthor=H.+Wonauthor=B.+Greenauthor=R.+A.+Sakrauthor=M.+Willauthor=Z.+Liauthor=K.+Galaauthor=S.+Fanningauthor=T.+A.+Kingauthor=C.+Hudisauthor=D.+Chenauthor=T.+Taranauthor=G.+Hortobagyiauthor=G.+Greeneauthor=M.+Bergerauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=ESR1+Ligand-Binding+Domain+Mutations+in+Hormone-Resistant+Breast+Cancer&doi=10.1038%2Fng.2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span></div><div class="casAuthors">Toy, Weiyi; Shen, Yang; Won, Helen; Green, Bradley; Sakr, Rita A.; Will, Marie; Li, Zhiqiang; Gala, Kinisha; Fanning, Sean; King, Tari A.; Hudis, Clifford; Chen, David; Taran, Tetiana; Hortobagyi, Gabriel; Greene, Geoffrey; Berger, Michael; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition.  However, many such tumors for unknown reasons become refractory to inhibition of estrogen action in the metastatic setting.  We conducted a comprehensive genetic anal. of two independent cohorts of metastatic ER-pos. breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases.  These included highly recurrent mutations encoding p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations.  Mol. dynamics simulations suggest that the structures of the Tyr537Ser and Asp538Gly mutants involve hydrogen bonding of the mutant amino acids with Asp351, thus favoring the agonist conformation of the receptor.  Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.  These data implicate LBD-mutant forms of ER in mediating clin. resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KQLxyqE3lrVg90H21EOLACvtfcHk0lgp2h34MUQpNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ&md5=1f7c247e079d08a463db4e20ec0f9d17</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1038%2Fng.2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2822%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DSakr%26aufirst%3DR.%2BA.%26aulast%3DWill%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DGala%26aufirst%3DK.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DESR1%2520Ligand-Binding%2520Domain%2520Mutations%2520in%2520Hormone-Resistant%2520Breast%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1439%26epage%3D1445%26doi%3D10.1038%2Fng.2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">The Search for ESR1 Mutations in Breast Cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1416</span>, <span class="refDoi"> DOI: 10.1038/ng.2831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fng.2831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24270445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVaitL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1415-1416&issue=12&author=S.+Oesterreichauthor=N.+E.+Davidson&title=The+Search+for+ESR1+Mutations+in+Breast+Cancer&doi=10.1038%2Fng.2831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">The search for ESR1 mutations in breast cancer</span></div><div class="casAuthors">Oesterreich, Steffi; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1415-1416</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Two new studies report the identification of activating ESR1 gene mutations in aromatase inhibitor-resistant metastatic breast cancers.  This insight into therapeutic resistance suggests new approaches that may be useful in the management of endocrine-resistant breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFpXltTLXBR7Vg90H21EOLACvtfcHk0ljP10gCHC6bxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVaitL7P&md5=e9cf29471564b577f3f8bcb1ee83f7b7</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fng.2831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2831%26sid%3Dliteratum%253Aachs%26aulast%3DOesterreich%26aufirst%3DS.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DThe%2520Search%2520for%2520ESR1%2520Mutations%2520in%2520Breast%2520Cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1415%26epage%3D1416%26doi%3D10.1038%2Fng.2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span> <span> </span><span class="NLM_article-title">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4887</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&issue=12&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+Selective+Estrogen+Receptor+Downregulators+%28SERDs%29%2C+a+Breakthrough+Endocrine+Therapy+for+Breast+Cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0ljP10gCHC6bxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520Selective%2520Estrogen%2520Receptor%2520Downregulators%2520%2528SERDs%2529%252C%2520a%2520Breakthrough%2520Endocrine%2520Therapy%2520for%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">A Potent Specific Pure Antiestrogen with Clinical Potential</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3867</span>– <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&issue=15&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+Potent+Specific+Pure+Antiestrogen+with+Clinical+Potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0lhixFGnp3j_aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520Potent%2520Specific%2520Pure%2520Antiestrogen%2520with%2520Clinical%2520Potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D15%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Kruchten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaudemans, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lanschot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Faassen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kema, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospers, G. A.</span></span> <span> </span><span class="NLM_article-title">Measuring Residual Estrogen Receptor Availability During Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&issue=1&author=M.+van%0AKruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schroderauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+Residual+Estrogen+Receptor+Availability+During+Fulvestrant+Therapy+in+Patients+with+Metastatic+Breast+Cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0lhixFGnp3j_aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchroder%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520Residual%2520Estrogen%2520Receptor%2520Availability%2520During%2520Fulvestrant%2520Therapy%2520in%2520Patients%2520with%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D1%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerstrom, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripnikova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannuti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant-3 Boronic Acid (ZB716): an Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8134</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00753</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00753" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8134-8140&issue=17&author=J.+Liuauthor=S.+Zhengauthor=V.+L.+Akerstromauthor=C.+Yuanauthor=Y.+Maauthor=Q.+Zhongauthor=C.+Zhangauthor=Q.+Zhangauthor=S.+Guoauthor=P.+Maauthor=E.+V.+Skripnikovaauthor=M.+R.+Brattonauthor=A.+Pannutiauthor=L.+Mieleauthor=T.+E.+Wieseauthor=G.+Wang&title=Fulvestrant-3+Boronic+Acid+%28ZB716%29%3A+an+Orally+Bioavailable+Selective+Estrogen+Receptor+Downregulator+%28SERD%29&doi=10.1021%2Facs.jmedchem.6b00753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)</span></div><div class="casAuthors">Liu, Jiawang; Zheng, Shilong; Akerstrom, Victoria L.; Yuan, Chester; Ma, Youning; Zhong, Qiu; Zhang, Changde; Zhang, Qiang; Guo, Shanchun; Ma, Peng; Skripnikova, Elena V.; Bratton, Melyssa R.; Pannuti, Antonio; Miele, Lucio; Wiese, Thomas E.; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8134-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Orally bioavailable SERDs may offer greater systemic drug exposure, improved clin. efficacy, and more durable treatment outcome for patients with ER-pos. endocrine-resistant breast cancer.  We report the design and synthesis of a boronic acid modified fulvestrant (ZB716), which binds to ERα competitively (IC50=4.1 nM) and effectively downregulates ERα in both tamoxifen-sensitive and tamoxifen-resistant breast cancer cells.  Furthermore, it has superior oral bioavailability (AUC=2547.1 ng•h/mL) in mice, indicating its promising clin. utility as an oral SERD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjvM1bnXTzLVg90H21EOLACvtfcHk0ljiv5Yu3L_QsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI&md5=d8c398dc337357fe36a387266a51d5ec</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00753%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DAkerstrom%26aufirst%3DV.%2BL.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DSkripnikova%26aufirst%3DE.%2BV.%26aulast%3DBratton%26aufirst%3DM.%2BR.%26aulast%3DPannuti%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DWiese%26aufirst%3DT.%2BE.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DFulvestrant-3%2520Boronic%2520Acid%2520%2528ZB716%2529%253A%2520an%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Downregulator%2520%2528SERD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D17%26spage%3D8134%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.6b00753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillen, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6336</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6321-6336&issue=14&author=J.+Minauthor=V.+S.+Guillenauthor=A.+Sharmaauthor=Y.+Zhaoauthor=Y.+Zieglerauthor=P.+Gongauthor=C.+G.+Mayneauthor=S.+Srinivasanauthor=S.+H.+Kimauthor=K.+E.+Carlsonauthor=K.+W.+Nettlesauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Adamantyl+Antiestrogens+with+Novel+Side+Chains+Reveal+a+Spectrum+of+Activities+in+Suppressing+Estrogen+Receptor+Mediated+Activities+in+Breast+Cancer+Cells&doi=10.1021%2Facs.jmedchem.7b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells</span></div><div class="casAuthors">Min, Jian; Guillen, Valeria Sanabria; Sharma, Abhishek; Zhao, Yuechao; Ziegler, Yvonne; Gong, Ping; Mayne, Christopher G.; Srinivasan, Sathish; Kim, Sung Hoon; Carlson, Kathryn E.; Nettles, Kendall W.; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6321-6336</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens.  To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochem. issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs.  All compds. were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-down-regulating agents.  There were large differences in activity between compds. having minor structural changes, but antiproliferative and ERα-down-regulating efficacies generally paralleled one another.  Some compds. with side chain polar groups had particularly high affinities.  The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression.  This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUZF-YO3F3uLVg90H21EOLACvtfcHk0ljiv5Yu3L_QsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP&md5=a22b96675e183041d48f7fb62e560f75</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00585%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DGuillen%26aufirst%3DV.%2BS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZiegler%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAdamantyl%2520Antiestrogens%2520with%2520Novel%2520Side%2520Chains%2520Reveal%2520a%2520Spectrum%2520of%2520Activities%2520in%2520Suppressing%2520Estrogen%2520Receptor%2520Mediated%2520Activities%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D6321%26epage%3D6336%26doi%3D10.1021%2Facs.jmedchem.7b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&issue=7&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+Acrylic+Acid+Based+Tetrahydroisoquinoline+as+an+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+for+ER%CE%B1%2B+Breast+Cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span></div><div class="casAuthors">Burks, Heather E.; Abrams, Tinya; Kirby, Christina A.; Baird, Jason; Fekete, Alexander; Hamann, Lawrence G.; Kim, Sunkyu; Lombardo, Franco; Loo, Alice; Lubicka, Danuta; Macchi, Kaitlin; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Saran, Chitra; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2790-2818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.  We outline the discovery and chem. optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclin. species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N78pDzgcpLVg90H21EOLACvtfcHk0ljiv5Yu3L_QsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D&md5=51ce5c93fb6dcaebb3e81fbb3ca67657</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520Acrylic%2520Acid%2520Based%2520Tetrahydroisoquinoline%2520as%2520an%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520for%2520ER%25CE%25B1%252B%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D7%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&issue=20&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+Novel+Binding+Motif+to+%28E%29-3-%283%2C5-Difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+Acid+%28AZD9496%29%2C+a+Potent+and+Orally+Bioavailable+Selective+Estrogen+Receptor+Downregulator+and+Antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0li9AHurw9QLbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520Novel%2520Binding%2520Motif%2520to%2520%2528E%2529-3-%25283%252C5-Difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520Acid%2520%2528AZD9496%2529%252C%2520a%2520Potent%2520and%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Downregulator%2520and%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span> <span> </span><span class="NLM_article-title">Tricyclic Indazoles—a Novel Class of Selective Estrogen Receptor Degrader Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1593-1608&issue=3&author=J.+S.+Scottauthor=A.+Baileyauthor=D.+Buttarauthor=R.+J.+Carbajoauthor=J.+Curwenauthor=P.+R.+J.+Daveyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=C.+Donaldauthor=E.+Ganglauthor=R.+Greenwoodauthor=S.+D.+Groombridgeauthor=T.+Johnsonauthor=S.+Lamontauthor=M.+Lawsonauthor=A.+Listerauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=J.+H.+Pinkauthor=R.+Polanski&title=Tricyclic+Indazoles%E2%80%94a+Novel+Class+of+Selective+Estrogen+Receptor+Degrader+Antagonists&doi=10.1021%2Facs.jmedchem.8b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Buttar, David; Carbajo, Rodrigo J.; Curwen, Jon; Davey, Paul R. J.; Davies, Robert D. M.; Degorce, Sebastien L.; Donald, Craig; Gangl, Eric; Greenwood, Ryan; Groombridge, Sam D.; Johnson, Tony; Lamont, Scott; Lawson, Mandy; Lister, Andrew; Morrow, Christopher J.; Moss, Thomas A.; Pink, Jennifer H.; Polanski, Radoslaw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1593-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tricyclic tetrahydropyridoindazoles such as I were prepd. as estrogen receptor degrader antagonists for potential use in the treatment of ERα-dependent breast cancer; the indazole moiety was prepd. as a replacement for a phenol moiety in a tetrahydroisoquinolinol which generated reactive metabolites in a glutathione trapping assay.  The structure of a nonracemic tetrahydropyridoindazole bound to an ERα ligand binding domain fragment was detd. by X-ray crystallog.  I demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhswxQKXWq7Vg90H21EOLACvtfcHk0li9AHurw9QLbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D&md5=753ed2af89e482d9d9e8aa0f49a54ddb</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDonald%26aufirst%3DC.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPolanski%26aufirst%3DR.%26atitle%3DTricyclic%2520Indazoles%25E2%2580%2594a%2520Novel%2520Class%2520of%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D3%26spage%3D1593%26epage%3D1608%26doi%3D10.1021%2Facs.jmedchem.8b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&issue=7&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.+L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+Potent%2C+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+%28SERD%29+for+the+Treatment+of+Estrogen+Receptor+Positive+Breast+Cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0lgo3dP2F-oOCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.%2BL.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520Potent%252C%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520for%2520the%2520Treatment%2520of%2520Estrogen%2520Receptor%2520Positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&issue=12&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+%28SERD%29+That+Demonstrates+Robust+Activity+in+Tamoxifen-Resistant+Breast+Cancer+Xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lgo3dP2F-oOCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520That%2520Demonstrates%2520Robust%2520Activity%2520in%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Selective Estrogen Receptor Degraders with Novel Structural Motifs Induce Regression in a Tamoxifen-Resistant Breast Cancer Xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.bmcl.2018.12.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=30587451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFynurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=367-372&issue=3&author=S.+P.+Govekauthor=C.+Bonnefousauthor=J.+D.+Julienauthor=J.+Y.+Nagasawaauthor=M.+Kahramanauthor=A.+G.+Laiauthor=K.+L.+Douglasauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.+J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Selective+Estrogen+Receptor+Degraders+with+Novel+Structural+Motifs+Induce+Regression+in+a+Tamoxifen-Resistant+Breast+Cancer+Xenograft&doi=10.1016%2Fj.bmcl.2018.12.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Bonnefous, Celine; Julien, Jackaline D.; Nagasawa, Johnny Y.; Kahraman, Mehmet; Lai, Andiliy G.; Douglas, Karensa L.; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-372</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Potent estrogen receptor ligands typically contain a phenolic hydrogen-bond donor.  The indazole of the selective estrogen receptor degrader (SERD) ARN-810 is believed to mimic this.  Disclosed herein is the discovery of ARN-810 analogs which lack this hydrogen-bond donor.  These SERDs induced tumor regression in a tamoxifen-resistant breast cancer xenograft, demonstrating that the indazole NH is not necessary for robust ER-modulation and antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUfIVe9l_ey7Vg90H21EOLACvtfcHk0ljhI7QMbIenVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFynurzO&md5=25f4c3838d63c8abe9166c3295c28926</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%2BD.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DSelective%2520Estrogen%2520Receptor%2520Degraders%2520with%2520Novel%2520Structural%2520Motifs%2520Induce%2520Regression%2520in%2520a%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D367%26epage%3D372%26doi%3D10.1016%2Fj.bmcl.2018.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges-Gallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span> <span> </span><span class="NLM_article-title">Specific Stereochemistry of OP-1074 Disrupts Estrogen Receptor Alpha Helix 12 and Confers Pure Antiestrogenic Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2368</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fs41467-018-04413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=29915250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2368&issue=1&author=S.+W.+Fanningauthor=L.+Hodges-Gallagherauthor=D.+C.+Mylesauthor=R.+Sunauthor=C.+E.+Fowlerauthor=I.+N.+Plantauthor=B.+D.+Greenauthor=C.+L.+Harmonauthor=G.+L.+Greeneauthor=P.+J.+Kushner&title=Specific+Stereochemistry+of+OP-1074+Disrupts+Estrogen+Receptor+Alpha+Helix+12+and+Confers+Pure+Antiestrogenic+Activity&doi=10.1038%2Fs41467-018-04413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span></div><div class="casAuthors">Fanning S W; Fowler C E; Green B D; Greene G L; Hodges-Gallagher L; Myles D C; Sun R; Harmon C L; Kushner P J; Plant I N</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer.  Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates.  Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay.  We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model.  Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYJ5LDE5uCtbjnyZkbE8yXfW6udTcc2eaYyj4DqrZXqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D&md5=a381a76b8363cda16ac9ac5ec0c702d8</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04413-3%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW.%26aulast%3DHodges-Gallagher%26aufirst%3DL.%26aulast%3DMyles%26aufirst%3DD.%2BC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DC.%2BE.%26aulast%3DPlant%26aufirst%3DI.%2BN.%26aulast%3DGreen%26aufirst%3DB.%2BD.%26aulast%3DHarmon%26aufirst%3DC.%2BL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26atitle%3DSpecific%2520Stereochemistry%2520of%2520OP-1074%2520Disrupts%2520Estrogen%2520Receptor%2520Alpha%2520Helix%252012%2520and%2520Confers%2520Pure%2520Antiestrogenic%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D2368%26doi%3D10.1038%2Fs41467-018-04413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&issue=17&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+Orally+Bioavailable+Chromene-Based+Selective+Estrogen+Receptor+Degrader+%28SERD%29+That+Demonstrates+Robust+Activity+in+a+Model+of+Tamoxifen-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0ljhI7QMbIenVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520Orally%2520Bioavailable%2520Chromene-Based%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520That%2520Demonstrates%2520Robust%2520Activity%2520in%2520a%2520Model%2520of%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-A Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&issue=1&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-A+Degradation+Maximizes+Activity+in+a+Tamoxifen-Resistant+Breast+Cancer+Model%3A+Identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0lgdX7GV1vTjqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-A%2520Degradation%2520Maximizes%2520Activity%2520in%2520a%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Model%253A%2520Identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmazeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courjaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginesty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic Acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=512-528&issue=2&author=Y.+El-Ahmadauthor=M.+Tabartauthor=F.+Halleyauthor=V.+Certalauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=F.+Gruss-Leleuauthor=C.+Mullerauthor=M.+Brolloauthor=L.+Fabienauthor=V.+Loyauauthor=L.+Bertinauthor=P.+Richepinauthor=F.+Pilorgeauthor=P.+Desmazeauauthor=C.+Girardetauthor=S.+Beccariauthor=A.+Louboutinauthor=G.+Lebourgauthor=J.+Le-Rouxauthor=C.+Terrierauthor=F.+Vall%C3%A9eauthor=V.+Steierauthor=M.+Mathieuauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=P.+Vicatauthor=T.+Benardauthor=M.+Bouaboulaauthor=F.+Sunauthor=M.+Shomaliauthor=A.+Hebertauthor=M.+Levitauthor=H.+Chengauthor=A.+Courjaudauthor=C.+Ginestyauthor=C.+Perraultauthor=C.+Garcia-Echeverriaauthor=G.+McCortauthor=L.+Schio&title=Discovery+of+6-%282%2C4-Dichlorophenyl%29-5-%5B4-%5B%283S%29-1-%283-fluoropropyl%29pyrrolidin-3-yl%5Doxyphenyl%5D-8%2C9-dihydro-7H-benzo%5B7%5Dannulene-2-carboxylic+Acid+%28SAR439859%29%2C+a+Potent+and+Selective+Estrogen+Receptor+Degrader+%28SERD%29+for+the+Treatment+of+Estrogen-Receptor-Positive+Breast+Cancer&doi=10.1021%2Facs.jmedchem.9b01293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span></div><div class="casAuthors">El-Ahmad Youssef; Tabart Michel; Halley Frank; Certal Victor; Thompson Fabienne; Filoche-Romme Bruno; Gruss-Leleu Florence; Muller Claire; Brollo Maurice; Fabien Laurence; Loyau Veronique; Bertin Luc; Richepin Patrick; Pilorge Fabienne; Desmazeau Pascal; Girardet Chrystelle; Beccari Sylvie; Louboutin Audrey; Lebourg Gilles; Le-Roux Jacques; Terrier Corinne; Vallee Francois; Steier Valerie; Mathieu Magali; Rak Alexey; Abecassis Pierre-Yves; Vicat Pascale; Benard Tsiala; Courjaud Albane; Ginesty Celine; Perrault Christelle; Garcia-Echeverria Carlos; McCort Gary; Schio Laurent; Bouaboula Monsif; Sun Fangxian; Shomali Maysoun; Hebert Andrew; Levit Mikhail; Cheng Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients.  Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective.  Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy.  However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections.  This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgG8wK4xhUykloaUqgkFHkfW6udTcc2eYsnqZzA5zlVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D&md5=40732bc5b74a05cf8551ad5baea64217</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DTabart%26aufirst%3DM.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DFabien%26aufirst%3DL.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDesmazeau%26aufirst%3DP.%26aulast%3DGirardet%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DS.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DLe-Roux%26aufirst%3DJ.%26aulast%3DTerrier%26aufirst%3DC.%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DSteier%26aufirst%3DV.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DVicat%26aufirst%3DP.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DHebert%26aufirst%3DA.%26aulast%3DLevit%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCourjaud%26aufirst%3DA.%26aulast%3DGinesty%26aufirst%3DC.%26aulast%3DPerrault%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DMcCort%26aufirst%3DG.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-Dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2520Acid%2520%2528SAR439859%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528SERD%2529%2520for%2520the%2520Treatment%2520of%2520Estrogen-Receptor-Positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D2%26spage%3D512%26epage%3D528%26doi%3D10.1021%2Facs.jmedchem.9b01293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&issue=4&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+Ligands+Antagonize+Estrogen+Receptor+Function+by+Impairing+Its+Mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0liFE9vRQ3oEwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520Ligands%2520Antagonize%2520Estrogen%2520Receptor%2520Function%2520by%2520Impairing%2520Its%2520Mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26issue%3D4%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Agostino, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span> <span> </span><span class="NLM_article-title">Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1592</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGjtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1592-1602&issue=12&author=P.+P.+Chamberlainauthor=L.+A.+D%E2%80%99Agostinoauthor=J.+M.+Ellisauthor=J.+D.+Hansenauthor=M.+E.+Matyskielaauthor=J.+J.+McDonaldauthor=J.+R.+Riggsauthor=L.+G.+Hamann&title=Evolution+of+Cereblon-Mediated+Protein+Degradation+as+a+Therapeutic+Modality&doi=10.1021%2Facsmedchemlett.9b00425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality</span></div><div class="casAuthors">Chamberlain, Philip P.; DAgostino, Laura A.; Ellis, J. Michael; Hansen, Joshua D.; Matyskiela, Mary E.; McDonald, Joseph J.; Riggs, Jennifer R.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1592-1602</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many cellular processes and pathways are mediated by the regulation of protein-protein complexes.  For example, E3 ubiquitin ligases recruit substrate proteins and transfer an ubiquitin tag to target those proteins for destruction by the proteasome.  It has now been shown that this cellular process for protein destruction can be redirected by small mols. in both lab. and clin. settings.  This presents a new paradigm in drug discovery, enabling the rapid removal of target proteins linked to disease.  In this review we will describe the work done on cereblon as a case study on the different strategies available for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppPyGPfBStwrVg90H21EOLACvtfcHk0liFE9vRQ3oEwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGjtL%252FL&md5=ee2c72a8f8e11216a491442165916237</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00425%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DL.%2BA.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DEvolution%2520of%2520Cereblon-Mediated%2520Protein%2520Degradation%2520as%2520a%2520Therapeutic%2520Modality%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D12%26spage%3D1592%26epage%3D1602%26doi%3D10.1021%2Facsmedchemlett.9b00425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a Primary Target of Thalidomide Teratogenicity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span> (<span class="NLM_issue">5971</span>),  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1126/science.1177319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1177319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=20223979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1345-1350&issue=5971&author=T.+Itoauthor=H.+Andoauthor=T.+Suzukiauthor=T.+Oguraauthor=K.+Hottaauthor=Y.+Imamuraauthor=Y.+Yamaguchiauthor=H.+Handa&title=Identification+of+a+Primary+Target+of+Thalidomide+Teratogenicity&doi=10.1126%2Fscience.1177319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Primary Target of Thalidomide Teratogenicity</span></div><div class="casAuthors">Ito, Takumi; Ando, Hideki; Suzuki, Takayuki; Ogura, Toshihiko; Hotta, Kentaro; Imamura, Yoshimasa; Yamaguchi, Yuki; Handa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5971</span>),
    <span class="NLM_cas:pages">1345-1350</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects.  Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown.  Here, we identified cereblon (CRBN) as a thalidomide-binding protein.  CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.  Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the assocd. ubiquitin ligase activity.  This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivs. without teratogenic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPC_7RXLkfabVg90H21EOLACvtfcHk0lin0a2lMtFuRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D&md5=4565a67837e0ec34ede2c93c1036f312</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1126%2Fscience.1177319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1177319%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Primary%2520Target%2520of%2520Thalidomide%2520Teratogenicity%26jtitle%3DScience%26date%3D2010%26volume%3D327%26issue%3D5971%26spage%3D1345%26epage%3D1350%26doi%3D10.1126%2Fscience.1177319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampaio, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galilly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>173</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1084/jem.173.3.699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1084%2Fjem.173.3.699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1997652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFKku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=1991&pages=699-703&issue=3&author=E.+P.+Sampaioauthor=E.+N.+Sarnoauthor=R.+Galillyauthor=Z.+A.+Cohnauthor=G.+Kaplan&title=Thalidomide+Selectively+Inhibits+Tumor+Necrosis+Factor+Alpha+Production+by+Stimulated+Human+Monocytes&doi=10.1084%2Fjem.173.3.699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes</span></div><div class="casAuthors">Sampaio, Elizabeth P.; Sarno, Euzenir N.; Galilly, Ruth; Cohn, Zanvil A.; Kaplan, Gilla</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">699-703</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">Thalidomide selectively inhibits the prodn. of human monocyte tumor necrosis factor-α (TNF-α) when these cells are triggered with lipopolysaccharide and other agonists in culture.  A 40% inhibition occurs at the clin. achievable concn. of 1 μg/mL.  The amt. of total protein and individual proteins labeled with [35S]methionine detected by SDS-PAGE are not affected by thalidomide.  The amts. of interleukin 1β (IL-1β), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered.  The selectivity of this drug may be useful in detg. the role of TNF-α in vivo and modulating its toxic effects in a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvBdYHP7onbVg90H21EOLACvtfcHk0lin0a2lMtFuRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFKku70%253D&md5=a33ea2da47d0845627665a96a1fd3688</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1084%2Fjem.173.3.699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.173.3.699%26sid%3Dliteratum%253Aachs%26aulast%3DSampaio%26aufirst%3DE.%2BP.%26aulast%3DSarno%26aufirst%3DE.%2BN.%26aulast%3DGalilly%26aufirst%3DR.%26aulast%3DCohn%26aufirst%3DZ.%2BA.%26aulast%3DKaplan%26aufirst%3DG.%26atitle%3DThalidomide%2520Selectively%2520Inhibits%2520Tumor%2520Necrosis%2520Factor%2520Alpha%2520Production%2520by%2520Stimulated%2520Human%2520Monocytes%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1991%26volume%3D173%26issue%3D3%26spage%3D699%26epage%3D703%26doi%3D10.1084%2Fjem.173.3.699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haslett, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>187</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1892</span>, <span class="refDoi"> DOI: 10.1084/jem.187.11.1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1084%2Fjem.187.11.1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=9607928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1cXjs1eht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1998&pages=1885-1892&issue=11&author=P.+A.+Haslettauthor=L.+G.+Corralauthor=M.+Albertauthor=G.+Kaplan&title=Thalidomide+Costimulates+Primary+Human+T+Lymphocytes%2C+Preferentially+Inducing+Proliferation%2C+Cytokine+Production%2C+and+Cytotoxic+Responses+in+the+CD8%2B+Subset&doi=10.1084%2Fjem.187.11.1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset</span></div><div class="casAuthors">Haslett, Patrick A. J.; Corral, Laura G.; Albert, Matthew; Kaplan, Gilla</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1885-1892</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The efficacy of thalidomide (α-phthalimidoglutarimide) therapy in leprosy patients with erythema nodosum leprosum is thought to be due to inhibition of tumor necrosis factor α.  In other diseases reported to respond to thalidomide, the mechanism of action of the drug is unclear.  We show that thalidomide is a potent costimulator of primary human T cells in vitro, synergizing with stimulation via the T cell receptor complex to increase interleukin 2-mediated T cell proliferation and interferon γ prodn.  The costimulatory effect is greater on the CD8+ than the CD4+ T cell subset.  The drug also increases the primary CD8+ cytotoxic T cell response induced by allogeneic dendritic cells in the absence of CD4+ T cells.  Therefore, human T cell costimulation can be achieved pharmacol. with thalidomide, and preferentially in the CD8+ T cell subset.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlxTfsUapj-bVg90H21EOLACvtfcHk0lin0a2lMtFuRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjs1eht7k%253D&md5=799f1ac43b794a37bb057f330a0ac5a7</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1084%2Fjem.187.11.1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.187.11.1885%26sid%3Dliteratum%253Aachs%26aulast%3DHaslett%26aufirst%3DP.%2BA.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DAlbert%26aufirst%3DM.%26aulast%3DKaplan%26aufirst%3DG.%26atitle%3DThalidomide%2520Costimulates%2520Primary%2520Human%2520T%2520Lymphocytes%252C%2520Preferentially%2520Inducing%2520Proliferation%252C%2520Cytokine%2520Production%252C%2520and%2520Cytotoxic%2520Responses%2520in%2520the%2520CD8%252B%2520Subset%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D187%26issue%3D11%26spage%3D1885%26epage%3D1892%26doi%3D10.1084%2Fjem.187.11.1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughnan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkman, J.</span></span> <span> </span><span class="NLM_article-title">Thalidomide Is an Inhibitor of Angiogenesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4082</span>– <span class="NLM_lpage">4085</span>, <span class="refDoi"> DOI: 10.1073/pnas.91.9.4082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1073%2Fpnas.91.9.4082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=7513432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFGmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=4082-4085&issue=9&author=R.+J.+D%E2%80%99Amatoauthor=M.+S.+Loughnanauthor=E.+Flynnauthor=J.+Folkman&title=Thalidomide+Is+an+Inhibitor+of+Angiogenesis&doi=10.1073%2Fpnas.91.9.4082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide is an inhibitor of angiogenesis</span></div><div class="casAuthors">D'Amato, Robert J.; Loughnan, Michael S.; Flynn, Evelyn; Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4082-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans.  The authors have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay.  Expts. including the anal. of thalidomide analogs revealed that the antiangiogenic activity correlated with the teratogenicity but not with the sedative or the mild immunosuppressive properties of thalidomide.  Electron microscopic examn. of the corneal neovascularization of thalidomide-treated rabbits revealed specific ultrastructural changes similar to those seen in the deformed limb bud vasculature of thalidomide-treated embryos.  These expts. shed light on the mechanism of thalidomide's teratogenicity and hold promise for the potential use of thalidomide as an orally administered drug for the treatment of many diverse diseases dependent on angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6LACOyP9P7Vg90H21EOLACvtfcHk0lin0a2lMtFuRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFGmsrY%253D&md5=e715297759cd4e5a8e1ec0c7b95f4540</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.9.4082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.9.4082%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DR.%2BJ.%26aulast%3DLoughnan%26aufirst%3DM.%2BS.%26aulast%3DFlynn%26aufirst%3DE.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DThalidomide%2520Is%2520an%2520Inhibitor%2520of%2520Angiogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D9%26spage%3D4082%26epage%3D4085%26doi%3D10.1073%2Fpnas.91.9.4082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span> <span> </span><span class="NLM_article-title">Amino-Substituted Thalidomide Analogs: Potent Inhibitors of TNF-Alpha Production</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1630</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00250-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS0960-894X%2899%2900250-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10386948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVKisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=1625-1630&issue=11&author=G.+W.+Mullerauthor=R.+Chenauthor=S.+Y.+Huangauthor=L.+G.+Corralauthor=L.+M.+Wongauthor=R.+T.+Pattersonauthor=Y.+Chenauthor=G.+Kaplanauthor=D.+I.+Stirling&title=Amino-Substituted+Thalidomide+Analogs%3A+Potent+Inhibitors+of+TNF-Alpha+Production&doi=10.1016%2FS0960-894X%2899%2900250-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production</span></div><div class="casAuthors">Muller, George W.; Chen, Roger; Huang, Shaei-Yun; Corral, Laura G.; Wong, Lu Min; Patterson, Rebecca T.; Chen, Yuxi; Kaplan, Gilla; Stirling, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1625-1630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Thalidomide is a known inhibitor of TNF-α release in LPS stimulated human PBMC.  Herein we describe the TNF-α inhibitory activity of amino substituted analogs of thalidomide and its isoindolin-1-one analog, EM-12.  The 4-amino substituted analogs were found to be potent inhibitors of TNF-α release in LPS stimulated human PBMC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-73DeaMOeK7Vg90H21EOLACvtfcHk0ljsTyrdM_k4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVKisbs%253D&md5=770d1a9078c6ffc93d743d6f59290dc6</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900250-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900250-4%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DG.%2BW.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DPatterson%26aufirst%3DR.%2BT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26atitle%3DAmino-Substituted%2520Thalidomide%2520Analogs%253A%2520Potent%2520Inhibitors%2520of%2520TNF-Alpha%2520Production%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D11%26spage%3D1625%26epage%3D1630%26doi%3D10.1016%2FS0960-894X%2899%2900250-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarlo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span> (<span class="NLM_issue">6168</span>),  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1126/science.1244851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1244851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24292625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=301-305&issue=6168&author=J.+Kr%C3%B6nkeauthor=N.+D.+Udeshiauthor=A.+Narlaauthor=P.+Graumanauthor=S.+N.+Hurstauthor=M.+McConkeyauthor=T.+Svinkinaauthor=D.+Hecklauthor=E.+Comerauthor=X.+Liauthor=C.+Ciarloauthor=E.+Hartmanauthor=N.+Munshiauthor=M.+Schenoneauthor=S.+L.+Schreiberauthor=S.+A.+Carrauthor=B.+L.+Ebert&title=Lenalidomide+Causes+Selective+Degradation+of+IKZF1+and+IKZF3+in+Multiple+Myeloma+Cells&doi=10.1126%2Fscience.1244851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span></div><div class="casAuthors">Kronke Jan; Udeshi Namrata D; Narla Anupama; Grauman Peter; Hurst Slater N; McConkey Marie; Svinkina Tanya; Heckl Dirk; Comer Eamon; Li Xiaoyu; Ciarlo Christie; Hartman Emily; Munshi Nikhil; Schenone Monica; Schreiber Stuart L; Carr Steven A; Ebert Benjamin L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown.  Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.  IKZF1 and IKZF3 are essential transcription factors in multiple myeloma.  A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth.  Similarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion of IKZF1 and IKZF3.  These findings reveal a previously unknown mechanism of action for a therapeutic agent: alteration of the activity of an E3 ubiquitin ligase, leading to selective degradation of specific targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiiGR0Yx7nuYFEOhA_Im3cfW6udTcc2ea6bht2qmBDF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D&md5=8cae3e554399308493aa38f0d05ed610</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244851%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DNarla%26aufirst%3DA.%26aulast%3DGrauman%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DHeckl%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCiarlo%26aufirst%3DC.%26aulast%3DHartman%26aufirst%3DE.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520Causes%2520Selective%2520Degradation%2520of%2520IKZF1%2520and%2520IKZF3%2520in%2520Multiple%2520Myeloma%2520Cells%26jtitle%3DScience%26date%3D2014%26volume%3D343%26issue%3D6168%26spage%3D301%26epage%3D305%26doi%3D10.1126%2Fscience.1244851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naniong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaelin, W. G.</span></span> <span> </span><span class="NLM_article-title">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span> (<span class="NLM_issue">6168</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&issue=6168&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.-K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+Myeloma+Drug+Lenalidomide+Promotes+the+Cereblon-Dependent+Destruction+of+Ikaros+Proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0ljsTyrdM_k4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520Myeloma%2520Drug%2520Lenalidomide%2520Promotes%2520the%2520Cereblon-Dependent%2520Destruction%2520of%2520Ikaros%2520Proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26issue%3D6168%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chie-Leon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakoshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span> <span> </span><span class="NLM_article-title">Structure of the Human Cereblon-DDB1-Lenalidomide Complex Reveals Basis for Responsiveness to Thalidomide Analogs</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnsmb.2874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=25108355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=803-810&issue=9&author=P.+P.+Chamberlainauthor=A.+Lopez-Gironaauthor=K.+Millerauthor=G.+Carmelauthor=B.+Pagariganauthor=B.+Chie-Leonauthor=E.+Rychakauthor=L.+G.+Corralauthor=Y.+J.+Renauthor=M.+Wangauthor=M.+Rileyauthor=S.+L.+Delkerauthor=T.+Itoauthor=H.+Andoauthor=T.+Moriauthor=Y.+Hiranoauthor=H.+Handaauthor=T.+Hakoshimaauthor=T.+O.+Danielauthor=B.+E.+Cathers&title=Structure+of+the+Human+Cereblon-DDB1-Lenalidomide+Complex+Reveals+Basis+for+Responsiveness+to+Thalidomide+Analogs&doi=10.1038%2Fnsmb.2874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs</span></div><div class="casAuthors">Chamberlain, Philip P.; Lopez-Girona, Antonia; Miller, Karen; Carmel, Gilles; Pagarigan, Barbra; Chie-Leon, Barbara; Rychak, Emily; Corral, Laura G.; Ren, Yan J.; Wang, Maria; Riley, Mariko; Delker, Silvia L.; Ito, Takumi; Ando, Hideki; Mori, Tomoyuki; Hirano, Yoshinori; Handa, Hiroshi; Hakoshima, Toshio; Daniel, Thomas O.; Cathers, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">803-809</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is the target of thalidomide, lenalidomide and pomalidomide, therapeutically important drugs for multiple myeloma and other B-cell malignancies.  These drugs directly bind Cereblon (CRBN) and promote the recruitment of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading to substrate ubiquitination and degrdn.  Here we present the crystal structure of human CRBN bound to DDB1 and the drug lenalidomide.  A hydrophobic pocket in the thalidomide-binding domain (TBD) of CRBN accommodates the glutarimide moiety of lenalidomide, whereas the isoindolinone ring is exposed to solvent.  We also solved the structures of the mouse TBD in the apo state and with thalidomide or pomalidomide.  Site-directed mutagenesis in lentiviral-expression myeloma models showed that key drug-binding residues are crit. for antiproliferative effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtN-ZCacB1m7Vg90H21EOLACvtfcHk0lgUk2SpQvI-JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI&md5=627fc3c8eae320059ca1cdc173bb56ed</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2874%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DChie-Leon%26aufirst%3DB.%26aulast%3DRychak%26aufirst%3DE.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DRen%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DDelker%26aufirst%3DS.%2BL.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHirano%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DHakoshima%26aufirst%3DT.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26atitle%3DStructure%2520of%2520the%2520Human%2520Cereblon-DDB1-Lenalidomide%2520Complex%2520Reveals%2520Basis%2520for%2520Responsiveness%2520to%2520Thalidomide%2520Analogs%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D9%26spage%3D803%26epage%3D810%26doi%3D10.1038%2Fnsmb.2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacBeth, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järås, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide Induces Ubiquitination and Degradation of CK1α in Del(5q) MDS</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>523</i></span> (<span class="NLM_issue">7559</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nature14610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature14610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26131937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=523&publication_year=2015&pages=183-188&issue=7559&author=J.+Kr%C3%B6nkeauthor=E.+C.+Finkauthor=P.+W.+Hollenbachauthor=K.+J.+MacBethauthor=S.+N.+Hurstauthor=N.+D.+Udeshiauthor=P.+P.+Chamberlainauthor=D.+R.+Maniauthor=H.-W.+Manauthor=A.+K.+Gandhiauthor=T.+Svinkinaauthor=R.+K.+Schneiderauthor=M.+McConkeyauthor=M.+J%C3%A4r%C3%A5sauthor=E.+Griffithsauthor=M.+Wetzlerauthor=L.+Bullingerauthor=B.+E.+Cathersauthor=S.+A.+Carrauthor=R.+Chopraauthor=B.+L.+Ebert&title=Lenalidomide+Induces+Ubiquitination+and+Degradation+of+CK1%CE%B1+in+Del%285q%29+MDS&doi=10.1038%2Fnature14610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS</span></div><div class="casAuthors">Kronke, Jan; Fink, Emma C.; Hollenbach, Paul W.; MacBeth, Kyle J.; Hurst, Slater N.; Udeshi, Namrata D.; Chamberlain, Philip P.; Mani, D. R.; Man, Hon Wah; Gandhi, Anita K.; Svinkina, Tanya; Schneider, Rebekka K.; McConkey, Marie; Jaras, Marcus; Griffiths, Elizabeth; Wetzler, Meir; Bullinger, Lars; Cathers, Brian E.; Carr, Steven A.; Chopra, Rajesh; Ebert, Benjamin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">523</span>
        (<span class="NLM_cas:issue">7559</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)).  Lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1α) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN), resulting in CK1α degrdn.  CK1α is encoded by a gene within the common deleted region for del(5q) MDS and haplo-insufficient expression sensitizes cells to lenalidomide therapy, providing a mechanistic basis for the therapeutic window of lenalidomide in del(5q) MDS.  The authors found that mouse cells are resistant to lenalidomide but that changing a single amino acid in mouse Crbn to the corresponding human residue enables lenalidomide-dependent degrdn. of CK1α.  The authors further demonstrate that minor side chain modifications in thalidomide and a novel analog, CC-122, can modulate the spectrum of substrates targeted by CRL4CRBN.  These findings have implications for the clin. activity of lenalidomide and related compds., and demonstrate the therapeutic potential of novel modulators of E3 ubiquitin ligases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLiHx3FKesbVg90H21EOLACvtfcHk0lgUk2SpQvI-JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN&md5=9b20a91c13e888e6569223ffa25af2cd</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1038%2Fnature14610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14610%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DFink%26aufirst%3DE.%2BC.%26aulast%3DHollenbach%26aufirst%3DP.%2BW.%26aulast%3DMacBeth%26aufirst%3DK.%2BJ.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DMani%26aufirst%3DD.%2BR.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DR.%2BK.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DJ%25C3%25A4r%25C3%25A5s%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DE.%26aulast%3DWetzler%26aufirst%3DM.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520Induces%2520Ubiquitination%2520and%2520Degradation%2520of%2520CK1%25CE%25B1%2520in%2520Del%25285q%2529%2520MDS%26jtitle%3DNature%26date%3D2015%26volume%3D523%26issue%3D7559%26spage%3D183%26epage%3D188%26doi%3D10.1038%2Fnature14610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Lenalidomide-Induced CK1α Degradation by the CRL4(CRBN) Ubiquitin Ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span> (<span class="NLM_issue">7597</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature16979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature16979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26909574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=127-130&issue=7597&author=G.+Petzoldauthor=E.+S.+Fischerauthor=N.+H.+Thom%C3%A4&title=Structural+Basis+of+Lenalidomide-Induced+CK1%CE%B1+Degradation+by+the+CRL4%28CRBN%29+Ubiquitin+Ligase&doi=10.1038%2Fnature16979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Petzold, Georg; Fischer, Eric S.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7597</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thalidomide and its derivs., lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of hematol. malignancies.  IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates.  Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degrdn.  Lenalidomide induces degrdn. of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clin. efficacy in the treatment of multiple myeloma and 5q-deletion assocd. myelodysplastic syndrome (del(5q) MDS), resp.  How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive.  Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α.  CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe.  We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD.  Binding of IKZF1 to CRBN similarly requires the compd. and both, IKZF1 and CK1α, use a related binding mode.  Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy.  We anticipate that high-affinity protein-protein interactions induced by small mols. will provide opportunities for drug development, particularly for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs4FxWriI1ObVg90H21EOLACvtfcHk0lgqsNnnzppUmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D&md5=320fc6ff811da335fa8e02feab2d702d</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1038%2Fnature16979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16979%26sid%3Dliteratum%253Aachs%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructural%2520Basis%2520of%2520Lenalidomide-Induced%2520CK1%25CE%25B1%2520Degradation%2520by%2520the%2520CRL4%2528CRBN%2529%2520Ubiquitin%2520Ligase%26jtitle%3DNature%26date%3D2016%26volume%3D532%26issue%3D7597%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fnature16979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorklund, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havens, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amantangelo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourdehnad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakurta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span> <span> </span><span class="NLM_article-title">CC-122, a Pleiotropic Pathway Modifier, Mimics an Interferon Response and Has Antitumor Activity in DLBCL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-02-628669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1182%2Fblood-2015-02-628669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=26002965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFahtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=779-789&issue=6&author=P.+R.+Hagnerauthor=H.-W.+Manauthor=C.+Fontanilloauthor=M.+Wangauthor=S.+Coutoauthor=M.+Breiderauthor=C.+Bjorklundauthor=C.+G.+Havensauthor=G.+Luauthor=E.+Rychakauthor=H.+Raymonauthor=R.+K.+Narlaauthor=L.+Barnesauthor=G.+Khambattaauthor=H.+Chiuauthor=J.+Kosekauthor=J.+Kangauthor=M.+D.+Amantangeloauthor=M.+Waldmanauthor=A.+Lopez-Gironaauthor=T.+Caiauthor=M.+Pourdehnadauthor=M.+Trotterauthor=T.+O.+Danielauthor=P.+H.+Schaferauthor=A.+Klippelauthor=A.+Thakurtaauthor=R.+Chopraauthor=A.+K.+Gandhi&title=CC-122%2C+a+Pleiotropic+Pathway+Modifier%2C+Mimics+an+Interferon+Response+and+Has+Antitumor+Activity+in+DLBCL&doi=10.1182%2Fblood-2015-02-628669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL</span></div><div class="casAuthors">Hagner, Patrick R.; Man, Hon-Wah; Fontanillo, Celia; Wang, Maria; Couto, Suzana; Breider, Mike; Bjorklund, Chad; Havens, Courtney G.; Lu, Gang; Rychak, Emily; Raymon, Heather; Narla, Rama Krishna; Barnes, Leo; Khambatta, Gody; Chiu, Hsiling; Kosek, Jolanta; Kang, Jian; Amantangelo, Michael D.; Waldman, Michelle; Lopez-Girona, Antonia; Cai, Ti; Pourdehnad, Michael; Trotter, Matthew; Daniel, Thomas O.; Schafer, Peter H.; Klippel, Anke; Thakurta, Anjan; Chopra, Rajesh; Gandhi, Anita K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-789</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.  Recently, it was demonstrated that binding of these drugs to CRBN promotes the ubiquitination and subsequent degrdn. of 2 common substrates, transcription factors Aiolos and Ikaros.  Here we report that CC-122, a new chem. entity termed pleiotropic pathway modifier, binds CRBN and promotes degrdn. of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo, and in patients, resulting in both cell autonomous as well as immunostimulatory effects.  In DLBCL cell lines, CC-122-induced degrdn. or short hairpin RNA-mediated knockdown of Aiolos and Ikaros correlates with increased transcription of interferon (IFN)-stimulated genes independent of IFN-α, -β, and -γ prodn. and/or secretion and results in apoptosis in both activated B-cell (ABC) and germinal center B-cell DLBCL cell lines.  Our results provide mechanistic insight into the cell-of-origin independent antilymphoma activity of CC-122, in contrast to the ABC subtype selective activity of lenalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Ayj7KrKYWrVg90H21EOLACvtfcHk0lgqsNnnzppUmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFahtL7K&md5=786ea247e42ebc90dec67fc6f7a4e48b</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-02-628669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-02-628669%26sid%3Dliteratum%253Aachs%26aulast%3DHagner%26aufirst%3DP.%2BR.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DFontanillo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCouto%26aufirst%3DS.%26aulast%3DBreider%26aufirst%3DM.%26aulast%3DBjorklund%26aufirst%3DC.%26aulast%3DHavens%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DRychak%26aufirst%3DE.%26aulast%3DRaymon%26aufirst%3DH.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBarnes%26aufirst%3DL.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DChiu%26aufirst%3DH.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DAmantangelo%26aufirst%3DM.%2BD.%26aulast%3DWaldman%26aufirst%3DM.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DPourdehnad%26aufirst%3DM.%26aulast%3DTrotter%26aufirst%3DM.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DKlippel%26aufirst%3DA.%26aulast%3DThakurta%26aufirst%3DA.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26atitle%3DCC-122%252C%2520a%2520Pleiotropic%2520Pathway%2520Modifier%252C%2520Mimics%2520an%2520Interferon%2520Response%2520and%2520Has%2520Antitumor%2520Activity%2520in%2520DLBCL%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26issue%3D6%26spage%3D779%26epage%3D789%26doi%3D10.1182%2Fblood-2015-02-628669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baculi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBrun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=535-542&issue=2&author=M.+E.+Matyskielaauthor=W.+Zhangauthor=H.-W.+Manauthor=G.+Mullerauthor=G.+Khambattaauthor=F.+Baculiauthor=M.+Hickmanauthor=L.+LeBrunauthor=B.+Pagariganauthor=G.+Carmelauthor=C.-C.+Luauthor=G.+Luauthor=M.+Rileyauthor=Y.+Satohauthor=P.+Schaferauthor=T.+O.+Danielauthor=J.+Carmichaelauthor=B.+E.+Cathersauthor=P.+P.+Chamberlain&title=A+Cereblon+Modulator+%28CC-220%29+with+Improved+Degradation+of+Ikaros+and+Aiolos&doi=10.1021%2Facs.jmedchem.6b01921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span></div><div class="casAuthors">Matyskiela, Mary E.; Zhang, Weihong; Man, Hon-Wah; Muller, George; Khambatta, Godrej; Baculi, Frans; Hickman, Matthew; LeBrun, Laurie; Pagarigan, Barbra; Carmel, Gilles; Lu, Chin-Chun; Lu, Gang; Riley, Mariko; Satoh, Yoshitaka; Schafer, Peter; Daniel, Thomas O.; Carmichael, James; Cathers, Brian E.; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the CRL4-CRBN E3 ligase toward the transcription factors Ikaros and Aiolos to cause their ubiquitination and degrdn.  Here we describe CC-220 (compd. 6), a cereblon modulator in clin. development for systemic lupus erythematosis and relapsed/refractory multiple myeloma.  Compd. 6 binds cereblon with a higher affinity than lenalidomide or pomalidomide.  Consistent with this, the cellular degrdn. of Ikaros and Aiolos is more potent and the extent of substrate depletion is greater.  The crystal structure of cereblon in complex with DDB1 and compd. 6 reveals that the increase in potency correlates with increased contacts between compd. 6 and cereblon away from the modeled binding site for Ikaros/Aiolos.  These results describe a new cereblon modulator which achieves greater substrate degrdn. via tighter binding to the cereblon E3 ligase and provides an example of the effect of E3 ligase binding affinity with relevance to other drug discovery efforts in targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropbvYIxr5j7Vg90H21EOLACvtfcHk0lgqsNnnzppUmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D&md5=8358ae8563f8f2c09dbf68683e5e4008</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01921%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBaculi%26aufirst%3DF.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DLeBrun%26aufirst%3DL.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520Cereblon%2520Modulator%2520%2528CC-220%2529%2520with%2520Improved%2520Degradation%2520of%2520Ikaros%2520and%2520Aiolos%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D535%26epage%3D542%26doi%3D10.1021%2Facs.jmedchem.6b01921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchelman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A Novel Cereblon Modulator Recruits GSPT1 to the CRL4(CRBN) Ubiquitin Ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span> (<span class="NLM_issue">7611</span>),  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1038/nature18611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1038%2Fnature18611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=27338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=252-257&issue=7611&author=M.+E.+Matyskielaauthor=G.+Luauthor=T.+Itoauthor=B.+Pagariganauthor=C.-C.+Luauthor=K.+Millerauthor=W.+Fangauthor=N.-Y.+Wangauthor=D.+Nguyenauthor=J.+Houstonauthor=G.+Carmelauthor=T.+Tranauthor=M.+Rileyauthor=L.+Nosakaauthor=G.+C.+Landerauthor=S.+Gaidarovaauthor=S.+Xuauthor=A.+L.+Ruchelmanauthor=H.+Handaauthor=J.+Carmichaelauthor=T.+O.+Danielauthor=B.+E.+Cathersauthor=A.+Lopez-Gironaauthor=P.+P.+Chamberlain&title=A+Novel+Cereblon+Modulator+Recruits+GSPT1+to+the+CRL4%28CRBN%29+Ubiquitin+Ligase&doi=10.1038%2Fnature18611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Matyskiela, Mary E.; Lu, Gang; Ito, Takumi; Pagarigan, Barbra; Lu, Chin-Chun; Miller, Karen; Fang, Wei; Wang, Nai-Yu; Nguyen, Derek; Houston, Jack; Carmel, Gilles; Tran, Tam; Riley, Mariko; Nosaka, Lyn'Al; Lander, Gabriel C.; Gaidarova, Svetlana; Xu, Shuichan; Ruchelman, Alexander L.; Handa, Hiroshi; Carmichael, James; Daniel, Thomas O.; Cathers, Brian E.; Lopez-Girona, Antonia; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7611</span>),
    <span class="NLM_cas:pages">252-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4CRBN E3 ubiquitin ligase.  Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumor activity.  The anti-tumor activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degrdn. of the translation termination factor GSPT1.  Patient-derived acute myeloid leukemia tumor cells exhibit high sensitivity to CC-885, indicating the clin. potential of this mechanism.  Crystallog. studies of the CRBN-DDB1-CC-885-GSPT1 complex reveal that GSPT1 binds to cereblon through a surface turn contg. a glycine residue at a key position, interacting with both CC-885 and a 'hotspot' on the cereblon surface.  Although GSPT1 possesses no obvious structural, sequence or functional homol. to previously known cereblon substrates, mutational anal. and modeling indicate that the cereblon substrate Ikaros uses a similar structural feature to bind cereblon, suggesting a common motif for substrate recruitment.  These findings define a structural degron underlying cereblon 'neosubstrate' selectivity, and identify an anti-tumor target rendered druggable by cereblon modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgAWiXdlJgYLVg90H21EOLACvtfcHk0lgFrnpZ7nWrUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI&md5=1d4e340416aa0b08fc0f123faf638c3f</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1038%2Fnature18611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18611%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DN.-Y.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DHouston%26aufirst%3DJ.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DNosaka%26aufirst%3DL.%26aulast%3DLander%26aufirst%3DG.%2BC.%26aulast%3DGaidarova%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DRuchelman%26aufirst%3DA.%2BL.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520Novel%2520Cereblon%2520Modulator%2520Recruits%2520GSPT1%2520to%2520the%2520CRL4%2528CRBN%2529%2520Ubiquitin%2520Ligase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26issue%3D7611%26spage%3D252%26epage%3D257%26doi%3D10.1038%2Fnature18611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goralski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaskill, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capota, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhawan, D.</span></span> <span> </span><span class="NLM_article-title">Anticancer Sulfonamides Target Splicing by Inducing RBM39 Degradation via Recruitment to DCAF15</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">6336</span>),  <span class="NLM_fpage">eaal3755</span>, <span class="refDoi"> DOI: 10.1126/science.aal3755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1126%2Fscience.aal3755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=28302793" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2017&pages=eaal3755&issue=6336&author=T.+Hanauthor=M.+Goralskiauthor=N.+Gaskillauthor=E.+Capotaauthor=J.+Kimauthor=T.+C.+Tingauthor=Y.+Xieauthor=N.+S.+Williamsauthor=D.+Nijhawan&title=Anticancer+Sulfonamides+Target+Splicing+by+Inducing+RBM39+Degradation+via+Recruitment+to+DCAF15&doi=10.1126%2Fscience.aal3755"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1126%2Fscience.aal3755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aal3755%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DT.%26aulast%3DGoralski%26aufirst%3DM.%26aulast%3DGaskill%26aufirst%3DN.%26aulast%3DCapota%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DTing%26aufirst%3DT.%2BC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DN.%2BS.%26aulast%3DNijhawan%26aufirst%3DD.%26atitle%3DAnticancer%2520Sulfonamides%2520Target%2520Splicing%2520by%2520Inducing%2520RBM39%2520Degradation%2520via%2520Recruitment%2520to%2520DCAF15%26jtitle%3DScience%26date%3D2017%26volume%3D356%26issue%3D6336%26spage%3Deaal3755%26doi%3D10.1126%2Fscience.aal3755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okauchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimatsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugi, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyanagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitoh, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3789</span>– <span class="NLM_lpage">3799</span>, <span class="refDoi"> DOI: 10.1021/jm9902638</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9902638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADyaK1MXltlyqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3789-3799&issue=19&author=T.+Owaauthor=H.+Yoshinoauthor=T.+Okauchiauthor=K.+Yoshimatsuauthor=Y.+Ozawaauthor=N.+H.+Sugiauthor=T.+Nagasuauthor=N.+Koyanagiauthor=K.+Kitoh&title=Discovery+of+Novel+Antitumor+Sulfonamides+Targeting+G1+Phase+of+the+Cell+Cycle&doi=10.1021%2Fjm9902638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle</span></div><div class="casAuthors">Owa, Takashi; Yoshino, Hiroshi; Okauchi, Tatsuo; Yoshimatsu, Kentaro; Ozawa, Yoichi; Sugi, Naoko Hata; Nagasu, Takeshi; Koyanagi, Nozomu; Kitoh, Kyosuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3789-3799</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein is the discovery of a novel series of antitumor sulfonamides targeting G1 phase of the cell cycle.  Cell cycle control in G1 phase has attracted considerable attention in recent cancer research, because many of the important proteins involved in G1 progression or G1/S transition have been found to play a crucial role in proliferation, differentiation, transformation, and programmed cell death (apoptosis).  We previously reported our first antitumor sulfonamide E7010 as a novel tubulin polymn. inhibitor.  Interestingly enough, continuous research on structurally related compds. led us to the finding of another class of antitumor sulfonamides that block cell cycle progression of P388 murine leukemia cells in G1 phase, but not in M phase.  Of the compds. examd., N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide (E7070) showed significant antitumor activity against HCT116 human colon carcinoma both in vitro (IC50 0.11 μg/mL in cell proliferation assay) and in vivo (not only growth suppression but also a marked redn. of tumor size in nude mice).  Because of its promising efficacy against human tumor xenografts and its unique mode of action, E7070 is currently undergoing phase I clin. trials in European countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJHw-oFWkEIbVg90H21EOLACvtfcHk0lgFrnpZ7nWrUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltlyqurY%253D&md5=5019173efb40da605c495fc0dd77475a</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1021%2Fjm9902638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9902638%26sid%3Dliteratum%253Aachs%26aulast%3DOwa%26aufirst%3DT.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DOkauchi%26aufirst%3DT.%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DOzawa%26aufirst%3DY.%26aulast%3DSugi%26aufirst%3DN.%2BH.%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DKoyanagi%26aufirst%3DN.%26aulast%3DKitoh%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520Novel%2520Antitumor%2520Sulfonamides%2520Targeting%2520G1%2520Phase%2520of%2520the%2520Cell%2520Cycle%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26issue%3D19%26spage%3D3789%26epage%3D3799%26doi%3D10.1021%2Fjm9902638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkov, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhawan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span> <span> </span><span class="NLM_article-title">Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1633</span>, <span class="refDoi"> DOI: 10.1016/j.str.2019.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2Fj.str.2019.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=31693911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFant7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1625-1633&issue=11&author=X.+Duauthor=O.+A.+Volkovauthor=R.+M.+Czerwinskiauthor=H.+Tanauthor=C.+Huertaauthor=E.+R.+Mortonauthor=J.+P.+Rizziauthor=P.+M.+Wehnauthor=R.+Xuauthor=D.+Nijhawanauthor=E.+M.+Wallace&title=Structural+Basis+and+Kinetic+Pathway+of+RBM39+Recruitment+to+DCAF15+by+a+Sulfonamide+Molecular+Glue+E7820&doi=10.1016%2Fj.str.2019.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820</span></div><div class="casAuthors">Du, Xinlin; Volkov, Oleg A.; Czerwinski, Robert M.; Tan, HuiLing; Huerta, Carlos; Morton, Emily R.; Rizzi, Jim P.; Wehn, Paul M.; Xu, Rui; Nijhawan, Deepak; Wallace, Eli M.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1625-1633.e3</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">E7820 and indisulam are two examples of aryl sulfonamides that recruit RBM39 to Rbx-Cul4-DDA1-DDB1-DCAF15 E3 ligase complex, leading to its ubiquitination and degrdn. by the proteasome.  To understand their mechanism of action, we performed kinetic anal. on the recruitment of RBM39 to DCAF15 and solved a crystal structure of DDA1-DDB1-DCAF15 in complex with E7820 and the RRM2 domain of RBM39.  E7820 packs in a shallow pocket on the surface of DCAF15 and the resulting modified interface binds RBM39 through the α1 helix of the RRM2 domain.  Our kinetic studies revealed that aryl sulfonamide and RBM39 bind to DCAF15 in a synergistic manner.  The structural and kinetic studies confirm aryl sulfonamides as mol. glues in the recruitment of RBM39 and provide a framework for future efforts to utilize DCAF15 to degrade other proteins of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptVt-FWWkhhrVg90H21EOLACvtfcHk0lg8pJGdlhWs0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFant7fJ&md5=295a6f13e258e6fffc4a6a0ff8c773b9</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2019.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2019.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DX.%26aulast%3DVolkov%26aufirst%3DO.%2BA.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DHuerta%26aufirst%3DC.%26aulast%3DMorton%26aufirst%3DE.%2BR.%26aulast%3DRizzi%26aufirst%3DJ.%2BP.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DNijhawan%26aufirst%3DD.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26atitle%3DStructural%2520Basis%2520and%2520Kinetic%2520Pathway%2520of%2520RBM39%2520Recruitment%2520to%2520DCAF15%2520by%2520a%2520Sulfonamide%2520Molecular%2520Glue%2520E7820%26jtitle%3DStructure%26date%3D2019%26volume%3D27%26issue%3D11%26spage%3D1625%26epage%3D1633%26doi%3D10.1016%2Fj.str.2019.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="note"><p class="first last">The SciFinder database was searched in May 2019 to enumerate the heterodimeric compounds in the following manner. The search was initiated using the keyword “PROTAC”. CRBN-directed compounds were identified by substructure sorting on the key 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione and 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione pharmacophores. VHL-directed compounds were identified by sorting on the most commonly used 1-(2-amino-3,3-dimethylbutanoyl)-4-hydroxy-<i>N</i>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide ligand. In both cases, compounds were manually removed that were not designed to be heterodimeric degraders. In both cases, compounds were included even if there were no activity data reported. A sdf file containing these structures and associated calculated properties is included as a supplemental to this perspective.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lg8pJGdlhWs0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoull, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Code, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petteruti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmusson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raubo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricchiuto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span> <span> </span><span class="NLM_article-title">Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC to Provide Insight Into Small Molecule Targeting of BCL6</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3131</span>– <span class="NLM_lpage">3141</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaisrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=3131-3141&issue=11&author=W.+McCoullauthor=T.+Cheungauthor=E.+Andersonauthor=P.+Bartonauthor=J.+Burgessauthor=K.+Bythauthor=Q.+Caoauthor=M.+P.+Castaldiauthor=H.+Chenauthor=E.+Chiarparinauthor=R.+J.+Carbajoauthor=E.+Codeauthor=S.+Cowanauthor=P.+R.+Daveyauthor=A.+D.+Fergusonauthor=S.+Filleryauthor=N.+O.+Fullerauthor=N.+Gaoauthor=D.+Hargreavesauthor=M.+R.+Howardauthor=J.+Huauthor=A.+Kawatkarauthor=P.+D.+Kemmittauthor=E.+Leoauthor=D.+M.+Molinaauthor=N.+O%E2%80%99Connellauthor=P.+Petterutiauthor=T.+Rasmussonauthor=P.+Rauboauthor=P.+B.+Rawlinsauthor=P.+Ricchiutoauthor=G.+R.+Robbauthor=M.+Schenoneauthor=M.+J.+Waringauthor=M.+Zindaauthor=S.+Fawellauthor=D.+M.+Wilson&title=Development+of+a+Novel+B-Cell+Lymphoma+6+%28BCL6%29+PROTAC+to+Provide+Insight+Into+Small+Molecule+Targeting+of+BCL6&doi=10.1021%2Facschembio.8b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6</span></div><div class="casAuthors">McCoull, William; Cheung, Tony; Anderson, Erica; Barton, Peter; Burgess, Jonathan; Byth, Kate; Cao, Qing; Castaldi, M. Paola; Chen, Huawei; Chiarparin, Elisabetta; Carbajo, Rodrigo J.; Code, Erin; Cowan, Suzanna; Davey, Paul R.; Ferguson, Andrew D.; Fillery, Shaun; Fuller, Nathan O.; Gao, Ning; Hargreaves, David; Howard, Martin R.; Hu, Jun; Kawatkar, Aarti; Kemmitt, Paul D.; Leo, Elisabetta; Molina, Daniel M.; O'Connell, Nichole; Petteruti, Philip; Rasmusson, Timothy; Raubo, Piotr; Rawlins, Philip B.; Ricchiuto, Piero; Robb, Graeme R.; Schenone, Monica; Waring, Michael J.; Zinda, Michael; Fawell, Stephen; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3131-3141</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">B-cell lymphoma 6 (BCL6) inhibition is a promising mechanism for treating hematol. cancers but high quality chem. probes are necessary to evaluate its therapeutic potential.  Here we report potent BCL6 inhibitors that demonstrate cellular target engagement and exhibit exquisite selectivity for BCL6 based on mass spectrometry analyses following chem. proteomic pull down.  Importantly, a proteolysis-targeting chimera, 4-((R)-25-Chloro-41-methyl-42-oxo-41,42,43,44-tetrahydro-5,8-dioxa-3-aza-4(6,8)-quinolina2(2,4)-pyrimidina-1(1,2)-piperazinacyclononaphane-14-yl)-N-(3-(2-(2-((2-((S)-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)propyl)-4-oxobutanamide trifluoroacetate, (PROTAC, 15) was also developed and shown to significantly degrade BCL6 in a no. of diffuse large B-cell lymphoma (DLBCL) cell lines, but neither BCL6 inhibition nor degrdn. selectively induced marked phenotypic response.  To investigate, we monitored PROTAC directed BCL6 degrdn. in DLBCL OCI-Ly1 cells by immunofluorescence and discovered a residual BCL6 population.  Anal. of subcellular fractions also showed incomplete BCL6 degrdn. in all fractions despite having measurable PROTAC concns., together providing a rationale for the weak antiproliferative response seen with both BCL6 inhibitor and degrader.  In summary, we have developed potent and selective BCL6 inhibitors and a BCL6 PROTAC that effectively degraded BCL6, but both modalities failed to induce a significant phenotypic response in DLBCL despite achieving cellular concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEe9aUjqcaHLVg90H21EOLACvtfcHk0ljOgUfPsdopvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaisrnF&md5=3d2c2d8acf143f05babee6ebdabddc8c</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00698%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoull%26aufirst%3DW.%26aulast%3DCheung%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBurgess%26aufirst%3DJ.%26aulast%3DByth%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DCastaldi%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCode%26aufirst%3DE.%26aulast%3DCowan%26aufirst%3DS.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DN.%2BO.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DHargreaves%26aufirst%3DD.%26aulast%3DHoward%26aufirst%3DM.%2BR.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKemmitt%26aufirst%3DP.%2BD.%26aulast%3DLeo%26aufirst%3DE.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DN.%26aulast%3DPetteruti%26aufirst%3DP.%26aulast%3DRasmusson%26aufirst%3DT.%26aulast%3DRaubo%26aufirst%3DP.%26aulast%3DRawlins%26aufirst%3DP.%2BB.%26aulast%3DRicchiuto%26aufirst%3DP.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520Novel%2520B-Cell%2520Lymphoma%25206%2520%2528BCL6%2529%2520PROTAC%2520to%2520Provide%2520Insight%2520Into%2520Small%2520Molecule%2520Targeting%2520of%2520BCL6%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D11%26spage%3D3131%26epage%3D3141%26doi%3D10.1021%2Facschembio.8b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span>; <span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Siu, K.</span>; <span class="NLM_string-name">Ferraro, C.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Qian, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for the Targeted Degradation of Androgen Receptor</span>. World Intellectual Property Organization, <span class="NLM_patent">WO2016118666 A1</span>, Jul 28, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jin%2C+M.%3B+Crew%2C+A.+P.%3B+Dong%2C+H.%3B+Wang%2C+J.%3B+Siu%2C+K.%3B+Ferraro%2C+C.%3B+Chen%2C+X.%3B+Qian%2C+Y.+Compounds+and+Methods+for+the+Targeted+Degradation+of+Androgen+Receptor.+World+Intellectual+Property+Organization%2C+WO2016118666+A1%2C+Jul+28%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520the%2520Targeted%2520Degradation%2520of%2520Androgen%2520Receptor" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Berlin, M.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Homberger, K. R.</span>; <span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">Snyder, L. B.</span>; <span class="NLM_string-name">Wang, J.</span>; <span class="NLM_string-name">Zimmermann, K.</span></span> <span> </span><span class="NLM_article-title">Cereblon Ligands and Bifunctional Compounds Comprising the Same</span>. United States Patent Application Publication, <span class="NLM_patent">US20180215731</span>, Aug 2, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Crew%2C+A.+P.%3B+Berlin%2C+M.%3B+Dong%2C+H.%3B+Homberger%2C+K.+R.%3B+Qian%2C+Y.%3B+Snyder%2C+L.+B.%3B+Wang%2C+J.%3B+Zimmermann%2C+K.+Cereblon+Ligands+and+Bifunctional+Compounds+Comprising+the+Same.+United+States+Patent+Application+Publication%2C+US20180215731%2C+Aug+2%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrew%26aufirst%3DA.%2BP.%26atitle%3DCereblon%2520Ligands%2520and%2520Bifunctional%2520Compounds%2520Comprising%2520the%2520Same" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span>; <span class="NLM_string-name">Crew, A. P.</span>; <span class="NLM_string-name">Crews, C. M.</span>; <span class="NLM_string-name">Dong, H.</span>; <span class="NLM_string-name">Hornberger, K. R.</span>; <span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Modulators of Estrogen Receptor Proteolysis and Associated Methods of Use</span>. World Intellectual Property Organization, <span class="NLM_patent">WO2018140809</span>, Aug 2, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Qian%2C+Y.%3B+Crew%2C+A.+P.%3B+Crews%2C+C.+M.%3B+Dong%2C+H.%3B+Hornberger%2C+K.+R.%3B+Wang%2C+J.+Modulators+of+Estrogen+Receptor+Proteolysis+and+Associated+Methods+of+Use.+World+Intellectual+Property+Organization%2C+WO2018140809%2C+Aug+2%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26atitle%3DModulators%2520of%2520Estrogen%2520Receptor%2520Proteolysis%2520and%2520Associated%2520Methods%2520of%2520Use" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzer, P.</span></span> <span> </span><span class="NLM_article-title">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3714</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&issue=20&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+Calculation+of+Molecular+Polar+Surface+Area+as+a+Sum+of+Fragment-Based+Contributions+and+Its+Application+to+the+Prediction+of+Drug+Transport+Properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0ljOgUfPsdopvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520Calculation%2520of%2520Molecular%2520Polar%2520Surface%2520Area%2520as%2520a%2520Sum%2520of%2520Fragment-Based%2520Contributions%2520and%2520Its%2520Application%2520to%2520the%2520Prediction%2520of%2520Drug%2520Transport%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D20%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWK','PDB','5FWK'); return false;">PDB: 5FWK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWP','PDB','5FWP'); return false;">PDB: 5FWP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FWM','PDB','5FWM'); return false;">PDB: 5FWM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96','PDB','2W96'); return false;">PDB: 2W96</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UW4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UW4','PDB','3UW4'); return false;">PDB: 3UW4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F','PDB','6B0F'); return false;">PDB: 6B0F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TZ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TZ4','PDB','4TZ4'); return false;">PDB: 4TZ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FQD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FQD','PDB','5FQD'); return false;">PDB: 5FQD</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes.si"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i25"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00093">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_86526"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00093?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00093</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Spatial data file as indicated in ref <a class="ref ref37" href="javascript:void(0);">(37)</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00093/suppl_file/jm0c00093_si_001.sdf">SDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00093/suppl_file/jm0c00093_si_001.sdf">jm0c00093_si_001.sdf (5.22 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00093&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00093%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00093" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992d1eed4323e0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
